Daidzein	O
and	O
genistein	O
glucuronides	O
in	O
vitro	O
are	O
weakly	O
estrogenic	O
and	O
activate	O
human	O
natural	O
killer	O
cells	O
at	O
nutritionally	O
relevant	O
concentrations	O
.	O

Daidzein	O
and	O
genistein	O
glucuronides	O
(	O
DG	O
and	O
GG	O
)	O
,	O
major	O
isoflavone	O
metabolites	O
,	O
may	O
be	O
partly	O
responsible	O
for	O
biological	O
effects	O
of	O
isoflavones	O
,	O
such	O
as	O
estrogen	B-Protein
receptor	I-Protein
binding	O
and	O
natural	O
killer	O
cell	O
(	O
NK	O
)	O
activation	O
or	O
inhibition	O
.	O

DG	O
and	O
GG	O
were	O
synthesized	O
using	O
3	O
-	O
methylcholanthrene	O
-	O
induced	O
rat	O
liver	O
microsomes	O
.	O

The	O
Km	O
and	O
Vmax	O
for	O
daidzein	O
and	O
genistein	O
were	O
9	O
.	O
0	O
and	O
7	O
.	O
7	O
micromol	O
/	O
L	O
,	O
and	O
0	O
.	O
7	O
and	O
1	O
.	O
6	O
micromol	O
/	O
(	O
mg	O
protein	O
.	O
min	O
)	O
,	O
respectively	O
.	O

The	O
absence	O
of	O
ultraviolet	O
absorbance	O
maxima	O
shifts	O
in	O
the	O
presence	O
of	O
sodium	O
acetate	O
confirmed	O
that	O
the	O
synthesized	O
products	O
were	O
7	O
-	O
O	O
-	O
glucuronides	O
.	O

DG	O
and	O
GG	O
were	O
further	O
purified	O
by	O
a	O
Sephadex	O
LH	O
-	O
20	O
column	O
.	O

DG	O
and	O
GG	O
competed	O
with	O
the	O
binding	O
of	O
17beta	O
-	O
(	O
3H	O
)	O
estradiol	O
to	O
estrogen	B-Protein
receptors	I-Protein
of	O
B6D2F1	O
mouse	O
uterine	O
cytosol	O
.	O

The	O
concentrations	O
required	O
for	O
50	O
%	O
displacement	O
of	O
17beta	O
-	O
(	O
3H	O
)	O
estradiol	O
(	O
CB50	O
)	O
were	O
:	O
17beta	O
-	O
estradiol	O
,	O
1	O
.	O
34	O
nmol	O
/	O
L	O
;	O
diethylstilbestrol	O
,	O
1	O
.	O
46	O
nmol	O
/	O
L	O
;	O
daidzein	O
,	O
1	O
.	O
6	O
micromol	O
/	O
L	O
;	O
DG	O
,	O
14	O
.	O
7	O
micromol	O
/	O
L	O
;	O
genistein	O
,	O
0	O
.	O
154	O
micromol	O
/	O
L	O
;	O
GG	O
,	O
7	O
.	O
27	O
micromol	O
/	O
L	O
.	O

In	O
human	O
peripheral	O
blood	O
NK	O
cells	O
,	O
genistein	O
at	O
<	O
0	O
.	O
5	O
micromol	O
/	O
L	O
and	O
DG	O
and	O
GG	O
at	O
0	O
.	O
1	O
-	O
10	O
micromol	O
/	O
L	O
enhanced	O
NK	O
cell	O
-	O
mediated	O
K562	O
cancer	O
cell	O
killing	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

At	O
>	O
0	O
.	O
5	O
micromol	O
/	O
L	O
,	O
genistein	O
inhibited	O
NK	O
cytotoxicity	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
glucuronides	O
only	O
inhibited	O
NK	O
cytotoxicity	O
at	O
50	O
micromol	O
/	O
L	O
.	O

Isoflavones	O
,	O
and	O
especially	O
the	O
isoflavone	O
glucuronides	O
,	O
enhanced	O
activation	O
of	O
NK	O
cells	O
by	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
(	O
IL	B-Protein
-	I-Protein
2	I-Protein
)	O
,	O
additively	O
.	O

At	O
physiological	O
concentrations	O
,	O
DG	O
and	O
GG	O
were	O
weakly	O
estrogenic	O
,	O
and	O
they	O
activated	O
human	O
NK	O
cells	O
in	O
nutritionally	O
relevant	O
concentrations	O
in	O
vitro	O
,	O
probably	O
at	O
a	O
site	O
different	O
from	O
IL	B-Protein
-	I-Protein
2	I-Protein
action	O
.	O

Osteoclast	O
markers	O
accumulate	O
on	O
cells	O
developing	O
from	O
human	O
peripheral	O
blood	O
mononuclear	O
precursors	O
.	O

Recent	O
studies	O
show	O
that	O
human	O
osteoclasts	O
develop	O
in	O
vitro	O
from	O
hematopoietic	O
cells	O
;	O
however	O
,	O
special	O
cultures	O
conditions	O
and	O
/	O
or	O
cytokine	O
mobilized	O
peripheral	O
blood	O
are	O
apparently	O
required	O
.	O

Here	O
,	O
we	O
report	O
that	O
cells	O
expressing	O
osteoclast	O
markers	O
differentiate	O
from	O
precursors	O
present	O
in	O
nonmobilized	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
,	O
without	O
the	O
addition	O
of	O
stromal	O
cells	O
,	O
growth	O
factors	O
,	O
cytokines	O
or	O
steroids	O
;	O
and	O
characterize	O
their	O
phenotype	O
.	O

Three	O
days	O
after	O
establishing	O
high	O
-	O
density	O
PBMC	O
cultures	O
(	O
1	O
.	O
5	O
x	O
10	O
(	O
6	O
)	O
cells	O
/	O
cm2	O
)	O
,	O
in	O
serum	O
-	O
containing	O
medium	O
,	O
small	O
adherent	O
colonies	O
of	O
tartrate	O
resistant	O
acid	O
phosphatase	O
positive	O
(	O
TRAP	B-Protein
+	O
)	O
cells	O
emerge	O
,	O
amidst	O
massive	O
monocyte	O
cell	O
death	O
.	O

These	O
adherent	O
cells	O
have	O
an	O
eccentrically	O
placed	O
,	O
round	O
nucleus	O
,	O
and	O
express	O
low	O
levels	O
of	O
TRAP	B-Protein
and	O
sodium	O
fluoride	O
-	O
resistant	O
-	O
alpha	O
-	O
naphthyl	O
-	O
acetate	O
-	O
esterase	O
(	O
NaF	O
-	O
R	O
-	O
NSE	O
)	O
.	O

Over	O
the	O
next	O
week	O
,	O
this	O
cell	O
population	O
accumulates	O
phenotypic	O
markers	O
of	O
osteoclasts	O
(	O
vitronectin	O
receptor	O
[	O
VR	O
]	O
,	O
calcitonin	O
receptor	O
,	O
TRAP	B-Protein
,	O
cathepsin	B-Protein
K	I-Protein
protein	O
,	O
and	O
mRNA	O
)	O
with	O
increased	O
nuclearity	O
,	O
covering	O
the	O
entire	O
surface	O
by	O
15	O
days	O
.	O

When	O
cultured	O
on	O
bone	O
,	O
VR	O
+	O
,	O
TRAP	B-Protein
+	O
cells	O
of	O
low	O
multinuclearity	O
appear	O
and	O
cover	O
up	O
to	O
50	O
%	O
of	O
the	O
surface	O
.	O

Resorption	O
lacunae	O
can	O
be	O
observed	O
by	O
day	O
22	O
.	O

Although	O
these	O
pits	O
are	O
not	O
nearly	O
as	O
numerous	O
as	O
the	O
cells	O
of	O
preosteoclast	O
phenotype	O
,	O
they	O
do	O
represent	O
the	O
activity	O
of	O
a	O
subset	O
of	O
osteoclast	O
-	O
like	O
cells	O
that	O
has	O
achieved	O
osteoclastic	O
maturity	O
under	O
these	O
culture	O
conditions	O
.	O

Transcripts	O
for	O
osteoprotegerin	B-Protein
ligand	I-Protein
(	O
OPGL	B-Protein
)	O
,	O
an	O
osteoclast	O
differentiation	O
factor	O
(	O
also	O
known	O
as	O
RANKL	B-Protein
and	O
TRANCE	B-Protein
)	O
are	O
expressed	O
,	O
likely	O
by	O
adherent	O
cells	O
.	O

Thus	O
,	O
an	O
adherent	O
population	O
of	O
cells	O
,	O
with	O
preosteoclast	O
/	O
osteoclast	O
phenotypic	O
properties	O
,	O
arises	O
selectively	O
under	O
simple	O
culture	O
conditions	O
from	O
normal	O
PBMC	O
.	O

Further	O
characterization	O
of	O
these	O
cells	O
should	O
identify	O
factors	O
involved	O
in	O
the	O
growth	O
,	O
terminal	O
differentiation	O
and	O
activation	O
of	O
osteoclasts	O
.	O

Phenotypic	O
and	O
functional	O
studies	O
of	O
leukocytes	O
in	O
human	O
endometrium	O
and	O
endometriosis	O
.	O

The	O
aetiology	O
of	O
endometriosis	O
,	O
a	O
common	O
and	O
disabling	O
disorder	O
,	O
is	O
presently	O
unknown	O
,	O
although	O
immune	O
dysfunction	O
could	O
allow	O
ectopic	O
endometrial	O
fragments	O
to	O
survive	O
outside	O
the	O
uterine	O
cavity	O
.	O

These	O
studies	O
investigate	O
the	O
relationship	O
between	O
leukocyte	O
populations	O
,	O
steroid	O
hormone	O
receptor	O
expression	O
,	O
proliferative	O
activity	O
,	O
bcl	B-Protein
-	I-Protein
2	I-Protein
expression	O
and	O
apoptosis	O
in	O
eutopic	O
and	O
ectopic	O
endometrium	O
from	O
women	O
with	O
endometriosis	O
or	O
adenomyosis	O
at	O
different	O
phases	O
of	O
the	O
menstrual	O
cycle	O
.	O

Significantly	O
increased	O
oestrogen	O
receptor	O
expression	O
,	O
bcl	B-Protein
-	I-Protein
2	I-Protein
expression	O
and	O
numbers	O
of	O
CD8	O
+	O
leukocytes	O
were	O
found	O
in	O
ectopic	O
compared	O
with	O
eutopic	O
endometrium	O
in	O
endometriosis	O
,	O
and	O
CD56	B-Protein
+	O
endometrial	O
granulated	O
lymphocytes	O
(	O
eGLs	O
)	O
were	O
significantly	O
reduced	O
in	O
ectopic	O
endometrium	O
.	O

Apoptotic	O
cells	O
were	O
rarely	O
found	O
in	O
control	O
and	O
subject	O
endometria	O
.	O

In	O
contrast	O
with	O
endometriosis	O
,	O
adenomyotic	O
lesions	O
showed	O
identical	O
steroid	O
hormone	O
receptor	O
expression	O
,	O
proliferative	O
activity	O
,	O
bcl	B-Protein
-	I-Protein
2	I-Protein
expression	O
and	O
leukocyte	O
subpopulations	O
to	O
eutopic	O
endometrium	O
,	O
indicating	O
different	O
aetiologies	O
for	O
these	O
disorders	O
.	O

The	O
unusual	O
CD56	B-Protein
+	O
CD16	B-Protein
-	O
eGLs	O
present	O
in	O
large	O
numbers	O
in	O
late	O
secretory	O
phase	O
eutopic	O
endometrium	O
were	O
highly	O
purified	O
(	O
>	O
98	O
%	O
)	O
by	O
immunomagnetic	O
separation	O
.	O

Except	O
for	O
a	O
negligible	O
cytotoxic	O
activity	O
of	O
eGLs	O
from	O
early	O
proliferative	O
samples	O
,	O
cytotoxic	O
activity	O
of	O
eGLs	O
from	O
non	O
-	O
pregnant	O
endometrium	O
during	O
the	O
menstrual	O
cycle	O
was	O
comparable	O
with	O
those	O
in	O
peripheral	O
blood	O
,	O
predominantly	O
CD56	B-Protein
+	O
CD16	B-Protein
+	O
natural	O
killer	O
cells	O
.	O

eGLs	O
from	O
non	O
-	O
pregnant	O
endometrium	O
and	O
early	O
pregnancy	O
showed	O
a	O
variable	O
proliferative	O
response	O
to	O
5	O
and	O
100	O
U	O
/	O
ml	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
over	O
48	O
-	O
h	O
and	O
120	O
-	O
h	O
time	O
courses	O
.	O

eGLs	O
are	O
evidently	O
functionally	O
important	O
in	O
the	O
eutopic	O
endometrium	O
.	O

Their	O
absence	O
in	O
endometriotic	O
lesions	O
together	O
with	O
increased	O
CD	O
+	O
8	O
T	O
-	O
cell	O
numbers	O
and	O
increased	O
oestrogen	O
receptor	O
and	O
bcl	B-Protein
-	I-Protein
2	I-Protein
expression	O
may	O
have	O
significant	O
effects	O
on	O
the	O
development	O
and	O
progression	O
of	O
endometriosis	O
.	O

Clonality	O
of	O
isolated	O
eosinophils	O
in	O
the	O
hypereosinophilic	O
syndrome	O
.	O

The	O
idiopathic	O
hypereosinophilic	O
syndrome	O
(	O
IHES	O
)	O
is	O
a	O
rare	O
disorder	O
characterized	O
by	O
unexplained	O
,	O
persistent	O
eosinophilia	O
associated	O
with	O
multiple	O
organ	O
dysfunction	O
due	O
to	O
eosinophilic	O
tissue	O
infiltration	O
.	O

In	O
the	O
absence	O
of	O
karyotypic	O
abnormalities	O
,	O
there	O
is	O
no	O
specific	O
test	O
to	O
detect	O
clonal	O
eosinophilia	O
in	O
IHES	O
.	O

Analysis	O
of	O
X	O
-	O
chromosome	O
inactivation	O
patterns	O
can	O
be	O
used	O
to	O
determine	O
whether	O
proliferative	O
disorders	O
are	O
clonal	O
in	O
origin	O
.	O

Methylation	O
of	O
HpaII	O
and	O
Hha	O
I	O
sites	O
near	O
the	O
polymorphic	O
trinucleotide	O
repeat	O
of	O
the	O
human	B-Protein
androgen	I-Protein
receptor	I-Protein
gene	O
(	O
HUMARA	B-Protein
)	O
has	O
been	O
shown	O
to	O
correlate	O
with	O
X	O
-	O
inactivation	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
used	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
with	O
nested	O
primers	O
to	O
analyze	O
X	O
-	O
inactivation	O
patterns	O
of	O
the	O
HUMARA	B-Protein
loci	O
in	O
purified	O
eosinophils	O
from	O
female	O
patients	O
with	O
eosinophilia	O
.	O

Peripheral	O
blood	O
eosinophils	O
were	O
isolated	O
by	O
their	O
autofluoresence	O
using	O
flow	O
cytometric	O
sorting	O
.	O

Eosinophils	O
purified	O
from	O
a	O
female	O
patient	O
presenting	O
with	O
IHES	O
were	O
found	O
to	O
show	O
a	O
clonal	O
pattern	O
of	O
X	O
-	O
inactivation	O
.	O

Eosinophil	O
-	O
depleted	O
leukocytes	O
from	O
this	O
patient	O
were	O
polyclonal	O
by	O
HUMARA	B-Protein
analysis	O
,	O
thus	O
excluding	O
skewedness	O
of	O
random	O
X	O
-	O
inactivation	O
.	O

After	O
corticosteroid	O
suppression	O
of	O
her	O
blood	O
eosinophilia	O
,	O
a	O
clonal	O
population	O
of	O
eosinophils	O
could	O
no	O
longer	O
be	O
detected	O
in	O
purified	O
eosinophils	O
.	O

In	O
contrast	O
,	O
eosinophils	O
purified	O
from	O
a	O
patient	O
with	O
Churg	O
-	O
Strauss	O
syndrome	O
and	O
from	O
six	O
patients	O
with	O
reactive	O
eosinophilias	O
attributed	O
to	O
allergy	O
,	O
parasitic	O
infection	O
,	O
or	O
drug	O
reaction	O
showed	O
a	O
polyclonal	O
pattern	O
of	O
X	O
-	O
inactivation	O
by	O
HUMARA	B-Protein
analysis	O
.	O

The	O
finding	O
of	O
clonal	O
eosinophilia	O
in	O
a	O
patient	O
presenting	O
with	O
IHES	O
indicates	O
that	O
such	O
patients	O
may	O
have	O
,	O
in	O
reality	O
,	O
a	O
low	O
-	O
grade	O
clonal	O
disorder	O
that	O
can	O
be	O
distinguished	O
from	O
reactive	O
eosinophilias	O
by	O
HUMARA	B-Protein
analysis	O
.	O

Further	O
,	O
the	O
method	O
described	O
can	O
be	O
used	O
to	O
monitor	O
disease	O
progression	O
.	O

Binding	O
of	O
c	B-Protein
-	I-Protein
Rel	I-Protein
to	O
STAT5	O
target	O
sequences	O
in	O
HTLV	O
-	O
I	O
-	O
transformed	O
T	O
cells	O
.	O

The	O
type	O
I	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
(	O
HTLV	O
-	O
I	O
)	O
induces	O
abnormal	O
growth	O
and	O
subsequent	O
transformation	O
of	O
T	O
cells	O
,	O
which	O
is	O
associated	O
with	O
the	O
development	O
of	O
an	O
acute	O
T	O
-	O
cell	O
malignancy	O
termed	O
adult	O
T	O
-	O
cell	O
leukemia	O
.	O

A	O
characteristic	O
of	O
HTLV	O
-	O
I	O
-	O
transformed	O
T	O
cells	O
is	O
the	O
constitutive	O
nuclear	O
expression	O
of	O
NF	O
-	O
kappaB	O
/	O
Rel	O
family	O
of	O
transcription	O
factors	O
,	O
which	O
appears	O
to	O
be	O
essential	O
for	O
the	O
growth	O
of	O
these	O
transformed	O
cells	O
.	O

Although	O
NF	O
-	O
kappaB	O
/	O
Rel	O
factors	O
are	O
known	O
to	O
induce	O
the	O
expression	O
of	O
T	O
-	O
cell	O
growth	O
factor	O
interleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
-	I-Protein
2	I-Protein
,	O
it	O
is	O
unclear	O
how	O
they	O
participate	O
in	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
independent	O
growth	O
of	O
HTLV	O
-	O
I	O
-	O
transformed	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
certain	O
NF	O
-	O
kappaB	O
/	O
Rel	O
members	O
,	O
predominantly	O
c	B-Protein
-	I-Protein
Rel	I-Protein
,	O
interact	O
with	O
enhancer	O
sequences	O
for	O
STAT5	O
,	O
a	O
key	O
transcription	O
factor	O
mediating	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
induced	O
T	O
-	O
cell	O
proliferation	O
.	O

Reporter	O
gene	O
assays	O
reveal	O
that	O
the	O
binding	O
of	O
c	B-Protein
-	I-Protein
Rel	I-Protein
to	O
the	O
STAT5	O
site	O
present	O
in	O
the	O
Fc	B-Protein
gammaR1	I-Protein
gene	O
leads	O
to	O
potent	O
transactivation	O
of	O
this	O
enhancer	O
.	O

Binding	O
of	O
c	B-Protein
-	I-Protein
Rel	I-Protein
to	O
the	O
Fc	B-Protein
gammaR1	I-Protein
STAT	O
site	O
also	O
occurs	O
in	O
human	O
peripheral	O
blood	O
T	O
cells	O
immortalized	O
with	O
HTLV	O
-	O
I	O
in	O
vitro	O
and	O
is	O
correlated	O
with	O
enhanced	O
levels	O
of	O
proliferation	O
of	O
these	O
cells	O
.	O

These	O
results	O
raise	O
the	O
possibility	O
that	O
NF	O
-	O
kappaB	O
/	O
Rel	O
may	O
participate	O
in	O
the	O
growth	O
control	O
of	O
HTLV	O
-	O
I	O
-	O
transformed	O
T	O
cells	O
by	O
regulating	O
genes	O
driven	O
by	O
both	O
kappaB	O
and	O
certain	O
STAT	O
enhancers	O
.	O

Alternative	O
polyadenylation	O
events	O
contribute	O
to	O
the	O
induction	O
of	O
NF	O
-	O
ATc	O
in	O
effector	O
T	O
cells	O
.	O

The	O
transcription	O
factor	O
NF	O
-	O
ATc	O
is	O
synthesized	O
in	O
three	O
prominent	O
isoforms	O
.	O

These	O
differ	O
in	O
the	O
length	O
of	O
their	O
C	O
terminal	O
peptides	O
and	O
mode	O
of	O
synthesis	O
.	O

Due	O
to	O
a	O
switch	O
from	O
the	O
use	O
of	O
a	O
3	O
'	O
polyA	O
site	O
to	O
a	O
more	O
proximal	O
polyA	O
site	O
,	O
NF	O
-	O
ATc	O
expression	O
switches	O
from	O
the	O
synthesis	O
of	O
the	O
two	O
longer	O
isoforms	O
in	O
naive	O
T	O
cells	O
to	O
that	O
of	O
short	O
isoform	O
A	O
in	O
T	O
effector	O
cells	O
.	O

The	O
relative	O
low	O
binding	O
affinity	O
of	O
cleavage	O
stimulation	O
factor	O
CstF	B-Protein
-	I-Protein
64	I-Protein
to	O
the	O
proximal	O
polyA	O
site	O
seems	O
to	O
contribute	O
to	O
its	O
neglect	O
in	O
naive	O
T	O
cells	O
.	O

These	O
alternative	O
polyadenylation	O
events	O
ensure	O
the	O
rapid	O
accumulation	O
of	O
high	O
concentrations	O
of	O
NF	O
-	O
ATc	O
necessary	O
to	O
exceed	O
critical	O
threshold	O
levels	O
of	O
NF	O
-	O
ATc	O
for	O
gene	O
induction	O
in	O
effector	O
T	O
cells	O
.	O

A	O
direct	O
interaction	O
between	O
the	O
adaptor	O
protein	O
Cbl	B-Protein
-	I-Protein
b	I-Protein
and	O
the	O
kinase	O
zap	B-Protein
-	I-Protein
70	I-Protein
induces	O
a	O
positive	O
signal	O
in	O
T	O
cells	O
.	O

Engagement	O
of	O
the	O
T	O
-	O
cell	O
receptor	O
(	O
TCR	O
)	O
-	O
CD3	O
complex	O
induces	O
a	O
rapid	O
increase	O
in	O
the	O
activities	O
of	O
Src	O
-	O
family	O
and	O
Syk	B-Protein
/	O
Zap	B-Protein
-	I-Protein
70	I-Protein
-	O
family	O
kinases	O
[	O
1	O
]	O
[	O
2	O
]	O
.	O

These	O
activated	O
kinases	O
then	O
induce	O
the	O
tyrosine	O
phosphorylation	O
of	O
multiple	O
intracellular	O
proteins	O
,	O
eventually	O
leading	O
to	O
T	O
-	O
cell	O
activation	O
.	O

One	O
of	O
the	O
prominent	O
substrates	O
for	O
these	O
kinases	O
is	O
the	O
adaptor	O
protein	O
Cbl	O
[	O
3	O
]	O
and	O
recent	O
studies	O
suggest	O
that	O
Cbl	O
negatively	O
regulates	O
upstream	O
kinases	O
such	O
as	O
Syk	B-Protein
and	O
Zap	B-Protein
-	I-Protein
70	I-Protein
[	O
4	O
]	O
[	O
5	O
]	O
.	O

Cbl	B-Protein
-	I-Protein
b	I-Protein
,	O
a	O
homologue	O
of	O
Cbl	O
,	O
is	O
widely	O
expressed	O
in	O
many	O
tissues	O
and	O
cells	O
including	O
hematopoietic	O
cells	O
[	O
6	O
]	O
[	O
7	O
]	O
.	O

Cbl	B-Protein
-	I-Protein
b	I-Protein
undergoes	O
rapid	O
tyrosine	O
phosphorylation	O
upon	O
stimulation	O
of	O
the	O
TCR	O
and	O
cytokine	O
receptors	O
[	O
8	O
]	O
[	O
9	O
]	O
.	O

The	O
role	O
of	O
Cbl	B-Protein
-	I-Protein
b	I-Protein
is	O
unclear	O
,	O
however	O
.	O

Here	O
,	O
we	O
show	O
that	O
overexpression	O
of	O
Cbl	B-Protein
-	I-Protein
b	I-Protein
in	O
T	O
cells	O
induced	O
the	O
constitutive	O
activation	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
.	O

A	O
loss	O
-	O
of	O
-	O
function	O
mutation	O
in	O
Cbl	B-Protein
-	I-Protein
b	I-Protein
disrupted	O
the	O
interaction	O
between	O
Cbl	B-Protein
-	I-Protein
b	I-Protein
and	O
Zap	B-Protein
-	I-Protein
70	I-Protein
and	O
nearly	O
completely	O
abrogated	O
the	O
Cbl	B-Protein
-	I-Protein
b	I-Protein
-	O
mediated	O
activation	O
of	O
NFAT	O
.	O

Unlike	O
the	O
proposed	O
role	O
of	O
Cbl	O
as	O
a	O
negative	O
regulator	O
,	O
our	O
results	O
suggest	O
that	O
the	O
Cbl	O
homologue	O
Cbl	B-Protein
-	I-Protein
b	I-Protein
has	O
a	O
positive	O
role	O
in	O
T	O
-	O
cell	O
signaling	O
,	O
most	O
likely	O
via	O
a	O
direct	O
interaction	O
with	O
the	O
upstream	O
kinase	O
Zap	B-Protein
-	I-Protein
70	I-Protein
.	O

Detection	O
of	O
intracellular	O
phosphorylated	O
STAT	B-Protein
-	I-Protein
1	I-Protein
by	O
flow	O
cytometry	O
.	O

We	O
have	O
applied	O
flow	O
cytometry	O
to	O
the	O
investigation	O
of	O
interferon	B-Protein
-	I-Protein
gamma	I-Protein
activation	O
of	O
human	O
monocytes	O
.	O

This	O
approach	O
uses	O
monoclonal	O
antibodies	O
that	O
distinguish	O
between	O
the	O
native	O
and	O
phosphorylated	O
forms	O
of	O
STAT	B-Protein
-	I-Protein
1	I-Protein
.	O

It	O
enables	O
rapid	O
and	O
quantitative	O
assessment	O
of	O
STAT	B-Protein
-	I-Protein
1	I-Protein
phosphorylation	O
on	O
a	O
discrete	O
cell	O
basis	O
and	O
is	O
both	O
more	O
sensitive	O
and	O
less	O
time	O
consuming	O
than	O
immunoblotting	O
.	O

Furthermore	O
,	O
it	O
allows	O
for	O
discrimination	O
between	O
a	O
mixture	O
of	O
cells	O
that	O
differ	O
in	O
their	O
response	O
to	O
interferon	B-Protein
-	I-Protein
gamma	I-Protein
.	O

This	O
approach	O
should	O
allow	O
for	O
the	O
evaluation	O
of	O
different	O
intracellular	O
signaling	O
pathways	O
using	O
a	O
combination	O
of	O
monoclonal	O
reagents	O
that	O
are	O
specific	O
for	O
native	O
and	O
activation	O
modified	O
proteins	O
.	O

Application	O
of	O
this	O
form	O
of	O
testing	O
should	O
prove	O
valuable	O
in	O
screening	O
for	O
signaling	O
defects	O
in	O
selected	O
patients	O
with	O
recurrent	O
infections	O
.	O

In	O
addition	O
,	O
this	O
technique	O
should	O
permit	O
dissection	O
of	O
a	O
full	O
range	O
of	O
cellular	O
signaling	O
pathways	O
at	O
the	O
protein	O
level	O
.	O

Glucocorticoid	O
hormone	O
suppression	O
of	O
human	O
neutrophil	O
-	O
mediated	O
tumor	O
cell	O
cytostasis	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
investigated	O
the	O
effect	O
of	O
glucocorticoid	O
hormones	O
on	O
neutrophil	O
-	O
mediated	O
tumor	O
cell	O
cytostasis	O
and	O
found	O
that	O
hydrocortisone	O
and	O
a	O
synthetic	O
hormone	O
,	O
dexamethasone	O
(	O
Dex	O
)	O
,	O
inhibited	O
cytostasis	O
in	O
the	O
presence	O
or	O
absence	O
of	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
.	O

The	O
effect	O
of	O
Dex	O
was	O
completely	O
reversed	O
by	O
a	O
glucocorticoid	B-Protein
receptor	I-Protein
antagonist	O
,	O
RU38486	O
.	O

To	O
clarify	O
the	O
underlying	O
mechanisms	O
,	O
we	O
examined	O
effects	O
of	O
Dex	O
on	O
the	O
binding	O
avidity	O
of	O
beta2	B-Protein
integrin	I-Protein
on	O
the	O
neutrophil	O
surface	O
and	O
how	O
these	O
might	O
in	O
turn	O
affect	O
neutrophil	O
-	O
to	O
-	O
tumor	O
cell	O
binding	O
.	O

Dex	O
was	O
found	O
to	O
inhibit	O
these	O
neutrophil	O
properties	O
,	O
and	O
RU38486	O
completely	O
suppressed	O
both	O
forms	O
of	O
Dex	O
inhibition	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
suggest	O
that	O
glucocorticoid	O
hormone	O
inhibition	O
of	O
neutrophil	O
-	O
mediated	O
tumor	O
cell	O
cytostasis	O
is	O
at	O
least	O
partially	O
due	O
to	O
a	O
lowering	O
of	O
the	O
ligand	O
binding	O
avidity	O
of	O
beta2	B-Protein
integrin	I-Protein
on	O
the	O
neutrophil	O
surface	O
.	O

Abnormalities	O
of	O
cyclic	O
adenosine	O
monophosphate	O
signaling	O
in	O
platelets	O
from	O
untreated	O
patients	O
with	O
bipolar	O
disorder	O
.	O

BACKGROUND	O
:	O
Abnormalities	O
in	O
the	O
cyclic	O
adenosine	O
monophosphate	O
(	O
cAMP	O
)	O
-	O
dependent	O
phosphorylation	O
system	O
have	O
been	O
recently	O
reported	O
in	O
patients	O
with	O
bipolar	O
disorder	O
.	O

We	O
evaluated	O
the	O
immunoreactivity	O
of	O
the	O
regulatory	O
and	O
catalytic	O
subunits	O
of	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
(	O
protein	O
kinase	O
A	O
)	O
and	O
1	O
of	O
its	O
substrates	O
,	O
Rap1	B-Protein
,	O
in	O
platelets	O
from	O
untreated	O
euthymic	O
,	O
manic	O
,	O
and	O
depressed	O
patients	O
with	O
bipolar	O
disorder	O
and	O
healthy	O
subjects	O
.	O

METHODS	O
:	O
Platelets	O
were	O
collected	O
from	O
112	O
drug	O
-	O
free	O
patients	O
with	O
bipolar	O
disorder	O
(	O
52	O
euthymic	O
,	O
29	O
depressed	O
,	O
and	O
31	O
manic	O
)	O
and	O
62	O
healthy	O
subjects	O
.	O

The	O
levels	O
of	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
and	O
Rap1	B-Protein
were	O
assessed	O
by	O
Western	O
blot	O
analysis	O
,	O
immunostaining	O
,	O
and	O
computer	O
-	O
assisted	O
imaging	O
.	O

RESULTS	O
:	O
The	O
immunolabeling	O
of	O
the	O
catalytic	O
subunit	O
of	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
was	O
significantly	O
different	O
among	O
groups	O
(	O
P	O
<	O
.	O
001	O
)	O
,	O
with	O
higher	O
values	O
in	O
untreated	O
depressed	O
and	O
manic	O
patients	O
with	O
bipolar	O
disorder	O
compared	O
with	O
untreated	O
euthymic	O
patients	O
with	O
bipolar	O
disorder	O
and	O
healthy	O
subjects	O
.	O

No	O
significant	O
differences	O
were	O
found	O
in	O
the	O
immunolabeling	O
of	O
the	O
regulatory	O
subunits	O
(	O
type	O
I	O
and	O
type	O
II	O
)	O
of	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
.	O

The	O
immunolabeling	O
of	O
Rap1	B-Protein
was	O
significantly	O
higher	O
(	O
P	O
<	O
.	O
001	O
)	O
in	O
untreated	O
euthymic	O
,	O
depressed	O
,	O
and	O
manic	O
patients	O
than	O
in	O
healthy	O
persons	O
.	O

CONCLUSIONS	O
:	O
Levels	O
of	O
Rap1	B-Protein
and	O
the	O
catalytic	O
subunit	O
of	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
are	O
altered	O
in	O
the	O
platelets	O
of	O
bipolar	O
patients	O
.	O

These	O
findings	O
may	O
provide	O
clues	O
toward	O
understanding	O
the	O
involvement	O
of	O
cAMP	O
signaling	O
in	O
the	O
pathogenesis	O
of	O
bipolar	O
disorder	O
.	O

Lineage	O
-	O
specific	O
activation	O
of	O
STAT3	B-Protein
by	O
interferon	B-Protein
-	I-Protein
gamma	I-Protein
in	O
human	O
neutrophils	O
.	O

Binding	O
of	O
interferon	B-Protein
-	I-Protein
gamma	I-Protein
(	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
)	O
to	O
its	O
heterodimeric	O
receptor	O
induces	O
activation	O
of	O
the	O
tyrosine	O
kinases	O
JAK1	B-Protein
and	O
JAK2	B-Protein
followed	O
by	O
tyrosine	O
phosphorylation	O
of	O
STAT1alpha	B-Protein
.	O

Selective	O
activation	O
of	O
STAT1alpha	B-Protein
at	O
the	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
receptor	O
is	O
achieved	O
by	O
specific	O
interaction	O
between	O
a	O
cytosolic	O
tyrosine	O
motif	O
including	O
Y440	O
in	O
the	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
receptor	I-Protein
alpha	I-Protein
-	I-Protein
chain	I-Protein
and	O
the	O
SH2	O
domain	O
of	O
STAT1alpha	B-Protein
.	O

We	O
demonstrate	O
that	O
,	O
in	O
addition	O
to	O
STAT1alpha	B-Protein
,	O
STAT3	B-Protein
is	O
also	O
activated	O
by	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
in	O
human	O
neutrophils	O
.	O

The	O
activation	O
of	O
STAT3	B-Protein
was	O
not	O
found	O
in	O
human	O
eosinophils	O
,	O
monocytes	O
,	O
and	O
HL	O
-	O
60	O
cells	O
,	O
although	O
the	O
STAT3	B-Protein
protein	O
was	O
expressed	O
in	O
these	O
cells	O
.	O

The	O
cell	O
type	O
-	O
specific	O
activation	O
of	O
STAT3	B-Protein
by	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
was	O
also	O
observed	O
in	O
neutrophils	O
that	O
are	O
differentiated	O
in	O
vitro	O
from	O
human	O
CD34	B-Protein
+	O
hematopoietic	O
stem	O
cells	O
.	O

These	O
results	O
indicate	O
that	O
a	O
single	O
cytokine	O
receptor	O
can	O
activate	O
different	O
STAT	O
family	O
members	O
in	O
a	O
cell	O
-	O
specific	O
manner	O
,	O
which	O
might	O
result	O
in	O
cell	O
-	O
specific	O
gene	O
transcription	O
.	O

Analysis	O
of	O
the	O
modulation	O
of	O
transcriptional	O
activity	O
in	O
myelopoiesis	O
and	O
leukemogenesis	O
.	O

Acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
is	O
still	O
associated	O
with	O
a	O
mortality	O
of	O
60	O
to	O
80	O
%	O
.	O

AML	O
is	O
characterized	O
by	O
a	O
block	O
in	O
myeloid	O
differentiation	O
.	O

The	O
transcription	O
factors	O
PU	B-Protein
.	I-Protein
1	I-Protein
and	O
C	B-Protein
/	I-Protein
EBPalpha	I-Protein
are	O
responsible	O
for	O
normal	O
myeloid	O
differentiation	O
from	O
stem	O
cells	O
to	O
monocytes	O
or	O
granulocytes	O
.	O

In	O
particular	O
,	O
PU	B-Protein
.	I-Protein
1	I-Protein
induces	O
expression	O
of	O
the	O
macrophage	B-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	I-Protein
(	O
M	B-Protein
-	I-Protein
CSF	I-Protein
)	O
receptor	O
and	O
the	O
development	O
of	O
monocytes	O
,	O
whereas	O
C	B-Protein
/	I-Protein
EBPalpha	I-Protein
increases	O
the	O
expression	O
of	O
the	O
granulocyte	B-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	I-Protein
(	I-Protein
G	I-Protein
-	I-Protein
CSF	I-Protein
)	I-Protein
receptor	I-Protein
and	O
leads	O
to	O
mature	O
granulocytes	O
.	O

In	O
AML	O
,	O
chromosomal	O
aberrations	O
result	O
in	O
oncoproteins	O
such	O
as	O
AML1	B-Protein
/	O
ETO	O
,	O
PML	B-Protein
/	O
RARalpha	B-Protein
,	O
or	O
activated	O
Ras	O
,	O
which	O
can	O
deregulate	O
genes	O
important	O
for	O
normal	O
myelopoiesis	O
.	O

Thus	O
,	O
AML1	B-Protein
/	O
ETO	O
can	O
bind	O
to	O
the	O
transcription	O
factor	O
C	B-Protein
/	I-Protein
EBPalpha	I-Protein
,	O
inhibit	O
C	B-Protein
/	I-Protein
EBPalpha	I-Protein
-	O
dependent	O
transcription	O
,	O
and	O
block	O
granulocytic	O
differentiation	O
.	O

However	O
,	O
AML1	B-Protein
/	O
ETO	O
can	O
also	O
synergize	O
with	O
the	O
transcription	O
factor	O
AML1	B-Protein
to	O
enhance	O
the	O
activity	O
of	O
the	O
M	B-Protein
-	I-Protein
CSF	I-Protein
receptor	O
promoter	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
PML	B-Protein
/	O
RARalpha	B-Protein
fusion	O
protein	O
causes	O
transcriptional	O
repression	O
by	O
recruiting	O
the	O
nuclear	O
corepressor	O
(	O
N	O
-	O
CoR	O
)	O
histone	O
deacetylase	O
complex	O
to	O
the	O
DNA	O
,	O
which	O
results	O
in	O
decreased	O
histone	O
acetylation	O
and	O
a	O
repressive	O
chromatin	O
organization	O
.	O

Here	O
we	O
describe	O
methods	O
to	O
investigate	O
whether	O
and	O
how	O
signaling	O
agonists	O
induce	O
myeloid	O
differentiation	O
and	O
how	O
oncoproteins	O
might	O
cause	O
AML	O
by	O
modulating	O
the	O
activity	O
of	O
transcription	O
factors	O
that	O
are	O
pivotal	O
for	O
normal	O
myeloid	O
development	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Impaired	O
binding	O
of	O
a	O
DQ2	B-Protein
and	O
DQ8	B-Protein
-	O
binding	O
HSV	O
VP16	O
peptide	O
to	O
a	O
DQA1	O
*	O
0501	O
/	O
DQB1	O
*	O
0302	O
trans	O
class	O
II	O
heterodimer	O
.	O

DQalpha	B-Protein
and	O
DQbeta	B-Protein
trans	O
heterodimeric	O
HLA	O
-	O
DQ	O
molecules	O
form	O
in	O
individuals	O
heterozygous	O
for	O
the	O
DQ2	O
and	O
DQ8	O
specificities	O
.	O

Unique	O
functions	O
and	O
disease	O
associations	O
have	O
been	O
postulated	O
for	O
such	O
trans	O
-	O
dimers	O
,	O
which	O
may	O
be	O
different	O
from	O
cis	O
-	O
encoded	O
DQ	O
molecules	O
encoded	O
by	O
the	O
corresponding	O
haplotypes	O
.	O

We	O
analyzed	O
the	O
ability	O
of	O
the	O
trans	O
-	O
dimer	O
encoded	O
by	O
HLA	O
-	O
DQA1	O
*	O
0501	O
/	O
DQB1	O
*	O
0302	O
to	O
bind	O
a	O
peptide	O
antigen	O
which	O
interacts	O
with	O
DQ	O
molecules	O
encoded	O
by	O
both	O
parental	O
haplotypes	O
.	O

Markedly	O
impaired	O
binding	O
was	O
observed	O
,	O
consistent	O
with	O
both	O
the	O
use	O
of	O
different	O
anchor	O
residues	O
and	O
with	O
changes	O
in	O
levels	O
of	O
DQ	O
cis	O
-	O
dimer	O
availability	O
for	O
peptide	O
binding	O
interactions	O
.	O

MDS1	B-Protein
/	O
EVI1	B-Protein
enhances	O
TGF	B-Protein
-	I-Protein
beta1	I-Protein
signaling	O
and	O
strengthens	O
its	O
growth	O
-	O
inhibitory	O
effect	O
but	O
the	O
leukemia	O
-	O
associated	O
fusion	O
protein	O
AML1	B-Protein
/	O
MDS1	B-Protein
/	O
EVI1	B-Protein
,	O
product	O
of	O
the	O
t	O
(	O
3	O
;	O
21	O
)	O
,	O
abrogates	O
growth	O
-	O
inhibition	O
in	O
response	O
to	O
TGF	B-Protein
-	I-Protein
beta1	I-Protein
.	O

MDS1	B-Protein
/	O
EVI1	B-Protein
,	O
located	O
on	O
chromosome	O
3	O
band	O
q26	O
,	O
encodes	O
a	O
zinc	O
-	O
finger	O
DNA	O
-	O
binding	O
transcription	O
activator	O
not	O
detected	O
in	O
normal	O
hematopoietic	O
cells	O
but	O
expressed	O
in	O
several	O
normal	O
tissues	O
.	O

MDS1	B-Protein
/	O
EVI1	B-Protein
is	O
inappropriately	O
activated	O
in	O
myeloid	O
leukemias	O
following	O
chromosomal	O
rearrangements	O
involving	O
band	O
3q26	O
.	O

The	O
rearrangements	O
lead	O
either	O
to	O
gene	O
truncation	O
,	O
and	O
to	O
expression	O
of	O
the	O
transcription	O
repressor	O
EVI1	B-Protein
,	O
as	O
seen	O
in	O
the	O
t	O
(	O
3	O
;	O
3	O
)	O
(	O
q21	O
;	O
q26	O
)	O
and	O
inv	O
(	O
3	O
)	O
(	O
q21q26	O
)	O
,	O
or	O
to	O
gene	O
fusion	O
,	O
as	O
seen	O
in	O
the	O
t	O
(	O
3	O
;	O
21	O
)	O
(	O
q26	O
;	O
q22	O
)	O
which	O
results	O
in	O
the	O
fusion	O
protein	O
AML1	B-Protein
/	O
MDS1	B-Protein
/	O
EVI1	B-Protein
.	O

This	O
fusion	O
protein	O
contains	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
the	O
transcription	O
factor	O
AML1	B-Protein
fused	O
in	O
-	O
frame	O
to	O
the	O
entire	O
MDS1	B-Protein
/	O
EVI1	B-Protein
with	O
the	O
exclusion	O
of	O
its	O
first	O
12	O
amino	O
acids	O
.	O

In	O
this	O
report	O
,	O
we	O
have	O
analyzed	O
the	O
response	O
of	O
the	O
hematopoietic	O
precursor	O
cell	O
line	O
32Dcl3	O
,	O
expressing	O
either	O
the	O
normal	O
protein	O
MDS1	B-Protein
/	O
EVI1	B-Protein
or	O
the	O
fusion	O
protein	O
AML1	B-Protein
/	O
MDS1	B-Protein
/	O
EVI1	B-Protein
,	O
to	O
factors	O
that	O
control	O
cell	O
differentiation	O
or	O
cell	O
replication	O
.	O

The	O
32Dcl3	O
cells	O
are	O
IL	B-Protein
-	I-Protein
3	I-Protein
-	O
dependent	O
for	O
growth	O
and	O
they	O
differentiate	O
into	O
granulocytes	O
when	O
exposed	O
to	O
G	B-Protein
-	I-Protein
CSF	I-Protein
.	O

They	O
are	O
growth	O
-	O
inhibited	O
by	O
TGF	B-Protein
-	I-Protein
beta1	I-Protein
.	O

We	O
show	O
that	O
whereas	O
the	O
expression	O
of	O
MDS1	B-Protein
/	O
EVI1	B-Protein
has	O
no	O
effect	O
on	O
granulocytic	O
differentiation	O
induced	O
by	O
G	B-Protein
-	I-Protein
CSF	I-Protein
,	O
expression	O
of	O
AML1	B-Protein
/	O
MDS1	B-Protein
/	O
EVI1	B-Protein
blocks	O
differentiation	O
resulting	O
in	O
cell	O
death	O
.	O

This	O
effect	O
is	O
similar	O
to	O
that	O
previously	O
described	O
by	O
others	O
for	O
32Dcl3	O
cells	O
that	O
express	O
transgenic	O
Evil	B-Protein
.	O

Furthermore	O
,	O
we	O
show	O
that	O
whereas	O
the	O
expression	O
of	O
the	O
fusion	O
protein	O
AML1	B-Protein
/	O
MDS1	B-Protein
/	O
EVI1	B-Protein
completely	O
abrogates	O
the	O
growth	O
-	O
inhibitory	O
effect	O
of	O
TGF	B-Protein
-	I-Protein
beta1	I-Protein
and	O
allows	O
32Dcl3	O
cells	O
to	O
proliferate	O
,	O
expression	O
of	O
the	O
normal	O
protein	O
MDS1	B-Protein
/	O
EVI1	B-Protein
has	O
the	O
opposite	O
effect	O
,	O
and	O
it	O
strengthens	O
the	O
response	O
of	O
cells	O
to	O
the	O
growth	O
-	O
inhibitory	O
effect	O
of	O
TGF	B-Protein
-	I-Protein
beta1	I-Protein
.	O

By	O
using	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
,	O
we	O
also	O
show	O
that	O
EVI1	B-Protein
(	O
contained	O
in	O
its	O
entirety	O
in	O
MDS1	B-Protein
/	O
EVI1	B-Protein
and	O
AML1	B-Protein
/	O
MDS1	B-Protein
/	O
EVI1	B-Protein
)	O
physically	O
interacts	O
with	O
SMAD3	B-Protein
,	O
which	O
is	O
an	O
intracellular	O
mediator	O
of	O
TGF	B-Protein
-	I-Protein
beta1	I-Protein
signaling	O
.	O

Finally	O
,	O
we	O
have	O
correlated	O
the	O
response	O
of	O
the	O
cells	O
to	O
G	B-Protein
-	I-Protein
CSF	I-Protein
or	O
TGF	B-Protein
-	I-Protein
beta1	I-Protein
with	O
the	O
ability	O
of	O
the	O
normal	O
and	O
fusion	O
proteins	O
to	O
activate	O
or	O
repress	O
promoters	O
which	O
they	O
can	O
directly	O
regulate	O
by	O
binding	O
to	O
the	O
promoter	O
site	O
.	O

We	O
propose	O
that	O
mutations	O
of	O
MDS1	B-Protein
/	O
EVI1	B-Protein
either	O
by	O
gene	O
truncation	O
resulting	O
in	O
the	O
transcription	O
repressor	O
EVI1	B-Protein
or	O
by	O
gene	O
fusion	O
to	O
AML1	B-Protein
lead	O
to	O
an	O
altered	O
cellular	O
response	O
to	O
growth	O
and	O
differentiation	O
factors	O
that	O
could	O
result	O
in	O
leukemic	O
transformation	O
.	O

The	O
different	O
response	O
of	O
myeloid	O
cells	O
ectopically	O
expressing	O
the	O
normal	O
or	O
the	O
fusion	O
protein	O
to	O
G	B-Protein
-	I-Protein
CSF	I-Protein
and	O
TGF	B-Protein
-	I-Protein
beta1	I-Protein
could	O
depend	O
on	O
the	O
different	O
transactivation	O
properties	O
of	O
these	O
proteins	O
resulting	O
in	O
divergent	O
expression	O
of	O
downstream	O
genes	O
regulated	O
by	O
the	O
two	O
proteins	O
.	O

Interferon	O
-	O
alpha	O
induction	O
of	O
STATs1	B-Protein
,	O
-	B-Protein
3	I-Protein
DNA	O
binding	O
and	O
growth	O
arrest	O
is	O
independent	O
of	O
Lck	B-Protein
and	O
active	O
mitogen	O
-	O
activated	O
kinase	O
in	O
T	O
cells	O
.	O

Type	O
I	O
interferons	O
(	O
IFNs	O
)	O
are	O
a	O
family	O
of	O
cytokines	O
that	O
have	O
antiviral	O
and	O
antiproliferative	O
effects	O
.	O

Data	O
regarding	O
the	O
processes	O
by	O
which	O
these	O
cytokines	O
transduce	O
signals	O
from	O
the	O
cell	O
membrane	O
to	O
the	O
nucleus	O
are	O
becoming	O
increasingly	O
complex	O
.	O

The	O
most	O
characterized	O
pathway	O
is	O
via	O
JAK	O
-	O
STAT	O
signaling	O
.	O

Previous	O
studies	O
established	O
a	O
potential	O
role	O
for	O
the	O
Src	O
-	O
family	O
kinase	O
Lck	B-Protein
in	O
JAK	O
-	O
STAT	O
signaling	O
.	O

Therefore	O
,	O
this	O
study	O
was	O
designed	O
to	O
analyze	O
the	O
role	O
of	O
Lck	B-Protein
in	O
IFN	O
-	O
alpha	O
signaling	O
by	O
using	O
the	O
Jurkat	O
,	O
JCam	O
(	O
an	O
Lck	B-Protein
-	O
defective	O
cell	O
line	O
derived	O
from	O
Jurkat	O
)	O
,	O
and	O
JCam	O
/	O
Lck	B-Protein
(	O
JCam	O
cells	O
with	O
Lck	B-Protein
restored	O
)	O
.	O

The	O
results	O
show	O
that	O
IFN	O
-	O
alpha	O
can	O
induce	O
MAPK	O
activity	O
,	O
but	O
only	O
in	O
cells	O
containing	O
Lck	B-Protein
.	O

Furthermore	O
,	O
STATs1	B-Protein
and	O
-	B-Protein
3	I-Protein
are	O
effectively	O
phosphorylated	O
and	O
activated	O
to	O
bind	O
DNA	O
in	O
the	O
absence	O
of	O
Lck	B-Protein
expression	O
in	O
IFN	O
-	O
alpha	O
-	O
treated	O
cells	O
.	O

Finally	O
,	O
the	O
results	O
demonstrate	O
that	O
IFN	O
-	O
alpha	O
exerts	O
an	O
antiproliferative	O
effect	O
in	O
all	O
three	O
cell	O
lines	O
.	O

These	O
data	O
indicate	O
that	O
Lck	B-Protein
and	O
active	O
MAPK	O
do	O
not	O
affect	O
IFN	O
-	O
alpha	O
-	O
induced	O
growth	O
arrest	O
or	O
induction	O
of	O
STAT1s1	O
and	O
-	O
3	O
DNA	O
binding	O
ability	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

T	O
helper	O
differentiation	O
proceeds	O
through	O
Stat1	B-Protein
-	O
dependent	O
,	O
Stat4	B-Protein
-	O
dependent	O
and	O
Stat4	B-Protein
-	O
independent	O
phases	O
.	O

Much	O
of	O
our	O
focus	O
in	O
understanding	O
Th1	O
/	O
Th2	O
development	O
has	O
been	O
on	O
the	O
signals	O
delivered	O
by	O
IL	O
-	O
12	O
and	O
IL	B-Protein
-	I-Protein
4	I-Protein
as	O
final	O
determinants	O
of	O
terminal	O
T	O
cell	O
differentiation	O
.	O

Because	O
extinction	O
of	O
IL	O
-	O
12	O
signaling	O
in	O
early	O
Th2	O
development	O
could	O
potentially	O
be	O
important	O
in	O
imprinting	O
a	O
more	O
permanent	O
Th2	O
phenotype	O
on	O
a	O
population	O
of	O
T	O
cells	O
,	O
we	O
have	O
also	O
examined	O
various	O
parameters	O
regulating	O
the	O
IL	O
-	O
12	O
signaling	O
pathway	O
.	O

Whereas	O
IL	B-Protein
-	I-Protein
4	I-Protein
appears	O
to	O
repress	O
functional	O
IL	O
-	O
12	O
signaling	O
through	O
inhibition	O
of	O
IL	B-Protein
-	I-Protein
12R	I-Protein
beta	I-Protein
2	I-Protein
expression	O
,	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
in	O
the	O
mouse	O
,	O
and	O
IFN	O
-	O
alpha	O
in	O
the	O
human	O
appear	O
to	O
induce	O
IL	B-Protein
-	I-Protein
12R	I-Protein
beta	I-Protein
2	I-Protein
expression	O
and	O
promote	O
IL	O
-	O
12	O
responsiveness	O
.	O

We	O
propose	O
that	O
Th1	O
development	O
can	O
be	O
considered	O
in	O
two	O
stages	O
,	O
capacitance	O
and	O
development	O
.	O

Capacitance	O
would	O
simply	O
involve	O
expression	O
of	O
IL	B-Protein
-	I-Protein
12R	I-Protein
beta	I-Protein
1	I-Protein
and	O
beta	B-Protein
2	I-Protein
subunits	O
,	O
regulated	O
by	O
TCR	O
,	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
IFNs	O
.	O

The	O
second	O
stage	O
,	O
development	O
,	O
we	O
propose	O
is	O
the	O
true	O
IL	O
-	O
12	O
induced	O
developmental	O
stage	O
,	O
involving	O
expression	O
of	O
Stat4	B-Protein
inducible	O
proteins	O
.	O

In	O
the	O
human	O
,	O
this	O
may	O
also	O
occur	O
via	O
IFN	O
-	O
alpha	O
,	O
which	O
is	O
able	O
to	O
activate	O
Stat4	B-Protein
.	O

It	O
is	O
perhaps	O
possible	O
that	O
all	O
of	O
Stat4	B-Protein
actions	O
on	O
Th1	O
development	O
may	O
be	O
exert	O
directly	O
by	O
Stat4	B-Protein
at	O
the	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
gene	O
,	O
however	O
we	O
suggest	O
that	O
,	O
more	O
likely	O
,	O
Stat4	B-Protein
may	O
act	O
to	O
induce	O
Th1	O
development	O
through	O
the	O
induction	O
of	O
other	O
non	O
-	O
cytokine	O
genes	O
,	O
whose	O
stable	O
expression	O
maintains	O
the	O
transcriptional	O
state	O
of	O
a	O
Th1	O
cell	O
.	O

1	O
,	O
25	O
-	O
Dihydroxyvitamin	O
D3	O
induces	O
differentiation	O
of	O
a	O
retinoic	O
acid	O
-	O
resistant	O
acute	O
promyelocytic	O
leukemia	O
cell	O
line	O
(	O
UF	O
-	O
1	O
)	O
associated	O
with	O
expression	O
of	O
p21	B-Protein
(	O
WAF1	B-Protein
/	O
CIP1	B-Protein
)	O
and	O
p27	B-Protein
(	O
KIP1	B-Protein
)	O
.	O

Retinoic	O
acid	O
(	O
RA	O
)	O
resistance	O
is	O
a	O
serious	O
problem	O
for	O
patients	O
with	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
who	O
are	O
receiving	O
all	O
-	O
trans	O
RA	O
.	O

However	O
,	O
the	O
mechanisms	O
and	O
strategies	O
to	O
overcome	O
RA	O
resistance	O
by	O
APL	O
cells	O
are	O
still	O
unclear	O
.	O

The	O
biologic	O
effects	O
of	O
RA	O
are	O
mediated	O
by	O
two	O
distinct	O
families	O
of	O
transcriptional	O
factors	O
:	O
RA	O
receptors	O
(	O
RARs	O
)	O
and	O
retinoid	O
X	O
receptors	O
(	O
RXRs	O
)	O
.	O

RXRs	O
heterodimerize	O
with	O
1	B-Protein
,	I-Protein
25	I-Protein
-	I-Protein
dihydroxyvitamin	I-Protein
D3	I-Protein
[	I-Protein
1	I-Protein
,	I-Protein
25	I-Protein
(	I-Protein
OH	I-Protein
)	I-Protein
2D3	I-Protein
]	I-Protein
receptor	I-Protein
(	O
VDR	B-Protein
)	O
,	O
enabling	O
their	O
efficient	O
transcriptional	O
activation	O
.	O

The	O
cyclin	O
-	O
dependent	O
kinase	O
(	O
cdk	O
)	O
inhibitor	O
p21	B-Protein
(	O
WAF1	B-Protein
/	O
CIP1	B-Protein
)	O
has	O
a	O
vitamin	O
D3	O
-	O
responsive	O
element	O
(	O
VDRE	O
)	O
in	O
its	O
promoter	O
,	O
and	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
enhances	O
the	O
expression	O
of	O
p21	B-Protein
(	O
WAF1	B-Protein
/	O
CIP1	B-Protein
)	O
and	O
induces	O
differentiation	O
of	O
selected	O
myeloid	O
leukemic	O
cell	O
lines	O
.	O

We	O
have	O
recently	O
established	O
a	O
novel	O
APL	O
cell	O
line	O
(	O
UF	O
-	O
1	O
)	O
with	O
features	O
of	O
RA	O
resistance	O
.	O

1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
can	O
induce	O
growth	O
inhibition	O
and	O
G1	O
arrest	O
of	O
UF	O
-	O
1	O
cells	O
,	O
resulting	O
in	O
differentiation	O
of	O
these	O
cells	O
toward	O
granulocytes	O
.	O

This	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
-	O
induced	O
G1	O
arrest	O
is	O
enhanced	O
by	O
all	O
-	O
trans	O
RA	O
.	O

Also	O
,	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
(	O
10	O
(	O
-	O
10	O
)	O
to	O
10	O
(	O
-	O
7	O
)	O
mol	O
/	O
L	O
)	O
in	O
combination	O
with	O
RA	O
markedly	O
inhibits	O
cellular	O
proliferation	O
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

Associated	O
with	O
these	O
findings	O
,	O
the	O
levels	O
of	O
p21	B-Protein
(	O
WAF1	B-Protein
/	O
CIP1	B-Protein
)	O
and	O
p27	B-Protein
(	O
KIP1	B-Protein
)	O
mRNA	O
and	O
protein	O
increased	O
in	O
these	O
cells	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
p21	B-Protein
(	O
WAF1	B-Protein
/	O
CIP1	B-Protein
)	O
and	O
p27	B-Protein
(	O
KIP1	B-Protein
)	O
mRNA	O
and	O
protein	O
increased	O
in	O
these	O
cells	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
p21	B-Protein
(	O
WAF1	B-Protein
/	O
CIP1	B-Protein
)	O
and	O
p27	B-Protein
(	O
KIP1	B-Protein
)	O
transcripts	O
were	O
induced	O
after	O
6	O
hours	O
'	O
exposure	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
and	O
then	O
decreased	O
to	O
basal	O
levels	O
over	O
48	O
hours	O
.	O

Western	O
blot	O
experiments	O
showed	O
that	O
p21	B-Protein
(	O
WAF1	B-Protein
/	O
CIP1	B-Protein
)	O
protein	O
levels	O
increased	O
and	O
became	O
detectable	O
after	O
12	O
hours	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
treatment	O
and	O
induction	O
of	O
p27	B-Protein
(	O
KIP1	B-Protein
)	O
protein	O
was	O
much	O
more	O
gradual	O
and	O
sustained	O
in	O
UF	O
-	O
1	O
cells	O
.	O

Interestingly	O
,	O
the	O
combination	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
and	O
RA	O
markedly	O
enhanced	O
the	O
levels	O
of	O
p27	B-Protein
(	O
KIP1	B-Protein
)	O
transcript	O
and	O
protein	O
as	O
compared	O
with	O
levels	O
induced	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
alone	O
.	O

In	O
addition	O
,	O
exogenous	O
p27	B-Protein
(	O
KIP1	B-Protein
)	O
expression	O
can	O
enhance	O
the	O
level	O
of	O
CD11b	B-Protein
antigen	O
in	O
myeloid	O
leukemic	O
cells	O
.	O

In	O
contrast	O
,	O
RA	O
alone	O
can	O
induce	O
G1	O
arrest	O
of	O
UF	O
-	O
1	O
cells	O
;	O
however	O
,	O
it	O
did	O
not	O
result	O
in	O
an	O
increase	O
of	O
p21	B-Protein
(	O
WAF1	B-Protein
/	O
CIP1	B-Protein
)	O
and	O
p27	B-Protein
(	O
KIP1	B-Protein
)	O
transcript	O
and	O
protein	O
expression	O
in	O
RA	O
-	O
resistant	O
cells	O
.	O

Taken	O
together	O
,	O
we	O
conclude	O
that	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
induces	O
increased	O
expression	O
of	O
cdk	O
inhibitors	O
,	O
which	O
mediates	O
a	O
G1	O
arrest	O
,	O
and	O
this	O
may	O
be	O
associated	O
with	O
differentiation	O
of	O
RA	O
-	O
resistant	O
UF	O
-	O
1	O
cells	O
toward	O
mature	O
granulocytes	O
.	O

Human	O
immunodeficiency	O
virus	O
-	O
associated	O
Hodgkin	O
'	O
s	O
disease	O
derives	O
from	O
post	O
-	O
germinal	O
center	O
B	O
cells	O
.	O

Human	O
immunodeficiency	O
virus	O
-	O
associated	O
Hodgkin	O
'	O
s	O
disease	O
(	O
HIV	O
-	O
HD	O
)	O
displays	O
several	O
peculiarities	O
when	O
compared	O
with	O
HD	O
of	O
the	O
general	O
population	O
.	O

These	O
include	O
overrepresentation	O
of	O
clinically	O
aggressive	O
histologic	O
types	O
and	O
frequent	O
infection	O
of	O
Reed	O
-	O
Sternberg	O
(	O
RS	O
)	O
cells	O
by	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
.	O

Recently	O
,	O
we	O
have	O
reported	O
that	O
the	O
histogenesis	O
of	O
HD	O
of	O
the	O
general	O
population	O
may	O
be	O
assessed	O
by	O
monitoring	O
the	O
expression	O
pattern	O
of	O
BCL	B-Protein
-	I-Protein
6	I-Protein
,	O
a	O
transcription	O
factor	O
expressed	O
in	O
germinal	O
center	O
(	O
GC	O
)	O
B	O
cells	O
,	O
and	O
of	O
CD138	B-Protein
/	O
syndecan	B-Protein
-	I-Protein
1	I-Protein
(	O
syn	B-Protein
-	I-Protein
1	I-Protein
)	O
,	O
a	O
proteoglycan	O
associated	O
with	O
post	O
-	O
GC	O
,	O
terminal	O
B	O
-	O
cell	O
differentiation	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
applied	O
these	O
two	O
markers	O
to	O
the	O
study	O
of	O
HIV	O
-	O
HD	O
histogenesis	O
and	O
correlated	O
their	O
expression	O
status	O
to	O
the	O
virologic	O
features	O
of	O
this	O
disease	O
.	O

We	O
have	O
found	O
that	O
RS	O
cells	O
of	O
all	O
histologic	O
categories	O
of	O
HIV	O
-	O
HD	O
consistently	O
display	O
the	O
BCL	B-Protein
-	I-Protein
6	I-Protein
(	O
-	O
)	O
/	O
syn	B-Protein
-	I-Protein
1	I-Protein
(	O
+	O
)	O
phenotype	O
and	O
thus	O
reflect	O
post	O
-	O
GC	O
B	O
cells	O
.	O

Although	O
BCL	B-Protein
-	I-Protein
6	I-Protein
(	O
-	O
)	O
/	O
syn	B-Protein
-	I-Protein
1	I-Protein
(	O
+	O
)	O
RS	O
cells	O
of	O
HIV	O
-	O
HD	O
express	O
CD40	B-Protein
,	O
they	O
are	O
not	O
surrounded	O
by	O
CD40	B-Protein
ligand	I-Protein
-	O
positive	O
(	O
CD40L	B-Protein
+	O
)	O
reactive	O
T	O
lymphocytes	O
,	O
which	O
,	O
in	O
HD	O
of	O
the	O
general	O
population	O
,	O
are	O
thought	O
to	O
regulate	O
the	O
disease	O
phenotype	O
through	O
CD40	B-Protein
/	O
CD40L	B-Protein
interactions	O
.	O

Conversely	O
,	O
RS	O
cells	O
of	O
virtually	O
all	O
HIV	O
-	O
HD	O
express	O
the	O
EBV	O
-	O
encoded	O
latent	B-Protein
membrane	I-Protein
protein	I-Protein
1	I-Protein
(	O
LMP1	B-Protein
)	O
,	O
which	O
,	O
being	O
functionally	O
homologous	O
to	O
CD40	B-Protein
,	O
may	O
contribute	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
the	O
modulation	O
of	O
the	O
HIV	O
-	O
HD	O
phenotype	O
.	O

Interferon	B-Protein
-	I-Protein
beta	I-Protein
mediates	O
stromal	O
cell	O
rescue	O
of	O
T	O
cells	O
from	O
apoptosis	O
.	O

The	O
resolution	O
of	O
immune	O
responses	O
is	O
characterized	O
by	O
extensive	O
apoptosis	O
of	O
activated	O
T	O
cells	O
.	O

However	O
,	O
to	O
generate	O
and	O
maintain	O
immunological	O
memory	O
,	O
some	O
antigen	O
-	O
specific	O
T	O
cells	O
must	O
survive	O
and	O
revert	O
to	O
a	O
resting	O
G0	O
/	O
G1	O
state	O
.	O

Cytokines	O
that	O
bind	O
to	O
the	O
common	O
gamma	O
chain	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
receptor	O
promote	O
the	O
survival	O
of	O
T	O
cell	O
blasts	O
,	O
but	O
also	O
induce	O
proliferation	O
.	O

In	O
contrast	O
,	O
soluble	O
factors	O
secreted	O
by	O
stromal	O
cells	O
induce	O
Tcell	O
survival	O
in	O
a	O
resting	O
G0	O
/	O
G1	O
state	O
.	O

We	O
now	O
report	O
that	O
interferon	B-Protein
-	I-Protein
beta	I-Protein
is	O
the	O
principal	O
mediator	O
of	O
stromal	O
cell	O
-	O
mediated	O
Tcell	O
rescue	O
from	O
apoptosis	O
.	O

Interferon	O
-	O
alpha	O
and	O
-	O
beta	O
promote	O
the	O
reversion	O
of	O
blast	O
Tcells	O
to	O
a	O
resting	O
G0	O
/	O
G1	O
configuration	O
with	O
all	O
the	O
characteristic	O
features	O
of	O
stromal	O
cell	O
rescue	O
;	O
such	O
as	O
high	O
Bcl	B-Protein
-	I-Protein
XL	I-Protein
expression	O
and	O
low	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
.	O

Type	O
I	O
interferons	O
and	O
stromal	O
cells	O
stimulate	O
apparently	O
identical	O
signaling	O
pathways	O
,	O
leading	O
to	O
STAT	B-Protein
-	I-Protein
1	I-Protein
activation	O
.	O

We	O
also	O
show	O
that	O
this	O
mechanism	O
may	O
play	O
a	O
fundamental	O
role	O
in	O
the	O
persistence	O
of	O
T	O
cells	O
at	O
sites	O
of	O
chronic	O
inflammation	O
;	O
suggesting	O
that	O
chronic	O
inflammation	O
is	O
an	O
aberrant	O
consequence	O
of	O
immunological	O
memory	O
.	O

Glucocorticoids	O
promote	O
nonphlogistic	O
phagocytosis	O
of	O
apoptotic	O
leukocytes	O
.	O

Phagocyte	O
recognition	O
,	O
uptake	O
,	O
and	O
nonphlogistic	O
degradation	O
of	O
neutrophils	O
and	O
other	O
leukocytes	O
undergoing	O
apoptosis	O
promote	O
the	O
resolution	O
of	O
inflammation	O
.	O

This	O
study	O
assessed	O
the	O
effects	O
of	O
anti	O
-	O
inflammatory	O
glucocorticoids	O
on	O
this	O
leukocyte	O
clearance	O
mechanism	O
.	O

Pretreatment	O
of	O
"	O
semimature	O
"	O
5	O
-	O
day	O
human	O
monocyte	O
-	O
derived	O
macrophages	O
(	O
M	O
phi	O
)	O
for	O
24	O
h	O
with	O
methylprednisolone	O
,	O
dexamethasone	O
,	O
and	O
hydrocortisone	O
,	O
but	O
not	O
the	O
nonglucocorticoid	O
steroids	O
aldosterone	O
,	O
estradiol	O
,	O
and	O
progesterone	O
,	O
potentiated	O
phagocytosis	O
of	O
apoptotic	O
neutrophils	O
.	O

These	O
effects	O
were	O
specific	O
in	O
that	O
the	O
potentiated	O
phagocytosis	O
of	O
apoptotic	O
neutrophils	O
was	O
completely	O
blocked	O
by	O
the	O
glucocorticoid	B-Protein
receptor	I-Protein
antagonist	O
RU38486	O
,	O
and	O
glucocorticoids	O
did	O
not	O
promote	O
5	O
-	O
day	O
M	O
phi	O
ingestion	O
of	O
opsonized	O
erythrocytes	O
.	O

Similar	O
glucocorticoid	O
-	O
mediated	O
potentiation	O
was	O
observed	O
with	O
5	O
-	O
day	O
M	O
phi	O
uptake	O
of	O
alternative	O
apoptotic	O
"	O
targets	O
"	O
(	O
eosinophils	O
and	O
Jurkat	O
T	O
cells	O
)	O
and	O
in	O
uptake	O
of	O
apoptotic	O
neutrophils	O
by	O
alternative	O
phagocytes	O
(	O
human	O
glomerular	O
mesangial	O
cells	O
and	O
murine	O
M	O
phi	O
elicited	O
into	O
the	O
peritoneum	O
or	O
derived	O
from	O
bone	O
marrow	O
)	O
.	O

Importantly	O
,	O
methylprednisolone	O
-	O
mediated	O
enhancement	O
of	O
the	O
uptake	O
of	O
apoptotic	O
neutrophils	O
did	O
not	O
trigger	O
the	O
release	O
of	O
the	O
chemokines	O
IL	B-Protein
-	I-Protein
8	I-Protein
and	O
monocyte	B-Protein
chemoattractant	I-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
.	O

Furthermore	O
,	O
longer	O
-	O
term	O
potentiation	O
by	O
methylprednisolone	O
was	O
observed	O
in	O
maturing	O
human	O
monocyte	O
-	O
derived	O
M	O
phi	O
,	O
with	O
greater	O
increases	O
in	O
5	O
-	O
day	O
M	O
phi	O
uptake	O
of	O
apoptotic	O
cells	O
being	O
observed	O
the	O
earlier	O
glucocorticoids	O
were	O
added	O
during	O
monocyte	O
maturation	O
into	O
M	O
phi	O
.	O

We	O
conclude	O
that	O
potentiation	O
of	O
nonphlogistic	O
clearance	O
of	O
apoptotic	O
leukocytes	O
by	O
phagocytes	O
is	O
a	O
hitherto	O
unrecognized	O
property	O
of	O
glucocorticoids	O
that	O
has	O
potential	O
implications	O
for	O
therapies	O
aimed	O
at	O
promoting	O
the	O
resolution	O
of	O
inflammatory	O
diseases	O
.	O

Glucocorticoid	O
-	O
induced	O
cell	O
death	O
requires	O
autoinduction	O
of	O
glucocorticoid	B-Protein
receptor	I-Protein
expression	O
in	O
human	O
leukemic	O
T	O
cells	O
.	O

In	O
contrast	O
to	O
the	O
negative	O
autoregulation	O
of	O
glucocorticoid	B-Protein
receptor	I-Protein
(	O
GR	B-Protein
)	O
expression	O
seen	O
in	O
most	O
cells	O
and	O
tissues	O
,	O
GR	B-Protein
expression	O
is	O
positively	O
autoregulated	O
in	O
human	O
leukemic	O
T	O
cells	O
and	O
in	O
other	O
cells	O
sensitive	O
to	O
glucocorticoid	O
-	O
induced	O
cell	O
death	O
.	O

To	O
determine	O
whether	O
positive	O
autoregulation	O
is	O
a	O
necessary	O
component	O
of	O
glucocorticoid	O
-	O
induced	O
cell	O
death	O
,	O
a	O
wild	O
-	O
type	O
GR	B-Protein
gene	O
under	O
the	O
control	O
of	O
a	O
tetracycline	O
-	O
regulated	O
promoter	O
was	O
stably	O
transfected	O
into	O
glucocorticoid	O
-	O
resistant	O
cells	O
lacking	O
endogenous	O
functional	O
receptor	O
.	O

Transfectants	O
grown	O
in	O
the	O
presence	O
of	O
tetracycline	O
contained	O
about	O
15	O
,	O
000	O
receptors	O
/	O
cell	O
,	O
a	O
value	O
approximately	O
equal	O
to	O
basal	O
level	O
GR	B-Protein
expression	O
in	O
glucocorticoid	O
-	O
sensitive	O
6TG1	O
.	O
1	O
cells	O
before	O
steroid	O
treatment	O
.	O

Under	O
these	O
conditions	O
,	O
dexamethasone	O
had	O
a	O
minimal	O
effect	O
on	O
cell	O
growth	O
,	O
elicited	O
little	O
internucleosomal	O
DNA	O
fragmentation	O
,	O
and	O
induced	O
no	O
cell	O
cycle	O
perturbation	O
.	O

In	O
the	O
absence	O
of	O
tetracycline	O
,	O
GR	B-Protein
mRNA	O
and	O
protein	O
expression	O
increased	O
2	O
-	O
3	O
-	O
fold	O
,	O
and	O
cells	O
expressed	O
48	O
,	O
000	O
receptors	O
,	O
a	O
level	O
nearly	O
equivalent	O
to	O
that	O
present	O
in	O
6TG1	O
.	O
1	O
cells	O
after	O
18	O
h	O
of	O
autoinduction	O
.	O

Under	O
these	O
conditions	O
,	O
dexamethasone	O
markedly	O
inhibited	O
cell	O
growth	O
,	O
caused	O
G1	O
arrest	O
,	O
and	O
induced	O
significant	O
internucleosomal	O
DNA	O
fragmentation	O
.	O

These	O
studies	O
therefore	O
suggest	O
that	O
basal	O
level	O
GR	B-Protein
expression	O
is	O
inadequate	O
to	O
mediate	O
glucocorticoid	O
-	O
induced	O
apoptosis	O
in	O
glucocorticoid	O
-	O
sensitive	O
T	O
cells	O
and	O
that	O
positive	O
autoregulation	O
is	O
a	O
necessary	O
component	O
of	O
this	O
process	O
.	O

Jeg	O
-	O
3	O
human	O
choriocarcinoma	O
-	O
induced	O
immunosuppression	O
:	O
downregulation	O
of	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
,	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
receptor	I-Protein
alpha	I-Protein
-	I-Protein
chain	I-Protein
,	O
and	O
its	O
Jak	O
/	O
Stat	O
signaling	O
pathway	O
.	O

PROBLEM	O
:	O
The	O
mechanisms	O
of	O
the	O
immunosuppressive	O
and	O
immunosuppression	O
-	O
inducing	O
capacities	O
of	O
Jeg	O
-	O
3	O
human	O
choriocarcinoma	O
cell	O
line	O
supernatants	O
(	O
HCSs	O
)	O
are	O
not	O
yet	O
completely	O
understood	O
.	O

The	O
influence	O
on	O
interleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
-	I-Protein
2	I-Protein
,	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
interferon	B-Protein
(	I-Protein
IFN	I-Protein
)	I-Protein
-	I-Protein
gamma	I-Protein
production	O
;	O
IL	O
-	O
2	O
receptor	O
(	O
IL	O
-	O
2R	O
)	O
alpha	O
-	O
,	O
beta	O
-	O
,	O
and	O
gamma	O
-	O
chain	O
;	O
and	O
the	O
signaling	O
pathway	O
molecules	O
Janus	B-Protein
kinase	I-Protein
(	I-Protein
Jak	I-Protein
)	I-Protein
1	I-Protein
,	O
Jak3	B-Protein
,	O
signal	B-Protein
transducers	I-Protein
and	I-Protein
activators	I-Protein
of	I-Protein
transcription	I-Protein
(	I-Protein
Stat	I-Protein
)	I-Protein
1	I-Protein
,	O
Stat3	B-Protein
,	O
and	O
Stat5	B-Protein
should	O
be	O
investigated	O
.	O

METHOD	O
OF	O
STUDY	O
:	O
For	O
assessment	O
of	O
IL	O
production	O
,	O
whole	O
peripheral	O
venous	O
blood	O
from	O
healthy	O
donors	O
was	O
stimulated	O
with	O
phorbol	O
-	O
myristate	O
-	O
acetate	O
and	O
ionomycine	O
.	O

Secretion	O
of	O
ILs	O
was	O
blocked	O
with	O
monensine	O
.	O

Intracellular	O
ILs	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
.	O

For	O
IL	O
-	O
2R	O
and	O
signaling	O
pathway	O
molecule	O
analysis	O
,	O
peripheral	O
blood	O
lymphocytes	O
were	O
stimulated	O
with	O
phytohemagglutinin	B-Protein
(	O
PHA	B-Protein
)	O
.	O

IL	O
-	O
2R	O
chains	O
were	O
measured	O
by	O
flow	O
cytometry	O
,	O
and	O
Jaks	O
/	O
Stats	O
by	O
sodium	O
dodecyl	O
sulfate	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
)	O
and	O
Western	O
blot	O
.	O

RESULTS	O
:	O
Phorbol	O
-	O
myristate	O
-	O
acetate	O
and	O
ionomycine	O
strongly	O
increase	O
the	O
percent	O
-	O
age	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
+	O
cells	O
;	O
an	O
additional	O
50	O
%	O
HCSs	O
significantly	O
suppresses	O
the	O
percentage	O
to	O
,	O
or	O
below	O
the	O
level	O
of	O
unstimulated	O
cells	O
.	O

IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
is	O
strongly	O
decreased	O
by	O
HCSs	O
in	O
some	O
cases	O
,	O
but	O
not	O
in	O
others	O
.	O

PHA	B-Protein
stimulates	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	I-Protein
-	I-Protein
,	O
beta	B-Protein
-	I-Protein
,	O
and	O
gamma	B-Protein
-	I-Protein
chain	I-Protein
expression	O
and	O
their	O
signaling	O
pathway	O
molecules	O
Jak1	B-Protein
,	O
Jak3	B-Protein
,	O
Stat1	B-Protein
,	O
Stat3	B-Protein
,	O
and	O
Stat5	B-Protein
.	O

50	O
%	O
HCS	O
downregulates	O
the	O
alpha	O
-	O
chain	O
and	O
slightly	O
upregulates	O
the	O
beta	O
-	O
chain	O
.	O

Jak1	B-Protein
,	O
Jak3	B-Protein
,	O
Stat1	B-Protein
,	O
Stat3	B-Protein
,	O
and	O
Stat5	B-Protein
expression	O
is	O
suppressed	O
approximately	O
to	O
,	O
or	O
below	O
the	O
level	O
of	O
unstimulated	O
cells	O
.	O

CONCLUSIONS	O
:	O
HCS	O
forcefully	O
blocks	O
the	O
production	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
;	O
the	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	I-Protein
-	I-Protein
chain	I-Protein
;	O
and	O
Jak1	B-Protein
,	O
Jak3	B-Protein
,	O
Stat1	B-Protein
,	O
Stat3	B-Protein
,	O
and	O
Stat5	B-Protein
expression	O
.	O

The	O
observed	O
phenomena	O
might	O
be	O
caused	O
by	O
downregulation	O
of	O
an	O
IL	O
-	O
2R	O
regulation	O
gene	O
,	O
and	O
might	O
play	O
a	O
key	O
role	O
in	O
the	O
expansion	O
of	O
choriocarcinoma	O
,	O
and	O
possibly	O
in	O
the	O
survival	O
of	O
the	O
fetal	O
allograft	O
.	O

Vitamin	B-Protein
D	I-Protein
receptor	I-Protein
3	O
'	O
-	O
untranslated	O
region	O
polymorphisms	O
:	O
lack	O
of	O
effect	O
on	O
mRNA	O
stability	O
.	O

Allelic	O
variation	O
at	O
the	O
3	O
'	O
-	O
end	O
of	O
the	O
vitamin	B-Protein
D	I-Protein
receptor	I-Protein
(	O
VDR	B-Protein
)	O
gene	O
has	O
been	O
associated	O
with	O
a	O
3	O
-	O
5	O
-	O
fold	O
increased	O
risk	O
of	O
developing	O
prostate	O
cancer	O
and	O
with	O
differences	O
in	O
bone	O
mineralization	O
.	O

This	O
genetic	O
diversity	O
does	O
not	O
alter	O
the	O
VDR	B-Protein
protein	O
structurally	O
,	O
but	O
instead	O
may	O
be	O
a	O
marker	O
(	O
s	O
)	O
of	O
other	O
,	O
nearby	O
polymorphisms	O
that	O
influence	O
message	O
stability	O
or	O
translation	O
.	O

The	O
work	O
reported	O
here	O
was	O
instigated	O
to	O
identify	O
additional	O
VDR	B-Protein
3	O
'	O
-	O
UTR	O
polymorphisms	O
that	O
may	O
have	O
functional	O
significance	O
and	O
to	O
then	O
test	O
whether	O
these	O
genetic	O
variants	O
alter	O
message	O
stability	O
.	O

Initially	O
,	O
four	O
novel	O
,	O
frequently	O
occurring	O
sequence	O
variants	O
were	O
identified	O
that	O
associated	O
with	O
two	O
common	O
haplotypes	O
that	O
were	O
described	O
previously	O
.	O

These	O
common	O
sequence	O
variants	O
were	O
not	O
found	O
within	O
three	O
message	O
-	O
destabilizing	O
elements	O
that	O
we	O
mapped	O
within	O
the	O
3	O
'	O
-	O
UTR	O
of	O
the	O
vitamin	B-Protein
D	I-Protein
receptor	I-Protein
mRNA	O
.	O

Furthermore	O
,	O
the	O
two	O
VDR	B-Protein
3	O
'	O
-	O
UTR	O
haplotypes	O
conferred	O
an	O
identical	O
half	O
-	O
life	O
on	O
a	O
heterologous	O
beta	O
-	O
globin	O
reporter	O
gene	O
,	O
in	O
an	O
in	O
vitro	O
assay	O
.	O

We	O
therefore	O
conclude	O
that	O
common	O
polymorphisms	O
within	O
the	O
VDR	B-Protein
3	O
'	O
-	O
UTR	O
do	O
not	O
influence	O
message	O
stability	O
.	O

[	O
Induction	O
of	O
apoptosis	O
in	O
lymphocytes	O
by	O
glucocorticoids	O
:	O
between	O
physiology	O
and	O
pharmacology	O
]	O

Glucocorticoids	O
are	O
physiological	O
molecules	O
that	O
are	O
also	O
extensively	O
used	O
in	O
clinics	O
as	O
anti	O
-	O
inflammatory	O
,	O
immunosuppressive	O
or	O
anti	O
-	O
tumoral	O
agents	O
.	O

Glucocorticoids	O
can	O
induce	O
apoptosis	O
on	O
normal	O
lymphoid	O
cells	O
and	O
play	O
a	O
key	O
role	O
in	O
the	O
physiology	O
of	O
thymic	O
selection	O
.	O

In	O
clinics	O
these	O
molecules	O
are	O
also	O
used	O
for	O
their	O
potencies	O
in	O
inducing	O
apoptosis	O
of	O
malignant	O
lymphoid	O
cells	O
.	O

Glucocorticoids	O
are	O
mediating	O
their	O
effects	O
after	O
binding	O
to	O
an	O
intracellular	O
receptor	O
belonging	O
to	O
the	O
steroid	O
receptor	O
superfamily	O
:	O
the	O
glucocorticoid	B-Protein
receptor	I-Protein
(	O
GR	B-Protein
)	O
.	O

Once	O
activated	O
,	O
the	O
GR	B-Protein
,	O
can	O
mediate	O
his	O
effects	O
through	O
direct	O
binding	O
on	O
the	O
DNA	O
or	O
via	O
protein	O
/	O
protein	O
interactions	O
with	O
transcription	O
factors	O
.	O

Depending	O
on	O
the	O
type	O
of	O
lymphocytes	O
,	O
the	O
mechanism	O
of	O
apoptosis	O
induced	O
by	O
glucocorticoids	O
fall	O
roughly	O
in	O
two	O
categories	O
:	O
induction	O
of	O
"	O
death	O
genes	O
"	O
by	O
the	O
activated	O
GR	B-Protein
(	O
I	O
kappa	O
B	O
,	O
c	B-Protein
-	I-Protein
jun	I-Protein
)	O
or	O
repression	O
of	O
survival	O
factors	O
(	O
AP	O
-	O
1	O
,	O
c	B-Protein
-	I-Protein
Myc	I-Protein
)	O
.	O

In	O
the	O
case	O
of	O
thymic	O
selection	O
the	O
mechanism	O
is	O
more	O
subtle	O
depending	O
on	O
the	O
mutual	O
repression	O
of	O
Nur77	B-Protein
and	O
GR	B-Protein
.	O

Cleavage	O
of	O
transcription	O
factor	O
SP1	B-Protein
by	O
caspases	O
during	O
anti	O
-	O
IgM	O
-	O
induced	O
B	O
-	O
cell	O
apoptosis	O
.	O

Apoptosis	O
is	O
instrumental	O
in	O
the	O
processes	O
generating	O
the	O
diversity	O
of	O
the	O
B	O
-	O
cell	O
repertoire	O
.	O

Autoreactive	O
B	O
-	O
cells	O
are	O
eliminated	O
by	O
anti	O
-	O
IgM	O
crosslinking	O
after	O
encountering	O
self	O
-	O
antigens	O
,	O
but	O
precise	O
mechanisms	O
leading	O
to	O
B	O
-	O
cell	O
apoptosis	O
are	O
still	O
not	O
well	O
understood	O
.	O

We	O
report	O
here	O
the	O
cleavage	O
of	O
the	O
transcription	O
factor	O
SP1	B-Protein
in	O
the	O
human	O
Burkitt	O
lymphoma	O
cell	O
line	O
BL60	O
during	O
anti	O
-	O
IgM	O
-	O
induced	O
apoptosis	O
.	O

Western	O
blot	O
analysis	O
revealed	O
two	O
cleavage	O
products	O
of	O
approximately	O
68	O
kDa	O
and	O
45	O
kDa	O
after	O
induction	O
of	O
apoptosis	O
.	O

Cleavage	O
could	O
be	O
completely	O
inhibited	O
by	O
zDEVD	O
-	O
fmk	O
,	O
an	O
inhibitor	O
specific	O
for	O
caspase	O
3	O
-	O
like	O
proteases	O
.	O

In	O
-	O
vitro	O
cleavage	O
of	O
recombinant	O
SP1	B-Protein
by	O
recombinant	O
caspase	B-Protein
3	I-Protein
(	O
CPP32	B-Protein
)	O
or	O
caspase	B-Protein
7	I-Protein
(	O
Mch	B-Protein
3	I-Protein
)	O
results	O
in	O
similar	O
cleavage	O
products	O
as	O
those	O
observed	O
in	O
vivo	O
.	O

Recombinant	O
caspase	B-Protein
6	I-Protein
(	O
Mch	B-Protein
2	I-Protein
)	O
primarily	O
generates	O
a	O
68	O
-	O
kDa	O
cleavage	O
product	O
,	O
as	O
observed	O
after	O
calcium	O
ionophore	O
(	O
CaI	O
)	O
induced	O
B	O
-	O
cell	O
apoptosis	O
.	O

In	O
contrast	O
,	O
caspase	B-Protein
1	I-Protein
(	O
ICE	B-Protein
)	O
did	O
not	O
cleave	O
SP1	B-Protein
in	O
vitro	O
.	O

The	O
time	O
course	O
of	O
SP1	B-Protein
cleavage	O
during	O
anti	O
-	O
IgM	O
-	O
induced	O
apoptosis	O
is	O
paralleled	O
by	O
an	O
increase	O
of	O
caspase	O
activity	O
measured	O
by	O
DEVD	O
-	O
p	O
-	O
nitroanilide	O
(	O
DEVD	O
-	O
pNA	O
)	O
cleavage	O
.	O

DNA	O
band	O
-	O
shift	O
assays	O
revealed	O
a	O
decrease	O
in	O
the	O
intensity	O
of	O
the	O
full	O
length	O
SP1	B-Protein
/	O
DNA	O
complex	O
and	O
an	O
increase	O
in	O
the	O
intensity	O
of	O
a	O
smaller	O
complex	O
due	O
to	O
the	O
binding	O
of	O
one	O
SP1	B-Protein
cleavage	O
product	O
.	O

By	O
Edman	O
sequencing	O
we	O
could	O
identify	O
a	O
caspase	B-Protein
3	I-Protein
cleavage	O
site	O
after	O
Asp584	O
(	O
D584AQPQAGR	O
)	O
,	O
generating	O
a	O
22	O
-	O
kDa	O
C	O
-	O
terminal	O
SP1	B-Protein
protein	O
fragment	O
which	O
still	O
contains	O
the	O
DNA	O
binding	O
site	O
.	O

Our	O
results	O
show	O
the	O
cleavage	O
of	O
the	O
human	O
transcription	O
factor	O
SP1	B-Protein
in	O
vivo	O
and	O
in	O
vitro	O
,	O
underlining	O
the	O
central	O
role	O
of	O
caspase	B-Protein
3	I-Protein
-	O
like	O
proteases	O
during	O
the	O
process	O
of	O
anti	O
-	O
IgM	O
-	O
induced	O
apoptosis	O
.	O

Spi	B-Protein
-	I-Protein
C	I-Protein
,	O
a	O
novel	O
Ets	O
protein	O
that	O
is	O
temporally	O
regulated	O
during	O
B	O
lymphocyte	O
development	O
.	O

A	O
novel	O
Ets	O
protein	O
was	O
isolated	O
by	O
yeast	O
one	O
-	O
hybrid	O
screening	O
of	O
a	O
cDNA	O
library	O
made	O
from	O
lipopolysaccharide	O
-	O
stimulated	O
mouse	O
splenic	O
B	O
cells	O
,	O
using	O
the	O
SP6	O
kappa	O
promoter	O
kappaY	O
element	O
as	O
a	O
bait	O
.	O

The	O
novel	O
Ets	O
protein	O
was	O
most	O
closely	O
related	O
to	O
PU	B-Protein
.	I-Protein
1	I-Protein
and	O
Spi	B-Protein
-	I-Protein
B	I-Protein
within	O
the	O
DNA	O
binding	O
Ets	O
domain	O
and	O
was	O
therefore	O
named	O
Spi	B-Protein
-	I-Protein
C	I-Protein
.	O

However	O
,	O
Spi	B-Protein
-	I-Protein
C	I-Protein
may	O
represent	O
a	O
novel	O
subgroup	O
within	O
the	O
Ets	O
protein	O
family	O
,	O
as	O
it	O
differed	O
significantly	O
from	O
Spi	B-Protein
-	I-Protein
B	I-Protein
and	O
PU	B-Protein
.	I-Protein
1	I-Protein
within	O
helix	O
1	O
of	O
the	O
Ets	O
domain	O
.	O

Spi	B-Protein
-	I-Protein
C	I-Protein
was	O
encoded	O
by	O
a	O
single	O
-	O
copy	O
gene	O
that	O
was	O
mapped	O
to	O
chromosome	O
10	O
,	O
region	O
C	O
.	O

Spi	B-Protein
-	I-Protein
C	I-Protein
interacted	O
with	O
DNA	O
similarly	O
to	O
PU	B-Protein
.	I-Protein
1	I-Protein
as	O
judged	O
by	O
methylation	O
interference	O
,	O
band	O
-	O
shift	O
and	O
site	O
selection	O
analysis	O
,	O
and	O
activated	O
transcription	O
of	O
a	O
kappaY	O
element	O
reporter	O
gene	O
upon	O
co	O
-	O
transfection	O
of	O
HeLa	O
cells	O
.	O

Spi	B-Protein
-	I-Protein
C	I-Protein
RNA	O
was	O
expressed	O
in	O
mature	O
B	O
lymphocytes	O
and	O
at	O
lower	O
levels	O
in	O
macrophages	O
.	O

Furthermore	O
,	O
pre	O
-	O
B	O
cell	O
and	O
plasma	O
cell	O
lines	O
were	O
Spi	B-Protein
-	I-Protein
C	I-Protein
-	O
negative	O
,	O
suggesting	O
that	O
Spi	B-Protein
-	I-Protein
C	I-Protein
might	O
be	O
a	O
regulatory	O
molecule	O
during	O
a	O
specific	O
phase	O
of	O
B	O
lymphoid	O
development	O
.	O

Evidence	O
for	O
a	O
polyclonal	O
etiology	O
of	O
palmar	O
fibromatosis	O
.	O

X	O
chromosome	O
inactivation	O
patterns	O
at	O
the	O
androgen	B-Protein
receptor	I-Protein
locus	O
were	O
evaluated	O
to	O
determine	O
clonality	O
in	O
microdissected	O
lesional	O
tissue	O
and	O
in	O
leukocytes	O
from	O
2	O
women	O
with	O
Dupuytren	O
'	O
s	O
disease	O
.	O

The	O
tissue	O
from	O
both	O
patients	O
generated	O
a	O
polyclonal	O
pattern	O
of	O
X	O
chromosome	O
inactivation	O
of	O
the	O
human	O
androgen	B-Protein
receptor	I-Protein
gene	O
.	O

This	O
finding	O
supports	O
a	O
polyclonal	O
reactive	O
process	O
as	O
the	O
underlying	O
etiology	O
for	O
palmar	O
fibromatosis	O
.	O

Transient	O
pseudo	O
-	O
hypoaldosteronism	O
following	O
resection	O
of	O
the	O
ileum	O
:	O
normal	O
level	O
of	O
lymphocytic	O
aldosterone	B-Protein
receptors	I-Protein
outside	O
the	O
acute	O
phase	O
.	O

Pseudo	O
-	O
hypoaldosteronism	O
(	O
PHA	O
)	O
is	O
due	O
to	O
mineralocorticoid	O
resistance	O
and	O
manifests	O
as	O
hyponatremia	O
and	O
hyperkalemia	O
with	O
increased	O
plasma	O
aldosterone	O
levels	O
.	O

It	O
may	O
be	O
familial	O
or	O
secondary	O
to	O
abnormal	O
renal	O
sodium	O
handling	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
54	O
-	O
year	O
-	O
old	O
woman	O
with	O
multifocal	O
cancer	O
of	O
the	O
colon	O
,	O
who	O
developed	O
PHA	O
after	O
subtotal	O
colectomy	O
,	O
ileal	O
resection	O
and	O
jejunostomy	O
.	O

She	O
was	O
treated	O
with	O
6	O
g	O
of	O
salt	O
daily	O
to	O
prevent	O
dehydration	O
,	O
which	O
she	O
stopped	O
herself	O
because	O
of	O
reduced	O
fecal	O
losses	O
.	O

One	O
month	O
later	O
she	O
was	O
admitted	O
with	O
signs	O
of	O
acute	O
adrenal	O
failure	O
,	O
i	O
.	O
e	O
.	O
fatigue	O
,	O
severe	O
nausea	O
,	O
blood	O
pressure	O
of	O
80	O
/	O
60	O
mmHg	O
,	O
extracellular	O
dehydration	O
,	O
hyponatremia	O
(	O
118	O
mmol	O
/	O
l	O
)	O
;	O
hyperkalemia	O
(	O
7	O
.	O
6	O
mmol	O
/	O
l	O
)	O
,	O
increased	O
blood	O
urea	O
nitrogen	O
(	O
BUN	O
)	O
(	O
200	O
mg	O
/	O
dl	O
)	O
and	O
creatininemia	O
(	O
2	O
.	O
5	O
mg	O
/	O
dl	O
)	O
,	O
and	O
decreased	O
plasma	O
bicarbonates	O
level	O
(	O
HCO3	O
-	O
:	O
16	O
mmol	O
/	O
l	O
;	O
N	O
:	O
27	O
-	O
30	O
)	O
.	O

However	O
,	O
the	O
plasma	O
cortisol	O
was	O
high	O
(	O
66	O
microg	O
/	O
100	O
ml	O
at	O
10	O
:	O
00	O
h	O
;	O
N	O
:	O
8	O
-	O
15	O
)	O
and	O
the	O
ACTH	O
was	O
normal	O
(	O
13	O
pg	O
/	O
ml	O
,	O
N	O
:	O
10	O
-	O
60	O
)	O
;	O
there	O
was	O
a	O
marked	O
increase	O
in	O
plasma	O
renin	B-Protein
activity	O
(	O
>	O
37	O
ng	O
/	O
ml	O
/	O
h	O
;	O
N	O
supine	O
<	O
3	O
)	O
,	O
active	O
renin	B-Protein
(	O
869	O
pg	O
/	O
ml	O
;	O
N	O
supine	O
:	O
1	O
.	O
120	O
)	O
,	O
aldosterone	O
(	O
>	O
2000	O
pg	O
/	O
ml	O
;	O
N	O
supine	O
<	O
150	O
)	O
and	O
plasma	O
AVP	O
(	O
20	O
pmol	O
/	O
l	O
;	O
N	O
:	O
0	O
.	O
5	O
-	O
2	O
.	O
5	O
)	O
.	O

The	O
plasma	O
ANH	O
level	O
was	O
38	O
pmol	O
/	O
l	O
(	O
N	O
supine	O
:	O
5	O
-	O
25	O
)	O
.	O

A	O
urinary	O
steroidogram	O
resulted	O
in	O
highly	O
elevated	O
tetrahydrocortisol	O
(	O
THF	O
:	O
13	O
.	O
3	O
mg	O
/	O
24h	O
;	O
N	O
:	O
1	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
8	O
)	O
with	O
no	O
increase	O
in	O
tetrahydrocortisone	O
(	O
THE	O
:	O
3	O
.	O
16	O
mg	O
/	O
24h	O
;	O
N	O
:	O
2	O
.	O
7	O
+	O
/	O
-	O
2	O
.	O
0	O
)	O
excretion	O
,	O
and	O
with	O
low	O
THE	O
/	O
THF	O
(	O
0	O
.	O
24	O
;	O
N	O
:	O
1	O
.	O
87	O
+	O
/	O
-	O
0	O
.	O
36	O
)	O
and	O
alpha	O
THF	O
/	O
THF	O
(	O
0	O
.	O
35	O
;	O
N	O
:	O
0	O
.	O
92	O
+	O
/	O
-	O
0	O
.	O
42	O
)	O
ratios	O
.	O

The	O
number	O
of	O
mineralocorticoid	B-Protein
receptors	I-Protein
in	O
mononuclear	O
leukocytes	O
was	O
in	O
the	O
lower	O
normal	O
range	O
for	O
age	O
,	O
while	O
the	O
number	O
of	O
glucocorticoid	B-Protein
receptors	I-Protein
was	O
reduced	O
.	O

Small	O
-	O
bowel	O
resection	O
in	O
ileostomized	O
patients	O
causes	O
excessive	O
fecal	O
sodium	O
losses	O
and	O
results	O
in	O
chronic	O
sodium	O
depletion	O
with	O
contraction	O
of	O
the	O
plasma	O
volume	O
and	O
severe	O
secondary	O
hyperaldosteronism	O
.	O

Nevertheless	O
,	O
this	O
hyperaldosteronism	O
may	O
be	O
associated	O
with	O
hyponatremia	O
and	O
hyperkalemia	O
suggesting	O
PHA	O
related	O
to	O
the	O
major	O
importance	O
of	O
the	O
colon	O
for	O
the	O
absorption	O
of	O
sodium	O
.	O

In	O
conclusion	O
,	O
this	O
case	O
report	O
emphasizes	O
1	O
)	O
the	O
possibility	O
of	O
a	O
syndrome	O
of	O
acquired	O
PHA	O
with	O
severe	O
hyperkalemia	O
after	O
resection	O
of	O
the	O
ileum	O
and	O
colon	O
responding	O
to	O
oral	O
salt	O
supplementation	O
;	O
2	O
)	O
the	O
major	O
increase	O
in	O
AVP	O
and	O
the	O
small	O
increase	O
in	O
ANH	O
;	O
3	O
)	O
the	O
strong	O
increase	O
in	O
urinary	O
THF	O
with	O
low	O
THE	O
/	O
THF	O
and	O
alpha	O
THF	O
/	O
THF	O
ratios	O
;	O
4	O
)	O
the	O
normal	O
number	O
of	O
lymphocytic	O
mineralocorticoid	B-Protein
receptors	I-Protein
outside	O
the	O
acute	O
episode	O
.	O

In	O
vivo	O
modulation	O
of	O
glucocorticoid	B-Protein
receptor	I-Protein
mRNA	O
by	O
inhaled	O
fluticasone	O
propionate	O
in	O
bronchial	O
mucosa	O
and	O
blood	O
lymphocytes	O
in	O
subjects	O
with	O
mild	O
asthma	O
.	O

BACKGROUND	O
:	O
In	O
vivo	O
regulation	O
of	O
the	O
glucocorticoid	B-Protein
receptor	I-Protein
(	O
GR	B-Protein
)	O
by	O
glucocorticoids	O
provides	O
a	O
means	O
of	O
modulating	O
sensitivity	O
of	O
targeted	O
cells	O
.	O

OBJECTIVE	O
:	O
We	O
sought	O
to	O
determine	O
the	O
in	O
vivo	O
modulation	O
of	O
GR	B-Protein
mRNA	O
expression	O
by	O
fluticasone	O
propionate	O
(	O
FP	O
)	O
in	O
subjects	O
with	O
mild	O
asthma	O
.	O

METHODS	O
:	O
Ten	O
atopic	O
asthmatic	O
subjects	O
were	O
treated	O
with	O
FP	O
250	O
microg	O
twice	O
daily	O
for	O
4	O
weeks	O
.	O

Before	O
and	O
after	O
treatment	O
,	O
the	O
patients	O
underwent	O
fiberoptic	O
bronchoscopy	O
with	O
endobronchial	O
biopsy	O
and	O
sampling	O
of	O
venous	O
blood	O
for	O
measurements	O
of	O
GR	B-Protein
mRNA	O
levels	O
.	O

A	O
solution	O
hybridization	O
assay	O
was	O
used	O
for	O
quantitative	O
analysis	O
of	O
GR	B-Protein
mRNA	O
.	O

In	O
addition	O
,	O
a	O
24	O
-	O
hour	O
urinary	O
cortisol	O
excretion	O
and	O
an	O
adrenocorticotropic	B-Protein
hormone	I-Protein
test	O
before	O
and	O
after	O
treatment	O
with	O
FP	O
were	O
performed	O
.	O

RESULTS	O
:	O
A	O
high	O
interindividual	O
variation	O
in	O
GR	B-Protein
mRNA	O
expression	O
was	O
seen	O
.	O

However	O
,	O
we	O
detected	O
a	O
significant	O
reduction	O
of	O
the	O
GR	B-Protein
mRNA	O
levels	O
in	O
the	O
endobronchial	O
biopsy	O
specimens	O
after	O
FP	O
treatment	O
(	O
36	O
.	O
6	O
+	O
/	O
-	O
23	O
.	O
1	O
and	O
25	O
.	O
0	O
+	O
/	O
-	O
10	O
.	O
9	O
amol	O
GR	B-Protein
mRNA	O
/	O
microg	O
RNA	O
,	O
respectively	O
;	O
P	O
<	O
.	O
01	O
)	O
.	O

In	O
the	O
peripheral	O
blood	O
lymphocytes	O
an	O
even	O
more	O
striking	O
downregulation	O
of	O
the	O
GR	B-Protein
by	O
its	O
cognate	O
ligand	O
was	O
documented	O
(	O
30	O
.	O
3	O
+	O
/	O
-	O
26	O
.	O
5	O
and	O
8	O
.	O
8	O
+	O
/	O
-	O
5	O
amol	O
GR	B-Protein
mRNA	O
/	O
microg	O
RNA	O
,	O
respectively	O
;	O
P	O
<	O
.	O
001	O
)	O
,	O
possibly	O
reflecting	O
differences	O
in	O
glucocorticoid	O
sensitivity	O
between	O
tissues	O
.	O

A	O
small	O
but	O
significant	O
reduction	O
of	O
the	O
24	O
-	O
hour	O
urinary	O
cortisol	O
excretion	O
was	O
observed	O
(	O
233	O
+	O
/	O
-	O
109	O
and	O
157	O
+	O
/	O
-	O
66	O
nmol	O
/	O
L	O
,	O
respectively	O
;	O
P	O
<	O
.	O
01	O
)	O
,	O
whereas	O
the	O
feedback	O
regulation	O
of	O
glucocorticoid	O
synthesis	O
by	O
means	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
as	O
assessed	O
by	O
the	O
adrenocorticotropic	B-Protein
hormone	I-Protein
test	O
remained	O
normal	O
after	O
treatment	O
with	O
FP	O
.	O

CONCLUSION	O
:	O
The	O
results	O
in	O
this	O
study	O
confirm	O
the	O
potency	O
of	O
the	O
inhaled	O
corticosteroid	O
FP	O
and	O
provide	O
evidence	O
for	O
a	O
considerable	O
tissue	O
-	O
specific	O
interindividual	O
variation	O
in	O
the	O
expression	O
of	O
the	O
GR	B-Protein
.	O

p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
mediates	O
signal	O
integration	O
of	O
TCR	O
/	O
CD28	B-Protein
costimulation	O
in	O
primary	O
murine	O
T	O
cells	O
.	O

Optimal	O
T	O
cell	O
activation	O
requires	O
two	O
signals	O
,	O
one	O
generated	O
by	O
TCR	O
and	O
another	O
by	O
the	O
CD28	B-Protein
costimulatory	I-Protein
receptor	I-Protein
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
regulation	O
of	O
costimulation	O
-	O
induced	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
activation	O
in	O
primary	O
mouse	O
T	O
cells	O
.	O

In	O
contrast	O
to	O
that	O
reported	O
for	O
human	O
Jurkat	O
T	O
cells	O
,	O
we	O
found	O
that	O
p38	O
MAPK	O
,	O
but	O
not	O
Jun	O
NH2	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
,	O
is	O
weakly	O
activated	O
upon	O
stimulation	O
with	O
either	O
anti	O
-	O
CD3	O
or	O
anti	O
-	O
CD28	B-Protein
in	O
murine	O
thymocytes	O
and	O
splenic	O
T	O
cells	O
.	O

However	O
,	O
p38	O
MAPK	O
is	O
activated	O
strongly	O
and	O
synergistically	O
by	O
either	O
CD3	O
/	O
CD28	B-Protein
coligation	O
or	O
PMA	O
/	O
Ca2	O
+	O
ionophore	O
stimulation	O
,	O
which	O
mimics	O
TCR	O
-	O
CD3	O
/	O
CD28	B-Protein
-	O
mediated	O
signaling	O
.	O

Activation	O
of	O
p38	O
MAPK	O
correlates	O
closely	O
with	O
the	O
stimulation	O
of	O
T	O
cell	O
proliferation	O
.	O

In	O
contrast	O
,	O
PMA	O
-	O
induced	O
JNK	O
activation	O
is	O
inhibited	O
by	O
Ca2	O
+	O
ionophore	O
.	O

T	O
cell	O
proliferation	O
and	O
production	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
induced	O
by	O
both	O
CD3	O
and	O
CD3	O
/	O
CD28	B-Protein
ligation	O
and	O
the	O
nuclear	O
expression	O
of	O
the	O
c	B-Protein
-	I-Protein
Jun	I-Protein
and	O
ATF	B-Protein
-	I-Protein
2	I-Protein
proteins	O
are	O
each	O
blocked	O
by	O
the	O
p38	O
MAPK	O
inhibitor	O
SB203580	O
.	O

Our	O
findings	O
demonstrate	O
that	O
p38	O
MAPK	O
1	O
)	O
plays	O
an	O
important	O
role	O
in	O
signal	O
integration	O
during	O
costimulation	O
of	O
primary	O
mouse	O
T	O
cells	O
,	O
2	O
)	O
may	O
be	O
involved	O
in	O
the	O
induction	O
of	O
c	B-Protein
-	I-Protein
Jun	I-Protein
activation	O
and	O
augmentation	O
of	O
AP	O
-	O
1	O
transcriptional	O
activity	O
,	O
and	O
3	O
)	O
regulates	O
whether	O
T	O
cells	O
enter	O
a	O
state	O
of	O
functional	O
unresponsiveness	O
.	O

The	O
functional	O
synergy	O
between	O
IL	O
-	O
12	O
and	O
IL	B-Protein
-	I-Protein
2	I-Protein
involves	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
and	O
is	O
associated	O
with	O
the	O
augmentation	O
of	O
STAT	O
serine	O
phosphorylation	O
.	O

IL	O
-	O
12	O
and	O
IL	B-Protein
-	I-Protein
2	I-Protein
can	O
stimulate	O
mitogen	O
-	O
or	O
CD3	O
-	O
activated	O
T	O
cells	O
to	O
proliferate	O
,	O
produce	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
and	O
kill	O
tumor	O
cells	O
.	O

The	O
magnitude	O
of	O
these	O
functional	O
responses	O
is	O
greatly	O
augmented	O
when	O
T	O
cells	O
are	O
activated	O
by	O
the	O
combination	O
of	O
IL	O
-	O
12	O
and	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O

Although	O
peripheral	O
blood	O
T	O
cells	O
are	O
largely	O
unresponsive	O
to	O
these	O
cytokines	O
without	O
prior	O
activation	O
,	O
a	O
small	O
subset	O
of	O
CD8	B-Protein
+	O
T	O
cells	O
(	O
CD8	B-Protein
+	O
CD18bright	O
)	O
is	O
strongly	O
activated	O
by	O
the	O
combination	O
of	O
IL	O
-	O
12	O
and	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O

In	O
this	O
report	O
we	O
show	O
that	O
the	O
functional	O
synergy	O
between	O
IL	O
-	O
12	O
and	O
IL	B-Protein
-	I-Protein
2	I-Protein
in	O
CD8	B-Protein
+	O
CD18bright	O
T	O
cells	O
correlates	O
with	O
the	O
activation	O
of	O
the	O
stress	O
kinases	O
,	O
p38	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinase	O
and	O
stress	O
-	O
activated	O
protein	O
kinase	O
(	O
SAPK	O
)	O
/	O
Jun	O
N	O
-	O
terminal	O
kinase	O
,	O
but	O
not	O
with	O
the	O
activation	O
of	O
the	O
extracellular	O
signal	O
-	O
regulated	O
kinases	O
.	O

The	O
functional	O
synergy	O
between	O
IL	B-Protein
-	I-Protein
2	I-Protein
and	O
IL	O
-	O
12	O
is	O
also	O
associated	O
with	O
a	O
prominent	O
increase	O
in	O
STAT1	B-Protein
and	O
STAT3	B-Protein
serine	O
phosphorylation	O
over	O
that	O
observed	O
with	O
IL	O
-	O
12	O
or	O
IL	B-Protein
-	I-Protein
2	I-Protein
alone	O
.	O

By	O
contrast	O
,	O
STAT	O
tyrosine	O
phosphorylation	O
is	O
not	O
augmented	O
over	O
that	O
seen	O
with	O
either	O
cytokine	O
alone	O
.	O

A	O
specific	O
inhibitor	O
of	O
p38	O
MAP	O
kinase	O
completely	O
inhibits	O
the	O
serine	O
phosphorylation	O
of	O
STAT1	B-Protein
and	O
STAT3	B-Protein
induced	O
by	O
IL	O
-	O
12	O
and	O
IL	B-Protein
-	I-Protein
2	I-Protein
and	O
abrogates	O
the	O
functional	O
synergy	O
between	O
IL	O
-	O
12	O
and	O
IL	B-Protein
-	I-Protein
2	I-Protein
without	O
affecting	O
STAT	O
tyrosine	O
phosphorylation	O
.	O

This	O
suggests	O
that	O
p38	O
MAP	O
kinase	O
may	O
play	O
an	O
important	O
role	O
in	O
regulating	O
STAT	O
serine	O
phosphorylation	O
in	O
response	O
to	O
the	O
combination	O
of	O
IL	O
-	O
12	O
and	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O

Furthermore	O
,	O
these	O
findings	O
indicate	O
that	O
the	O
optimal	O
activation	O
of	O
T	O
cells	O
by	O
IL	O
-	O
12	O
and	O
IL	B-Protein
-	I-Protein
2	I-Protein
may	O
depend	O
on	O
an	O
interaction	O
between	O
the	O
p38	O
MAP	O
kinase	O
and	O
Janus	O
kinase	O
/	O
STAT	O
signaling	O
pathways	O
.	O

Modulation	O
of	O
E2F	O
complexes	O
during	O
G0	O
to	O
S	O
phase	O
transition	O
in	O
human	O
primary	O
B	O
-	O
lymphocytes	O
.	O

The	O
pocket	O
protein	O
-	O
E2F	O
complexes	O
are	O
convergence	O
points	O
for	O
cell	O
cycle	O
signaling	O
.	O

In	O
the	O
present	O
report	O
,	O
we	O
identified	O
and	O
monitored	O
the	O
pocket	O
protein	O
-	O
E2F	O
complexes	O
in	O
human	O
primary	O
B	O
-	O
lymphocytes	O
after	O
activation	O
by	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
.	O

Consistent	O
with	O
previous	O
data	O
from	O
human	O
and	O
mouse	O
fibroblasts	O
and	O
T	O
-	O
lymphocytes	O
,	O
E2F4	B-Protein
and	O
DP1	B-Protein
form	O
the	O
predominant	O
E2F	O
heterodimers	O
both	O
in	O
G0	O
and	O
G1	O
phases	O
of	O
the	O
human	O
B	O
-	O
lymphocyte	O
cell	O
cycle	O
,	O
whereas	O
E2F1	B-Protein
and	O
-	B-Protein
3	I-Protein
are	O
first	O
detected	O
in	O
late	O
G1	O
,	O
and	O
their	O
expression	O
levels	O
increase	O
towards	O
S	O
phase	O
.	O

Intriguingly	O
,	O
the	O
major	O
E2F	O
complex	O
that	O
we	O
detected	O
in	O
quiescent	O
human	O
B	O
-	O
lymphocytes	O
is	O
consisted	O
of	O
pRB	B-Protein
,	O
E2F4	B-Protein
,	O
and	O
DP1	B-Protein
.	O

Though	O
the	O
levels	O
of	O
DP1	B-Protein
and	O
-	B-Protein
2	I-Protein
increase	O
when	O
cells	O
progress	O
from	O
G0	O
to	O
S	O
,	O
the	O
proportion	O
of	O
DP1	B-Protein
to	O
DP2	B-Protein
remains	O
relatively	O
constant	O
during	O
the	O
cell	O
cycle	O
.	O

We	O
also	O
observed	O
an	O
increase	O
in	O
electrophoretic	O
mobility	O
of	O
the	O
predominant	O
E2F	O
components	O
,	O
DP1	B-Protein
and	O
E2F4	B-Protein
,	O
as	O
B	O
-	O
lymphocytes	O
progressed	O
from	O
G0	O
into	O
early	O
G1	O
.	O

This	O
increase	O
in	O
mobility	O
was	O
attributable	O
to	O
dephosphorylation	O
,	O
as	O
lambda	O
phosphatase	O
treatment	O
could	O
convert	O
the	O
slower	O
migrating	O
forms	O
into	O
the	O
corresponding	O
faster	O
mobility	O
forms	O
.	O

We	O
further	O
demonstrated	O
that	O
this	O
change	O
in	O
phosphorylation	O
status	O
correlates	O
with	O
a	O
decrease	O
in	O
DNA	O
binding	O
activity	O
.	O

This	O
modulation	O
of	O
DNA	O
binding	O
activity	O
mediated	O
through	O
the	O
dephosphorylation	O
of	O
DP1	B-Protein
and	O
E2F4	B-Protein
could	O
help	O
to	O
explain	O
the	O
lack	O
of	O
in	O
vivo	O
DNA	O
footprinting	O
in	O
late	O
G1	O
and	O
S	O
phases	O
of	O
gene	O
promoters	O
negatively	O
regulated	O
through	O
E2F	O
sites	O
and	O
suggests	O
a	O
novel	O
mechanism	O
for	O
controlling	O
E2F	O
transcriptional	O
activity	O
during	O
the	O
transition	O
from	O
quiescence	O
to	O
proliferation	O
.	O

Retinoid	O
X	O
receptor	O
(	O
RXR	O
)	O
agonist	O
-	O
induced	O
activation	O
of	O
dominant	O
-	O
negative	O
RXR	O
-	O
retinoic	B-Protein
acid	I-Protein
receptor	I-Protein
alpha403	I-Protein
heterodimers	O
is	O
developmentally	O
regulated	O
during	O
myeloid	O
differentiation	O
.	O

The	O
multiple	O
biologic	O
activities	O
of	O
retinoic	O
acid	O
(	O
RA	O
)	O
are	O
mediated	O
through	O
RAR	O
and	O
retinoid	O
X	O
receptor	O
(	O
RXR	O
)	O
nuclear	O
receptors	O
that	O
interact	O
with	O
specific	O
DNA	O
target	O
sequences	O
as	O
heterodimers	O
(	O
RXR	O
-	O
RAR	O
)	O
or	O
homodimers	O
(	O
RXR	O
-	O
RXR	O
)	O
.	O

RA	O
receptor	O
activation	O
appears	O
critical	O
to	O
regulating	O
important	O
aspects	O
of	O
hematopoiesis	O
,	O
since	O
transducing	O
a	O
COOH	O
-	O
terminally	O
truncated	O
RARalpha	B-Protein
exhibiting	O
dominant	O
-	O
negative	O
activity	O
(	O
RARalpha403	B-Protein
)	O
into	O
normal	O
mouse	O
bone	O
marrow	O
generates	O
hematopoietic	O
growth	O
factor	O
-	O
dependent	O
cell	O
lines	O
frozen	O
at	O
the	O
multipotent	O
progenitor	O
(	O
EML	O
)	O
or	O
committed	O
promyelocyte	O
(	O
MPRO	O
)	O
stages	O
.	O

Nevertheless	O
,	O
relatively	O
high	O
,	O
pharmacological	O
concentrations	O
of	O
RA	O
(	O
1	O
to	O
10	O
&	O
mgr	O
;	O
M	O
)	O
overcome	O
these	O
differentiation	O
blocks	O
and	O
induce	O
terminal	O
granulocytic	O
differentiation	O
of	O
the	O
MPRO	O
promyelocytes	O
while	O
potentiating	O
interleukin	B-Protein
-	I-Protein
3	I-Protein
(	O
IL	B-Protein
-	I-Protein
3	I-Protein
)	O
-	O
induced	O
commitment	O
of	O
EML	O
cells	O
to	O
the	O
granulocyte	O
/	O
monocyte	O
lineage	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
utilized	O
RXR	O
-	O
and	O
RAR	O
-	O
specific	O
agonists	O
and	O
antagonists	O
to	O
determine	O
how	O
RA	O
overcomes	O
the	O
dominant	O
-	O
negative	O
activity	O
of	O
the	O
truncated	O
RARalpha	B-Protein
in	O
these	O
different	O
myeloid	O
developmental	O
stages	O
.	O

Unexpectedly	O
,	O
we	O
observed	O
that	O
an	O
RXR	O
-	O
specific	O
,	O
rather	O
than	O
an	O
RAR	O
-	O
specific	O
,	O
agonist	O
induces	O
terminal	O
granulocytic	O
differentiation	O
of	O
MPRO	O
promyelocytes	O
,	O
and	O
this	O
differentiation	O
is	O
associated	O
with	O
activation	O
of	O
DNA	O
response	O
elements	O
corresponding	O
to	O
RAR	O
-	O
RXR	O
heterodimers	O
rather	O
than	O
RXR	O
-	O
RXR	O
homodimers	O
.	O

This	O
RXR	O
agonist	O
activity	O
is	O
blocked	O
by	O
RAR	O
-	O
specific	O
antagonists	O
,	O
suggesting	O
extensive	O
cross	O
-	O
talk	O
between	O
the	O
partners	O
of	O
the	O
RXR	O
-	O
RARalpha403	B-Protein
heterodimer	O
.	O

In	O
contrast	O
,	O
in	O
the	O
more	O
immature	O
,	O
multipotent	O
EML	O
cells	O
we	O
observed	O
that	O
this	O
RXR	O
-	O
specific	O
agonist	O
is	O
inactive	O
either	O
in	O
potentiating	O
IL	B-Protein
-	I-Protein
3	I-Protein
-	O
mediated	O
commitment	O
of	O
EML	O
cells	O
to	O
the	O
granulocyte	O
lineage	O
or	O
in	O
transactivating	O
RAR	O
-	O
RXR	O
response	O
elements	O
.	O

RA	O
-	O
triggered	O
GALdbd	O
-	O
RARalpha	B-Protein
hybrid	O
activity	O
in	O
these	O
cells	O
indicates	O
that	O
the	O
multipotent	O
EML	O
cells	O
harbor	O
substantial	O
nuclear	O
hormone	O
receptor	O
coactivator	O
activity	O
.	O

However	O
,	O
the	O
histone	O
deacetylase	O
(	O
HDAC	O
)	O
inhibitor	O
trichostatin	O
A	O
readily	O
activates	O
an	O
RXR	O
-	O
RAR	O
reporter	O
construct	O
in	O
the	O
multipotent	O
EML	O
cells	O
but	O
not	O
in	O
the	O
committed	O
MPRO	O
promyelocytes	O
,	O
indicating	O
that	O
differences	O
in	O
HDAC	O
-	O
containing	O
repressor	O
complexes	O
in	O
these	O
two	O
closely	O
related	O
but	O
distinct	O
hematopoietic	O
lineages	O
might	O
account	O
for	O
the	O
differential	O
activation	O
of	O
the	O
RXR	O
-	O
RARalpha403	B-Protein
heterodimers	O
that	O
we	O
observed	O
at	O
these	O
different	O
stages	O
of	O
myeloid	O
development	O
.	O

Bcl	B-Protein
-	I-Protein
6	I-Protein
expression	O
in	O
reactive	O
follicular	O
hyperplasia	O
,	O
follicular	O
lymphoma	O
,	O
and	O
angioimmunoblastic	O
T	O
-	O
cell	O
lymphoma	O
with	O
hyperplastic	O
germinal	O
centers	O
:	O
heterogeneity	O
of	O
intrafollicular	O
T	O
-	O
cells	O
and	O
their	O
altered	O
distribution	O
in	O
the	O
pathogenesis	O
of	O
angioimmunoblastic	O
T	O
-	O
cell	O
lymphoma	O
.	O

BACKGROUND	O
:	O
The	O
Bcl	B-Protein
-	I-Protein
6	I-Protein
gene	O
product	O
,	O
a	O
nuclear	O
phosphoprotein	O
,	O
is	O
expressed	O
independently	O
of	O
Bcl	B-Protein
-	I-Protein
6	I-Protein
gene	O
rearrangement	O
.	O

In	O
lymph	O
nodes	O
,	O
expression	O
of	O
Bcl	B-Protein
-	I-Protein
6	I-Protein
protein	O
is	O
restricted	O
to	O
germinal	O
center	O
(	O
GC	O
)	O
B	O
-	O
cells	O
and	O
10	O
%	O
to	O
15	O
%	O
of	O
CD3	O
/	O
CD4	B-Protein
+	O
intrafollicular	O
T	O
cells	O
.	O

Interfollicular	O
cells	O
are	O
negative	O
for	O
Bcl	B-Protein
-	I-Protein
6	I-Protein
protein	O
,	O
except	O
for	O
rare	O
CD3	O
+	O
/	O
CD4	B-Protein
+	O
T	O
cells	O
.	O

Recently	O
,	O
we	O
reported	O
cases	O
of	O
angioimmunoblastic	O
T	O
-	O
cell	O
lymphoma	O
(	O
AITL	O
)	O
with	O
hyperplastic	O
GCs	O
(	O
AITL	O
/	O
GC	O
)	O
,	O
and	O
observed	O
that	O
borders	O
of	O
enlarged	O
GCs	O
were	O
ill	O
defined	O
,	O
with	O
features	O
suggestive	O
of	O
an	O
outward	O
migration	O
of	O
GC	O
cells	O
to	O
surrounding	O
interfollicular	O
zones	O
.	O

This	O
prompted	O
a	O
study	O
of	O
follicular	O
borders	O
with	O
Bcl	B-Protein
-	I-Protein
6	I-Protein
staining	O
in	O
reactive	O
follicular	O
hyperplasias	O
and	O
follicular	O
lymphomas	O
to	O
compare	O
with	O
AITL	O
/	O
GC	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Formalin	O
-	O
fixed	O
paraffin	O
sections	O
were	O
used	O
for	O
immunostaining	O
of	O
Bcl	B-Protein
-	I-Protein
6	I-Protein
.	O

Six	O
cases	O
of	O
AITL	O
/	O
GC	O
,	O
12	O
nonspecific	O
reactive	O
follicular	O
hyperplasia	O
(	O
FH	O
)	O
,	O
7	O
HIV	O
adenopathy	O
,	O
10	O
follicular	O
lymphoma	O
(	O
FL	O
)	O
,	O
and	O
8	O
typical	O
AITL	O
(	O
ie	O
,	O
AITL	O
without	O
GC	O
)	O
were	O
studied	O
.	O

Double	O
staining	O
for	O
Bcl	B-Protein
-	I-Protein
6	I-Protein
/	O
CD20	B-Protein
,	O
Bcl	B-Protein
-	I-Protein
6	I-Protein
/	O
CD3	O
,	O
and	O
Bcl	B-Protein
-	I-Protein
6	I-Protein
/	O
CD57	B-Protein
was	O
performed	O
in	O
selected	O
cases	O
.	O

RESULTS	O
:	O
In	O
FH	O
and	O
HIV	O
adenopathy	O
,	O
staining	O
for	O
Bcl	B-Protein
-	I-Protein
6	I-Protein
revealed	O
densely	O
populated	O
GCs	O
with	O
well	O
-	O
defined	O
and	O
regular	O
GC	O
borders	O
,	O
whereas	O
Bcl	B-Protein
-	I-Protein
6	I-Protein
+	O
cells	O
were	O
rare	O
in	O
the	O
interfollicular	O
areas	O
.	O

An	O
occasional	O
GC	O
with	O
an	O
ill	O
-	O
defined	O
border	O
was	O
invariably	O
surrounded	O
by	O
a	O
broad	O
mantle	O
zone	O
;	O
those	O
with	O
indistinct	O
mantle	O
zones	O
had	O
well	O
-	O
defined	O
,	O
regular	O
borders	O
.	O

In	O
FL	O
,	O
follicles	O
were	O
densely	O
populated	O
,	O
and	O
their	O
borders	O
were	O
irregular	O
,	O
with	O
some	O
Bcl	B-Protein
-	I-Protein
6	I-Protein
+	O
cells	O
in	O
the	O
interfollicular	O
zones	O
.	O

In	O
AITL	O
/	O
GC	O
,	O
GCs	O
were	O
less	O
dense	O
,	O
GC	O
borders	O
were	O
ill	O
defined	O
and	O
irregular	O
,	O
and	O
the	O
number	O
of	O
interfollicular	O
Bcl	B-Protein
-	I-Protein
6	I-Protein
+	O
cells	O
was	O
markedly	O
increased	O
.	O

Double	O
staining	O
revealed	O
that	O
these	O
interfollicular	O
Bcl	B-Protein
-	I-Protein
6	I-Protein
+	O
cells	O
in	O
AITL	O
/	O
GC	O
were	O
Bcl6	B-Protein
+	O
/	O
CD3	O
+	O
/	O
CD20	B-Protein
-	O
/	O
CD57	B-Protein
-	O
T	O
cells	O
.	O

Moreover	O
,	O
CD3	O
+	O
intrafollicular	O
T	O
cells	O
were	O
depleted	O
in	O
AITL	O
/	O
GC	O
,	O
whereas	O
they	O
were	O
abundant	O
in	O
FH	O
.	O

Intrafollicular	O
CD57	B-Protein
+	O
cells	O
did	O
not	O
stain	O
for	O
Bcl	B-Protein
-	I-Protein
6	I-Protein
,	O
and	O
were	O
also	O
depleted	O
in	O
AITL	O
/	O
GC	O
.	O

In	O
typical	O
AITL	O
,	O
some	O
neoplastic	O
cells	O
were	O
positive	O
for	O
Bcl	B-Protein
-	I-Protein
6	I-Protein
,	O
showing	O
variable	O
degrees	O
of	O
staining	O
.	O

CONCLUSIONS	O
:	O
(	O
1	O
)	O
GCs	O
of	O
AITL	O
/	O
GC	O
differed	O
from	O
those	O
of	O
other	O
reactive	O
follicular	O
hyperplasias	O
and	O
follicular	O
lymphomas	O
,	O
and	O
staining	O
for	O
Bcl	B-Protein
-	I-Protein
6	I-Protein
was	O
useful	O
to	O
discern	O
them	O
.	O

(	O
2	O
)	O
Intrafollicular	O
CD3	O
+	O
T	O
cells	O
,	O
many	O
of	O
which	O
were	O
also	O
positive	O
for	O
Bcl	B-Protein
-	I-Protein
6	I-Protein
,	O
were	O
markedly	O
depleted	O
in	O
AITL	O
/	O
GC	O
,	O
with	O
increased	O
interfollicular	O
Bcl	B-Protein
-	I-Protein
6	I-Protein
+	O
/	O
CD3	O
+	O
cells	O
,	O
suggesting	O
an	O
outward	O
migration	O
of	O
intrafollicular	O
T	O
cells	O
in	O
this	O
condition	O
.	O

(	O
3	O
)	O
Interfollicular	O
Bcl	B-Protein
-	I-Protein
6	I-Protein
+	O
/	O
CD3	O
+	O
cells	O
in	O
AITL	O
/	O
GC	O
were	O
too	O
numerous	O
to	O
be	O
accounted	O
for	O
by	O
migration	O
alone	O
,	O
suggesting	O
local	O
proliferation	O
.	O

(	O
4	O
)	O
Intrafollicular	O
CD57	B-Protein
+	O
cells	O
were	O
negative	O
for	O
Bcl	B-Protein
-	I-Protein
6	I-Protein
,	O
indicating	O
heterogeneity	O
of	O
the	O
intrafollicular	O
T	O
-	O
cell	O
population	O
.	O

(	O
5	O
)	O
Some	O
neoplastic	O
cells	O
in	O
AITL	O
stained	O
for	O
Bcl	B-Protein
-	I-Protein
6	I-Protein
,	O
suggesting	O
up	O
-	O
regulation	O
of	O
Bcl	B-Protein
-	I-Protein
6	I-Protein
expression	O
in	O
this	O
tumor	O
.	O

Differential	O
inhibition	O
of	O
Smad6	B-Protein
and	O
Smad7	B-Protein
on	O
bone	O
morphogenetic	O
protein	O
-	O
and	O
activin	O
-	O
mediated	O
growth	O
arrest	O
and	O
apoptosis	O
in	O
B	O
cells	O
.	O

Smad6	B-Protein
and	O
Smad7	B-Protein
prevent	O
ligand	O
-	O
induced	O
activation	O
of	O
signal	O
-	O
transducing	O
Smad	O
proteins	O
in	O
the	O
transforming	O
growth	O
factor	O
-	O
beta	O
family	O
.	O

Here	O
we	O
demonstrate	O
that	O
both	O
Smad6	B-Protein
and	O
Smad7	B-Protein
are	O
human	B-Protein
bone	I-Protein
morphogenetic	I-Protein
protein	I-Protein
-	I-Protein
2	I-Protein
(	O
hBMP	B-Protein
-	I-Protein
2	I-Protein
)	O
-	O
inducible	O
antagonists	O
of	O
hBMP	B-Protein
-	I-Protein
2	I-Protein
-	O
induced	O
growth	O
arrest	O
and	O
apoptosis	O
in	O
mouse	O
B	O
cell	O
hybridoma	O
HS	O
-	O
72	O
cells	O
.	O

Moreover	O
,	O
we	O
confirmed	O
that	O
the	O
ectopic	O
expressions	O
of	O
Smad6	B-Protein
and	O
Smad7	B-Protein
inhibited	O
the	O
hBMP	B-Protein
-	I-Protein
2	I-Protein
-	O
induced	O
Smad1	B-Protein
/	O
Smad5	B-Protein
phosphorylation	O
.	O

We	O
previously	O
reported	O
that	O
Smad7	B-Protein
is	O
an	O
activin	B-Protein
A	I-Protein
-	O
inducible	O
antagonist	O
of	O
activin	B-Protein
A	I-Protein
-	O
induced	O
growth	O
arrest	O
and	O
apoptosis	O
in	O
HS	O
-	O
72	O
cells	O
.	O

Interestingly	O
,	O
although	O
mRNA	O
expression	O
of	O
Smad6	B-Protein
was	O
induced	O
by	O
activin	B-Protein
A	I-Protein
in	O
HS	O
-	O
72	O
cells	O
,	O
Smad6	B-Protein
showed	O
no	O
antagonistic	O
effect	O
on	O
activin	B-Protein
A	I-Protein
-	O
induced	O
growth	O
arrest	O
and	O
apoptosis	O
.	O

Moreover	O
,	O
we	O
found	O
that	O
the	O
ectopic	O
expression	O
of	O
Smad7	B-Protein
,	O
but	O
not	O
Smad6	B-Protein
,	O
inhibited	O
the	O
activin	B-Protein
A	I-Protein
-	O
induced	O
Smad2	B-Protein
phosphorylation	O
in	O
HS	O
-	O
72	O
cells	O
.	O

Thus	O
,	O
Smad6	B-Protein
and	O
Smad7	B-Protein
exhibit	O
differential	O
inhibitory	O
effects	O
in	O
bone	B-Protein
morphogenetic	I-Protein
protein	I-Protein
-	I-Protein
2	I-Protein
-	O
and	O
activin	B-Protein
A	I-Protein
-	O
mediated	O
signaling	O
in	O
B	O
lineage	O
cells	O
.	O

Transcription	O
factors	O
Sp1	B-Protein
and	O
AP	O
-	O
2	O
mediate	O
induction	O
of	O
acid	O
sphingomyelinase	O
during	O
monocytic	O
differentiation	O
.	O

Cells	O
from	O
the	O
human	O
monocytic	O
leukemia	O
cell	O
line	O
THP	O
-	O
1	O
differentiate	O
towards	O
a	O
macrophage	O
-	O
like	O
phenotype	O
when	O
stimulated	O
with	O
phorbol	O
12	O
-	O
myristate	O
-	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
,	O
1	O
,	O
25	O
-	O
dihydroxy	O
-	O
vitamin	O
D3	O
,	O
and	O
various	O
other	O
agents	O
.	O

We	O
demonstrate	O
here	O
that	O
the	O
expression	O
of	O
the	O
lysosomal	O
enzyme	O
acid	O
sphingomyelinase	O
(	O
ASM	O
;	O
E	O
.	O
C	O
.	O
3	O
.	O
1	O
.	O
4	O
.	O
12	O
)	O
is	O
induced	O
during	O
this	O
process	O
and	O
is	O
strongly	O
elevated	O
in	O
differentiated	O
THP	O
-	O
1	O
cells	O
,	O
as	O
well	O
as	O
in	O
differentiated	O
human	O
mononuclear	O
phagocytes	O
.	O

Using	O
Northern	O
blotting	O
,	O
RNase	O
protection	O
assay	O
,	O
and	O
nuclear	O
run	O
-	O
on	O
analyses	O
,	O
we	O
show	O
that	O
the	O
up	O
-	O
regulation	O
of	O
ASM	O
expression	O
is	O
regulated	O
mainly	O
at	O
the	O
level	O
of	O
transcription	O
and	O
that	O
new	O
protein	O
synthesis	O
is	O
required	O
for	O
enhanced	O
ASM	O
activity	O
.	O

This	O
cell	O
-	O
type	O
specific	O
induction	O
by	O
PMA	O
treatment	O
was	O
further	O
investigated	O
with	O
respect	O
to	O
transcriptional	O
control	O
.	O

A	O
series	O
of	O
5	O
'	O
deletion	O
derivatives	O
of	O
the	O
upstream	O
regulatory	O
region	O
were	O
used	O
in	O
transient	O
transfection	O
assays	O
to	O
identify	O
promoter	O
elements	O
required	O
for	O
basal	O
and	O
inducible	O
gene	O
expression	O
.	O

A	O
PMA	O
responsive	O
element	O
was	O
localized	O
to	O
a	O
region	O
between	O
-	O
319	O
and	O
-	O
219	O
bp	O
upstream	O
of	O
the	O
initiation	O
codon	O
and	O
co	O
-	O
transfections	O
with	O
transcription	O
factor	O
expression	O
plasmids	O
for	O
AP	O
-	O
2	O
and	O
Sp1	B-Protein
resulted	O
in	O
augmented	O
ASM	O
promoter	O
activity	O
,	O
which	O
was	O
abolished	O
when	O
the	O
binding	O
sites	O
for	O
these	O
two	O
factors	O
were	O
deleted	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
supershift	O
assays	O
we	O
demonstrate	O
that	O
this	O
region	O
is	O
specifically	O
bound	O
by	O
Sp1	B-Protein
and	O
AP	O
-	O
2	O
.	O

These	O
factors	O
are	O
present	O
in	O
nuclear	O
extracts	O
prepared	O
from	O
both	O
induced	O
and	O
uninduced	O
THP	O
-	O
1	O
cells	O
.	O

However	O
,	O
the	O
intensity	O
of	O
the	O
complex	O
formed	O
appeared	O
to	O
increase	O
when	O
nuclear	O
extracts	O
from	O
PMA	O
-	O
treated	O
cells	O
were	O
used	O
.	O

From	O
these	O
studies	O
,	O
we	O
conclude	O
that	O
a	O
concerted	O
action	O
of	O
the	O
transcription	O
factors	O
AP	O
-	O
2	O
and	O
Sp1	B-Protein
is	O
essential	O
for	O
the	O
up	O
-	O
regulation	O
of	O
ASM	O
expression	O
during	O
the	O
process	O
of	O
macrophage	O
differentiation	O
.	O

Estrogen	O
and	O
progesterone	O
induction	O
of	O
survival	O
of	O
monoblastoid	O
cells	O
undergoing	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
-	O
induced	O
apoptosis	O
.	O

Induction	O
of	O
apoptosis	O
of	O
mononucleated	O
cells	O
is	O
a	O
physiological	O
process	O
for	O
regulating	O
the	O
intensity	O
of	O
the	O
immune	O
response	O
.	O

The	O
female	O
steroid	O
hormones	O
estrogen	O
(	O
E2	O
)	O
and	O
progesterone	O
(	O
Prog	O
)	O
are	O
known	O
to	O
modulate	O
the	O
reactivity	O
of	O
the	O
immune	O
system	O
;	O
recently	O
it	O
has	O
been	O
demonstrated	O
that	O
they	O
can	O
regulate	O
induction	O
of	O
apoptosis	O
of	O
endothelial	O
cells	O
and	O
osteoblasts	O
.	O

TNF	B-Protein
-	I-Protein
alpha	I-Protein
-	O
mediated	O
induction	O
of	O
apoptosis	O
has	O
been	O
well	O
characterized	O
in	O
myeloid	O
cells	O
.	O

We	O
investigated	O
whether	O
E2	O
and	O
Prog	O
could	O
interfere	O
with	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
-	O
induced	O
apoptosis	O
of	O
the	O
monoblastoid	O
U937	O
cell	O
line	O
.	O

Treatment	O
with	O
E2	O
or	O
Prog	O
increased	O
survival	O
and	O
prevented	O
apoptosis	O
induced	O
by	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
in	O
both	O
undifferentiated	O
and	O
macrophage	O
-	O
like	O
PMA	O
-	O
differentiated	O
U937	O
cells	O
,	O
as	O
assessed	O
by	O
trypan	O
blue	O
exclusion	O
cell	O
counting	O
,	O
thymidine	O
incorporation	O
,	O
AnnexinV	O
labeling	O
,	O
followed	O
by	O
flow	O
cytometry	O
and	O
DNA	O
fragmentation	O
studies	O
.	O

This	O
effect	O
can	O
be	O
associated	O
with	O
the	O
activation	O
of	O
specific	O
hormone	O
receptors	O
,	O
since	O
we	O
observed	O
the	O
expression	O
of	O
the	O
estrogen	O
receptor	O
alpha	O
(	O
ER	B-Protein
-	I-Protein
alpha	I-Protein
)	O
,	O
ER	B-Protein
-	I-Protein
beta	I-Protein
,	O
and	O
progesterone	B-Protein
receptor	I-Protein
(	O
PR	B-Protein
)	O
mRNAs	O
;	O
the	O
ER	B-Protein
-	I-Protein
alpha	I-Protein
protein	O
expression	O
was	O
confirmed	O
by	O
immunocytochemical	O
analysis	O
.	O

In	O
addition	O
,	O
hormone	O
-	O
mediated	O
survival	O
against	O
apoptosis	O
was	O
concentration	O
dependent	O
,	O
reaching	O
the	O
half	O
-	O
maximal	O
effect	O
at	O
10	O
nM	O
and	O
blocked	O
by	O
the	O
ER	O
antagonist	O
ICI	O
182	O
,	O
780	O
in	O
undifferentiated	O
cells	O
,	O
further	O
supporting	O
a	O
receptor	O
-	O
mediated	O
mechanism	O
of	O
cell	O
survival	O
.	O

Other	O
steroid	O
receptor	O
drugs	O
such	O
as	O
Raloxifene	O
,	O
RU486	O
,	O
or	O
the	O
ICI	O
182	O
,	O
780	O
in	O
PMA	O
-	O
differentiated	O
cells	O
displayed	O
agonist	O
activity	O
by	O
preventing	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
-	O
induced	O
apoptosis	O
as	O
efficiently	O
as	O
the	O
hormones	O
alone	O
,	O
providing	O
further	O
evidence	O
to	O
the	O
notion	O
that	O
steroid	O
receptor	O
drugs	O
may	O
manifest	O
agonist	O
or	O
antagonist	O
activities	O
depending	O
on	O
the	O
cellular	O
context	O
in	O
which	O
they	O
are	O
studied	O
.	O

Treatment	O
with	O
E2	O
was	O
also	O
associated	O
with	O
a	O
time	O
-	O
dependent	O
decrease	O
in	O
the	O
mRNA	O
level	O
of	O
the	O
proapoptotic	O
Nip	O
-	O
2	O
protein	O
,	O
supporting	O
the	O
hypothesis	O
that	O
hormone	O
responsiveness	O
of	O
U937	O
cells	O
is	O
mediated	O
by	O
target	O
gene	O
transcription	O
.	O

Together	O
,	O
these	O
results	O
demonstrate	O
that	O
ER	O
and	O
PR	B-Protein
can	O
be	O
activated	O
by	O
endogenous	O
or	O
exogenous	O
ligands	O
to	O
induce	O
a	O
genetic	O
response	O
that	O
impairs	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
-	O
induced	O
apoptosis	O
in	O
U937	O
cells	O
.	O

The	O
data	O
presented	O
here	O
suggest	O
that	O
the	O
female	O
steroid	O
receptors	O
play	O
a	O
role	O
in	O
regulation	O
of	O
the	O
immune	O
response	O
by	O
preventing	O
apoptosis	O
of	O
monoblastoid	O
cells	O
;	O
this	O
effect	O
might	O
have	O
important	O
consequences	O
in	O
the	O
clinical	O
use	O
of	O
steroid	O
receptor	O
drugs	O
.	O

-	O
-	O
Vegeto	O
,	O
E	O
.	O
,	O
Pollio	O
,	O
G	O
.	O
,	O
Pellicciari	O
,	O
C	O
.	O
,	O
Maggi	O
,	O
A	O
.	O

Estrogen	O
and	O
progesterone	O
induction	O
of	O
survival	O
of	O
monoblastoid	O
cells	O
undergoing	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
-	O
inuced	O
apoptosis	O
.	O

Grf40	B-Protein
,	O
A	O
novel	O
Grb2	O
family	O
member	O
,	O
is	O
involved	O
in	O
T	O
cell	O
signaling	O
through	O
interaction	O
with	O
SLP	B-Protein
-	I-Protein
76	I-Protein
and	O
LAT	B-Protein
.	O

We	O
molecularly	O
cloned	O
a	O
new	O
Grb2	O
family	O
member	O
,	O
named	O
Grf40	B-Protein
,	O
containing	O
the	O
common	O
SH3	O
-	O
SH2	O
-	O
SH3	O
motif	O
.	O

Expression	O
of	O
Grf40	B-Protein
is	O
predominant	O
in	O
hematopoietic	O
cells	O
,	O
particularly	O
T	O
cells	O
.	O

Grf40	B-Protein
binds	O
to	O
the	O
SH2	B-Protein
domain	I-Protein
-	I-Protein
containing	I-Protein
leukocyte	I-Protein
protein	I-Protein
of	I-Protein
76	I-Protein
kD	I-Protein
(	O
SLP	B-Protein
-	I-Protein
76	I-Protein
)	O
via	O
its	O
SH3	O
domain	O
more	O
tightly	O
than	O
Grb2	B-Protein
.	O

Incidentally	O
,	O
Grf40	B-Protein
binds	O
to	O
linker	B-Protein
for	I-Protein
activation	I-Protein
of	I-Protein
T	I-Protein
cells	I-Protein
(	O
LAT	B-Protein
)	O
possibly	O
via	O
its	O
SH2	O
domain	O
.	O

Overexpression	O
of	O
wild	O
-	O
type	O
Grf40	B-Protein
in	O
Jurkat	O
cells	O
induced	O
a	O
significant	O
increase	O
of	O
SLP	B-Protein
-	I-Protein
76	I-Protein
-	O
dependent	O
interleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
-	I-Protein
2	I-Protein
promoter	O
and	O
nuclear	O
factor	O
of	O
activated	O
T	O
cell	O
(	O
NF	O
-	O
AT	O
)	O
activation	O
upon	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
stimulation	O
,	O
whereas	O
the	O
COOH	O
-	O
terminal	O
SH3	O
-	O
deleted	O
Grf40	B-Protein
mutant	O
lacked	O
any	O
recognizable	O
increase	O
in	O
IL	B-Protein
-	I-Protein
2	I-Protein
promoter	O
activity	O
.	O

Furthermore	O
,	O
the	O
SH2	O
-	O
deleted	O
Grf40	B-Protein
mutant	O
led	O
to	O
a	O
marked	O
inhibition	O
of	O
these	O
regulatory	O
activities	O
,	O
the	O
effect	O
of	O
which	O
is	O
apparently	O
stronger	O
than	O
that	O
of	O
the	O
SH2	O
-	O
deleted	O
Grb2	B-Protein
mutant	O
.	O

Our	O
data	O
suggest	O
that	O
Grf40	B-Protein
is	O
an	O
adaptor	O
molecule	O
involved	O
in	O
TCR	O
-	O
mediated	O
signaling	O
through	O
a	O
more	O
efficient	O
interaction	O
than	O
Grb2	B-Protein
with	O
SLP	B-Protein
-	I-Protein
76	I-Protein
and	O
LAT	B-Protein
.	O

Signal	O
transduction	O
through	O
interferon	O
-	O
gamma	O
receptor	O
on	O
human	O
eosinophils	O
.	O

BACKGROUND	O
:	O
We	O
reported	O
on	O
the	O
constitutive	O
interferon	O
-	O
gamma	O
receptor	O
(	O
IFN	O
-	O
gammaR	O
)	O
expression	O
on	O
eosinophils	O
.	O

But	O
signal	O
transduction	O
through	O
IFN	O
-	O
gammaR	O
on	O
eosinophils	O
remains	O
to	O
be	O
elucidated	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
involvement	O
of	O
the	O
Jak	O
/	O
Stat	O
pathway	O
in	O
the	O
signaling	O
of	O
eosinophils	O
after	O
IFN	O
-	O
gammaR	O
conjugation	O
by	O
the	O
ligand	O
binding	O
.	O

METHODS	O
:	O
Purified	O
peripheral	O
eosinophils	O
were	O
stimulated	O
with	O
IFN	O
-	O
gamma	O
at	O
37	O
degrees	O
C	O
for	O
1	O
-	O
60	O
min	O
.	O

Tyrosine	O
phosphorylation	O
of	O
IFN	O
-	O
gammaR	O
,	O
Jak1	B-Protein
,	O
Jak2	B-Protein
,	O
and	O
Stat1alpha	B-Protein
was	O
examined	O
by	O
immunoblotting	O
.	O

Gel	O
-	O
shift	O
assay	O
was	O
also	O
examined	O
to	O
show	O
the	O
formation	O
of	O
Stat1alpha	B-Protein
-	O
DNA	O
complexes	O
.	O

RESULTS	O
:	O
We	O
show	O
that	O
binding	O
of	O
IFN	O
-	O
gamma	O
to	O
human	O
eosinophils	O
initiated	O
a	O
series	O
of	O
events	O
that	O
resulted	O
in	O
the	O
rapid	O
tyrosine	O
phosphorylation	O
of	O
not	O
only	O
the	O
IFN	B-Protein
-	I-Protein
gammaRalpha	I-Protein
chain	I-Protein
but	O
also	O
Jak1	B-Protein
,	O
Jak2	B-Protein
,	O
and	O
Stat1alpha	B-Protein
.	O

In	O
addition	O
,	O
IFN	O
-	O
gamma	O
enhanced	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
Stat1alpha	B-Protein
.	O

CONCLUSION	O
:	O
These	O
data	O
indicate	O
that	O
IFN	O
-	O
gamma	O
affects	O
eosinophils	O
through	O
its	O
specific	O
receptor	O
and	O
utilizes	O
the	O
Jak	O
/	O
Stat	O
pathway	O
as	O
its	O
mode	O
of	O
signaling	O
.	O

Constitutive	O
activation	O
of	O
an	O
epithelial	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	O
)	O
pathway	O
in	O
asthma	O
.	O

Cytokine	O
effects	O
on	O
immunity	O
and	O
inflammation	O
often	O
depend	O
on	O
the	O
transcription	O
factors	O
termed	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STATs	O
)	O
,	O
so	O
STAT	O
signaling	O
pathways	O
are	O
candidates	O
for	O
influencing	O
inflammatory	O
disease	O
.	O

We	O
reasoned	O
that	O
selective	O
IFN	O
responsiveness	O
of	O
the	O
first	O
STAT	O
family	O
member	O
(	O
Stat1	B-Protein
)	O
and	O
Stat1	B-Protein
-	O
dependent	O
immune	O
-	O
response	O
genes	O
such	O
as	O
intercellular	B-Protein
adhesion	I-Protein
molecule	I-Protein
-	I-Protein
1	I-Protein
(	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
)	O
,	O
IFN	B-Protein
regulatory	I-Protein
factor	I-Protein
-	I-Protein
1	I-Protein
(	O
IRF	B-Protein
-	I-Protein
1	I-Protein
)	O
,	O
and	O
Stat1	B-Protein
itself	O
in	O
airway	O
epithelial	O
cells	O
provides	O
a	O
basis	O
for	O
detecting	O
cytokine	O
signaling	O
abnormalities	O
in	O
inflammatory	O
airway	O
disease	O
.	O

On	O
the	O
basis	O
of	O
nuclear	O
localization	O
and	O
phosphorylation	O
,	O
we	O
found	O
that	O
epithelial	O
Stat1	B-Protein
(	O
but	O
not	O
other	O
control	O
transcription	O
factors	O
)	O
was	O
invariably	O
activated	O
in	O
asthmatic	O
compared	O
with	O
normal	O
control	O
or	O
chronic	O
bronchitis	O
subjects	O
.	O

Furthermore	O
,	O
epithelial	O
levels	O
of	O
activated	O
Stat1	B-Protein
correlated	O
with	O
levels	O
of	O
expression	O
for	O
epithelial	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
,	O
IRF	B-Protein
-	I-Protein
1	I-Protein
,	O
and	O
Stat1	B-Protein
,	O
and	O
in	O
turn	O
,	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
levels	O
correlated	O
with	O
T	O
-	O
cell	O
accumulation	O
in	O
tissue	O
.	O

However	O
,	O
only	O
low	O
levels	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
or	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
-	O
producing	O
cells	O
were	O
detected	O
in	O
airway	O
tissue	O
in	O
all	O
subjects	O
.	O

The	O
results	O
therefore	O
provide	O
initial	O
evidence	O
linking	O
abnormal	O
behavior	O
of	O
STAT	O
pathways	O
for	O
cytokine	O
signaling	O
to	O
the	O
development	O
of	O
an	O
inflammatory	O
disease	O
.	O

In	O
that	O
context	O
,	O
the	O
results	O
also	O
change	O
the	O
current	O
scheme	O
for	O
asthma	O
pathogenesis	O
to	O
one	O
that	O
must	O
include	O
a	O
localized	O
gain	O
in	O
transcriptional	O
signal	O
ordinarily	O
used	O
for	O
a	O
T	O
helper	O
1	O
-	O
type	O
cytokine	O
(	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
)	O
in	O
combination	O
with	O
allergy	O
-	O
driven	O
overproduction	O
of	O
T	O
helper	O
2	O
-	O
type	O
cytokines	O
.	O

HLA	O
class	O
I	O
-	O
mediated	O
induction	O
of	O
cell	O
proliferation	O
involves	O
cyclin	O
E	O
-	O
mediated	O
inactivation	O
of	O
Rb	B-Protein
function	O
and	O
induction	O
of	O
E2F	O
activity	O
.	O

Chronic	O
rejection	O
of	O
transplanted	O
organs	O
is	O
manifested	O
as	O
atherosclerosis	O
of	O
the	O
blood	O
vessels	O
of	O
the	O
allograft	O
.	O

HLA	O
class	O
I	O
Ags	O
have	O
been	O
implicated	O
to	O
play	O
a	O
major	O
role	O
in	O
this	O
process	O
,	O
since	O
signaling	O
via	O
HLA	O
class	O
I	O
molecules	O
can	O
induce	O
the	O
proliferation	O
of	O
aortic	O
endothelial	O
as	O
well	O
as	O
smooth	O
muscle	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
HLA	O
class	O
I	O
-	O
mediated	O
induction	O
of	O
cell	O
proliferation	O
correlates	O
with	O
inactivation	O
of	O
the	O
Rb	B-Protein
protein	O
in	O
the	O
T	O
cell	O
line	O
Jurkat	O
as	O
well	O
as	O
human	O
aortic	O
endothelial	O
cells	O
.	O

HLA	O
class	O
I	O
-	O
mediated	O
inactivation	O
of	O
Rb	B-Protein
can	O
be	O
inhibited	O
specifically	O
by	O
neutralizing	O
Abs	O
to	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
,	O
suggesting	O
a	O
role	O
for	O
FGF	O
receptors	O
in	O
the	O
signaling	O
process	O
.	O

Signaling	O
through	O
HLA	O
class	O
I	O
molecules	O
induced	O
cyclin	O
E	O
-	O
associated	O
kinase	O
activity	O
within	O
4	O
h	O
in	O
quiescent	O
endothelial	O
cells	O
,	O
and	O
appeared	O
to	O
mediate	O
the	O
inactivation	O
of	O
Rb	B-Protein
.	O

A	O
cdk2	B-Protein
inhibitor	O
,	O
Olomoucine	O
,	O
as	O
well	O
as	O
a	O
dominant	O
-	O
negative	O
cdk2	B-Protein
construct	O
prevented	O
HLA	O
class	O
I	O
-	O
mediated	O
inactivation	O
of	O
Rb	B-Protein
;	O
in	O
contrast	O
,	O
dominant	O
-	O
negative	O
cdk4	B-Protein
and	O
cdk6	B-Protein
constructs	O
had	O
no	O
effect	O
.	O

Furthermore	O
,	O
there	O
was	O
no	O
increase	O
in	O
cyclin	O
D	O
-	O
associated	O
kinase	O
activity	O
upon	O
HLA	O
class	O
I	O
ligation	O
,	O
suggesting	O
that	O
cyclin	O
E	O
-	O
dependent	O
kinase	O
activity	O
mediates	O
Rb	B-Protein
inactivation	O
,	O
leading	O
to	O
E2F	O
activation	O
and	O
cell	O
proliferation	O
.	O

Increased	O
glucocorticoid	B-Protein
receptor	I-Protein
beta	I-Protein
in	O
airway	O
cells	O
of	O
glucocorticoid	O
-	O
insensitive	O
asthma	O
.	O

Glucocorticoid	O
(	O
GC	O
)	O
-	O
insensitive	O
asthma	O
is	O
a	O
challenging	O
clinical	O
problem	O
that	O
can	O
be	O
associated	O
with	O
life	O
-	O
threatening	O
disease	O
progression	O
.	O

The	O
molecular	O
basis	O
of	O
GC	O
insensitivity	O
is	O
unknown	O
.	O

Alternative	O
splicing	O
of	O
the	O
GC	B-Protein
receptor	I-Protein
(	O
GCR	B-Protein
)	O
pre	O
-	O
mRNA	O
generates	O
a	O
second	O
GCR	O
,	O
termed	O
GCRbeta	B-Protein
,	O
which	O
does	O
not	O
bind	O
GC	O
but	O
antagonizes	O
the	O
transactivating	O
activity	O
of	O
the	O
classic	O
GCR	B-Protein
.	O

Thus	O
increased	O
expression	O
of	O
GCRbeta	B-Protein
could	O
account	O
for	O
glucocorticoid	O
insensitivity	O
.	O

Bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
cells	O
and	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
were	O
examined	O
for	O
GCRbeta	B-Protein
immunoreactivity	O
using	O
a	O
GCRbeta	B-Protein
-	O
specific	O
antibody	O
by	O
immunohistochemical	O
staining	O
.	O

Cell	O
localization	O
of	O
GCRbeta	B-Protein
expression	O
was	O
performed	O
using	O
a	O
double	O
immunostaining	O
technique	O
.	O

Patients	O
with	O
GC	O
-	O
insensitive	O
asthma	O
expressed	O
a	O
significantly	O
higher	O
number	O
of	O
GCRbeta	B-Protein
-	O
immunoreactive	O
cells	O
in	O
their	O
BAL	O
and	O
peripheral	O
blood	O
than	O
GC	O
-	O
sensitive	O
asthmatics	O
or	O
normal	O
control	O
subjects	O
.	O

Furthermore	O
,	O
GCRbeta	B-Protein
expression	O
in	O
GC	O
-	O
insensitive	O
asthma	O
was	O
particularly	O
high	O
in	O
airway	O
T	O
cells	O
,	O
which	O
are	O
thought	O
to	O
play	O
a	O
major	O
role	O
in	O
the	O
pathogenesis	O
of	O
asthma	O
.	O

We	O
also	O
examined	O
the	O
expression	O
of	O
GCRbeta	B-Protein
in	O
specimens	O
from	O
the	O
airways	O
of	O
patients	O
with	O
chronic	O
bronchitis	O
.	O

In	O
chronic	O
bronchitis	O
,	O
few	O
cells	O
were	O
GCRbeta	B-Protein
-	O
positive	O
and	O
their	O
numbers	O
did	O
not	O
differ	O
significantly	O
from	O
normal	O
control	O
subjects	O
.	O

We	O
conclude	O
that	O
GC	O
-	O
insensitive	O
asthma	O
is	O
associated	O
with	O
increased	O
expression	O
of	O
GCRbeta	B-Protein
in	O
airway	O
T	O
cells	O
.	O

Differences	O
in	O
phosphorylation	O
of	O
the	O
IL	O
-	O
2R	O
associated	O
JAK	O
/	O
STAT	O
proteins	O
between	O
HTLV	O
-	O
I	O
(	O
+	O
)	O
,	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
independent	O
and	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
dependent	O
cell	O
lines	O
and	O
uncultured	O
leukemic	O
cells	O
from	O
patients	O
with	O
adult	O
T	O
-	O
cell	O
lymphoma	O
/	O
leukemia	O
.	O

To	O
determine	O
activation	O
status	O
of	O
the	O
IL	O
-	O
2R	O
-	O
associated	O
(	O
Jak	O
/	O
STAT	O
)	O
pathway	O
in	O
the	O
HTLV	O
-	O
I	O
infected	O
cells	O
,	O
we	O
examined	O
tyrosine	O
phosphorylation	O
of	O
Jak3	B-Protein
,	O
STAT3	B-Protein
,	O
and	O
STAT5	O
in	O
several	O
HTLV	O
-	O
I	O
(	O
+	O
)	O
T	O
-	O
cell	O
lines	O
and	O
in	O
uncultured	O
leukemic	O
T	O
cells	O
isolated	O
from	O
patients	O
with	O
adult	O
T	O
-	O
cell	O
lymphoma	O
/	O
leukemia	O
(	O
ATLL	O
)	O
.	O

Constitutive	O
basal	O
phosphorylation	O
of	O
Jak3	B-Protein
and	O
,	O
usually	O
,	O
STAT3	B-Protein
and	O
STAT5	O
was	O
detected	O
in	O
all	O
four	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
independent	O
cell	O
lines	O
tested	O
,	O
but	O
in	O
none	O
of	O
the	O
three	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
dependent	O
cell	O
lines	O
.	O

Similarly	O
,	O
there	O
was	O
no	O
detectable	O
basal	O
phosphorylation	O
of	O
Jak3	B-Protein
and	O
STAT5	O
in	O
the	O
leukemic	O
cells	O
from	O
ATLL	O
patients	O
(	O
0	O
/	O
8	O
and	O
0	O
/	O
3	O
,	O
respectively	O
)	O
.	O

However	O
,	O
stimulation	O
with	O
IL	B-Protein
-	I-Protein
2	I-Protein
resulted	O
in	O
Jak3	B-Protein
and	O
STAT5	O
phosphorylation	O
in	O
both	O
leukemic	O
ATLL	O
cells	O
and	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
dependent	O
lines	O
.	O

Furthermore	O
,	O
expression	O
of	O
SHP	B-Protein
-	I-Protein
1	I-Protein
phosphatase	I-Protein
which	O
is	O
a	O
negative	O
regulator	O
of	O
cytokine	O
receptor	O
signaling	O
,	O
was	O
lost	O
in	O
most	O
IL	B-Protein
-	I-Protein
2	I-Protein
independent	O
cell	O
lines	O
(	O
3	O
/	O
4	O
)	O
but	O
not	O
in	O
the	O
leukemic	O
ATLL	O
cells	O
(	O
0	O
/	O
3	O
)	O
.	O

Finally	O
,	O
the	O
HTLV	O
-	O
I	O
(	O
+	O
)	O
T	O
-	O
cell	O
lines	O
(	O
313	O
)	O
but	O
not	O
the	O
control	O
,	O
HTLV	O
-	O
I	O
(	O
-	O
)	O
T	O
-	O
cell	O
lines	O
were	O
resistant	O
to	O
rapamycin	O
and	O
its	O
novel	O
analog	O
RAD	O
.	O

We	O
conclude	O
that	O
(	O
1	O
)	O
HTLV	O
-	O
I	O
infection	O
per	O
se	O
does	O
not	O
result	O
in	O
a	O
constitutive	O
phosphorylation	O
of	O
the	O
Jak3	B-Protein
,	O
STAT3	B-Protein
,	O
and	O
STAT5	O
proteins	O
;	O
(	O
2	O
)	O
malignant	O
transformation	O
in	O
at	O
least	O
some	O
cases	O
of	O
ATLL	O
does	O
not	O
require	O
the	O
constitutive	O
,	O
but	O
may	O
require	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
induced	O
,	O
activation	O
of	O
the	O
IL	O
-	O
2R	O
Jak	O
/	O
STAT	O
pathway	O
;	O
and	O
(	O
3	O
)	O
there	O
are	O
major	O
differences	O
in	O
T	O
-	O
cell	O
immortalization	O
mechanism	O
(	O
s	O
)	O
which	O
appear	O
to	O
involve	O
SHP	B-Protein
-	I-Protein
1	I-Protein
and	O
target	O
molecules	O
for	O
rapamycin	O
and	O
RAD	O
.	O

USF	O
/	O
c	B-Protein
-	I-Protein
Myc	I-Protein
enhances	O
,	O
while	O
Yin	B-Protein
-	I-Protein
Yang	I-Protein
1	I-Protein
suppresses	O
,	O
the	O
promoter	O
activity	O
of	O
CXCR4	B-Protein
,	O
a	O
coreceptor	O
for	O
HIV	O
-	O
1	O
entry	O
.	O

Transcription	O
factors	O
USF1	B-Protein
and	O
USF2	B-Protein
up	O
-	O
regulate	O
gene	O
expression	O
(	O
i	O
.	O
e	O
.	O
,	O
HIV	O
-	O
1	O
long	O
terminal	O
repeats	O
)	O
via	O
interaction	O
with	O
an	O
E	O
box	O
on	O
their	O
target	O
promoters	O
,	O
which	O
is	O
also	O
a	O
binding	O
site	O
for	O
c	B-Protein
-	I-Protein
Myc	I-Protein
.	O

The	O
c	B-Protein
-	I-Protein
Myc	I-Protein
oncoprotein	O
is	O
important	O
in	O
control	O
of	O
cellular	O
proliferation	O
and	O
differentiation	O
,	O
while	O
Yin	B-Protein
-	I-Protein
Yang	I-Protein
1	I-Protein
(	O
YY1	B-Protein
)	O
has	O
been	O
shown	O
to	O
control	O
the	O
expression	O
of	O
a	O
number	O
of	O
cellular	O
and	O
viral	O
genes	O
.	O

These	O
two	O
proteins	O
physically	O
interact	O
with	O
each	O
other	O
and	O
mutually	O
inhibit	O
their	O
respective	O
biological	O
functions	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
USF	O
/	O
c	B-Protein
-	I-Protein
Myc	I-Protein
up	O
-	O
regulates	O
,	O
while	O
YY1	B-Protein
down	O
-	O
regulates	O
the	O
promoter	O
activity	O
of	O
CXCR4	B-Protein
,	O
a	O
coreceptor	O
for	O
T	O
cell	O
-	O
tropic	O
HIV	O
-	O
1	O
entry	O
.	O

We	O
have	O
identified	O
an	O
E	O
box	O
around	O
-	O
260	O
and	O
a	O
YY1	B-Protein
binding	O
site	O
around	O
-	O
300	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
.	O

Mutation	O
of	O
the	O
E	O
box	O
abolished	O
USF	O
/	O
c	B-Protein
-	I-Protein
Myc	I-Protein
-	O
mediated	O
up	O
-	O
regulation	O
of	O
CXCR4	B-Protein
promoter	O
activity	O
,	O
and	O
mutation	O
of	O
the	O
YY1	B-Protein
binding	O
site	O
was	O
associated	O
with	O
unresponsiveness	O
to	O
YY1	B-Protein
-	O
mediated	O
inhibition	O
.	O

These	O
data	O
suggest	O
that	O
USF	O
/	O
c	B-Protein
-	I-Protein
Myc	I-Protein
and	O
YY1	B-Protein
may	O
play	O
an	O
important	O
role	O
in	O
the	O
HIV	O
-	O
1	O
-	O
replicative	O
cycle	O
,	O
by	O
modulating	O
both	O
the	O
viral	O
fusion	O
/	O
entry	O
process	O
and	O
viral	O
expression	O
.	O

Glucocorticoid	B-Protein
receptors	I-Protein
are	O
down	O
-	O
regulated	O
in	O
inflamed	O
colonic	O
mucosa	O
but	O
not	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
from	O
patients	O
with	O
inflammatory	O
bowel	O
disease	O
[	O
see	O
comments	O
]	O

BACKGROUND	O
:	O
Growing	O
evidence	O
indicates	O
that	O
the	O
immune	O
system	O
and	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
system	O
are	O
linked	O
by	O
several	O
mechanisms	O
,	O
for	O
example	O
intracellular	O
glucocorticoid	B-Protein
receptors	I-Protein
(	O
hGR	B-Protein
)	O
.	O

Glucocorticoids	O
are	O
the	O
standard	O
treatment	O
of	O
acute	O
attacks	O
of	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
.	O

Binding	O
of	O
glucocorticoids	O
to	O
hGR	B-Protein
down	O
-	O
regulates	O
the	O
transcription	O
of	O
inflammatory	O
genes	O
that	O
can	O
propagate	O
IBD	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
IBD	O
patients	O
were	O
either	O
treated	O
with	O
5	O
-	O
60	O
mg	O
of	O
prednisolone	O
for	O
more	O
than	O
1	O
week	O
or	O
were	O
without	O
glucocorticoid	O
treatment	O
for	O
more	O
than	O
4	O
weeks	O
.	O

hGR	B-Protein
levels	O
were	O
determined	O
from	O
isolated	O
cytosol	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
or	O
mucosal	O
biopsies	O
using	O
a	O
radioassay	O
with	O
[	O
3H	O
]	O
-	O
dexamethasone	O
.	O

Interleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
6	I-Protein
levels	O
were	O
determined	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
.	O

RESULTS	O
:	O
The	O
systemic	O
(	O
PBMC	O
)	O
hGR	B-Protein
levels	O
of	O
corticosteroid	O
-	O
treated	O
IBD	O
patients	O
were	O
significantly	O
lower	O
than	O
those	O
of	O
control	O
subjects	O
(	O
59	O
.	O
6	O
+	O
/	O
-	O
57	O
.	O
1	O
dpm	O
mg	O
-	O
1	O
cytosol	O
protein	O
vs	O
.	O
227	O
.	O
0	O
+	O
/	O
-	O
90	O
.	O
8	O
dpm	O
mg	O
-	O
1	O
cytosol	O
protein	O
,	O
P	O
=	O
0	O
.	O
007	O
)	O
and	O
IBD	O
patients	O
not	O
receiving	O
glucocorticoid	O
treatment	O
(	O
179	O
.	O
7	O
+	O
/	O
-	O
171	O
.	O
3	O
dpm	O
mg	O
-	O
1	O
cytosol	O
protein	O
,	O
P	O
=	O
0	O
.	O
002	O
)	O
.	O

Systemic	O
hGR	B-Protein
levels	O
in	O
untreated	O
IBD	O
patients	O
did	O
not	O
differ	O
significantly	O
from	O
those	O
in	O
control	O
subjects	O
.	O

In	O
patients	O
with	O
connective	O
tissue	O
diseases	O
,	O
systemic	O
hGR	B-Protein
levels	O
were	O
also	O
found	O
to	O
be	O
decreased	O
in	O
the	O
absence	O
of	O
glucocorticoid	O
treatment	O
.	O

Systemic	O
hGR	B-Protein
levels	O
in	O
patients	O
with	O
Crohn	O
'	O
s	O
disease	O
(	O
CD	O
)	O
treated	O
with	O
steroids	O
(	O
66	O
.	O
6	O
+	O
/	O
-	O
61	O
.	O
0	O
dpm	O
mg	O
-	O
1	O
cytosol	O
protein	O
)	O
were	O
not	O
different	O
from	O
those	O
in	O
patients	O
with	O
ulcerative	O
colitis	O
(	O
UC	O
)	O
(	O
56	O
.	O
1	O
+	O
/	O
-	O
51	O
.	O
6	O
dpm	O
mg	O
-	O
1	O
cytosol	O
protein	O
)	O
.	O

In	O
contrast	O
to	O
these	O
findings	O
,	O
mucosal	O
hGR	B-Protein
levels	O
were	O
significantly	O
decreased	O
in	O
both	O
steroid	O
-	O
treated	O
(	O
18	O
.	O
0	O
+	O
/	O
-	O
15	O
.	O
5	O
)	O
and	O
not	O
steroid	O
-	O
treated	O
(	O
37	O
.	O
8	O
+	O
/	O
-	O
30	O
.	O
5	O
)	O
patients	O
compared	O
with	O
control	O
subjects	O
(	O
125	O
.	O
6	O
+	O
/	O
-	O
97	O
.	O
1	O
;	O
P	O
=	O
0	O
.	O
00009	O
and	O
P	O
=	O
0	O
.	O
0008	O
respectively	O
)	O
.	O

IL	B-Protein
-	I-Protein
6	I-Protein
levels	O
in	O
all	O
IBD	O
groups	O
with	O
and	O
without	O
steroids	O
were	O
significantly	O
different	O
from	O
those	O
in	O
control	O
subjects	O
.	O

CONCLUSION	O
:	O
In	O
IBD	O
there	O
is	O
no	O
difference	O
in	O
systemic	O
hGR	B-Protein
levels	O
between	O
not	O
steroid	O
-	O
treated	O
patients	O
and	O
control	O
subjects	O
,	O
in	O
spite	O
of	O
inflammatory	O
activity	O
(	O
IL	B-Protein
-	I-Protein
6	I-Protein
)	O
.	O

Mucosal	O
hGR	B-Protein
levels	O
were	O
decreased	O
independently	O
of	O
treatment	O
,	O
probably	O
leading	O
to	O
a	O
decreased	O
protection	O
against	O
NF	O
-	O
kappaB	O
action	O
in	O
the	O
intestinal	O
mucosa	O
.	O

Bacterial	O
peptidoglycan	O
induces	O
CD14	B-Protein
-	O
dependent	O
activation	O
of	O
transcription	O
factors	O
CREB	O
/	O
ATF	O
and	O
AP	O
-	O
1	O
.	O

Peptidoglycan	O
(	O
PGN	O
)	O
,	O
the	O
major	O
cell	O
wall	O
component	O
of	O
Gram	O
-	O
positive	O
bacteria	O
,	O
induces	O
secretion	O
of	O
cytokines	O
in	O
macrophages	O
through	O
CD14	B-Protein
,	O
the	O
pattern	O
recognition	O
receptor	O
that	O
binds	O
lipopolysaccharide	O
and	O
other	O
microbial	O
products	O
.	O

To	O
begin	O
to	O
elucidate	O
the	O
mechanisms	O
that	O
regulate	O
the	O
transcription	O
of	O
cytokine	O
genes	O
,	O
we	O
wanted	O
to	O
determine	O
which	O
transcription	O
factors	O
are	O
activated	O
by	O
PGN	O
in	O
mouse	O
RAW264	O
.	O
7	O
and	O
human	O
THP	O
-	O
1	O
macrophage	O
cells	O
.	O

Our	O
results	O
demonstrated	O
that	O
:	O
(	O
i	O
)	O
PGN	O
induced	O
phosphorylation	O
of	O
the	O
transcription	O
factors	O
ATF	B-Protein
-	I-Protein
1	I-Protein
and	O
CREB	B-Protein
;	O
(	O
ii	O
)	O
ATF	B-Protein
-	I-Protein
1	I-Protein
and	O
CREB	B-Protein
bound	O
DNA	O
as	O
a	O
dimer	O
and	O
induced	O
transcriptional	O
activation	O
of	O
a	O
CRE	O
reporter	O
plasmid	O
,	O
which	O
was	O
inhibited	O
by	O
dominant	O
negative	O
CREB	B-Protein
and	O
ATF	B-Protein
-	I-Protein
1	I-Protein
;	O
(	O
iii	O
)	O
PGN	O
induced	O
phosphorylation	O
of	O
c	B-Protein
-	I-Protein
Jun	I-Protein
,	O
protein	O
synthesis	O
of	O
JunB	B-Protein
and	O
c	B-Protein
-	I-Protein
Fos	I-Protein
,	O
and	O
transcriptional	O
activation	O
of	O
the	O
AP	O
-	O
1	O
reporter	O
plasmid	O
,	O
which	O
was	O
inhibited	O
by	O
dominant	O
negative	O
c	B-Protein
-	I-Protein
Fos	I-Protein
;	O
and	O
(	O
iv	O
)	O
PGN	O
-	O
induced	O
activation	O
of	O
CREB	O
/	O
ATF	O
and	O
AP	O
-	O
1	O
was	O
mediated	O
through	O
CD14	B-Protein
.	O

This	O
is	O
the	O
first	O
study	O
to	O
demonstrate	O
activation	O
of	O
CREB	O
/	O
ATF	O
and	O
AP	O
-	O
1	O
transcription	O
factors	O
by	O
PGN	O
or	O
by	O
any	O
other	O
component	O
of	O
Gram	O
-	O
positive	O
bacteria	O
.	O

Nuclear	B-Protein
factor	I-Protein
-	I-Protein
90	I-Protein
of	I-Protein
activated	I-Protein
T	I-Protein
-	I-Protein
cells	I-Protein
:	O
A	O
double	O
-	O
stranded	O
RNA	O
-	O
binding	O
protein	O
and	O
substrate	O
for	O
the	O
double	O
-	O
stranded	O
RNA	O
-	O
dependent	O
protein	O
kinase	O
,	O
PKR	B-Protein
.	O

NFAT	O
transcription	O
factors	O
play	O
a	O
central	O
role	O
in	O
initiating	O
T	O
-	O
cell	O
activation	O
through	O
the	O
induction	O
of	O
immediate	O
-	O
early	O
T	O
-	O
cell	O
specific	O
genes	O
including	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
(	O
IL	B-Protein
-	I-Protein
2	I-Protein
)	O
.	O

NFAT	O
transcription	O
factors	O
bind	O
to	O
a	O
sequence	O
in	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
enhancer	O
known	O
as	O
the	O
antigen	O
receptor	O
response	O
element	O
2	O
(	O
ARRE	O
-	O
2	O
)	O
.	O

Multiple	O
proteins	O
exhibiting	O
ARRE	O
-	O
2	O
binding	O
activity	O
have	O
been	O
isolated	O
,	O
including	O
a	O
heterodimer	O
from	O
stimulated	O
T	O
-	O
cell	O
nuclear	O
extracts	O
consisting	O
of	O
Mr	O
=	O
90	O
000	O
(	O
NF90	B-Protein
)	O
and	O
Mr	O
=	O
45	O
000	O
(	O
NF45	B-Protein
)	O
subunits	O
.	O

The	O
subunits	O
of	O
this	O
heterodimer	O
have	O
been	O
cloned	O
,	O
and	O
NF90	B-Protein
was	O
found	O
to	O
encode	O
a	O
protein	O
containing	O
two	O
domains	O
that	O
are	O
predicted	O
to	O
form	O
motifs	O
capable	O
of	O
binding	O
to	O
double	O
-	O
stranded	O
RNA	O
.	O

Using	O
in	O
vitro	O
translated	O
polypeptides	O
,	O
we	O
have	O
demonstrated	O
that	O
NF90	B-Protein
specifically	O
binds	O
to	O
double	O
-	O
stranded	O
RNA	O
.	O

Furthermore	O
,	O
NF90	B-Protein
was	O
phosphorylated	O
in	O
a	O
double	O
-	O
stranded	O
RNA	O
-	O
dependent	O
manner	O
likely	O
by	O
the	O
interferon	B-Protein
-	I-Protein
induced	I-Protein
,	I-Protein
double	I-Protein
-	I-Protein
stranded	I-Protein
RNA	I-Protein
-	I-Protein
dependent	I-Protein
protein	I-Protein
kinase	I-Protein
,	O
PKR	B-Protein
.	O

The	O
NF90	B-Protein
protein	O
was	O
found	O
to	O
be	O
expressed	O
not	O
only	O
in	O
T	O
-	O
cells	O
,	O
but	O
also	O
in	O
nonimmune	O
HeLa	O
cells	O
.	O

In	O
HeLa	O
cells	O
,	O
the	O
protein	O
was	O
almost	O
exclusively	O
localized	O
to	O
the	O
ribosome	O
salt	O
wash	O
fraction	O
of	O
cell	O
lysates	O
.	O

c	B-Protein
-	I-Protein
Myc	I-Protein
and	O
E1A	B-Protein
induced	O
cellular	O
sensitivity	O
to	O
activated	O
NK	O
cells	O
involves	O
cytotoxic	O
granules	O
as	O
death	O
effectors	O
.	O

The	O
contact	O
of	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
with	O
foreign	O
cells	O
and	O
with	O
certain	O
virus	O
-	O
infected	O
or	O
tumor	O
cells	O
triggers	O
the	O
cytolytic	O
machinery	O
of	O
NK	O
cells	O
.	O

This	O
triggering	O
leads	O
to	O
exocytosis	O
of	O
the	O
cytotoxic	O
NK	O
cell	O
granules	O
.	O

The	O
oncoproteins	O
c	B-Protein
-	I-Protein
Myc	I-Protein
and	O
E1A	B-Protein
render	O
cells	O
vulnerable	O
to	O
NK	O
cell	O
mediated	O
cytolysis	O
yet	O
the	O
mechanisms	O
of	O
sensitization	O
are	O
not	O
well	O
understood	O
.	O

In	O
a	O
model	O
where	O
foreign	O
cells	O
(	O
rat	O
fibroblasts	O
)	O
were	O
cocultured	O
with	O
human	O
IL	B-Protein
-	I-Protein
2	I-Protein
activated	O
NK	O
cells	O
,	O
we	O
observed	O
that	O
NK	O
cells	O
were	O
capable	O
of	O
efficiently	O
killing	O
their	O
targets	O
only	O
if	O
the	O
cells	O
overexpressed	O
the	O
oncogene	O
c	B-Protein
-	I-Protein
Myc	I-Protein
or	O
E1A	B-Protein
.	O

Both	O
the	O
parental	O
and	O
the	O
oncogene	O
expressing	O
fibroblasts	O
similarly	O
triggered	O
phosphoinositide	O
hydrolysis	O
in	O
the	O
bound	O
NK	O
cells	O
,	O
demonstrating	O
that	O
NK	O
cells	O
were	O
cytolytically	O
activated	O
in	O
contact	O
with	O
both	O
resistant	O
parental	O
and	O
oncogene	O
expressing	O
sensitive	O
target	O
fibroblasts	O
.	O

The	O
cell	O
death	O
was	O
independent	O
of	O
wild	O
-	O
type	O
p53	B-Protein
and	O
was	O
not	O
inhibited	O
by	O
an	O
anti	O
-	O
apoptotic	O
protein	O
EIB19K	B-Protein
.	O

These	O
results	O
provided	O
evidence	O
that	O
c	B-Protein
-	I-Protein
Myc	I-Protein
and	O
E1A	B-Protein
activated	O
the	O
NK	O
cell	O
induced	O
cytolysis	O
at	O
a	O
post	O
-	O
triggering	O
stage	O
of	O
NK	O
cell	O
-	O
target	O
cell	O
interaction	O
.	O

In	O
consistence	O
,	O
the	O
c	B-Protein
-	I-Protein
Myc	I-Protein
and	O
E1A	B-Protein
overexpressing	O
fibroblasts	O
were	O
more	O
sensitive	O
to	O
the	O
cytolytic	O
effects	O
of	O
isolated	O
NK	O
cell	O
-	O
derived	O
granules	O
than	O
parental	O
cells	O
.	O

The	O
data	O
indicate	O
that	O
oncogenes	O
activate	O
the	O
cytotoxicity	O
of	O
NK	O
cell	O
granules	O
.	O

This	O
mechanism	O
can	O
have	O
a	O
role	O
in	O
directing	O
the	O
cytolytic	O
action	O
of	O
NK	O
cells	O
towards	O
the	O
virus	O
-	O
infected	O
and	O
cancer	O
cells	O
.	O

Apoptosis	O
and	O
growth	O
inhibition	O
in	O
malignant	O
lymphocytes	O
after	O
treatment	O
with	O
arsenic	O
trioxide	O
at	O
clinically	O
achievable	O
concentrations	O
[	O
see	O
comments	O
]	O

BACKGROUND	O
:	O
Arsenic	O
trioxide	O
(	O
As2O3	O
)	O
can	O
induce	O
clinical	O
remission	O
in	O
patients	O
with	O
acute	O
promyelocytic	O
leukemia	O
via	O
induction	O
of	O
differentiation	O
and	O
programmed	O
cell	O
death	O
(	O
apoptosis	O
)	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
As2O3	O
on	O
a	O
panel	O
of	O
malignant	O
lymphocytes	O
to	O
determine	O
whether	O
growth	O
-	O
inhibitory	O
and	O
apoptotic	O
effects	O
of	O
As2O3	O
can	O
be	O
observed	O
in	O
these	O
cells	O
at	O
clinically	O
achievable	O
concentrations	O
.	O

METHODS	O
:	O
Eight	O
malignant	O
lymphocytic	O
cell	O
lines	O
and	O
primary	O
cultures	O
of	O
lymphocytic	O
leukemia	O
and	O
lymphoma	O
cells	O
were	O
treated	O
with	O
As2O3	O
,	O
with	O
or	O
without	O
dithiothreitol	O
(	O
DTT	O
)	O
or	O
buthionine	O
sulfoximine	O
(	O
BSO	O
)	O
(	O
an	O
inhibitor	O
of	O
glutathione	O
synthesis	O
)	O
.	O

Apoptosis	O
was	O
assessed	O
by	O
cell	O
morphology	O
,	O
flow	O
cytometry	O
,	O
annexin	B-Protein
V	I-Protein
protein	O
level	O
,	O
and	O
terminal	B-Protein
deoxynucleotidyl	I-Protein
transferase	I-Protein
labeling	O
of	O
DNA	O
fragments	O
.	O

Cellular	O
proliferation	O
was	O
determined	O
by	O
5	O
-	O
bromo	O
-	O
2	O
'	O
-	O
deoxyuridine	O
incorporation	O
into	O
DNA	O
and	O
flow	O
cytometry	O
and	O
by	O
use	O
of	O
a	O
mitotic	O
arrest	O
assay	O
.	O

Mitochondrial	O
transmembrane	O
potential	O
(	O
delta	O
psi	O
(	O
m	O
)	O
)	O
was	O
measured	O
by	O
means	O
of	O
rhodamine	O
123	O
staining	O
and	O
flow	O
cytometry	O
.	O

Protein	O
expression	O
was	O
assessed	O
by	O
western	O
blot	O
analysis	O
or	O
immunofluorescence	O
.	O

RESULTS	O
:	O
Therapeutic	O
concentrations	O
of	O
As2O3	O
(	O
1	O
-	O
2	O
microM	O
)	O
had	O
dual	O
effects	O
on	O
malignant	O
lymphocytes	O
:	O
1	O
)	O
inhibition	O
of	O
growth	O
through	O
adenosine	O
triphosphate	O
(	O
ATP	O
)	O
depletion	O
and	O
prolongation	O
of	O
cell	O
cycle	O
time	O
and	O
2	O
)	O
induction	O
of	O
apoptosis	O
.	O

As2O3	O
-	O
induced	O
apoptosis	O
was	O
preceded	O
by	O
delta	O
psi	O
(	O
m	O
)	O
collapse	O
.	O

DTT	O
antagonized	O
and	O
BSO	O
enhanced	O
As2O3	O
-	O
induced	O
ATP	O
depletion	O
,	O
delta	O
psi	O
(	O
m	O
)	O
collapse	O
,	O
and	O
apoptosis	O
.	O

Caspase	B-Protein
-	I-Protein
3	I-Protein
activation	O
,	O
usually	O
resulting	O
from	O
delta	O
psi	O
(	O
m	O
)	O
collapse	O
,	O
was	O
not	O
always	O
associated	O
with	O
As2O3	O
-	O
induced	O
apoptosis	O
.	O

As2O3	O
induced	O
PML	B-Protein
(	O
promyelocytic	O
leukemia	O
)	O
protein	O
degradation	O
but	O
did	O
not	O
modulate	O
expression	O
of	O
cell	O
cycle	O
-	O
related	O
proteins	O
,	O
including	O
c	B-Protein
-	I-Protein
myc	I-Protein
,	O
retinoblastoma	B-Protein
protein	I-Protein
,	O
cyclin	B-Protein
-	I-Protein
dependent	I-Protein
kinase	I-Protein
4	I-Protein
,	O
cyclin	B-Protein
D1	I-Protein
,	O
and	O
p53	B-Protein
,	O
or	O
expression	O
of	O
differentiation	O
-	O
related	O
antigens	O
.	O

CONCLUSIONS	O
:	O
Substantial	O
growth	O
inhibition	O
and	O
apoptosis	O
without	O
evidence	O
of	O
differentiation	O
were	O
induced	O
in	O
most	O
malignant	O
lymphocytic	O
cells	O
treated	O
with	O
1	O
-	O
2	O
microM	O
As2O3	O
.	O

As2O3	O
may	O
prove	O
useful	O
in	O
the	O
treatment	O
of	O
malignant	O
lymphoproliferative	O
disorders	O
.	O

A	O
role	O
for	O
RanBP1	B-Protein
in	O
the	O
release	O
of	O
CRM1	B-Protein
from	O
the	O
nuclear	O
pore	O
complex	O
in	O
a	O
terminal	O
step	O
of	O
nuclear	O
export	O
.	O

We	O
recently	O
developed	O
an	O
assay	O
in	O
which	O
nuclear	O
export	O
of	O
the	O
shuttling	O
transcription	O
factor	O
NFAT	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
)	O
can	O
be	O
reconstituted	O
in	O
permeabilized	O
cells	O
with	O
the	O
GTPase	O
Ran	B-Protein
and	O
the	O
nuclear	O
export	O
receptor	O
CRM1	B-Protein
.	O

We	O
have	O
now	O
used	O
this	O
assay	O
to	O
identify	O
another	O
export	O
factor	O
.	O

After	O
preincubation	O
of	O
permeabilized	O
cells	O
with	O
a	O
Ran	B-Protein
mutant	O
that	O
cannot	O
hydrolyze	O
GTP	O
(	O
RanQ69L	O
)	O
,	O
cytosol	O
supports	O
NFAT	O
export	O
,	O
but	O
CRM1	B-Protein
and	O
Ran	B-Protein
alone	O
do	O
not	O
.	O

The	O
RanQ69L	O
preincubation	O
leads	O
to	O
accumulation	O
of	O
CRM1	B-Protein
at	O
the	O
cytoplasmic	O
periphery	O
of	O
the	O
nuclear	O
pore	O
complex	O
(	O
NPC	O
)	O
in	O
association	O
with	O
the	O
p62	B-Protein
complex	O
and	O
Can	B-Protein
/	O
Nup214	B-Protein
.	O

RanGTP	O
-	O
dependent	O
association	O
of	O
CRM1	B-Protein
with	O
these	O
nucleoporins	O
was	O
reconstituted	O
in	O
vitro	O
.	O

By	O
biochemical	O
fractionation	O
and	O
reconstitution	O
,	O
we	O
showed	O
that	O
RanBP1	B-Protein
restores	O
nuclear	O
export	O
after	O
the	O
RanQ69L	O
preincubation	O
.	O

It	O
also	O
stimulates	O
nuclear	O
export	O
in	O
cells	O
that	O
have	O
not	O
been	O
preincubated	O
with	O
RanQ69L	O
.	O

RanBP1	B-Protein
as	O
well	O
as	O
Ran	B-Protein
-	O
binding	O
domains	O
of	O
the	O
cytoplasmic	O
nucleoporin	O
RanBP2	B-Protein
promote	O
the	O
release	O
of	O
CRM1	B-Protein
from	O
the	O
NPC	O
.	O

Taken	O
together	O
,	O
our	O
results	O
indicate	O
that	O
RanGTP	O
is	O
important	O
for	O
the	O
targeting	O
of	O
export	O
complexes	O
to	O
the	O
cytoplasmic	O
side	O
of	O
the	O
NPC	O
and	O
that	O
RanBP1	B-Protein
and	O
probably	O
RanBP2	B-Protein
are	O
involved	O
in	O
the	O
dissociation	O
of	O
nuclear	O
export	O
complexes	O
from	O
the	O
NPC	O
in	O
a	O
terminal	O
step	O
of	O
transport	O
.	O

Expression	O
of	O
Th1	O
and	O
Th2	O
type	O
cytokines	O
responding	O
to	O
HBsAg	B-Protein
and	O
HBxAg	B-Protein
in	O
chronic	O
hepatitis	O
B	O
patients	O
.	O

The	O
cytokine	O
pattern	O
on	O
viral	O
antigen	O
recognition	O
is	O
believed	O
to	O
exert	O
a	O
profound	O
influence	O
on	O
the	O
resolution	O
of	O
viral	O
infections	O
and	O
viral	O
clearance	O
.	O

This	O
study	O
was	O
initiated	O
to	O
investigate	O
whether	O
a	O
cytokine	O
imbalance	O
oriented	O
toward	O
Th2	O
type	O
response	O
plays	O
a	O
role	O
in	O
chronic	O
hepatitis	O
B	O
.	O

Cytokine	O
profiles	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
associated	O
with	O
chronic	O
hepatitis	O
B	O
were	O
analysed	O
by	O
RT	O
-	O
PCR	O
.	O

Upon	O
HBsAg	B-Protein
stimulation	O
,	O
expression	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
was	O
detected	O
in	O
41	O
%	O
,	O
8	O
%	O
,	O
41	O
%	O
,	O
and	O
50	O
%	O
of	O
the	O
patients	O
,	O
respectively	O
.	O

Among	O
these	O
cytokines	O
,	O
the	O
expression	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
was	O
associated	O
with	O
high	O
levels	O
of	O
serum	O
AST	O
/	O
ALT	O
.	O

However	O
,	O
we	O
could	O
not	O
prove	O
that	O
Th2	O
type	O
cytokines	O
had	O
a	O
protective	O
effect	O
on	O
hepatocytes	O
.	O

Upon	O
HBxAg	B-Protein
stimulation	O
,	O
there	O
was	O
no	O
recognizable	O
association	O
of	O
cytokine	O
patterns	O
with	O
AST	O
/	O
ALT	O
levels	O
.	O

In	O
conclusion	O
,	O
production	O
of	O
a	O
Th1	O
cytokine	O
,	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
by	O
HBsAg	B-Protein
-	O
reactive	O
cells	O
was	O
associated	O
with	O
hepatocyte	O
damage	O
in	O
chronic	O
hepatitis	O
B	O
,	O
while	O
no	O
counteracting	O
effect	O
of	O
Th2	O
cytokines	O
produced	O
by	O
those	O
cells	O
was	O
observed	O
.	O

Protein	B-Protein
kinase	I-Protein
B	I-Protein
(	O
c	B-Protein
-	I-Protein
Akt	I-Protein
)	O
,	O
phosphatidylinositol	O
3	O
-	O
kinase	O
,	O
and	O
STAT5	B-Protein
are	O
activated	O
by	O
erythropoietin	B-Protein
(	O
EPO	B-Protein
)	O
in	O
HCD57	O
erythroid	O
cells	O
but	O
are	O
constitutively	O
active	O
in	O
an	O
EPO	B-Protein
-	O
independent	O
,	O
apoptosis	O
-	O
resistant	O
subclone	O
(	O
HCD57	O
-	O
SREI	O
cells	O
)	O
.	O

We	O
found	O
that	O
erythropoietin	B-Protein
(	O
EPO	B-Protein
)	O
and	O
stem	B-Protein
cell	I-Protein
factor	I-Protein
(	O
SCF	B-Protein
)	O
activated	O
protein	B-Protein
kinase	I-Protein
B	I-Protein
(	O
PKB	B-Protein
/	O
Akt	B-Protein
)	O
in	O
EPO	B-Protein
-	O
dependent	O
HCD57	O
erythroid	O
cells	O
.	O

To	O
better	O
understand	O
signals	O
controlling	O
proliferation	O
and	O
viability	O
,	O
erythroid	O
cells	O
that	O
resist	O
apoptosis	O
in	O
the	O
absence	O
of	O
EPO	B-Protein
were	O
subcloned	O
and	O
characterized	O
(	O
HCD57	O
-	O
SREI	O
cells	O
)	O
.	O

Constitutive	O
activations	O
of	O
PKB	B-Protein
/	O
Akt	B-Protein
,	O
STAT5a	B-Protein
,	O
and	O
STAT5b	B-Protein
were	O
noted	O
in	O
these	O
EPO	B-Protein
-	O
independent	O
cells	O
.	O

PI3	O
-	O
kinase	O
activity	O
was	O
an	O
upstream	O
activator	O
of	O
PKB	B-Protein
/	O
Akt	B-Protein
because	O
the	O
PI3	O
-	O
kinase	O
inhibitor	O
LY294002	O
blocked	O
both	O
constitutive	O
PKB	B-Protein
/	O
Akt	B-Protein
and	O
factor	O
-	O
dependent	O
PKB	B-Protein
/	O
Akt	B-Protein
activity	O
.	O

The	O
LY294002	O
study	O
showed	O
that	O
proliferation	O
and	O
viability	O
of	O
both	O
HCD57	O
-	O
SREI	O
and	O
HCD57	O
cells	O
correlated	O
with	O
the	O
activity	O
of	O
PKB	B-Protein
/	O
Akt	B-Protein
;	O
however	O
,	O
PKB	B-Protein
/	O
Akt	B-Protein
activity	O
alone	O
did	O
not	O
protect	O
these	O
cells	O
from	O
apoptosis	O
.	O

Treatment	O
of	O
HCD57	O
cells	O
with	O
SCF	B-Protein
also	O
activated	O
PKB	B-Protein
/	O
Akt	B-Protein
,	O
but	O
did	O
not	O
protect	O
from	O
apoptosis	O
.	O

This	O
result	O
suggested	O
that	O
PKB	B-Protein
/	O
PI3	O
-	O
kinase	O
activity	O
is	O
necessary	O
but	O
not	O
sufficient	O
to	O
promote	O
viability	O
and	O
/	O
or	O
proliferation	O
.	O

Constitutive	O
STAT5	B-Protein
activity	O
,	O
activated	O
through	O
an	O
unknown	O
pathway	O
not	O
including	O
JAK2	B-Protein
or	O
EPOR	B-Protein
,	O
may	O
act	O
in	O
concert	O
with	O
the	O
constitutive	O
PI3	O
-	O
kinase	O
/	O
PKB	B-Protein
/	O
Akt	B-Protein
pathway	O
to	O
protect	O
the	O
EPO	B-Protein
-	O
independent	O
HCD57	O
-	O
SREI	O
cells	O
from	O
apoptosis	O
and	O
promote	O
limited	O
proliferation	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
Tax	B-Protein
protein	O
induces	O
the	O
expression	O
of	O
STAT1	B-Protein
and	O
STAT5	B-Protein
genes	O
in	O
T	O
-	O
cells	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
Tax	B-Protein
transforms	O
normal	O
T	O
-	O
cells	O
in	O
the	O
presence	O
of	O
interleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
-	I-Protein
2	I-Protein
in	O
vitro	O
.	O

STAT	O
is	O
a	O
family	O
of	O
transcription	O
factors	O
that	O
play	O
a	O
pivotal	O
role	O
in	O
cytokine	O
-	O
induced	O
functions	O
of	O
a	O
various	O
type	O
of	O
cells	O
.	O

We	O
investigated	O
the	O
involvement	O
of	O
STATs	O
in	O
the	O
transformation	O
of	O
T	O
-	O
cells	O
by	O
HTLV	O
-	O
1	O
.	O

HTLV	O
-	O
1	O
-	O
transformed	O
T	O
-	O
cell	O
lines	O
expressed	O
higher	O
amounts	O
of	O
STAT1	B-Protein
,	O
STAT3	B-Protein
and	O
STAT5	B-Protein
RNA	O
and	O
proteins	O
than	O
virus	O
-	O
negative	O
T	O
cells	O
.	O

The	O
expression	O
of	O
STAT1	B-Protein
and	O
STAT5	B-Protein
in	O
a	O
human	O
T	O
-	O
cell	O
line	O
was	O
induced	O
by	O
Tax	B-Protein
.	O

IL	B-Protein
-	I-Protein
2	I-Protein
induced	O
the	O
DNA	O
binding	O
activity	O
of	O
STAT3	B-Protein
and	O
STAT5	B-Protein
of	O
a	O
HTLV	O
-	O
1	O
-	O
transformed	O
cell	O
line	O
and	O
then	O
stimulated	O
its	O
proliferation	O
.	O

In	O
contrast	O
,	O
IL	B-Protein
-	I-Protein
2	I-Protein
did	O
neither	O
in	O
a	O
cell	O
line	O
lacking	O
STAT3	B-Protein
and	O
STAT5	B-Protein
.	O

The	O
expression	O
of	O
STAT1	B-Protein
,	O
STAT3	B-Protein
and	O
STAT5	B-Protein
mRNAs	O
were	O
also	O
induced	O
by	O
a	O
T	O
-	O
cell	O
mitogen	O
in	O
normal	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
induction	O
of	O
STAT1	B-Protein
and	O
STAT5	B-Protein
by	O
Tax	B-Protein
enhances	O
cytokine	O
-	O
induced	O
functions	O
of	O
virus	O
-	O
infected	O
T	O
-	O
cells	O
,	O
hence	O
the	O
induction	O
may	O
play	O
a	O
role	O
in	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
dependent	O
transformation	O
steps	O
of	O
T	O
-	O
cells	O
by	O
HTLV	O
-	O
1	O
.	O

Modulation	O
of	O
CD28	B-Protein
expression	O
:	O
distinct	O
regulatory	O
pathways	O
during	O
activation	O
and	O
replicative	O
senescence	O
.	O

The	O
costimulatory	O
molecule	O
CD28	B-Protein
has	O
a	O
restricted	O
tissue	O
distribution	O
and	O
is	O
expressed	O
on	O
T	O
cells	O
and	O
some	O
plasmacytoma	O
cells	O
.	O

Although	O
CD28	B-Protein
is	O
constitutively	O
expressed	O
,	O
its	O
expression	O
is	O
transiently	O
down	O
-	O
regulated	O
following	O
T	O
cell	O
activation	O
and	O
declines	O
progressively	O
with	O
in	O
vitro	O
senescence	O
.	O

In	O
vivo	O
,	O
CD8	O
+	O
T	O
cells	O
and	O
,	O
less	O
frequently	O
,	O
CD4	O
+	O
T	O
cells	O
may	O
completely	O
lose	O
CD28	B-Protein
surface	O
expression	O
during	O
chronic	O
infections	O
and	O
with	O
aging	O
.	O

This	O
correlates	O
with	O
changes	O
of	O
nuclear	O
protein	O
-	O
binding	O
activities	O
to	O
two	O
motifs	O
,	O
site	O
alpha	O
and	O
beta	O
,	O
within	O
the	O
CD28	B-Protein
minimal	O
promoter	O
.	O

Both	O
alpha	O
-	O
and	O
beta	O
-	O
bound	O
complexes	O
are	O
found	O
only	O
in	O
lymphoid	O
tissues	O
,	O
in	O
CD28	B-Protein
+	O
T	O
cells	O
,	O
and	O
in	O
some	O
transformed	O
B	O
cells	O
.	O

These	O
complexes	O
are	O
coordinately	O
expressed	O
except	O
during	O
replicative	O
senescence	O
,	O
which	O
is	O
characterized	O
by	O
the	O
down	O
-	O
modulation	O
of	O
site	O
beta	O
-	O
but	O
not	O
site	O
alpha	O
-	O
binding	O
activities	O
.	O

In	O
contrast	O
,	O
T	O
cell	O
activation	O
induces	O
a	O
parallel	O
decline	O
in	O
both	O
site	O
alpha	O
-	O
and	O
beta	O
-	O
binding	O
activities	O
.	O

CD4	B-Protein
+	O
and	O
CD8	O
+	O
T	O
cells	O
differ	O
in	O
their	O
beta	O
-	O
binding	O
profiles	O
,	O
which	O
may	O
explain	O
the	O
more	O
pronounced	O
down	O
-	O
regulation	O
of	O
CD28	B-Protein
in	O
senescent	O
CD8	O
+	O
T	O
cells	O
.	O

In	O
vivo	O
expanded	O
CD4	B-Protein
+	O
CD28null	B-Protein
and	O
CD8	O
+	O
CD28null	B-Protein
T	O
cells	O
uniformly	O
lack	O
alpha	O
-	O
and	O
beta	O
-	O
bound	O
complexes	O
,	O
resembling	O
the	O
pattern	O
seen	O
in	O
chronically	O
activated	O
cells	O
and	O
not	O
of	O
senescent	O
cells	O
.	O

Glucocorticoid	B-Protein
receptors	I-Protein
in	O
anorexia	O
nervosa	O
and	O
Cushing	O
'	O
s	O
disease	O
.	O

BACKGROUND	O
:	O
Patients	O
with	O
anorexia	O
nervosa	O
do	O
not	O
display	O
cushingoid	O
features	O
in	O
spite	O
of	O
elevated	O
cortisol	O
plasma	O
levels	O
.	O

Whether	O
a	O
cortisol	O
resistance	O
or	O
a	O
reduced	O
availability	O
of	O
the	O
metabolic	O
substrates	O
necessary	O
to	O
develop	O
the	O
effect	O
of	O
glucocorticoids	O
is	O
responsible	O
for	O
this	O
has	O
not	O
been	O
established	O
.	O

METHODS	O
:	O
Twenty	O
-	O
two	O
patients	O
with	O
severe	O
restrictive	O
anorexia	O
nervosa	O
,	O
10	O
patients	O
with	O
active	O
Cushing	O
'	O
s	O
disease	O
,	O
and	O
24	O
healthy	O
volunteers	O
without	O
psychiatric	O
disorders	O
or	O
mood	O
alterations	O
were	O
investigated	O
.	O

Glucocorticoid	B-Protein
receptor	I-Protein
characteristics	O
were	O
examined	O
on	O
mononuclear	O
leukocytes	O
by	O
measuring	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
and	O
the	O
effect	O
of	O
dexamethasone	O
on	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
,	O
which	O
represents	O
an	O
index	O
of	O
DNA	O
synthesis	O
.	O

RESULTS	O
:	O
The	O
number	O
of	O
glucocorticoid	B-Protein
receptors	I-Protein
on	O
mononuclear	O
leukocytes	O
(	O
MNL	O
)	O
was	O
comparable	O
in	O
patients	O
with	O
anorexia	O
nervosa	O
,	O
patients	O
with	O
active	O
Cushing	O
'	O
s	O
disease	O
,	O
and	O
normal	O
subjects	O
(	O
binding	O
capacity	O
3	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
23	O
vs	O
.	O
3	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
30	O
and	O
3	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
20	O
fmol	O
/	O
10	O
(	O
6	O
)	O
cells	O
)	O
.	O

Conversely	O
,	O
glucocorticoid	B-Protein
receptor	I-Protein
affinity	O
was	O
significantly	O
decreased	O
in	O
anorexia	O
nervosa	O
as	O
well	O
as	O
in	O
Cushing	O
'	O
s	O
patients	O
compared	O
to	O
control	O
subjects	O
(	O
dissociation	O
constant	O
4	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
31	O
and	O
4	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
34	O
vs	O
.	O
2	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
29	O
nmol	O
/	O
L	O
,	O
p	O
<	O
.	O
001	O
)	O
and	O
inversely	O
correlated	O
with	O
the	O
levels	O
of	O
urinary	O
free	O
cortisol	O
in	O
both	O
groups	O
of	O
patients	O
.	O

Basal	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
in	O
MNL	O
was	O
significantly	O
reduced	O
in	O
anorexia	O
nervosa	O
as	O
well	O
as	O
in	O
Cushing	O
'	O
s	O
patients	O
compared	O
to	O
control	O
subjects	O
(	O
p	O
<	O
.	O
001	O
)	O
and	O
was	O
diminished	O
by	O
dexamethasone	O
to	O
an	O
extent	O
similar	O
to	O
control	O
subjects	O
in	O
patients	O
with	O
anorexia	O
nervosa	O
,	O
but	O
significantly	O
(	O
p	O
<	O
.	O
001	O
)	O
less	O
in	O
those	O
with	O
Cushing	O
'	O
s	O
disease	O
.	O

In	O
patients	O
with	O
anorexia	O
nervosa	O
,	O
the	O
incorporation	O
of	O
[	O
3H	O
]	O
thymidine	O
into	O
the	O
MNL	O
was	O
inversely	O
correlated	O
with	O
urinary	O
free	O
cortisol	O
levels	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
indicate	O
that	O
the	O
lack	O
of	O
cushingoid	O
features	O
in	O
patients	O
with	O
anorexia	O
nervosa	O
is	O
not	O
ascribable	O
to	O
a	O
reduced	O
sensitivity	O
to	O
glucocorticoids	O
but	O
is	O
more	O
likely	O
due	O
to	O
the	O
paucity	O
of	O
metabolic	O
substrates	O
.	O

Latent	B-Protein
membrane	I-Protein
protein	I-Protein
1	I-Protein
of	O
Epstein	O
-	O
Barr	O
virus	O
interacts	O
with	O
JAK3	B-Protein
and	O
activates	O
STAT	O
proteins	O
.	O

Latent	B-Protein
membrane	I-Protein
protein	I-Protein
1	I-Protein
(	O
LMP1	B-Protein
)	O
acts	O
like	O
a	O
permanently	O
activated	O
receptor	O
of	O
the	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
receptor	O
superfamily	O
and	O
is	O
absolutely	O
required	O
for	O
B	O
cell	O
immortalization	O
by	O
Epstein	O
-	O
Barr	O
virus	O
.	O

Molecular	O
and	O
biochemical	O
approaches	O
demonstrated	O
that	O
LMP1	B-Protein
usurps	O
cellular	O
signaling	O
pathways	O
resulting	O
in	O
the	O
induction	O
of	O
NF	O
-	O
kappaB	O
and	O
AP	O
-	O
1	O
via	O
two	O
C	O
-	O
terminal	O
activating	O
regions	O
.	O

We	O
demonstrate	O
here	O
that	O
a	O
third	O
region	O
encompassing	O
a	O
proline	O
rich	O
sequence	O
within	O
the	O
33	O
bp	O
repetitive	O
stretch	O
of	O
LMP1	B-Protein
'	O
s	O
C	O
-	O
terminus	O
is	O
required	O
for	O
the	O
activation	O
of	O
Janus	B-Protein
kinase	I-Protein
3	I-Protein
(	O
JAK3	B-Protein
)	O
.	O

The	O
interaction	O
of	O
LMP1	B-Protein
and	O
JAK3	B-Protein
leads	O
to	O
the	O
enhanced	O
tyrosine	O
auto	O
/	O
transphosphorylation	O
of	O
JAK3	B-Protein
within	O
minutes	O
after	O
crosslinking	O
of	O
a	O
conditional	O
NGF	B-Protein
-	I-Protein
R	I-Protein
:	O
LMP1	B-Protein
chimera	O
and	O
is	O
a	O
prerequisite	O
for	O
the	O
activation	O
of	O
STAT	O
transcription	O
factors	O
.	O

These	O
results	O
reveal	O
a	O
novel	O
activating	O
region	O
in	O
the	O
LMP1	B-Protein
C	O
-	O
terminus	O
and	O
identify	O
the	O
JAK	O
/	O
STAT	O
pathway	O
as	O
a	O
target	O
of	O
this	O
viral	O
integral	O
membrane	O
protein	O
in	O
B	O
cells	O
.	O

20	O
-	O
Epi	O
analogues	O
of	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
are	O
highly	O
potent	O
inducers	O
of	O
DRIP	O
coactivator	O
complex	O
binding	O
to	O
the	O
vitamin	B-Protein
D3	I-Protein
receptor	I-Protein
.	O

1	O
,	O
25	O
-	O
Dihydroxyvitamin	O
D3	O
(	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
plays	O
a	O
major	O
role	O
in	O
the	O
stimulation	O
of	O
bone	O
growth	O
,	O
mineralization	O
,	O
and	O
intestinal	O
calcium	O
and	O
phosphate	O
absorption	O
;	O
it	O
also	O
acts	O
as	O
a	O
general	O
inhibitor	O
of	O
cellular	O
proliferation	O
.	O

Several	O
new	O
,	O
clinically	O
relevant	O
compounds	O
dissociate	O
antiproliferative	O
and	O
calcemic	O
activities	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
but	O
the	O
molecular	O
basis	O
for	O
this	O
has	O
not	O
been	O
clearly	O
elucidated	O
.	O

Here	O
,	O
we	O
tested	O
whether	O
the	O
potency	O
of	O
one	O
class	O
of	O
compounds	O
,	O
20	O
-	O
epi	O
analogues	O
,	O
to	O
induce	O
myeloid	O
cell	O
differentiation	O
,	O
is	O
because	O
of	O
direct	O
molecular	O
effects	O
on	O
vitamin	B-Protein
D	I-Protein
receptor	I-Protein
(	O
VDR	B-Protein
)	O
.	O

We	O
report	O
that	O
two	O
20	O
-	O
epi	O
analogues	O
,	O
MC1627	O
and	O
MC1288	O
,	O
induced	O
differentiation	O
and	O
transcription	O
of	O
p21	B-Protein
(	O
Waf1	B-Protein
,	O
Cip1	B-Protein
)	O
,	O
a	O
key	O
VDR	B-Protein
target	O
gene	O
involved	O
in	O
growth	O
inhibition	O
,	O
at	O
a	O
concentration	O
100	O
-	O
fold	O
lower	O
than	O
that	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

We	O
compared	O
this	O
sensitivity	O
to	O
analogue	O
effects	O
on	O
VDR	B-Protein
interacting	O
proteins	O
:	O
RXR	O
,	O
GRIP	B-Protein
-	I-Protein
1	I-Protein
,	O
and	O
DRIP205	B-Protein
,	O
a	O
subunit	O
of	O
the	O
DRIP	O
coactivator	O
complex	O
.	O

Compared	O
with	O
the	O
interaction	O
of	O
VDR	B-Protein
with	O
RXR	O
or	O
GRIP	B-Protein
-	I-Protein
1	I-Protein
,	O
the	O
differentiation	O
dose	O
-	O
response	O
most	O
closely	O
correlated	O
to	O
the	O
ligand	O
-	O
dependent	O
recruitment	O
of	O
the	O
DRIP	O
coactivator	O
complex	O
to	O
VDR	B-Protein
and	O
to	O
the	O
ability	O
of	O
the	O
receptor	O
to	O
activate	O
transcription	O
in	O
a	O
cell	O
-	O
free	O
system	O
.	O

These	O
results	O
provide	O
compelling	O
links	O
between	O
the	O
efficiency	O
of	O
the	O
20	O
-	O
epi	O
analogue	O
in	O
inducing	O
VDR	B-Protein
/	O
DRIP	O
interactions	O
,	O
transactivation	O
in	O
vitro	O
,	O
and	O
its	O
enhanced	O
ability	O
to	O
induce	O
cellular	O
differentiation	O
.	O

Multiple	O
NF	B-Protein
-	I-Protein
ATc	I-Protein
isoforms	O
with	O
individual	O
transcriptional	O
properties	O
are	O
synthesized	O
in	O
T	O
lymphocytes	O
.	O

The	O
transcription	O
factor	O
NF	B-Protein
-	I-Protein
ATc	I-Protein
that	O
controls	O
gene	O
expression	O
in	O
T	O
lymphocytes	O
and	O
embryonic	O
cardiac	O
cells	O
is	O
expressed	O
in	O
three	O
prominent	O
isoforms	O
.	O

This	O
is	O
due	O
to	O
alternative	O
splice	O
/	O
polyadenylation	O
events	O
that	O
lead	O
to	O
the	O
predominant	O
synthesis	O
of	O
two	O
long	O
isoforms	O
in	O
naive	O
T	O
cells	O
and	O
a	O
shorter	O
NF	B-Protein
-	I-Protein
ATc	I-Protein
isoform	O
in	O
effector	O
T	O
cells	O
.	O

Whereas	O
the	O
previously	O
described	O
isoform	O
NF	B-Protein
-	I-Protein
ATc	I-Protein
/	O
A	O
contains	O
a	O
relatively	O
short	O
C	O
terminus	O
,	O
the	O
longer	O
isoforms	O
,	O
B	O
and	O
C	O
,	O
span	O
extra	O
C	O
-	O
terminal	O
peptides	O
of	O
128	O
and	O
246	O
aa	O
,	O
respectively	O
.	O

We	O
show	O
here	O
that	O
in	O
addition	O
to	O
the	O
strong	O
N	O
-	O
terminal	O
trans	O
-	O
activation	O
domain	O
,	O
TAD	O
-	O
A	O
,	O
which	O
is	O
common	O
to	O
all	O
three	O
NF	B-Protein
-	I-Protein
ATc	I-Protein
isoforms	O
,	O
NF	B-Protein
-	I-Protein
ATc	I-Protein
/	O
C	O
contains	O
a	O
second	O
trans	O
-	O
activation	O
domain	O
,	O
TAD	O
-	O
B	O
,	O
in	O
its	O
C	O
-	O
terminal	O
peptide	O
.	O

Various	O
stimuli	O
of	O
T	O
cells	O
that	O
induce	O
the	O
activity	O
of	O
TAD	O
-	O
A	O
also	O
enhance	O
the	O
activity	O
of	O
TAD	O
-	O
B	O
,	O
but	O
,	O
unlike	O
TAD	O
-	O
A	O
,	O
TAD	O
-	O
B	O
remains	O
unphosphorylated	O
by	O
protein	O
from	O
12	O
-	O
O	O
-	O
tetradecanoyl	O
12	O
-	O
phorbol	O
13	O
-	O
acetate	O
-	O
stimulated	O
T	O
cells	O
.	O

The	O
shorter	O
C	O
-	O
terminal	O
peptide	O
of	O
isoform	O
NF	B-Protein
-	I-Protein
ATc	I-Protein
/	O
B	O
exerts	O
a	O
suppressive	O
transcriptional	O
effect	O
.	O

These	O
properties	O
of	O
NF	B-Protein
-	I-Protein
ATc	I-Protein
/	O
B	O
and	O
-	O
C	O
might	O
be	O
of	O
importance	O
for	O
gene	O
regulation	O
in	O
naive	O
T	O
lymphocytes	O
in	O
which	O
NF	B-Protein
-	I-Protein
ATc	I-Protein
/	O
B	O
and	O
-	O
C	O
are	O
predominantly	O
synthesized	O
.	O

Phorbol	O
ester	O
-	O
induced	O
mononuclear	O
cell	O
differentiation	O
is	O
blocked	O
by	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
kinase	O
(	O
MEK	O
)	O
inhibitor	O
PD98059	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
whether	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
signaling	O
pathway	O
contributes	O
to	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
-	O
induced	O
mononuclear	O
differentiation	O
in	O
the	O
human	O
myeloblastic	O
leukemia	O
ML	O
-	O
1	O
cells	O
.	O

Upon	O
TPA	O
treatment	O
,	O
the	O
activity	O
of	O
ERK1	B-Protein
and	O
ERK2	B-Protein
rapidly	O
increased	O
,	O
with	O
maximal	O
induction	O
between	O
1	O
and	O
3	O
h	O
,	O
while	O
ERK2	B-Protein
protein	O
levels	O
remained	O
constant	O
.	O

The	O
activity	O
of	O
JNK1	B-Protein
was	O
also	O
significantly	O
induced	O
,	O
with	O
JNK1	B-Protein
protein	O
levels	O
increasing	O
moderately	O
during	O
exposure	O
to	O
TPA	O
.	O

Treatment	O
of	O
cells	O
with	O
PD98059	O
,	O
a	O
specific	O
inhibitor	O
of	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
kinase	O
(	O
MEK	O
)	O
,	O
inhibited	O
TPA	O
-	O
induced	O
ERK2	B-Protein
activity	O
.	O

Furthermore	O
,	O
PD98059	O
completely	O
blocked	O
the	O
TPA	O
-	O
induced	O
differentiation	O
of	O
ML	O
-	O
1	O
cells	O
,	O
as	O
assessed	O
by	O
a	O
number	O
of	O
features	O
associated	O
with	O
mononuclear	O
differentiation	O
including	O
changes	O
in	O
morphology	O
,	O
nonspecific	O
esterase	O
activity	O
,	O
phagocytic	O
ability	O
,	O
NADPH	O
oxidase	O
activity	O
,	O
mitochondrial	O
respiration	O
,	O
and	O
c	B-Protein
-	I-Protein
jun	I-Protein
mRNA	O
inducibility	O
.	O

We	O
conclude	O
that	O
activation	O
of	O
the	O
MEK	O
/	O
ERK	O
signaling	O
pathway	O
is	O
necessary	O
for	O
TPA	O
-	O
induced	O
mononuclear	O
cell	O
differentiation	O
.	O

Immune	O
functions	O
,	O
clinical	O
parameters	O
and	O
hormone	O
receptor	O
status	O
in	O
breast	O
cancer	O
patients	O
.	O

We	O
have	O
carried	O
out	O
a	O
detailed	O
analysis	O
of	O
the	O
cellular	O
immune	O
functions	O
of	O
breast	O
cancer	O
patients	O
in	O
comparison	O
with	O
healthy	O
controls	O
.	O

A	O
possible	O
correlation	O
between	O
immune	O
and	O
clinical	O
parameters	O
was	O
analysed	O
in	O
50	O
breast	O
cancer	O
patients	O
.	O

Immune	O
parameters	O
,	O
natural	O
killer	O
cell	O
and	O
T	O
lymphocyte	O
functions	O
and	O
the	O
numbers	O
of	O
circulating	O
T	O
lymphocytes	O
were	O
analysed	O
against	O
the	O
clinical	O
parameters	O
comprising	O
the	O
tumour	O
burden	O
,	O
the	O
stage	O
of	O
the	O
disease	O
and	O
the	O
expression	O
of	O
hormone	O
receptors	O
on	O
the	O
tumour	O
.	O

In	O
order	O
to	O
analyse	O
the	O
immune	O
function	O
data	O
effectively	O
,	O
low	O
responders	O
were	O
identified	O
with	O
stringent	O
cut	O
-	O
off	O
values	O
.	O

Considerably	O
higher	O
proportions	O
of	O
low	O
responders	O
were	O
found	O
among	O
the	O
patient	O
population	O
.	O

Elevated	O
numbers	O
of	O
circulating	O
T	O
lymphocytes	O
and	O
CD3	O
-	O
directed	O
cytolysis	O
correlated	O
with	O
the	O
expression	O
of	O
oestrogen	B-Protein
receptors	I-Protein
independently	O
of	O
the	O
clinical	O
/	O
histological	O
parameters	O
.	O

UV	O
-	O
induced	O
CYP1A1	B-Protein
gene	O
expression	O
in	O
human	O
cells	O
is	O
mediated	O
by	O
tryptophan	O
.	O

Induction	O
of	O
cytochrome	B-Protein
P	I-Protein
-	I-Protein
4501A1	I-Protein
(	O
CYP1A1	B-Protein
)	O
activity	O
by	O
UV	O
has	O
been	O
observed	O
earlier	O
in	O
animal	O
studies	O
via	O
a	O
mechanism	O
that	O
has	O
not	O
yet	O
been	O
resolved	O
.	O

Our	O
previous	O
data	O
have	O
indicated	O
that	O
formylated	O
indolocarbazoles	O
which	O
are	O
formed	O
by	O
UV	O
irradiation	O
of	O
tryptophan	O
solutions	O
are	O
very	O
potent	O
Ah	B-Protein
-	I-Protein
receptor	I-Protein
agonists	O
.	O

To	O
evaluate	O
the	O
effect	O
of	O
UV	O
light	O
on	O
cytochrome	B-Protein
P4501A1	I-Protein
gene	O
expression	O
,	O
we	O
studied	O
the	O
induction	O
of	O
CYP1A1	B-Protein
mRNA	O
by	O
UV	O
irradiation	O
of	O
cultured	O
human	O
keratinocytes	O
(	O
HaCaT	O
cell	O
line	O
)	O
,	O
primary	O
human	O
blood	O
lymphocytes	O
and	O
mouse	O
Hepa	O
-	O
1	O
cells	O
.	O

The	O
cells	O
were	O
exposed	O
to	O
UV	O
light	O
delivered	O
by	O
a	O
bank	O
of	O
6	O
Philips	O
TL20	O
/	O
12RS	O
sun	O
lamps	O
emitting	O
primarily	O
in	O
the	O
UVB	O
range	O
in	O
the	O
absence	O
and	O
presence	O
of	O
tryptophan	O
.	O

A	O
semiquantitative	O
reverse	O
transcriptase	O
-	O
linked	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
was	O
used	O
for	O
analysis	O
of	O
gene	O
expression	O
in	O
the	O
treated	O
cells	O
.	O

The	O
results	O
show	O
that	O
the	O
CYP1A1	B-Protein
mRNA	O
level	O
induced	O
by	O
UV	O
in	O
the	O
presence	O
of	O
tryptophan	O
was	O
higher	O
than	O
that	O
induced	O
by	O
UV	O
alone	O
in	O
both	O
HaCaT	O
cells	O
and	O
lymphocytes	O
after	O
3	O
h	O
of	O
incubation	O
post	O
-	O
UV	O
irradiation	O
.	O

To	O
find	O
out	O
if	O
the	O
induction	O
by	O
UV	O
light	O
is	O
caused	O
by	O
the	O
formation	O
of	O
an	O
Ah	B-Protein
receptor	I-Protein
ligand	O
,	O
Hepa	O
-	O
1	O
wild	O
-	O
type	O
and	O
Ah	B-Protein
receptor	I-Protein
deficient	O
c12	O
cell	O
lines	O
were	O
applied	O
.	O

Wild	O
-	O
type	O
(	O
wt	O
)	O
cells	O
were	O
inducible	O
either	O
by	O
the	O
tryptophan	O
photoproduct	O
6	O
-	O
formylindolo	O
[	O
3	O
,	O
2	O
-	O
b	O
]	O
carbazole	O
(	O
FICZ	O
)	O
or	O
by	O
UV	O
-	O
irradiation	O
but	O
very	O
low	O
or	O
undetectable	O
levels	O
were	O
observed	O
in	O
the	O
c12	O
cells	O
.	O

This	O
shows	O
that	O
the	O
induction	O
of	O
gene	O
expression	O
by	O
FICZ	O
and	O
UV	O
is	O
Ah	B-Protein
receptor	I-Protein
dependent	O
.	O

Together	O
,	O
these	O
results	O
indicate	O
that	O
UV	O
-	O
induced	O
CYP1A1	B-Protein
gene	O
expression	O
in	O
mammalian	O
cells	O
is	O
mediated	O
by	O
an	O
Ah	B-Protein
receptor	I-Protein
ligand	O
formed	O
from	O
tryptophan	O
.	O

Thus	O
,	O
the	O
photoproducts	O
of	O
tryptophan	O
are	O
suggested	O
to	O
be	O
mediators	O
of	O
light	O
via	O
binding	O
to	O
the	O
Ah	B-Protein
receptor	I-Protein
and	O
as	O
such	O
also	O
could	O
have	O
a	O
role	O
in	O
light	O
-	O
regulated	O
biological	O
rhythms	O
.	O

Effects	O
of	O
diesel	O
organic	O
extracts	O
on	O
chemokine	O
production	O
by	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

BACKGROUND	O
:	O
Polyaromatic	O
hydrocarbons	O
(	O
PAHs	O
)	O
associated	O
with	O
diesel	O
exhaust	O
particles	O
(	O
DEPs	O
)	O
are	O
found	O
in	O
the	O
atmospheric	O
urban	O
pollution	O
.	O

Such	O
compounds	O
have	O
been	O
shown	O
to	O
favor	O
IgE	O
production	O
,	O
bronchial	O
hyperresponsiveness	O
,	O
and	O
airway	O
inflammation	O
.	O

Chemokines	O
are	O
a	O
group	O
of	O
chemotactic	O
cytokines	O
involved	O
in	O
the	O
recruitment	O
of	O
inflammatory	O
cells	O
.	O

OBJECTIVE	O
:	O
We	O
investigated	O
the	O
effect	O
of	O
DEP	O
-	O
PAHs	O
on	O
the	O
release	O
and	O
mRNA	O
expression	O
of	O
IL	B-Protein
-	I-Protein
8	I-Protein
,	O
MCP	B-Protein
-	I-Protein
1	I-Protein
,	O
and	O
RANTES	B-Protein
by	O
PBMCs	O
obtained	O
from	O
healthy	O
subjects	O
.	O

METHODS	O
:	O
Protein	O
production	O
in	O
supernatants	O
was	O
assessed	O
by	O
ELISA	O
,	O
and	O
mRNA	O
expression	O
was	O
evaluated	O
by	O
semiquantitative	O
RT	O
-	O
PCR	O
.	O

RESULTS	O
:	O
Secretion	O
of	O
IL	B-Protein
-	I-Protein
8	I-Protein
and	O
RANTES	B-Protein
increased	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
with	O
increasing	O
concentrations	O
of	O
DEP	O
-	O
PAHs	O
(	O
range	O
,	O
0	O
.	O
5	O
ng	O
to	O
50	O
ng	O
/	O
mL	O
)	O
.	O

On	O
the	O
contrary	O
,	O
the	O
release	O
of	O
MCP	B-Protein
-	I-Protein
1	I-Protein
was	O
significantly	O
inhibited	O
,	O
also	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Messenger	O
RNA	O
production	O
coding	O
for	O
IL	B-Protein
-	I-Protein
8	I-Protein
,	O
RANTES	B-Protein
,	O
and	O
MCP	B-Protein
-	I-Protein
1	I-Protein
showed	O
parallel	O
variations	O
to	O
the	O
production	O
of	O
the	O
correspondent	O
proteins	O
.	O

Effects	O
of	O
DEP	O
-	O
PAHs	O
became	O
significant	O
at	O
7	O
hours	O
and	O
up	O
to	O
48	O
hours	O
time	O
culture	O
for	O
MCP	B-Protein
-	I-Protein
1	I-Protein
,	O
and	O
up	O
to	O
24	O
hours	O
time	O
culture	O
for	O
IL	B-Protein
-	I-Protein
8	I-Protein
and	O
RANTES	B-Protein
.	O

Moreover	O
,	O
supernatants	O
from	O
DEP	O
-	O
PAH	O
-	O
activated	O
cells	O
,	O
compared	O
with	O
those	O
of	O
controls	O
,	O
exhibited	O
a	O
significantly	O
enhanced	O
chemotactic	O
activity	O
for	O
neutrophils	O
and	O
eosinophils	O
,	O
which	O
was	O
significantly	O
inhibited	O
by	O
pretreatment	O
with	O
anti	O
-	O
IL	B-Protein
-	I-Protein
8	I-Protein
and	O
anti	O
-	O
RANTES	B-Protein
neutralizing	O
antibodies	O
,	O
respectively	O
.	O

CONCLUSION	O
:	O
These	O
findings	O
suggest	O
that	O
the	O
chemokine	O
pathways	O
are	O
modulated	O
by	O
DEP	O
-	O
PAHs	O
at	O
the	O
transcriptional	O
level	O
,	O
reinforcing	O
the	O
idea	O
that	O
the	O
development	O
of	O
inflammatory	O
reactions	O
might	O
be	O
affected	O
by	O
diesel	O
exhaust	O
emission	O
.	O

Oxidative	O
stress	O
triggers	O
STAT3	B-Protein
tyrosine	O
phosphorylation	O
and	O
nuclear	O
translocation	O
in	O
human	O
lymphocytes	O
.	O

Oxidizing	O
agents	O
are	O
powerful	O
activators	O
of	O
factors	O
responsible	O
for	O
the	O
transcriptional	O
activation	O
of	O
cytokine	O
-	O
encoding	O
genes	O
involved	O
in	O
tissue	O
injury	O
.	O

In	O
this	O
study	O
we	O
show	O
evidence	O
that	O
STAT3	B-Protein
is	O
a	O
transcription	O
factor	O
whose	O
activity	O
is	O
modulated	O
by	O
H2O2	O
in	O
human	O
lymphocytes	O
,	O
in	O
which	O
endogenous	O
catalase	O
had	O
previously	O
been	O
inhibited	O
.	O

H2O2	O
-	O
induced	O
nuclear	O
translocation	O
of	O
STAT3	B-Protein
to	O
form	O
sequence	O
-	O
specific	O
DNA	O
-	O
bound	O
complexes	O
was	O
evidenced	O
by	O
immunoblotting	O
of	O
nuclear	O
fractions	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
and	O
vanadate	O
was	O
found	O
to	O
strongly	O
synergize	O
with	O
H2O2	O
.	O

Moreover	O
,	O
anti	O
-	O
STAT3	B-Protein
antibodies	O
specifically	O
precipitated	O
a	O
protein	O
of	O
92	O
kDa	O
that	O
becomes	O
phosphorylated	O
on	O
tyrosine	O
upon	O
lymphocyte	O
treatment	O
with	O
H2O2	O
.	O

Phenylarsine	O
oxide	O
,	O
a	O
tyrosine	O
phosphatase	O
inhibitor	O
,	O
and	O
genistein	O
,	O
a	O
tyrosine	O
kinase	O
inhibitor	O
,	O
cooperated	O
and	O
cancelled	O
,	O
respectively	O
,	O
the	O
H2O2	O
-	O
promoted	O
STAT3	B-Protein
nuclear	O
translocation	O
.	O

Evidence	O
is	O
also	O
presented	O
,	O
using	O
Fe2	O
+	O
/	O
Cu2	O
+	O
ions	O
,	O
that	O
.	O
OH	O
generated	O
from	O
H2O2	O
through	O
Fenton	O
reactions	O
could	O
be	O
a	O
candidate	O
oxygen	O
reactive	O
species	O
to	O
directly	O
activate	O
STAT3	B-Protein
.	O

Present	O
data	O
suggest	O
that	O
H2O2	O
and	O
vanadate	O
are	O
likely	O
to	O
inhibit	O
the	O
activity	O
of	O
intracellular	O
tyrosine	O
phosphatase	O
(	O
s	O
)	O
,	O
leading	O
to	O
enhanced	O
STAT3	B-Protein
tyrosine	O
phosphorylation	O
and	O
hence	O
its	O
translocation	O
to	O
the	O
nucleus	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
DNA	O
binding	O
activity	O
of	O
STAT3	B-Protein
can	O
be	O
modulated	O
by	O
oxidizing	O
agents	O
and	O
provide	O
a	O
framework	O
to	O
understand	O
the	O
effects	O
of	O
oxidative	O
stress	O
on	O
the	O
JAK	O
-	O
STAT	O
signaling	O
pathway	O
.	O

Binding	O
characteristics	O
of	O
the	O
glucocorticoid	B-Protein
receptor	I-Protein
in	O
peripheral	O
blood	O
lymphocytes	O
in	O
multiple	O
sclerosis	O
.	O

Although	O
the	O
exact	O
etiology	O
of	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
remains	O
unresolved	O
,	O
immune	O
reactions	O
are	O
believed	O
to	O
be	O
the	O
central	O
pathogenic	O
mechanisms	O
.	O

Endogenous	O
and	O
therapeutic	O
steroid	O
hormones	O
affect	O
the	O
immune	O
system	O
,	O
and	O
inflammatory	O
diseases	O
are	O
associated	O
with	O
activation	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
,	O
providing	O
evidence	O
of	O
an	O
immune	O
-	O
endocrine	O
interplay	O
.	O

Function	O
tests	O
in	O
MS	O
have	O
revealed	O
dysregulation	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
system	O
in	O
a	O
substantial	O
proportion	O
of	O
patients	O
.	O

We	O
characterized	O
glucocorticoid	B-Protein
receptor	I-Protein
(	O
GR	B-Protein
)	O
binding	O
in	O
peripheral	O
blood	O
lymphocytes	O
from	O
39	O
MS	O
patients	O
and	O
14	O
age	O
-	O
and	O
sex	O
-	O
matched	O
controls	O
with	O
respect	O
to	O
dissociation	O
constant	O
and	O
binding	O
capacity	O
,	O
using	O
a	O
whole	O
-	O
cell	O
binding	O
assay	O
with	O
[	O
3H	O
]	O
dexamethasone	O
as	O
the	O
ligand	O
.	O

GR	B-Protein
binding	O
parameters	O
did	O
not	O
differ	O
significantly	O
between	O
patients	O
(	O
Kd	O
8	O
.	O
98	O
+	O
/	O
-	O
1	O
.	O
07	O
nM	O
,	O
Bmax	O
183	O
+	O
/	O
-	O
29	O
.	O
8	O
fmol	O
/	O
mg	O
)	O
and	O
controls	O
(	O
Kd	O
9	O
.	O
36	O
+	O
/	O
-	O
1	O
.	O
17	O
nM	O
,	O
Bmax	O
158	O
+	O
/	O
-	O
16	O
fmol	O
/	O
mg	O
)	O
.	O

No	O
effect	O
of	O
age	O
,	O
sex	O
,	O
course	O
,	O
duration	O
or	O
severity	O
of	O
disease	O
,	O
or	O
prior	O
steroid	O
treatments	O
was	O
detected	O
.	O

GR	B-Protein
binding	O
parameters	O
were	O
analyzed	O
in	O
relation	O
to	O
the	O
results	O
of	O
the	O
combined	O
dexamethasone	O
-	O
CRH	B-Protein
test	O
,	O
which	O
reflects	O
corticosteroid	O
receptor	O
function	O
at	O
the	O
hypothalamus	O
,	O
in	O
30	O
patients	O
and	O
9	O
controls	O
.	O

While	O
controls	O
showed	O
a	O
moderate	O
correlation	O
between	O
binding	O
affinity	O
of	O
the	O
GR	B-Protein
in	O
lymphocytes	O
and	O
regulatory	O
function	O
at	O
the	O
hypothalamic	O
level	O
,	O
the	O
patients	O
did	O
not	O
.	O

These	O
data	O
suggest	O
that	O
the	O
physiological	O
relationship	O
between	O
binding	O
and	O
function	O
of	O
the	O
glucocorticoid	B-Protein
receptor	I-Protein
is	O
disturbed	O
in	O
MS	O
.	O

CBP	B-Protein
/	O
p300	B-Protein
integrates	O
Raf	O
/	O
Rac	O
-	O
signaling	O
pathways	O
in	O
the	O
transcriptional	O
induction	O
of	O
NF	B-Protein
-	I-Protein
ATc	I-Protein
during	O
T	O
cell	O
activation	O
.	O

NF	B-Protein
-	I-Protein
ATc	I-Protein
,	O
an	O
inducibly	O
expressed	O
transcription	O
factor	O
,	O
controls	O
gene	O
expression	O
in	O
T	O
lymphocytes	O
and	O
cardiomyocytes	O
.	O

We	O
show	O
here	O
that	O
the	O
transcriptional	O
co	O
-	O
activators	O
CBP	B-Protein
/	O
p300	B-Protein
bind	O
to	O
and	O
control	O
the	O
activity	O
of	O
the	O
inducible	O
N	O
-	O
terminal	O
transactivation	O
domain	O
of	O
NF	B-Protein
-	I-Protein
ATc	I-Protein
,	O
TAD	O
-	O
A	O
.	O

Similar	O
to	O
the	O
N	O
terminal	O
transactivation	O
domain	O
of	O
c	B-Protein
-	I-Protein
Jun	I-Protein
,	O
TAD	O
-	O
A	O
is	O
inducibly	O
phosphorylated	O
,	O
but	O
this	O
phosphorylation	O
is	O
dispensable	O
for	O
the	O
interaction	O
with	O
CBP	B-Protein
/	O
p300	B-Protein
.	O

Constitutive	O
active	O
versions	O
of	O
c	B-Protein
-	I-Protein
Raf	I-Protein
and	O
Rac	O
synergistically	O
enhance	O
the	O
CBP	B-Protein
/	O
p300	B-Protein
-	O
mediated	O
increase	O
of	O
TAD	O
-	O
A	O
activity	O
,	O
indicating	O
the	O
important	O
role	O
CBP	B-Protein
/	O
p300	B-Protein
plays	O
in	O
the	O
integration	O
of	O
T	O
cell	O
activation	O
signals	O
.	O

Since	O
a	O
mutation	O
of	O
CBP	B-Protein
abolishing	O
HAT	O
activity	O
is	O
almost	O
as	O
active	O
as	O
wild	O
-	O
type	O
CBP	B-Protein
in	O
T	O
cells	O
,	O
functions	O
of	O
CBP	B-Protein
/	O
p300	B-Protein
other	O
than	O
histone	O
acetylation	O
appear	O
to	O
control	O
the	O
NF	O
-	O
AT	O
-	O
dependent	O
transcription	O
in	O
T	O
cells	O
.	O

Association	O
of	O
the	O
interleukin	B-Protein
-	I-Protein
4	I-Protein
receptor	I-Protein
alpha	I-Protein
chain	I-Protein
with	O
p47phox	B-Protein
,	O
an	O
activator	O
of	O
the	O
phagocyte	O
NADPH	O
oxidase	O
in	O
B	O
cells	O
.	O

Interleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
-	I-Protein
4	I-Protein
plays	O
an	O
important	O
role	O
in	O
IgE	O
synthesis	O
in	O
B	O
cells	O
and	O
in	O
Th2	O
differentiation	O
in	O
T	O
cells	O
.	O

IL	B-Protein
-	I-Protein
4	I-Protein
conducts	O
its	O
biological	O
activities	O
through	O
binding	O
to	O
the	O
IL	O
-	O
4	O
receptor	O
(	O
IL	O
-	O
4R	O
)	O
on	O
the	O
surface	O
of	O
target	O
cells	O
.	O

IL	O
-	O
4R	O
are	O
thought	O
to	O
be	O
composed	O
of	O
the	O
IL	B-Protein
-	I-Protein
4R	I-Protein
alpha	I-Protein
chain	I-Protein
(	O
IL	B-Protein
-	I-Protein
4R	I-Protein
alpha	I-Protein
)	O
and	O
either	O
the	O
IL	B-Protein
-	I-Protein
2R	I-Protein
gamma	I-Protein
chain	I-Protein
or	O
the	O
IL	B-Protein
-	I-Protein
13R	I-Protein
alpha	I-Protein
chain	I-Protein
.	O

We	O
have	O
previously	O
shown	O
that	O
the	O
membrane	O
-	O
proximal	O
portion	O
in	O
the	O
cytoplasmic	O
domain	O
of	O
the	O
human	O
IL	B-Protein
-	I-Protein
4R	I-Protein
alpha	I-Protein
(	O
hIL	B-Protein
-	I-Protein
4R	I-Protein
alpha	I-Protein
)	O
is	O
critical	O
for	O
proliferation	O
,	O
generation	O
of	O
germline	O
epsilon	O
transcript	O
,	O
and	O
activation	O
of	O
STAT6	B-Protein
,	O
based	O
on	O
analyses	O
of	O
truncated	O
hIL	B-Protein
-	I-Protein
4R	I-Protein
alphas	I-Protein
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
p47phox	B-Protein
,	O
an	O
activator	O
of	O
the	O
phagocyte	O
NADPH	O
oxidase	O
,	O
binds	O
to	O
this	O
portion	O
by	O
the	O
two	O
-	O
hybrid	O
system	O
.	O

Furthermore	O
,	O
we	O
observed	O
the	O
association	O
of	O
p47phox	B-Protein
with	O
the	O
hIL	B-Protein
-	I-Protein
4R	I-Protein
alpha	I-Protein
in	O
B	O
cells	O
derived	O
from	O
a	O
normal	O
donor	O
.	O

These	O
results	O
suggest	O
that	O
p47phox	B-Protein
is	O
involved	O
in	O
the	O
signal	O
transduction	O
of	O
IL	B-Protein
-	I-Protein
4	I-Protein
in	O
B	O
cells	O
.	O

However	O
,	O
activation	O
of	O
STAT6	B-Protein
,	O
CD23	B-Protein
expression	O
,	O
and	O
IgE	O
synthesis	O
induced	O
by	O
IL	B-Protein
-	I-Protein
4	I-Protein
were	O
not	O
affected	O
in	O
p47phox	B-Protein
-	O
deficient	O
patients	O
,	O
which	O
raises	O
the	O
possibility	O
that	O
p47phox	B-Protein
may	O
be	O
important	O
in	O
other	O
signaling	O
activities	O
as	O
well	O
in	O
B	O
cells	O
.	O

Aiolos	B-Protein
transcription	O
factor	O
controls	O
cell	O
death	O
in	O
T	O
cells	O
by	O
regulating	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
expression	O
and	O
its	O
cellular	O
localization	O
.	O

We	O
searched	O
for	O
proteins	O
that	O
interact	O
with	O
Ras	O
in	O
interleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
-	I-Protein
2	I-Protein
-	O
stimulated	O
or	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
deprived	O
cells	O
,	O
and	O
found	O
that	O
the	O
transcription	O
factor	O
Aiolos	B-Protein
interacts	O
with	O
Ras	O
.	O

The	O
Ras	O
-	O
Aiolos	B-Protein
interaction	O
was	O
confirmed	O
in	O
vitro	O
and	O
in	O
vivo	O
by	O
co	O
-	O
immunoprecipitation	O
.	O

Indirect	O
immunofluorescence	O
shows	O
that	O
IL	B-Protein
-	I-Protein
2	I-Protein
controls	O
the	O
cellular	O
distribution	O
of	O
Aiolos	B-Protein
and	O
induces	O
its	O
tyrosine	O
phosphorylation	O
,	O
required	O
for	O
dissociation	O
from	O
Ras	O
.	O

We	O
also	O
identified	O
functional	O
Aiolos	B-Protein
-	O
binding	O
sites	O
in	O
the	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
promoter	O
,	O
which	O
are	O
able	O
to	O
activate	O
the	O
luciferase	B-Protein
reporter	O
gene	O
.	O

Mutation	O
of	O
Aiolos	B-Protein
-	O
binding	O
sites	O
within	O
the	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
promoter	O
inhibits	O
transactivation	O
of	O
the	O
reporter	O
gene	O
luciferase	B-Protein
,	O
suggesting	O
direct	O
control	O
of	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
expression	O
by	O
Aiolos	B-Protein
.	O

Co	O
-	O
transfection	O
experiments	O
confirm	O
that	O
Aiolos	B-Protein
induces	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
expression	O
and	O
prevents	O
apoptosis	O
in	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
deprived	O
cells	O
.	O

We	O
propose	O
a	O
model	O
for	O
the	O
regulation	O
of	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
expression	O
via	O
Aiolos	B-Protein
.	O

C	B-Protein
/	I-Protein
EBP	I-Protein
beta	I-Protein
in	O
rheumatoid	O
arthritis	O
:	O
correlation	O
with	O
inflammation	O
,	O
not	O
disease	O
specificity	O
.	O

Rheumatoid	O
arthritis	O
synovial	O
tissue	O
was	O
examined	O
and	O
compared	O
with	O
osteoarthritis	O
tissue	O
for	O
the	O
presence	O
of	O
the	O
nuclear	O
transcription	O
factor	O
C	B-Protein
/	I-Protein
EBP	I-Protein
beta	I-Protein
(	O
NF	B-Protein
-	I-Protein
IL	I-Protein
-	I-Protein
6	I-Protein
)	O
.	O

The	O
region	O
(	O
lining	O
or	O
sublining	O
)	O
,	O
cell	O
type	O
,	O
and	O
subcellular	O
distribution	O
(	O
cytoplasmic	O
or	O
nuclear	O
)	O
of	O
the	O
expression	O
of	O
C	O
/	O
EBP	O
beta	O
was	O
characterized	O
.	O

Rheumatoid	O
arthritis	O
synovial	O
fluid	O
and	O
blood	O
and	O
normal	O
peripheral	O
blood	O
were	O
also	O
examined	O
.	O

C	B-Protein
/	I-Protein
EBP	I-Protein
beta	I-Protein
was	O
detected	O
in	O
the	O
synovial	O
lining	O
and	O
in	O
sublining	O
cells	O
of	O
synovial	O
tissue	O
from	O
patients	O
with	O
both	O
rheumatoid	O
and	O
osteoarthritis	O
.	O

A	O
significant	O
(	O
P	O
<	O
0	O
.	O
001	O
and	O
<	O
0	O
.	O
05	O
,	O
respectively	O
)	O
increase	O
in	O
the	O
percentage	O
of	O
cells	O
with	O
nuclear	O
staining	O
was	O
seen	O
in	O
the	O
lining	O
layer	O
,	O
compared	O
to	O
cells	O
in	O
the	O
sublining	O
region	O
,	O
in	O
rheumatoid	O
and	O
osteoarthritis	O
.	O

In	O
both	O
diseases	O
a	O
strong	O
correlation	O
(	O
r	O
=	O
0	O
.	O
79	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
was	O
observed	O
between	O
the	O
percentage	O
of	O
cells	O
in	O
the	O
synovial	O
lining	O
that	O
were	O
positive	O
for	O
nuclear	O
C	B-Protein
/	I-Protein
EBP	I-Protein
beta	I-Protein
and	O
lining	O
cell	O
depth	O
.	O

Two	O
-	O
color	O
immunohistochemistry	O
demonstrated	O
that	O
both	O
macrophages	O
and	O
fibroblast	O
-	O
like	O
synoviocytes	O
were	O
positive	O
for	O
nuclear	O
C	B-Protein
/	I-Protein
EBP	I-Protein
beta	I-Protein
.	O

The	O
presence	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
beta	I-Protein
was	O
confirmed	O
by	O
immunohistochemistry	O
and	O
Western	O
blot	O
analysis	O
with	O
isolated	O
synovial	O
fibroblasts	O
.	O

Nuclear	O
C	B-Protein
/	I-Protein
EBP	I-Protein
beta	I-Protein
was	O
also	O
detected	O
in	O
rheumatoid	O
synovial	O
fluid	O
monocytes	O
/	O
macrophages	O
,	O
but	O
not	O
in	O
lymphocytes	O
or	O
neutrophils	O
.	O

Western	O
blot	O
analysis	O
confirmed	O
the	O
presence	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
beta	I-Protein
in	O
these	O
cells	O
.	O

The	O
intensity	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
beta	I-Protein
staining	O
was	O
greater	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
synovial	O
fluid	O
monocytes	O
than	O
in	O
those	O
from	O
normal	O
or	O
rheumatoid	O
peripheral	O
blood	O
.	O

In	O
conclusion	O
,	O
the	O
enhanced	O
nuclear	O
staining	O
for	O
C	B-Protein
/	I-Protein
EBP	I-Protein
beta	I-Protein
in	O
the	O
synovial	O
lining	O
,	O
compared	O
to	O
the	O
sublining	O
,	O
suggesting	O
activation	O
in	O
the	O
lining	O
,	O
and	O
the	O
positive	O
correlation	O
of	O
lining	O
layer	O
depth	O
with	O
the	O
percentage	O
of	O
cells	O
in	O
the	O
lining	O
positive	O
for	O
nuclear	O
C	B-Protein
/	I-Protein
EBP	I-Protein
beta	I-Protein
,	O
suggest	O
a	O
potential	O
role	O
for	O
C	B-Protein
/	I-Protein
EBP	I-Protein
beta	I-Protein
in	O
chronic	O
inflammation	O
.	O

The	O
regulation	O
of	O
the	O
production	O
or	O
activity	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
beta	I-Protein
,	O
to	O
inhibit	O
inflammatory	O
mediator	O
expression	O
by	O
synovial	O
macrophages	O
and	O
fibroblasts	O
,	O
offers	O
a	O
novel	O
approach	O
to	O
therapeutic	O
intervention	O
.	O

p70	B-Protein
(	I-Protein
s6k	I-Protein
)	I-Protein
integrates	O
phosphatidylinositol	O
3	O
-	O
kinase	O
and	O
rapamycin	O
-	O
regulated	O
signals	O
for	O
E2F	O
regulation	O
in	O
T	O
lymphocytes	O
.	O

In	O
T	O
lymphocytes	O
,	O
the	O
hematopoietic	O
cytokine	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
(	O
IL	B-Protein
-	I-Protein
2	I-Protein
)	O
uses	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PI	O
3	O
-	O
kinase	O
)	O
-	O
induced	O
signaling	O
pathways	O
to	O
regulate	O
E2F	O
transcriptional	O
activity	O
,	O
a	O
critical	O
cell	O
cycle	O
checkpoint	O
.	O

PI	O
3	O
-	O
kinase	O
also	O
regulates	O
the	O
activity	O
of	O
p70	B-Protein
(	I-Protein
s6k	I-Protein
)	I-Protein
,	O
the	O
40S	O
ribosomal	O
protein	O
S6	O
kinase	O
,	O
a	O
response	O
that	O
is	O
abrogated	O
by	O
the	O
macrolide	O
rapamycin	O
.	O

This	O
immunosuppressive	O
drug	O
is	O
known	O
to	O
prevent	O
T	O
-	O
cell	O
proliferation	O
,	O
but	O
the	O
precise	O
point	O
at	O
which	O
rapamycin	O
regulates	O
T	O
-	O
cell	O
cycle	O
progression	O
has	O
yet	O
to	O
be	O
elucidated	O
.	O

Moreover	O
,	O
the	O
effects	O
of	O
rapamycin	O
on	O
,	O
and	O
the	O
role	O
of	O
p70	B-Protein
(	I-Protein
s6k	I-Protein
)	I-Protein
in	O
,	O
IL	B-Protein
-	I-Protein
2	I-Protein
and	O
PI	O
3	O
-	O
kinase	O
activation	O
of	O
E2Fs	O
have	O
not	O
been	O
characterized	O
.	O

Our	O
present	O
results	O
show	O
that	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
and	O
PI	O
3	O
-	O
kinase	O
-	O
induced	O
pathways	O
for	O
the	O
regulation	O
of	O
E2F	O
transcriptional	O
activity	O
include	O
both	O
rapamycin	O
-	O
resistant	O
and	O
rapamycin	O
-	O
sensitive	O
components	O
.	O

Expression	O
of	O
a	O
rapamycin	O
-	O
resistant	O
mutant	O
of	O
p70	B-Protein
(	I-Protein
s6k	I-Protein
)	I-Protein
in	O
T	O
cells	O
could	O
restore	O
rapamycin	O
-	O
suppressed	O
E2F	O
responses	O
.	O

Thus	O
,	O
the	O
rapamycin	O
-	O
controlled	O
processes	O
involved	O
in	O
E2F	O
regulation	O
appear	O
to	O
be	O
mediated	O
by	O
p70	B-Protein
(	I-Protein
s6k	I-Protein
)	I-Protein
.	O

However	O
,	O
the	O
rapamycin	O
-	O
resistant	O
p70	B-Protein
(	I-Protein
s6k	I-Protein
)	I-Protein
could	O
not	O
rescue	O
rapamycin	O
inhibition	O
of	O
T	O
-	O
cell	O
cycle	O
entry	O
,	O
consistent	O
with	O
the	O
involvement	O
of	O
additional	O
,	O
rapamycin	O
-	O
sensitive	O
pathways	O
in	O
the	O
control	O
of	O
T	O
-	O
cell	O
cycle	O
progression	O
.	O

The	O
present	O
results	O
thus	O
show	O
that	O
p70	B-Protein
(	I-Protein
s6k	I-Protein
)	I-Protein
is	O
able	O
to	O
regulate	O
E2F	O
transcriptional	O
activity	O
and	O
provide	O
direct	O
evidence	O
for	O
the	O
first	O
time	O
for	O
a	O
link	O
between	O
IL	B-Protein
-	I-Protein
2	I-Protein
receptors	O
,	O
PI	O
3	O
-	O
kinase	O
,	O
and	O
p70	B-Protein
(	I-Protein
s6k	I-Protein
)	I-Protein
that	O
regulates	O
a	O
crucial	O
G1	O
checkpoint	O
in	O
T	O
lymphocytes	O
.	O

SOCS	B-Protein
-	I-Protein
3	I-Protein
is	O
tyrosine	O
phosphorylated	O
in	O
response	O
to	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
and	O
suppresses	O
STAT5	B-Protein
phosphorylation	O
and	O
lymphocyte	O
proliferation	O
.	O

Members	O
of	O
the	O
recently	O
discovered	O
SOCS	O
/	O
CIS	O
/	O
SSI	O
family	O
have	O
been	O
proposed	O
as	O
regulators	O
of	O
cytokine	O
signaling	O
,	O
and	O
while	O
targets	O
and	O
mechanisms	O
have	O
been	O
suggested	O
for	O
some	O
family	O
members	O
,	O
the	O
precise	O
role	O
of	O
these	O
proteins	O
remains	O
to	O
be	O
defined	O
.	O

To	O
date	O
no	O
SOCS	O
proteins	O
have	O
been	O
specifically	O
implicated	O
in	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
(	O
IL	B-Protein
-	I-Protein
2	I-Protein
)	O
signaling	O
in	O
T	O
cells	O
.	O

Here	O
we	O
report	O
SOCS	B-Protein
-	I-Protein
3	I-Protein
expression	O
in	O
response	O
to	O
IL	B-Protein
-	I-Protein
2	I-Protein
in	O
both	O
T	O
-	O
cell	O
lines	O
and	O
human	O
peripheral	O
blood	O
lymphocytes	O
.	O

SOCS	B-Protein
-	I-Protein
3	I-Protein
protein	O
was	O
detectable	O
as	O
early	O
as	O
30	O
min	O
following	O
IL	B-Protein
-	I-Protein
2	I-Protein
stimulation	O
,	O
while	O
CIS	B-Protein
was	O
seen	O
only	O
at	O
low	O
levels	O
after	O
2	O
h	O
.	O

Unlike	O
CIS	B-Protein
,	O
SOCS	B-Protein
-	I-Protein
3	I-Protein
was	O
rapidly	O
tyrosine	O
phosphorylated	O
in	O
response	O
to	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O

Tyrosine	O
phosphorylation	O
of	O
SOCS	B-Protein
-	I-Protein
3	I-Protein
was	O
observed	O
upon	O
coexpression	O
with	O
Jak1	B-Protein
and	O
Jak2	B-Protein
but	O
only	O
weakly	O
with	O
Jak3	B-Protein
.	O

In	O
these	O
experiments	O
,	O
SOCS	B-Protein
-	I-Protein
3	I-Protein
associated	O
with	O
Jak1	B-Protein
and	O
inhibited	O
Jak1	B-Protein
phosphorylation	O
,	O
and	O
this	O
inhibition	O
was	O
markedly	O
enhanced	O
by	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
receptor	I-Protein
beta	I-Protein
chain	I-Protein
(	O
IL	B-Protein
-	I-Protein
2Rbeta	I-Protein
)	O
.	O

Moreover	O
,	O
following	O
IL	B-Protein
-	I-Protein
2	I-Protein
stimulation	O
of	O
T	O
cells	O
,	O
SOCS	B-Protein
-	I-Protein
3	I-Protein
was	O
able	O
to	O
interact	O
with	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
receptor	O
complex	O
,	O
and	O
in	O
particular	O
tyrosine	O
phosphorylated	O
Jak1	B-Protein
and	O
IL	B-Protein
-	I-Protein
2Rbeta	I-Protein
.	O

Additionally	O
,	O
in	O
lymphocytes	O
expressing	O
SOCS	B-Protein
-	I-Protein
3	I-Protein
but	O
not	O
CIS	B-Protein
,	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
STAT5b	B-Protein
was	O
markedly	O
reduced	O
,	O
while	O
there	O
was	O
only	O
a	O
weak	O
effect	O
on	O
IL	B-Protein
-	I-Protein
3	I-Protein
-	O
mediated	O
STAT5b	B-Protein
tyrosine	O
phosphorylation	O
.	O

Finally	O
,	O
proliferation	O
induced	O
by	O
both	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
and	O
IL	B-Protein
-	I-Protein
3	I-Protein
was	O
significantly	O
inhibited	O
in	O
the	O
presence	O
of	O
SOCS	B-Protein
-	I-Protein
3	I-Protein
.	O

The	O
findings	O
suggest	O
that	O
when	O
SOCS	B-Protein
-	I-Protein
3	I-Protein
is	O
rapidly	O
induced	O
by	O
IL	B-Protein
-	I-Protein
2	I-Protein
in	O
T	O
cells	O
,	O
it	O
acts	O
to	O
inhibit	O
IL	B-Protein
-	I-Protein
2	I-Protein
responses	O
in	O
a	O
classical	O
negative	O
feedback	O
loop	O
.	O

The	O
role	O
of	O
gamma	O
/	O
delta	O
T	O
cell	O
receptor	O
positive	O
cells	O
in	O
pregnancy	O
.	O

PROBLEM	O
:	O
Due	O
to	O
the	O
lack	O
of	O
classical	O
HLA	O
antigens	O
on	O
the	O
trophoblast	O
,	O
fetal	O
antigens	O
are	O
possibly	O
presented	O
in	O
a	O
non	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
restricted	O
way	O
.	O

Decidual	O
gammadelta	O
T	O
cells	O
,	O
which	O
significantly	O
increase	O
in	O
number	O
during	O
pregnancy	O
,	O
might	O
play	O
a	O
role	O
in	O
recognition	O
of	O
fetal	O
antigens	O
and	O
also	O
in	O
determining	O
the	O
quality	O
of	O
the	O
response	O
to	O
these	O
antigens	O
.	O

Our	O
study	O
was	O
aimed	O
at	O
investigating	O
the	O
role	O
of	O
this	O
cell	O
population	O
in	O
progesterone	O
-	O
dependent	O
immunomodulation	O
.	O

METHOD	O
OF	O
STUDY	O
:	O
Peripheral	O
lymphocytes	O
from	O
healthy	O
pregnant	O
women	O
and	O
from	O
habitual	O
aborters	O
were	O
tested	O
by	O
immunocytochemistry	O
for	O
the	O
presence	O
of	O
gamma	O
/	O
delta	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
and	O
progesterone	B-Protein
receptor	I-Protein
.	O

To	O
investigate	O
the	O
effect	O
of	O
treatment	O
with	O
a	O
pan	O
anti	O
gamma	O
/	O
delta	O
antibody	O
,	O
lymphocytes	O
were	O
incubated	O
for	O
3	O
hr	O
with	O
the	O
antibody	O
,	O
and	O
then	O
interleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
-	I-Protein
10	I-Protein
,	O
IL	O
-	O
12	O
and	O
progesterone	B-Protein
-	I-Protein
induced	I-Protein
blocking	I-Protein
factor	I-Protein
(	O
PIBF	B-Protein
)	O
expression	O
(	O
by	O
immuno	O
-	O
cytochemistry	O
)	O
as	O
well	O
as	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
activity	O
were	O
determined	O
.	O

RESULTS	O
:	O
In	O
peripheral	O
blood	O
of	O
healthy	O
pregnant	O
women	O
the	O
percentage	O
of	O
gamma	O
/	O
delta	O
TCR	O
+	O
cells	O
was	O
significantly	O
higher	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
than	O
in	O
that	O
of	O
recurrent	O
aborters	O
or	O
of	O
non	O
-	O
pregnant	O
individuals	O
.	O

Ninety	O
-	O
seven	O
percent	O
of	O
gamma	O
/	O
delta	O
TCR	O
+	O
pregnancy	O
lymphocytes	O
expressed	O
progesterone	B-Protein
receptor	I-Protein
.	O

Binding	O
of	O
a	O
specific	O
antibody	O
to	O
the	O
gamma	O
/	O
delta	O
TCR	O
inhibited	O
PIBF	B-Protein
-	O
as	O
well	O
as	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
,	O
whereas	O
it	O
increased	O
NK	O
activity	O
and	O
IL	O
-	O
12	O
expression	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
suggest	O
the	O
role	O
of	O
gamma	O
/	O
delta	O
TCR	O
-	O
bearing	O
lymphocytes	O
in	O
progesterone	O
-	O
dependent	O
immunomodulation	O
.	O

Expression	O
and	O
role	O
of	O
PML	B-Protein
gene	O
in	O
normal	O
adult	O
hematopoiesis	O
:	O
functional	O
interaction	O
between	O
PML	B-Protein
and	O
Rb	B-Protein
proteins	O
in	O
erythropoiesis	O
.	O

The	O
expression	O
of	O
the	O
PML	B-Protein
gene	O
was	O
investigated	O
in	O
purified	O
early	O
hematopoietic	O
progenitor	O
cells	O
(	O
HPCs	O
)	O
induced	O
to	O
unilineage	O
erythroid	O
or	O
granulocytic	O
differentiation	O
.	O

PML	B-Protein
mRNA	O
and	O
protein	O
,	O
while	O
barely	O
detectable	O
in	O
quiescent	O
HPCs	O
,	O
are	O
consistently	O
induced	O
by	O
growth	O
factor	O
stimulation	O
through	O
the	O
erythroid	O
or	O
granulocytic	O
lineage	O
.	O

Thereafter	O
,	O
PML	B-Protein
is	O
downmodulated	O
in	O
late	O
granulocytic	O
maturation	O
,	O
whereas	O
it	O
is	O
sustainably	O
expressed	O
through	O
the	O
erythroid	O
pathway	O
.	O

In	O
functional	O
studies	O
,	O
PML	B-Protein
expression	O
was	O
inhibited	O
by	O
addition	O
of	O
antisense	O
oligomers	O
targeting	O
PML	B-Protein
mRNA	O
(	O
alpha	O
-	O
PML	O
)	O
.	O

Interestingly	O
,	O
early	O
treatment	O
(	O
day	O
0	O
HPCs	O
)	O
with	O
alpha	O
-	O
PML	O
reduced	O
the	O
number	O
of	O
both	O
erythroid	O
and	O
granulocytic	O
colonies	O
,	O
whereas	O
late	O
treatment	O
(	O
day	O
5	O
culture	O
)	O
reduced	O
erythroid	O
,	O
but	O
not	O
granulocytic	O
,	O
clonogenesis	O
.	O

These	O
findings	O
suggest	O
that	O
PML	B-Protein
is	O
required	O
for	O
early	O
hematopoiesis	O
and	O
erythroid	O
,	O
but	O
not	O
granulocytic	O
maturation	O
.	O

The	O
pattern	O
of	O
PML	B-Protein
expression	O
in	O
normal	O
hematopoiesis	O
mimics	O
that	O
of	O
retinoblastoma	O
pRb	B-Protein
105	I-Protein
.	O

Combined	O
treatment	O
of	O
HPCs	O
with	O
alpha	O
-	O
PML	O
and	O
alpha	O
-	O
Rb	O
oligomers	O
inhibited	O
both	O
PML	B-Protein
and	O
Rb	B-Protein
protein	O
expression	O
and	O
completely	O
blocked	O
erythroid	O
colony	O
development	O
.	O

Furthermore	O
,	O
PML	B-Protein
and	O
pRb	B-Protein
105	I-Protein
were	O
co	O
-	O
immunoprecipitated	O
in	O
cellular	O
lysates	O
derived	O
from	O
erythroid	O
precursors	O
indicating	O
that	O
this	O
functional	O
interaction	O
may	O
have	O
a	O
biochemical	O
basis	O
.	O

These	O
results	O
suggest	O
a	O
key	O
functional	O
role	O
of	O
PML	B-Protein
in	O
early	O
hematopoiesis	O
and	O
late	O
erythropoiesis	O
:	O
the	O
latter	O
phenomenon	O
may	O
be	O
related	O
to	O
the	O
molecular	O
and	O
functional	O
interaction	O
of	O
PML	B-Protein
with	O
pRb	B-Protein
105	I-Protein
.	O

Signal	O
transduction	O
pathways	O
in	O
normal	O
human	O
monocytes	O
stimulated	O
by	O
cytokines	O
and	O
mediators	O
:	O
comparative	O
study	O
with	O
normal	O
human	O
neutrophils	O
or	O
transformed	O
cells	O
and	O
the	O
putative	O
roles	O
in	O
functionality	O
and	O
cell	O
biology	O
.	O

Granulocyte	B-Protein
-	I-Protein
macrophage	I-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	I-Protein
(	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
)	O
and	O
interleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
-	I-Protein
3	I-Protein
induced	O
tyrosine	O
phosphorylation	O
of	O
92	O
-	O
kDa	O
protein	O
in	O
normal	O
human	O
monocytes	O
.	O

We	O
identified	O
this	O
92	O
-	O
kDa	O
protein	O
as	O
STAT5	B-Protein
,	O
but	O
not	O
as	O
STATs1	B-Protein
,	O
3	B-Protein
,	O
and	O
6	B-Protein
nor	O
c	B-Protein
-	I-Protein
fes	I-Protein
and	O
vav	B-Protein
protooncogene	O
products	O
,	O
and	O
demonstrated	O
its	O
translocation	O
to	O
the	O
nucleus	O
,	O
enhancement	O
of	O
specific	O
DNA	O
binding	O
capacity	O
,	O
and	O
potentiation	O
of	O
trancriptional	O
activity	O
by	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
.	O

N	O
-	O
formyl	O
-	O
methionyl	O
-	O
leucyl	O
-	O
phenylalanine	O
(	O
FMLP	O
)	O
and	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
induced	O
tyrosine	O
phosphorylation	O
of	O
42	O
-	O
and	O
44	O
-	O
kDa	O
proteins	O
,	O
which	O
were	O
identified	O
as	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)	O
,	O
in	O
human	O
monocytes	O
.	O

In	O
marked	O
contrast	O
to	O
neutrophils	O
and	O
MO7e	O
cells	O
,	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
did	O
not	O
induce	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
ERK	O
in	O
monocytes	O
.	O

Among	O
upstream	O
signaling	O
molecules	O
of	O
ERK	O
,	O
Shc	B-Protein
was	O
constitutively	O
associated	O
with	O
Grb2	B-Protein
and	O
was	O
not	O
tyrosine	O
-	O
phosphorylated	O
by	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
and	O
FMLP	O
,	O
and	O
Sos1	B-Protein
and	O
c	B-Protein
-	I-Protein
Raf	I-Protein
-	I-Protein
1	I-Protein
were	O
not	O
phosphorylated	O
by	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
,	O
IL	B-Protein
-	I-Protein
3	I-Protein
,	O
TNF	B-Protein
,	O
and	O
FMLP	O
in	O
monocytes	O
,	O
whereas	O
all	O
these	O
signaling	O
molecules	O
were	O
affected	O
and	O
/	O
or	O
utilized	O
by	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
in	O
MO7e	O
cells	O
.	O

In	O
contrast	O
to	O
neutrophils	O
,	O
p38	O
was	O
constitutively	O
phosphorylated	O
and	O
agonist	O
-	O
dependent	O
phosphorylation	O
and	O
activation	O
was	O
not	O
detected	O
in	O
human	O
monocytes	O
.	O

Superoxide	O
release	O
stimulated	O
by	O
FMLP	O
was	O
inhibited	O
partially	O
by	O
PD98059	O
or	O
SB203580	O
,	O
a	O
specific	O
inhibitor	O
of	O
ERK	O
or	O
p38	O
pathway	O
,	O
and	O
was	O
almost	O
completely	O
inhibited	O
by	O
the	O
combination	O
of	O
both	O
inhibitors	O
,	O
whereas	O
PMA	O
-	O
induced	O
superoxide	O
release	O
was	O
resistant	O
to	O
these	O
two	O
inhibitors	O
in	O
monocytes	O
.	O

PD98059	O
inhibited	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
-	O
dependent	O
proliferation	O
of	O
MO7e	O
cells	O
.	O

Present	O
results	O
indicate	O
trancriptional	O
roles	O
of	O
STAT5	B-Protein
and	O
functional	O
roles	O
of	O
ERK	O
and	O
/	O
or	O
p38	O
in	O
normal	O
human	O
monocytes	O
stimulated	O
by	O
physiological	O
receptor	O
-	O
mediated	O
agonists	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
and	O
FMLP	O
.	O

Possible	O
roles	O
of	O
ERK	O
in	O
proliferation	O
of	O
transformed	O
cells	O
were	O
also	O
suggested	O
.	O

Tyrphostin	O
AG	O
-	O
490	O
inhibits	O
cytokine	O
-	O
mediated	O
JAK3	B-Protein
/	O
STAT5a	B-Protein
/	O
b	B-Protein
signal	O
transduction	O
and	O
cellular	O
proliferation	O
of	O
antigen	O
-	O
activated	O
human	O
T	O
cells	O
.	O

Janus	B-Protein
kinase	I-Protein
3	I-Protein
(	O
JAK3	B-Protein
)	O
is	O
a	O
cytoplasmic	O
tyrosine	O
kinase	O
required	O
for	O
T	O
cell	O
development	O
and	O
activated	O
by	O
cytokines	O
that	O
utilize	O
the	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
(	I-Protein
IL	I-Protein
-	I-Protein
2	I-Protein
)	I-Protein
receptor	I-Protein
common	I-Protein
gamma	I-Protein
chain	I-Protein
(	O
gamma	B-Protein
(	I-Protein
c	I-Protein
)	I-Protein
)	O
.	O

Genetic	O
inactivation	O
of	O
JAK3	B-Protein
is	O
manifested	O
as	O
severe	O
combined	O
immunodeficiency	O
disease	O
(	O
SCID	O
)	O
in	O
humans	O
and	O
mice	O
.	O

These	O
findings	O
have	O
suggested	O
that	O
JAK3	B-Protein
represents	O
a	O
pharmacological	O
target	O
to	O
control	O
certain	O
lymphoid	O
-	O
derived	O
diseases	O
.	O

Here	O
we	O
provide	O
novel	O
evidence	O
that	O
AG	O
-	O
490	O
potently	O
inhibits	O
the	O
autokinase	O
activity	O
of	O
JAK3	B-Protein
and	O
tyrosine	O
phosphorylation	O
and	O
DNA	O
binding	O
of	O
signal	B-Protein
transducer	I-Protein
and	I-Protein
activator	I-Protein
of	I-Protein
transcription	I-Protein
5a	I-Protein
and	O
5b	B-Protein
(	O
STAT5a	B-Protein
/	O
b	B-Protein
)	O
.	O

Similar	O
inhibitory	O
effects	O
were	O
observed	O
with	O
other	O
cytokines	O
that	O
use	O
gamma	B-Protein
(	I-Protein
c	I-Protein
)	I-Protein
.	O

AG	O
-	O
490	O
also	O
inhibited	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
mediated	O
proliferative	O
growth	O
in	O
human	O
T	O
cells	O
with	O
an	O
IC50	O
)	O
=	O
25	O
microM	O
that	O
was	O
partially	O
recoverable	O
.	O

Moreover	O
,	O
we	O
demonstrate	O
that	O
this	O
inhibitor	O
prevented	O
tetanus	O
toxoid	O
antigen	O
-	O
specific	O
T	O
cell	O
proliferation	O
and	O
expansion	O
but	O
failed	O
to	O
block	O
activation	O
of	O
Zap70	B-Protein
or	O
p56Lck	B-Protein
after	O
anti	O
-	O
CD3	O
stimulation	O
of	O
human	O
T	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
AG	O
-	O
490	O
inhibits	O
the	O
JAK3	B-Protein
-	O
mediated	O
Type	O
II	O
signaling	O
pathway	O
but	O
not	O
the	O
T	O
cell	O
receptor	O
-	O
derived	O
Type	O
I	O
pathway	O
and	O
possesses	O
therapeutic	O
potential	O
for	O
T	O
cell	O
-	O
derived	O
pathologies	O
such	O
as	O
graft	O
-	O
versus	O
-	O
host	O
disease	O
,	O
allergy	O
,	O
and	O
autoimmune	O
disorders	O
.	O

Genetic	O
evidence	O
for	O
an	O
additional	O
factor	O
required	O
for	O
erythropoietin	B-Protein
-	O
induced	O
signal	O
transduction	O
.	O

Erythropoietin	B-Protein
(	O
EPO	B-Protein
)	O
and	O
its	O
receptor	O
(	O
EPOR	B-Protein
)	O
are	O
required	O
for	O
the	O
development	O
of	O
mature	O
erythrocytes	O
.	O

After	O
binding	O
of	O
ligand	O
,	O
the	O
EPOR	B-Protein
activates	O
a	O
variety	O
of	O
signaling	O
pathways	O
that	O
ultimately	O
control	O
cellular	O
proliferation	O
,	O
survival	O
,	O
and	O
specific	O
gene	O
expression	O
.	O

Although	O
erythroid	O
progenitors	O
appear	O
to	O
be	O
the	O
principal	O
EPO	B-Protein
-	O
responsive	O
cell	O
type	O
in	O
vivo	O
due	O
to	O
the	O
restricted	O
expression	O
of	O
the	O
EPOR	B-Protein
,	O
many	O
growth	O
factor	O
-	O
dependent	O
cell	O
lines	O
expressing	O
the	O
EPOR	B-Protein
can	O
respond	O
to	O
EPO	B-Protein
by	O
activating	O
many	O
or	O
all	O
of	O
these	O
pathways	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
identified	O
a	O
cellular	O
context	O
(	O
the	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
[	O
IL	B-Protein
-	I-Protein
2	I-Protein
]	O
-	O
dependent	O
HT	O
-	O
2	O
line	O
)	O
in	O
which	O
the	O
EPO	B-Protein
stimulation	O
of	O
the	O
EPOR	B-Protein
fails	O
to	O
support	O
cellular	O
proliferation	O
,	O
STAT	B-Protein
-	I-Protein
5	I-Protein
induction	O
,	O
or	O
MAPK	O
activation	O
,	O
despite	O
efficient	O
phosphorylation	O
of	O
the	O
EPOR	B-Protein
and	O
JAK2	B-Protein
and	O
inhibition	O
of	O
apoptosis	O
after	O
withdrawal	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O

Interestingly	O
,	O
when	O
we	O
fused	O
HT	O
-	O
2	O
cells	O
expressing	O
the	O
EPOR	B-Protein
with	O
Ba	O
/	O
F3	O
cells	O
in	O
a	O
complementation	O
assay	O
,	O
the	O
resulting	O
hybridomas	O
proliferated	O
and	O
potently	O
activated	O
STAT	B-Protein
-	I-Protein
5	I-Protein
and	O
MAPK	O
in	O
response	O
to	O
EPO	B-Protein
.	O

These	O
data	O
indicate	O
that	O
an	O
unidentified	O
cellular	O
factor	O
is	O
needed	O
to	O
mediate	O
signaling	O
by	O
the	O
EPOR	B-Protein
.	O

Moreover	O
,	O
Ba	O
/	O
F3	O
cells	O
apparently	O
express	O
this	O
factor	O
(	O
s	O
)	O
and	O
somatic	O
fusions	O
can	O
,	O
therefore	O
,	O
confer	O
EPO	B-Protein
-	O
responsiveness	O
to	O
HT	O
-	O
2	O
cells	O
that	O
lack	O
this	O
factor	O
.	O

Cutting	O
edge	O
:	O
expression	O
of	O
the	O
NF	O
of	O
activated	O
T	O
cells	O
in	O
eosinophils	O
:	O
regulation	O
by	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
IL	B-Protein
-	I-Protein
5	I-Protein
.	O

We	O
report	O
that	O
NF	B-Protein
-	I-Protein
AT1	I-Protein
and	O
NF	B-Protein
-	I-Protein
AT4	I-Protein
are	O
expressed	O
cytoplasmically	O
in	O
resting	O
eosinophils	O
,	O
whereas	O
NF	B-Protein
-	I-Protein
AT2	I-Protein
and	O
NF	B-Protein
-	I-Protein
AT3	I-Protein
have	O
not	O
been	O
seen	O
.	O

Likewise	O
,	O
NF	B-Protein
-	I-Protein
AT1	I-Protein
mRNA	O
and	O
NF	B-Protein
-	I-Protein
AT4	I-Protein
mRNA	O
have	O
been	O
detected	O
in	O
resting	O
eosinophils	O
,	O
and	O
their	O
levels	O
can	O
be	O
significantly	O
up	O
-	O
regulated	O
by	O
the	O
Th2	O
-	O
associated	O
cytokines	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
IL	B-Protein
-	I-Protein
5	I-Protein
.	O

There	O
is	O
no	O
detectable	O
NF	O
-	O
AT	O
protein	O
expression	O
in	O
the	O
nuclei	O
of	O
resting	O
eosinophils	O
.	O

However	O
NF	O
-	O
ATs	O
appear	O
in	O
the	O
nuclei	O
of	O
IL	B-Protein
-	I-Protein
4	I-Protein
-	O
,	O
IL	B-Protein
-	I-Protein
5	I-Protein
-	O
,	O
or	O
ionomycin	O
-	O
stimulated	O
eosinophils	O
.	O

Only	O
NF	B-Protein
-	I-Protein
AT1	I-Protein
and	O
NF	B-Protein
-	I-Protein
AT4	I-Protein
,	O
but	O
not	O
NF	B-Protein
-	I-Protein
AT2	I-Protein
and	O
NF	B-Protein
-	I-Protein
AT3	I-Protein
,	O
have	O
translocated	O
into	O
the	O
nuclei	O
in	O
IL	B-Protein
-	I-Protein
4	I-Protein
-	O
or	O
IL	B-Protein
-	I-Protein
5	I-Protein
-	O
stimulated	O
eosinophils	O
.	O

These	O
findings	O
delineate	O
a	O
novel	O
pathway	O
in	O
the	O
cytokine	O
network	O
in	O
which	O
Th2	O
lymphocytes	O
"	O
control	O
"	O
eosinophils	O
via	O
the	O
release	O
of	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
IL	B-Protein
-	I-Protein
5	I-Protein
,	O
and	O
activation	O
of	O
NF	O
-	O
AT	O
in	O
eosinophils	O
.	O

The	O
findings	O
also	O
suggest	O
that	O
a	O
later	O
feedback	O
"	O
talking	O
"	O
may	O
exist	O
between	O
eosinophils	O
and	O
Th2	O
lymphocytes	O
.	O

Altered	O
memory	O
T	O
cell	O
differentiation	O
in	O
patients	O
with	O
early	O
rheumatoid	O
arthritis	O
.	O

The	O
chronic	O
immune	O
response	O
in	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
might	O
be	O
driven	O
by	O
activated	O
Th1	O
cells	O
without	O
sufficient	O
Th2	O
cell	O
differentiation	O
to	O
down	O
-	O
modulate	O
inflammation	O
.	O

To	O
test	O
whether	O
disordered	O
memory	O
T	O
cell	O
differentiation	O
contributes	O
to	O
the	O
typical	O
Th1	O
-	O
dominated	O
chronic	O
inflammation	O
in	O
RA	O
we	O
investigated	O
differentiation	O
of	O
resting	O
CD4	O
+	O
memory	O
T	O
cells	O
in	O
patients	O
with	O
early	O
(	O
6	O
wk	O
to	O
12	O
mo	O
)	O
untreated	O
RA	O
and	O
in	O
age	O
-	O
and	O
sex	O
-	O
matched	O
healthy	O
controls	O
in	O
vitro	O
.	O

No	O
difference	O
in	O
cytokine	O
secretion	O
profiles	O
of	O
freshly	O
isolated	O
memory	O
T	O
cells	O
was	O
detected	O
between	O
patients	O
and	O
controls	O
.	O

A	O
cell	O
culture	O
system	O
was	O
then	O
employed	O
that	O
permitted	O
the	O
differentiation	O
of	O
Th	O
effectors	O
from	O
resting	O
memory	O
T	O
cells	O
by	O
short	O
term	O
priming	O
.	O

Marked	O
differences	O
were	O
found	O
in	O
response	O
to	O
priming	O
.	O

Th2	O
cells	O
could	O
be	O
induced	O
in	O
all	O
healthy	O
controls	O
by	O
priming	O
with	O
anti	O
-	O
CD28	B-Protein
in	O
the	O
absence	O
of	O
TCR	O
ligation	O
.	O

By	O
contrast	O
,	O
priming	O
under	O
those	O
conditions	O
resulted	O
in	O
Th2	O
differentiation	O
in	O
only	O
9	O
of	O
24	O
RA	O
patients	O
.	O

Exogenous	O
IL	B-Protein
-	I-Protein
4	I-Protein
could	O
overcome	O
the	O
apparent	O
Th2	O
differentiation	O
defect	O
in	O
seven	O
patients	O
but	O
was	O
without	O
effect	O
in	O
the	O
remaining	O
eight	O
patients	O
.	O

In	O
all	O
patients	O
a	O
marked	O
decrease	O
in	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
producing	O
cells	O
and	O
a	O
significant	O
increase	O
in	O
well	O
-	O
differentiated	O
Th1	O
cells	O
that	O
produced	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
but	O
not	O
IL	B-Protein
-	I-Protein
2	I-Protein
were	O
evident	O
after	O
priming	O
with	O
anti	O
-	O
CD3	O
and	O
anti	O
-	O
CD28	B-Protein
.	O

The	O
data	O
suggest	O
that	O
CD4	B-Protein
+	O
memory	O
T	O
cells	O
from	O
patients	O
with	O
early	O
untreated	O
RA	O
manifest	O
an	O
intrinsic	O
abnormality	O
in	O
their	O
ability	O
to	O
differentiate	O
into	O
specific	O
cytokine	O
-	O
producing	O
effector	O
cells	O
that	O
might	O
contribute	O
to	O
the	O
characteristic	O
Th1	O
-	O
dominated	O
chronic	O
(	O
auto	O
)	O
immune	O
inflammation	O
in	O
RA	O
.	O

ICSAT	B-Protein
overexpression	O
is	O
not	O
sufficient	O
to	O
cause	O
adult	O
T	O
-	O
cell	O
leukemia	O
or	O
multiple	O
myeloma	O
.	O

ICSAT	B-Protein
(	O
Interferon	B-Protein
Consensus	I-Protein
Sequence	I-Protein
binding	I-Protein
protein	I-Protein
for	I-Protein
Activated	I-Protein
T	I-Protein
cells	I-Protein
)	O
is	O
a	O
lymphocyte	O
-	O
specific	O
member	O
of	O
the	O
interferon	O
regulatory	O
factor	O
(	O
IRF	O
)	O
family	O
of	O
transcription	O
factors	O
,	O
originally	O
identified	O
through	O
Southwestern	O
screening	O
of	O
the	O
ATL	O
(	O
Adult	O
T	O
-	O
cell	O
leukemia	O
)	O
-	O
16T	O
expression	O
library	O
.	O

In	O
this	O
study	O
,	O
we	O
created	O
transgenic	O
mice	O
overexpressing	O
ICSAT	B-Protein
in	O
lymphocytes	O
.	O

Although	O
spontaneous	O
tumorigenesis	O
was	O
not	O
observed	O
,	O
IL	B-Protein
-	I-Protein
2	I-Protein
production	O
with	O
Concanavalin	O
A	O
stimulation	O
was	O
significantly	O
increased	O
in	O
transgenic	O
mice	O
overexpressing	O
ICSAT	B-Protein
.	O

ICSAT	B-Protein
overexpression	O
in	O
lymphocytes	O
seems	O
insufficient	O
for	O
the	O
leukemogenesis	O
of	O
ATL	O
or	O
multiple	O
myeloma	O
(	O
MM	O
)	O
,	O
however	O
,	O
it	O
may	O
regulate	O
T	O
cell	O
activation	O
and	O
its	O
overexpression	O
may	O
lead	O
to	O
leukemogenesis	O
via	O
controlling	O
IL	B-Protein
-	I-Protein
2	I-Protein
production	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Extracellular	B-Protein
signal	I-Protein
-	I-Protein
regulated	I-Protein
protein	I-Protein
kinase	I-Protein
(	O
ERK	B-Protein
)	O
-	O
dependent	O
and	O
ERK	B-Protein
-	O
independent	O
pathways	O
target	O
STAT3	B-Protein
on	O
serine	O
-	O
727	O
in	O
human	O
neutrophils	O
stimulated	O
by	O
chemotactic	O
factors	O
and	O
cytokines	O
.	O

STAT3	B-Protein
(	O
signal	B-Protein
transducer	I-Protein
and	I-Protein
activator	I-Protein
of	I-Protein
transcription	I-Protein
3	I-Protein
)	O
is	O
a	O
latent	O
transcription	O
factor	O
that	O
is	O
activated	O
by	O
tyrosine	O
phosphorylation	O
(	O
Tyr	O
-	O
705	O
)	O
in	O
cells	O
stimulated	O
with	O
cytokines	O
or	O
growth	O
factors	O
.	O

Recent	O
studies	O
suggest	O
that	O
one	O
or	O
more	O
cytoplasmic	O
serine	O
kinases	O
also	O
phosphorylate	O
STAT3	B-Protein
and	O
are	O
necessary	O
for	O
maximal	O
gene	O
activation	O
.	O

Here	O
we	O
demonstrate	O
,	O
with	O
a	O
site	O
-	O
specific	O
antibody	O
,	O
that	O
STAT3	B-Protein
is	O
phosphorylated	O
on	O
Ser	O
-	O
727	O
in	O
human	O
neutrophils	O
stimulated	O
with	O
chemotactic	O
factors	O
(	O
N	O
-	O
formyl	O
-	O
methionyl	O
-	O
leucyl	O
-	O
phenylalanine	O
and	O
complement	O
C5a	O
)	O
,	O
cytokines	O
[	O
granulocyte	B-Protein
/	I-Protein
macrophage	I-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	I-Protein
(	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
)	O
and	O
granulocyte	B-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	I-Protein
(	O
G	B-Protein
-	I-Protein
CSF	I-Protein
)	O
]	O
,	O
or	O
a	O
protein	O
kinase	O
C	O
activator	O
(	O
PMA	O
)	O
.	O

(	O
2	O
-	O
Amino	O
-	O
3	O
'	O
-	O
methoxyphenyl	O
)	O
oxanaphthalen	O
-	O
4	O
-	O
one	O
(	O
PD	O
98059	O
)	O
,	O
an	O
inhibitor	O
of	O
extracellular	B-Protein
signal	I-Protein
-	I-Protein
regulated	I-Protein
protein	I-Protein
kinase	I-Protein
(	O
ERK	B-Protein
)	O
activation	O
,	O
blocked	O
the	O
serine	O
phosphorylation	O
of	O
STAT3	B-Protein
induced	O
by	O
chemotactic	O
factors	O
or	O
PMA	O
.	O

The	O
drug	O
was	O
less	O
effective	O
on	O
cytokines	O
:	O
it	O
virtually	O
abolished	O
the	O
response	O
to	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
that	O
occurred	O
5	O
min	O
after	O
stimulation	O
but	O
only	O
partly	O
decreased	O
those	O
at	O
15	O
-	O
30	O
min	O
and	O
did	O
not	O
appreciably	O
alter	O
responses	O
to	O
G	B-Protein
-	I-Protein
CSF	I-Protein
regardless	O
of	O
incubation	O
time	O
.	O

1	O
-	O
(	O
5	O
-	O
Isoquinolinylsulphonyl	O
)	O
-	O
2	O
-	O
methylpiperazine	O
dihydrochloride	O
(	O
H7	O
)	O
,	O
an	O
inhibitor	O
of	O
a	O
putative	O
STAT3	B-Protein
serine	O
kinase	O
,	O
and	O
4	O
-	O
(	O
4	O
-	O
fluorophenyl	O
)	O
-	O
2	O
-	O
(	O
4	O
-	O
methylsulphinylphenyl	O
)	O
-	O
5	O
-	O
(	O
4	O
-	O
pyridyl	O
)	O
1H	O
-	O
imidazole	O
(	O
SB	O
203580	O
)	O
,	O
an	O
inhibitor	O
of	O
p38	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinase	O
,	O
did	O
not	O
dampen	O
any	O
of	O
these	O
serine	O
phosphorylation	O
responses	O
.	O

We	O
propose	O
that	O
neutrophils	O
use	O
both	O
ERK	B-Protein
-	O
dependent	O
and	O
ERK	B-Protein
-	O
independent	O
pathways	O
to	O
phosphorylate	O
Ser	O
-	O
727	O
on	O
STAT3	B-Protein
.	O

The	O
former	O
pathway	O
is	O
recruited	O
by	O
all	O
ERK	B-Protein
-	O
activating	O
stimuli	O
,	O
whereas	O
the	O
latter	O
pathway	O
uses	O
an	O
undefined	O
serine	O
kinase	O
and	O
is	O
recruited	O
selectively	O
by	O
cytokines	O
.	O

Activation	O
of	O
STAT5	O
by	O
IL	B-Protein
-	I-Protein
4	I-Protein
relies	O
on	O
Janus	O
kinase	O
function	O
but	O
not	O
on	O
receptor	O
tyrosine	O
phosphorylation	O
,	O
and	O
can	O
contribute	O
to	O
both	O
cell	O
proliferation	O
and	O
gene	O
regulation	O
.	O

We	O
have	O
investigated	O
mechanisms	O
and	O
consequences	O
of	O
STAT5	O
activation	O
through	O
the	O
human	O
IL	B-Protein
-	I-Protein
4	I-Protein
receptor	O
(	O
IL	O
-	O
4R	O
)	O
.	O

By	O
functionally	O
expressing	O
receptor	O
mutants	O
in	O
the	O
murine	O
pro	O
-	O
B	O
cell	O
line	O
Ba	O
/	O
F3	O
,	O
we	O
could	O
show	O
that	O
phosphorylated	O
tyrosine	O
residues	O
within	O
the	O
IL	B-Protein
-	I-Protein
4R	I-Protein
alpha	I-Protein
chain	I-Protein
are	O
dispensable	O
for	O
IL	B-Protein
-	I-Protein
4	I-Protein
-	O
induced	O
STAT5	O
activity	O
.	O

However	O
,	O
disruption	O
of	O
a	O
membrane	O
-	O
proximal	O
proline	O
-	O
rich	O
sequence	O
motif	O
(	O
'	O
box1	O
'	O
)	O
in	O
either	O
subunit	O
of	O
the	O
bipartite	O
IL	O
-	O
4R	O
abolished	O
not	O
only	O
ligand	O
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
Janus	O
kinases	O
JAK1	B-Protein
and	O
JAK3	B-Protein
,	O
but	O
also	O
IL	B-Protein
-	I-Protein
4	I-Protein
-	O
triggered	O
activation	O
of	O
STAT5	O
and	O
concomitant	O
cell	O
proliferation	O
.	O

A	O
dominant	O
-	O
negative	O
version	O
of	O
STAT5b	B-Protein
,	O
but	O
not	O
of	O
STAT5a	B-Protein
,	O
interfered	O
with	O
IL	B-Protein
-	I-Protein
4	I-Protein
-	O
induced	O
DNA	O
synthesis	O
in	O
Ba	O
/	O
F3	O
cells	O
,	O
suggesting	O
an	O
involvement	O
of	O
STAT5b	B-Protein
in	O
the	O
control	O
of	O
cell	O
proliferation	O
through	O
IL	O
-	O
4R	O
.	O

Reporter	O
gene	O
experiments	O
finally	O
showed	O
that	O
transcription	O
from	O
promoters	O
of	O
STAT5	O
target	O
genes	O
can	O
be	O
specifically	O
induced	O
by	O
challenging	O
cells	O
with	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
and	O
that	O
both	O
STAT5a	B-Protein
and	O
STAT5b	B-Protein
can	O
contribute	O
to	O
IL	B-Protein
-	I-Protein
4	I-Protein
-	O
triggered	O
transcriptional	O
control	O
.	O

Diminished	O
responses	O
to	O
IL	B-Protein
-	I-Protein
13	I-Protein
by	O
human	O
monocytes	O
differentiated	O
in	O
vitro	O
:	O
role	O
of	O
the	O
IL	B-Protein
-	I-Protein
13Ralpha1	I-Protein
chain	I-Protein
and	O
STAT6	B-Protein
.	O

The	O
primary	O
IL	B-Protein
-	I-Protein
13	I-Protein
receptor	O
complex	O
on	O
human	O
monocytes	O
is	O
believed	O
to	O
be	O
a	O
heterodimer	O
comprised	O
of	O
the	O
IL	B-Protein
-	I-Protein
4R	I-Protein
alpha	I-Protein
chain	I-Protein
and	O
the	O
IL	B-Protein
-	I-Protein
2R	I-Protein
gamma	I-Protein
chain	I-Protein
(	O
gamma	O
(	O
c	O
)	O
)	O
-	O
like	O
molecule	O
,	O
IL	B-Protein
-	I-Protein
13R	I-Protein
alpha1	I-Protein
.	O

mRNA	O
levels	O
for	O
IL	B-Protein
-	I-Protein
13R	I-Protein
alpha1	I-Protein
,	O
but	O
not	O
IL	B-Protein
-	I-Protein
4R	I-Protein
alpha	I-Protein
,	O
were	O
markedly	O
decreased	O
in	O
in	O
vitro	O
monocyte	O
-	O
derived	O
macrophages	O
(	O
MDMac	O
)	O
,	O
and	O
with	O
increasing	O
time	O
of	O
monocytes	O
in	O
culture	O
correlated	O
with	O
the	O
loss	O
of	O
IL	B-Protein
-	I-Protein
13	I-Protein
regulation	O
of	O
lipopolysaccharide	O
-	O
induced	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
.	O

Analysis	O
of	O
cell	O
lines	O
Daudi	O
and	O
THP	O
-	O
1	O
that	O
differentially	O
express	O
gamma	O
(	O
c	O
)	O
and	O
IL	B-Protein
-	I-Protein
13R	I-Protein
alpha1	I-Protein
showed	O
that	O
IL	B-Protein
-	I-Protein
13	I-Protein
can	O
activate	O
STAT6	B-Protein
in	O
IL	B-Protein
-	I-Protein
13R	I-Protein
alpha1	I-Protein
-	O
positive	O
THP	O
-	O
1	O
cells	O
but	O
not	O
in	O
gamma	O
(	O
c	O
)	O
-	O
positive	O
,	O
IL	B-Protein
-	I-Protein
13R	I-Protein
alpha1	I-Protein
-	O
negative	O
Daudi	O
cells	O
.	O

IL	B-Protein
-	I-Protein
13	I-Protein
activation	O
of	O
STAT6	B-Protein
was	O
reduced	O
in	O
MDMac	O
which	O
was	O
associated	O
with	O
diminished	O
IL	B-Protein
-	I-Protein
13	I-Protein
-	O
induced	O
expression	O
of	O
CD23	B-Protein
and	O
MHC	O
class	O
II	O
.	O

However	O
,	O
with	O
reduced	O
IL	B-Protein
-	I-Protein
13R	I-Protein
alpha1	I-Protein
expression	O
and	O
low	O
nuclear	O
STAT6	B-Protein
activity	O
,	O
some	O
IL	B-Protein
-	I-Protein
13	I-Protein
-	O
induced	O
responses	O
were	O
unaltered	O
in	O
magnitude	O
in	O
MDMac	O
.	O

In	O
the	O
absence	O
of	O
functional	O
IL	B-Protein
-	I-Protein
13R	I-Protein
alpha1	I-Protein
and	O
gamma	O
(	O
c	O
)	O
,	O
IL	B-Protein
-	I-Protein
13	I-Protein
must	O
signal	O
through	O
an	O
alternative	O
receptor	O
complex	O
on	O
MDMac	O
.	O

Experiments	O
with	O
a	O
blocking	O
antibody	O
to	O
IL	B-Protein
-	I-Protein
4R	I-Protein
alpha	I-Protein
showed	O
that	O
this	O
chain	O
remains	O
an	O
essential	O
component	O
of	O
the	O
IL	B-Protein
-	I-Protein
13	I-Protein
receptor	O
complex	O
on	O
MDMac	O
.	O

Monoallelic	O
expression	O
of	O
Pax5	B-Protein
:	O
a	O
paradigm	O
for	O
the	O
haploinsufficiency	O
of	O
mammalian	O
Pax	O
genes	O
?	O

It	O
is	O
generally	O
assumed	O
that	O
most	O
mammalian	O
genes	O
are	O
transcribed	O
from	O
both	O
alleles	O
.	O

Hence	O
,	O
the	O
diploid	O
state	O
of	O
the	O
genome	O
offers	O
the	O
advantage	O
that	O
a	O
loss	O
-	O
of	O
-	O
function	O
mutation	O
in	O
one	O
allele	O
can	O
be	O
compensated	O
for	O
by	O
the	O
remaining	O
wild	O
-	O
type	O
allele	O
of	O
the	O
same	O
gene	O
.	O

Indeed	O
,	O
the	O
vast	O
majority	O
of	O
human	O
disease	O
syndromes	O
and	O
engineered	O
mutations	O
in	O
the	O
mouse	O
genome	O
are	O
recessive	O
,	O
indicating	O
that	O
recessiveness	O
is	O
the	O
'	O
default	O
'	O
state	O
.	O

However	O
,	O
a	O
minority	O
of	O
genes	O
are	O
semi	O
-	O
dominant	O
,	O
as	O
heterozygous	O
loss	O
-	O
of	O
-	O
function	O
mutation	O
in	O
these	O
genes	O
leads	O
to	O
phenotypic	O
abnormalities	O
.	O

This	O
condition	O
,	O
known	O
as	O
haploinsufficiency	O
,	O
has	O
been	O
described	O
for	O
five	O
of	O
the	O
nine	O
mammalian	O
Pax	O
genes	O
,	O
which	O
are	O
associated	O
with	O
mouse	O
developmental	O
mutants	O
and	O
human	O
disease	O
syndromes	O
.	O

Recently	O
we	O
have	O
reported	O
that	O
the	O
Pax5	B-Protein
gene	O
is	O
subject	O
to	O
allele	O
-	O
specific	O
regulation	O
during	O
B	O
cell	O
development	O
.	O

Pax5	B-Protein
is	O
predominantly	O
transcribed	O
from	O
only	O
one	O
of	O
its	O
two	O
alleles	O
in	O
early	O
B	O
-	O
lymphoid	O
progenitors	O
and	O
mature	O
B	O
cells	O
,	O
while	O
it	O
transiently	O
switches	O
to	O
a	O
biallelic	O
mode	O
of	O
transcription	O
in	O
pre	O
-	O
B	O
and	O
immature	O
B	O
cells	O
.	O

As	O
a	O
consequence	O
,	O
B	O
-	O
lymphoid	O
tissues	O
are	O
mosaic	O
with	O
regard	O
to	O
the	O
transcribed	O
allele	O
,	O
and	O
heterozygous	O
mutation	O
of	O
Pax5	B-Protein
therefore	O
results	O
in	O
deletion	O
of	O
B	O
lymphocytes	O
expressing	O
only	O
the	O
mutant	O
allele	O
.	O

The	O
allele	O
-	O
specific	O
regulation	O
of	O
Pax5	B-Protein
raises	O
the	O
intriguing	O
possibility	O
that	O
monoallelic	O
expression	O
may	O
also	O
be	O
the	O
mechanism	O
causing	O
the	O
haploinsufficiency	O
of	O
other	O
Pax	O
genes	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
different	O
models	O
accounting	O
for	O
the	O
haploinsufficiency	O
of	O
mammalian	O
Pax	O
genes	O
,	O
provide	O
further	O
evidence	O
in	O
support	O
of	O
the	O
allele	O
-	O
specific	O
regulation	O
of	O
Pax5	B-Protein
and	O
discuss	O
the	O
implication	O
of	O
these	O
findings	O
in	O
the	O
context	O
of	O
the	O
recent	O
literature	O
describing	O
the	O
stochastic	O
and	O
monoallelic	O
activation	O
of	O
other	O
hematopoietic	O
genes	O
.	O

The	O
Epstein	O
-	O
Barr	O
virus	O
latency	O
BamHI	O
-	O
Q	O
promoter	O
is	O
positively	O
regulated	O
by	O
STATs	O
and	O
Zta	B-Protein
interference	O
with	O
JAK	O
/	O
STAT	O
activation	O
leads	O
to	O
loss	O
of	O
BamHI	O
-	O
Q	O
promoter	O
activity	O
.	O

In	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
-	O
associated	O
tumors	O
in	O
nonimmunocompromised	O
patients	O
,	O
EBV	O
gene	O
expression	O
is	O
highly	O
restricted	O
.	O

EBV	B-Protein
-	I-Protein
encoded	I-Protein
nuclear	I-Protein
antigen	I-Protein
(	I-Protein
EBNA	I-Protein
)	I-Protein
-	I-Protein
1	I-Protein
is	O
expressed	O
,	O
whereas	O
the	O
immunogenic	O
and	O
proliferative	O
EBNAs	O
are	O
not	O
.	O

This	O
pattern	O
of	O
EBNA	O
expression	O
is	O
generated	O
by	O
usage	O
of	O
the	O
BamHI	O
-	O
Q	O
promoter	O
(	O
Qp	O
)	O
.	O

We	O
have	O
determined	O
that	O
the	O
JAK	O
/	O
STAT	O
pathway	O
positively	O
regulates	O
Qp	O
activity	O
.	O

In	O
transient	O
-	O
transfection	O
assays	O
,	O
a	O
Qp	O
-	O
CAT	O
reporter	O
was	O
activated	O
by	O
cotransfected	O
JAK	B-Protein
-	I-Protein
1	I-Protein
and	O
by	O
treatment	O
of	O
cells	O
with	O
the	O
cytokine	O
IL	B-Protein
-	I-Protein
6	I-Protein
.	O

The	O
ability	O
of	O
Qp	O
to	O
bind	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	O
)	O
proteins	O
was	O
directly	O
demonstrated	O
by	O
electrophoretic	O
mobility	O
-	O
shift	O
assay	O
,	O
and	O
mutation	O
of	O
potential	O
STAT	O
-	O
binding	O
sites	O
reduced	O
Qp	O
responsiveness	O
to	O
Janus	B-Protein
kinase	I-Protein
(	I-Protein
JAK	I-Protein
)	I-Protein
-	I-Protein
1	I-Protein
.	O

Consistent	O
with	O
a	O
role	O
for	O
STATs	O
in	O
Qp	O
function	O
,	O
Qp	O
using	O
Burkitt	O
'	O
s	O
lymphoma	O
Rael	O
cells	O
and	O
cultured	O
nasopharyngeal	O
carcinoma	O
(	O
NPC	O
)	O
cells	O
contained	O
nuclear	O
STAT	O
protein	O
.	O

We	O
investigated	O
whether	O
the	O
inability	O
to	O
maintain	O
EBV	O
-	O
positive	O
NPC	O
cell	O
lines	O
in	O
culture	O
was	O
related	O
to	O
Qp	O
activity	O
.	O

Passaging	O
of	O
the	O
NPC	O
cell	O
line	O
HK666	O
led	O
to	O
activation	O
of	O
expression	O
of	O
BZLF1	B-Protein
,	O
which	O
encodes	O
Zta	B-Protein
and	O
loss	O
of	O
Qp	O
function	O
.	O

Transient	O
expression	O
assays	O
linked	O
Zta	B-Protein
expression	O
to	O
the	O
down	O
-	O
regulation	O
of	O
Qp	O
.	O

Cotransfection	O
of	O
Zta	B-Protein
reduced	O
Qp	O
activity	O
in	O
reporter	O
assays	O
.	O

This	O
negative	O
regulation	O
required	O
Zta	B-Protein
DNA	O
-	O
binding	O
activity	O
.	O

We	O
provide	O
evidence	O
that	O
Zta	B-Protein
up	O
-	O
regulation	O
of	O
p53	B-Protein
leads	O
to	O
p53	B-Protein
-	O
mediated	O
interference	O
with	O
JAK	O
/	O
STAT	O
activation	O
of	O
Qp	O
.	O

The	O
data	O
imply	O
that	O
JAK	O
/	O
STAT	O
signaling	O
has	O
a	O
role	O
in	O
EBV	O
-	O
associated	O
malignancies	O
.	O

Selective	O
DNA	O
-	O
binding	O
activity	O
of	O
interleukin	B-Protein
-	I-Protein
10	I-Protein
-	O
stimulated	O
STAT	O
molecules	O
in	O
human	O
monocytes	O
.	O

It	O
has	O
been	O
demonstrated	O
that	O
interferon	B-Protein
-	I-Protein
gamma	I-Protein
(	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
)	O
and	O
interleukin	B-Protein
-	I-Protein
10	I-Protein
(	O
IL	B-Protein
-	I-Protein
10	I-Protein
)	O
have	O
various	O
reverse	O
effects	O
on	O
macrophages	O
;	O
however	O
,	O
the	O
molecular	O
mechanism	O
of	O
this	O
difference	O
has	O
not	O
been	O
fully	O
understood	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
binding	O
activity	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
-	O
activated	O
STAT	O
molecules	O
to	O
two	O
kinds	O
of	O
GAS	O
-	O
motif	O
sequences	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
-	O
activated	O
STAT1	B-Protein
could	O
bind	O
to	O
the	O
GAS	O
-	O
motif	O
sequence	O
in	O
the	O
promoter	O
region	O
of	O
the	O
Fcgamma	O
receptor	O
,	O
but	O
not	O
to	O
that	O
in	O
the	O
promoter	O
region	O
of	O
the	O
COX	B-Protein
-	I-Protein
2	I-Protein
gene	O
,	O
whereas	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
-	O
activated	O
STAT1	B-Protein
and	O
STAT5	B-Protein
could	O
bind	O
to	O
both	O
sequences	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
inhibited	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
-	O
induced	O
STAT	O
activation	O
without	O
newly	O
synthesized	O
protein	O
.	O

We	O
further	O
demonstrated	O
that	O
aspirin	O
,	O
but	O
not	O
dexamethasone	O
,	O
suppressed	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
-	O
induced	O
STAT	O
activation	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
activated	O
STAT1	B-Protein
has	O
a	O
specificity	O
in	O
binding	O
to	O
the	O
GAS	O
-	O
motif	O
sequences	O
,	O
whereas	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
-	O
activated	O
STAT1	B-Protein
and	O
STAT5	B-Protein
have	O
a	O
broader	O
spectrum	O
in	O
binding	O
to	O
the	O
GAS	O
-	O
motif	O
sequences	O
.	O

This	O
may	O
explain	O
the	O
difference	O
between	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
in	O
biological	O
activity	O
,	O
and	O
the	O
inhibitory	O
effect	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
on	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
activities	O
.	O

Block	O
of	O
granulocytic	O
differentiation	O
of	O
32Dcl3	O
cells	O
by	O
AML1	O
/	O
ETO	O
(	O
MTG8	O
)	O
but	O
not	O
by	O
highly	O
expressed	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
.	O

The	O
chimeric	O
gene	O
,	O
AML1	O
/	O
ETO	O
(	O
MTG8	O
)	O
,	O
generated	O
in	O
t	O
(	O
8	O
;	O
21	O
)	O
acute	O
myeloid	O
leukemia	O
enhances	O
the	O
expression	O
of	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
.	O

To	O
evaluate	O
whether	O
this	O
enhancement	O
is	O
the	O
primary	O
role	O
of	O
AML1	O
/	O
ETO	O
in	O
leukemogenesis	O
,	O
effects	O
of	O
over	O
-	O
expression	O
of	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
in	O
the	O
murine	O
myeloid	O
precursor	O
cell	O
line	O
,	O
32Dcl3	O
,	O
were	O
examined	O
.	O

When	O
32Dcl3	O
cells	O
expressing	O
exogenous	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
were	O
induced	O
to	O
differentiate	O
,	O
the	O
onset	O
of	O
morphological	O
differentiation	O
was	O
delayed	O
.	O

However	O
,	O
even	O
the	O
cells	O
expressing	O
very	O
high	O
levels	O
of	O
exogenous	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
eventually	O
underwent	O
differentiation	O
without	O
a	O
significant	O
decrease	O
in	O
the	O
synthesis	O
of	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
.	O

On	O
the	O
contrary	O
,	O
32Dcl3	O
cells	O
stably	O
expressing	O
AML1	O
/	O
ETO	O
were	O
completely	O
resistant	O
to	O
differentiation	O
and	O
continued	O
to	O
grow	O
in	O
the	O
presence	O
of	O
G	B-Protein
-	I-Protein
CSF	I-Protein
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
interpretation	O
that	O
stimulation	O
of	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
expression	O
is	O
not	O
the	O
primary	O
target	O
of	O
AML1	O
/	O
ETO	O
.	O

The	O
Legionella	O
pneumophila	O
rpoS	B-Protein
gene	O
is	O
required	O
for	O
growth	O
within	O
Acanthamoeba	O
castellanii	O
.	O

To	O
investigate	O
regulatory	O
networks	O
in	O
Legionella	O
pneumophila	O
,	O
the	O
gene	O
encoding	O
the	O
homolog	O
of	O
the	O
Escherichia	O
coli	O
stress	O
and	O
stationary	O
-	O
phase	O
sigma	O
factor	O
RpoS	B-Protein
was	O
identified	O
by	O
complementation	O
of	O
an	O
E	O
.	O
coli	O
rpoS	B-Protein
mutation	O
.	O

An	O
open	O
reading	O
frame	O
that	O
is	O
approximately	O
60	O
%	O
identical	O
to	O
the	O
E	O
.	O
coli	O
rpoS	B-Protein
gene	O
was	O
identified	O
.	O

Western	O
blot	O
analysis	O
showed	O
that	O
the	O
level	O
of	O
L	O
.	O
pneumophila	O
RpoS	B-Protein
increased	O
in	O
stationary	O
phase	O
.	O

An	O
insertion	O
mutation	O
was	O
constructed	O
in	O
the	O
rpoS	B-Protein
gene	O
on	O
the	O
chromosome	O
of	O
L	O
.	O
pneumophila	O
,	O
and	O
the	O
ability	O
of	O
this	O
mutant	O
strain	O
to	O
survive	O
various	O
stress	O
conditions	O
was	O
assayed	O
and	O
compared	O
with	O
results	O
for	O
the	O
wild	O
-	O
type	O
strain	O
.	O

Both	O
the	O
mutant	O
and	O
wild	O
-	O
type	O
strains	O
were	O
more	O
resistant	O
to	O
stress	O
when	O
in	O
stationary	O
phase	O
than	O
when	O
in	O
the	O
logarithmic	O
phase	O
of	O
growth	O
.	O

This	O
finding	O
indicates	O
that	O
L	O
.	O
pneumophila	O
RpoS	B-Protein
is	O
not	O
required	O
for	O
a	O
stationary	O
-	O
phase	O
-	O
dependent	O
resistance	O
to	O
stress	O
.	O

Although	O
the	O
mutant	O
strain	O
was	O
able	O
to	O
kill	O
HL	O
-	O
60	O
-	O
and	O
THP	O
-	O
1	O
-	O
derived	O
macrophages	O
,	O
it	O
could	O
not	O
replicate	O
within	O
a	O
protozoan	O
host	O
,	O
Acanthamoeba	O
castellanii	O
.	O

These	O
data	O
suggest	O
that	O
L	O
.	O
pneumophila	O
possesses	O
a	O
growth	O
phase	O
-	O
dependent	O
resistance	O
to	O
stress	O
that	O
is	O
independent	O
of	O
RpoS	B-Protein
control	O
and	O
that	O
RpoS	B-Protein
likely	O
regulates	O
genes	O
that	O
enable	O
it	O
to	O
survive	O
in	O
the	O
environment	O
within	O
protozoa	O
.	O

Our	O
data	O
indicate	O
that	O
the	O
role	O
of	O
rpoS	B-Protein
in	O
L	O
.	O
pneumophila	O
is	O
very	O
different	O
from	O
what	O
has	O
previously	O
been	O
reported	O
for	O
E	O
.	O
coli	O
rpoS	B-Protein
.	O

Cutting	O
edge	O
:	O
TCR	O
stimulation	O
by	O
antibody	O
and	O
bacterial	O
superantigen	O
induces	O
Stat3	B-Protein
activation	O
in	O
human	O
T	O
cells	O
.	O

Recent	O
data	O
show	O
that	O
TCR	O
/	O
CD3	O
stimulation	O
induces	O
activation	O
of	O
Stat5	B-Protein
in	O
murine	O
T	O
cells	O
.	O

Here	O
,	O
we	O
show	O
that	O
CD3	O
ligation	O
by	O
mAb	O
and	O
Staphylococcal	O
enterotoxin	O
(	O
SE	O
)	O
induce	O
a	O
rapid	O
,	O
gradually	O
accumulating	O
,	O
long	O
-	O
lasting	O
tyrosine	O
,	O
and	O
serine	O
phosphorylation	O
of	O
Stat3	B-Protein
(	O
but	O
not	O
Stat5	B-Protein
)	O
in	O
allogen	O
-	O
specific	O
human	O
CD4	O
+	O
T	O
cell	O
lines	O
.	O

In	O
contrast	O
,	O
IL	B-Protein
-	I-Protein
2	I-Protein
induces	O
a	O
rapid	O
and	O
transient	O
tyrosine	O
and	O
serine	O
phosphorylation	O
of	O
Stat3	B-Protein
.	O

Compared	O
with	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
CD3	B-Protein
ligation	O
induces	O
a	O
delayed	O
Stat3	B-Protein
binding	O
to	O
oligonucleotide	O
probes	O
from	O
the	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
and	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	I-Protein
promoter	O
.	O

CD3	B-Protein
-	O
mediated	O
activation	O
of	O
Stat3	B-Protein
is	O
almost	O
completely	O
inhibited	O
by	O
a	O
Src	O
kinase	O
inhibitor	O
(	O
PP1	O
)	O
,	O
whereas	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
induced	O
Stat3	B-Protein
activation	O
is	O
unaffected	O
.	O

In	O
conclusion	O
,	O
we	O
show	O
that	O
CD3	B-Protein
ligation	O
by	O
mAb	O
and	O
SE	O
triggers	O
a	O
rapid	O
,	O
PP1	O
-	O
sensitive	O
tyrosine	O
and	O
serine	O
phosphorylation	O
of	O
Stat3	B-Protein
in	O
human	O
CD4	O
+	O
T	O
cells	O
.	O

Moreover	O
,	O
we	O
provide	O
evidence	O
that	O
TCR	O
/	O
CD3	O
and	O
IL	B-Protein
-	I-Protein
2	I-Protein
induce	O
Stat3	B-Protein
activation	O
via	O
distinct	O
signaling	O
pathways	O
.	O

[	O
Hormonal	O
metabolic	O
status	O
in	O
breast	O
cancer	O
patients	O
after	O
conservative	O
surgery	O
:	O
comparison	O
with	O
known	O
prognostic	O
criteria	O
]	O

Body	O
weight	O
,	O
body	O
mass	O
index	O
,	O
body	O
fat	O
,	O
lean	O
body	O
mass	O
,	O
blood	O
-	O
glucose	O
,	O
cholesterol	O
,	O
HDL	O
-	O
cholesterol	O
,	O
triglyceride	O
,	O
beta	O
-	O
lipoproteins	O
,	O
insulin	O
,	O
gonadotropin	O
,	O
estradiol	O
,	O
testosterone	O
,	O
SHBG	B-Protein
,	O
T3	O
,	O
T4	O
and	O
TSH	O
levels	O
as	O
well	O
as	O
estradiol	B-Protein
and	O
progesterone	B-Protein
receptor	I-Protein
levels	O
in	O
excised	O
tumor	O
were	O
studied	O
in	O
40	O
patients	O
with	O
breast	O
cancer	O
prior	O
to	O
conservative	O
treatment	O
.	O

Said	O
anthropometric	O
,	O
metabolic	O
and	O
hormonal	O
parameters	O
were	O
compared	O
with	O
the	O
index	O
of	O
lymphocytic	O
infiltration	O
of	O
tumor	O
selected	O
as	O
a	O
prognostic	O
factor	O
.	O

A	O
significant	O
correlation	O
between	O
high	O
lymphocytic	O
infiltration	O
(	O
2	O
.	O
5	O
points	O
)	O
,	O
low	O
body	O
mass	O
and	O
fat	O
was	O
identified	O
.	O

Also	O
,	O
smoking	O
contributed	O
to	O
loss	O
of	O
body	O
mass	O
and	O
fat	O
;	O
however	O
,	O
it	O
caused	O
lymphocytic	O
infiltration	O
to	O
rise	O
.	O

Moderate	O
body	O
mass	O
,	O
relatively	O
low	O
fat	O
level	O
and	O
positive	O
receptor	O
status	O
are	O
among	O
factors	O
of	O
good	O
prognosis	O
in	O
breast	O
cancer	O
of	O
early	O
stages	O
.	O

Tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
alpha	I-Protein
decreases	O
,	O
and	O
interleukin	B-Protein
-	I-Protein
10	I-Protein
increases	O
,	O
the	O
sensitivity	O
of	O
human	O
monocytes	O
to	O
dexamethasone	O
:	O
potential	O
regulation	O
of	O
the	O
glucocorticoid	B-Protein
receptor	I-Protein
.	O

Resistance	O
to	O
glucocorticoid	O
therapy	O
has	O
been	O
observed	O
in	O
patients	O
with	O
autoimmune	O
/	O
inflammatory	O
diseases	O
and	O
may	O
be	O
related	O
to	O
the	O
inflammatory	O
process	O
itself	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
ability	O
of	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
alpha	I-Protein
(	O
TNFalpha	B-Protein
,	O
a	O
proinflammatory	O
cytokine	O
)	O
and	O
interleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
-	I-Protein
10	I-Protein
(	O
an	O
anti	O
-	O
inflammatory	O
cytokine	O
)	O
to	O
differentially	O
regulate	O
the	O
sensitivity	O
of	O
human	O
monocytes	O
/	O
macrophages	O
to	O
glucocorticoids	O
.	O

To	O
accomplish	O
this	O
,	O
we	O
first	O
analyzed	O
the	O
pattern	O
of	O
TNFalpha	B-Protein
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
inhibition	O
by	O
dexamethasone	O
in	O
LPS	O
-	O
stimulated	O
whole	O
-	O
blood	O
cell	O
cultures	O
.	O

Second	O
,	O
we	O
studied	O
the	O
modulation	O
of	O
the	O
sensitivity	O
of	O
these	O
cells	O
to	O
dexamethasone	O
by	O
preincubation	O
with	O
TNFalpha	B-Protein
or	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
measurement	O
of	O
LPS	O
-	O
stimulated	O
IL	B-Protein
-	I-Protein
6	I-Protein
secretion	O
.	O

In	O
addition	O
,	O
we	O
evaluated	O
the	O
effect	O
of	O
dexamethasone	O
on	O
phorbolmyristate	O
-	O
acetate	O
-	O
stimulated	O
IL	B-Protein
-	I-Protein
1	I-Protein
receptor	I-Protein
antagonist	I-Protein
secretion	O
by	O
the	O
human	O
monocytic	O
cell	O
line	O
U937	O
.	O

Finally	O
,	O
we	O
investigated	O
whether	O
the	O
modulation	O
of	O
corticosensitivity	O
in	O
TNFalpha	B-Protein
-	O
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
pretreated	O
U937	O
cells	O
was	O
related	O
to	O
a	O
change	O
of	O
the	O
glucocorticoid	B-Protein
receptor	I-Protein
concentration	O
and	O
affinity	O
.	O

Dexamethasone	O
had	O
different	O
effects	O
on	O
LPS	O
-	O
induced	O
TNFalpha	B-Protein
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
secretion	O
;	O
whereas	O
it	O
suppressed	O
TNFalpha	B-Protein
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
,	O
its	O
effect	O
on	O
IL	B-Protein
-	I-Protein
10	I-Protein
secretion	O
was	O
biphasic	O
,	O
producing	O
stimulation	O
at	O
lower	O
,	O
and	O
inhibition	O
at	O
higher	O
doses	O
.	O

The	O
concentration	O
of	O
LPS	O
employed	O
influenced	O
the	O
effect	O
of	O
dexamethasone	O
on	O
IL	B-Protein
-	I-Protein
10	I-Protein
secretion	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Pretreatment	O
with	O
TNFalpha	B-Protein
diminished	O
,	O
and	O
with	O
IL	B-Protein
-	I-Protein
10	I-Protein
improved	O
,	O
the	O
ability	O
of	O
dexamethasone	O
to	O
suppress	O
IL	B-Protein
-	I-Protein
6	I-Protein
secretion	O
in	O
whole	O
-	O
blood	O
cell	O
cultures	O
(	O
P	O
<	O
0	O
.	O
01	O
for	O
both	O
)	O
and	O
to	O
enhance	O
IL	B-Protein
-	I-Protein
1	I-Protein
receptor	I-Protein
antagonist	I-Protein
secretion	O
by	O
U937	O
cells	O
(	O
P	O
<	O
0	O
.	O
05	O
for	O
both	O
)	O
.	O

TNFalpha	B-Protein
decreased	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
while	O
IL	B-Protein
-	I-Protein
10	I-Protein
increased	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
the	O
concentration	O
of	O
dexamethasone	O
binding	O
sites	O
in	O
these	O
cells	O
,	O
with	O
no	O
discernible	O
effect	O
on	O
their	O
binding	O
affinity	O
.	O

We	O
conclude	O
that	O
glucocorticoids	O
differentially	O
modulate	O
TNFalpha	B-Protein
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
secretion	O
by	O
human	O
monocytes	O
in	O
a	O
LPS	O
dose	O
-	O
dependent	O
fashion	O
and	O
that	O
the	O
sensitivity	O
of	O
these	O
cells	O
to	O
glucocorticoids	O
is	O
altered	O
by	O
TNFalpha	B-Protein
or	O
IL	B-Protein
-	I-Protein
10	I-Protein
pretreatment	O
;	O
TNFalpha	B-Protein
blocks	O
their	O
effects	O
,	O
whereas	O
IL	B-Protein
-	I-Protein
10	I-Protein
acts	O
synergistically	O
with	O
glucocorticoids	O
.	O

This	O
is	O
accompanied	O
by	O
opposite	O
glucocorticoid	B-Protein
receptor	I-Protein
changes	O
,	O
respectively	O
opposing	O
and	O
favoring	O
glucocorticoid	O
actions	O
.	O

This	O
study	O
suggests	O
that	O
the	O
pattern	O
of	O
pro	O
-	O
/	O
antiinflammatory	O
cytokine	O
secretion	O
may	O
alter	O
the	O
response	O
of	O
patients	O
to	O
glucocorticoid	O
therapy	O
.	O

Modulation	O
of	O
normal	O
erythroid	O
differentiation	O
by	O
the	O
endogenous	O
thyroid	O
hormone	O
and	O
retinoic	O
acid	O
receptors	O
:	O
a	O
possible	O
target	O
for	O
v	B-Protein
-	I-Protein
erbA	I-Protein
oncogene	O
action	O
.	O

The	O
v	B-Protein
-	I-Protein
erbA	I-Protein
oncogene	O
,	O
a	O
mutated	O
version	O
of	O
the	O
thyroid	B-Protein
hormone	I-Protein
receptor	I-Protein
alpha	I-Protein
(	O
c	B-Protein
-	I-Protein
erbA	I-Protein
/	O
TR	B-Protein
-	I-Protein
alpha	I-Protein
)	O
,	O
inhibits	O
erythroid	O
differentiation	O
and	O
constitutively	O
represses	O
transcription	O
of	O
certain	O
erythrocyte	O
genes	O
,	O
suggesting	O
a	O
normal	O
function	O
of	O
the	O
proto	O
-	O
oncogene	O
c	B-Protein
-	I-Protein
erbA	I-Protein
in	O
erythropoiesis	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
endogenous	O
thyroid	B-Protein
hormone	I-Protein
receptor	I-Protein
alpha	I-Protein
(	O
c	B-Protein
-	I-Protein
erbA	I-Protein
/	O
TR	B-Protein
-	I-Protein
alpha	I-Protein
)	O
and	O
the	O
closely	O
related	O
retinoic	B-Protein
acid	I-Protein
receptor	I-Protein
alpha	I-Protein
(	O
RAR	B-Protein
-	I-Protein
alpha	I-Protein
)	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
normal	O
erythroid	O
differentiation	O
.	O

Retinoic	O
acid	O
(	O
RA	O
)	O
distinctly	O
modulated	O
the	O
erythroid	O
differentiation	O
program	O
of	O
normal	O
erythroid	O
progenitors	O
and	O
erythroblasts	O
reversibly	O
transformed	O
by	O
a	O
conditional	O
tyrosine	O
kinase	O
oncogene	O
.	O

When	O
added	O
pulsewise	O
to	O
immature	O
cells	O
,	O
differentiation	O
was	O
accelerated	O
while	O
more	O
mature	O
cells	O
underwent	O
premature	O
cell	O
death	O
.	O

Thyroid	O
hormone	O
(	O
T3	O
)	O
alone	O
caused	O
similar	O
but	O
weaker	O
effects	O
.	O

Interestingly	O
,	O
T3	O
strongly	O
enhanced	O
the	O
action	O
of	O
RA	O
,	O
suggesting	O
cooperative	O
action	O
of	O
the	O
two	O
receptors	O
in	O
modulating	O
erythroid	O
differentiation	O
.	O

Expression	O
of	O
the	O
human	O
RAR	B-Protein
-	I-Protein
alpha	I-Protein
in	O
receptor	O
-	O
negative	O
erythroblasts	O
conferred	O
RA	O
-	O
induced	O
regulation	O
of	O
differentiation	O
to	O
the	O
otherwise	O
unresponsive	O
cells	O
,	O
thus	O
showing	O
that	O
the	O
RAR	B-Protein
-	I-Protein
alpha	I-Protein
is	O
essential	O
for	O
the	O
RA	O
effect	O
.	O

Likewise	O
,	O
enhanced	O
expression	O
of	O
exogenous	O
c	B-Protein
-	I-Protein
erbA	I-Protein
/	O
TR	B-Protein
-	I-Protein
alpha	I-Protein
in	O
erythroblasts	O
rendered	O
them	O
susceptible	O
to	O
modulation	O
of	O
differentiation	O
by	O
T3	O
,	O
suggesting	O
a	O
similar	O
function	O
of	O
both	O
receptors	O
.	O

Glucocorticoid	B-Protein
receptor	I-Protein
in	O
patients	O
with	O
lupus	O
nephritis	O
:	O
relationship	O
between	O
receptor	O
levels	O
in	O
mononuclear	O
leukocytes	O
and	O
effect	O
of	O
glucocorticoid	O
therapy	O
.	O

We	O
investigated	O
the	O
clinical	O
significance	O
of	O
glucocorticoid	B-Protein
receptor	I-Protein
determination	O
in	O
20	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
who	O
afterwards	O
developed	O
nephrotic	O
syndrome	O
.	O

Glucocorticoid	B-Protein
receptor	I-Protein
concentrations	O
in	O
mononuclear	O
leukocytes	O
(	O
MNL	O
)	O
in	O
these	O
patients	O
were	O
comparable	O
with	O
those	O
in	O
both	O
other	O
patients	O
with	O
SLE	O
and	O
healthy	O
persons	O
.	O

Improvement	O
in	O
urinary	O
protein	O
excretion	O
and	O
in	O
disease	O
activity	O
,	O
which	O
was	O
scored	O
according	O
to	O
the	O
SLE	O
Disease	O
Activity	O
Index	O
system	O
of	O
the	O
University	O
of	O
Toronto	O
,	O
closely	O
related	O
to	O
the	O
glucocorticoid	B-Protein
receptor	I-Protein
concentrations	O
in	O
MNL	O
isolated	O
from	O
the	O
corresponding	O
patients	O
.	O

In	O
summary	O
,	O
glucocorticoid	B-Protein
receptor	I-Protein
determination	O
in	O
patients	O
with	O
lupus	O
nephritis	O
may	O
be	O
a	O
predictive	O
clue	O
for	O
assessing	O
responsiveness	O
to	O
glucocorticoid	O
therapy	O
.	O

A	O
microtitre	O
assay	O
system	O
for	O
glucocorticoid	B-Protein
receptors	I-Protein
:	O
decreased	O
receptor	O
concentration	O
in	O
myocardial	O
infarction	O
.	O

A	O
major	O
difficulty	O
in	O
determination	O
of	O
glucocorticoid	B-Protein
receptor	I-Protein
sites	O
is	O
the	O
very	O
complicated	O
assay	O
procedure	O
.	O

Therefore	O
,	O
we	O
describe	O
a	O
microtitre	O
assay	O
system	O
for	O
glucocorticoid	B-Protein
receptors	I-Protein
which	O
is	O
a	O
whole	O
-	O
cell	O
competitive	O
binding	O
radioassay	O
using	O
[	O
3H	O
]	O
-	O
dexamethasone	O
as	O
radioligand	O
.	O

This	O
modification	O
of	O
a	O
previously	O
described	O
protocol	O
simplifies	O
and	O
reduces	O
laboratory	O
work	O
and	O
allows	O
assay	O
reproducibility	O
to	O
be	O
controlled	O
more	O
reliably	O
.	O

Thus	O
enabled	O
to	O
perform	O
the	O
test	O
on	O
multiple	O
blood	O
samples	O
in	O
parallel	O
,	O
we	O
investigated	O
cardiac	O
infarction	O
patients	O
over	O
a	O
12	O
-	O
day	O
period	O
to	O
test	O
if	O
glucocorticoid	B-Protein
receptor	I-Protein
binding	O
is	O
altered	O
in	O
this	O
'	O
stressful	O
'	O
disease	O
.	O

On	O
the	O
first	O
day	O
of	O
the	O
disease	O
,	O
glucocorticoid	B-Protein
receptor	I-Protein
capacity	O
was	O
significantly	O
decreased	O
without	O
alteration	O
of	O
the	O
receptor	O
-	O
ligand	O
affinity	O
,	O
whereas	O
on	O
days	O
4	O
and	O
12	O
the	O
number	O
of	O
receptor	O
sites	O
was	O
normal	O
again	O
.	O

This	O
result	O
fits	O
well	O
into	O
the	O
general	O
observation	O
of	O
stress	O
-	O
induced	O
down	O
-	O
regulation	O
of	O
immune	O
responses	O
.	O

Single	O
point	O
estimation	O
of	O
glucocorticoid	B-Protein
receptors	I-Protein
in	O
lymphocytes	O
of	O
normal	O
subjects	O
and	O
of	O
children	O
under	O
long	O
term	O
glucocorticoid	O
treatment	O
.	O

A	O
single	O
point	O
assay	O
of	O
glucocorticoid	B-Protein
receptors	I-Protein
(	O
GR	B-Protein
)	O
in	O
human	O
lymphocytes	O
based	O
on	O
the	O
measurement	O
of	O
specific	O
dexamethasone	O
binding	O
has	O
been	O
developed	O
and	O
compared	O
with	O
a	O
common	O
multi	O
-	O
point	O
Scatchard	O
analysis	O
.	O

The	O
assay	O
conditions	O
-	O
concentration	O
of	O
the	O
ligand	O
20	O
nmol	O
/	O
l	O
,	O
incubation	O
time	O
2	O
h	O
and	O
the	O
cell	O
count	O
2	O
-	O
6	O
mil	O
.	O

cells	O
/	O
tube	O
in	O
the	O
assay	O
volume	O
0	O
.	O
25	O
ml	O
were	O
found	O
to	O
be	O
optimal	O
.	O

An	O
attempt	O
was	O
also	O
undertaken	O
to	O
use	O
a	O
cell	O
harvester	O
for	O
the	O
separation	O
of	O
cells	O
from	O
unbound	O
ligand	O
.	O

Though	O
specifically	O
bound	O
dexamethasone	O
measured	O
by	O
whole	O
-	O
cell	O
assay	O
and	O
that	O
using	O
cell	O
harvester	O
correlated	O
well	O
,	O
almost	O
by	O
one	O
order	O
lower	O
values	O
obtained	O
with	O
the	O
latter	O
method	O
render	O
it	O
non	O
-	O
applicable	O
for	O
receptor	O
quantitation	O
.	O

The	O
results	O
from	O
9	O
healthy	O
volunteers	O
(	O
average	O
GR	B-Protein
concentration	O
7131	O
+	O
/	O
-	O
1256	O
sites	O
/	O
cell	O
)	O
correlated	O
excellently	O
with	O
those	O
obtained	O
by	O
the	O
Scatchard	O
analysis	O
.	O

The	O
single	O
point	O
assay	O
has	O
been	O
also	O
applied	O
for	O
determination	O
of	O
GH	O
in	O
10	O
children	O
treated	O
with	O
large	O
doses	O
of	O
prednisone	O
.	O

The	O
average	O
values	O
from	O
healthy	O
volunteers	O
did	O
not	O
differ	O
significantly	O
from	O
those	O
found	O
in	O
these	O
children	O
,	O
though	O
much	O
broader	O
range	O
was	O
found	O
in	O
patients	O
.	O

A	O
novel	O
B	O
cell	O
-	O
derived	O
coactivator	O
potentiates	O
the	O
activation	O
of	O
immunoglobulin	O
promoters	O
by	O
octamer	O
-	O
binding	O
transcription	O
factors	O
.	O

A	O
novel	O
B	O
cell	O
-	O
restricted	O
activity	O
,	O
required	O
for	O
high	O
levels	O
of	O
octamer	O
/	O
Oct	O
-	O
dependent	O
transcription	O
from	O
an	O
immunoglobulin	O
heavy	O
chain	O
(	O
IgH	O
)	O
promoter	O
,	O
was	O
detected	O
in	O
an	O
in	O
vitro	O
system	O
consisting	O
of	O
HeLa	O
cell	O
-	O
derived	O
extracts	O
complemented	O
with	O
fractionated	O
B	O
cell	O
nuclear	O
proteins	O
.	O

The	O
factor	O
responsible	O
for	O
this	O
activity	O
was	O
designated	O
Oct	O
coactivator	O
from	O
B	O
cells	O
(	O
OCA	B-Protein
-	I-Protein
B	I-Protein
)	O
.	O

OCA	B-Protein
-	I-Protein
B	I-Protein
stimulates	O
the	O
transcription	O
from	O
an	O
IgH	O
promoter	O
in	O
conjunction	O
with	O
either	O
Oct	B-Protein
-	I-Protein
1	I-Protein
or	O
Oct	B-Protein
-	I-Protein
2	I-Protein
but	O
shows	O
no	O
significant	O
effect	O
on	O
the	O
octamer	O
/	O
Oct	O
-	O
dependent	O
transcription	O
of	O
the	O
ubiquitously	O
expressed	O
histone	O
H2B	O
promoter	O
and	O
the	O
transcription	O
of	O
USF	B-Protein
-	O
and	O
Sp1	B-Protein
-	O
regulated	O
promoters	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
OCA	B-Protein
-	I-Protein
B	I-Protein
is	O
a	O
tissue	O
-	O
,	O
promoter	O
-	O
,	O
and	O
factor	O
-	O
specific	O
coactivator	O
and	O
that	O
OCA	B-Protein
-	I-Protein
B	I-Protein
may	O
be	O
a	O
major	O
determinant	O
for	O
B	O
cell	O
-	O
specific	O
activation	O
of	O
immunoglobulin	O
promoters	O
.	O

In	O
light	O
of	O
the	O
evidence	O
showing	O
physical	O
and	O
functional	O
interactions	O
between	O
Oct	O
factors	O
and	O
OCA	B-Protein
-	I-Protein
B	I-Protein
,	O
we	O
propose	O
a	O
mechanism	O
of	O
action	O
for	O
OCA	B-Protein
-	I-Protein
B	I-Protein
and	O
discuss	O
the	O
implications	O
of	O
OCA	B-Protein
-	I-Protein
B	I-Protein
for	O
the	O
transcriptional	O
regulation	O
of	O
other	O
tissue	O
-	O
specific	O
promoters	O
.	O

Expression	O
of	O
c	B-Protein
-	I-Protein
fos	I-Protein
,	O
c	B-Protein
-	I-Protein
jun	I-Protein
and	O
jun	B-Protein
B	I-Protein
in	O
peripheral	O
blood	O
lymphocytes	O
from	O
young	O
and	O
elderly	O
adults	O
.	O

The	O
expression	O
of	O
c	B-Protein
-	I-Protein
fos	I-Protein
,	O
c	B-Protein
-	I-Protein
jun	I-Protein
and	O
jun	B-Protein
B	I-Protein
proto	O
-	O
oncogenes	O
was	O
studied	O
in	O
phytohemagglutinin	B-Protein
(	O
PHA	B-Protein
)	O
activated	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
from	O
young	O
and	O
aged	O
humans	O
.	O

Specific	O
mRNAs	O
for	O
c	B-Protein
-	I-Protein
fos	I-Protein
and	O
c	B-Protein
-	I-Protein
jun	I-Protein
were	O
detectable	O
within	O
30	O
min	O
after	O
cell	O
activation	O
and	O
reached	O
maximal	O
levels	O
within	O
2	O
h	O
.	O

Both	O
c	B-Protein
-	I-Protein
fos	I-Protein
and	O
jun	B-Protein
B	I-Protein
mRNAs	O
decreased	O
to	O
pre	O
-	O
activation	O
levels	O
within	O
6	O
h	O
,	O
while	O
c	B-Protein
-	I-Protein
jun	I-Protein
mRNA	O
remained	O
elevated	O
.	O

In	O
PHA	B-Protein
-	O
activated	O
PBL	O
,	O
no	O
age	O
-	O
related	O
differences	O
were	O
observed	O
in	O
c	B-Protein
-	I-Protein
fos	I-Protein
or	O
jun	B-Protein
B	I-Protein
mRNA	O
expression	O
.	O

However	O
,	O
c	B-Protein
-	I-Protein
jun	I-Protein
mRNA	O
levels	O
decreased	O
significantly	O
(	O
1	O
.	O
73	O
+	O
/	O
-	O
0	O
.	O
08	O
vs	O
.	O
1	O
.	O
16	O
+	O
/	O
-	O
0	O
.	O
09	O
arbitrary	O
units	O
,	O
P	O
<	O
0	O
.	O
01	O
,	O
young	O
vs	O
.	O
old	O
)	O
in	O
PBL	O
from	O
elderly	O
individuals	O
activated	O
with	O
PHA	B-Protein
.	O

Because	O
previous	O
work	O
has	O
demonstrated	O
that	O
T	O
cells	O
from	O
elderly	O
individuals	O
may	O
display	O
normal	O
proliferative	O
responses	O
when	O
activated	O
via	O
the	O
anti	O
-	O
CD2	B-Protein
pathway	O
,	O
c	B-Protein
-	I-Protein
jun	I-Protein
and	O
jun	B-Protein
B	I-Protein
mRNA	O
expression	O
was	O
also	O
studied	O
in	O
anti	O
-	O
CD2	B-Protein
-	O
activated	O
purified	O
T	O
cells	O
.	O

No	O
age	O
-	O
related	O
differences	O
were	O
found	O
in	O
the	O
expression	O
of	O
either	O
of	O
these	O
two	O
proto	O
-	O
oncogenes	O
by	O
anti	O
-	O
CD2	B-Protein
activated	O
T	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
the	O
decreased	O
IL	B-Protein
-	I-Protein
2	I-Protein
production	O
and	O
proliferative	O
response	O
displayed	O
by	O
PHA	B-Protein
-	O
activated	O
PBL	O
from	O
elderly	O
adults	O
may	O
be	O
related	O
to	O
age	O
-	O
related	O
changes	O
in	O
c	B-Protein
-	I-Protein
jun	I-Protein
mRNA	O
expression	O
and	O
in	O
the	O
ratio	O
of	O
c	B-Protein
-	I-Protein
fos	I-Protein
to	O
c	B-Protein
-	I-Protein
jun	I-Protein
mRNA	O
.	O

SCL	B-Protein
and	O
related	O
hemopoietic	O
helix	O
-	O
loop	O
-	O
helix	O
transcription	O
factors	O
.	O

The	O
helix	O
-	O
loop	O
-	O
helix	O
(	O
HLH	O
)	O
proteins	O
are	O
a	O
family	O
of	O
transcription	O
factors	O
that	O
include	O
proteins	O
critical	O
to	O
differentiation	O
and	O
development	O
in	O
species	O
ranging	O
from	O
plants	O
to	O
mammals	O
.	O

Five	O
members	O
of	O
this	O
family	O
(	O
MYC	O
,	O
SCL	B-Protein
,	O
TAL	B-Protein
-	I-Protein
2	I-Protein
,	O
LYL	B-Protein
-	I-Protein
1	I-Protein
and	O
E2A	B-Protein
)	O
are	O
implicated	O
in	O
oncogenic	O
events	O
in	O
human	O
lymphoid	O
tumors	O
because	O
of	O
their	O
consistent	O
involvement	O
in	O
chromosomal	O
translocations	O
.	O

Although	O
activated	O
in	O
T	O
cell	O
leukemias	O
,	O
expression	O
of	O
SCL	B-Protein
and	O
LYL	B-Protein
-	I-Protein
1	I-Protein
is	O
low	O
or	O
undetectable	O
in	O
normal	O
T	O
cell	O
populations	O
.	O

SCL	B-Protein
is	O
expressed	O
in	O
erythroid	O
,	O
megakaryocyte	O
and	O
mast	O
cell	O
populations	O
(	O
the	O
same	O
cell	O
lineages	O
as	O
GATA	B-Protein
-	I-Protein
1	I-Protein
,	O
a	O
zinc	O
-	O
finger	O
transcription	O
factor	O
)	O
.	O

In	O
addition	O
,	O
both	O
SCL	B-Protein
and	O
GATA	B-Protein
-	I-Protein
1	I-Protein
undergo	O
coordinate	O
modulation	O
during	O
chemically	O
induced	O
erythroid	O
differentiation	O
of	O
mouse	O
erythroleukemia	O
cells	O
and	O
are	O
down	O
-	O
modulated	O
during	O
myeloid	O
differentiation	O
of	O
human	O
K562	O
cells	O
,	O
thus	O
implying	O
a	O
role	O
for	O
SCL	B-Protein
in	O
erythroid	O
differentiation	O
events	O
.	O

However	O
,	O
in	O
contrast	O
to	O
GATA	B-Protein
-	I-Protein
1	I-Protein
,	O
SCL	B-Protein
is	O
expressed	O
in	O
the	O
developing	O
brain	O
.	O

Studies	O
of	O
the	O
function	O
of	O
SCL	B-Protein
suggest	O
it	O
is	O
also	O
important	O
in	O
proliferation	O
and	O
self	O
-	O
renewal	O
events	O
in	O
erythroid	O
cells	O
.	O

Mutations	O
in	O
the	O
Pit	B-Protein
-	I-Protein
1	I-Protein
gene	O
in	O
children	O
with	O
combined	O
pituitary	O
hormone	O
deficiency	O
.	O

Pit	B-Protein
-	I-Protein
1	I-Protein
is	O
a	O
pituitary	O
-	O
specific	O
transcription	O
factor	O
that	O
binds	O
to	O
and	O
transactivates	O
promoters	O
of	O
growth	O
hormone	O
and	O
prolactin	O
genes	O
.	O

In	O
three	O
unrelated	O
Japanese	O
children	O
with	O
combined	O
pituitary	O
hormone	O
deficiency	O
,	O
we	O
identified	O
three	O
point	O
mutations	O
in	O
the	O
Pit	B-Protein
-	I-Protein
1	I-Protein
gene	O
,	O
Pro24Leu	O
,	O
Arg143Gln	O
,	O
and	O
Arg271Trp	O
,	O
located	O
on	O
the	O
major	O
transactivation	O
region	O
,	O
POU	O
-	O
specific	O
domain	O
,	O
and	O
POU	O
-	O
homeodomain	O
,	O
respectively	O
.	O

Cell	O
cycle	O
-	O
dependent	O
initiation	O
and	O
lineage	O
-	O
dependent	O
abrogation	O
of	O
GATA	B-Protein
-	I-Protein
1	I-Protein
expression	O
in	O
pure	O
differentiating	O
hematopoietic	O
progenitors	O
.	O

The	O
programmed	O
activation	O
/	O
repression	O
of	O
transcription	O
factors	O
in	O
early	O
hematopoietic	O
differentiation	O
has	O
not	O
yet	O
been	O
explored	O
.	O

The	O
DNA	O
-	O
binding	O
protein	O
GATA	B-Protein
-	I-Protein
1	I-Protein
is	O
required	O
for	O
normal	O
erythroid	O
development	O
and	O
regulates	O
erythroid	O
-	O
expressed	O
genes	O
in	O
maturing	O
erythroblasts	O
.	O

We	O
analyzed	O
GATA	B-Protein
-	I-Protein
1	I-Protein
expression	O
in	O
early	O
human	O
adult	O
hematopoiesis	O
by	O
using	O
an	O
in	O
vitro	O
system	O
in	O
which	O
"	O
pure	O
"	O
early	O
hematopoietic	O
progenitors	O
are	O
induced	O
to	O
gradual	O
and	O
synchronized	O
differentiation	O
selectively	O
along	O
the	O
erythroid	O
or	O
granulocyte	O
-	O
macrophage	O
pathway	O
by	O
differential	O
treatment	O
with	O
hematopoietic	O
growth	O
factors	O
.	O

The	O
GATA	B-Protein
-	I-Protein
1	I-Protein
gene	O
,	O
though	O
virtually	O
silent	O
in	O
quiescent	O
progenitors	O
,	O
is	O
activated	O
after	O
entrance	O
into	O
the	O
cell	O
cycle	O
upon	O
stimulation	O
with	O
hematopoietic	O
growth	O
factors	O
.	O

Subsequently	O
,	O
increasing	O
expression	O
along	O
the	O
erythroid	O
pathway	O
contrasts	O
with	O
an	O
abrupt	O
downregulation	O
in	O
the	O
granulocyte	O
-	O
macrophage	O
lineage	O
.	O

These	O
results	O
suggest	O
a	O
microenvironment	O
-	O
directed	O
,	O
two	O
-	O
step	O
model	O
for	O
GATA	B-Protein
-	I-Protein
1	I-Protein
expression	O
in	O
differentiating	O
hematopoietic	O
progenitors	O
that	O
involves	O
(	O
i	O
)	O
cycle	O
-	O
dependent	O
initiation	O
and	O
(	O
ii	O
)	O
lineage	O
-	O
dependent	O
maintenance	O
or	O
suppression	O
.	O

Hypothetically	O
,	O
on	O
/	O
off	O
switches	O
of	O
lineage	O
-	O
restricted	O
transactivators	O
may	O
underlie	O
the	O
binary	O
fate	O
decisions	O
of	O
hematopoietic	O
progenitors	O
.	O

Activation	O
of	O
human	O
CD4	B-Protein
T	O
lymphocytes	O
.	O

Interaction	O
of	O
fibronectin	B-Protein
with	O
VLA	B-Protein
-	I-Protein
5	I-Protein
receptor	I-Protein
on	O
CD4	B-Protein
cells	O
induces	O
the	O
AP	O
-	O
1	O
transcription	O
factor	O
.	O

Fibronectin	B-Protein
synergized	O
with	O
anti	O
-	O
CD3	O
antibody	O
to	O
promote	O
CD4	B-Protein
cell	O
proliferation	O
in	O
a	O
serum	O
-	O
free	O
culture	O
system	O
whereas	O
no	O
proliferation	O
was	O
observed	O
when	O
CD4	B-Protein
cells	O
were	O
cultured	O
with	O
anti	O
-	O
CD3	O
alone	O
or	O
fibronectin	B-Protein
alone	O
.	O

In	O
addition	O
,	O
anti	O
-	O
CD29	B-Protein
(	O
integrin	B-Protein
beta	I-Protein
1	I-Protein
)	O
as	O
well	O
as	O
anti	O
-	O
VLA	B-Protein
-	I-Protein
5	I-Protein
(	O
human	O
fibronectin	O
receptor	O
)	O
antibodies	O
blocked	O
this	O
CD4	B-Protein
cell	O
activation	O
in	O
this	O
system	O
.	O

Although	O
anti	O
-	O
CD3	O
alone	O
or	O
fibronectin	B-Protein
alone	O
cannot	O
induce	O
IL	B-Protein
-	I-Protein
2	I-Protein
message	O
by	O
CD4	B-Protein
cells	O
,	O
the	O
combination	O
of	O
anti	O
-	O
CD3	O
plus	O
fibronectin	B-Protein
induced	O
IL	B-Protein
-	I-Protein
2	I-Protein
message	O
by	O
CD4	O
cells	O
.	O

In	O
an	O
analysis	O
of	O
the	O
molecular	O
mechanism	O
by	O
which	O
IL	B-Protein
-	I-Protein
2	I-Protein
message	O
was	O
generated	O
,	O
we	O
showed	O
that	O
a	O
fibronectin	B-Protein
-	O
VLA	B-Protein
-	I-Protein
5	I-Protein
fibronectin	B-Protein
receptor	O
interaction	O
may	O
contribute	O
an	O
independent	O
signal	O
distinct	O
from	O
the	O
CD3	O
pathway	O
of	O
activation	O
by	O
the	O
induction	O
of	O
an	O
AP	O
-	O
1	O
transcriptional	O
factor	O
.	O

Thus	O
the	O
VLA	B-Protein
-	I-Protein
5	I-Protein
fibronectin	I-Protein
receptor	I-Protein
on	O
CD4	B-Protein
cells	O
can	O
play	O
a	O
complementary	O
role	O
in	O
CD3	O
-	O
TCR	O
-	O
mediated	O
signal	O
transduction	O
through	O
its	O
interaction	O
with	O
fibronectin	B-Protein
.	O

1	B-Protein
,	I-Protein
25	I-Protein
-	I-Protein
Dihydroxyvitamin	I-Protein
D3	I-Protein
receptor	I-Protein
RNA	O
:	O
expression	O
in	O
hematopoietic	O
cells	O
.	O

1	O
,	O
25	O
-	O
Dihydroxyvitamin	O
D3	O
[	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
]	O
induces	O
differentiation	O
and	O
inhibits	O
proliferation	O
of	O
myeloid	O
leukemic	O
cells	O
from	O
various	O
lines	O
and	O
patients	O
;	O
these	O
effects	O
are	O
probably	O
mediated	O
through	O
the	O
1	B-Protein
,	I-Protein
25	I-Protein
(	I-Protein
OH	I-Protein
)	I-Protein
2D3	I-Protein
receptor	I-Protein
.	O

Little	O
is	O
known	O
of	O
expression	O
of	O
1	B-Protein
,	I-Protein
25	I-Protein
(	I-Protein
OH	I-Protein
)	I-Protein
2D3	I-Protein
receptor	I-Protein
RNA	O
in	O
hematopoietic	O
cells	O
.	O

We	O
examined	O
the	O
expression	O
and	O
modulation	O
of	O
expression	O
of	O
1	B-Protein
,	I-Protein
25	I-Protein
(	I-Protein
OH	I-Protein
)	I-Protein
2D3	I-Protein
receptor	I-Protein
RNA	O
in	O
various	O
proliferating	O
and	O
nonproliferating	O
hematopoietic	O
cells	O
.	O

Constitutive	O
expression	O
of	O
1	B-Protein
,	I-Protein
25	I-Protein
(	I-Protein
OH	I-Protein
)	I-Protein
2D3	I-Protein
receptor	I-Protein
RNA	O
was	O
detected	O
in	O
various	O
kinds	O
of	O
hematopoietic	O
cells	O
,	O
including	O
macrophages	O
and	O
activated	O
T	O
lymphocytes	O
,	O
as	O
well	O
as	O
in	O
cell	O
lines	O
KG	O
-	O
1	O
(	O
myeloblasts	O
)	O
,	O
HL	O
-	O
60	O
(	O
promyelocytes	O
)	O
,	O
ML	O
-	O
3	O
(	O
myelomonoblasts	O
)	O
,	O
U937	O
,	O
THP	O
-	O
1	O
(	O
monoblasts	O
)	O
,	O
K562	O
(	O
erythroblasts	O
)	O
,	O
and	O
S	O
-	O
LB1	O
(	O
HTLV	O
-	O
1	O
-	O
transfected	O
T	O
lymphocytes	O
)	O
.	O

Receptor	O
transcripts	O
were	O
4	O
.	O
6	O
kilobases	O
(	O
kb	O
)	O
,	O
and	O
no	O
variant	O
sizes	O
were	O
observed	O
.	O

All	O
cell	O
lines	O
examined	O
in	O
this	O
group	O
also	O
expressed	O
1	B-Protein
,	I-Protein
25	I-Protein
(	I-Protein
OH	I-Protein
)	I-Protein
2D3	I-Protein
receptors	I-Protein
.	O

Most	O
B	O
lymphocyte	O
lines	O
expressed	O
negligible	O
levels	O
of	O
1	B-Protein
,	I-Protein
25	I-Protein
(	I-Protein
OH	I-Protein
)	I-Protein
2D3	I-Protein
receptor	I-Protein
RNA	O
and	O
protein	O
;	O
however	O
;	O
analysis	O
of	O
a	O
lymphoid	O
/	O
myeloid	O
somatic	O
hybrid	O
suggested	O
that	O
suppression	O
of	O
expression	O
of	O
1	B-Protein
,	I-Protein
25	I-Protein
(	I-Protein
OH	I-Protein
)	I-Protein
2D3	I-Protein
receptor	I-Protein
RNA	O
in	O
B	O
lymphocytes	O
may	O
be	O
a	O
dominant	O
characteristic	O
.	O

HL	O
-	O
60	O
cells	O
were	O
cultured	O
with	O
10	O
(	O
-	O
7	O
)	O
mol	O
/	O
L	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
for	O
24	O
to	O
72	O
hours	O
,	O
and	O
levels	O
of	O
expression	O
of	O
1	B-Protein
,	I-Protein
25	I-Protein
(	I-Protein
OH	I-Protein
)	I-Protein
2D3	I-Protein
receptor	I-Protein
and	O
its	O
RNA	O
were	O
examined	O
.	O

Levels	O
of	O
RNA	O
coding	O
for	O
the	O
receptor	O
were	O
not	O
modulated	O
by	O
exposure	O
to	O
high	O
levels	O
of	O
ligand	O
.	O

Levels	O
of	O
occupied	O
1	B-Protein
,	I-Protein
25	I-Protein
(	I-Protein
OH	I-Protein
)	I-Protein
2D3	I-Protein
receptor	I-Protein
protein	O
increased	O
in	O
these	O
HL	O
-	O
60	O
cells	O
;	O
but	O
the	O
total	O
number	O
of	O
1	B-Protein
,	I-Protein
25	I-Protein
(	I-Protein
OH	I-Protein
)	I-Protein
2D3	I-Protein
receptors	I-Protein
decreased	O
about	O
50	O
%	O
at	O
24	O
hours	O
and	O
returned	O
toward	O
normal	O
at	O
72	O
hours	O
.	O

Steady	O
-	O
state	O
levels	O
of	O
1	B-Protein
,	I-Protein
25	I-Protein
(	I-Protein
OH	I-Protein
)	I-Protein
2D3	I-Protein
receptor	I-Protein
RNA	O
were	O
not	O
affected	O
by	O
terminal	O
differentiation	O
of	O
HL	O
-	O
60	O
toward	O
either	O
granulocytes	O
or	O
macrophages	O
.	O

Nondividing	O
macrophages	O
from	O
normal	O
individuals	O
also	O
expressed	O
1	B-Protein
,	I-Protein
25	I-Protein
(	I-Protein
OH	I-Protein
)	I-Protein
2D3	I-Protein
receptor	I-Protein
RNA	O
.	O

In	O
contrast	O
,	O
nondividing	O
peripheral	O
blood	O
lymphocytes	O
from	O
normal	O
individuals	O
did	O
not	O
express	O
1	B-Protein
,	I-Protein
25	I-Protein
(	I-Protein
OH	I-Protein
)	I-Protein
2D3	I-Protein
receptor	I-Protein
RNA	O
;	O
with	O
stimulation	O
of	O
proliferation	O
of	O
these	O
cells	O
,	O
accumulation	O
of	O
1	B-Protein
,	I-Protein
25	I-Protein
(	I-Protein
OH	I-Protein
)	I-Protein
2D3	I-Protein
receptor	I-Protein
RNA	O
increased	O
markedly	O
.	O

Half	O
-	O
life	O
(	O
t1	O
/	O
2	O
)	O
of	O
1	B-Protein
,	I-Protein
25	I-Protein
(	I-Protein
OH	I-Protein
)	I-Protein
2D3	I-Protein
receptor	I-Protein
RNA	O
in	O
T	O
lymphocytes	O
was	O
short	O
(	O
1	O
hour	O
)	O
as	O
determined	O
by	O
measuring	O
decay	O
of	O
the	O
message	O
after	O
addition	O
of	O
actinomycin	O
D	O
.	O

Consistent	O
with	O
this	O
short	O
t1	O
/	O
2	O
,	O
accumulation	O
of	O
1	B-Protein
,	I-Protein
25	I-Protein
(	I-Protein
OH	I-Protein
)	I-Protein
2D3	I-Protein
receptor	I-Protein
RNA	O
increased	O
in	O
cells	O
as	O
their	O
protein	O
synthesis	O
was	O
inhibited	O
.	O

Further	O
studies	O
are	O
required	O
to	O
understand	O
the	O
physiologic	O
role	O
of	O
1	B-Protein
,	I-Protein
25	I-Protein
(	I-Protein
OH	I-Protein
)	I-Protein
2D3	I-Protein
receptors	I-Protein
in	O
myeloid	O
cells	O
and	O
proliferating	O
T	O
lymphocytes	O
.	O

Charybdotoxin	O
-	O
sensitive	O
,	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
membrane	O
potential	O
changes	O
are	O
not	O
involved	O
in	O
human	O
T	O
or	O
B	O
cell	O
activation	O
and	O
proliferation	O
.	O

The	O
involvement	O
of	O
ion	O
channels	O
in	O
B	O
and	O
T	O
lymphocyte	O
activation	O
is	O
supported	O
by	O
many	O
reports	O
of	O
changes	O
in	O
ion	O
fluxes	O
and	O
membrane	O
potential	O
after	O
mitogen	O
binding	O
.	O

Human	O
T	O
and	O
B	O
lymphocytes	O
demonstrate	O
an	O
early	O
and	O
transient	O
hyperpolarization	O
after	O
ligand	O
binding	O
.	O

Inasmuch	O
as	O
the	O
change	O
in	O
membrane	O
potential	O
is	O
dependent	O
on	O
elevation	O
of	O
free	O
cytosolic	O
calcium	O
,	O
the	O
hyperpolarization	O
is	O
presumably	O
through	O
opening	O
of	O
Ca	O
(	O
2	O
+	O
)	O
-	O
stimulated	O
K	O
+	O
channels	O
.	O

We	O
have	O
used	O
charybdotoxin	O
,	O
a	O
known	O
inhibitor	O
of	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
K	O
+	O
channels	O
,	O
to	O
study	O
the	O
role	O
of	O
these	O
channels	O
in	O
lymphocyte	O
activation	O
and	O
mitogenesis	O
.	O

We	O
demonstrate	O
that	O
charybdotoxin	O
inhibits	O
the	O
ligand	O
-	O
induced	O
transient	O
membrane	O
hyperpolarization	O
in	O
B	O
and	O
T	O
cells	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
,	O
without	O
affecting	O
changes	O
in	O
cytosolic	O
Ca2	O
+	O
.	O

However	O
,	O
blockade	O
of	O
the	O
Ca	O
(	O
2	O
+	O
)	O
-	O
activated	O
K	O
+	O
channel	O
is	O
not	O
associated	O
with	O
changes	O
in	O
cell	O
-	O
cycle	O
gene	O
activation	O
,	O
IL	B-Protein
-	I-Protein
2	I-Protein
production	O
,	O
IL	O
-	O
2R	O
expression	O
or	O
B	O
and	O
T	O
cell	O
mitogenesis	O
.	O

These	O
results	O
imply	O
that	O
membrane	O
potential	O
changes	O
secondary	O
to	O
the	O
ligand	O
-	O
dependent	O
opening	O
of	O
Ca	O
(	O
2	O
+	O
)	O
-	O
activated	O
K	O
+	O
channels	O
are	O
not	O
involved	O
in	O
B	O
and	O
T	O
lymphocyte	O
activation	O
and	O
mitogenesis	O
.	O

Cloning	O
of	O
murine	O
TCF	B-Protein
-	I-Protein
1	I-Protein
,	O
a	O
T	O
cell	O
-	O
specific	O
transcription	O
factor	O
interacting	O
with	O
functional	O
motifs	O
in	O
the	O
CD3	O
-	O
epsilon	O
and	O
T	O
cell	O
receptor	O
alpha	O
enhancers	O
.	O

CD3	B-Protein
-	I-Protein
epsilon	I-Protein
gene	O
expression	O
is	O
confined	O
to	O
the	O
T	O
cell	O
lineage	O
.	O

We	O
have	O
recently	O
identified	O
and	O
cloned	O
a	O
human	O
transcription	O
factor	O
,	O
TCF	B-Protein
-	I-Protein
1	I-Protein
,	O
that	O
binds	O
to	O
a	O
functional	O
element	O
in	O
the	O
T	O
lymphocyte	O
-	O
specific	O
enhancer	O
of	O
CD3	B-Protein
-	I-Protein
epsilon	I-Protein
.	O

In	O
a	O
panel	O
of	O
human	O
cell	O
lines	O
,	O
TCF	B-Protein
-	I-Protein
1	I-Protein
expression	O
was	O
restricted	O
to	O
T	O
lineage	O
cells	O
.	O

TCF	B-Protein
-	I-Protein
1	I-Protein
belonged	O
to	O
a	O
novel	O
family	O
of	O
genes	O
that	O
contain	O
the	O
so	O
-	O
called	O
high	O
mobility	O
group	O
1	O
(	O
HMG	O
)	O
box	O
.	O

Here	O
we	O
report	O
the	O
cloning	O
of	O
murine	O
TCF	B-Protein
-	I-Protein
1	I-Protein
.	O

Two	O
splice	O
alternatives	O
were	O
identified	O
that	O
were	O
not	O
previously	O
observed	O
in	O
human	O
TCF	B-Protein
-	I-Protein
1	I-Protein
.	O

Murine	O
and	O
human	O
TCF	B-Protein
-	I-Protein
1	I-Protein
displayed	O
a	O
95	O
.	O
5	O
%	O
overall	O
amino	O
acid	O
homology	O
.	O

Recombinant	O
murine	O
and	O
human	O
TCF	B-Protein
-	I-Protein
1	I-Protein
recognized	O
the	O
same	O
sequence	O
motif	O
in	O
the	O
CD3	O
-	O
epsilon	O
enhancer	O
as	O
judged	O
by	O
gel	O
retardation	O
and	O
methylation	O
interference	O
assays	O
.	O

With	O
the	O
murine	O
cDNA	O
clones	O
several	O
aspects	O
of	O
TCF	B-Protein
-	I-Protein
1	I-Protein
were	O
analyzed	O
.	O

First	O
,	O
deletion	O
analysis	O
revealed	O
that	O
a	O
region	O
of	O
TCF	B-Protein
-	I-Protein
1	I-Protein
containing	O
the	O
HMG	O
box	O
was	O
sufficient	O
for	O
sequence	O
-	O
specific	O
binding	O
.	O

Second	O
,	O
by	O
high	O
stringency	O
Northern	O
blotting	O
and	O
in	O
situ	O
hybridization	O
,	O
TCF	B-Protein
-	I-Protein
1	I-Protein
expression	O
was	O
shown	O
to	O
be	O
confined	O
to	O
the	O
thymus	O
and	O
to	O
the	O
T	O
cell	O
areas	O
of	O
the	O
spleen	O
.	O

Third	O
,	O
TCF	B-Protein
-	I-Protein
1	I-Protein
bound	O
specifically	O
to	O
a	O
functional	O
T	O
cell	O
-	O
specific	O
element	O
in	O
the	O
T	B-Protein
cell	I-Protein
receptor	I-Protein
alpha	I-Protein
(	O
TCR	B-Protein
-	I-Protein
alpha	I-Protein
)	O
enhancer	O
.	O

The	O
T	O
lineage	O
-	O
specific	O
expression	O
and	O
the	O
affinity	O
for	O
functional	O
motifs	O
in	O
the	O
TCR	B-Protein
-	I-Protein
alpha	I-Protein
and	O
CD3	B-Protein
-	I-Protein
epsilon	I-Protein
enhancers	O
imply	O
an	O
important	O
role	O
for	O
TCF	B-Protein
-	I-Protein
1	I-Protein
in	O
the	O
establishment	O
of	O
the	O
mature	O
T	O
cell	O
phenotype	O
.	O

HTLV	O
-	O
1	O
Tax	B-Protein
induces	O
expression	O
of	O
various	O
immediate	O
early	O
serum	O
responsive	O
genes	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
is	O
an	O
etiological	O
agent	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
(	O
ATL	O
)	O
.	O

We	O
showed	O
here	O
by	O
mobility	O
-	O
shift	O
assay	O
that	O
T	O
-	O
cell	O
lines	O
transformed	O
with	O
the	O
virus	O
contained	O
high	O
levels	O
of	O
AP	O
-	O
1	O
activities	O
.	O

Consistent	O
with	O
this	O
result	O
,	O
these	O
cell	O
lines	O
expressed	O
increased	O
levels	O
of	O
mRNAs	O
encoding	O
the	O
AP	O
-	O
1	O
proteins	O
,	O
c	B-Protein
-	I-Protein
Fos	I-Protein
,	O
Fra	B-Protein
-	I-Protein
1	I-Protein
,	O
c	B-Protein
-	I-Protein
Jun	I-Protein
,	O
JunB	B-Protein
,	O
and	O
JunD	B-Protein
.	O

Previously	O
,	O
transcription	O
of	O
the	O
c	B-Protein
-	I-Protein
fos	I-Protein
gene	O
has	O
been	O
reported	O
to	O
be	O
transactivated	O
by	O
the	O
viral	O
transcription	O
factor	O
,	O
Tax1	B-Protein
.	O

By	O
using	O
the	O
human	O
T	O
-	O
cell	O
line	O
(	O
JPX	O
-	O
9	O
)	O
,	O
in	O
which	O
expression	O
of	O
the	O
Tax1	B-Protein
is	O
inducible	O
,	O
we	O
showed	O
that	O
expression	O
of	O
mRNAs	O
for	O
Fra	B-Protein
-	I-Protein
1	I-Protein
,	O
c	B-Protein
-	I-Protein
Jun	I-Protein
,	O
and	O
JunD	B-Protein
was	O
also	O
transactivated	O
by	O
Tax1	B-Protein
.	O

Moreover	O
,	O
Tax1	B-Protein
activated	O
expression	O
of	O
two	O
other	O
transcription	O
factors	O
having	O
zinc	O
finger	O
motifs	O
,	O
Egr	B-Protein
-	I-Protein
1	I-Protein
and	O
Egr	B-Protein
-	I-Protein
2	I-Protein
,	O
in	O
the	O
same	O
cells	O
.	O

The	O
Tax1	B-Protein
-	O
inducible	O
transcription	O
factors	O
identified	O
here	O
are	O
encoded	O
by	O
the	O
members	O
of	O
immediate	O
early	O
genes	O
under	O
the	O
control	O
of	O
growth	O
signals	O
.	O

Thus	O
,	O
Tax1	B-Protein
was	O
suggested	O
to	O
replace	O
growth	O
signals	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
this	O
mechanism	O
.	O

Tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
mRNA	O
accumulation	O
in	O
human	O
myelomonocytic	O
cell	O
lines	O
.	O

Role	O
of	O
transcriptional	O
regulation	O
by	O
DNA	O
sequence	O
motifs	O
and	O
mRNA	O
stabilization	O
.	O

The	O
cytokine	O
TNF	B-Protein
mediates	O
many	O
of	O
the	O
pathologic	O
signs	O
of	O
cachexia	O
,	O
inflammation	O
,	O
and	O
sepsis	O
.	O

The	O
current	O
work	O
describes	O
the	O
regulation	O
of	O
TNF	B-Protein
in	O
human	O
myelomonocytic	O
cell	O
lines	O
after	O
PMA	O
stimulation	O
.	O

The	O
cell	O
lines	O
exhibit	O
a	O
low	O
level	O
of	O
constitutive	O
TNF	B-Protein
mRNA	O
expression	O
.	O

Within	O
2	O
to	O
4	O
h	O
of	O
PMA	O
exposure	O
,	O
steady	O
state	O
levels	O
of	O
TNF	B-Protein
mRNA	O
are	O
markedly	O
elevated	O
in	O
all	O
myelomonocytic	O
cell	O
lines	O
studied	O
.	O

This	O
rise	O
is	O
due	O
to	O
increased	O
mRNA	O
stability	O
,	O
which	O
increased	O
by	O
almost	O
twofold	O
,	O
and	O
to	O
an	O
overall	O
increase	O
in	O
transcription	O
,	O
which	O
rises	O
by	O
more	O
than	O
sixfold	O
.	O

At	O
the	O
level	O
of	O
the	O
genomic	O
TNF	B-Protein
gene	O
,	O
a	O
DNase	O
I	O
hypersensitive	O
site	O
is	O
detected	O
within	O
the	O
TNF	B-Protein
promoter	O
between	O
-	O
200	O
to	O
-	O
100	O
bp	O
relative	O
to	O
the	O
transcription	O
initiation	O
site	O
.	O

Although	O
absent	O
in	O
nonexpressing	O
erythroleukemia	O
cell	O
lines	O
,	O
the	O
DNase	O
I	O
site	O
is	O
present	O
in	O
uninduced	O
myelomonocytic	O
cell	O
lines	O
and	O
is	O
not	O
changed	O
after	O
PMA	O
induction	O
.	O

The	O
PMA	O
induction	O
of	O
c	B-Protein
-	I-Protein
fos	I-Protein
mRNA	O
correlated	O
well	O
with	O
TNF	B-Protein
gene	O
induction	O
;	O
expression	O
of	O
genes	O
encoding	O
other	O
proteins	O
in	O
the	O
AP	O
-	O
1	O
complex	O
(	O
junB	B-Protein
and	O
junD	B-Protein
)	O
were	O
also	O
induced	O
by	O
PMA	O
.	O

The	O
nuclear	O
extracts	O
from	O
resting	O
and	O
induced	O
ML	O
-	O
1	O
cells	O
contain	O
proteins	O
binding	O
specifically	O
to	O
the	O
AP	O
-	O
1	O
,	O
AP	O
-	O
2	O
,	O
and	O
NF	O
kappa	O
B	O
sequence	O
located	O
within	O
the	O
TNF	B-Protein
promoter	O
.	O

PMA	O
induction	O
increases	O
the	O
level	O
of	O
a	O
number	O
of	O
specific	O
binding	O
complexes	O
relative	O
to	O
the	O
resting	O
cells	O
.	O

The	O
regulatory	O
mechanisms	O
of	O
the	O
human	O
and	O
murine	O
TNF	B-Protein
genes	O
are	O
discussed	O
.	O

The	O
rhombotin	O
family	O
of	O
cysteine	O
-	O
rich	O
LIM	O
-	O
domain	O
oncogenes	O
:	O
distinct	O
members	O
are	O
involved	O
in	O
T	O
-	O
cell	O
translocations	O
to	O
human	O
chromosomes	O
11p15	O
and	O
11p13	O
.	O

A	O
chromosomal	O
translocation	O
in	O
a	O
T	O
-	O
cell	O
leukemia	O
involving	O
the	O
short	O
arm	O
of	O
human	O
chromosome	O
11	O
at	O
band	O
11p15	O
disrupts	O
the	O
rhombotin	B-Protein
gene	O
.	O

This	O
gene	O
encodes	O
a	O
protein	O
with	O
duplicated	O
cysteine	O
-	O
rich	O
regions	O
called	O
LIM	O
domains	O
,	O
which	O
show	O
homology	O
to	O
zinc	O
-	O
binding	O
proteins	O
and	O
to	O
iron	O
-	O
sulfur	O
centers	O
of	O
ferredoxins	O
.	O

Two	O
homologues	O
of	O
the	O
rhombotin	B-Protein
gene	O
have	O
now	O
been	O
isolated	O
.	O

One	O
of	O
these	O
,	O
designated	O
Rhom	B-Protein
-	I-Protein
2	I-Protein
,	O
is	O
located	O
on	O
human	O
chromosome	O
11	O
at	O
band	O
11p13	O
,	O
where	O
a	O
cluster	O
of	O
T	O
-	O
cell	O
leukemia	O
-	O
specific	O
translocations	O
occur	O
;	O
all	O
translocation	O
breakpoints	O
at	O
11p13	O
are	O
upstream	O
of	O
the	O
Rhom	B-Protein
-	I-Protein
2	I-Protein
gene	O
.	O

Human	O
and	O
mouse	O
Rhom	B-Protein
-	I-Protein
2	I-Protein
are	O
highly	O
conserved	O
and	O
,	O
like	O
rhombotin	B-Protein
,	O
encode	O
two	O
tandem	O
cysteine	O
-	O
rich	O
LIM	O
domains	O
.	O

Rhom	B-Protein
-	I-Protein
2	I-Protein
mRNA	O
is	O
expressed	O
in	O
early	O
mouse	O
development	O
in	O
central	O
nervous	O
system	O
,	O
lung	O
,	O
kidney	O
,	O
liver	O
,	O
and	O
spleen	O
but	O
only	O
very	O
low	O
levels	O
occur	O
in	O
thymus	O
.	O

The	O
other	O
gene	O
,	O
designated	O
Rhom	B-Protein
-	I-Protein
3	I-Protein
,	O
is	O
not	O
on	O
chromosome	O
11	O
but	O
also	O
retains	O
homology	O
to	O
the	O
LIM	O
domain	O
of	O
rhombotin	B-Protein
.	O

Since	O
the	O
Rhom	B-Protein
-	I-Protein
2	I-Protein
gene	O
is	O
such	O
a	O
common	O
site	O
of	O
chromosomal	O
damage	O
in	O
T	O
-	O
cell	O
tumors	O
,	O
the	O
consistency	O
of	O
translocations	O
near	O
the	O
rhombotin	B-Protein
gene	O
was	O
further	O
examined	O
.	O

A	O
second	O
translocation	O
adjacent	O
to	O
rhombotin	B-Protein
was	O
found	O
and	O
at	O
the	O
same	O
position	O
as	O
in	O
the	O
previous	O
example	O
.	O

Therefore	O
,	O
chromosome	O
bands	O
11p15	O
(	O
rhombotin	B-Protein
)	O
and	O
11p13	O
(	O
Rhom	B-Protein
-	I-Protein
2	I-Protein
)	O
are	O
consistent	O
sites	O
of	O
chromosome	O
translocation	O
in	O
T	O
-	O
cell	O
leukemia	O
,	O
with	O
the	O
11p15	O
target	O
more	O
rarely	O
involved	O
.	O

The	O
results	O
define	O
the	O
rhombotin	O
gene	O
family	O
as	O
a	O
class	O
of	O
T	O
-	O
cell	O
oncogenes	O
with	O
duplicated	O
cysteine	O
-	O
rich	O
LIM	O
domains	O
.	O

Two	O
distinct	O
forms	O
of	O
active	O
transcription	O
factor	O
CREB	B-Protein
(	O
cAMP	B-Protein
response	I-Protein
element	I-Protein
binding	I-Protein
protein	I-Protein
)	O
.	O

Mammalian	O
cells	O
express	O
two	O
distinct	O
forms	O
of	O
transcription	O
factor	O
CREB	B-Protein
(	O
cAMP	B-Protein
response	I-Protein
element	I-Protein
binding	I-Protein
protein	I-Protein
)	O
that	O
are	O
apparently	O
the	O
products	O
of	O
alternative	O
splicing	O
of	O
the	O
CREB	B-Protein
gene	O
transcript	O
.	O

The	O
two	O
proteins	O
differ	O
by	O
a	O
14	O
-	O
amino	O
acid	O
serine	O
-	O
rich	O
insertion	O
present	O
in	O
one	O
of	O
the	O
CREB	B-Protein
isoforms	O
.	O

We	O
show	O
that	O
both	O
CREB	B-Protein
isoforms	O
are	O
expressed	O
in	O
many	O
cell	O
types	O
and	O
mammalian	O
species	O
.	O

Both	O
encode	O
proteins	O
that	O
bind	O
specifically	O
to	O
a	O
cAMP	O
response	O
element	O
in	O
vitro	O
.	O

As	O
expected	O
for	O
proteins	O
of	O
this	O
class	O
,	O
the	O
CREB	B-Protein
proteins	O
bind	O
DNA	O
as	O
dimers	O
.	O

Both	O
proteins	O
impart	O
cAMP	O
-	O
regulated	O
transcriptional	O
activity	O
to	O
a	O
heterologous	O
DNA	O
-	O
binding	O
domain	O
,	O
showing	O
that	O
cAMP	O
directly	O
modulates	O
the	O
transcriptional	O
stimulatory	O
activity	O
of	O
CREB	B-Protein
.	O

The	O
presence	O
of	O
multiple	O
CREB	B-Protein
isoforms	O
with	O
identical	O
DNA	O
-	O
binding	O
specificities	O
but	O
differences	O
in	O
the	O
presumed	O
regulatory	O
domain	O
raises	O
the	O
possibility	O
that	O
CREB	B-Protein
proteins	O
may	O
be	O
able	O
to	O
integrate	O
distinct	O
regulatory	O
signals	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
.	O

Constitutive	O
expression	O
of	O
HIV	O
-	O
1	O
tat	B-Protein
protein	O
in	O
human	O
Jurkat	O
T	O
cells	O
using	O
a	O
BK	O
virus	O
vector	O
.	O

The	O
production	O
and	O
characterization	O
of	O
Jurkat	O
cell	O
lines	O
that	O
constitutively	O
express	O
functional	O
human	O
immune	O
deficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
tat	B-Protein
protein	O
,	O
using	O
a	O
BK	O
virus	O
plasmid	O
expression	O
vector	O
and	O
HIV	O
-	O
1	O
tat	B-Protein
cDNA	O
,	O
is	O
described	O
.	O

An	O
increased	O
growth	O
rate	O
of	O
these	O
Jurkat	O
-	O
tat	B-Protein
cell	O
lines	O
as	O
compared	O
with	O
control	O
cell	O
lines	O
was	O
observed	O
.	O

Effects	O
of	O
1	O
alpha	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
on	O
the	O
human	O
chronic	O
myelogenous	O
leukemia	O
cell	O
line	O
RWLeu	O
-	O
4	O
.	O

The	O
effects	O
of	O
1	O
alpha	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
(	O
VD3	O
)	O
on	O
proliferation	O
,	O
differentiation	O
,	O
and	O
macromolecular	O
synthesis	O
in	O
the	O
new	O
Philadelphia	O
chromosome	O
-	O
positive	O
chronic	O
myelogenous	O
leukemia	O
cell	O
line	O
,	O
RWLeu	O
-	O
4	O
,	O
were	O
investigated	O
.	O

Binding	O
of	O
[	O
3H	O
]	O
VD3	O
was	O
saturable	O
,	O
with	O
approximately	O
2000	O
-	O
3000	O
sites	O
/	O
cell	O
,	O
and	O
half	O
-	O
maximal	O
binding	O
occurring	O
at	O
0	O
.	O
21	O
-	O
0	O
.	O
33	O
nM	O
.	O

Treatment	O
of	O
RWLeu	O
-	O
4	O
cells	O
with	O
VD3	O
induced	O
24R	O
-	O
hydroxylase	O
activity	O
,	O
a	O
marker	O
of	O
vitamin	O
D3	O
responsiveness	O
in	O
many	O
tissues	O
.	O

Exposure	O
of	O
RWLeu	O
-	O
4	O
cells	O
to	O
VD3	O
also	O
inhibited	O
proliferation	O
and	O
DNA	O
synthesis	O
with	O
a	O
50	O
%	O
effective	O
dose	O
of	O
3	O
.	O
5	O
-	O
10	O
nM	O
within	O
72	O
h	O
;	O
in	O
addition	O
,	O
protein	O
and	O
RNA	O
synthesis	O
were	O
inhibited	O
by	O
VD3	O
treatment	O
.	O

Exposure	O
of	O
RWLeu	O
-	O
4	O
cells	O
to	O
5	O
nM	O
VD3	O
for	O
72	O
h	O
caused	O
50	O
%	O
of	O
the	O
cells	O
to	O
differentiate	O
into	O
macrophage	O
/	O
monocyte	O
type	O
cells	O
as	O
judged	O
by	O
nitroblue	O
tetrazolium	O
staining	O
and	O
adherence	O
to	O
plastic	O
.	O

Progressive	O
expression	O
of	O
cell	O
surface	O
maturation	O
-	O
specific	O
antigens	O
of	O
the	O
monocyte	O
/	O
macrophage	O
lineage	O
was	O
induced	O
by	O
treatment	O
of	O
RWLeu	O
-	O
4	O
cells	O
with	O
VD3	O
for	O
24	O
to	O
72	O
h	O
at	O
doses	O
that	O
inhibited	O
cellular	O
proliferation	O
.	O

c	B-Protein
-	I-Protein
myc	I-Protein
RNA	O
,	O
which	O
is	O
constitutively	O
expressed	O
in	O
RWLeu	O
-	O
4	O
cells	O
,	O
increased	O
after	O
0	O
.	O
5	O
h	O
of	O
treatment	O
with	O
50	O
nM	O
VD3	O
and	O
then	O
rapidly	O
decreased	O
to	O
barely	O
detectable	O
levels	O
after	O
4	O
h	O
of	O
treatment	O
.	O

Finally	O
,	O
the	O
in	O
vitro	O
tyrosine	O
kinase	O
activity	O
associated	O
with	O
the	O
p210bcr	B-Protein
-	I-Protein
abl	I-Protein
oncogene	I-Protein
product	O
was	O
decreased	O
approximately	O
50	O
%	O
by	O
VD3	O
treatment	O
.	O

Because	O
of	O
the	O
presence	O
of	O
a	O
functional	O
receptor	O
-	O
effector	O
system	O
for	O
VD3	O
and	O
multiple	O
biological	O
responses	O
to	O
the	O
hormone	O
,	O
these	O
cells	O
provide	O
a	O
unique	O
model	O
system	O
with	O
which	O
to	O
probe	O
the	O
specific	O
effects	O
of	O
VD3	O
on	O
cell	O
growth	O
and	O
differentiation	O
in	O
chronic	O
myelogenous	O
leukemia	O
.	O

Lymphocyte	O
cell	O
lines	O
from	O
vitamin	O
D	O
-	O
dependent	O
rickets	O
type	O
II	O
show	O
functional	O
defects	O
in	O
the	O
1	B-Protein
alpha	I-Protein
,	I-Protein
25	I-Protein
-	I-Protein
dihydroxyvitamin	I-Protein
D3	I-Protein
receptor	I-Protein
.	O

Lymphocyte	O
cell	O
lines	O
were	O
established	O
from	O
five	O
patients	O
with	O
vitamin	O
D	O
-	O
dependent	O
rickets	O
,	O
type	O
II	O
(	O
VDDR	O
-	O
II	O
)	O
.	O

These	O
lines	O
were	O
established	O
by	O
infection	O
with	O
human	O
T	O
-	O
lymphotrophic	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
.	O

Binding	O
of	O
[	O
3H	O
]	O
1	O
alpha	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
(	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
to	O
its	O
receptor	O
in	O
these	O
cell	O
lines	O
was	O
compared	O
to	O
binding	O
studies	O
using	O
a	O
T	O
-	O
lymphocyte	O
cell	O
line	O
(	O
S	O
-	O
LB1	O
)	O
from	O
a	O
normal	O
individual	O
.	O

The	O
1	B-Protein
,	I-Protein
25	I-Protein
(	I-Protein
OH	I-Protein
)	I-Protein
2D3	I-Protein
receptor	I-Protein
of	O
S	O
-	O
LB1	O
was	O
comparable	O
to	O
the	O
well	O
-	O
characterized	O
chick	O
intestinal	O
1	B-Protein
,	I-Protein
25	I-Protein
(	I-Protein
OH	I-Protein
)	I-Protein
2D3	I-Protein
receptor	I-Protein
in	O
terms	O
of	O
its	O
ligand	O
binding	O
affinity	O
and	O
capacity	O
,	O
its	O
mobility	O
on	O
5	O
-	O
20	O
%	O
sucrose	O
gradients	O
,	O
and	O
its	O
adsorption	O
to	O
and	O
elution	O
properties	O
from	O
DNA	O
-	O
cellulose	O
.	O

Three	O
cell	O
lines	O
established	O
from	O
patients	O
with	O
VDDR	O
-	O
II	O
(	O
Rh	O
-	O
VDR	O
,	O
Sh	O
-	O
VDR	O
,	O
and	O
Ab	O
-	O
VDR	O
)	O
showed	O
no	O
specific	O
binding	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
to	O
a	O
receptor	O
and	O
treatment	O
of	O
the	O
cultured	O
cells	O
with	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
did	O
not	O
stimulate	O
production	O
of	O
24	O
,	O
25	O
-	O
dihydroxy	O
-	O
vitamin	O
D3	O
(	O
24	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
,	O
a	O
response	O
which	O
is	O
diagnostic	O
of	O
the	O
presence	O
of	O
a	O
functional	O
1	B-Protein
,	I-Protein
25	I-Protein
(	I-Protein
OH	I-Protein
)	I-Protein
2D3	I-Protein
receptor	I-Protein
.	O

In	O
a	O
fourth	O
cell	O
line	O
,	O
A1	O
-	O
VDR	O
,	O
the	O
receptor	O
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
had	O
a	O
low	O
binding	O
capacity	O
and	O
25	B-Protein
(	I-Protein
OH	I-Protein
)	I-Protein
D3	I-Protein
-	I-Protein
24	I-Protein
-	I-Protein
hydroxylase	I-Protein
activity	O
was	O
not	O
detectable	O
.	O

Induction	O
of	O
24	O
,	O
25	O
-	O
(	O
OH	O
)	O
2D3	O
synthesis	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
was	O
observed	O
in	O
the	O
fifth	O
cell	O
line	O
,	O
designated	O
Ro	O
-	O
VDR	O
,	O
although	O
the	O
sensitivity	O
to	O
hormone	O
treatment	O
was	O
lower	O
than	O
in	O
the	O
control	O
cell	O
line	O
from	O
a	O
normal	O
donor	O
.	O

The	O
capacity	O
of	O
the	O
receptor	O
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
was	O
low	O
in	O
Ro	O
-	O
VDR	O
.	O

In	O
all	O
cell	O
lines	O
where	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
binding	O
to	O
a	O
receptor	O
was	O
detectable	O
,	O
the	O
receptor	O
had	O
the	O
typical	O
sedimentation	O
coefficient	O
of	O
3	O
.	O
7	O
S	O
on	O
sucrose	O
density	O
gradient	O
analysis	O
.	O

Binding	O
and	O
elution	O
properties	O
to	O
DNA	O
-	O
cellulose	O
,	O
however	O
,	O
differed	O
from	O
normal	O
in	O
both	O
Ro	O
-	O
VDR	O
and	O
A1	O
-	O
VDR	O
cells	O
where	O
elution	O
from	O
DNA	O
-	O
cellulose	O
occurred	O
at	O
a	O
lower	O
salt	O
concentration	O
than	O
is	O
typical	O
of	O
the	O
1	B-Protein
,	I-Protein
25	I-Protein
(	I-Protein
OH	I-Protein
)	I-Protein
2D3	I-Protein
receptor	I-Protein
.	O

While	O
Ro	O
-	O
VDR	O
cells	O
showed	O
typical	O
nuclear	O
localization	O
of	O
the	O
unoccupied	O
1	B-Protein
,	I-Protein
25	I-Protein
(	I-Protein
OH	I-Protein
)	I-Protein
2D3	I-Protein
receptor	I-Protein
,	O
neither	O
the	O
unoccupied	O
nor	O
the	O
occupied	O
receptor	O
from	O
A1	O
-	O
VDR	O
cells	O
was	O
completely	O
localized	O
in	O
the	O
nucleus	O
.	O

In	O
a	O
series	O
of	O
functional	O
studies	O
we	O
found	O
that	O
modulation	O
of	O
the	O
level	O
of	O
the	O
mRNAs	O
coding	O
for	O
both	O
the	O
c	B-Protein
-	I-Protein
myc	I-Protein
oncogene	O
and	O
the	O
growth	O
factor	O
known	O
as	O
granulocyte	O
-	O
monocyte	O
colony	O
stimulating	O
activity	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
correlated	O
with	O
the	O
1	B-Protein
,	I-Protein
25	I-Protein
(	I-Protein
OH	I-Protein
)	I-Protein
2D3	I-Protein
receptor	I-Protein
status	O
of	O
these	O
cells	O
.	O

Use	O
of	O
these	O
cell	O
lines	O
will	O
facilitate	O
further	O
study	O
of	O
the	O
molecular	O
defect	O
(	O
s	O
)	O
in	O
the	O
receptor	O
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
in	O
vitamin	O
D	O
-	O
dependent	O
rickets	O
type	O
II	O
and	O
will	O
allow	O
a	O
correlation	O
with	O
impairment	O
of	O
cellular	O
functions	O
.	O

Heterogeneity	O
of	O
antigen	O
molecules	O
recognized	O
by	O
anti	O
-	O
tax1	B-Protein
monoclonal	O
antibody	O
Lt	O
-	O
4	O
in	O
cell	O
lines	O
bearing	O
human	O
T	O
cell	O
leukemia	O
virus	O
type	O
I	O
and	O
related	O
retroviruses	O
.	O

Using	O
a	O
monoclonal	O
antibody	O
,	O
Lt	O
-	O
4	O
,	O
directed	O
against	O
human	O
T	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
trans	O
-	O
activator	O
(	O
tax1	B-Protein
)	O
antigen	O
,	O
we	O
examined	O
the	O
expression	O
of	O
tax1	B-Protein
and	O
related	O
antigens	O
in	O
a	O
variety	O
of	O
T	O
cell	O
lines	O
bearing	O
HTLV	O
-	O
I	O
and	O
related	O
retroviruses	O
,	O
simian	O
T	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
STLV	O
-	O
I	O
)	O
and	O
HTLV	O
-	O
II	O
,	O
by	O
immunofluorescence	O
and	O
immunoblot	O
assays	O
.	O

Lt	O
-	O
4	O
reacted	O
with	O
all	O
HTLV	O
-	O
I	O
-	O
bearing	O
cell	O
lines	O
tested	O
and	O
five	O
out	O
of	O
eight	O
simian	O
cell	O
lines	O
bearing	O
STLV	O
-	O
I	O
,	O
but	O
not	O
with	O
an	O
HTLV	O
-	O
II	O
-	O
bearing	O
cell	O
line	O
.	O

Lt	O
-	O
4	O
detected	O
40	O
kd	O
tax1	B-Protein
antigen	O
molecules	O
in	O
most	O
HTLV	O
-	O
I	O
-	O
bearing	O
cell	O
lines	O
except	O
one	O
cell	O
line	O
that	O
expressed	O
39	O
kd	O
tax1	B-Protein
antigen	O
.	O

In	O
the	O
STLV	O
-	O
I	O
-	O
bearing	O
T	O
cell	O
lines	O
,	O
tax1	B-Protein
-	O
related	O
antigen	O
molecules	O
detected	O
by	O
Lt	O
-	O
4	O
were	O
heterogeneous	O
,	O
having	O
molecular	O
weights	O
in	O
the	O
range	O
of	O
36	O
-	O
41	O
kd	O
.	O

The	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
BMRF1	B-Protein
promoter	O
for	O
early	O
antigen	O
(	O
EA	B-Protein
-	I-Protein
D	I-Protein
)	O
is	O
regulated	O
by	O
the	O
EBV	O
transactivators	O
,	O
BRLF1	B-Protein
and	O
BZLF1	B-Protein
,	O
in	O
a	O
cell	O
-	O
specific	O
manner	O
.	O

The	O
Epstein	O
-	O
Barr	O
virus	O
early	O
antigen	O
diffuse	O
component	O
(	O
EA	B-Protein
-	I-Protein
D	I-Protein
)	O
is	O
essential	O
for	O
Epstein	O
-	O
Barr	O
virus	O
DNA	O
polymerase	O
activity	O
,	O
and	O
its	O
activity	O
is	O
suppressed	O
during	O
latent	O
infection	O
.	O

We	O
investigated	O
the	O
regulation	O
of	O
the	O
promoter	O
(	O
BMRF1	B-Protein
)	O
for	O
this	O
early	O
gene	O
by	O
studying	O
its	O
responsiveness	O
in	O
vitro	O
to	O
two	O
immediate	O
-	O
early	O
viral	O
transactivators	O
,	O
BZLF1	B-Protein
(	O
Z	O
)	O
and	O
BRLF1	B-Protein
(	O
R	O
)	O
,	O
focusing	O
on	O
the	O
differences	O
in	O
response	O
in	O
lymphoid	O
cells	O
and	O
epithelial	O
cells	O
.	O

In	O
lymphoid	O
cells	O
,	O
Z	O
or	O
R	O
alone	O
produced	O
only	O
small	O
increases	O
in	O
EA	B-Protein
-	I-Protein
D	I-Protein
promoter	O
activity	O
,	O
whereas	O
both	O
transactivators	O
together	O
produced	O
a	O
large	O
stimulatory	O
effect	O
.	O

In	O
epithelial	O
cells	O
,	O
the	O
Z	O
transactivator	O
alone	O
produced	O
maximal	O
stimulation	O
of	O
the	O
EA	B-Protein
-	I-Protein
D	I-Protein
promoter	O
;	O
the	O
effect	O
of	O
R	O
and	O
Z	O
together	O
was	O
no	O
greater	O
than	O
that	O
of	O
Z	O
alone	O
.	O

Deletional	O
analysis	O
and	O
site	O
-	O
directed	O
mutagenesis	O
of	O
the	O
EA	B-Protein
-	I-Protein
D	I-Protein
promoter	O
demonstrated	O
that	O
in	O
epithelial	O
cells	O
the	O
potential	O
AP	O
-	O
1	O
binding	O
site	O
plays	O
an	O
essential	O
role	O
in	O
Z	O
responsiveness	O
,	O
although	O
sequences	O
further	O
upstream	O
are	O
also	O
important	O
.	O

In	O
lymphoid	O
cells	O
,	O
only	O
the	O
upstream	O
sequences	O
are	O
required	O
for	O
transactivation	O
by	O
the	O
Z	O
/	O
R	O
combination	O
,	O
and	O
the	O
AP	O
-	O
1	O
site	O
is	O
dispensable	O
.	O

These	O
data	O
suggest	O
that	O
EA	B-Protein
-	I-Protein
D	I-Protein
(	O
BMRF1	B-Protein
)	O
promoter	O
regulation	O
by	O
Z	O
and	O
R	O
is	O
cell	O
type	O
specific	O
and	O
appears	O
to	O
involve	O
different	O
mechanisms	O
in	O
each	O
cell	O
type	O
.	O

Decreased	O
concentration	O
of	O
1	B-Protein
,	I-Protein
25	I-Protein
-	I-Protein
dihydroxyvitamin	I-Protein
D3	I-Protein
receptors	I-Protein
in	O
peripheral	O
mononuclear	O
cells	O
of	O
patients	O
with	O
X	O
-	O
linked	O
hypophosphatemic	O
rickets	O
:	O
effect	O
of	O
phosphate	O
supplementation	O
.	O

Abnormal	O
renal	O
tubular	O
phosphate	O
transport	O
is	O
considered	O
to	O
be	O
the	O
primary	O
defect	O
in	O
X	O
-	O
linked	O
hypophosphatemic	O
rickets	O
(	O
XLH	O
)	O
.	O

However	O
,	O
the	O
resistance	O
to	O
vitamin	O
D	O
treatment	O
in	O
XLH	O
cannot	O
be	O
explained	O
by	O
hypophosphatemia	O
alone	O
.	O

Since	O
most	O
of	O
the	O
actions	O
of	O
vitamin	O
D	O
are	O
mediated	O
by	O
its	O
receptors	O
(	O
VDR	B-Protein
)	O
,	O
abnormalities	O
of	O
VDR	B-Protein
have	O
been	O
postulated	O
in	O
XLH	O
.	O

In	O
order	O
to	O
investigate	O
this	O
possibility	O
,	O
we	O
measured	O
the	O
concentration	O
of	O
VDR	B-Protein
in	O
PHA	O
-	O
activated	O
peripheral	O
mononuclear	O
cells	O
from	O
10	O
XLH	O
patients	O
.	O

Patients	O
without	O
phosphate	O
supplementation	O
showed	O
significantly	O
lower	O
concentration	O
(	O
21	O
.	O
7	O
+	O
/	O
-	O
5	O
.	O
1	O
fmol	O
/	O
mg	O
protein	O
,	O
mean	O
+	O
/	O
-	O
SEM	O
)	O
compared	O
to	O
the	O
normal	O
controls	O
(	O
60	O
.	O
7	O
+	O
/	O
-	O
4	O
.	O
0	O
)	O
.	O

On	O
the	O
contrary	O
,	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
phosphate	O
-	O
supplemented	O
patients	O
(	O
58	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
7	O
)	O
and	O
controls	O
.	O

There	O
was	O
a	O
significant	O
positive	O
correlation	O
between	O
VDR	B-Protein
concentration	O
and	O
serum	O
phosphate	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

In	O
two	O
patients	O
,	O
VDR	B-Protein
was	O
increased	O
after	O
daily	O
phosphate	O
supplementation	O
was	O
started	O
.	O

These	O
results	O
indicate	O
that	O
a	O
decreased	O
concentration	O
of	O
VDR	B-Protein
secondary	O
to	O
persistent	O
hypophosphatemia	O
is	O
one	O
of	O
the	O
causes	O
of	O
vitamin	O
D	O
resistance	O
in	O
XLH	O
.	O

Two	O
glucocorticoid	O
binding	O
sites	O
on	O
the	O
human	O
glucocorticoid	O
receptor	O
.	O

Glucocorticoids	O
are	O
known	O
to	O
have	O
a	O
lytic	O
effect	O
in	O
leukemic	O
cells	O
via	O
interactions	O
with	O
the	O
glucocorticoid	B-Protein
receptor	I-Protein
(	O
GR	B-Protein
)	O
.	O

Cortisol	O
and	O
various	O
synthetic	O
glucocorticoids	O
bind	O
to	O
the	O
GR	B-Protein
with	O
one	O
-	O
site	O
kinetics	O
.	O

Cortivazol	O
(	O
CVZ	O
)	O
is	O
a	O
unique	O
,	O
high	O
potency	O
synthetic	O
glucocorticoid	O
,	O
which	O
has	O
a	O
phenylpyrazol	O
fused	O
to	O
the	O
A	O
-	O
ring	O
of	O
the	O
steroid	O
nucleus	O
and	O
displays	O
binding	O
consistent	O
with	O
two	O
or	O
more	O
sites	O
in	O
the	O
cytosol	O
from	O
CEM	O
C7	O
cells	O
(	O
a	O
human	O
acute	O
lymphoblastic	O
T	O
-	O
cell	O
line	O
)	O
.	O

It	O
has	O
previously	O
been	O
shown	O
that	O
the	O
lower	O
affinity	O
class	O
of	O
sites	O
are	O
similar	O
in	O
affinity	O
and	O
site	O
molarity	O
to	O
those	O
recognized	O
by	O
dexamethasone	O
.	O

The	O
higher	O
affinity	O
sites	O
bind	O
CVZ	O
with	O
20	O
-	O
to	O
50	O
-	O
fold	O
greater	O
affinity	O
,	O
consistent	O
with	O
CVZ	O
'	O
s	O
enhanced	O
biological	O
effects	O
.	O

In	O
mutant	O
leukemic	O
cells	O
resistant	O
to	O
the	O
lytic	O
effects	O
of	O
dexamethasone	O
,	O
CVZ	O
both	O
lyses	O
the	O
cells	O
and	O
recognizes	O
a	O
single	O
class	O
of	O
sites	O
similar	O
to	O
the	O
high	O
affinity	O
site	O
in	O
CEM	O
C7	O
cells	O
.	O

We	O
have	O
carried	O
out	O
experiments	O
to	O
define	O
the	O
nature	O
of	O
the	O
higher	O
affinity	O
CVZ	O
binding	O
site	O
.	O

We	O
now	O
show	O
that	O
:	O
1	O
)	O
CVZ	O
has	O
more	O
than	O
one	O
binding	O
site	O
in	O
a	O
second	O
,	O
independent	O
,	O
B	O
-	O
cell	O
line	O
,	O
IM	O
-	O
9	O
;	O
2	O
)	O
the	O
antiglucocorticoid	O
RU	O
38486	O
is	O
able	O
to	O
block	O
both	O
CVZ	O
'	O
s	O
higher	O
and	O
lower	O
affinity	O
sites	O
;	O
3	O
)	O
all	O
of	O
CVZ	O
'	O
s	O
binding	O
sites	O
are	O
on	O
a	O
protein	O
immunologically	O
indistinguishable	O
from	O
the	O
human	O
GR	B-Protein
;	O
and	O
4	O
)	O
freshly	O
isolated	O
clones	O
of	O
CVZ	O
-	O
resistant	O
cells	O
have	O
lost	O
all	O
binding	O
sites	O
for	O
CVZ	O
.	O

These	O
data	O
indicate	O
that	O
CVZ	O
is	O
recognizing	O
two	O
glucocorticoid	O
binding	O
sites	O
on	O
the	O
human	O
GR	B-Protein
or	O
a	O
protein	O
very	O
similar	O
to	O
it	O
.	O

[	O
The	O
role	O
of	O
glucocorticoid	B-Protein
receptors	I-Protein
and	O
HLA	O
antigens	O
in	O
the	O
pathogenesis	O
of	O
Cushing	O
'	O
s	O
syndrome	O
]	O

Lymphocytic	O
levels	O
of	O
glucocorticoid	B-Protein
receptors	I-Protein
were	O
evaluated	O
in	O
114	O
patients	O
suffering	O
from	O
Icenko	O
-	O
Cushing	O
'	O
s	O
syndrome	O
.	O

Incidence	O
of	O
HLA	O
antigens	O
was	O
determined	O
in	O
94	O
of	O
them	O
.	O

A	O
significant	O
rise	O
of	O
A10	B-Protein
and	O
B27	B-Protein
antigen	I-Protein
incidence	O
compared	O
to	O
that	O
in	O
normal	O
subjects	O
allows	O
these	O
antigens	O
to	O
be	O
considered	O
genetic	O
markers	O
of	O
Icenko	O
-	O
Cushing	O
'	O
s	O
syndrome	O
.	O

The	O
levels	O
of	O
glucocorticoid	B-Protein
receptors	I-Protein
in	O
lymphocytes	O
of	O
the	O
patients	O
are	O
lower	O
than	O
in	O
normal	O
subjects	O
both	O
in	O
the	O
active	O
stage	O
of	O
the	O
disease	O
and	O
following	O
bilateral	O
total	O
adrenalectomy	O
.	O

The	O
patients	O
carrying	O
B27	B-Protein
antigen	I-Protein
had	O
lymphocytic	O
receptor	O
concentrations	O
under	O
the	O
levels	O
of	O
such	O
in	O
patients	O
free	O
of	O
the	O
antigen	O
carriage	O
.	O

Antigen	B-Protein
B27	I-Protein
seems	O
to	O
be	O
a	O
cause	O
of	O
lower	O
levels	O
of	O
glucocorticoid	B-Protein
receptors	I-Protein
in	O
blood	O
lymphocytes	O
.	O

Circadian	O
rhythm	O
of	O
glucocorticoid	B-Protein
receptors	I-Protein
in	O
human	O
peripheral	O
leukocytes	O
and	O
their	O
reactivity	O
to	O
glucocorticoids	O
.	O

1	O
)	O
There	O
exists	O
a	O
CR	O
of	O
GR	B-Protein
in	O
human	O
leukocytes	O
,	O
PMN	O
,	O
and	O
monocytes	O
with	O
the	O
peak	O
values	O
from	O
0400	O
to	O
0800	O
hr	O
and	O
the	O
trough	O
values	O
between	O
2300	O
and	O
0000	O
hr	O
.	O

The	O
difference	O
between	O
them	O
was	O
significant	O
statistically	O
.	O

2	O
)	O
The	O
FI	O
of	O
the	O
chemotactic	O
migration	O
rate	O
of	O
PMN	O
by	O
cortisol	O
also	O
showed	O
diurnal	O
changes	O
which	O
were	O
synchronous	O
with	O
that	O
of	O
GR	B-Protein
.	O

This	O
indicates	O
that	O
the	O
CR	O
of	O
GR	B-Protein
may	O
be	O
of	O
functional	O
significance	O
.	O

3	O
)	O
In	O
Cushing	O
'	O
s	O
syndrome	O
,	O
the	O
CR	O
of	O
GR	B-Protein
was	O
normal	O
in	O
spite	O
of	O
the	O
fact	O
that	O
the	O
CR	O
of	O
plasma	O
cortisol	O
was	O
disturbed	O
.	O

This	O
indicates	O
the	O
independency	O
of	O
the	O
CR	O
of	O
GR	B-Protein
from	O
that	O
of	O
cortisol	O
.	O

4	O
)	O
In	O
apoplexy	O
caused	O
by	O
brain	O
ischemia	O
,	O
the	O
CR	O
of	O
GR	B-Protein
was	O
abolished	O
in	O
patients	O
with	O
basal	O
lesions	O
but	O
preserved	O
when	O
the	O
lesions	O
were	O
located	O
in	O
the	O
cerebral	O
cortex	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
the	O
main	O
"	O
circadian	O
pacemaker	O
"	O
of	O
GR	B-Protein
is	O
located	O
in	O
the	O
basal	O
brain	O
,	O
most	O
probably	O
in	O
the	O
suprachiasmatic	O
nuclei	O
as	O
has	O
been	O
suggested	O
for	O
rodents	O
.	O

Progesterone	O
suppression	O
of	O
pregnancy	O
lymphocytes	O
is	O
not	O
mediated	O
by	O
glucocorticoid	O
effect	O
.	O

This	O
study	O
investigated	O
whether	O
the	O
suppressive	O
effect	O
of	O
progesterone	O
on	O
pregnancy	O
lymphocytes	O
is	O
mediated	O
by	O
specific	O
progesterone	O
receptors	O
.	O

The	O
effects	O
of	O
a	O
competitive	O
progesterone	O
antagonist	O
(	O
RU486	O
)	O
and	O
a	O
specific	O
glucocorticoid	B-Protein
receptor	I-Protein
blocker	O
(	O
RU43044	O
)	O
were	O
tested	O
on	O
the	O
release	O
of	O
a	O
blocking	O
factor	O
by	O
progesterone	O
-	O
treated	O
pregnancy	O
lymphocytes	O
.	O

RU	O
486	O
tested	O
at	O
an	O
equal	O
concentration	O
as	O
progesterone	O
significantly	O
inhibited	O
the	O
production	O
of	O
the	O
blocking	O
factor	O
,	O
while	O
RU	O
43044	O
was	O
without	O
effect	O
.	O

These	O
data	O
suggest	O
that	O
in	O
pregnancy	O
,	O
lymphocyte	O
progesterone	O
acts	O
on	O
specific	O
progesterone	O
receptors	O
and	O
glucocorticoid	O
binding	O
sites	O
are	O
not	O
involved	O
.	O

[	O
The	O
effect	O
of	O
24	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
(	O
dioxyvit	O
)	O
on	O
Ca	O
metabolism	O
and	O
immune	O
status	O
during	O
chronic	O
kidney	O
failure	O
]	O

Active	O
metabolite	O
of	O
vitamin	O
D3	O
,	O
24R	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
(	O
dioxyvit	O
)	O
was	O
used	O
at	O
a	O
daily	O
dose	O
of	O
100	O
micrograms	O
in	O
treatment	O
of	O
children	O
affected	O
with	O
tubulointerstitial	O
disease	O
of	O
kidney	O
and	O
with	O
chronic	O
glomerulonephritis	O
under	O
conditions	O
of	O
kidney	O
insufficiency	O
.	O

The	O
drug	O
exhibited	O
distinct	O
normalizing	O
effect	O
on	O
patterns	O
of	O
calcium	O
metabolism	O
:	O
increase	O
of	O
total	O
and	O
ionized	O
Ca2	O
+	O
and	O
of	O
25	O
-	O
OHD	O
,	O
decrease	O
in	O
concentration	O
of	O
parath	O
hormone	O
and	O
osteocalcine	B-Protein
in	O
blood	O
serum	O
as	O
well	O
as	O
on	O
immunological	O
parameters	O
:	O
restoration	O
of	O
decreased	O
content	O
of	O
T	O
-	O
and	O
0	O
-	O
lymphocytes	O
.	O

Concentration	O
of	O
receptors	O
of	O
hormonal	O
form	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
was	O
found	O
to	O
be	O
minimal	O
in	O
lymphocytes	O
under	O
conditions	O
of	O
chronic	O
kidney	O
insufficiency	O
,	O
while	O
their	O
expression	O
,	O
after	O
the	O
dioxyvit	O
action	O
,	O
was	O
detected	O
only	O
in	O
patients	O
with	O
glomerulonephritis	O
.	O

Specific	O
calcitropic	O
effect	O
of	O
dioxyvit	O
with	O
simultaneous	O
correction	O
of	O
vitamin	O
D	O
deficiency	O
were	O
apparently	O
responsible	O
for	O
high	O
efficacy	O
of	O
the	O
drug	O
in	O
treatment	O
of	O
calcium	O
metabolism	O
and	O
immunity	O
impairments	O
in	O
children	O
with	O
renal	O
deteriorations	O
at	O
the	O
step	O
of	O
chronic	O
kidney	O
insufficiency	O
.	O

Disruption	O
of	O
the	O
human	O
SCL	B-Protein
locus	O
by	O
"	O
illegitimate	O
"	O
V	O
-	O
(	O
D	O
)	O
-	O
J	O
recombinase	O
activity	O
.	O

A	O
fusion	O
complementary	O
DNA	O
in	O
the	O
T	O
cell	O
line	O
HSB	O
-	O
2	O
elucidates	O
a	O
provocative	O
mechanism	O
for	O
the	O
disruption	O
of	O
the	O
putative	O
hematopoietic	O
transcription	O
factor	O
SCL	B-Protein
.	O

The	O
fusion	O
cDNA	O
results	O
from	O
an	O
interstitial	O
deletion	O
between	O
a	O
previously	O
unknown	O
locus	O
,	O
SIL	O
(	O
SCL	B-Protein
interrupting	O
locus	O
)	O
,	O
and	O
the	O
5	O
'	O
untranslated	O
region	O
of	O
SCL	B-Protein
.	O

Similar	O
to	O
1	O
;	O
14	O
translocations	O
,	O
this	O
deletion	O
disrupts	O
the	O
SCL	B-Protein
5	O
'	O
regulatory	O
region	O
.	O

This	O
event	O
is	O
probably	O
mediated	O
by	O
V	O
-	O
(	O
D	O
)	O
-	O
J	O
recombinase	O
activity	O
,	O
although	O
neither	O
locus	O
is	O
an	O
immunoglobulin	O
or	O
a	O
T	O
cell	O
receptor	O
.	O

Two	O
other	O
T	O
cell	O
lines	O
,	O
CEM	O
and	O
RPMI	O
8402	O
,	O
have	O
essentially	O
identical	O
deletions	O
.	O

Thus	O
,	O
in	O
lymphocytes	O
,	O
growth	O
-	O
affecting	O
genes	O
other	O
than	O
immune	O
receptors	O
risk	O
rearrangements	O
.	O

[	O
Effect	O
of	O
the	O
regimen	O
of	O
kidney	O
-	O
tonifying	O
and	O
qi	O
-	O
invigorating	O
on	O
aging	O
changes	O
of	O
glucocorticoid	B-Protein
receptor	I-Protein
]	O

The	O
plasma	O
cortisol	O
concentration	O
and	O
the	O
sites	O
of	O
glucocorticoid	B-Protein
receptor	I-Protein
(	O
GCR	B-Protein
)	O
in	O
the	O
peripheral	O
lymphocytes	O
were	O
measured	O
in	O
32	O
healthy	O
aged	O
persons	O
and	O
13	O
young	O
adults	O
.	O

In	O
animal	O
experiment	O
,	O
GCR	B-Protein
of	O
spleen	O
lymphocytic	O
cell	O
was	O
also	O
measured	O
in	O
18	O
aged	O
rats	O
and	O
9	O
young	O
rats	O
.	O

The	O
results	O
showed	O
that	O
GCR	B-Protein
was	O
significantly	O
lower	O
in	O
the	O
aged	O
persons	O
or	O
rats	O
than	O
that	O
in	O
the	O
young	O
while	O
the	O
plasma	O
cortisol	O
level	O
didn	O
'	O
t	O
change	O
with	O
aging	O
.	O

So	O
we	O
think	O
that	O
GCR	B-Protein
is	O
more	O
sensitive	O
than	O
the	O
plasma	O
cortisol	O
level	O
to	O
reflect	O
the	O
aging	O
change	O
of	O
the	O
adrenal	O
cortex	O
function	O
.	O

After	O
the	O
treatment	O
with	O
the	O
regimen	O
of	O
Kidney	O
-	O
tonifying	O
and	O
Qi	O
-	O
invigorating	O
,	O
the	O
GCR	B-Protein
of	O
the	O
aged	O
persons	O
and	O
rats	O
was	O
enhanced	O
,	O
and	O
in	O
this	O
way	O
,	O
the	O
function	O
of	O
the	O
aged	O
adrenal	O
cortex	O
was	O
improved	O
.	O

Thyroid	O
hormone	O
receptors	O
form	O
distinct	O
nuclear	O
protein	O
-	O
dependent	O
and	O
independent	O
complexes	O
with	O
a	O
thyroid	O
hormone	O
response	O
element	O
.	O

We	O
have	O
examined	O
the	O
binding	O
of	O
nuclear	O
proteins	O
and	O
recombinant	O
thyroid	O
hormone	O
receptors	O
(	O
TRs	O
)	O
to	O
the	O
palindromic	O
thyroid	O
hormone	O
responsive	O
element	O
AGGTCATGACCT	O
(	O
TREp	O
)	O
using	O
a	O
gel	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Four	O
specific	O
protein	O
-	O
DNA	O
complexes	O
were	O
detected	O
after	O
incubation	O
of	O
nuclear	O
extracts	O
(	O
NE	O
)	O
from	O
T3	O
-	O
responsive	O
pituitary	O
(	O
GH3	O
)	O
cells	O
with	O
a	O
TREp	O
-	O
containing	O
DNA	O
fragment	O
.	O

This	O
was	O
compared	O
with	O
the	O
TREp	O
binding	O
of	O
reticulocyte	O
lysate	O
-	O
synthesized	O
TRs	O
.	O

TR	B-Protein
alpha	I-Protein
1	I-Protein
and	O
TR	B-Protein
beta	I-Protein
2	I-Protein
each	O
formed	O
a	O
single	O
major	O
TR	O
:	O
TREp	O
complex	O
which	O
comigrated	O
with	O
the	O
least	O
retarded	O
complex	O
formed	O
by	O
GH3	O
NE	O
,	O
while	O
TR	B-Protein
beta	I-Protein
1	I-Protein
formed	O
multiple	O
complexes	O
suggesting	O
that	O
it	O
can	O
bind	O
to	O
TREp	O
as	O
an	O
oligomer	O
.	O

Interestingly	O
,	O
coincubation	O
of	O
35S	O
-	O
TR	B-Protein
alpha	I-Protein
1	I-Protein
,	O
GH3	O
NE	O
,	O
and	O
unlabeled	O
TREp	O
resulted	O
in	O
not	O
only	O
the	O
35S	O
-	O
TR	O
:	O
TREp	O
complex	O
,	O
but	O
in	O
two	O
additional	O
more	O
greatly	O
retarded	O
complexes	O
containing	O
35S	O
-	O
TR	B-Protein
alpha	I-Protein
1	I-Protein
and	O
comigrating	O
with	O
those	O
formed	O
by	O
GH3	O
extract	O
alone	O
.	O

Incubation	O
of	O
each	O
of	O
the	O
TRs	O
with	O
NE	O
from	O
COS	O
-	O
7	O
cells	O
,	O
which	O
do	O
not	O
possess	O
sufficient	O
endogenous	O
TRs	O
to	O
mediate	O
T3	O
-	O
responses	O
,	O
resulted	O
in	O
formation	O
of	O
a	O
new	O
,	O
more	O
greatly	O
shifted	O
complex	O
.	O

A	O
similar	O
,	O
heat	O
labile	O
activity	O
which	O
altered	O
mobility	O
of	O
the	O
TR	O
:	O
TRE	O
complex	O
was	O
also	O
present	O
in	O
NE	O
from	O
T3	O
-	O
unresponsive	O
JEG	O
-	O
3	O
cells	O
.	O

At	O
high	O
concentration	O
of	O
NE	O
,	O
all	O
of	O
the	O
TR	O
bound	O
to	O
TREp	O
was	O
more	O
greatly	O
retarded	O
than	O
in	O
the	O
absence	O
of	O
NE	O
.	O

Truncation	O
of	O
TR	B-Protein
alpha	I-Protein
1	I-Protein
at	O
amino	O
acid	O
210	O
prevented	O
additional	O
complex	O
formation	O
in	O
the	O
presence	O
of	O
NE	O
without	O
affecting	O
DNA	O
binding	O
,	O
suggesting	O
that	O
the	O
carboxyl	O
-	O
terminus	O
of	O
the	O
TRs	O
is	O
essential	O
for	O
interaction	O
with	O
nuclear	O
proteins	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

[	O
Glucocorticoid	B-Protein
receptors	I-Protein
in	O
peripheral	O
blood	O
lymphocytes	O
of	O
patients	O
with	O
bronchial	O
asthma	O
]	O

Quantitation	O
of	O
glucocorticoid	B-Protein
receptors	I-Protein
(	O
GCR	B-Protein
)	O
and	O
the	O
study	O
of	O
their	O
affinity	O
for	O
glucocorticosteroids	O
(	O
GCS	O
)	O
were	O
made	O
in	O
peripheral	O
blood	O
lymphocytes	O
of	O
bronchial	O
asthma	O
(	O
BA	O
)	O
patients	O
in	O
consideration	O
of	O
GCR	B-Protein
treatment	O
and	O
serum	O
levels	O
of	O
endogenous	O
cortisol	O
.	O

It	O
is	O
stated	O
that	O
GCR	B-Protein
of	O
healthy	O
controls	O
and	O
GCS	O
-	O
untreated	O
patients	O
outnumbered	O
those	O
of	O
cortisol	O
-	O
dependent	O
BA	O
patients	O
on	O
hormone	O
therapy	O
.	O

Following	O
discontinuation	O
of	O
glucocorticoid	O
drugs	O
GCR	B-Protein
count	O
in	O
cortisol	O
-	O
dependent	O
BA	O
tends	O
to	O
rise	O
.	O

Endogenous	O
cortisol	O
has	O
no	O
effect	O
on	O
GCR	B-Protein
level	O
estimated	O
by	O
3H	O
-	O
triamcinolone	O
acetonide	O
.	O

Megakaryocytic	O
and	O
erythrocytic	O
lineages	O
share	O
specific	O
transcription	O
factors	O
.	O

Erythroid	O
-	O
specific	O
genes	O
contain	O
binding	O
sites	O
for	O
NF	B-Protein
-	I-Protein
E1	I-Protein
(	O
also	O
called	O
GF	B-Protein
-	I-Protein
1	I-Protein
and	O
Eryf	B-Protein
-	I-Protein
1	I-Protein
;	O
refs	O
1	O
-	O
3	O
respectively	O
)	O
,	O
the	O
principal	O
DNA	O
-	O
binding	O
protein	O
of	O
the	O
erythrocytic	O
lineage	O
.	O

NF	B-Protein
-	I-Protein
E1	I-Protein
expression	O
seems	O
to	O
be	O
restricted	O
to	O
the	O
erythrocytic	O
lineage	O
.	O

A	O
closely	O
related	O
(	O
if	O
not	O
identical	O
)	O
protein	O
is	O
found	O
in	O
both	O
a	O
human	O
megakaryocytic	O
cell	O
line	O
and	O
purified	O
human	O
megakaryocytes	O
;	O
it	O
binds	O
to	O
promoter	O
regions	O
of	O
two	O
megakaryocytic	O
-	O
specific	O
genes	O
.	O

The	O
binding	O
sites	O
and	O
partial	O
proteolysis	O
profile	O
of	O
this	O
protein	O
are	O
indistinguishable	O
from	O
those	O
of	O
the	O
erythroid	O
protein	O
;	O
also	O
,	O
NF	B-Protein
-	I-Protein
E1	I-Protein
messenger	O
RNA	O
is	O
the	O
same	O
size	O
in	O
both	O
the	O
megakaryocytic	O
and	O
erythroid	O
cell	O
lines	O
.	O

Furthermore	O
,	O
point	O
mutations	O
that	O
abolish	O
binding	O
of	O
NF	B-Protein
-	I-Protein
E1	I-Protein
result	O
in	O
a	O
70	O
%	O
decrease	O
in	O
the	O
transcriptional	O
activity	O
of	O
a	O
megakaryocytic	O
-	O
specific	O
promoter	O
.	O

We	O
also	O
find	O
that	O
NF	O
-	O
E2	O
,	O
another	O
trans	O
-	O
acting	O
factor	O
of	O
the	O
erythrocytic	O
lineage	O
,	O
is	O
present	O
in	O
megakaryocytes	O
.	O

Transcriptional	O
effects	O
in	O
both	O
lineages	O
might	O
then	O
be	O
mediated	O
in	O
part	O
by	O
the	O
same	O
specific	O
trans	O
-	O
acting	O
factors	O
.	O

Our	O
data	O
strengthen	O
the	O
idea	O
of	O
a	O
close	O
association	O
between	O
the	O
erythrocytic	O
and	O
the	O
megakaryocytic	O
lineages	O
and	O
could	O
also	O
explain	O
the	O
expression	O
of	O
markers	O
specific	O
to	O
the	O
erythrocytic	O
and	O
megakaryocytic	O
lineages	O
in	O
most	O
erythroblastic	O
and	O
megakaryoblastic	O
permanent	O
cell	O
lines	O
.	O

A	O
new	O
member	O
of	O
the	O
leucine	O
zipper	O
class	O
of	O
proteins	O
that	O
binds	O
to	O
the	O
HLA	B-Protein
DR	I-Protein
alpha	I-Protein
promoter	O
.	O

Several	O
mutants	O
derived	O
from	O
transformed	O
human	O
B	O
cell	O
lines	O
are	O
defective	O
in	O
expressing	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
genes	O
.	O

The	O
failure	O
to	O
express	O
a	O
class	O
II	O
gene	O
in	O
at	O
least	O
one	O
such	O
mutant	O
line	O
has	O
been	O
mapped	O
to	O
the	O
MHC	O
class	O
II	O
X	O
box	O
,	O
a	O
conserved	O
transcriptional	O
element	O
in	O
the	O
promoter	O
region	O
.	O

A	O
complementary	O
DNA	O
encoding	O
a	O
DNA	O
-	O
binding	O
protein	O
(	O
human	B-Protein
X	I-Protein
box	I-Protein
binding	I-Protein
protein	I-Protein
,	O
hXBP	B-Protein
-	I-Protein
1	I-Protein
)	O
whose	O
target	O
is	O
the	O
human	O
DR	B-Protein
alpha	I-Protein
X	O
box	O
and	O
the	O
3	O
'	O
flanking	O
region	O
has	O
now	O
been	O
cloned	O
.	O

This	O
complementary	O
DNA	O
encoded	O
a	O
protein	O
with	O
structural	O
similarities	O
to	O
the	O
c	B-Protein
-	I-Protein
jun	I-Protein
proto	O
-	O
oncogene	O
product	O
,	O
and	O
its	O
target	O
sequence	O
was	O
closely	O
related	O
to	O
the	O
palindromic	O
target	O
sequence	O
of	O
c	B-Protein
-	I-Protein
jun	I-Protein
.	O

Mutation	O
of	O
the	O
hXBP	B-Protein
-	I-Protein
1	I-Protein
DNA	O
target	O
sequence	O
decreased	O
DR	B-Protein
alpha	I-Protein
promoter	O
activity	O
in	O
vivo	O
.	O

These	O
studies	O
suggest	O
that	O
the	O
hXBP	B-Protein
-	I-Protein
1	I-Protein
protein	O
acts	O
as	O
a	O
transcription	O
factor	O
in	O
B	O
cells	O
.	O

Epstein	B-Protein
-	I-Protein
Barr	I-Protein
virus	I-Protein
nuclear	I-Protein
antigen	I-Protein
2	I-Protein
transactivates	O
latent	O
membrane	O
protein	O
LMP1	B-Protein
.	O

Several	O
lines	O
of	O
evidence	O
are	O
compatible	O
with	O
the	O
hypothesis	O
that	O
Epstein	B-Protein
-	I-Protein
Barr	I-Protein
virus	I-Protein
(	I-Protein
EBV	I-Protein
)	I-Protein
nuclear	I-Protein
antigen	I-Protein
2	I-Protein
(	O
EBNA	B-Protein
-	I-Protein
2	I-Protein
)	O
or	O
leader	O
protein	O
(	O
EBNA	B-Protein
-	I-Protein
LP	I-Protein
)	O
affects	O
expression	O
of	O
the	O
EBV	O
latent	O
infection	O
membrane	O
protein	O
LMP1	B-Protein
.	O

We	O
now	O
demonstrate	O
the	O
following	O
.	O

(	O
i	O
)	O
Acute	O
transfection	O
and	O
expression	O
of	O
EBNA	B-Protein
-	I-Protein
2	I-Protein
under	O
control	O
of	O
simian	O
virus	O
40	O
or	O
Moloney	O
murine	O
leukemia	O
virus	O
promoters	O
resulted	O
in	O
increased	O
LMP1	B-Protein
expression	O
in	O
P3HR	O
-	O
1	O
-	O
infected	O
Burkitt	O
'	O
s	O
lymphoma	O
cells	O
and	O
the	O
P3HR	O
-	O
1	O
or	O
Daudi	O
cell	O
line	O
.	O

(	O
ii	O
)	O
Transfection	O
and	O
expression	O
of	O
EBNA	B-Protein
-	I-Protein
LP	I-Protein
alone	O
had	O
no	O
effect	O
on	O
LMP1	B-Protein
expression	O
and	O
did	O
not	O
act	O
synergistically	O
with	O
EBNA	B-Protein
-	I-Protein
2	I-Protein
to	O
affect	O
LMP1	B-Protein
expression	O
.	O

(	O
iii	O
)	O
LMP1	B-Protein
expression	O
in	O
Daudi	O
and	O
P3HR	O
-	O
1	O
-	O
infected	O
cells	O
was	O
controlled	O
at	O
the	O
mRNA	O
level	O
,	O
and	O
EBNA	B-Protein
-	I-Protein
2	I-Protein
expression	O
in	O
Daudi	O
cells	O
increased	O
LMP1	B-Protein
mRNA	O
.	O

(	O
iv	O
)	O
No	O
other	O
EBV	O
genes	O
were	O
required	O
for	O
EBNA	B-Protein
-	I-Protein
2	I-Protein
transactivation	O
of	O
LMP1	B-Protein
since	O
cotransfection	O
of	O
recombinant	O
EBNA	B-Protein
-	I-Protein
2	I-Protein
expression	O
vectors	O
and	O
genomic	O
LMP1	B-Protein
DNA	O
fragments	O
enhanced	O
LMP1	B-Protein
expression	O
in	O
the	O
EBV	O
-	O
negative	O
B	O
-	O
lymphoma	O
cell	O
lines	O
BJAB	O
,	O
Louckes	O
,	O
and	O
BL30	O
.	O

(	O
v	O
)	O
An	O
EBNA	B-Protein
-	I-Protein
2	I-Protein
-	O
responsive	O
element	O
was	O
found	O
within	O
the	O
-	O
512	O
to	O
+	O
40	O
LMP1	B-Protein
DNA	O
since	O
this	O
DNA	O
linked	O
to	O
a	O
chloramphenicol	B-Protein
acetyltransferase	I-Protein
reporter	O
gene	O
was	O
transactivated	O
by	O
cotransfection	O
with	O
an	O
EBNA	B-Protein
-	I-Protein
2	I-Protein
expression	O
vector	O
.	O

(	O
vi	O
)	O
The	O
EBV	O
type	O
2	O
EBNA	B-Protein
-	I-Protein
2	I-Protein
transactivated	O
LMP1	B-Protein
as	O
well	O
as	O
the	O
EBV	O
type	O
1	O
EBNA	B-Protein
-	I-Protein
2	I-Protein
.	O

(	O
vii	O
)	O
Two	O
deletions	O
within	O
the	O
EBNA	B-Protein
-	I-Protein
2	I-Protein
gene	O
which	O
rendered	O
EBV	O
transformation	O
incompetent	O
did	O
not	O
transactivate	O
LMP1	B-Protein
,	O
whereas	O
a	O
transformation	O
-	O
competent	O
EBNA	B-Protein
-	I-Protein
2	I-Protein
deletion	O
mutant	O
did	O
transactivate	O
LMP1	B-Protein
.	O

LMP1	B-Protein
is	O
a	O
potent	O
effector	O
of	O
B	O
-	O
lymphocyte	O
activation	O
and	O
can	O
act	O
synergistically	O
with	O
EBNA	B-Protein
-	I-Protein
2	I-Protein
to	O
induce	O
cellular	O
CD23	B-Protein
gene	O
expression	O
.	O

Thus	O
,	O
EBNA	B-Protein
-	I-Protein
2	I-Protein
transactivation	O
of	O
LMP1	B-Protein
amplifies	O
the	O
biological	O
impact	O
of	O
EBNA	B-Protein
-	I-Protein
2	I-Protein
and	O
underscores	O
its	O
central	O
role	O
in	O
EBV	O
-	O
induced	O
growth	O
transformation	O
.	O

Protein	O
kinase	O
inhibitor	O
H	O
-	O
7	O
blocks	O
accumulation	O
of	O
unspliced	O
mRNA	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
.	O

Rex	B-Protein
,	O
the	O
post	O
-	O
transcriptional	O
regulator	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
,	O
is	O
known	O
to	O
induce	O
accumulation	O
of	O
the	O
unspliced	O
viral	O
gag	B-Protein
-	O
pol	B-Protein
mRNA	O
.	O

Rex	B-Protein
is	O
a	O
phosphoprotein	O
found	O
in	O
the	O
cell	O
nucleolus	O
,	O
whose	O
function	O
may	O
be	O
regulated	O
by	O
its	O
localization	O
and	O
phosphorylation	O
.	O

We	O
have	O
examined	O
the	O
role	O
of	O
phosphorylation	O
on	O
Rex	B-Protein
function	O
by	O
using	O
a	O
protein	O
kinase	O
inhibitor	O
,	O
H	O
-	O
7	O
[	O
1	O
-	O
(	O
5	O
-	O
isoquinolinyl	O
-	O
sulfonyl	O
)	O
-	O
2	O
-	O
methylpiperazine	O
]	O
.	O

Treatment	O
of	O
an	O
HTLV	O
-	O
I	O
infected	O
human	O
T	O
-	O
cell	O
line	O
with	O
H	O
-	O
7	O
blocked	O
specifically	O
accumulation	O
of	O
the	O
unspliced	O
gag	B-Protein
-	O
pol	B-Protein
mRNA	O
,	O
resulting	O
in	O
the	O
decreased	O
Gag	B-Protein
protein	O
synthesis	O
that	O
corresponds	O
with	O
the	O
decreased	O
in	O
vivo	O
phosphorylation	O
of	O
Rex	B-Protein
.	O

In	O
contrast	O
,	O
other	O
viral	O
and	O
cellular	O
products	O
have	O
not	O
been	O
influenced	O
by	O
the	O
level	O
of	O
H	O
-	O
7	O
used	O
.	O

Therefore	O
,	O
the	O
phosphorylation	O
of	O
Rex	B-Protein
is	O
required	O
for	O
the	O
viral	O
RNA	O
partition	O
of	O
HTLV	O
-	O
I	O
.	O

Mononuclear	O
leukocyte	O
glucocorticoid	B-Protein
receptor	I-Protein
binding	O
characteristics	O
and	O
down	O
-	O
regulation	O
in	O
major	O
depression	O
.	O

Some	O
patients	O
with	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
have	O
elevated	O
plasma	O
cortisol	O
concentrations	O
and	O
show	O
failure	O
to	O
suppress	O
cortisol	O
secretion	O
upon	O
administration	O
of	O
dexamethasone	O
(	O
DEX	O
)	O
,	O
yet	O
they	O
do	O
not	O
have	O
Cushingoid	O
features	O
.	O

To	O
study	O
whether	O
this	O
represents	O
glucocorticoid	O
(	O
GC	O
)	O
resistance	O
,	O
[	O
3H	O
]	O
-	O
DEX	O
-	O
binding	O
assays	O
were	O
used	O
to	O
measure	O
,	O
in	O
vitro	O
,	O
the	O
GC	O
receptor	O
affinity	O
(	O
1	O
/	O
Kd	O
)	O
and	O
number	O
(	O
Bmax	O
)	O
in	O
mononuclear	O
leukocytes	O
of	O
11	O
MDD	O
patients	O
and	O
15	O
control	O
subjects	O
.	O

No	O
receptor	O
abnormalities	O
were	O
detected	O
in	O
the	O
MDD	O
group	O
;	O
thus	O
any	O
cellular	O
defect	O
leading	O
to	O
a	O
lack	O
of	O
responsiveness	O
to	O
GC	O
in	O
the	O
MDD	O
patients	O
,	O
if	O
present	O
,	O
probably	O
lies	O
beyond	O
the	O
initial	O
receptor	O
binding	O
.	O

DEX	O
(	O
1	O
.	O
0	O
mg	O
orally	O
)	O
was	O
administered	O
to	O
study	O
in	O
vivo	O
GC	O
receptor	O
down	O
-	O
regulation	O
.	O

Compared	O
to	O
the	O
control	O
group	O
,	O
fewer	O
depressed	O
subjects	O
down	O
-	O
regulated	O
Bmax	O
after	O
DEX	O
.	O

By	O
paired	O
t	O
-	O
test	O
,	O
Bmax	O
decreased	O
significantly	O
in	O
the	O
control	O
group	O
but	O
not	O
in	O
the	O
depressed	O
group	O
.	O

Receptor	O
number	O
on	O
the	O
control	O
day	O
did	O
not	O
correlate	O
significantly	O
with	O
the	O
degree	O
of	O
receptor	O
down	O
-	O
regulation	O
,	O
severity	O
of	O
depression	O
or	O
cortisol	O
concentrations	O
across	O
all	O
the	O
subjects	O
.	O

These	O
results	O
do	O
not	O
lend	O
support	O
to	O
previous	O
reports	O
suggesting	O
that	O
GC	O
resistance	O
in	O
MDD	O
results	O
from	O
a	O
GC	O
receptor	O
-	O
binding	O
abnormality	O
,	O
and	O
they	O
emphasize	O
the	O
importance	O
of	O
considering	O
receptor	O
studies	O
in	O
the	O
context	O
of	O
GC	O
-	O
mediated	O
cell	O
processes	O
in	O
order	O
to	O
identify	O
the	O
exact	O
cellular	O
defect	O
(	O
s	O
)	O
leading	O
to	O
GC	O
resistance	O
.	O

The	O
56	O
-	O
59	O
-	O
kilodalton	O
protein	O
identified	O
in	O
untransformed	O
steroid	O
receptor	O
complexes	O
is	O
a	O
unique	O
protein	O
that	O
exists	O
in	O
cytosol	O
in	O
a	O
complex	O
with	O
both	O
the	O
70	B-Protein
-	I-Protein
and	O
90	B-Protein
-	I-Protein
kilodalton	I-Protein
heat	I-Protein
shock	I-Protein
proteins	I-Protein
.	O

It	O
has	O
previously	O
been	O
shown	O
that	O
9S	O
,	O
untransformed	O
progestin	O
,	O
estrogen	O
,	O
androgen	O
,	O
and	O
glucocorticoid	O
receptor	O
complexes	O
in	O
rabbit	O
uterine	O
and	O
liver	O
cytosols	O
contain	O
a	O
59	O
-	O
kDa	O
protein	O
[	O
Tai	O
,	O
P	O
.	O
K	O
.	O
,	O
Maeda	O
,	O
Y	O
.	O
,	O
Nakao	O
,	O
K	O
.	O
,	O
Wakim	O
,	O
N	O
.	O
G	O
.	O
,	O
Duhring	O
,	O
J	O
.	O
L	O
.	O
,	O
&	O
Faber	O
,	O
L	O
.	O
E	O
.	O
(	O
1986	O
)	O
Biochemistry	O
25	O
,	O
5269	O
-	O
5275	O
]	O
.	O

In	O
this	O
work	O
we	O
show	O
that	O
the	O
monoclonal	O
antibody	O
KN	O
382	O
/	O
EC1	O
raised	O
against	O
the	O
rabbit	O
59	O
-	O
kDa	O
protein	O
reacts	O
with	O
9S	O
,	O
untransformed	O
glucocorticoid	O
receptor	O
complexes	O
in	O
cytosol	O
prepared	O
from	O
human	O
IM	O
-	O
9	O
lymphocytes	O
but	O
not	O
with	O
4S	O
salt	O
-	O
transformed	O
receptors	O
.	O

The	O
human	O
protein	O
recognized	O
by	O
the	O
EC1	O
antibody	O
is	O
a	O
56	O
-	O
kDa	O
protein	O
(	O
p56	O
)	O
of	O
moderate	O
abundance	O
located	O
predominantly	O
in	O
the	O
cytoplasm	O
by	O
indirect	O
immunofluorescence	O
.	O

There	O
are	O
at	O
least	O
six	O
isomorphs	O
of	O
p56	O
by	O
two	O
-	O
dimensional	O
gel	O
analysis	O
.	O

N	O
-	O
Terminal	O
sequencing	O
(	O
20	O
amino	O
acids	O
)	O
shows	O
that	O
p56	O
is	O
a	O
unique	O
human	O
protein	O
.	O

When	O
p56	O
is	O
immunoadsorbed	O
from	O
IM	O
-	O
9	O
cell	O
cytosol	O
,	O
both	O
the	O
70	B-Protein
-	I-Protein
and	O
90	B-Protein
-	I-Protein
kDa	I-Protein
heat	I-Protein
shock	I-Protein
proteins	I-Protein
are	O
coadsorbed	O
in	O
an	O
immune	O
-	O
specific	O
manner	O
.	O

Neither	O
heat	O
shock	O
protein	O
reacts	O
directly	O
with	O
the	O
EC1	O
antibody	O
.	O

We	O
conclude	O
that	O
p56	O
exists	O
in	O
cytosol	O
in	O
a	O
higher	O
order	O
complex	O
containing	O
hsp70	B-Protein
and	O
hsp90	B-Protein
,	O
both	O
of	O
which	O
in	O
turn	O
have	O
been	O
found	O
to	O
be	O
associated	O
with	O
untransformed	O
steroid	O
receptors	O
.	O

Detection	O
in	O
non	O
-	O
erythroid	O
cells	O
of	O
a	O
factor	O
with	O
the	O
binding	O
characteristics	O
of	O
the	O
erythroid	O
cell	O
transcription	O
factor	O
EF1	B-Protein
.	O

The	O
erythroid	O
transcription	O
factor	O
erythroid	B-Protein
factor	I-Protein
-	I-Protein
1	I-Protein
(	O
EF1	B-Protein
)	O
plays	O
a	O
critical	O
role	O
in	O
the	O
transcription	O
of	O
erythroid	O
-	O
specific	O
genes	O
.	O

Here	O
we	O
report	O
the	O
presence	O
of	O
a	O
factor	O
with	O
the	O
mobility	O
and	O
sequence	O
-	O
specific	O
DNA	O
-	O
binding	O
characteristics	O
of	O
EF1	B-Protein
at	O
low	O
abundance	O
in	O
a	O
wide	O
variety	O
of	O
non	O
-	O
erythroid	O
cell	O
types	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
an	O
EF1	B-Protein
-	O
like	O
activity	O
in	O
non	O
-	O
erythroid	O
cells	O
and	O
indicates	O
that	O
this	O
factor	O
may	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
genes	O
expressed	O
in	O
such	O
cells	O
.	O

The	O
internal	O
methionine	O
codons	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
II	O
rex	B-Protein
gene	O
are	O
not	O
required	O
for	O
p24rex	B-Protein
production	O
or	O
virus	O
replication	O
and	O
transformation	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
types	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
and	O
II	O
(	O
HTLV	O
-	O
II	O
)	O
have	O
two	O
nonstructural	O
trans	O
-	O
acting	O
regulatory	O
genes	O
,	O
tax	B-Protein
and	O
rex	B-Protein
,	O
located	O
in	O
the	O
3	O
'	O
region	O
of	O
the	O
viral	O
genome	O
.	O

The	O
tax	B-Protein
gene	O
product	O
(	O
HTLV	O
-	O
I	O
p40tax	B-Protein
and	O
HTLV	O
-	O
II	O
p37tax	B-Protein
)	O
is	O
the	O
transcriptional	O
activator	O
of	O
the	O
viral	O
long	O
terminal	O
repeat	O
.	O

The	O
rex	B-Protein
gene	O
encodes	O
two	O
protein	O
products	O
,	O
p27rex	B-Protein
/	O
p21rex	B-Protein
and	O
p26rex	B-Protein
/	O
p24rex	B-Protein
in	O
HTLV	O
-	O
I	O
and	O
HTLV	O
-	O
II	O
,	O
respectively	O
.	O

Rex	B-Protein
acts	O
posttranscriptionally	O
to	O
facilitate	O
accumulation	O
of	O
full	O
-	O
length	O
gag	B-Protein
/	O
pol	B-Protein
and	O
singly	O
spliced	O
env	B-Protein
mRNA	O
in	O
the	O
cytoplasm	O
of	O
HTLV	O
-	O
infected	O
cells	O
.	O

Previous	O
studies	O
showed	O
that	O
the	O
first	O
ATG	O
of	O
the	O
rex	B-Protein
gene	O
is	O
critical	O
for	O
Rex	B-Protein
production	O
and	O
function	O
.	O

The	O
importance	O
of	O
the	O
internal	O
ATGs	O
to	O
Rex	B-Protein
function	O
is	O
not	O
known	O
.	O

However	O
,	O
in	O
vitro	O
mutagenesis	O
of	O
the	O
HTLV	O
-	O
I	O
rex	B-Protein
gene	O
has	O
provided	O
indirect	O
evidence	O
which	O
suggests	O
that	O
p21rex	B-Protein
,	O
and	O
by	O
analogy	O
HTLV	O
-	O
II	O
p24rex	B-Protein
,	O
results	O
from	O
initiation	O
at	O
an	O
internal	O
AUG	O
of	O
the	O
tax	B-Protein
/	I-Protein
rex	I-Protein
mRNA	O
.	O

By	O
using	O
an	O
infectious	O
molecular	O
clone	O
of	O
HTLV	O
-	O
II	O
,	O
we	O
investigated	O
the	O
importance	O
of	O
the	O
internal	O
ATGs	O
of	O
the	O
rex	B-Protein
gene	O
on	O
Rex	B-Protein
protein	O
production	O
and	O
function	O
.	O

Our	O
results	O
indicate	O
that	O
p24rex	B-Protein
of	O
HTLV	O
-	O
II	O
is	O
not	O
initiated	O
at	O
an	O
internal	O
AUG	O
and	O
that	O
the	O
internal	O
methionine	O
codons	O
are	O
not	O
crucial	O
to	O
the	O
function	O
of	O
the	O
rex	B-Protein
gene	O
and	O
,	O
ultimately	O
,	O
the	O
transforming	O
properties	O
of	O
the	O
virus	O
.	O

[	O
Glucocorticoid	B-Protein
receptors	I-Protein
on	O
human	O
peripheral	O
mononuclear	O
and	O
polymorphonuclear	O
leucocytes	O
:	O
changes	O
in	O
patients	O
with	O
yang	O
-	O
deficiency	O
]	O

It	O
was	O
found	O
that	O
,	O
in	O
former	O
works	O
,	O
the	O
glucocorticoid	B-Protein
receptors	I-Protein
(	O
GCR	B-Protein
)	O
on	O
peripheral	O
mixed	O
leucocytes	O
in	O
patients	O
with	O
Yang	O
-	O
deficiency	O
were	O
decreased	O
.	O

In	O
this	O
work	O
,	O
the	O
mixed	O
leucocytes	O
were	O
further	O
separated	O
into	O
mononuclear	O
(	O
MNL	O
)	O
and	O
polymorphonuclear	O
(	O
PML	O
)	O
leucocytes	O
,	O
and	O
GCR	B-Protein
were	O
determined	O
in	O
each	O
part	O
of	O
leucocytes	O
.	O

GCR	B-Protein
on	O
MNL	O
and	O
PML	O
in	O
6	O
Yang	O
deficient	O
patients	O
were	O
3473	O
+	O
/	O
-	O
413	O
and	O
4433	O
+	O
/	O
-	O
651	O
sites	O
/	O
cell	O
respectively	O
,	O
statistically	O
significant	O
from	O
the	O
normal	O
control	O
group	O
(	O
4462	O
+	O
/	O
-	O
962	O
and	O
5622	O
+	O
/	O
-	O
782	O
sites	O
/	O
cell	O
respectively	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

GCR	B-Protein
on	O
MNL	O
,	O
PML	O
and	O
mixed	O
leucocytes	O
in	O
5	O
patients	O
were	O
determined	O
simultaneously	O
,	O
and	O
all	O
lowered	O
from	O
the	O
control	O
group	O
.	O

The	O
results	O
were	O
3369	O
+	O
/	O
-	O
370	O
,	O
4986	O
+	O
/	O
-	O
419	O
and	O
4524	O
+	O
/	O
-	O
852	O
sites	O
/	O
cell	O
respectively	O
,	O
with	O
the	O
lowest	O
GCR	B-Protein
on	O
MNL	O
and	O
highest	O
on	O
PML	O
.	O

The	O
murine	O
BCL6	B-Protein
gene	O
is	O
induced	O
in	O
activated	O
lymphocytes	O
as	O
an	O
immediate	O
early	O
gene	O
.	O

The	O
chromosomal	O
translocation	O
involving	O
3q27	O
is	O
often	O
detected	O
in	O
human	O
B	O
-	O
cell	O
lymphomas	O
,	O
especially	O
diffuse	O
lymphomas	O
with	O
a	O
large	O
-	O
cell	O
component	O
.	O

The	O
BCL6	B-Protein
gene	O
has	O
been	O
isolated	O
from	O
the	O
chromosomal	O
breakpoint	O
in	O
these	O
lymphomas	O
.	O

Here	O
we	O
cloned	O
the	O
murine	O
BCL6	B-Protein
(	O
mBCL6	B-Protein
)	O
cDNA	O
from	O
the	O
muscle	O
cDNA	O
library	O
using	O
the	O
human	O
BCL6	B-Protein
(	O
hBCL6	B-Protein
)	O
cDNA	O
as	O
a	O
probe	O
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
was	O
95	O
%	O
identical	O
to	O
that	O
of	O
hBCL6	B-Protein
.	O

It	O
contains	O
six	O
repeats	O
of	O
the	O
Kruppel	O
-	O
like	O
zinc	O
-	O
finger	O
motif	O
that	O
are	O
completely	O
identical	O
to	O
those	O
of	O
hBCL6	B-Protein
,	O
indicating	O
that	O
the	O
BCL6	B-Protein
gene	O
is	O
well	O
conserved	O
between	O
humans	O
and	O
mice	O
.	O

Expression	O
of	O
the	O
mBCL6	B-Protein
gene	O
was	O
ubiquitously	O
detected	O
in	O
adult	O
mouse	O
tissues	O
including	O
lymphatic	O
organs	O
.	O

Furthermore	O
,	O
it	O
was	O
induced	O
in	O
lymphocytes	O
activated	O
with	O
phorbol	O
ester	O
and	O
Ca2	O
+	O
ionophore	O
within	O
30	O
min	O
after	O
stimulation	O
.	O

This	O
induction	O
was	O
not	O
inhibited	O
by	O
treatment	O
of	O
the	O
cells	O
with	O
a	O
protein	O
synthesis	O
inhibitor	O
,	O
cycloheximide	O
.	O

These	O
results	O
suggest	O
that	O
BCL6	B-Protein
plays	O
a	O
role	O
in	O
activated	O
lymphocytes	O
as	O
an	O
immediate	O
early	O
gene	O
.	O

Bik	B-Protein
,	O
a	O
novel	O
death	O
-	O
inducing	O
protein	O
shares	O
a	O
distinct	O
sequence	O
motif	O
with	O
Bcl	O
-	O
2	O
family	O
proteins	O
and	O
interacts	O
with	O
viral	O
and	O
cellular	O
survival	O
-	O
promoting	O
proteins	O
.	O

The	O
survival	O
-	O
promoting	O
activity	O
of	O
the	O
Bcl	O
-	O
2	O
family	O
of	O
proteins	O
appears	O
to	O
be	O
modulated	O
by	O
interactions	O
between	O
various	O
cellular	O
proteins	O
.	O

We	O
have	O
identified	O
a	O
novel	O
cellular	O
protein	O
,	O
Bik	B-Protein
,	O
that	O
interacts	O
with	O
the	O
cellular	O
survival	O
-	O
promoting	O
proteins	O
,	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
and	O
Bcl	B-Protein
-	I-Protein
xL	I-Protein
,	O
as	O
well	O
as	O
the	O
viral	O
survival	O
-	O
promoting	O
proteins	O
,	O
Epstein	O
Barr	O
virus	O
-	O
BHRF1	B-Protein
and	O
adenovirus	O
E1B	B-Protein
-	I-Protein
19	I-Protein
kDa	I-Protein
.	O

In	O
transient	O
transfection	O
assays	O
,	O
Bik	B-Protein
promotes	O
cell	O
death	O
in	O
a	O
manner	O
similar	O
to	O
the	O
death	O
-	O
promoting	O
members	O
of	O
the	O
Bcl	O
-	O
2	O
family	O
,	O
Bax	B-Protein
and	O
Bak	B-Protein
.	O

This	O
death	O
-	O
promoting	O
activity	O
of	O
Bik	B-Protein
can	O
be	O
suppressed	O
by	O
coexpression	O
of	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
,	O
Bcl	B-Protein
-	I-Protein
XL	I-Protein
,	O
EBV	B-Protein
-	I-Protein
BHRF1	I-Protein
and	O
E1B	O
-	O
19	O
kDa	O
proteins	O
suggesting	O
that	O
Bik	B-Protein
may	O
be	O
a	O
common	O
target	O
for	O
both	O
cellular	O
and	O
viral	O
anti	O
-	O
apoptotic	O
proteins	O
.	O

While	O
Bik	B-Protein
does	O
not	O
show	O
overt	O
homology	O
to	O
the	O
BH1	B-Protein
and	O
BH2	B-Protein
conserved	O
domains	O
characteristic	O
of	O
the	O
Bcl	O
-	O
2	O
family	O
,	O
it	O
does	O
share	O
a	O
9	O
amino	O
acid	O
domain	O
(	O
BH3	B-Protein
)	O
with	O
Bax	B-Protein
and	O
Bak	B-Protein
which	O
may	O
be	O
a	O
critical	O
determinant	O
for	O
the	O
death	O
-	O
promoting	O
activity	O
of	O
these	O
proteins	O
.	O

Staphylococcal	O
enterotoxins	O
modulate	O
interleukin	O
2	O
receptor	O
expression	O
and	O
ligand	O
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
Janus	B-Protein
protein	I-Protein
-	I-Protein
tyrosine	I-Protein
kinase	I-Protein
3	I-Protein
(	O
Jak3	B-Protein
)	O
and	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
Stat	O
proteins	O
)	O
.	O

Staphylococcal	O
enterotoxins	O
(	O
SE	O
)	O
stimulate	O
T	O
cells	O
expressing	O
the	O
appropriate	O
variable	O
region	O
beta	O
chain	O
of	O
(	O
V	O
beta	O
)	O
T	O
-	O
cell	O
receptors	O
and	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
several	O
autoimmune	O
diseases	O
.	O

Depending	O
on	O
costimulatory	O
signals	O
,	O
SE	O
induce	O
either	O
proliferation	O
or	O
anergy	O
in	O
T	O
cells	O
.	O

In	O
addition	O
,	O
SE	O
can	O
induce	O
an	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
(	O
IL	B-Protein
-	I-Protein
2	I-Protein
)	O
nonresponsive	O
state	O
and	O
apoptosis	O
.	O

Here	O
,	O
we	O
show	O
that	O
SE	O
induce	O
dynamic	O
changes	O
in	O
the	O
expression	O
of	O
and	O
signal	O
transduction	O
through	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
receptor	I-Protein
(	I-Protein
IL	I-Protein
-	I-Protein
2R	I-Protein
)	I-Protein
beta	I-Protein
and	O
gamma	B-Protein
chains	I-Protein
(	O
IL	B-Protein
-	I-Protein
2R	I-Protein
beta	I-Protein
and	O
IL	B-Protein
-	I-Protein
2R	I-Protein
gamma	I-Protein
)	O
in	O
human	O
antigen	O
-	O
specific	O
CD4	B-Protein
+	O
T	O
-	O
cell	O
lines	O
.	O

Thus	O
,	O
after	O
4	O
hr	O
of	O
exposure	O
to	O
SEA	B-Protein
and	O
SEB	B-Protein
,	O
the	O
expression	O
of	O
IL	B-Protein
-	I-Protein
2R	I-Protein
beta	I-Protein
was	O
down	O
-	O
regulated	O
,	O
IL	B-Protein
-	I-Protein
2R	I-Protein
gamma	I-Protein
was	O
slightly	O
up	O
-	O
regulated	O
,	O
while	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	I-Protein
remained	O
largely	O
unaffected	O
.	O

The	O
changes	O
in	O
the	O
composition	O
of	O
IL	O
-	O
2Rs	O
were	O
accompanied	O
by	O
inhibition	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
Janus	B-Protein
protein	I-Protein
-	I-Protein
tyrosine	I-Protein
kinase	I-Protein
3	I-Protein
(	O
Jak3	B-Protein
)	O
and	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
called	O
Stat3	B-Protein
and	O
Stat5	B-Protein
.	O

In	O
parallel	O
experiments	O
,	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
driven	O
proliferation	O
was	O
inhibited	O
significantly	O
.	O

After	O
16	O
hr	O
of	O
exposure	O
to	O
SE	O
,	O
the	O
expression	O
of	O
IL	B-Protein
-	I-Protein
2R	I-Protein
beta	I-Protein
remained	O
low	O
,	O
while	O
that	O
of	O
IL2R	B-Protein
alpha	I-Protein
and	O
IL2R	B-Protein
gamma	I-Protein
was	O
further	O
up	O
-	O
regulated	O
,	O
and	O
ligand	O
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
Jak3	B-Protein
and	O
Stat	O
proteins	O
was	O
partly	O
normalized	O
.	O

Yet	O
,	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
driven	O
proliferation	O
remained	O
profoundly	O
inhibited	O
,	O
suggesting	O
that	O
signaling	O
events	O
other	O
than	O
Jak3	B-Protein
/	O
Stat	O
activation	O
had	O
also	O
been	O
changed	O
following	O
SE	O
stimulation	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
SE	O
can	O
modulate	O
IL	O
-	O
2R	O
expression	O
and	O
signal	O
transduction	O
involving	O
the	O
Jak	O
/	O
Stat	O
pathway	O
in	O
CD4	B-Protein
+	O
T	O
-	O
cell	O
lines	O
.	O

Mutation	O
of	O
Jak3	B-Protein
in	O
a	O
patient	O
with	O
SCID	O
:	O
essential	O
role	O
of	O
Jak3	B-Protein
in	O
lymphoid	O
development	O
.	O

Males	O
with	O
X	O
-	O
linked	O
severe	O
combined	O
immunodeficiency	O
(	O
XSCID	O
)	O
have	O
defects	O
in	O
the	O
common	O
cytokine	B-Protein
receptor	I-Protein
gamma	I-Protein
chain	I-Protein
(	O
gamma	B-Protein
c	I-Protein
)	O
gene	O
that	O
encodes	O
a	O
shared	O
,	O
essential	O
component	O
of	O
the	O
receptors	O
of	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
(	O
IL	B-Protein
-	I-Protein
2	I-Protein
)	O
,	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
IL	B-Protein
-	I-Protein
7	I-Protein
,	O
IL	B-Protein
-	I-Protein
9	I-Protein
,	O
and	O
IL	B-Protein
-	I-Protein
15	I-Protein
.	O

The	O
Janus	O
family	O
tyrosine	O
kinase	O
Jak3	B-Protein
is	O
the	O
only	O
signaling	O
molecule	O
known	O
to	O
be	O
associated	O
with	O
gamma	B-Protein
c	I-Protein
,	O
so	O
it	O
was	O
hypothesized	O
that	O
defects	O
in	O
Jak3	B-Protein
might	O
cause	O
an	O
XSCID	O
-	O
like	O
phenotype	O
.	O

A	O
girl	O
with	O
immunological	O
features	O
indistinguishable	O
from	O
those	O
of	O
XSCID	O
was	O
therefore	O
selected	O
for	O
analysis	O
.	O

An	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
-	O
transformed	O
cell	O
line	O
derived	O
from	O
her	O
lymphocytes	O
had	O
normal	O
gamma	B-Protein
c	I-Protein
expression	O
but	O
lacked	O
Jak3	B-Protein
protein	O
and	O
had	O
greatly	O
diminished	O
Jak3	B-Protein
messenger	O
RNA	O
.	O

Sequencing	O
revealed	O
a	O
different	O
mutation	O
on	O
each	O
allele	O
:	O
a	O
single	O
nucleotide	O
insertion	O
resulting	O
in	O
a	O
frame	O
shift	O
and	O
premature	O
termination	O
in	O
the	O
Jak3	B-Protein
JH4	O
domain	O
and	O
a	O
nonsense	O
mutation	O
in	O
the	O
Jak3	B-Protein
JH2	O
domain	O
.	O

The	O
lack	O
of	O
Jak3	B-Protein
expression	O
correlated	O
with	O
impaired	O
B	O
cell	O
signaling	O
,	O
as	O
demonstrated	O
by	O
the	O
inability	O
of	O
IL	B-Protein
-	I-Protein
4	I-Protein
to	O
activate	O
Stat6	B-Protein
in	O
the	O
EBV	O
-	O
transformed	O
cell	O
line	O
from	O
the	O
patient	O
.	O

These	O
observations	O
indicate	O
that	O
the	O
functions	O
of	O
gamma	B-Protein
c	I-Protein
are	O
dependent	O
on	O
Jak3	B-Protein
and	O
that	O
Jak3	B-Protein
is	O
essential	O
for	O
lymphoid	O
development	O
and	O
signaling	O
.	O

Inhibition	O
of	O
dexamethasone	O
binding	O
to	O
human	O
glucocorticoid	B-Protein
receptor	I-Protein
by	O
New	O
World	O
primate	O
cell	O
extracts	O
.	O

To	O
determine	O
if	O
New	O
World	O
primates	O
express	O
an	O
inhibitor	O
that	O
influences	O
glucocorticoid	B-Protein
receptor	I-Protein
(	O
GR	B-Protein
)	O
binding	O
characteristics	O
,	O
we	O
examined	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
in	O
cytosol	O
prepared	O
from	O
B95	O
-	O
8	O
lymphoid	O
cells	O
,	O
derived	O
from	O
the	O
cotton	O
top	O
tamarin	O
(	O
Saguinus	O
oedipus	O
)	O
,	O
in	O
combination	O
with	O
cytosol	O
prepared	O
from	O
human	O
or	O
rat	O
tissues	O
.	O

B95	O
-	O
8	O
cytosol	O
inhibited	O
specific	O
binding	O
of	O
[	O
3H	O
]	O
dexamethasone	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
when	O
mixed	O
with	O
cytosol	O
prepared	O
from	O
either	O
a	O
human	O
lymphoid	O
cell	O
line	O
(	O
HL	O
)	O
or	O
rat	O
thymus	O
.	O

The	O
inhibitory	O
activity	O
was	O
heat	O
labile	O
and	O
trypsin	O
sensitive	O
.	O

Peak	O
inhibitory	O
activity	O
was	O
found	O
in	O
the	O
150	O
-	O
200	O
kd	O
fractions	O
after	O
Sephacryl	O
G	O
-	O
200	O
ultrafiltration	O
.	O

Scatchard	O
analysis	O
of	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
using	O
mixed	O
cytosol	O
showed	O
a	O
diminished	O
GR	B-Protein
apparent	O
binding	O
affinity	O
when	O
compared	O
to	O
HL	O
cytosol	O
.	O

Kinetic	O
studies	O
using	O
mixed	O
cytosol	O
indicated	O
that	O
B95	O
-	O
8	O
cytosol	O
did	O
not	O
affect	O
the	O
apparent	O
dissociation	O
rate	O
of	O
[	O
3H	O
]	O
dexamethasone	O
.	O

These	O
data	O
demonstrate	O
that	O
B95	O
-	O
8	O
cells	O
contain	O
a	O
competitive	O
inhibitor	O
that	O
prevents	O
binding	O
of	O
dexamethasone	O
to	O
its	O
cognate	O
receptor	O
.	O

Expression	O
of	O
the	O
chemokine	O
receptor	O
BLR2	B-Protein
/	O
EBI1	B-Protein
is	O
specifically	O
transactivated	O
by	O
Epstein	B-Protein
-	I-Protein
Barr	I-Protein
virus	I-Protein
nuclear	I-Protein
antigen	I-Protein
2	I-Protein
.	O

In	O
our	O
attempt	O
to	O
identify	O
chemokine	O
receptors	O
that	O
are	O
related	O
to	O
Burkitt	B-Protein
'	I-Protein
s	I-Protein
lymphoma	I-Protein
receptor	I-Protein
1	I-Protein
(	O
BLR1	B-Protein
)	O
and	O
are	O
expressed	O
in	O
activated	O
lymphocytes	O
we	O
used	O
RT	O
-	O
PCR	O
resulting	O
in	O
the	O
isolation	O
of	O
a	O
cDNA	O
encoding	O
a	O
seven	O
transmembrane	O
receptor	O
termed	O
BLR2	B-Protein
.	O

The	O
protein	O
shows	O
significant	O
sequence	O
similarities	O
to	O
the	O
family	O
of	O
G	O
-	O
protein	O
coupled	O
chemokine	O
receptors	O
and	O
turned	O
out	O
to	O
be	O
identical	O
to	O
the	O
recently	O
described	O
receptor	O
EBI1	B-Protein
.	O

Northern	O
blot	O
analysis	O
revealed	O
that	O
BLR2	B-Protein
mRNA	O
could	O
be	O
highly	O
stimulated	O
in	O
mitogen	O
-	O
and	O
anti	O
-	O
CD3	O
-	O
treated	O
peripheral	O
blood	O
lymphocytes	O
.	O

BLR2	B-Protein
-	O
specific	O
mRNA	O
could	O
be	O
detected	O
in	O
all	O
Epstein	O
-	O
Barr	O
virus	O
positive	O
B	O
cell	O
lines	O
.	O

We	O
show	O
that	O
transcription	O
of	O
the	O
BLR2	B-Protein
gene	O
could	O
be	O
specifically	O
induced	O
in	O
Epstein	O
-	O
Barr	O
virus	O
negative	O
BL	O
41	O
cells	O
via	O
estrogen	O
-	O
mediated	O
activation	O
of	O
Epstein	B-Protein
-	I-Protein
Barr	I-Protein
virus	I-Protein
nuclear	I-Protein
antigen	I-Protein
2	I-Protein
,	O
a	O
key	O
regulator	O
of	O
viral	O
and	O
cellular	O
genes	O
in	O
immortalized	O
B	O
cells	O
.	O

Our	O
data	O
suggest	O
an	O
involvement	O
of	O
BLR2	B-Protein
in	O
the	O
regulation	O
of	O
migration	O
in	O
activated	O
lymphocytes	O
and	O
in	O
viral	O
pathogenesis	O
.	O

Interleukin	B-Protein
-	I-Protein
7	I-Protein
can	O
induce	O
the	O
activation	O
of	O
Jak	B-Protein
1	I-Protein
,	O
Jak	B-Protein
3	I-Protein
and	O
STAT	B-Protein
5	I-Protein
proteins	O
in	O
murine	O
T	O
cells	O
.	O

The	O
activation	O
of	O
Janus	O
protein	O
tyrosine	O
kinases	O
(	O
Jak	O
)	O
and	O
STAT	O
(	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
)	O
proteins	O
has	O
recently	O
been	O
linked	O
to	O
the	O
signal	O
transduction	O
mechanism	O
of	O
several	O
cytokines	O
.	O

IL	B-Protein
-	I-Protein
7	I-Protein
was	O
observed	O
to	O
induce	O
a	O
rapid	O
and	O
dose	O
-	O
dependent	O
tyrosine	O
phosphorylation	O
of	O
Jak	B-Protein
1	I-Protein
and	O
Jak	B-Protein
3	I-Protein
and	O
concomitantly	O
,	O
the	O
tyrosine	O
phosphorylation	O
and	O
DNA	O
binding	O
activity	O
of	O
multiple	O
STAT	O
proteins	O
.	O

The	O
STAT	O
proteins	O
utilized	O
by	O
IL	B-Protein
-	I-Protein
7	I-Protein
were	O
identical	O
to	O
those	O
induced	O
by	O
IL	B-Protein
-	I-Protein
2	I-Protein
and	O
could	O
be	O
identified	O
as	O
various	O
STAT	O
5	O
isoforms	O
.	O

Moreover	O
,	O
the	O
induction	O
of	O
both	O
Jak	B-Protein
1	I-Protein
and	O
3	B-Protein
,	O
and	O
STAT	B-Protein
5	I-Protein
activity	O
strongly	O
correlated	O
with	O
the	O
growth	O
-	O
promoting	O
effects	O
of	O
IL	B-Protein
-	I-Protein
7	I-Protein
,	O
suggesting	O
that	O
this	O
signal	O
transduction	O
mechanism	O
may	O
play	O
a	O
key	O
role	O
in	O
IL	B-Protein
-	I-Protein
7	I-Protein
-	O
induced	O
proliferation	O
.	O

Lymphocyte	O
glucocorticoid	B-Protein
receptor	I-Protein
:	O
predictor	O
of	O
sertraline	O
response	O
in	O
adolescent	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
.	O

Major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
in	O
adolescents	O
demonstrates	O
resistance	O
to	O
tricyclic	O
antidepressants	O
and	O
absence	O
of	O
hypercortisolemia	O
.	O

The	O
efficacy	O
of	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SRIs	O
)	O
is	O
uncertain	O
,	O
and	O
response	O
predictors	O
are	O
unavailable	O
.	O

Abnormal	O
fast	O
feedback	O
and	O
negative	O
feedback	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
implicates	O
a	O
dampened	O
limbic	O
-	O
hippocampal	O
glucocorticoid	B-Protein
type	I-Protein
II	I-Protein
receptor	I-Protein
(	O
GCII	B-Protein
)	O
.	O

We	O
hypothesized	O
that	O
lymphocyte	O
GCII	B-Protein
is	O
altered	O
in	O
adolescent	O
MDD	O
and	O
could	O
serve	O
as	O
a	O
marker	O
for	O
response	O
to	O
SRIs	O
.	O

In	O
an	O
open	O
-	O
label	O
study	O
,	O
adolescents	O
(	O
n	O
=	O
20	O
)	O
meeting	O
DSM	O
-	O
III	O
-	O
R	O
criteria	O
for	O
MDD	O
showed	O
baseline	O
lymphocyte	O
GCII	B-Protein
sites	O
per	O
cell	O
(	O
sites	O
/	O
cell	O
)	O
values	O
of	O
793	O
+	O
/	O
-	O
106	O
versus	O
2	O
,	O
563	O
+	O
/	O
-	O
499	O
(	O
+	O
/	O
-	O
SEM	O
)	O
for	O
matched	O
controls	O
(	O
n	O
=	O
18	O
)	O
(	O
t	O
=	O
3	O
.	O
5	O
;	O
df	O
=	O
36	O
;	O
p	O
<	O
.	O
001	O
)	O
.	O

GCII	B-Protein
was	O
bimodally	O
distributed	O
,	O
with	O
SRI	O
responders	O
differing	O
from	O
nonresponders	O
(	O
t	O
=	O
3	O
.	O
9	O
;	O
df	O
=	O
14	O
;	O
p	O
<	O
.	O
001	O
)	O
.	O

GCII	B-Protein
accurately	O
classified	O
90	O
percent	O
of	O
sertraline	O
responders	O
and	O
80	O
percent	O
of	O
nonresponders	O
.	O

Only	O
SRI	O
responders	O
showed	O
GCII	B-Protein
sites	O
/	O
cell	O
upregulated	O
after	O
6	O
weeks	O
of	O
treatment	O
(	O
t	O
=	O
2	O
.	O
1	O
,	O
df	O
=	O
10	O
;	O
p	O
<	O
.	O
05	O
)	O
.	O

Oncogenicity	O
of	O
human	O
papillomavirus	O
-	O
or	O
adenovirus	O
-	O
transformed	O
cells	O
correlates	O
with	O
resistance	O
to	O
lysis	O
by	O
natural	O
killer	O
cells	O
.	O

The	O
reasons	O
for	O
the	O
dissimilar	O
oncogenicities	O
of	O
human	O
adenoviruses	O
and	O
human	O
papillomaviruses	O
(	O
HPV	O
)	O
in	O
humans	O
are	O
unknown	O
but	O
may	O
relate	O
to	O
differences	O
in	O
the	O
capacities	O
of	O
the	O
E1A	B-Protein
and	O
E7	B-Protein
proteins	O
to	O
target	O
cells	O
for	O
rejection	O
by	O
the	O
host	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
response	O
.	O

As	O
one	O
test	O
of	O
this	O
hypothesis	O
,	O
we	O
compared	O
the	O
abilities	O
of	O
E1A	B-Protein
-	O
and	O
E7	B-Protein
-	O
expressing	O
human	O
fibroblastic	O
or	O
keratinocyte	O
-	O
derived	O
human	O
cells	O
to	O
be	O
selectively	O
killed	O
by	O
either	O
unstimulated	O
or	O
interferon	O
(	O
IFN	O
)	O
-	O
activated	O
NK	O
cells	O
.	O

Cells	O
expressing	O
the	O
E1A	B-Protein
oncoprotein	O
were	O
selectively	O
killed	O
by	O
unstimulated	O
NK	O
cells	O
,	O
while	O
the	O
same	O
parental	O
cells	O
but	O
expressing	O
the	O
HPV	O
type	O
16	O
(	O
HPV	O
-	O
16	O
)	O
or	O
HPV	O
-	O
18	O
E7	B-Protein
oncoprotein	O
were	O
resistant	O
to	O
NK	O
cell	O
lysis	O
.	O

The	O
ability	O
of	O
IFN	O
-	O
activated	O
NK	O
cells	O
to	O
selectively	O
kill	O
virally	O
transformed	O
cells	O
depends	O
on	O
IFN	O
'	O
s	O
ability	O
to	O
induce	O
resistance	O
to	O
NK	O
cell	O
lysis	O
in	O
normal	O
(	O
i	O
.	O
e	O
.	O
,	O
non	O
-	O
viral	O
oncogene	O
-	O
expressing	O
)	O
but	O
not	O
virally	O
transformed	O
cells	O
.	O

E1A	B-Protein
blocked	O
IFN	O
'	O
s	O
induction	O
of	O
cytolytic	O
resistance	O
,	O
resulting	O
in	O
the	O
selective	O
lysis	O
of	O
adenovirus	O
-	O
transformed	O
cells	O
by	O
IFN	O
-	O
activated	O
NK	O
cells	O
.	O

The	O
extent	O
of	O
IFN	O
-	O
induced	O
NK	O
cell	O
killing	O
of	O
E1A	B-Protein
-	O
expressing	O
cells	O
was	O
proportional	O
to	O
the	O
level	O
of	O
E1A	B-Protein
expression	O
and	O
correlated	O
with	O
the	O
ability	O
of	O
E1A	B-Protein
to	O
block	O
IFN	O
-	O
stimulated	O
gene	O
expression	O
in	O
target	O
cells	O
.	O

In	O
contrast	O
,	O
E7	B-Protein
blocked	O
neither	O
IFN	O
-	O
stimulated	O
gene	O
expression	O
nor	O
IFN	O
'	O
s	O
induction	O
of	O
cytolytic	O
resistance	O
,	O
thereby	O
precluding	O
the	O
selective	O
lysis	O
of	O
HPV	O
-	O
transformed	O
cells	O
by	O
IFN	O
-	O
activated	O
NK	O
cells	O
.	O

In	O
conclusion	O
,	O
E1A	B-Protein
expression	O
marks	O
cells	O
for	O
destruction	O
by	O
the	O
host	O
NK	O
cell	O
response	O
,	O
whereas	O
the	O
E7	B-Protein
oncoprotein	O
lacks	O
this	O
activity	O
.	O

Regulation	O
of	O
the	O
balance	O
of	O
cytokine	O
production	O
and	O
the	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	O
)	O
transcription	O
factor	O
activity	O
by	O
cytokines	O
and	O
inflammatory	O
synovial	O
fluids	O
.	O

The	O
balance	O
between	O
type	O
1	O
and	O
2	O
T	O
helper	O
cell	O
cytokine	O
production	O
plays	O
an	O
important	O
role	O
in	O
several	O
animal	O
models	O
of	O
autoimmunity	O
,	O
and	O
skewed	O
patterns	O
of	O
cytokine	O
expression	O
have	O
been	O
described	O
in	O
human	O
inflammatory	O
diseases	O
.	O

Many	O
cytokines	O
activate	O
signal	O
transducer	O
and	O
activation	O
of	O
transcription	O
(	O
STAT	O
)	O
transcription	O
factors	O
,	O
which	O
,	O
in	O
turn	O
,	O
activate	O
transcription	O
of	O
inflammatory	O
effector	O
genes	O
.	O

We	O
used	O
mononuclear	O
cell	O
priming	O
cultures	O
and	O
inflammatory	O
synovial	O
fluids	O
(	O
SFs	O
)	O
derived	O
from	O
arthritis	O
patients	O
to	O
examine	O
the	O
regulation	O
of	O
cytokine	O
production	O
and	O
STAT	O
activity	O
by	O
an	O
inflammatory	O
synovial	O
microenvironment	O
.	O

Exposure	O
to	O
SFs	O
during	O
priming	O
resulted	O
in	O
an	O
81	O
%	O
inhibition	O
of	O
interferon	B-Protein
(	I-Protein
IFN	I-Protein
)	I-Protein
-	I-Protein
gamma	I-Protein
,	O
but	O
not	O
interleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
4	I-Protein
,	O
production	O
by	O
effector	O
cells	O
generated	O
in	O
priming	O
cultures	O
.	O

SF	O
suppression	O
was	O
mediated	O
by	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
inhibition	O
of	O
IL	O
-	O
12	O
expression	O
,	O
and	O
it	O
was	O
reversed	O
in	O
a	O
dominant	O
fashion	O
by	O
exogenous	O
IL	O
-	O
12	O
.	O

SFs	O
blocked	O
the	O
sustained	O
activity	O
of	O
transcription	O
factor	O
Stat1	B-Protein
,	O
but	O
not	O
Stat3	B-Protein
,	O
during	O
the	O
priming	O
period	O
,	O
and	O
Stat1	B-Protein
activity	O
was	O
differentially	O
regulated	O
by	O
cytokines	O
in	O
parallel	O
with	O
their	O
positive	O
or	O
negative	O
regulation	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
.	O

Active	O
Stat3	B-Protein
,	O
but	O
not	O
Stat1	B-Protein
,	O
was	O
detected	O
in	O
cells	O
from	O
inflamed	O
joints	O
.	O

These	O
results	O
suggest	O
a	O
role	O
for	O
altered	O
balance	O
of	O
Stat1	B-Protein
and	O
Stat3	B-Protein
transcriptional	O
activity	O
in	O
the	O
regulation	O
of	O
T	O
cell	O
differentiation	O
and	O
in	O
the	O
pathogenesis	O
of	O
inflammatory	O
synovitis	O
.	O

Anti	O
-	O
immunoglobulin	O
M	O
activates	O
nuclear	O
calcium	B-Protein
/	I-Protein
calmodulin	I-Protein
-	I-Protein
dependent	I-Protein
protein	I-Protein
kinase	I-Protein
II	I-Protein
in	O
human	O
B	O
lymphocytes	O
.	O

We	O
and	O
others	O
have	O
previously	O
shown	O
that	O
the	O
nuclear	O
protein	O
,	O
Ets	B-Protein
-	I-Protein
1	I-Protein
,	O
is	O
phosphorylated	O
in	O
a	O
calcium	O
-	O
dependent	O
manner	O
after	O
ligation	O
of	O
immunoglobulin	O
(	O
Ig	O
)	O
M	O
on	O
B	O
lymphocytes	O
.	O

As	O
this	O
phosphorylation	O
was	O
independent	O
of	O
protein	O
kinase	O
C	O
activity	O
,	O
we	O
tested	O
whether	O
a	O
calcium	O
/	O
calmodulin	O
-	O
dependent	O
protein	O
kinase	O
(	O
CaM	O
kinase	O
)	O
might	O
phosphorylate	O
the	O
Ets	B-Protein
-	I-Protein
1	I-Protein
protein	O
after	O
elevation	O
of	O
intracellular	O
free	O
calcium	O
concentrations	O
.	O

The	O
dephosphorylated	O
form	O
of	O
Ets	B-Protein
-	I-Protein
1	I-Protein
has	O
been	O
shown	O
to	O
bind	O
to	O
chromatin	O
,	O
suggesting	O
that	O
the	O
operative	O
kinase	O
should	O
be	O
detectable	O
in	O
the	O
nucleus	O
.	O

We	O
prepared	O
nuclear	O
extracts	O
from	O
two	O
human	O
B	O
cell	O
lines	O
in	O
which	O
increased	O
intracellular	O
free	O
calcium	O
levels	O
correlated	O
with	O
increased	O
phosphorylation	O
of	O
the	O
Ets	B-Protein
-	I-Protein
1	I-Protein
protein	O
.	O

Activity	O
of	O
the	O
CaM	O
kinases	O
was	O
determined	O
using	O
a	O
synthetic	O
peptide	O
substrate	O
both	O
in	O
the	O
absence	O
and	O
presence	O
of	O
an	O
inhibitor	O
specific	O
for	O
the	O
CaM	O
kinase	O
family	O
,	O
KN	O
-	O
62	O
.	O

Stimulation	O
of	O
cells	O
with	O
anti	O
-	O
IgM	O
led	O
to	O
increased	O
activity	O
of	O
a	O
nuclear	O
kinase	O
that	O
could	O
phosphorylate	O
the	O
peptide	O
,	O
and	O
this	O
activity	O
was	O
reduced	O
by	O
10	O
microM	O
KN	O
-	O
62	O
.	O

Kinase	O
activity	O
was	O
reduced	O
in	O
lysates	O
preadsorbed	O
using	O
an	O
antibody	O
specific	O
for	O
CaM	B-Protein
kinase	I-Protein
II	I-Protein
.	O

Two	O
-	O
dimensional	O
phosphopeptide	O
maps	O
of	O
the	O
Ets	B-Protein
-	I-Protein
1	I-Protein
protein	O
from	O
cells	O
incubated	O
with	O
ionomycin	O
or	O
anti	O
-	O
IgM	O
contained	O
two	O
unique	O
phosphopeptides	O
that	O
were	O
absent	O
in	O
untreated	O
cells	O
.	O

Incubation	O
of	O
isolated	O
Ets	B-Protein
-	I-Protein
1	I-Protein
protein	O
with	O
purified	O
CaM	B-Protein
kinase	I-Protein
II	I-Protein
produced	O
phosphorylation	O
of	O
peptides	O
that	O
migrated	O
identically	O
to	O
those	O
found	O
in	O
cells	O
incubated	O
with	O
either	O
anti	O
-	O
IgM	O
or	O
ionomycin	O
.	O

These	O
data	O
suggest	O
a	O
model	O
of	O
signal	O
transduction	O
by	O
the	O
antigen	O
receptor	O
on	O
B	O
lymphocytes	O
in	O
which	O
increased	O
intracellular	O
free	O
calcium	O
can	O
rapidly	O
activate	O
nuclear	O
CaM	B-Protein
kinase	I-Protein
II	I-Protein
,	O
potentially	O
resulting	O
in	O
phosphorylation	O
and	O
regulation	O
of	O
DNA	O
-	O
binding	O
proteins	O
.	O

rel	B-Protein
Is	O
rapidly	O
tyrosine	O
-	O
phosphorylated	O
following	O
granulocyte	B-Protein
-	I-Protein
colony	I-Protein
stimulating	I-Protein
factor	I-Protein
treatment	O
of	O
human	O
neutrophils	O
.	O

Stimulation	O
of	O
neutrophils	O
with	O
granulocyte	B-Protein
-	I-Protein
colony	I-Protein
stimulating	I-Protein
factor	I-Protein
(	O
G	B-Protein
-	I-Protein
CSF	I-Protein
)	O
results	O
in	O
an	O
enhanced	O
respiratory	O
burst	O
,	O
prolonged	O
survival	O
,	O
and	O
increased	O
tumor	O
cell	O
killing	O
.	O

The	O
effects	O
of	O
G	B-Protein
-	I-Protein
CSF	I-Protein
are	O
mediated	O
by	O
binding	O
to	O
specific	O
,	O
high	O
affinity	O
receptors	O
.	O

G	B-Protein
-	I-Protein
CSF	I-Protein
receptors	O
lack	O
intrinsic	O
tyrosine	O
kinase	O
activity	O
,	O
but	O
activation	O
of	O
the	O
receptor	O
results	O
in	O
the	O
rapid	O
induction	O
of	O
tyrosine	O
kinase	O
activity	O
.	O

Antiphosphotyrosine	O
immunoblots	O
of	O
whole	O
cell	O
lysates	O
prepared	O
from	O
neutrophils	O
show	O
that	O
the	O
G	B-Protein
-	I-Protein
CSF	I-Protein
rapidly	O
induces	O
prominent	O
tyrosine	O
phosphorylation	O
of	O
a	O
protein	O
of	O
a	O
relative	O
molecular	O
mass	O
of	O
80	O
kDa	O
.	O

Using	O
monospecific	O
antibodies	O
,	O
the	O
80	O
-	O
kDa	O
tyrosine	O
-	O
phosphorylated	O
protein	O
has	O
been	O
shown	O
to	O
be	O
p80c	B-Protein
-	I-Protein
rel	I-Protein
,	O
a	O
proto	O
-	O
oncogene	O
belonging	O
to	O
a	O
family	O
of	O
transcriptional	O
regulators	O
which	O
include	O
NF	O
-	O
kB	O
.	O

The	O
induction	O
of	O
tyrosine	O
phosphorylation	O
of	O
p80c	B-Protein
-	I-Protein
rel	I-Protein
was	O
unique	O
to	O
G	B-Protein
-	I-Protein
CSF	I-Protein
in	O
that	O
granulocyte	B-Protein
-	I-Protein
macrophage	I-Protein
colony	I-Protein
stimulating	I-Protein
factor	I-Protein
which	O
also	O
stimulates	O
neutrophils	O
and	O
induces	O
tyrosine	O
phosphorylation	O
does	O
not	O
result	O
in	O
tyrosine	O
phosphorylation	O
of	O
p80c	B-Protein
-	I-Protein
rel	I-Protein
.	O

The	O
consequences	O
of	O
p80c	B-Protein
-	I-Protein
rel	I-Protein
tyrosine	O
phosphorylation	O
are	O
not	O
yet	O
known	O
;	O
however	O
,	O
tyrosine	O
-	O
phosphorylated	O
p80c	B-Protein
-	I-Protein
rel	I-Protein
is	O
capable	O
of	O
binding	O
to	O
DNA	O
,	O
and	O
G	B-Protein
-	I-Protein
CSF	I-Protein
stimulation	O
results	O
in	O
an	O
increase	O
in	O
the	O
amount	O
of	O
p80c	B-Protein
-	I-Protein
rel	I-Protein
which	O
binds	O
to	O
DNA	O
.	O

These	O
results	O
demonstrate	O
that	O
one	O
of	O
the	O
first	O
biochemical	O
events	O
which	O
occurs	O
in	O
neutrophils	O
following	O
G	B-Protein
-	I-Protein
CSF	I-Protein
stimulation	O
,	O
activation	O
of	O
a	O
tyrosine	O
kinase	O
,	O
leads	O
directly	O
to	O
the	O
tyrosine	O
phosphorylation	O
of	O
p80c	B-Protein
-	I-Protein
rel	I-Protein
.	O

Thus	O
,	O
the	O
tyrosine	O
kinase	O
activated	O
by	O
G	B-Protein
-	I-Protein
CSF	I-Protein
appears	O
to	O
directly	O
transduce	O
a	O
signal	O
to	O
a	O
protein	O
which	O
functions	O
as	O
a	O
transcriptional	O
regulator	O
.	O

Retinoic	O
acid	O
-	O
induced	O
expression	O
of	O
CD38	B-Protein
antigen	O
in	O
myeloid	O
cells	O
is	O
mediated	O
through	O
retinoic	B-Protein
acid	I-Protein
receptor	I-Protein
-	I-Protein
alpha	I-Protein
.	O

CD38	B-Protein
is	O
a	O
leukocyte	O
differentiation	O
antigen	O
that	O
has	O
been	O
thought	O
to	O
be	O
a	O
phenotypic	O
marker	O
of	O
different	O
subpopulations	O
of	O
T	O
-	O
and	O
B	O
-	O
lymphocytes	O
.	O

In	O
myeloid	O
cells	O
,	O
CD38	B-Protein
is	O
expressed	O
during	O
early	O
stages	O
of	O
differentiation	O
.	O

Virtually	O
no	O
information	O
is	O
available	O
on	O
regulation	O
and	O
functions	O
of	O
CD38	B-Protein
.	O

Recently	O
we	O
reported	O
that	O
all	O
-	O
trans	O
-	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
is	O
a	O
potent	O
and	O
highly	O
specific	O
inducer	O
of	O
CD38	B-Protein
expression	O
in	O
human	O
promyelocytic	O
leukemia	O
cells	O
.	O

Here	O
we	O
report	O
that	O
ATRA	O
-	O
induced	O
expression	O
of	O
CD38	B-Protein
antigen	O
in	O
myeloid	O
cells	O
is	O
mediated	O
through	O
retinoic	B-Protein
acid	I-Protein
-	I-Protein
alpha	I-Protein
receptor	I-Protein
(	O
RAR	B-Protein
alpha	I-Protein
)	O
.	O

ATRA	O
failed	O
to	O
induce	O
CD38	B-Protein
expression	O
in	O
a	O
mutant	O
subclone	O
of	O
the	O
HL	O
-	O
60	O
myeloid	O
leukemia	O
cell	O
line	O
(	O
designated	O
HL	O
-	O
60R	O
)	O
that	O
is	O
relatively	O
resistant	O
to	O
ATRA	O
-	O
induced	O
granulocytic	O
differentiation	O
.	O

Retroviral	O
vector	O
-	O
mediated	O
transduction	O
of	O
RA	O
receptor	O
(	O
RAR	B-Protein
alpha	I-Protein
)	O
into	O
this	O
HL	O
-	O
60R	O
subclone	O
completely	O
restored	O
the	O
sensitivity	O
of	O
these	O
cells	O
to	O
ATRA	O
in	O
terms	O
of	O
their	O
ability	O
to	O
express	O
CD38	B-Protein
.	O

In	O
contrast	O
,	O
CD38	B-Protein
expression	O
was	O
not	O
inducible	O
by	O
ATRA	O
in	O
HL	O
-	O
60R	O
cells	O
,	O
transfected	O
with	O
a	O
functional	O
RAR	B-Protein
beta	I-Protein
,	O
RAR	B-Protein
gamma	I-Protein
,	O
or	O
RXR	B-Protein
alpha	I-Protein
receptor	O
.	O

Induction	O
of	O
CD38	B-Protein
in	O
acute	O
promyelocytic	O
and	O
acute	O
myeloblastic	O
leukemia	O
cells	O
was	O
independent	O
of	O
ATRA	O
-	O
induced	O
cytodifferentiation	O
.	O

Following	O
culture	O
with	O
ATRA	O
,	O
increased	O
CD38	B-Protein
protein	O
levels	O
were	O
also	O
observed	O
in	O
normal	O
CD34	O
+	O
bone	O
marrow	O
cells	O
,	O
but	O
not	O
on	O
normal	O
circulating	O
granulocytes	O
.	O

From	O
these	O
results	O
,	O
we	O
conclude	O
that	O
CD38	B-Protein
is	O
ATRA	O
inducible	O
in	O
myeloid	O
leukemia	O
cells	O
and	O
normal	O
CD34	O
+	O
bone	O
marrow	O
cells	O
.	O

This	O
effect	O
is	O
independent	O
of	O
differentiation	O
and	O
is	O
mediated	O
by	O
RAR	B-Protein
alpha	I-Protein
in	O
HL	O
-	O
60	O
cells	O
,	O
suggesting	O
a	O
similar	O
role	O
for	O
RAR	B-Protein
alpha	I-Protein
in	O
CD38	B-Protein
expression	O
in	O
other	O
hematopoietic	O
cells	O
.	O

Comparison	O
of	O
retinoic	O
acid	O
and	O
phorbol	O
myristate	O
acetate	O
as	O
inducers	O
of	O
monocytic	O
differentiation	O
.	O

Several	O
human	O
myeloid	O
leukemia	O
cell	O
lines	O
growing	O
in	O
vitro	O
can	O
be	O
induced	O
to	O
differentiate	O
to	O
more	O
mature	O
monocyte	O
/	O
macrophage	O
-	O
like	O
cells	O
by	O
treatment	O
with	O
protein	O
kinase	O
C	O
-	O
activating	O
phorbol	O
esters	O
,	O
such	O
as	O
PMA	O
.	O

In	O
addition	O
to	O
PMA	O
,	O
cells	O
of	O
the	O
THP	O
-	O
1	O
myeloid	O
leukemia	O
cell	O
line	O
acquire	O
macrophage	O
-	O
like	O
characteristics	O
after	O
treatment	O
with	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
.	O

To	O
analyze	O
the	O
signal	O
transduction	O
mechanisms	O
induced	O
by	O
RA	O
,	O
we	O
first	O
compared	O
the	O
effects	O
of	O
PMA	O
and	O
RA	O
on	O
the	O
expression	O
of	O
genes	O
which	O
are	O
known	O
to	O
be	O
regulated	O
during	O
monocytic	O
differentiation	O
.	O

Both	O
RA	O
and	O
PMA	O
effectively	O
down	O
-	O
regulated	O
c	B-Protein
-	I-Protein
myc	I-Protein
expression	O
,	O
while	O
c	B-Protein
-	I-Protein
myb	I-Protein
expression	O
decreased	O
only	O
after	O
PMA	O
treatment	O
.	O

Expression	O
of	O
the	O
beta	O
2	O
-	O
integrin	O
genes	O
,	O
CD11a	B-Protein
and	O
CD11b	B-Protein
,	O
was	O
clearly	O
increased	O
after	O
both	O
of	O
these	O
treatments	O
.	O

Their	O
effects	O
on	O
the	O
src	O
-	O
family	O
tyrosine	O
kinase	O
genes	O
were	O
different	O
:	O
hck	B-Protein
expression	O
was	O
similarly	O
induced	O
by	O
these	O
agents	O
but	O
lyn	B-Protein
expression	O
was	O
stronger	O
and	O
more	O
rapid	O
after	O
RA	O
treatment	O
.	O

RA	O
also	O
enhanced	O
lyn	B-Protein
mRNA	O
production	O
rapidly	O
in	O
HL	O
-	O
60	O
,	O
indicating	O
that	O
the	O
activation	O
of	O
lyn	B-Protein
gene	O
expression	O
is	O
common	O
in	O
monocytic	O
and	O
granulocytic	O
maturation	O
of	O
myeloid	O
leukemia	O
cells	O
.	O

To	O
examine	O
whether	O
the	O
AP	O
-	O
1	O
enhancer	O
activity	O
is	O
involved	O
in	O
RA	O
-	O
induced	O
monocytic	O
differentiation	O
,	O
THP	O
-	O
1	O
cells	O
were	O
transiently	O
transfected	O
with	O
a	O
chloramphenicol	B-Protein
acetyl	I-Protein
transferase	I-Protein
(	O
CAT	B-Protein
)	O
-	O
reporter	O
gene	O
containing	O
5	O
copies	O
of	O
the	O
AP	O
-	O
1	O
binding	O
sites	O
.	O

In	O
contrast	O
to	O
PMA	O
,	O
RA	O
did	O
not	O
induce	O
any	O
CAT	B-Protein
activity	O
in	O
these	O
cells	O
,	O
thus	O
suggesting	O
that	O
the	O
RA	O
-	O
induced	O
changes	O
in	O
the	O
expression	O
of	O
those	O
genes	O
described	O
above	O
were	O
not	O
dependent	O
on	O
the	O
AP	O
-	O
1	O
enhancer	O
activity	O
.	O

Inhibition	O
of	O
T	O
cell	O
activation	O
by	O
the	O
extracellular	O
matrix	O
protein	O
tenascin	O
.	O

Tenascin	O
(	O
TN	O
)	O
is	O
an	O
extracellular	O
matrix	O
protein	O
that	O
is	O
expressed	O
widely	O
in	O
the	O
fetus	O
and	O
sparingly	O
in	O
the	O
adult	O
,	O
but	O
reappears	O
at	O
high	O
levels	O
in	O
certain	O
areas	O
of	O
tissue	O
insult	O
such	O
as	O
tumor	O
matrices	O
and	O
sites	O
of	O
wound	O
healing	O
.	O

We	O
show	O
here	O
that	O
soluble	O
TN	O
inhibits	O
proliferation	O
of	O
human	O
T	O
cells	O
in	O
response	O
to	O
alpha	O
CD3	O
Ab	O
co	O
-	O
immobilized	O
with	O
the	O
extracellular	O
matrix	O
protein	O
fibronectin	B-Protein
(	O
FN	B-Protein
)	O
.	O

TN	O
also	O
inhibits	O
proliferation	O
driven	O
by	O
alpha	O
CD3	O
/	O
IL	B-Protein
-	I-Protein
2	I-Protein
or	O
by	O
phorbol	O
ester	O
/	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
and	O
it	O
prevents	O
high	O
level	O
induction	O
of	O
IL	O
-	O
2R	O
.	O

The	O
presence	O
of	O
TN	O
in	O
culture	O
medium	O
does	O
not	O
detectably	O
alter	O
the	O
pattern	O
of	O
tyrosine	O
phosphorylation	O
resulting	O
from	O
T	O
cell	O
triggering	O
with	O
alpha	O
CD3	O
,	O
but	O
at	O
later	O
time	O
points	O
prevents	O
the	O
appearance	O
of	O
functional	O
NF	O
-	O
AT1	O
transcription	O
factor	O
complexes	O
in	O
T	O
cell	O
nuclear	O
extracts	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
the	O
postulated	O
role	O
for	O
TN	O
as	O
a	O
natural	O
antagonist	O
to	O
FN	B-Protein
action	O
,	O
and	O
suggest	O
that	O
T	O
cell	O
responses	O
occurring	O
at	O
tissue	O
sites	O
in	O
which	O
TN	O
is	O
expressed	O
could	O
be	O
influenced	O
by	O
its	O
presence	O
.	O

HLA	O
-	O
DR	O
-	O
,	O
CD33	B-Protein
+	O
,	O
CD56	B-Protein
+	O
,	O
CD16	B-Protein
-	O
myeloid	O
/	O
natural	O
killer	O
cell	O
acute	O
leukemia	O
:	O
a	O
previously	O
unrecognized	O
form	O
of	O
acute	O
leukemia	O
potentially	O
misdiagnosed	O
as	O
French	O
-	O
American	O
-	O
British	O
acute	O
myeloid	O
leukemia	O
-	O
M3	O
[	O
see	O
comments	O
]	O

We	O
have	O
identified	O
and	O
characterized	O
a	O
previously	O
unrecognized	O
form	O
of	O
acute	O
leukemia	O
that	O
shares	O
features	O
of	O
both	O
myeloid	O
and	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
.	O

From	O
a	O
consecutive	O
series	O
of	O
350	O
cases	O
of	O
adult	O
de	O
novo	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
,	O
we	O
identified	O
20	O
cases	O
(	O
6	O
%	O
)	O
with	O
a	O
unique	O
immunophenotype	O
:	O
CD33	B-Protein
+	O
,	O
CD56	B-Protein
+	O
,	O
CD11a	B-Protein
+	O
,	O
CD13lo	B-Protein
,	O
CD15lo	B-Protein
,	O
CD34	B-Protein
+	O
/	O
-	O
,	O
HLA	O
-	O
DR	O
-	O
,	O
CD16	B-Protein
-	O
.	O

Multicolor	O
flow	O
cytometric	O
assays	O
confirmed	O
the	O
coexpression	O
of	O
myeloid	O
(	O
CD33	B-Protein
,	O
CD13	B-Protein
,	O
CD15	B-Protein
)	O
and	O
NK	O
cell	O
-	O
associated	O
(	O
CD56	B-Protein
)	O
antigens	O
in	O
each	O
case	O
,	O
whereas	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assays	O
confirmed	O
the	O
identity	O
of	O
CD56	B-Protein
(	O
neural	O
cell	O
adhesion	O
molecule	O
)	O
in	O
leukemic	O
blasts	O
.	O

Although	O
two	O
cases	O
expressed	O
CD4	B-Protein
,	O
no	O
case	O
expressed	O
CD2	B-Protein
,	O
CD3	O
,	O
or	O
CD8	B-Protein
and	O
no	O
case	O
showed	O
clonal	O
rearrangement	O
of	O
genes	O
encoding	O
the	O
T	O
-	O
cell	O
receptor	O
(	O
TCR	B-Protein
beta	I-Protein
,	O
gamma	B-Protein
,	O
delta	B-Protein
)	O
.	O

Leukemic	O
blasts	O
in	O
the	O
majority	O
of	O
cases	O
shared	O
unique	O
morphologic	O
features	O
(	O
deeply	O
invaginated	O
nuclear	O
membranes	O
,	O
scant	O
cytoplasm	O
with	O
fine	O
azurophilic	O
granularity	O
,	O
and	O
finely	O
granular	O
Sudan	O
black	O
B	O
and	O
myeloperoxidase	B-Protein
cytochemical	O
reactivity	O
)	O
that	O
were	O
remarkably	O
similar	O
to	O
those	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
;	O
particularly	O
the	O
microgranular	O
variant	O
(	O
FAB	O
AML	O
-	O
M3v	O
)	O
.	O

However	O
,	O
all	O
20	O
cases	O
lacked	O
the	O
t	O
(	O
15	O
;	O
17	O
)	O
and	O
17	O
cases	O
tested	O
lacked	O
the	O
promyelocytic	B-Protein
/	I-Protein
retinoic	I-Protein
acid	I-Protein
receptor	I-Protein
alpha	I-Protein
(	O
RAR	B-Protein
alpha	I-Protein
)	O
fusion	O
transcript	O
in	O
RT	O
-	O
PCR	O
assays	O
;	O
12	O
cases	O
had	O
46	O
,	O
XX	O
or	O
46	O
,	O
XY	O
karyotypes	O
,	O
whereas	O
2	O
cases	O
had	O
abnormalities	O
of	O
chromosome	O
17q	O
:	O
1	O
with	O
del	O
(	O
17	O
)	O
(	O
q25	O
)	O
and	O
the	O
other	O
with	O
t	O
(	O
11	O
;	O
17	O
)	O
(	O
q23	O
;	O
q21	O
)	O
and	O
the	O
promyelocytic	B-Protein
leukemia	I-Protein
zinc	I-Protein
finger	I-Protein
/	O
RAR	B-Protein
alpha	I-Protein
fusion	O
transcript	O
.	O

All	O
cases	O
tested	O
(	O
6	O
/	O
20	O
)	O
,	O
including	O
the	O
case	O
with	O
t	O
(	O
11	O
;	O
17	O
)	O
,	O
failed	O
to	O
differentiate	O
in	O
vitro	O
in	O
response	O
to	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
,	O
suggesting	O
that	O
these	O
cases	O
may	O
account	O
for	O
some	O
APLs	O
that	O
have	O
not	O
shown	O
a	O
clinical	O
response	O
to	O
ATRA	O
.	O

Four	O
of	O
6	O
cases	O
tested	O
showed	O
functional	O
NK	O
cell	O
-	O
mediated	O
cytotoxicity	O
,	O
suggesting	O
a	O
relationship	O
between	O
these	O
unique	O
CD33	B-Protein
+	O
,	O
CD56	B-Protein
+	O
,	O
CD16	B-Protein
-	O
acute	O
leukemias	O
and	O
normal	O
CD56	B-Protein
+	O
,	O
CD16	B-Protein
-	O
NK	O
precursor	O
cells	O
.	O

Using	O
a	O
combination	O
of	O
panning	O
and	O
multiparameter	O
flow	O
cytometric	O
sorting	O
,	O
we	O
identified	O
a	O
normal	O
CD56	B-Protein
+	O
,	O
CD33	B-Protein
+	O
,	O
CD16	B-Protein
-	O
counterpart	O
cell	O
at	O
a	O
frequency	O
of	O
1	O
%	O
to	O
2	O
%	O
in	O
the	O
peripheral	O
blood	O
of	O
healthy	O
individuals	O
.	O

Our	O
studies	O
suggest	O
that	O
this	O
form	O
of	O
acute	O
leukemia	O
may	O
arise	O
from	O
transformation	O
of	O
a	O
precursor	O
cell	O
common	O
to	O
both	O
the	O
myeloid	O
and	O
NK	O
cell	O
lineages	O
;	O
thus	O
we	O
propose	O
the	O
designation	O
myeloid	O
/	O
NK	O
acute	O
leukemia	O
.	O

Recognition	O
of	O
this	O
new	O
leukemic	O
entity	O
will	O
be	O
important	O
in	O
distinguishing	O
these	O
ATRA	O
-	O
nonresponsive	O
cases	O
from	O
ATRA	O
-	O
responsive	O
true	O
APL	O
.	O

Inhibition	O
of	O
the	O
differentiation	O
of	O
human	O
myeloid	O
cell	O
lines	O
by	O
redox	O
changes	O
induced	O
through	O
glutathione	O
depletion	O
.	O

We	O
have	O
investigated	O
the	O
effect	O
of	O
redox	O
changes	O
in	O
vivo	O
on	O
the	O
differentiation	O
of	O
two	O
human	O
myeloid	O
cell	O
lines	O
,	O
HL	O
-	O
60	O
and	O
KG	O
-	O
1	O
.	O

The	O
glutathione	O
-	O
depleting	O
agent	O
diethyl	O
maleate	O
(	O
DEM	O
)	O
prevented	O
the	O
development	O
of	O
differentiated	O
features	O
in	O
response	O
to	O
phorbol	O
esters	O
,	O
including	O
adherence	O
of	O
the	O
cells	O
to	O
plastic	O
surfaces	O
and	O
repression	O
of	O
the	O
myeloperoxidase	B-Protein
and	O
CD34	B-Protein
genes	O
.	O

Moreover	O
,	O
DEM	O
abolished	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
-	O
induced	O
activation	O
of	O
the	O
transcription	O
factors	O
AP	O
-	O
1	O
and	O
Egr	B-Protein
-	I-Protein
1	I-Protein
,	O
suggesting	O
that	O
inhibition	O
of	O
differentiation	O
may	O
be	O
due	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
redox	O
modifications	O
of	O
these	O
proteins	O
.	O

Interleukin	B-Protein
-	I-Protein
2	I-Protein
induces	O
tyrosine	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
stat3	B-Protein
in	O
human	O
T	O
lymphocytes	O
.	O

An	O
early	O
biochemical	O
event	O
associated	O
with	O
T	O
cell	O
activation	O
through	O
the	O
interleukin	O
-	O
2	O
receptor	O
(	O
IL	O
-	O
2R	O
)	O
is	O
tyrosine	O
phosphorylation	O
of	O
several	O
intracellular	O
substrates	O
.	O

The	O
exact	O
mechanism	O
by	O
which	O
IL	B-Protein
-	I-Protein
2	I-Protein
regulates	O
transcription	O
of	O
different	O
genes	O
is	O
presently	O
unknown	O
.	O

Here	O
,	O
we	O
report	O
that	O
stimulation	O
through	O
the	O
IL	O
-	O
2R	O
induced	O
tyrosine	O
phosphorylation	O
and	O
subsequent	O
nuclear	O
translocation	O
of	O
stat3	B-Protein
,	O
a	O
newly	O
identified	O
member	O
of	O
the	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STAT	O
)	O
family	O
of	O
proteins	O
.	O

In	O
contrast	O
,	O
stat1	O
proteins	O
were	O
not	O
tyrosine	O
phosphorylated	O
after	O
IL	B-Protein
-	I-Protein
2	I-Protein
ligation	O
,	O
whereas	O
tyrosine	O
-	O
phosphorylated	O
stat1	O
proteins	O
(	O
91	O
and	O
84	O
kDa	O
proteins	O
)	O
were	O
translocated	O
to	O
the	O
nucleus	O
following	O
interferon	B-Protein
-	I-Protein
gamma	I-Protein
treatment	O
of	O
HeLa	O
cells	O
.	O

Apart	O
from	O
stat3	B-Protein
,	O
another	O
cytoplasmic	O
protein	O
was	O
tyrosine	O
phosphorylated	O
and	O
subsequently	O
translocated	O
to	O
the	O
nucleus	O
in	O
response	O
to	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O

This	O
protein	O
had	O
an	O
apparent	O
molecular	O
mass	O
of	O
84	O
kDa	O
and	O
was	O
not	O
recognized	O
by	O
stat3	B-Protein
or	O
stat1	O
mAb	O
or	O
antisera	O
.	O

Since	O
IL	B-Protein
-	I-Protein
2	I-Protein
induced	O
nuclear	O
translocation	O
of	O
the	O
84	O
kDa	O
protein	O
and	O
stat3	B-Protein
followed	O
identical	O
kinetics	O
,	O
p84	O
is	O
a	O
candidate	O
for	O
a	O
new	O
,	O
yet	O
undefined	O
,	O
member	O
of	O
the	O
STAT	O
family	O
.	O

Taken	O
together	O
,	O
we	O
report	O
that	O
IL	B-Protein
-	I-Protein
2	I-Protein
induces	O
tyrosine	O
phosphorylation	O
and	O
subsequent	O
nuclear	O
translocation	O
of	O
stat3	B-Protein
and	O
an	O
as	O
yet	O
undefined	O
84	O
-	O
kDa	O
protein	O
in	O
antigen	O
-	O
specific	O
human	O
T	O
cell	O
lines	O
.	O

Induction	O
of	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
and	O
LFA	B-Protein
-	I-Protein
3	I-Protein
by	O
Tax1	B-Protein
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
and	O
mechanism	O
of	O
down	O
-	O
regulation	O
of	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
or	O
LFA	O
-	O
1	O
in	O
adult	O
-	O
T	O
-	O
cell	O
-	O
leukemia	O
cell	O
lines	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
determine	O
the	O
role	O
of	O
HTLV	O
-	O
I	O
TaxI	B-Protein
in	O
the	O
up	O
-	O
regulation	O
of	O
ICAM	B-Protein
-	I-Protein
I	I-Protein
and	O
LFA	B-Protein
-	I-Protein
3	I-Protein
in	O
human	O
T	O
cells	O
transformed	O
with	O
HTLV	O
-	O
I	O
and	O
the	O
mechanism	O
of	O
down	O
-	O
regulation	O
of	O
ICAM	B-Protein
-	I-Protein
I	I-Protein
and	O
LFA	O
-	O
I	O
in	O
ATL	O
-	O
derived	O
cell	O
lines	O
.	O

Induction	O
of	O
TaxI	B-Protein
in	O
a	O
human	O
T	O
-	O
cell	O
line	O
Jurkat	O
carrying	O
the	O
TaxI	B-Protein
gene	O
under	O
the	O
metallothionein	O
promoter	O
led	O
to	O
increases	O
in	O
mRNA	O
and	O
surface	O
expression	O
of	O
ICAM	B-Protein
-	I-Protein
I	I-Protein
.	O

The	O
response	O
of	O
LFA	B-Protein
-	I-Protein
3	I-Protein
to	O
TaxI	B-Protein
induction	O
was	O
,	O
on	O
the	O
other	O
hand	O
,	O
relatively	O
slow	O
and	O
weak	O
,	O
and	O
might	O
be	O
indirect	O
.	O

Transactivation	O
of	O
the	O
ICAM	B-Protein
-	I-Protein
I	I-Protein
promoter	O
by	O
TaxI	B-Protein
was	O
further	O
shown	O
by	O
co	O
-	O
transfection	O
of	O
a	O
CAT	B-Protein
reporter	O
construct	O
with	O
the	O
ICAM	B-Protein
-	I-Protein
I	I-Protein
promoter	O
and	O
a	O
plasmid	O
expressing	O
TaxI	B-Protein
.	O

The	O
mechanism	O
of	O
down	O
-	O
regulation	O
of	O
ICAM	B-Protein
-	I-Protein
I	I-Protein
or	O
LFA	O
-	O
I	O
in	O
4	O
ATL	O
cell	O
lines	O
was	O
next	O
examined	O
.	O

ICAM	B-Protein
-	I-Protein
I	I-Protein
mRNA	O
was	O
quite	O
low	O
in	O
MT	O
-	O
I	O
,	O
but	O
no	O
genomic	O
changes	O
were	O
found	O
.	O

The	O
CAT	B-Protein
reporter	O
with	O
the	O
ICAM	B-Protein
-	I-Protein
I	I-Protein
promoter	O
was	O
inactive	O
in	O
MT	O
-	O
I	O
.	O

Finally	O
,	O
combined	O
treatment	O
of	O
MT	O
-	O
I	O
with	O
5	O
-	O
azacytidine	O
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
induced	O
re	O
-	O
expression	O
of	O
ICAM	B-Protein
-	I-Protein
I	I-Protein
.	O

Collectively	O
,	O
(	O
a	O
)	O
transcriptional	O
factor	O
(	O
s	O
)	O
necessary	O
for	O
expression	O
of	O
ICAM	B-Protein
-	I-Protein
I	I-Protein
gene	O
may	O
be	O
repressed	O
in	O
MT	O
-	O
I	O
through	O
DNA	O
methylation	O
.	O

Three	O
other	O
ATL	O
cell	O
lines	O
(	O
TL	O
-	O
OmI	O
,	O
H582	O
,	O
HuT102	O
)	O
were	O
found	O
to	O
have	O
little	O
mRNA	O
for	O
the	O
LFA	B-Protein
-	I-Protein
I	I-Protein
beta	I-Protein
chain	I-Protein
(	O
CD18	B-Protein
)	O
.	O

H582	O
and	O
HuT102	O
were	O
also	O
negative	O
for	O
the	O
LFA	B-Protein
-	I-Protein
I	I-Protein
alpha	I-Protein
chain	I-Protein
(	O
CDIIa	B-Protein
)	O
mRNA	O
.	O

No	O
genomic	O
changes	O
were	O
found	O
,	O
and	O
a	O
CAT	B-Protein
reporter	O
gene	O
with	O
the	O
CD18	B-Protein
promoter	O
was	O
inactive	O
in	O
the	O
3	O
of	O
them	O
,	O
again	O
suggesting	O
lack	O
of	O
(	O
a	O
)	O
transcriptional	O
factor	O
(	O
s	O
)	O
necessary	O
for	O
CD18	B-Protein
expression	O
.	O

Growth	O
regulation	O
and	O
cellular	O
changes	O
during	O
differentiation	O
of	O
human	O
prostatic	O
cancer	O
LNCaP	O
cells	O
as	O
induced	O
by	O
T	O
lymphocyte	O
-	O
conditioned	O
medium	O
.	O

Human	O
prostatic	O
epithelial	O
cells	O
from	O
an	O
androgen	O
-	O
dependent	O
LNCaP	O
cell	O
line	O
were	O
examined	O
in	O
response	O
to	O
conditioned	O
medium	O
(	O
CM	O
)	O
derived	O
from	O
phytohemagglutinin	B-Protein
(	O
PHA	B-Protein
)	O
-	O
stimulated	O
lymphocytes	O
.	O

Addition	O
of	O
CM	O
caused	O
a	O
greater	O
than	O
70	O
%	O
reduction	O
of	O
cell	O
proliferation	O
by	O
cell	O
counting	O
and	O
cell	O
cycle	O
.	O

These	O
cells	O
showed	O
G1	O
phase	O
arrest	O
and	O
the	O
clonogenicity	O
was	O
reduced	O
.	O

The	O
growth	O
-	O
modulating	O
effect	O
was	O
dose	O
-	O
dependent	O
and	O
not	O
due	O
to	O
cell	O
lysis	O
or	O
apoptosis	O
.	O

The	O
binding	O
of	O
androgen	O
to	O
androgen	O
receptor	O
on	O
these	O
cells	O
showed	O
approximately	O
50	O
%	O
reduction	O
,	O
underlining	O
a	O
proliferation	O
reduction	O
mechanism	O
.	O

The	O
prostate	B-Protein
-	I-Protein
specific	I-Protein
antigen	I-Protein
(	O
PSA	B-Protein
)	O
was	O
downregulated	O
to	O
approximately	O
75	O
%	O
during	O
the	O
process	O
.	O

Cell	O
morphology	O
showed	O
dendritic	O
processes	O
extending	O
from	O
cytoplasm	O
and	O
other	O
neuroendocrine	O
cell	O
characteristics	O
.	O

The	O
expression	O
of	O
several	O
cytoskeleton	O
and	O
intracellular	O
proteins	O
increased	O
as	O
determined	O
by	O
immunostaining	O
on	O
slides	O
and	O
by	O
ELISA	O
procedures	O
.	O

These	O
included	O
vimentin	B-Protein
,	O
correlating	O
to	O
cell	O
shape	O
changes	O
,	O
cytokeratins	O
8	O
and	O
18	O
,	O
associated	O
with	O
differentiated	O
cell	O
types	O
of	O
prostate	O
epithelia	O
,	O
and	O
neuron	B-Protein
-	I-Protein
specific	I-Protein
enolase	I-Protein
and	O
serotonin	O
,	O
associated	O
with	O
neuroendocrine	O
cells	O
.	O

From	O
these	O
cellular	O
changes	O
,	O
we	O
can	O
infer	O
that	O
the	O
cell	O
growth	O
was	O
modulated	O
along	O
with	O
induction	O
of	O
terminal	O
differentiation	O
.	O

Activated	O
T	O
cells	O
were	O
demonstrated	O
to	O
be	O
important	O
in	O
providing	O
the	O
modulating	O
activity	O
.	O

This	O
growth	O
modulator	O
was	O
semipurified	O
and	O
had	O
an	O
estimated	O
molecular	O
weight	O
13	O
,	O
000	O
to	O
24	O
,	O
000	O
Da	O
.	O

The	O
activity	O
was	O
determined	O
to	O
be	O
distinct	O
from	O
TGF	O
,	O
TNF	O
,	O
and	O
some	O
commonly	O
known	O
lymphokines	O
.	O

The	O
interaction	O
between	O
lymphoid	O
and	O
prostatic	O
cells	O
in	O
growth	O
and	O
development	O
is	O
described	O
.	O

The	O
Ah	B-Protein
receptor	I-Protein
recognizes	O
DNA	O
binding	O
sites	O
for	O
the	O
B	B-Protein
cell	I-Protein
transcription	I-Protein
factor	I-Protein
,	O
BSAP	B-Protein
:	O
a	O
possible	O
mechanism	O
for	O
dioxin	O
-	O
mediated	O
alteration	O
of	O
CD19	B-Protein
gene	O
expression	O
in	O
human	O
B	O
lymphocytes	O
.	O

2	O
,	O
3	O
,	O
7	O
,	O
8	O
-	O
tetrachlorodibenzo	O
-	O
p	O
-	O
dioxin	O
(	O
TCDD	O
)	O
inhibits	O
murine	O
and	O
human	O
B	O
lymphocyte	O
immunoglobulin	O
production	O
through	O
an	O
unknown	O
mechanism	O
.	O

This	O
study	O
investigated	O
the	O
effect	O
of	O
TCDD	O
on	O
expression	O
of	O
the	O
CD19	B-Protein
gene	O
in	O
a	O
human	O
B	O
lymphocyte	O
cell	O
line	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
TCDD	O
treatment	O
decreased	O
steady	O
state	O
levels	O
of	O
CD19	B-Protein
mRNA	O
by	O
67	O
%	O
in	O
the	O
IM	O
-	O
9	O
cell	O
line	O
.	O

Using	O
a	O
gel	O
mobility	O
shift	O
assay	O
,	O
we	O
identified	O
a	O
DNA	O
-	O
binding	O
complex	O
in	O
IM	O
-	O
9	O
nuclear	O
extracts	O
that	O
by	O
several	O
criteria	O
appears	O
to	O
be	O
the	O
Ah	B-Protein
receptor	I-Protein
.	O

In	O
addition	O
,	O
the	O
Ah	B-Protein
receptor	I-Protein
complex	O
recognized	O
a	O
DNA	O
binding	O
site	O
for	O
B	B-Protein
cell	I-Protein
lineage	I-Protein
-	I-Protein
specific	I-Protein
activator	I-Protein
protein	I-Protein
(	O
BSAP	B-Protein
)	O
in	O
the	O
promoter	O
region	O
of	O
the	O
human	O
CD19	B-Protein
gene	O
which	O
is	O
similar	O
to	O
the	O
consensus	O
Ah	B-Protein
receptor	I-Protein
DNA	O
binding	O
site	O
.	O

These	O
results	O
suggest	O
that	O
the	O
AhR	B-Protein
could	O
interfere	O
with	O
BSAP	B-Protein
-	O
stimulated	O
CD19	B-Protein
gene	O
transcription	O
by	O
competition	O
for	O
a	O
common	O
DNA	O
binding	O
site	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
induces	O
the	O
tyrosine	O
phosphorylation	O
of	O
tyk2	B-Protein
and	O
Jak1	B-Protein
and	O
the	O
differential	O
assembly	O
of	O
STAT1	B-Protein
alpha	I-Protein
and	O
STAT3	B-Protein
complexes	O
in	O
human	O
T	O
cells	O
and	O
monocytes	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
affects	O
monocytes	O
and	O
T	O
cells	O
by	O
driving	O
the	O
progression	O
of	O
immune	O
responsiveness	O
such	O
that	O
Th2	O
lymphocyte	O
-	O
mediated	O
effects	O
predominate	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
in	O
monocytes	O
and	O
T	O
cells	O
IL	B-Protein
-	I-Protein
10	I-Protein
stimulates	O
tyrosine	O
phosphorylation	O
of	O
the	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
,	O
STAT1	B-Protein
alpha	I-Protein
and	O
STAT3	B-Protein
,	O
in	O
a	O
differential	O
manner	O
such	O
that	O
the	O
relative	O
formation	O
of	O
homo	O
-	O
and	O
heterodimers	O
varies	O
between	O
the	O
two	O
cell	O
types	O
.	O

Moreover	O
,	O
monocytes	O
express	O
a	O
novel	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
stimulated	O
STAT	O
protein	O
with	O
an	O
M	O
(	O
r	O
)	O
of	O
70	O
kDa	O
that	O
is	O
recognized	O
by	O
the	O
anti	O
-	O
STAT3	B-Protein
Ab	O
but	O
is	O
not	O
observed	O
in	O
T	O
cells	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
treatment	O
of	O
both	O
T	O
cells	O
and	O
monocytes	O
results	O
in	O
the	O
ligand	O
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
tyk2	B-Protein
and	O
Jak1	B-Protein
,	O
but	O
not	O
Jak2	B-Protein
or	O
Jak3	B-Protein
.	O

Selective	O
modulation	O
of	O
immune	O
responsiveness	O
by	O
IL	B-Protein
-	I-Protein
10	I-Protein
in	O
cells	O
such	O
as	O
monocytes	O
and	O
T	O
cells	O
may	O
result	O
in	O
part	O
from	O
the	O
differential	O
activation	O
of	O
STAT	O
protein	O
pairs	O
.	O

Interleukin	B-Protein
2	I-Protein
signaling	O
involves	O
the	O
phosphorylation	O
of	O
Stat	O
proteins	O
.	O

One	O
of	O
the	O
most	O
important	O
cytokines	O
involved	O
in	O
immune	O
response	O
regulation	O
is	O
interleukin	B-Protein
2	I-Protein
(	O
IL	B-Protein
-	I-Protein
2	I-Protein
)	O
,	O
a	O
potent	O
activator	O
of	O
the	O
proliferation	O
and	O
function	O
of	O
T	O
lymphocytes	O
and	O
natural	O
killer	O
cells	O
.	O

The	O
mechanisms	O
by	O
which	O
the	O
effects	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
are	O
propagated	O
within	O
cells	O
are	O
not	O
understood	O
.	O

While	O
the	O
binding	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
to	O
its	O
receptor	O
was	O
recently	O
shown	O
to	O
lead	O
to	O
the	O
activation	O
of	O
two	O
kinases	O
,	O
Jak	B-Protein
-	I-Protein
1	I-Protein
and	O
Jak	B-Protein
-	I-Protein
3	I-Protein
,	O
subsequent	O
steps	O
in	O
the	O
signaling	O
pathway	O
to	O
the	O
nucleus	O
that	O
lead	O
to	O
the	O
activation	O
of	O
specific	O
genes	O
had	O
not	O
been	O
characterized	O
.	O

Since	O
many	O
cytokines	O
that	O
activate	O
Jak	O
kinases	O
also	O
lead	O
to	O
the	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
members	O
of	O
the	O
Stat	O
family	O
of	O
transcription	O
factors	O
,	O
the	O
ability	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
to	O
trigger	O
Stat	O
phosphorylation	O
was	O
examined	O
.	O

Exposure	O
of	O
activated	O
human	O
T	O
lymphocytes	O
or	O
of	O
a	O
natural	O
killer	O
cell	O
line	O
(	O
NKL	O
)	O
to	O
IL	B-Protein
-	I-Protein
2	I-Protein
leads	O
to	O
the	O
phosphorylation	O
of	O
Stat1	B-Protein
alpha	I-Protein
,	O
Stat1	B-Protein
beta	I-Protein
,	O
and	O
Stat3	B-Protein
,	O
as	O
well	O
as	O
of	O
two	O
Stat	O
-	O
related	O
proteins	O
,	O
p94	B-Protein
and	O
p95	B-Protein
.	O

p94	B-Protein
and	O
p95	B-Protein
share	O
homology	O
with	O
Stat1	B-Protein
at	O
the	O
phosphorylation	O
site	O
and	O
in	O
the	O
Src	O
homology	O
2	O
(	O
SH2	O
)	O
domain	O
,	O
but	O
otherwise	O
are	O
immunologically	O
distinct	O
from	O
Stat1	B-Protein
.	O

These	O
Stat	O
proteins	O
were	O
found	O
to	O
translocate	O
to	O
the	O
nucleus	O
and	O
to	O
bind	O
to	O
a	O
specific	O
DNA	O
sequence	O
.	O

These	O
findings	O
suggest	O
a	O
mechanism	O
by	O
which	O
IL	B-Protein
-	I-Protein
2	I-Protein
binding	O
to	O
its	O
receptor	O
may	O
activate	O
specific	O
genes	O
involved	O
in	O
immune	O
cell	O
function	O
.	O

Direct	O
demonstration	O
of	O
NFATp	B-Protein
dephosphorylation	O
and	O
nuclear	O
localization	O
in	O
activated	O
HT	O
-	O
2	O
cells	O
using	O
a	O
specific	O
NFATp	B-Protein
polyclonal	O
antibody	O
.	O

Nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
regulates	O
transcription	O
of	O
a	O
number	O
of	O
cytokine	O
genes	O
,	O
and	O
NFAT	O
DNA	O
binding	O
activity	O
is	O
stimulated	O
following	O
T	O
cell	O
activation	O
.	O

Several	O
lines	O
of	O
evidence	O
have	O
suggested	O
that	O
NFAT	O
is	O
a	O
substrate	O
for	O
calcineurin	O
,	O
a	O
serine	O
/	O
threonine	O
phosphatase	O
.	O

Using	O
a	O
polyclonal	O
antibody	O
to	O
murine	O
NFATp	B-Protein
,	O
Western	O
blot	O
analysis	O
of	O
various	O
mouse	O
tissues	O
demonstrated	O
that	O
the	O
110	O
-	O
130	O
-	O
kDa	O
NFATp	B-Protein
protein	O
was	O
highly	O
expressed	O
in	O
thymus	O
and	O
spleen	O
.	O

Treatment	O
of	O
immunoprecipitated	O
NFATp	B-Protein
from	O
untreated	O
HT	O
-	O
2	O
cells	O
with	O
calcineurin	O
resulted	O
in	O
the	O
dephosphorylation	O
of	O
NFATp	B-Protein
,	O
demonstrating	O
that	O
NFATp	B-Protein
is	O
an	O
in	O
vitro	O
substrate	O
for	O
calcineurin	O
.	O

NFATp	B-Protein
immunoprecipitated	O
from	O
32P	O
-	O
labeled	O
HT	O
-	O
2	O
cells	O
migrated	O
as	O
an	O
approximately	O
120	O
-	O
kDa	O
protein	O
that	O
was	O
localized	O
to	O
the	O
cytosol	O
of	O
the	O
cells	O
.	O

Treatment	O
of	O
the	O
cells	O
with	O
ionomycin	O
resulted	O
in	O
a	O
decrease	O
in	O
the	O
molecular	O
weight	O
of	O
NFATp	B-Protein
and	O
a	O
loss	O
of	O
32P	O
,	O
consistent	O
with	O
NFATp	B-Protein
dephosphorylation	O
.	O

The	O
dephosphorylation	O
of	O
NFATp	B-Protein
was	O
accompanied	O
by	O
localization	O
of	O
the	O
protein	O
to	O
the	O
nuclear	O
fraction	O
.	O

Both	O
of	O
these	O
events	O
were	O
blocked	O
by	O
preincubation	O
of	O
the	O
cells	O
with	O
FK506	O
,	O
a	O
calcineurin	O
inhibitor	O
,	O
consistent	O
with	O
the	O
hypothesis	O
that	O
NFATp	B-Protein
is	O
a	O
calcineurin	O
substrate	O
in	O
cells	O
.	O

Temperature	O
-	O
induced	O
down	O
-	O
regulation	O
of	O
the	O
glucocorticoid	B-Protein
receptor	I-Protein
in	O
peripheral	O
blood	O
mononuclear	O
leucocyte	O
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
.	O

OBJECTIVE	O
:	O
Activation	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
is	O
of	O
vital	O
importance	O
during	O
critical	O
illness	O
.	O

We	O
have	O
studied	O
the	O
adaptive	O
mechanisms	O
which	O
occur	O
at	O
the	O
level	O
of	O
the	O
glucocorticoid	B-Protein
receptor	I-Protein
in	O
glucocorticoid	O
target	O
tissues	O
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
.	O

DESIGN	O
:	O
The	O
effects	O
of	O
hypercortisolaemia	O
,	O
hyperthermia	O
and	O
cellular	O
composition	O
on	O
number	O
of	O
glucocorticoid	B-Protein
receptors	I-Protein
per	O
cell	O
and	O
their	O
affinity	O
were	O
evaluated	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
in	O
peripheral	O
blood	O
mononuclear	O
leucocytes	O
of	O
control	O
subjects	O
and	O
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
.	O

SUBJECTS	O
:	O
Fifteen	O
patients	O
(	O
age	O
25	O
-	O
79	O
)	O
with	O
sepsis	O
or	O
septic	O
shock	O
who	O
were	O
admitted	O
to	O
an	O
intensive	O
care	O
unit	O
were	O
studied	O
.	O

The	O
control	O
group	O
consisted	O
of	O
24	O
healthy	O
laboratory	O
employees	O
.	O

MEASUREMENTS	O
:	O
The	O
binding	O
capacity	O
and	O
affinity	O
of	O
the	O
glucocorticoid	B-Protein
receptors	I-Protein
were	O
measured	O
and	O
compared	O
to	O
clinical	O
data	O
and	O
the	O
plasma	O
cortisol	O
concentrations	O
.	O

RESULTS	O
:	O
Hypercortisolaemia	O
,	O
in	O
vitro	O
,	O
resulted	O
in	O
a	O
decreased	O
affinity	O
and	O
a	O
decreased	O
binding	O
capacity	O
of	O
the	O
glucocorticoid	B-Protein
receptor	I-Protein
.	O

In	O
vitro	O
,	O
hyperthermia	O
as	O
well	O
as	O
variations	O
in	O
the	O
cellular	O
composition	O
did	O
not	O
influence	O
the	O
glucocorticoid	B-Protein
receptor	I-Protein
.	O

In	O
vivo	O
,	O
there	O
was	O
no	O
change	O
in	O
the	O
number	O
of	O
receptors	O
per	O
cell	O
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
as	O
compared	O
to	O
healthy	O
controls	O
.	O

However	O
,	O
a	O
decreased	O
affinity	O
of	O
the	O
glucocorticoid	B-Protein
receptor	I-Protein
was	O
observed	O
.	O

There	O
was	O
a	O
weak	O
but	O
significant	O
negative	O
correlation	O
between	O
body	O
temperature	O
and	O
the	O
number	O
of	O
glucocorticoid	B-Protein
receptors	I-Protein
in	O
the	O
patient	O
group	O
.	O

There	O
was	O
no	O
relation	O
between	O
circulating	O
cortisol	O
concentrations	O
and	O
glucocorticoid	B-Protein
receptor	I-Protein
affinity	O
and	O
number	O
.	O

CONCLUSIONS	O
:	O
There	O
is	O
no	O
obvious	O
regulation	O
of	O
the	O
number	O
of	O
glucocorticoid	B-Protein
receptors	I-Protein
by	O
plasma	O
cortisol	O
concentrations	O
in	O
vivo	O
.	O

The	O
decreased	O
affinity	O
of	O
the	O
glucocorticoid	B-Protein
receptor	I-Protein
together	O
with	O
the	O
negative	O
correlation	O
between	O
hyperthermia	O
and	O
the	O
number	O
of	O
glucocorticoid	B-Protein
receptors	I-Protein
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
suggest	O
that	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
activation	O
during	O
critical	O
illness	O
is	O
accompanied	O
by	O
peripheral	O
adaptation	O
in	O
glucocorticoid	B-Protein
receptor	I-Protein
number	O
and	O
affinity	O
.	O

Evidence	O
for	O
normal	O
vitamin	B-Protein
D	I-Protein
receptor	I-Protein
messenger	O
ribonucleic	O
acid	O
and	O
genotype	O
in	O
absorptive	O
hypercalciuria	O
.	O

Absorptive	O
hypercalciuria	O
(	O
a	O
stone	O
-	O
forming	O
condition	O
)	O
is	O
characterized	O
by	O
gut	O
hyperabsorption	O
of	O
calcium	O
,	O
hypercalciuria	O
,	O
and	O
reduced	O
bone	O
density	O
.	O

Inasmuch	O
as	O
these	O
features	O
implicate	O
enhanced	O
calcitriol	O
action	O
in	O
gut	O
and	O
bone	O
,	O
we	O
analyzed	O
the	O
vitamin	B-Protein
D	I-Protein
receptor	I-Protein
(	O
VDR	B-Protein
)	O
gene	O
to	O
ascertain	O
whether	O
an	O
abnormality	O
of	O
this	O
gene	O
marks	O
patients	O
with	O
intestinal	O
hyperabsorption	O
of	O
calcium	O
.	O

We	O
have	O
compared	O
the	O
frequency	O
of	O
a	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
Bsm	O
I	O
)	O
associated	O
with	O
different	O
alleles	O
of	O
the	O
VDR	B-Protein
gene	O
in	O
a	O
group	O
of	O
33	O
well	O
characterized	O
absorptive	O
hypercalciuric	O
patients	O
and	O
a	O
group	O
of	O
36	O
normal	O
race	O
-	O
and	O
age	O
-	O
matched	O
control	O
subjects	O
.	O

There	O
was	O
no	O
difference	O
between	O
the	O
distribution	O
of	O
the	O
VDR	B-Protein
alleles	O
in	O
the	O
patient	O
population	O
when	O
compared	O
with	O
the	O
normal	O
population	O
.	O

The	O
coding	O
region	O
of	O
VDR	B-Protein
messenger	O
RNA	O
was	O
also	O
normal	O
,	O
as	O
determined	O
by	O
both	O
DNA	O
sequence	O
analysis	O
and	O
chemical	O
mismatch	O
cleavage	O
analysis	O
of	O
copy	O
DNA	O
from	O
11	O
index	O
absorptive	O
hypercalciuric	O
patients	O
.	O

On	O
the	O
basis	O
of	O
these	O
results	O
,	O
we	O
propose	O
that	O
the	O
enhanced	O
intestinal	O
calcium	O
absorption	O
invariably	O
seen	O
in	O
absorptive	O
hypercalciuria	O
and	O
attendant	O
symptoms	O
of	O
this	O
disorder	O
are	O
not	O
attributable	O
to	O
mutations	O
of	O
the	O
VDR	B-Protein
and	O
are	O
not	O
linked	O
to	O
a	O
common	O
VDR	B-Protein
genotype	O
.	O

The	O
DNA	O
-	O
binding	O
properties	O
of	O
two	O
heat	O
shock	O
factors	O
,	O
HSF1	B-Protein
and	O
HSF3	B-Protein
,	O
are	O
induced	O
in	O
the	O
avian	O
erythroblast	O
cell	O
line	O
HD6	O
.	O

Avian	O
cells	O
express	O
three	O
heat	O
shock	O
transcription	O
factor	O
(	O
HSF	O
)	O
genes	O
corresponding	O
to	O
a	O
novel	O
factor	O
,	O
HSF3	B-Protein
,	O
and	O
homologs	O
of	O
mouse	O
and	O
human	O
HSF1	B-Protein
and	O
HSF2	B-Protein
.	O

Analysis	O
of	O
the	O
biochemical	O
and	O
cell	O
biological	O
properties	O
of	O
these	O
HSFs	O
reveals	O
that	O
HSF3	B-Protein
has	O
properties	O
in	O
common	O
with	O
both	O
HSF1	B-Protein
and	O
HSF2	B-Protein
and	O
yet	O
has	O
features	O
which	O
are	O
distinct	O
from	O
both	O
.	O

HSF3	B-Protein
is	O
constitutively	O
expressed	O
in	O
the	O
erythroblast	O
cell	O
line	O
HD6	O
,	O
the	O
lymphoblast	O
cell	O
line	O
MSB	O
,	O
and	O
embryo	O
fibroblasts	O
,	O
and	O
yet	O
its	O
DNA	O
-	O
binding	O
activity	O
is	O
induced	O
only	O
upon	O
exposure	O
of	O
HD6	O
cells	O
to	O
heat	O
shock	O
.	O

Acquisition	O
of	O
HSF3	B-Protein
DNA	O
-	O
binding	O
activity	O
in	O
HD6	O
cells	O
is	O
accompanied	O
by	O
oligomerization	O
from	O
a	O
non	O
-	O
DNA	O
-	O
binding	O
dimer	O
to	O
a	O
DNA	O
-	O
binding	O
trimer	O
,	O
whereas	O
the	O
effect	O
of	O
heat	O
shock	O
on	O
HSF1	B-Protein
is	O
oligomerization	O
of	O
an	O
inert	O
monomer	O
to	O
a	O
DNA	O
-	O
binding	O
trimer	O
.	O

Induction	O
of	O
HSF3	B-Protein
DNA	O
-	O
binding	O
activity	O
is	O
delayed	O
compared	O
with	O
that	O
of	O
HSF1	B-Protein
.	O

As	O
occurs	O
for	O
HSF1	B-Protein
,	O
heat	O
shock	O
leads	O
to	O
the	O
translocation	O
of	O
HSF3	B-Protein
to	O
the	O
nucleus	O
.	O

HSF	O
exhibits	O
the	O
properties	O
of	O
a	O
transcriptional	O
activator	O
,	O
as	O
judged	O
from	O
the	O
stimulatory	O
activity	O
of	O
transiently	O
overexpressed	O
HSF3	B-Protein
measured	O
by	O
using	O
a	O
heat	O
shock	O
element	O
-	O
containing	O
reporter	O
construct	O
and	O
as	O
independently	O
assayed	O
by	O
the	O
activity	O
of	O
a	O
chimeric	O
GAL4	B-Protein
-	O
HSF3	B-Protein
protein	O
on	O
a	O
GAL4	B-Protein
reporter	O
construct	O
.	O

These	O
results	O
reveal	O
that	O
HSF3	B-Protein
is	O
negatively	O
regulated	O
in	O
avian	O
cells	O
and	O
acquires	O
DNA	O
-	O
binding	O
activity	O
in	O
certain	O
cells	O
upon	O
heat	O
shock	O
.	O

A	O
central	O
role	O
for	O
a	O
single	O
c	B-Protein
-	I-Protein
Myb	I-Protein
binding	O
site	O
in	O
a	O
thymic	O
locus	O
control	O
region	O
.	O

Locus	O
control	O
regions	O
(	O
LCRs	O
)	O
are	O
powerful	O
assemblies	O
of	O
cis	O
elements	O
that	O
organize	O
the	O
actions	O
of	O
cell	O
-	O
type	O
-	O
specific	O
trans	O
-	O
acting	O
factors	O
.	O

A	O
2	O
.	O
3	O
-	O
kb	O
LCR	O
in	O
the	O
human	O
adenosine	B-Protein
deaminase	I-Protein
(	O
ADA	B-Protein
)	O
gene	O
first	O
intron	O
,	O
which	O
controls	O
expression	O
in	O
thymocytes	O
,	O
is	O
composed	O
of	O
a	O
200	O
-	O
bp	O
enhancer	O
domain	O
and	O
extended	O
flanking	O
sequences	O
that	O
facilitate	O
activation	O
from	O
within	O
chromatin	O
.	O

Prior	O
analyses	O
have	O
demonstrated	O
that	O
the	O
enhancer	O
contains	O
a	O
28	O
-	O
bp	O
core	O
region	O
and	O
local	O
adjacent	O
augmentative	O
cis	O
elements	O
.	O

We	O
now	O
show	O
that	O
the	O
core	O
contains	O
a	O
single	O
critical	O
c	B-Protein
-	I-Protein
Myb	I-Protein
binding	O
site	O
.	O

In	O
both	O
transiently	O
cotransfected	O
human	O
cells	O
and	O
stable	O
chromatin	O
-	O
integrated	O
yeast	O
cells	O
,	O
c	B-Protein
-	I-Protein
Myb	I-Protein
strongly	O
transactivated	O
reporter	O
constructs	O
that	O
contained	O
polymerized	O
core	O
sequences	O
.	O

c	B-Protein
-	I-Protein
Myb	I-Protein
protein	O
was	O
strongly	O
evident	O
in	O
T	O
lymphoblasts	O
in	O
which	O
the	O
enhancer	O
was	O
active	O
and	O
was	O
localized	O
within	O
discrete	O
nuclear	O
structures	O
.	O

Fetal	O
murine	O
thymus	O
exhibited	O
a	O
striking	O
concordance	O
of	O
endogenous	O
c	B-Protein
-	I-Protein
myb	I-Protein
expression	O
with	O
that	O
of	O
mouse	O
ADA	B-Protein
and	O
human	O
ADA	B-Protein
LCR	O
-	O
directed	O
transgene	O
expression	O
.	O

Point	O
mutation	O
of	O
the	O
c	B-Protein
-	I-Protein
Myb	I-Protein
site	O
within	O
the	O
intact	O
2	O
.	O
3	O
-	O
kb	O
LCR	O
severely	O
attenuated	O
enhancer	O
activity	O
in	O
transfections	O
and	O
LCR	O
activity	O
in	O
transgenic	O
thymocytes	O
.	O

Within	O
the	O
context	O
of	O
a	O
complex	O
enhancer	O
and	O
LCR	O
,	O
c	B-Protein
-	I-Protein
Myb	I-Protein
can	O
act	O
as	O
an	O
organizer	O
of	O
thymocyte	O
-	O
specific	O
gene	O
expression	O
via	O
a	O
single	O
binding	O
site	O
.	O

PU	B-Protein
.	I-Protein
1	I-Protein
(	O
Spi	B-Protein
-	I-Protein
1	I-Protein
)	O
and	O
C	B-Protein
/	I-Protein
EBP	I-Protein
alpha	I-Protein
regulate	O
expression	O
of	O
the	O
granulocyte	B-Protein
-	I-Protein
macrophage	I-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	I-Protein
receptor	I-Protein
alpha	I-Protein
gene	O
.	O

Growth	O
factor	O
receptors	O
play	O
an	O
important	O
role	O
in	O
hematopoiesis	O
.	O

In	O
order	O
to	O
further	O
understand	O
the	O
mechanisms	O
directing	O
the	O
expression	O
of	O
these	O
key	O
regulators	O
of	O
hematopoiesis	O
,	O
we	O
initiated	O
a	O
study	O
investigating	O
the	O
transcription	O
factors	O
activating	O
the	O
expression	O
of	O
the	O
granulocyte	B-Protein
-	I-Protein
macrophage	I-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	I-Protein
(	I-Protein
GM	I-Protein
-	I-Protein
CSF	I-Protein
)	I-Protein
receptor	I-Protein
alpha	I-Protein
gene	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
the	O
human	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
receptor	I-Protein
alpha	I-Protein
promoter	O
directs	O
reporter	O
gene	O
activity	O
in	O
a	O
tissue	O
-	O
specific	O
fashion	O
in	O
myelomonocytic	O
cells	O
,	O
which	O
correlates	O
with	O
its	O
expression	O
pattern	O
as	O
analyzed	O
by	O
reverse	O
transcription	O
PCR	O
.	O

The	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
receptor	I-Protein
alpha	I-Protein
promoter	O
contains	O
an	O
important	O
functional	O
site	O
between	O
positions	O
-	O
53	O
and	O
-	O
41	O
as	O
identified	O
by	O
deletion	O
analysis	O
of	O
reporter	O
constructs	O
.	O

We	O
show	O
that	O
the	O
myeloid	O
and	O
B	O
cell	O
transcription	O
factor	O
PU	B-Protein
.	I-Protein
1	I-Protein
binds	O
specifically	O
to	O
this	O
site	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
a	O
CCAAT	O
site	O
located	O
upstream	O
of	O
the	O
PU	B-Protein
.	I-Protein
1	I-Protein
site	O
between	O
positions	O
-	O
70	O
and	O
-	O
54	O
is	O
involved	O
in	O
positive	O
-	O
negative	O
regulation	O
of	O
the	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
receptor	I-Protein
alpha	I-Protein
promoter	O
activity	O
.	O

C	B-Protein
/	I-Protein
EBP	I-Protein
alpha	I-Protein
is	O
the	O
major	O
CCAAT	O
/	O
enhancer	O
-	O
binding	O
protein	O
(	O
C	O
/	O
EBP	O
)	O
form	O
binding	O
to	O
this	O
site	O
in	O
nuclear	O
extracts	O
of	O
U937	O
cells	O
.	O

Point	O
mutations	O
of	O
either	O
the	O
PU	B-Protein
.	I-Protein
1	I-Protein
site	O
or	O
the	O
C	O
/	O
EBP	O
site	O
that	O
abolish	O
the	O
binding	O
of	O
the	O
respective	O
factors	O
result	O
in	O
a	O
significant	O
decrease	O
of	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
receptor	I-Protein
alpha	I-Protein
promoter	O
activity	O
in	O
myelomonocytic	O
cells	O
only	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
in	O
myeloid	O
and	O
B	O
cell	O
extracts	O
,	O
PU	B-Protein
.	I-Protein
1	I-Protein
forms	O
a	O
novel	O
,	O
specific	O
,	O
more	O
slowly	O
migrating	O
complex	O
(	O
PU	O
-	O
SF	O
)	O
when	O
binding	O
the	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
receptor	I-Protein
alpha	I-Protein
promoter	O
PU	B-Protein
.	I-Protein
1	I-Protein
site	O
.	O

This	O
is	O
the	O
first	O
demonstration	O
of	O
a	O
specific	O
interaction	O
with	O
PU	B-Protein
.	I-Protein
1	I-Protein
on	O
a	O
myeloid	O
PU	B-Protein
.	I-Protein
1	I-Protein
binding	O
site	O
.	O

The	O
novel	O
complex	O
is	O
distinct	O
from	O
that	O
described	O
previously	O
as	O
binding	O
to	O
B	O
cell	O
enhancer	O
sites	O
and	O
can	O
be	O
formed	O
by	O
addition	O
of	O
PU	B-Protein
.	I-Protein
1	I-Protein
to	O
extracts	O
from	O
certain	O
nonmyeloid	O
cell	O
types	O
which	O
do	O
not	O
express	O
PU	B-Protein
.	I-Protein
1	I-Protein
,	O
including	O
T	O
cells	O
and	O
epithelial	O
cells	O
,	O
but	O
not	O
from	O
erythroid	O
cells	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
the	O
PU	O
-	O
SF	O
complex	O
binds	O
to	O
PU	B-Protein
.	I-Protein
1	I-Protein
sites	O
found	O
on	O
a	O
number	O
of	O
myeloid	O
promoters	O
,	O
and	O
its	O
formation	O
requires	O
an	O
intact	O
PU	B-Protein
.	I-Protein
1	I-Protein
site	O
adjacent	O
to	O
a	O
single	O
-	O
stranded	O
region	O
.	O

Expression	O
of	O
PU	B-Protein
.	I-Protein
1	I-Protein
in	O
nonmyeloid	O
cells	O
can	O
activate	O
the	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
receptor	I-Protein
alpha	I-Protein
promoter	O
.	O

Deletion	O
of	O
the	O
amino	O
-	O
terminal	O
region	O
of	O
PU	B-Protein
.	I-Protein
1	I-Protein
results	O
in	O
a	O
failure	O
to	O
form	O
the	O
PU	O
-	O
SF	O
complex	O
and	O
in	O
a	O
concomitant	O
loss	O
of	O
transactivation	O
,	O
suggesting	O
that	O
formation	O
of	O
the	O
PU	O
-	O
SF	O
complex	O
is	O
of	O
functional	O
importance	O
for	O
the	O
activity	O
of	O
the	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
receptor	I-Protein
alpha	I-Protein
promoter	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
C	B-Protein
/	I-Protein
EBP	I-Protein
alpha	I-Protein
can	O
also	O
active	O
the	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
receptor	I-Protein
alpha	I-Protein
promoter	O
in	O
nonmyeloid	O
cells	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Expression	O
of	O
the	O
nucleoside	B-Protein
diphosphate	I-Protein
kinase	I-Protein
in	O
human	O
skin	O
cancers	O
:	O
an	O
immunohistochemical	O
study	O
.	O

Expression	O
of	O
nucleoside	B-Protein
diphosphate	I-Protein
(	I-Protein
NDP	I-Protein
)	I-Protein
kinase	I-Protein
,	O
which	O
is	O
homologous	O
to	O
the	O
nm23	B-Protein
gene	O
product	O
in	O
a	O
variety	O
of	O
species	O
,	O
has	O
been	O
found	O
to	O
be	O
inversely	O
associated	O
with	O
metastatic	O
potential	O
.	O

However	O
,	O
the	O
relationship	O
remains	O
controversial	O
according	O
to	O
the	O
tumor	O
cell	O
types	O
and	O
experimental	O
system	O
,	O
with	O
conflicting	O
results	O
from	O
different	O
research	O
groups	O
.	O

In	O
order	O
to	O
determine	O
whether	O
NDP	B-Protein
kinase	I-Protein
expression	O
serves	O
as	O
a	O
marker	O
for	O
metastatic	O
potential	O
in	O
human	O
skin	O
cancer	O
,	O
we	O
assessed	O
the	O
levels	O
of	O
NDP	B-Protein
kinase	I-Protein
expression	O
in	O
9	O
keratoacanthomas	O
(	O
KAs	O
)	O
,	O
26	O
squamous	O
cell	O
carcinomas	O
(	O
SCCs	O
)	O
,	O
and	O
25	O
basal	O
cell	O
carcinomas	O
(	O
BCCs	O
)	O
using	O
immunohistochemistry	O
.	O

The	O
expression	O
of	O
NDP	B-Protein
kinase	I-Protein
was	O
intense	O
in	O
KA	O
and	O
SCC	O
compared	O
with	O
BCC	O
.	O

However	O
,	O
the	O
difference	O
of	O
NDP	B-Protein
kinase	I-Protein
expression	O
between	O
KA	O
and	O
SCC	O
was	O
not	O
statistically	O
significant	O
.	O

And	O
there	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
NDP	B-Protein
kinase	I-Protein
expression	O
between	O
SCC	O
with	O
metastasis	O
and	O
SCC	O
without	O
metastasis	O
.	O

Our	O
results	O
contradict	O
the	O
hypothesis	O
concerning	O
the	O
possible	O
role	O
of	O
nm23	B-Protein
gene	O
as	O
a	O
metastatic	O
suppressor	O
gene	O
in	O
human	O
skin	O
cancer	O
.	O

The	O
mechanism	O
of	O
overexpression	O
in	O
various	O
tumor	O
cell	O
types	O
and	O
its	O
biological	O
significance	O
in	O
cutaneous	O
carcinogenesis	O
remain	O
to	O
be	O
determined	O
.	O

Cloning	O
a	O
cDNA	O
from	O
human	O
NK	O
/	O
T	O
cells	O
which	O
codes	O
for	O
a	O
protein	O
with	O
high	O
proline	O
content	O
.	O

A	O
cDNA	O
clone	O
,	O
B4	B-Protein
-	I-Protein
2	I-Protein
,	O
was	O
isolated	O
from	O
a	O
natural	O
killer	O
(	O
NK	O
)	O
minus	O
T	O
cell	O
subtractive	O
library	O
.	O

The	O
B4	B-Protein
-	I-Protein
2	I-Protein
clone	O
coded	O
for	O
an	O
mRNA	O
of	O
2061	O
bp	O
in	O
length	O
.	O

It	O
encodes	O
a	O
deduced	O
327	O
aa	O
protein	O
with	O
a	O
calculated	O
molecular	O
mass	O
of	O
35	O
.	O
2	O
kDa	O
.	O

Searching	O
of	O
B4	B-Protein
-	I-Protein
2	I-Protein
DNA	O
and	O
protein	O
sequences	O
against	O
various	O
databases	O
revealed	O
no	O
high	O
homology	O
to	O
other	O
sequences	O
.	O

However	O
,	O
B4	B-Protein
-	I-Protein
2	I-Protein
has	O
an	O
unusually	O
high	O
proline	O
content	O
(	O
13	O
%	O
)	O
,	O
contains	O
a	O
putative	O
nuclear	O
targeting	O
sequence	O
,	O
and	O
has	O
several	O
SPXX	O
motifs	O
which	O
are	O
frequently	O
found	O
in	O
gene	O
regulatory	O
proteins	O
.	O

One	O
of	O
the	O
stretches	O
of	O
prolines	O
in	O
B4	B-Protein
-	I-Protein
2	I-Protein
closely	O
resembles	O
the	O
ligand	O
for	O
proteins	O
with	O
SH3	O
domains	O
.	O

Northern	O
hybridization	O
data	O
showed	O
that	O
B4	B-Protein
-	I-Protein
2	I-Protein
is	O
not	O
a	O
lymphoid	O
specific	O
gene	O
and	O
is	O
expressed	O
in	O
a	O
hepatoma	O
cell	O
line	O
and	O
also	O
weakly	O
transcribed	O
or	O
absent	O
in	O
a	O
variety	O
of	O
other	O
cells	O
.	O

A	O
polyclonal	O
antiserum	O
raised	O
against	O
recombinant	O
B4	B-Protein
-	I-Protein
2	I-Protein
recognizes	O
a	O
32	O
-	O
34	O
kDa	O
protein	O
in	O
lymphocytes	O
.	O

The	O
human	O
TCF	B-Protein
-	I-Protein
1	I-Protein
gene	O
encodes	O
a	O
nuclear	O
DNA	O
-	O
binding	O
protein	O
uniquely	O
expressed	O
in	O
normal	O
and	O
neoplastic	O
T	O
-	O
lineage	O
lymphocytes	O
.	O

The	O
TCF	B-Protein
-	I-Protein
1	I-Protein
gene	O
encodes	O
a	O
putative	O
transcription	O
factor	O
with	O
affinity	O
for	O
a	O
sequence	O
motif	O
occurring	O
in	O
a	O
number	O
of	O
T	O
-	O
cell	O
enhancers	O
.	O

TCF	B-Protein
-	I-Protein
1	I-Protein
mRNA	O
was	O
originally	O
found	O
to	O
be	O
expressed	O
in	O
a	O
T	O
cell	O
-	O
specific	O
fashion	O
within	O
a	O
set	O
of	O
human	O
and	O
mouse	O
cell	O
lines	O
.	O

In	O
contrast	O
,	O
expression	O
reportedly	O
occurs	O
in	O
multiple	O
nonlymphoid	O
tissues	O
during	O
murine	O
embryogenesis	O
.	O

We	O
have	O
now	O
raised	O
a	O
monoclonal	O
antibody	O
to	O
document	O
expression	O
and	O
biochemistry	O
of	O
the	O
human	O
TCF	B-Protein
-	I-Protein
1	I-Protein
protein	O
.	O

As	O
expected	O
,	O
the	O
TCF	B-Protein
-	I-Protein
1	I-Protein
protein	O
was	O
detectable	O
only	O
in	O
cell	O
lines	O
of	O
T	O
lineage	O
.	O

Its	O
expression	O
was	O
always	O
restricted	O
to	O
the	O
nucleus	O
.	O

Immunohistochemistry	O
on	O
a	O
panel	O
of	O
human	O
tissues	O
revealed	O
that	O
the	O
TCF	B-Protein
-	I-Protein
1	I-Protein
protein	O
was	O
found	O
exclusively	O
in	O
thymocytes	O
and	O
in	O
CD3	O
+	O
T	O
cells	O
in	O
peripheral	O
lymphoid	O
tissues	O
.	O

Western	O
blotting	O
yielded	O
a	O
set	O
of	O
bands	O
ranging	O
from	O
25	O
kD	O
to	O
55	O
kD	O
,	O
resulting	O
from	O
extensive	O
alternative	O
splicing	O
.	O

The	O
TCF	B-Protein
-	I-Protein
1	I-Protein
protein	O
was	O
detectable	O
in	O
all	O
samples	O
of	O
a	O
set	O
of	O
22	O
T	O
-	O
cell	O
malignancies	O
of	O
various	O
stages	O
of	O
maturation	O
,	O
but	O
was	O
absent	O
from	O
a	O
large	O
number	O
of	O
other	O
hematologic	O
neoplasms	O
.	O

These	O
observations	O
imply	O
a	O
T	O
cell	O
-	O
specific	O
function	O
for	O
TCF	B-Protein
-	I-Protein
1	I-Protein
,	O
a	O
notion	O
corroborated	O
by	O
recent	O
observations	O
on	O
Tcf	B-Protein
-	I-Protein
1	I-Protein
knock	O
-	O
out	O
mice	O
.	O

In	O
addition	O
,	O
these	O
results	O
indicate	O
that	O
nuclear	O
TCF	B-Protein
-	I-Protein
1	I-Protein
expression	O
can	O
serve	O
as	O
a	O
pan	O
-	O
T	O
-	O
lineage	O
marker	O
in	O
the	O
diagnosis	O
of	O
lymphoid	O
malignancies	O
.	O

Constitutive	O
overexpression	O
of	O
the	O
L	B-Protein
-	I-Protein
selectin	I-Protein
gene	O
in	O
fresh	O
leukemic	O
cells	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
that	O
can	O
be	O
transactivated	O
by	O
human	O
T	O
-	O
cell	O
lymphotropic	O
virus	O
type	O
1	O
Tax	B-Protein
.	O

L	B-Protein
-	I-Protein
selectin	I-Protein
is	O
an	O
adhesion	O
molecule	O
of	O
the	O
selectin	O
family	O
that	O
mediates	O
the	O
initial	O
step	O
of	O
leukocyte	O
adhesion	O
to	O
vascular	O
endothelium	O
.	O

Upon	O
cellular	O
activation	O
,	O
expression	O
of	O
the	O
L	B-Protein
-	I-Protein
selectin	I-Protein
gene	O
is	O
downregulated	O
at	O
both	O
the	O
protein	O
and	O
mRNA	O
levels	O
.	O

To	O
understand	O
the	O
mechanism	O
of	O
leukemic	O
cell	O
infiltration	O
into	O
organs	O
,	O
we	O
studied	O
the	O
expression	O
and	O
regulation	O
of	O
L	B-Protein
-	I-Protein
selectin	I-Protein
mRNA	O
in	O
fresh	O
leukemic	O
cells	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
(	O
ATL	O
)	O
patients	O
and	O
investigated	O
the	O
response	O
of	O
the	O
L	B-Protein
-	I-Protein
selectin	I-Protein
promoter	O
to	O
human	O
T	O
-	O
cell	O
lymphotropic	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
Tax	B-Protein
,	O
which	O
is	O
a	O
viral	O
transcriptional	O
transactivator	O
.	O

Flow	O
cytometry	O
showed	O
that	O
L	B-Protein
-	I-Protein
selectin	I-Protein
was	O
expressed	O
on	O
fresh	O
ATL	O
cells	O
along	O
with	O
other	O
activation	O
antigens	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
ATL	O
cells	O
overexpressed	O
that	O
L	B-Protein
-	I-Protein
selectin	I-Protein
mRNA	O
and	O
that	O
the	O
level	O
was	O
aberrantly	O
upregulated	O
after	O
PMA	O
stimulation	O
.	O

Studies	O
using	O
in	O
situ	O
hybridization	O
showed	O
expression	O
of	O
the	O
L	B-Protein
-	I-Protein
selectin	I-Protein
mRNA	O
in	O
the	O
infiltrating	O
leukemic	O
cells	O
in	O
the	O
liver	O
of	O
two	O
ATL	O
patients	O
.	O

Intravenous	O
injection	O
of	O
a	O
rat	O
T	O
-	O
cell	O
line	O
that	O
overexpresses	O
L	B-Protein
-	I-Protein
selectin	I-Protein
showed	O
increased	O
organ	O
infiltration	O
.	O

The	O
induction	O
of	O
Tax	B-Protein
expression	O
in	O
JPX9	O
cells	O
resulted	O
in	O
about	O
a	O
twofold	O
increase	O
in	O
the	O
mRNA	O
expression	O
levels	O
compared	O
with	O
the	O
basal	O
level	O
.	O

Chloramphenicol	B-Protein
acetyltransferase	I-Protein
(	O
CAT	B-Protein
)	O
assay	O
after	O
transient	O
cotransfection	O
showed	O
about	O
a	O
fivefold	O
transactivation	O
of	O
the	O
L	B-Protein
-	I-Protein
selectin	I-Protein
promoter	O
by	O
Tax	B-Protein
.	O

The	O
serum	O
level	O
of	O
the	O
shed	O
form	O
of	O
L	B-Protein
-	I-Protein
selectin	I-Protein
was	O
significantly	O
increased	O
in	O
ATL	O
patients	O
(	O
mean	O
+	O
/	O
-	O
SD	O
,	O
4	O
,	O
215	O
.	O
4	O
+	O
/	O
-	O
4	O
,	O
111	O
ng	O
/	O
mL	O
)	O
compared	O
with	O
those	O
of	O
asymptomatic	O
carriers	O
and	O
healthy	O
blood	O
donors	O
(	O
mean	O
+	O
/	O
-	O
SD	O
,	O
1	O
,	O
148	O
.	O
0	O
+	O
/	O
-	O
269	O
.	O
0	O
ng	O
/	O
mL	O
and	O
991	O
.	O
9	O
+	O
/	O
-	O
224	O
ng	O
/	O
mL	O
,	O
respectively	O
)	O
.	O

These	O
results	O
indicated	O
that	O
ATL	O
cells	O
constitutively	O
overexpress	O
the	O
L	B-Protein
-	I-Protein
selectin	I-Protein
gene	O
that	O
can	O
be	O
transactivated	O
by	O
HTLV	O
-	O
1	O
Tax	B-Protein
.	O

The	O
overexpression	O
of	O
L	B-Protein
-	I-Protein
selectin	I-Protein
,	O
as	O
well	O
as	O
of	O
inflammatory	O
cytokines	O
,	O
by	O
ATL	O
cells	O
may	O
provide	O
a	O
basis	O
for	O
ATL	O
cells	O
to	O
attach	O
the	O
vascular	O
endothelium	O
,	O
leading	O
to	O
transmigration	O
and	O
organ	O
infitration	O
.	O

The	O
DNA	O
and	O
steroid	O
binding	O
domains	O
of	O
the	O
glucocorticoid	B-Protein
receptor	I-Protein
are	O
not	O
altered	O
in	O
mononuclear	O
cells	O
of	O
treated	O
CLL	O
patients	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
mutations	O
in	O
the	O
glucocorticoid	B-Protein
receptor	I-Protein
could	O
account	O
for	O
the	O
increasing	O
unresponsiveness	O
of	O
patients	O
with	O
chronic	O
lymphatic	O
leukemia	O
(	O
CLL	O
)	O
to	O
combination	O
chemotherapy	O
.	O

The	O
receptor	O
was	O
tested	O
immunocytochemically	O
,	O
in	O
steroid	O
binding	O
assays	O
,	O
and	O
by	O
a	O
mutation	O
screening	O
(	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
)	O
of	O
the	O
receptor	O
-	O
cDNA	O
.	O

The	O
receptor	O
concentration	O
,	O
as	O
measured	O
by	O
staining	O
and	O
steroid	O
binding	O
test	O
,	O
varied	O
considerably	O
but	O
showed	O
no	O
clear	O
correlation	O
to	O
clinical	O
response	O
.	O

Using	O
a	O
highly	O
sensitive	O
mutation	O
screening	O
assay	O
of	O
the	O
DNA	O
-	O
and	O
the	O
steroid	O
-	O
binding	O
region	O
,	O
none	O
of	O
the	O
treated	O
patients	O
revealed	O
any	O
mutation	O
,	O
suggesting	O
that	O
the	O
glucocorticoid	B-Protein
receptor	I-Protein
in	O
the	O
CLL	O
patients	O
tested	O
is	O
not	O
altered	O
in	O
these	O
domains	O
.	O

In	O
one	O
individual	O
who	O
had	O
not	O
been	O
treated	O
before	O
analysis	O
a	O
silent	O
mutation	O
was	O
found	O
in	O
one	O
receptor	O
allele	O
.	O

The	O
results	O
suggest	O
that	O
mechanisms	O
other	O
than	O
altered	O
ligand	O
or	O
DNA	O
binding	O
of	O
the	O
receptor	O
may	O
be	O
responsible	O
for	O
the	O
lack	O
of	O
response	O
to	O
chemotherapy	O
.	O

This	O
conclusion	O
is	O
discussed	O
in	O
relation	O
to	O
the	O
mechanism	O
of	O
corticoid	O
resistance	O
in	O
mouse	O
and	O
human	O
lymphoma	O
cells	O
in	O
culture	O
.	O

BCL	B-Protein
-	I-Protein
6	I-Protein
and	O
the	O
molecular	O
pathogenesis	O
of	O
B	O
-	O
cell	O
lymphoma	O
.	O

The	O
results	O
presented	O
identify	O
the	O
first	O
genetic	O
lesion	O
associated	O
with	O
DLCL	O
,	O
the	O
most	O
clinically	O
relevant	O
form	O
of	O
NHL	O
.	O

Although	O
no	O
proof	O
yet	O
exists	O
of	O
a	O
role	O
for	O
these	O
lesions	O
in	O
DLCL	O
pathogenesis	O
,	O
the	O
feature	O
of	O
the	O
BCL	B-Protein
-	I-Protein
6	I-Protein
gene	O
product	O
,	O
its	O
specific	O
pattern	O
of	O
expression	O
in	O
B	O
cells	O
,	O
and	O
the	O
clustering	O
of	O
lesions	O
disrupting	O
its	O
regulatory	O
domain	O
strongly	O
suggest	O
that	O
deregulation	O
of	O
BCL	B-Protein
-	I-Protein
6	I-Protein
expression	O
may	O
contribute	O
to	O
DLCL	O
development	O
.	O

A	O
more	O
precise	O
definition	O
of	O
the	O
role	O
of	O
BCL	B-Protein
-	I-Protein
6	I-Protein
in	O
normal	O
and	O
neoplastic	O
B	O
-	O
cell	O
development	O
is	O
the	O
goal	O
of	O
ongoing	O
study	O
of	O
transgenic	O
mice	O
engineered	O
either	O
to	O
express	O
BCL	B-Protein
-	I-Protein
6	I-Protein
under	O
heterologous	O
promoters	O
or	O
lacking	O
BCL	B-Protein
-	I-Protein
6	I-Protein
function	O
due	O
to	O
targeted	O
deletions	O
.	O

In	O
addition	O
to	O
contributing	O
to	O
the	O
understanding	O
of	O
DLCL	O
pathogenesis	O
,	O
the	O
identification	O
of	O
BCL	B-Protein
-	I-Protein
6	I-Protein
lesions	O
may	O
have	O
relevant	O
clinical	O
implications	O
.	O

DLCL	O
represent	O
a	O
heterogeneous	O
group	O
of	O
neoplasms	O
which	O
are	O
treated	O
homogeneously	O
despite	O
the	O
fact	O
that	O
only	O
50	O
%	O
of	O
patients	O
experience	O
long	O
-	O
term	O
disease	O
-	O
free	O
survival	O
(	O
Schneider	O
et	O
al	O
.	O
1990	O
)	O
.	O

The	O
fact	O
that	O
BCL	B-Protein
-	I-Protein
6	I-Protein
rearrangements	O
identify	O
biologically	O
and	O
clinically	O
distinct	O
subsets	O
of	O
DLCL	O
suggests	O
that	O
these	O
lesions	O
may	O
be	O
useful	O
as	O
markers	O
in	O
selection	O
of	O
differential	O
therapeutic	O
strategies	O
based	O
on	O
different	O
risk	O
groups	O
.	O

Furthermore	O
,	O
the	O
BCL	B-Protein
-	I-Protein
6	I-Protein
rearrangements	O
can	O
be	O
used	O
to	O
identify	O
and	O
monitor	O
the	O
malignant	O
clone	O
with	O
sensitive	O
PCR	O
-	O
based	O
techniques	O
.	O

Since	O
clinical	O
remission	O
has	O
been	O
observed	O
in	O
a	O
significant	O
fraction	O
of	O
DLCL	O
cases	O
,	O
these	O
markers	O
may	O
serve	O
as	O
critical	O
tools	O
for	O
sensitive	O
monitoring	O
of	O
minimal	O
residual	O
disease	O
and	O
early	O
diagnosis	O
of	O
relapse	O
(	O
Gribben	O
et	O
al	O
.	O
1993	O
)	O
.	O

Prolactin	B-Protein
and	O
interleukin	O
-	O
2	O
receptors	O
in	O
T	O
lymphocytes	O
signal	O
through	O
a	O
MGF	O
-	O
STAT5	O
-	O
like	O
transcription	O
factor	O
.	O

The	O
cell	O
surface	O
receptors	O
for	O
PRL	B-Protein
and	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
(	O
IL	B-Protein
-	I-Protein
2	I-Protein
)	O
are	O
structurally	O
distinct	O
,	O
but	O
share	O
regulatory	O
tasks	O
in	O
T	O
lymphocytes	O
.	O

They	O
can	O
stimulate	O
proliferation	O
and	O
activate	O
transcription	O
of	O
over	O
-	O
lapping	O
sets	O
of	O
genes	O
of	O
T	O
cells	O
.	O

PRL	O
and	O
IL	O
-	O
2	O
receptor	O
activation	O
are	O
both	O
linked	O
to	O
the	O
Jak	O
/	O
Stat	O
(	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
)	O
pathway	O
.	O

We	O
investigated	O
the	O
ability	O
of	O
PRL	B-Protein
and	O
IL	B-Protein
-	I-Protein
2	I-Protein
to	O
activate	O
Stat	O
proteins	O
in	O
different	O
T	O
cell	O
lines	O
.	O

The	O
DNA	O
binding	O
specificities	O
,	O
the	O
reactivities	O
toward	O
Stat	O
-	O
specific	O
antisera	O
,	O
and	O
the	O
mol	O
wt	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
and	O
PRL	B-Protein
-	O
induced	O
DNA	O
-	O
binding	O
proteins	O
in	O
Nb2	O
and	O
C196	O
T	O
cell	O
lines	O
were	O
investigated	O
.	O

A	O
comparison	O
with	O
the	O
Stat	O
proteins	O
induced	O
by	O
interferon	B-Protein
-	I-Protein
gamma	I-Protein
,	O
PRL	B-Protein
,	O
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
in	O
T47D	O
mammary	O
tumor	O
cells	O
was	O
made	O
.	O

We	O
found	O
that	O
these	O
parameters	O
were	O
indistinguishable	O
for	O
one	O
of	O
the	O
PRL	B-Protein
-	O
and	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
induced	O
factors	O
.	O

A	O
transcription	O
factor	O
closely	O
related	O
to	O
mammary	O
gland	O
factor	O
-	O
Stat5	O
is	O
rapidly	O
activated	O
upon	O
interaction	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
and	O
PRL	B-Protein
with	O
their	O
respective	O
receptors	O
.	O

Activation	O
of	O
a	O
second	O
protein	O
related	O
to	O
Stat1	O
was	O
also	O
observed	O
.	O

Our	O
results	O
emphasize	O
the	O
role	O
of	O
PRL	B-Protein
as	O
a	O
regulator	O
of	O
the	O
immune	O
response	O
and	O
indicate	O
that	O
the	O
Stat	O
factors	O
mammary	O
gland	O
factor	O
-	O
Stat5	O
and	O
Stat1	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
during	O
T	O
cell	O
development	O
.	O

Attenuation	O
of	O
gamma	B-Protein
interferon	I-Protein
-	O
induced	O
tyrosine	O
phosphorylation	O
in	O
mononuclear	O
phagocytes	O
infected	O
with	O
Leishmania	O
donovani	O
:	O
selective	O
inhibition	O
of	O
signaling	O
through	O
Janus	O
kinases	O
and	O
Stat1	O
.	O

The	O
induction	O
of	O
gene	O
transcription	O
in	O
response	O
to	O
gamma	B-Protein
interferon	I-Protein
is	O
impaired	O
in	O
mononuclear	O
phagocytes	O
infected	O
with	O
Leishmania	O
donovani	O
,	O
and	O
the	O
mechanisms	O
involved	O
are	O
not	O
fully	O
understood	O
.	O

The	O
changes	O
in	O
gene	O
expression	O
brought	O
about	O
by	O
gamma	B-Protein
interferon	I-Protein
are	O
thought	O
to	O
involve	O
transient	O
increases	O
in	O
the	O
activities	O
of	O
cellular	O
protein	O
tyrosine	O
kinases	O
,	O
including	O
the	O
Janus	O
kinases	O
Jak1	B-Protein
and	O
Jak2	B-Protein
,	O
leading	O
to	O
tyrosine	O
phosphorylation	O
of	O
the	O
transcription	O
factor	O
Stat1	O
.	O

To	O
investigate	O
the	O
mechanisms	O
accounting	O
for	O
the	O
impaired	O
responses	O
to	O
gamma	B-Protein
interferon	I-Protein
,	O
a	O
model	O
system	O
for	O
examining	O
overall	O
changes	O
in	O
protein	O
tyrosine	O
phosphorylation	O
,	O
activation	O
of	O
Jak1	B-Protein
and	O
Jak2	B-Protein
and	O
phosphorylation	O
of	O
Stat1	O
was	O
developed	O
in	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
-	O
differentiated	O
U	O
-	O
937	O
cells	O
.	O

Analysis	O
of	O
whole	O
-	O
cell	O
lysates	O
by	O
antiphosphotyrosine	O
immunoblotting	O
showed	O
that	O
incubation	O
with	O
gamma	B-Protein
interferon	I-Protein
brought	O
about	O
specific	O
increases	O
in	O
phosphotyrosine	O
labeling	O
of	O
several	O
proteins	O
.	O

Increased	O
labeling	O
of	O
these	O
proteins	O
occurred	O
to	O
similar	O
extents	O
in	O
control	O
cells	O
and	O
in	O
cells	O
that	O
had	O
been	O
infected	O
with	O
L	O
.	O
donovani	O
for	O
16	O
h	O
.	O

Jak1	B-Protein
,	O
Jak2	B-Protein
,	O
and	O
Stat1	O
were	O
immunoprecipitated	O
from	O
control	O
and	O
interferon	O
-	O
treated	O
cells	O
,	O
and	O
tyrosine	O
phosphorylation	O
of	O
these	O
proteins	O
,	O
detected	O
by	O
antiphosphotyrosine	O
immunoblotting	O
was	O
used	O
to	O
measured	O
their	O
activation	O
.	O

Tyrosine	O
phosphorylation	O
of	O
Jak1	B-Protein
,	O
Jak2	B-Protein
,	O
and	O
Stat1	O
increased	O
markedly	O
,	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
in	O
U	O
-	O
937	O
cells	O
incubated	O
with	O
gamma	B-Protein
interferon	I-Protein
.	O

In	O
contrast	O
,	O
in	O
cells	O
infected	O
with	O
L	O
.	O
donovani	O
,	O
tyrosine	O
phosphorylation	O
of	O
Jak1	B-Protein
,	O
Jak2	B-Protein
,	O
and	O
Stat1	O
was	O
markedly	O
impaired	O
.	O

This	O
effect	O
was	O
dependent	O
upon	O
the	O
duration	O
of	O
exposure	O
to	O
L	O
.	O
donovani	O
and	O
was	O
maximal	O
and	O
complete	O
at	O
16	O
h	O
.	O

Results	O
similar	O
to	O
those	O
observed	O
with	O
U	O
-	O
937	O
cells	O
were	O
also	O
obtained	O
with	O
human	O
peripheral	O
blood	O
monocytes	O
.	O

These	O
findings	O
indicate	O
that	O
infection	O
of	O
human	O
mononuclear	O
phagocytes	O
with	O
L	O
.	O
donovani	O
leads	O
to	O
impaired	O
gamma	B-Protein
interferon	I-Protein
-	O
mediated	O
tyrosine	O
phosphorylation	O
and	O
selective	O
effects	O
on	O
the	O
Jak	O
-	O
Stat1	O
pathway	O
.	O

Unresponsiveness	O
to	O
gamma	B-Protein
interferon	I-Protein
for	O
activation	O
of	O
this	O
pathway	O
may	O
explain	O
impaired	O
transcriptional	O
responses	O
in	O
leishmania	O
-	O
infected	O
cells	O
.	O

Nonopsonic	O
phagocytosis	O
of	O
Pseudomonas	O
aeruginosa	O
by	O
macrophages	O
and	O
polymorphonuclear	O
leukocytes	O
requires	O
the	O
presence	O
of	O
the	O
bacterial	O
flagellum	O
.	O

Whereas	O
the	O
mechanism	O
of	O
nonopsonic	O
phagocytosis	O
of	O
Pseudomonas	O
aeruginosa	O
has	O
been	O
described	O
,	O
the	O
bacterial	O
ligands	O
required	O
are	O
poorly	O
understood	O
.	O

To	O
identify	O
the	O
requisite	O
bacterial	O
ligands	O
,	O
studies	O
with	O
isogenic	O
mutants	O
of	O
P	O
.	O
aeruginosa	O
PAK	O
lacking	O
pili	O
,	O
flagella	O
,	O
and	O
the	O
RpoN	B-Protein
sigma	I-Protein
factor	I-Protein
were	O
undertaken	O
.	O

The	O
RpoN	O
mutant	O
,	O
lacking	O
pili	O
,	O
flagella	O
,	O
and	O
nonpilus	O
adhesins	O
,	O
bound	O
poorly	O
and	O
was	O
resistant	O
to	O
ingestion	O
by	O
both	O
macrophages	O
and	O
neutrophils	O
.	O

Pili	O
were	O
not	O
absolutely	O
required	O
for	O
binding	O
or	O
phagocytosis	O
of	O
P	O
.	O
aeruginosa	O
.	O

The	O
presence	O
of	O
a	O
flagellum	O
was	O
not	O
required	O
for	O
binding	O
of	O
P	O
.	O
aeruginosa	O
to	O
macrophages	O
but	O
was	O
critical	O
for	O
the	O
subsequent	O
internalization	O
of	O
the	O
bacterium	O
,	O
suggesting	O
that	O
this	O
factor	O
or	O
a	O
surface	O
ligand	O
associated	O
with	O
its	O
assembly	O
was	O
responsible	O
for	O
stimulation	O
of	O
nonopsonic	O
phagocytosis	O
.	O

Identification	O
of	O
essential	O
GATA	O
and	O
Ets	O
binding	O
motifs	O
within	O
the	O
promoter	O
of	O
the	O
platelet	B-Protein
glycoprotein	I-Protein
Ib	I-Protein
alpha	I-Protein
gene	O
.	O

Platelet	O
glycoprotein	O
(	O
GP	O
)	O
Ib	O
-	O
IX	O
-	O
V	O
is	O
a	O
multisubunit	O
adhesion	O
receptor	O
that	O
supports	O
platelet	O
attachment	O
to	O
thrombogenic	O
surfaces	O
at	O
sites	O
of	O
vascular	O
injury	O
.	O

The	O
congenital	O
absence	O
of	O
the	O
receptor	O
results	O
in	O
a	O
bleeding	O
disorder	O
associated	O
with	O
"	O
giant	O
"	O
platelets	O
,	O
a	O
condition	O
linking	O
the	O
expression	O
of	O
the	O
complex	O
to	O
platelet	O
morphogenesis	O
.	O

To	O
understand	O
better	O
the	O
expression	O
of	O
the	O
GP	O
Ib	O
-	O
IX	O
-	O
V	O
complex	O
,	O
studies	O
were	O
undertaken	O
to	O
define	O
the	O
essential	O
genetic	O
elements	O
supporting	O
the	O
expression	O
of	O
the	O
alpha	O
-	O
subunit	O
of	O
the	O
complex	O
(	O
GP	B-Protein
Ib	I-Protein
alpha	I-Protein
)	O
.	O

GP	B-Protein
Ib	I-Protein
alpha	I-Protein
promoter	O
activity	O
was	O
evaluated	O
by	O
transfection	O
of	O
human	O
erythroleukemia	O
cells	O
with	O
reporter	O
plasmids	O
coding	O
for	O
the	O
enzyme	O
,	O
luciferase	O
.	O

Studies	O
were	O
initiated	O
with	O
a	O
fragment	O
extending	O
2	O
,	O
738	O
nucleotides	O
5	O
'	O
to	O
the	O
transcription	O
start	O
site	O
and	O
lead	O
to	O
the	O
identification	O
of	O
253	O
nucleotides	O
retaining	O
full	O
promoter	O
activity	O
in	O
human	O
erythroleukemia	O
cells	O
.	O

In	O
cells	O
of	O
nonhematopoietic	O
lineage	O
,	O
human	O
endothelial	O
and	O
HeLa	O
cells	O
,	O
the	O
GP	B-Protein
Ib	I-Protein
alpha	I-Protein
promoter	O
activity	O
was	O
no	O
greater	O
than	O
background	O
levels	O
obtained	O
with	O
promoterless	O
constructs	O
.	O

Gel	O
shift	O
assays	O
and	O
site	O
-	O
directed	O
mutagenesis	O
studies	O
defined	O
essential	O
GATA	O
and	O
Ets	O
binding	O
motifs	O
93	O
and	O
150	O
nucleotides	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
,	O
a	O
finding	O
which	O
further	O
substantiates	O
these	O
elements	O
as	O
important	O
determinants	O
of	O
megakaryocytic	O
gene	O
expression	O
.	O

The	O
results	O
define	O
essential	O
cis	O
-	O
acting	O
elements	O
responsible	O
for	O
the	O
expression	O
of	O
GP	B-Protein
Ib	I-Protein
alpha	I-Protein
and	O
provide	O
insights	O
into	O
molecular	O
events	O
coinciding	O
with	O
the	O
release	O
of	O
normal	O
platelets	O
into	O
the	O
bloodstream	O
.	O

Multiple	O
proteins	O
interact	O
with	O
the	O
nuclear	O
inhibitory	O
protein	O
repressor	O
element	O
in	O
the	O
human	O
interleukin	B-Protein
-	I-Protein
3	I-Protein
promoter	O
.	O

T	O
cell	O
expression	O
of	O
interleukin	B-Protein
3	I-Protein
(	O
IL	B-Protein
-	I-Protein
3	I-Protein
)	O
is	O
directed	O
by	O
positive	O
and	O
negative	O
cis	O
-	O
acting	O
DNA	O
elements	O
clustered	O
within	O
300	O
base	O
pairs	O
of	O
the	O
transcriptional	O
start	O
site	O
.	O

A	O
strong	O
repressor	O
element	O
,	O
termed	O
nuclear	O
inhibitory	O
protein	O
(	O
NIP	O
)	O
,	O
was	O
previously	O
mapped	O
to	O
a	O
segment	O
of	O
the	O
IL	B-Protein
-	I-Protein
3	I-Protein
promoter	O
between	O
nucleotides	O
-	O
271	O
and	O
-	O
250	O
.	O

Functional	O
characterization	O
of	O
this	O
element	O
demonstrates	O
that	O
it	O
can	O
mediate	O
repression	O
when	O
linked	O
in	O
cis	O
to	O
a	O
heterologous	O
promoter	O
.	O

DNA	O
binding	O
experiments	O
were	O
carried	O
out	O
to	O
characterize	O
the	O
repressor	O
activity	O
.	O

Using	O
varying	O
conditions	O
,	O
three	O
distinct	O
complexes	O
were	O
shown	O
to	O
interact	O
specifically	O
with	O
the	O
NIP	O
region	O
,	O
although	O
only	O
one	O
correlates	O
with	O
repressor	O
activity	O
.	O

Complex	O
1	O
results	O
from	O
binding	O
of	O
a	O
ubiquitous	O
polypeptide	O
that	O
recognizes	O
the	O
3	O
'	O
portion	O
of	O
this	O
sequence	O
and	O
is	O
not	O
required	O
for	O
repression	O
.	O

Complex	O
2	O
corresponds	O
to	O
binding	O
of	O
transcription	O
factor	O
(	O
upstream	O
stimulatory	O
factor	O
)	O
to	O
an	O
E	O
-	O
box	O
motif	O
in	O
the	O
5	O
'	O
portion	O
of	O
the	O
NIP	O
region	O
.	O

DNA	O
binding	O
specificity	O
of	O
complex	O
3	O
overlaps	O
with	O
that	O
of	O
upstream	O
stimulatory	O
factor	O
but	O
is	O
clearly	O
distinct	O
.	O

To	O
determine	O
which	O
of	O
the	O
latter	O
two	O
complexes	O
represents	O
NIP	O
activity	O
,	O
we	O
incorporated	O
small	O
alterations	O
into	O
the	O
NIP	O
site	O
of	O
an	O
IL	B-Protein
-	I-Protein
3	I-Protein
promoter	O
-	O
linked	O
reporter	O
construct	O
and	O
examined	O
their	O
effects	O
on	O
NIP	O
-	O
mediated	O
repression	O
.	O

Functional	O
specificity	O
for	O
repression	O
matches	O
the	O
DNA	O
binding	O
specificity	O
of	O
complex	O
3	O
;	O
both	O
repressor	O
activity	O
and	O
complex	O
3	O
binding	O
require	O
the	O
consensus	O
sequence	O
CTCACNTNC	O
.	O

The	O
activation	O
of	O
the	O
Jak	O
-	O
STAT	B-Protein
1	I-Protein
signaling	O
pathway	O
by	O
IL	B-Protein
-	I-Protein
5	I-Protein
in	O
eosinophils	O
.	O

The	O
intracellular	O
signal	O
transduction	O
of	O
IL	B-Protein
-	I-Protein
5	I-Protein
in	O
eosinophils	O
is	O
unknown	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
involvement	O
of	O
the	O
newly	O
discovered	O
Jak	O
-	O
STAT	O
pathway	O
in	O
the	O
IL	B-Protein
-	I-Protein
5	I-Protein
signal	O
transduction	O
mechanism	O
.	O

Eosinophils	O
were	O
purified	O
from	O
peripheral	O
blood	O
by	O
discontinuous	O
Percoll	O
gradients	O
and	O
stimulated	O
with	O
IL	B-Protein
-	I-Protein
5	I-Protein
.	O

The	O
involvement	O
of	O
Jak	B-Protein
2	I-Protein
was	O
investigated	O
by	O
immunoprecipitation	O
followed	O
by	O
immunoblotting	O
for	O
tyrosine	O
phosphorylation	O
.	O

The	O
activation	O
of	O
Jak	B-Protein
2	I-Protein
was	O
studied	O
by	O
autophosphorylation	O
of	O
the	O
immunoprecipitated	O
kinase	O
.	O

Jak	B-Protein
2	I-Protein
was	O
tyrosine	O
phosphorylated	O
within	O
1	O
to	O
3	O
min	O
after	O
stimulation	O
of	O
eosinophils	O
with	O
IL	B-Protein
-	I-Protein
5	I-Protein
.	O

Further	O
,	O
the	O
immunoprecipitated	O
Jak	B-Protein
2	I-Protein
obtained	O
from	O
IL	B-Protein
-	I-Protein
5	I-Protein
-	O
stimulated	O
cells	O
underwent	O
autophosphorylation	O
.	O

Jak	B-Protein
2	I-Protein
coprecipitated	O
with	O
the	O
beta	O
-	O
subunit	O
of	O
the	O
IL	O
-	O
5	O
receptor	O
,	O
suggesting	O
a	O
physical	O
association	O
of	O
the	O
kinase	O
with	O
the	O
receptor	O
.	O

The	O
nuclear	O
factor	O
STAT	B-Protein
-	I-Protein
1	I-Protein
(	O
p91	B-Protein
)	O
was	O
investigated	O
by	O
immunoprecipitation	O
followed	O
by	O
immunoblotting	O
for	O
tyrosine	O
phosphorylation	O
.	O

STAT	B-Protein
-	I-Protein
1	I-Protein
was	O
tyrosine	O
phosphorylated	O
within	O
15	O
min	O
of	O
IL	B-Protein
-	I-Protein
5	I-Protein
stimulation	O
.	O

The	O
presence	O
of	O
STAT	B-Protein
-	I-Protein
1	I-Protein
in	O
the	O
nuclear	O
extract	O
was	O
studied	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

IL	B-Protein
-	I-Protein
5	I-Protein
induced	O
two	O
proteins	O
that	O
bound	O
to	O
the	O
gamma	O
-	O
activating	O
sequence	O
.	O

In	O
the	O
presence	O
of	O
an	O
anti	O
-	O
STAT	B-Protein
-	I-Protein
1	I-Protein
Ab	O
,	O
the	O
band	O
was	O
supershifted	O
.	O

Thus	O
,	O
we	O
demonstrated	O
that	O
IL	B-Protein
-	I-Protein
5	I-Protein
activated	O
the	O
Jak	B-Protein
2	I-Protein
-	O
STAT	B-Protein
1	I-Protein
signaling	O
pathway	O
in	O
eosinophils	O
.	O

We	O
speculate	O
that	O
the	O
Jak	B-Protein
2	I-Protein
-	O
STAT	B-Protein
1	I-Protein
pathway	O
may	O
be	O
involved	O
in	O
the	O
activation	O
of	O
IL	B-Protein
-	I-Protein
5	I-Protein
-	O
inducible	O
genes	O
in	O
eosinophils	O
.	O

Constitutively	O
activated	O
Jak	O
-	O
STAT	O
pathway	O
in	O
T	O
cells	O
transformed	O
with	O
HTLV	O
-	O
I	O
.	O

Human	O
T	O
cell	O
lymphotropic	O
virus	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
is	O
the	O
etiological	O
agent	O
for	O
adult	O
T	O
cell	O
leukemia	O
and	O
tropical	O
spastic	O
paraparesis	O
(	O
also	O
termed	O
HTLV	O
-	O
I	O
-	O
associated	O
myelopathy	O
)	O
.	O

HTLV	O
-	O
I	O
-	O
infected	O
peripheral	O
blood	O
T	O
cells	O
exhibit	O
an	O
initial	O
phase	O
of	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
(	O
IL	B-Protein
-	I-Protein
2	I-Protein
)	O
-	O
dependent	O
growth	O
;	O
over	O
time	O
,	O
by	O
an	O
unknown	O
mechanism	O
,	O
the	O
cells	O
become	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
independent	O
.	O

Whereas	O
the	O
Jak	O
kinases	O
Jak1	B-Protein
and	O
Jak3	B-Protein
and	O
the	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
proteins	O
Stat3	B-Protein
and	O
Stat5	B-Protein
are	O
activated	O
in	O
normal	O
T	O
cells	O
in	O
response	O
to	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
this	O
signaling	O
pathway	O
was	O
constitutively	O
activated	O
in	O
HTLV	O
-	O
I	O
-	O
transformed	O
cells	O
.	O

In	O
HTLV	O
-	O
I	O
-	O
infected	O
cord	O
blood	O
lymphocytes	O
,	O
the	O
transition	O
from	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
dependent	O
to	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
independent	O
growth	O
correlated	O
with	O
the	O
acquisition	O
of	O
a	O
constitutively	O
activated	O
Jak	O
-	O
STAT	O
pathway	O
,	O
which	O
suggests	O
that	O
this	O
pathway	O
participates	O
in	O
HTLV	O
-	O
I	O
-	O
mediated	O
T	O
cell	O
transformation	O
.	O

Heterogeneous	O
expression	O
of	O
Epstein	O
-	O
Barr	O
virus	O
latent	O
proteins	O
in	O
endemic	O
Burkitt	O
'	O
s	O
lymphoma	O
.	O

Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
-	O
infected	O
cells	O
may	O
sustain	O
three	O
distinct	O
forms	O
of	O
virus	O
latency	O
.	O

In	O
lymphoblastoid	O
cell	O
lines	O
,	O
six	O
EBV	O
-	O
encoded	O
nuclear	O
antigens	O
(	O
EBNA1	B-Protein
,	O
2	B-Protein
,	O
3A	B-Protein
,	O
3B	B-Protein
,	O
3C	B-Protein
,	O
-	B-Protein
LP	I-Protein
)	O
,	O
three	O
latent	O
membrane	O
proteins	O
(	O
LMP1	B-Protein
,	O
2A	B-Protein
,	O
2B	B-Protein
)	O
,	O
and	O
two	O
nuclear	O
RNAs	O
(	O
EBERs	O
)	O
are	O
expressed	O
.	O

This	O
form	O
of	O
latency	O
,	O
termed	O
latency	O
III	O
,	O
is	O
also	O
encountered	O
in	O
some	O
posttransplant	O
lymphoproliferative	O
disorders	O
.	O

In	O
EBV	O
-	O
positive	O
cases	O
of	O
Hodgkin	O
'	O
s	O
disease	O
,	O
the	O
EBERs	O
,	O
EBNA1	B-Protein
,	O
and	O
the	O
LMPs	O
are	O
expressed	O
(	O
latency	O
II	O
)	O
,	O
whereas	O
in	O
Burkitt	O
'	O
s	O
lymphoma	O
(	O
BL	O
)	O
only	O
the	O
EBERs	O
and	O
EBNA1	B-Protein
have	O
been	O
detected	O
(	O
latency	O
I	O
)	O
.	O

We	O
have	O
studied	O
the	O
expression	O
of	O
EBV	O
proteins	O
in	O
17	O
cases	O
of	O
EBV	O
-	O
positive	O
endemic	O
BL	O
by	O
immunohistology	O
.	O

Expression	O
of	O
LMP1	B-Protein
was	O
seen	O
in	O
variable	O
proportions	O
of	O
tumor	O
cells	O
in	O
two	O
cases	O
and	O
EBNA2	B-Protein
was	O
detected	O
in	O
some	O
tumor	O
cells	O
in	O
three	O
other	O
cases	O
.	O

Also	O
,	O
the	O
BZLF1	B-Protein
trans	I-Protein
-	I-Protein
activator	I-Protein
protein	I-Protein
was	O
expressed	O
in	O
a	O
few	O
tumor	O
cells	O
in	O
6	O
cases	O
,	O
indicating	O
entry	O
into	O
the	O
lytic	O
cycle	O
.	O

A	O
phenotypic	O
drift	O
from	O
latency	O
I	O
to	O
latency	O
III	O
has	O
been	O
observed	O
previously	O
in	O
some	O
BL	O
cell	O
lines	O
.	O

Our	O
results	O
suggest	O
that	O
a	O
similar	O
phenomenon	O
may	O
occur	O
in	O
BL	O
in	O
vivo	O
and	O
indicate	O
that	O
the	O
operational	O
definition	O
of	O
EBV	O
latencies	O
is	O
not	O
easily	O
applied	O
to	O
human	O
tumors	O
.	O

Does	O
activation	O
of	O
the	O
TAL1	B-Protein
gene	O
occur	O
in	O
a	O
majority	O
of	O
patients	O
with	O
T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemia	O
?	O

A	O
pediatric	O
oncology	O
group	O
study	O
.	O

Almost	O
25	O
%	O
of	O
patients	O
with	O
T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemia	O
(	O
T	O
-	O
ALL	O
)	O
have	O
tumor	O
-	O
specific	O
rearrangements	O
of	O
the	O
TAL1	B-Protein
gene	O
.	O

Although	O
TAL1	B-Protein
expression	O
has	O
not	O
been	O
observed	O
in	O
normal	O
lymphocytes	O
,	O
TAL1	B-Protein
gene	O
products	O
are	O
readily	O
detected	O
in	O
leukemic	O
cells	O
that	O
harbor	O
a	O
rearranged	O
TAL1	B-Protein
allele	O
.	O

Hence	O
,	O
it	O
has	O
been	O
proposed	O
that	O
ectopic	O
expression	O
of	O
TAL1	B-Protein
promotes	O
the	O
development	O
of	O
T	O
-	O
ALL	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
TAL1	B-Protein
is	O
expressed	O
in	O
the	O
leukemic	O
cells	O
of	O
most	O
patients	O
with	O
T	O
-	O
ALL	O
,	O
including	O
many	O
that	O
do	O
not	O
display	O
an	O
apparent	O
TAL1	B-Protein
gene	O
alteration	O
.	O

A	O
polymorphic	O
dinucleotide	O
repeat	O
in	O
the	O
transcribed	O
sequences	O
of	O
TAL1	B-Protein
was	O
used	O
to	O
determine	O
the	O
allele	O
specificity	O
of	O
TAL1	B-Protein
transcription	O
in	O
primary	O
T	O
-	O
ALL	O
cells	O
.	O

Monoallelic	O
expression	O
of	O
TAL1	B-Protein
was	O
observed	O
in	O
the	O
leukemic	O
cells	O
of	O
all	O
patients	O
(	O
8	O
of	O
8	O
)	O
bearing	O
a	O
TAL1	B-Protein
gene	O
rearrangement	O
.	O

In	O
the	O
leukemic	O
cells	O
of	O
patients	O
without	O
detectable	O
TAL1	B-Protein
rearrangements	O
,	O
TAL1	B-Protein
transcription	O
occurred	O
in	O
either	O
a	O
monoallelic	O
(	O
3	O
of	O
7	O
patients	O
)	O
or	O
a	O
biallelic	O
(	O
4	O
of	O
7	O
patients	O
)	O
fashion	O
.	O

Thus	O
,	O
TAL1	B-Protein
activation	O
in	O
these	O
patients	O
may	O
result	O
from	O
subtle	O
alterations	O
in	O
cis	O
-	O
acting	O
regulatory	O
sequences	O
(	O
affecting	O
expression	O
of	O
a	O
single	O
TAL1	B-Protein
allele	O
)	O
or	O
changes	O
in	O
trans	O
-	O
acting	O
factors	O
that	O
control	O
TAL1	B-Protein
transcription	O
(	O
affecting	O
expression	O
of	O
both	O
TAL1	B-Protein
alleles	O
)	O
.	O

A	O
conserved	O
motif	O
in	O
the	O
promoters	O
of	O
several	O
cytokines	O
expressed	O
by	O
human	O
Th2	O
-	O
type	O
lymphocytes	O
.	O

We	O
have	O
recently	O
found	O
a	O
novel	O
conserved	O
motif	O
in	O
the	O
promoters	O
of	O
several	O
T	O
-	O
cell	O
-	O
expressed	O
cytokines	O
[	O
human	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
,	O
-	B-Protein
4	I-Protein
,	O
-	B-Protein
5	I-Protein
and	O
-	B-Protein
13	I-Protein
and	O
human	O
and	O
mouse	O
granulocyte	B-Protein
/	I-Protein
macrophage	I-Protein
-	I-Protein
colony	I-Protein
stimulating	I-Protein
factor	I-Protein
(	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
)	O
]	O
.	O

It	O
contains	O
a	O
core	O
sequence	O
CTTGG	O
.	O
.	O
.	O

CCAAG	O
which	O
is	O
present	O
as	O
part	O
of	O
larger	O
palindromic	O
sequences	O
in	O
each	O
gene	O
.	O

This	O
suggest	O
that	O
they	O
may	O
interact	O
with	O
a	O
new	O
family	O
of	O
trans	O
-	O
acting	O
factors	O
.	O

In	O
transfection	O
assays	O
,	O
the	O
human	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
element	O
has	O
a	O
strong	O
positive	O
effect	O
on	O
the	O
expression	O
of	O
a	O
reporter	O
gene	O
by	O
the	O
human	O
T	O
cell	O
line	O
Jurkat	O
J6	O
upon	O
stimulation	O
.	O

In	O
DNA	O
mobility	O
shift	O
assays	O
,	O
this	O
sequence	O
can	O
give	O
either	O
six	O
different	O
specific	O
bands	O
which	O
are	O
competed	O
out	O
by	O
different	O
parts	O
of	O
the	O
sequence	O
or	O
one	O
specific	O
band	O
which	O
is	O
competed	O
out	O
by	O
each	O
of	O
the	O
inverted	O
repeats	O
,	O
depending	O
on	O
the	O
reconstitution	O
conditions	O
.	O

In	O
different	O
genes	O
,	O
the	O
core	O
sequences	O
are	O
separated	O
by	O
integer	O
numbers	O
of	O
helical	O
turns	O
.	O

Considering	O
the	O
strong	O
positive	O
regulatory	O
effect	O
of	O
this	O
element	O
and	O
its	O
presence	O
in	O
several	O
T	O
-	O
cell	O
-	O
expressed	O
cytokine	O
genes	O
,	O
it	O
may	O
be	O
crucial	O
to	O
the	O
coordinated	O
expression	O
of	O
these	O
cytokines	O
in	O
T	O
helper	O
cells	O
.	O

The	O
interleukin	B-Protein
-	I-Protein
5	I-Protein
/	O
receptor	O
interaction	O
activates	O
Lyn	B-Protein
and	O
Jak2	B-Protein
tyrosine	I-Protein
kinases	I-Protein
and	O
propagates	O
signals	O
via	O
the	O
Ras	O
-	O
Raf	B-Protein
-	I-Protein
1	I-Protein
-	O
MAP	O
kinase	O
and	O
the	O
Jak	O
-	O
STAT	O
pathways	O
in	O
eosinophils	O
.	O

We	O
have	O
shown	O
that	O
the	O
interaction	O
of	O
interleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
-	I-Protein
5	I-Protein
with	O
the	O
receptor	O
activates	O
Lyn	B-Protein
tyrosine	I-Protein
kinase	I-Protein
within	O
1	O
min	O
and	O
Jak2	B-Protein
tyrosine	I-Protein
kinase	I-Protein
within	O
1	O
-	O
3	O
min	O
.	O

IL	B-Protein
-	I-Protein
5	I-Protein
also	O
stimulates	O
GTP	O
binding	O
to	O
p21ras	B-Protein
.	O

The	O
signal	O
is	O
subsequently	O
propagated	O
through	O
the	O
activation	O
of	O
Raf	B-Protein
-	I-Protein
1	I-Protein
,	O
MEK	O
,	O
and	O
MAP	O
kinases	O
as	O
shown	O
by	O
their	O
increased	O
autophosphorylation	O
in	O
vitro	O
and	O
phosphorylation	O
in	O
situ	O
.	O

Jak2	B-Protein
kinase	I-Protein
has	O
been	O
shown	O
to	O
phosphorylate	O
STAT	O
nuclear	O
proteins	O
.	O

The	O
activation	O
of	O
STAT	O
nuclear	O
factors	O
was	O
studied	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
using	O
a	O
gamma	O
activation	O
site	O
(	O
GAS	O
)	O
probe	O
.	O

We	O
found	O
that	O
IL	B-Protein
-	I-Protein
5	I-Protein
induces	O
two	O
GAS	O
-	O
binding	O
proteins	O
in	O
eosinophils	O
,	O
one	O
of	O
which	O
is	O
STAT1	O
.	O

We	O
conclude	O
that	O
IL	B-Protein
-	I-Protein
5	I-Protein
induced	O
signals	O
are	O
propagated	O
through	O
two	O
distinct	O
pathways	O
:	O
(	O
1	O
)	O
Lyn	B-Protein
-	O
-	O
>	O
Ras	O
-	O
-	O
>	O
Raf	B-Protein
-	I-Protein
1	I-Protein
-	O
-	O
>	O
MEK	O
-	O
-	O
>	O
MAP	O
kinase	O
and	O
(	O
2	O
)	O
Jak2	B-Protein
-	O
-	O
>	O
STAT1	O
.	O

E1A	B-Protein
gene	O
expression	O
induces	O
susceptibility	O
to	O
killing	O
by	O
NK	O
cells	O
following	O
immortalization	O
but	O
not	O
adenovirus	O
infection	O
of	O
human	O
cells	O
.	O

Adenovirus	O
(	O
Ad	O
)	O
infection	O
and	O
E1A	B-Protein
transfection	O
were	O
used	O
to	O
model	O
changes	O
in	O
susceptibility	O
to	O
NK	O
cell	O
killing	O
caused	O
by	O
transient	O
vs	O
stable	O
E1A	B-Protein
expression	O
in	O
human	O
cells	O
.	O

Only	O
stably	O
transfected	O
target	O
cells	O
exhibited	O
cytolytic	O
susceptibility	O
,	O
despite	O
expression	O
of	O
equivalent	O
levels	O
of	O
E1A	B-Protein
proteins	O
in	O
Ad	O
-	O
infected	O
targets	O
.	O

The	O
inability	O
of	O
E1A	B-Protein
gene	O
products	O
to	O
induce	O
cytolytic	O
susceptibility	O
during	O
infection	O
was	O
not	O
explained	O
by	O
an	O
inhibitory	O
effect	O
of	O
viral	O
infection	O
on	O
otherwise	O
susceptible	O
target	O
cells	O
or	O
by	O
viral	O
gene	O
effects	O
on	O
class	O
I	O
MHC	O
antigen	O
expression	O
on	O
target	O
cells	O
.	O

This	O
differential	O
effect	O
of	O
E1A	B-Protein
expression	O
on	O
the	O
cytolytic	O
phenotypes	O
of	O
infected	O
and	O
stably	O
transfected	O
human	O
cells	O
suggests	O
that	O
human	O
NK	O
cells	O
provide	O
an	O
effective	O
immunologic	O
barrier	O
against	O
the	O
in	O
vivo	O
survival	O
and	O
neoplastic	O
progression	O
of	O
E1A	B-Protein
-	O
immortalized	O
cells	O
that	O
may	O
emerge	O
from	O
the	O
reservoir	O
of	O
persistently	O
infected	O
cells	O
in	O
the	O
human	O
host	O
.	O

RB	B-Protein
and	O
a	O
novel	O
E2F	B-Protein
-	I-Protein
1	I-Protein
binding	O
protein	O
in	O
MHC	O
class	O
II	O
deficient	O
B	O
-	O
cell	O
lines	O
and	O
normal	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
induction	O
of	O
the	O
class	O
IL	O
transactivator	O
CIITA	B-Protein
in	O
class	O
II	O
non	O
-	O
inducible	O
RB	B-Protein
-	O
defective	O
tumor	O
lines	O
.	O

The	O
major	O
histocompatibility	O
(	O
MHC	O
)	O
class	O
II	O
genes	O
encode	O
cell	O
surface	O
proteins	O
that	O
bind	O
antigenic	O
peptide	O
for	O
presentation	O
to	O
T	O
-	O
cells	O
.	O

The	O
class	O
II	O
proteins	O
are	O
expressed	O
constitutively	O
on	O
B	O
-	O
cells	O
and	O
EBV	O
-	O
transformed	O
B	O
-	O
cells	O
,	O
and	O
are	O
inducible	O
by	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
on	O
a	O
wide	O
variety	O
of	O
cell	O
types	O
.	O

Retinoblastoma	B-Protein
protein	I-Protein
(	O
RB	B-Protein
)	O
is	O
a	O
tumor	O
suppressor	O
and	O
functions	O
as	O
a	O
transcriptional	O
repressor	O
by	O
binding	O
and	O
inactivating	O
the	O
transactivator	O
E2F	B-Protein
-	I-Protein
I	I-Protein
.	O

RB	B-Protein
-	O
defective	O
tumor	O
lines	O
are	O
non	O
-	O
inducible	O
for	O
MHC	O
class	O
II	O
by	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
or	O
very	O
weakly	O
inducible	O
,	O
but	O
transfection	O
of	O
2	O
different	O
lines	O
with	O
RB	B-Protein
expression	O
vectors	O
re	O
-	O
establishes	O
or	O
substantially	O
enhances	O
class	O
II	O
inducibility	O
.	O

Therefore	O
,	O
we	O
examined	O
the	O
RB	B-Protein
status	O
of	O
a	O
series	O
of	O
B	O
-	O
cell	O
mutants	O
that	O
are	O
defective	O
in	O
class	O
II	O
expression	O
,	O
generated	O
either	O
in	O
vitro	O
or	O
derived	O
from	O
Bare	O
Lymphocyte	O
Syndrome	O
(	O
BLS	O
)	O
patients	O
.	O

Nuclear	O
matrix	O
-	O
bound	O
RB	B-Protein
was	O
detectable	O
in	O
all	O
cases	O
,	O
indicating	O
that	O
loss	O
of	O
RB	B-Protein
is	O
not	O
responsible	O
for	O
decreased	O
class	O
II	O
expression	O
in	O
these	O
lines	O
.	O

A	O
second	O
E2F	B-Protein
-	I-Protein
I	I-Protein
binding	O
protein	O
,	O
most	O
likely	O
DP	B-Protein
-	I-Protein
I	I-Protein
,	O
was	O
also	O
apparently	O
normal	O
in	O
both	O
class	O
II	O
-	O
positive	O
and	O
-	O
negative	O
B	O
-	O
cell	O
lines	O
.	O

We	O
also	O
examined	O
the	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
induction	O
of	O
CIITA	B-Protein
in	O
RB	B-Protein
-	O
defective	O
lines	O
.	O

CIITA	B-Protein
is	O
a	O
class	O
II	O
gene	O
transactivator	O
known	O
to	O
be	O
defective	O
in	O
one	O
form	O
of	O
BLS	O
and	O
to	O
be	O
required	O
for	O
the	O
induction	O
of	O
MHC	O
class	O
II	O
by	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
.	O

CIITA	B-Protein
mRNA	O
is	O
normally	O
inducible	O
by	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
in	O
class	O
II	O
non	O
-	O
inducible	O
,	O
RB	B-Protein
-	O
defective	O
lines	O
,	O
and	O
in	O
one	O
line	O
,	O
re	O
-	O
expression	O
of	O
RB	B-Protein
has	O
no	O
effect	O
on	O
CIITA	B-Protein
mRNA	O
induction	O
levels	O
.	O

Thus	O
,	O
the	O
block	O
in	O
MHC	O
class	O
II	O
inducibility	O
in	O
RB	B-Protein
-	O
defective	O
cells	O
is	O
not	O
due	O
to	O
a	O
block	O
in	O
CIITA	B-Protein
inducibility	O
.	O

Latent	B-Protein
membrane	I-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
induces	O
cyclin	B-Protein
D2	I-Protein
expression	O
,	O
pRb	B-Protein
hyperphosphorylation	O
,	O
and	O
loss	O
of	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
1	I-Protein
-	O
mediated	O
growth	O
inhibition	O
in	O
EBV	O
-	O
positive	O
B	O
cells	O
.	O

The	O
normal	O
cell	O
cycle	O
is	O
regulated	O
by	O
several	O
molecules	O
,	O
such	O
as	O
the	O
tumor	O
-	O
suppressor	O
protein	O
pRb	B-Protein
,	O
the	O
G1	O
cyclins	O
,	O
the	O
cyclin	O
-	O
dependent	O
kinases	O
,	O
and	O
their	O
inhibitors	O
.	O

These	O
regulators	O
are	O
targeted	O
by	O
negative	O
growth	O
regulatory	O
signals	O
,	O
such	O
as	O
that	O
provided	O
by	O
TGF	O
-	O
beta	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
presence	O
of	O
either	O
wild	O
-	O
type	O
EBV	O
or	O
its	O
transforming	O
latent	B-Protein
membrane	I-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
(	O
LMP	B-Protein
-	I-Protein
1	I-Protein
)	O
results	O
in	O
the	O
loss	O
of	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
1	I-Protein
-	O
mediated	O
growth	O
inhibition	O
in	O
human	O
B	O
cells	O
.	O

Chemical	O
cross	O
-	O
linking	O
with	O
125I	O
-	O
labeled	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
1	I-Protein
showed	O
an	O
essentially	O
normal	O
TGF	O
-	O
beta	O
receptor	O
profile	O
in	O
EBV	O
-	O
positive	O
and	O
EBV	O
-	O
negative	O
Burkitt	O
'	O
s	O
lymphoma	O
cell	O
lines	O
,	O
and	O
these	O
receptors	O
were	O
shown	O
to	O
be	O
functional	O
in	O
transducing	O
signals	O
,	O
as	O
evidenced	O
by	O
the	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
1	I-Protein
-	O
mediated	O
modulation	O
of	O
junB	B-Protein
gene	O
expression	O
.	O

However	O
,	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
1	I-Protein
did	O
not	O
induce	O
dephosphorylation	O
of	O
pRb	B-Protein
in	O
EBV	O
(	O
or	O
LMP	B-Protein
-	I-Protein
1	I-Protein
)	O
-	O
positive	O
cells	O
as	O
opposed	O
to	O
EBV	O
-	O
negative	O
cells	O
,	O
suggesting	O
a	O
dichotomy	O
in	O
the	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
1	I-Protein
signaling	O
pathway	O
leading	O
to	O
separable	O
gene	O
regulatory	O
and	O
growth	O
inhibitory	O
responses	O
.	O

Furthermore	O
,	O
LMP	B-Protein
-	I-Protein
1	I-Protein
was	O
found	O
to	O
induce	O
the	O
expression	O
of	O
cyclin	B-Protein
D2	I-Protein
;	O
normal	O
B	O
cells	O
or	O
EBV	O
-	O
negative	O
Burkitt	O
'	O
s	O
lymphoma	O
cells	O
do	O
not	O
express	O
D	O
-	O
type	O
cyclins	O
.	O

Taken	O
together	O
,	O
these	O
data	O
point	O
to	O
a	O
potential	O
mechanism	O
underlying	O
EBV	O
-	O
mediated	O
B	O
cell	O
transformation	O
whereby	O
constitutive	O
induction	O
of	O
key	O
cell	O
cycle	O
regulators	O
by	O
LMP	B-Protein
-	I-Protein
1	I-Protein
can	O
lead	O
to	O
pRb	B-Protein
hyperphosphorylation	O
and	O
uncontrolled	O
cell	O
proliferation	O
.	O

C	O
/	O
EBP	O
proteins	O
activate	O
transcription	O
from	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeat	O
in	O
macrophages	O
/	O
monocytes	O
.	O

Three	O
binding	O
sites	O
for	O
C	O
/	O
EBP	O
proteins	O
are	O
found	O
in	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
(	O
V	O
.	O
M	O
.	O
Tesmer	O
,	O
A	O
.	O
Rajadhyaksha	O
,	O
J	O
.	O
Babin	O
,	O
and	O
M	O
.	O
Bina	O
,	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
USA	O
90	O
:	O
7298	O
-	O
7302	O
,	O
1993	O
)	O
.	O

We	O
have	O
determined	O
the	O
functional	O
role	O
of	O
C	O
/	O
EBP	O
proteins	O
and	O
C	O
/	O
EBP	O
sites	O
in	O
regulating	O
transcription	O
from	O
the	O
HIV	O
-	O
1	O
LTR	O
in	O
monocytes	O
/	O
macrophages	O
.	O

Inhibition	O
of	O
endogenous	O
C	O
/	O
EBP	O
proteins	O
,	O
using	O
either	O
an	O
excess	O
of	O
C	O
/	O
EBP	O
binding	O
sites	O
or	O
a	O
trans	O
-	O
dominant	O
negative	O
inhibitor	O
,	O
demonstrated	O
that	O
C	O
/	O
EBP	O
proteins	O
are	O
required	O
for	O
basal	O
and	O
activated	O
levels	O
of	O
HIV	O
-	O
1	O
LTR	O
transcription	O
in	O
the	O
promonocytic	O
cell	O
line	O
U937	O
.	O

Northern	O
(	O
RNA	O
)	O
blots	O
and	O
binding	O
assays	O
showed	O
that	O
NF	B-Protein
-	I-Protein
IL6	I-Protein
is	O
the	O
only	O
known	O
C	O
/	O
EBP	O
family	O
member	O
which	O
is	O
increased	O
when	O
U937	O
cells	O
are	O
activated	O
.	O

Mutational	O
analyses	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
showed	O
that	O
one	O
C	O
/	O
EBP	O
site	O
is	O
required	O
for	O
normal	O
LTR	O
transcription	O
both	O
before	O
and	O
after	O
cellular	O
activation	O
and	O
that	O
the	O
two	O
3	O
'	O
C	O
/	O
EBP	O
sites	O
are	O
functionally	O
equivalent	O
.	O

However	O
,	O
transcription	O
from	O
crippled	O
HIV	O
-	O
1	O
LTRs	O
lacking	O
C	O
/	O
EBP	O
sites	O
can	O
still	O
be	O
induced	O
following	O
activation	O
of	O
U937	O
cells	O
.	O

Several	O
models	O
are	O
suggested	O
for	O
how	O
elevated	O
NF	B-Protein
-	I-Protein
IL6	I-Protein
may	O
participate	O
in	O
an	O
autostimulatory	O
loop	O
involving	O
HIV	O
infection	O
,	O
macrophage	O
activation	O
,	O
cytokine	O
expression	O
,	O
and	O
HIV	O
replication	O
.	O

Sp1	B-Protein
functions	O
in	O
a	O
chromatin	O
-	O
dependent	O
manner	O
to	O
augment	O
human	O
alpha	B-Protein
-	I-Protein
globin	I-Protein
promoter	O
activity	O
.	O

The	O
5	O
'	O
flanking	O
region	O
of	O
the	O
human	O
alpha	B-Protein
-	I-Protein
globin	I-Protein
gene	O
is	O
highly	O
G	O
+	O
C	O
rich	O
and	O
contains	O
multiple	O
copies	O
of	O
the	O
consensus	O
sequence	O
for	O
the	O
Sp1	B-Protein
binding	O
site	O
.	O

We	O
investigated	O
the	O
role	O
of	O
this	O
G	O
+	O
C	O
-	O
rich	O
region	O
in	O
augmenting	O
alpha	B-Protein
-	I-Protein
globin	I-Protein
promoter	O
activity	O
in	O
the	O
presence	O
of	O
the	O
far	O
-	O
upstream	O
alpha	B-Protein
-	I-Protein
globin	I-Protein
enhancer	O
,	O
HS	B-Protein
-	I-Protein
40	I-Protein
.	O

We	O
show	O
that	O
in	O
transiently	O
transfected	O
erythroid	O
cells	O
,	O
deletion	O
of	O
the	O
alpha	B-Protein
-	I-Protein
globin	I-Protein
G	O
+	O
C	O
-	O
rich	O
5	O
'	O
flanking	O
region	O
has	O
no	O
effect	O
on	O
alpha	B-Protein
-	I-Protein
globin	I-Protein
promoter	O
activity	O
.	O

However	O
,	O
upon	O
stable	O
integration	O
into	O
chromatin	O
,	O
deletion	O
of	O
this	O
region	O
causes	O
a	O
nearly	O
90	O
%	O
decrease	O
in	O
promoter	O
activity	O
compared	O
with	O
expression	O
from	O
an	O
alpha	B-Protein
-	I-Protein
globin	I-Protein
promoter	O
retaining	O
this	O
region	O
.	O

These	O
results	O
suggest	O
that	O
the	O
alpha	B-Protein
-	I-Protein
globin	I-Protein
G	O
+	O
C	O
-	O
rich	O
5	O
'	O
flanking	O
region	O
augments	O
alpha	B-Protein
-	I-Protein
globin	I-Protein
promoter	O
activity	O
in	O
a	O
chromatin	O
-	O
dependent	O
manner	O
.	O

We	O
further	O
show	O
that	O
this	O
G	O
+	O
C	O
-	O
rich	O
region	O
is	O
required	O
for	O
the	O
activation	O
of	O
alpha	B-Protein
-	I-Protein
globin	I-Protein
gene	O
expression	O
during	O
erythroid	O
differentiation	O
.	O

Finally	O
,	O
we	O
show	O
by	O
both	O
footprint	O
analysis	O
and	O
functional	O
assays	O
that	O
the	O
ability	O
of	O
the	O
G	O
+	O
C	O
-	O
rich	O
region	O
to	O
increase	O
alpha	B-Protein
-	I-Protein
globin	I-Protein
promoter	O
activity	O
from	O
a	O
stably	O
integrated	O
alpha	B-Protein
-	I-Protein
globin	I-Protein
gene	O
is	O
mediated	O
by	O
its	O
multiple	O
binding	O
sites	O
for	O
the	O
transcription	O
factor	O
Sp1	B-Protein
.	O

Interleukin	O
12	O
induces	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
STAT4	B-Protein
in	O
human	O
lymphocytes	O
.	O

Interleukin	O
12	O
(	O
IL	O
-	O
12	O
)	O
is	O
an	O
important	O
immunoregulatory	O
cytokine	O
whose	O
receptor	O
is	O
a	O
member	O
of	O
the	O
hematopoietin	O
receptor	O
superfamily	O
.	O

We	O
have	O
recently	O
demonstrated	O
that	O
stimulation	O
of	O
human	O
T	O
and	O
natural	O
killer	O
cells	O
with	O
IL	O
-	O
12	O
induces	O
tyrosine	O
phosphorylation	O
of	O
the	O
Janus	O
family	O
tyrosine	O
kinase	O
JAK2	B-Protein
and	O
Tyk2	B-Protein
,	O
implicating	O
these	O
kinases	O
in	O
the	O
immediate	O
biochemical	O
response	O
to	O
IL	O
-	O
12	O
.	O

Recently	O
,	O
transcription	O
factors	O
known	O
as	O
STATs	O
(	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
)	O
have	O
been	O
shown	O
to	O
be	O
tyrosine	O
phosphorylated	O
and	O
activated	O
in	O
response	O
to	O
a	O
number	O
of	O
cytokines	O
that	O
bind	O
hematopoietin	O
receptors	O
and	O
activate	O
JAK	O
kinases	O
.	O

In	O
this	O
report	O
we	O
demonstrate	O
that	O
IL	O
-	O
12	O
induces	O
tyrosine	O
phosphorylation	O
of	O
a	O
recently	O
identified	O
STAT	O
family	O
member	O
,	O
STAT4	B-Protein
,	O
and	O
show	O
that	O
STAT4	B-Protein
expression	O
is	O
regulated	O
by	O
T	O
-	O
cell	O
activation	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
IL	O
-	O
12	O
stimulates	O
formation	O
of	O
a	O
DNA	O
-	O
binding	O
complex	O
that	O
recognizes	O
a	O
DNA	O
sequence	O
previously	O
shown	O
to	O
bind	O
STAT	O
proteins	O
and	O
that	O
this	O
complex	O
contains	O
STAT4	B-Protein
.	O

These	O
data	O
,	O
and	O
the	O
recent	O
demonstration	O
of	O
JAK	O
phosphorylation	O
by	O
IL	O
-	O
12	O
,	O
identify	O
a	O
rapid	O
signal	O
-	O
transduction	O
pathway	O
likely	O
to	O
mediate	O
IL	O
-	O
12	O
-	O
induced	O
gene	O
expression	O
.	O

Overexpression	O
of	O
DR	B-Protein
-	I-Protein
nm23	I-Protein
,	O
a	O
protein	O
encoded	O
by	O
a	O
member	O
of	O
the	O
nm23	O
gene	O
family	O
,	O
inhibits	O
granulocyte	O
differentiation	O
and	O
induces	O
apoptosis	O
in	O
32Dc13	O
myeloid	O
cells	O
.	O

Chronic	O
myelogenous	O
leukemia	O
evolves	O
in	O
two	O
clinically	O
distinct	O
stages	O
:	O
a	O
chronic	O
and	O
a	O
blast	O
crisis	O
phase	O
.	O

The	O
molecular	O
changes	O
associated	O
with	O
chronic	O
phase	O
to	O
blast	O
crisis	O
transition	O
are	O
largely	O
unknown	O
.	O

We	O
have	O
identified	O
a	O
cDNA	O
clone	O
,	O
DR	B-Protein
-	I-Protein
nm23	I-Protein
,	O
differentially	O
expressed	O
in	O
a	O
blast	O
-	O
crisis	O
cDNA	O
library	O
,	O
which	O
has	O
approximately	O
70	O
%	O
sequence	O
similarity	O
to	O
the	O
putative	O
metastatic	O
suppressor	O
genes	O
,	O
nm23	B-Protein
-	I-Protein
H1	I-Protein
and	O
nm23	B-Protein
-	I-Protein
H2	I-Protein
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
similarity	O
to	O
the	O
proteins	O
encoded	O
by	O
these	O
two	O
latter	O
genes	O
is	O
approximately	O
65	O
%	O
and	O
includes	O
domains	O
and	O
amino	O
acid	O
residues	O
(	O
the	O
leucine	O
zipper	O
-	O
like	O
and	O
the	O
RGD	O
domain	O
,	O
a	O
serine	O
and	O
a	O
histidine	O
residue	O
in	O
the	O
NH2	O
-	O
and	O
in	O
the	O
COOH	O
-	O
terminal	O
portion	O
of	O
the	O
protein	O
,	O
respectively	O
)	O
postulated	O
to	O
be	O
important	O
for	O
nm23	O
function	O
.	O

DR	B-Protein
-	I-Protein
nm23	I-Protein
mRNA	O
is	O
preferentially	O
expressed	O
at	O
early	O
stages	O
of	O
myeloid	O
differentiation	O
of	O
highly	O
purified	O
CD34	B-Protein
+	O
cells	O
.	O

Its	O
constitutive	O
expression	O
in	O
the	O
myeloid	O
precursor	O
32Dc13	O
cell	O
line	O
,	O
which	O
is	O
growth	O
-	O
factor	O
dependent	O
for	O
both	O
proliferation	O
and	O
differentiation	O
,	O
results	O
in	O
inhibition	O
of	O
granulocytic	O
differentiation	O
induced	O
by	O
granulocyte	B-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	I-Protein
and	O
causes	O
apoptotic	O
cell	O
death	O
.	O

These	O
results	O
are	O
consistent	O
with	O
a	O
role	O
for	O
DR	B-Protein
-	I-Protein
nm23	I-Protein
in	O
normal	O
hematopoiesis	O
and	O
raise	O
the	O
possibility	O
that	O
its	O
overexpression	O
contributes	O
to	O
differentiation	O
arrest	O
,	O
a	O
feature	O
of	O
blastic	O
transformation	O
in	O
chronic	O
myelogenous	O
leukemia	O
.	O

Transcription	O
factors	O
as	O
targets	O
for	O
oxidative	O
signalling	O
during	O
lymphocyte	O
activation	O
.	O

We	O
previously	O
have	O
demonstrated	O
a	O
requirement	O
for	O
oxidative	O
events	O
during	O
cell	O
cycle	O
entry	O
in	O
T	O
lymphocytes	O
and	O
have	O
hypothesised	O
that	O
reactive	O
oxygen	O
species	O
may	O
act	O
as	O
intracellular	O
signalling	O
agents	O
during	O
lymphocyte	O
activation	O
.	O

In	O
the	O
current	O
study	O
,	O
cysteamine	O
,	O
an	O
aminothiol	O
compound	O
with	O
antioxidant	O
activity	O
,	O
has	O
been	O
used	O
to	O
further	O
investigate	O
the	O
role	O
of	O
oxidative	O
signalling	O
during	O
lymphocyte	O
activation	O
.	O

Treatment	O
of	O
normal	O
human	O
peripheral	O
blood	O
lymphocytes	O
with	O
cysteamine	O
in	O
vitro	O
was	O
found	O
to	O
inhibit	O
proliferation	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
with	O
essentially	O
complete	O
inhibition	O
occurring	O
at	O
a	O
dose	O
of	O
400	O
microM	O
.	O

This	O
inhibitory	O
effect	O
was	O
limited	O
to	O
the	O
first	O
2	O
h	O
after	O
mitogenic	O
activation	O
,	O
localizing	O
the	O
time	O
-	O
frame	O
of	O
action	O
of	O
cysteamine	O
to	O
within	O
the	O
commitment	O
period	O
.	O

It	O
therefore	O
was	O
of	O
interest	O
to	O
establish	O
which	O
,	O
if	O
any	O
,	O
commitment	O
events	O
were	O
affected	O
by	O
oxidative	O
signalling	O
during	O
cell	O
cycle	O
entry	O
.	O

Taking	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
gene	O
as	O
a	O
candidate	O
,	O
we	O
examined	O
the	O
effect	O
of	O
cysteamine	O
treatment	O
on	O
early	O
gene	O
expression	O
during	O
lymphocyte	O
activation	O
,	O
and	O
on	O
the	O
activity	O
of	O
transcription	O
factors	O
AP	O
-	O
1	O
,	O
NF	O
-	O
kappa	O
B	O
,	O
NF	O
-	O
AT	O
and	O
Oct1	B-Protein
,	O
whose	O
functions	O
are	O
required	O
for	O
expression	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
mRNA	O
.	O

Cysteamine	O
treatment	O
inhibited	O
both	O
expression	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
mRNA	O
and	O
secretion	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
into	O
the	O
culture	O
medium	O
.	O

The	O
inhibitory	O
effect	O
of	O
cysteamine	O
may	O
be	O
mediated	O
at	O
least	O
in	O
part	O
by	O
an	O
effect	O
on	O
transcription	O
factor	O
function	O
,	O
as	O
the	O
DNA	O
binding	O
activities	O
of	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
extracted	O
from	O
mitogen	O
-	O
stimulated	O
cells	O
were	O
significantly	O
inhibited	O
by	O
cysteamine	O
treatment	O
.	O

Interestingly	O
,	O
Oct1	B-Protein
and	O
NF	O
-	O
AT	O
DNA	O
binding	O
activity	O
were	O
not	O
affected	O
by	O
cysteamine	O
treatment	O
,	O
suggesting	O
that	O
oxidative	O
signalling	O
processes	O
operate	O
in	O
a	O
selective	O
manner	O
.	O

The	O
identification	O
of	O
regulatory	O
proteins	O
,	O
such	O
as	O
transcription	O
factors	O
,	O
as	O
molecular	O
targets	O
for	O
oxidative	O
signalling	O
provides	O
further	O
evidence	O
to	O
implicate	O
oxidative	O
signalling	O
as	O
being	O
intimately	O
involved	O
in	O
the	O
G0	O
to	O
G1	O
phase	O
transition	O
in	O
T	O
lymphocytes	O
.	O

Flutamide	O
in	O
the	O
treatment	O
of	O
hirsutism	O
:	O
long	O
-	O
term	O
clinical	O
effects	O
,	O
endocrine	O
changes	O
,	O
and	O
androgen	B-Protein
receptor	I-Protein
behavior	O
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
long	O
-	O
term	O
effects	O
of	O
treatment	O
with	O
low	O
doses	O
of	O
flutamide	O
on	O
clinical	O
and	O
hormonal	O
parameters	O
,	O
as	O
well	O
as	O
on	O
the	O
androgen	B-Protein
receptor	I-Protein
status	O
,	O
in	O
hirsute	O
women	O
.	O

DESIGN	O
:	O
Eighteen	O
hirsute	O
patients	O
with	O
regular	O
menses	O
were	O
studied	O
basally	O
and	O
during	O
treatment	O
with	O
125	O
mg	O
flutamide	O
,	O
three	O
times	O
per	O
day	O
for	O
12	O
months	O
.	O

Barrier	O
or	O
intrauterine	O
contraception	O
was	O
used	O
during	O
the	O
study	O
in	O
sexually	O
active	O
women	O
.	O

Safety	O
parameters	O
were	O
assessed	O
throughout	O
the	O
study	O
.	O

Hirsutism	O
,	O
graded	O
by	O
the	O
modified	O
Ferriman	O
-	O
Gallwey	O
score	O
,	O
and	O
hormonal	O
parameters	O
were	O
evaluated	O
basally	O
and	O
at	O
4	O
-	O
month	O
intervals	O
during	O
treatment	O
.	O

Gonadotropin	O
-	O
releasing	O
hormone	O
and	O
ACTH	O
stimulation	O
tests	O
were	O
performed	O
before	O
and	O
after	O
3	O
to	O
4	O
months	O
of	O
therapy	O
.	O

In	O
addition	O
,	O
the	O
concentration	O
of	O
androgen	B-Protein
receptors	I-Protein
in	O
mononuclear	O
leukocytes	O
was	O
measured	O
,	O
in	O
both	O
the	O
follicular	O
and	O
luteal	O
phases	O
of	O
the	O
menstrual	O
cycle	O
,	O
basally	O
and	O
after	O
4	O
months	O
of	O
flutamide	O
treatment	O
.	O

RESULTS	O
:	O
Flutamide	O
was	O
well	O
tolerated	O
in	O
all	O
women	O
,	O
with	O
the	O
noticeable	O
exception	O
of	O
one	O
patient	O
who	O
presented	O
increased	O
serum	O
transaminase	O
after	O
8	O
months	O
of	O
therapy	O
.	O

Hirsutism	O
markedly	O
improved	O
in	O
all	O
women	O
during	O
the	O
treatment	O
(	O
Ferriman	O
-	O
Gallwey	O
score	O
after	O
1	O
year	O
:	O
4	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
5	O
versus	O
14	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
9	O
)	O
.	O

A	O
reduction	O
of	O
serum	O
androgens	O
was	O
found	O
,	O
whereas	O
no	O
change	O
was	O
observed	O
in	O
either	O
basal	O
or	O
GnRH	O
-	O
stimulated	O
gonadotropins	O
or	O
in	O
the	O
cortisol	O
and	O
17	O
alpha	O
-	O
hydroxyprogesterone	O
response	O
to	O
ACTH	O
.	O

Cycles	O
remained	O
ovulatory	O
.	O

Before	O
treatment	O
,	O
the	O
number	O
of	O
androgen	B-Protein
receptors	I-Protein
was	O
higher	O
in	O
the	O
luteal	O
than	O
in	O
the	O
follicular	O
phase	O
.	O

This	O
rhythmic	O
differentiation	O
disappeared	O
after	O
the	O
patients	O
had	O
been	O
given	O
the	O
antiandrogen	O
drug	O
.	O

CONCLUSIONS	O
:	O
Flutamide	O
is	O
effective	O
in	O
the	O
treatment	O
of	O
hirsutism	O
but	O
requires	O
constant	O
surveillance	O
of	O
liver	O
function	O
.	O

Androgen	B-Protein
receptor	I-Protein
blockade	O
might	O
be	O
potentiated	O
by	O
a	O
reduction	O
of	O
serum	O
androgens	O
.	O

Flutamide	O
affects	O
androgen	B-Protein
receptor	I-Protein
behavior	O
during	O
the	O
menstrual	O
cycle	O
.	O

The	O
meaning	O
of	O
this	O
finding	O
remains	O
to	O
be	O
elucidated	O
.	O

HIV	O
-	O
1	O
envelope	O
glycoproteins	O
induce	O
activation	O
of	O
activated	O
protein	O
-	O
1	O
in	O
CD4	B-Protein
+	O
T	O
cells	O
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1995	O
Dec	O
1	O
;	O
270	O
(	O
48	O
)	O
:	O
29038	O
]	O

Activation	O
of	O
CD4	B-Protein
positive	O
T	O
cells	O
is	O
a	O
primary	O
requirement	O
for	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
entry	O
,	O
efficient	O
HIV	O
replication	O
,	O
and	O
progression	O
to	O
AIDS	O
,	O
Utilizing	O
CD4	B-Protein
positive	O
T	O
cell	O
lines	O
and	O
purified	O
T	O
cells	O
from	O
normal	O
individuals	O
,	O
we	O
have	O
demonstrated	O
that	O
native	O
envelope	O
glycoproteins	O
of	O
HIV	O
,	O
gp	B-Protein
160	I-Protein
,	O
can	O
induce	O
activation	O
of	O
transcription	O
factor	O
,	O
activated	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
.	O

The	O
stimulatory	O
effects	O
of	O
gp160	B-Protein
are	O
mediated	O
through	O
the	O
CD4	B-Protein
molecule	O
,	O
since	O
treatment	O
of	O
gp160	B-Protein
with	O
soluble	O
CD4	B-Protein
-	O
IgG	O
abrogates	O
its	O
activity	O
,	O
and	O
CD4	B-Protein
negative	O
T	O
cell	O
lines	O
fail	O
to	O
be	O
stimulated	O
with	O
gp160	B-Protein
.	O

Immunoprecipitation	O
of	O
the	O
gp	B-Protein
160	I-Protein
-	O
induced	O
nuclear	O
extracts	O
with	O
polyclonal	O
antibodies	O
to	O
Fos	O
and	O
Jun	O
proteins	O
indicates	O
that	O
AP	O
-	O
1	O
complex	O
is	O
comprised	O
of	O
members	O
of	O
these	O
family	O
of	O
proteins	O
.	O

The	O
gp160	B-Protein
-	O
induced	O
AP	O
-	O
1	O
complex	O
is	O
dependent	O
upon	O
protein	O
tyrosine	O
phosphorylation	O
and	O
is	O
protein	O
synthesis	O
-	O
independent	O
.	O

This	O
stimulation	O
can	O
also	O
be	O
abolished	O
by	O
inhibitors	O
of	O
protein	O
kinase	O
C	O
,	O
but	O
it	O
is	O
unaffected	O
by	O
calcium	O
channel	O
blocker	O
or	O
cyclosporine	O
A	O
.	O

This	O
gp160	B-Protein
treatment	O
adversely	O
affects	O
the	O
functional	O
capabilities	O
of	O
T	O
cells	O
:	O
pre	O
-	O
treatment	O
of	O
CD4	B-Protein
+	O
T	O
cells	O
with	O
gp160	B-Protein
for	O
4	O
h	O
at	O
37	O
degrees	O
C	O
inhibited	O
anti	O
-	O
CD3	O
-	O
induced	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
secretion	O
.	O

Effects	O
similar	O
to	O
gp160	B-Protein
were	O
seen	O
with	O
anti	O
-	O
CD4	B-Protein
mAb	O
.	O

The	O
aberrant	O
activation	O
of	O
AP	O
-	O
1	O
by	O
gp160	B-Protein
in	O
CD4	B-Protein
positive	O
T	O
cells	O
could	O
result	O
in	O
up	O
-	O
regulation	O
of	O
cytokines	O
containing	O
AP	O
-	O
1	O
sites	O
,	O
e	O
.	O
g	O
.	O
interleukin	B-Protein
-	I-Protein
3	I-Protein
and	O
granulocyte	B-Protein
macrophage	I-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	I-Protein
,	O
and	O
concurrently	O
lead	O
to	O
T	O
cell	O
unresponsiveness	O
by	O
inhibiting	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
secretion	O
.	O

Cellular	O
and	O
molecular	O
mechanisms	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
induced	O
by	O
IL	B-Protein
-	I-Protein
2	I-Protein
and	O
IL	O
-	O
12	O
in	O
a	O
human	O
NK	O
cell	O
line	O
.	O

Interferon	B-Protein
-	I-Protein
gamma	I-Protein
(	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
)	O
is	O
an	O
important	O
immunoregulatory	O
protein	O
produced	O
predominantly	O
by	O
T	O
cells	O
and	O
large	O
granular	O
lymphocytes	O
(	O
LGL	O
)	O
in	O
response	O
to	O
different	O
extracellular	O
signals	O
.	O

In	O
particular	O
,	O
two	O
interleukins	O
(	O
ILs	O
)	O
,	O
IL	B-Protein
-	I-Protein
2	I-Protein
and	O
IL	O
-	O
12	O
,	O
have	O
been	O
shown	O
to	O
be	O
potent	O
inducers	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
gene	O
expression	O
in	O
both	O
T	O
cells	O
and	O
LGL	O
.	O

Although	O
it	O
has	O
been	O
reported	O
that	O
there	O
are	O
some	O
T	O
cell	O
lines	O
that	O
produce	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
in	O
response	O
to	O
IL	B-Protein
-	I-Protein
2	I-Protein
and	O
IL	O
-	O
12	O
stimulation	O
,	O
there	O
has	O
as	O
yet	O
been	O
no	O
report	O
of	O
a	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
line	O
that	O
responds	O
in	O
a	O
similar	O
manner	O
.	O

In	O
this	O
report	O
we	O
present	O
evidence	O
that	O
the	O
cell	O
line	O
NK3	O
.	O
3	O
derived	O
from	O
human	O
NK	O
cells	O
,	O
responds	O
to	O
both	O
IL	B-Protein
-	I-Protein
2	I-Protein
and	O
IL	O
-	O
12	O
,	O
as	O
measured	O
by	O
increases	O
in	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
granulocyte	B-Protein
-	I-Protein
macrophage	I-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	I-Protein
(	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
)	O
cytoplasmic	O
mRNA	O
and	O
protein	O
expression	O
.	O

In	O
addition	O
,	O
when	O
used	O
together	O
IL	B-Protein
-	I-Protein
2	I-Protein
and	O
IL	O
-	O
12	O
synergized	O
in	O
the	O
induction	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
and	O
this	O
synergy	O
was	O
attributed	O
to	O
an	O
increased	O
accumulation	O
and	O
stability	O
of	O
the	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
mRNAs	O
.	O

To	O
investigate	O
the	O
signaling	O
pathways	O
involved	O
in	O
the	O
gene	O
induction	O
,	O
five	O
inhibitors	O
,	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
,	O
transforming	B-Protein
growth	I-Protein
factor	I-Protein
-	I-Protein
beta	I-Protein
,	O
cycloheximide	O
,	O
genistein	O
,	O
and	O
staurosporine	O
A	O
,	O
were	O
used	O
in	O
analyzing	O
the	O
effects	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
and	O
IL	O
-	O
12	O
on	O
NK3	O
.	O
3	O
cells	O
.	O

The	O
results	O
suggest	O
that	O
activation	O
of	O
protein	O
kinase	O
C	O
,	O
but	O
not	O
new	O
protein	O
synthesis	O
,	O
is	O
required	O
for	O
IL	B-Protein
-	I-Protein
2	I-Protein
induction	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
cytoplasmic	O
mRNA	O
.	O

In	O
contrast	O
,	O
IL	O
-	O
12	O
induction	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
cytoplasmic	O
mRNA	O
appears	O
to	O
only	O
partially	O
depend	O
on	O
activation	O
of	O
protein	O
kinase	O
C	O
.	O

Furthermore	O
,	O
both	O
transforming	O
growth	O
factor	O
-	O
beta	O
and	O
genistein	O
,	O
a	O
tyrosine	O
kinase	O
inhibitor	O
,	O
could	O
suppress	O
IL	B-Protein
-	I-Protein
2	I-Protein
and	O
IL	O
-	O
12	O
signaling	O
but	O
CsA	O
was	O
generally	O
inactive	O
.	O

It	O
also	O
was	O
observed	O
that	O
suppression	O
of	O
cytokine	O
gene	O
expression	O
by	O
these	O
agents	O
was	O
independent	O
of	O
the	O
inhibition	O
of	O
proliferation	O
.	O

In	O
addition	O
,	O
IL	B-Protein
-	I-Protein
2	I-Protein
but	O
not	O
IL	O
-	O
12	O
induced	O
nuclear	O
factors	O
NF	O
-	O
kappa	O
B	O
and	O
AP1	O
,	O
and	O
regulation	O
of	O
the	O
nuclear	O
levels	O
of	O
these	O
two	O
DNA	O
binding	O
protein	O
complexes	O
is	O
correlated	O
with	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
gene	O
expression	O
.	O

These	O
data	O
indicate	O
that	O
IL	B-Protein
-	I-Protein
2	I-Protein
and	O
IL	O
-	O
12	O
may	O
have	O
distinct	O
signaling	O
pathways	O
leading	O
to	O
the	O
induction	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
gene	O
expression	O
,	O
and	O
that	O
the	O
NK3	O
.	O
3	O
cell	O
line	O
may	O
serve	O
as	O
a	O
novel	O
model	O
for	O
dissecting	O
the	O
biochemical	O
and	O
molecular	O
events	O
involved	O
in	O
these	O
pathways	O
.	O

Expression	O
of	O
erythroid	O
-	O
specific	O
genes	O
in	O
acute	O
megakaryoblastic	O
leukaemia	O
and	O
transient	O
myeloproliferative	O
disorder	O
in	O
Down	O
'	O
s	O
syndrome	O
.	O

Acute	O
megakaryoblastic	O
leukaemia	O
(	O
M7	O
)	O
and	O
transient	O
myeloproliferative	O
disorder	O
in	O
Down	O
'	O
s	O
syndrome	O
(	O
TMD	O
)	O
are	O
characterized	O
by	O
rapid	O
growth	O
of	O
abnormal	O
blast	O
cells	O
which	O
express	O
megakaryocytic	O
markers	O
.	O

To	O
clarify	O
properties	O
of	O
the	O
blast	O
cells	O
in	O
M7	O
and	O
TMD	O
cases	O
,	O
we	O
examined	O
erythroid	O
markers	O
expression	O
in	O
blasts	O
from	O
six	O
cases	O
with	O
M7	O
and	O
seven	O
cases	O
with	O
TMD	O
in	O
this	O
study	O
.	O

Erythroid	O
-	O
specific	O
mRNAs	O
encoding	O
gamma	O
-	O
globin	O
and	O
erythroid	O
delta	B-Protein
-	I-Protein
aminolevulinate	I-Protein
synthase	I-Protein
were	O
found	O
to	O
be	O
expressed	O
in	O
blasts	O
from	O
most	O
of	O
these	O
cases	O
,	O
indicating	O
that	O
majorities	O
of	O
the	O
blasts	O
in	O
M7	O
and	O
TMD	O
cases	O
have	O
erythroid	O
and	O
megakaryocytic	O
phenotypes	O
.	O

We	O
also	O
found	O
that	O
mRNAs	O
encoding	O
GATA	B-Protein
-	I-Protein
1	I-Protein
and	O
GATA	B-Protein
-	I-Protein
2	I-Protein
are	O
expressed	O
in	O
all	O
these	O
cases	O
.	O

These	O
results	O
suggest	O
that	O
M7	O
blasts	O
and	O
TMD	O
blasts	O
correspond	O
to	O
the	O
erythroid	O
/	O
megakaryocytic	O
bipotential	O
progenitor	O
cells	O
.	O

Activation	O
of	O
the	O
HIV	O
-	O
1	O
enhancer	O
by	O
the	O
LEF	B-Protein
-	I-Protein
1	I-Protein
HMG	O
protein	O
on	O
nucleosome	O
-	O
assembled	O
DNA	O
in	O
vitro	O
.	O

Lymphoid	B-Protein
enhancer	I-Protein
-	I-Protein
binding	I-Protein
factor	I-Protein
1	I-Protein
(	O
LEF	B-Protein
-	I-Protein
1	I-Protein
)	O
is	O
a	O
regulatory	O
high	O
mobility	O
group	O
(	O
HMG	O
)	O
protein	O
that	O
activates	O
the	O
T	B-Protein
cell	I-Protein
receptor	I-Protein
alpha	I-Protein
(	O
TCR	B-Protein
alpha	I-Protein
)	O
enhancer	O
in	O
a	O
context	O
-	O
restricted	O
manner	O
in	O
T	O
cells	O
.	O

In	O
this	O
paper	O
we	O
demonstrate	O
that	O
the	O
distal	O
region	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
-	O
1	O
(	O
HIV	O
-	O
1	O
)	O
enhancer	O
,	O
which	O
contains	O
DNA	O
-	O
binding	O
sites	O
for	O
LEF	B-Protein
-	I-Protein
1	I-Protein
and	O
Ets	B-Protein
-	I-Protein
1	I-Protein
,	O
also	O
provides	O
a	O
functional	O
context	O
for	O
activation	O
by	O
LEF	B-Protein
-	I-Protein
1	I-Protein
.	O

First	O
,	O
we	O
show	O
that	O
mutations	O
in	O
the	O
LEF	B-Protein
-	I-Protein
1	I-Protein
-	O
binding	O
site	O
inhibit	O
the	O
activity	O
of	O
multimerized	O
copies	O
of	O
the	O
HIV	O
-	O
1	O
enhancer	O
in	O
Jurkat	O
T	O
cells	O
,	O
and	O
that	O
LEF	B-Protein
-	I-Protein
1	I-Protein
/	O
GAL4	B-Protein
can	O
activate	O
a	O
GAL4	B-Protein
-	O
substituted	O
HIV	O
-	O
1	O
enhancer	O
80	O
-	O
to	O
100	O
-	O
fold	O
in	O
vivo	O
.	O

Second	O
,	O
recombinant	O
LEF	B-Protein
-	I-Protein
1	I-Protein
is	O
shown	O
to	O
activate	O
HIV	O
-	O
1	O
transcription	O
on	O
chromatin	O
-	O
assembled	O
DNA	O
in	O
vitro	O
.	O

By	O
using	O
a	O
nucleosome	O
-	O
assembly	O
system	O
derived	O
from	O
Drosophila	O
embryos	O
,	O
we	O
find	O
that	O
the	O
packaging	O
of	O
DNA	O
into	O
chromatin	O
in	O
vitro	O
strongly	O
represses	O
HIV	O
-	O
1	O
transcription	O
and	O
that	O
repression	O
can	O
be	O
counteracted	O
efficiently	O
by	O
preincubation	O
of	O
the	O
DNA	O
with	O
LEF	B-Protein
-	I-Protein
1	I-Protein
(	O
or	O
LEF	B-Protein
-	I-Protein
1	I-Protein
and	O
Ets	B-Protein
-	I-Protein
1	I-Protein
)	O
supplemented	O
with	O
fractions	O
containing	O
the	O
promoter	O
-	O
binding	O
protein	O
,	O
Sp1	B-Protein
.	O

Addition	O
of	O
TFE	B-Protein
-	I-Protein
3	I-Protein
,	O
which	O
binds	O
to	O
an	O
E	O
-	O
box	O
motif	O
upstream	O
of	O
the	O
LEF	B-Protein
-	I-Protein
1	I-Protein
and	O
Ets	B-Protein
-	I-Protein
1	I-Protein
sites	O
,	O
further	O
augments	O
transcription	O
in	O
this	O
system	O
.	O

Individually	O
or	O
collectively	O
,	O
none	O
of	O
the	O
three	O
enhancer	O
-	O
binding	O
proteins	O
(	O
LEF	B-Protein
-	I-Protein
1	I-Protein
,	O
Ets	B-Protein
-	I-Protein
1	I-Protein
,	O
and	O
TFE	B-Protein
-	I-Protein
3	I-Protein
)	O
could	O
activate	O
transcription	O
in	O
the	O
absence	O
of	O
Sp1	B-Protein
.	O

A	O
truncation	O
mutant	O
of	O
LEF	B-Protein
-	I-Protein
1	I-Protein
(	O
HMG	O
-	O
88	O
)	O
,	O
which	O
contains	O
the	O
HMG	O
box	O
but	O
lacks	O
the	O
trans	O
-	O
activation	O
domain	O
,	O
did	O
not	O
activate	O
transcription	O
from	O
nucleosomal	O
DNA	O
,	O
indicating	O
that	O
bending	O
of	O
DNA	O
by	O
the	O
HMG	O
domain	O
is	O
not	O
sufficient	O
to	O
activate	O
transcription	O
in	O
vitro	O
.	O

We	O
conclude	O
that	O
transcription	O
activation	O
by	O
LEF	B-Protein
-	I-Protein
1	I-Protein
in	O
vitro	O
is	O
a	O
chromatin	O
-	O
dependent	O
process	O
that	O
requires	O
a	O
functional	O
trans	O
-	O
activation	O
domain	O
in	O
addition	O
to	O
the	O
HMG	O
domain	O
.	O

Phosphorylation	O
of	O
the	O
transcription	O
factor	O
NFATp	B-Protein
inhibits	O
its	O
DNA	O
binding	O
activity	O
in	O
cyclosporin	O
A	O
-	O
treated	O
human	O
B	O
and	O
T	O
cells	O
.	O

Cyclosporin	O
A	O
(	O
CsA	O
)	O
exerts	O
its	O
immunosuppressive	O
effect	O
by	O
inhibiting	O
the	O
activity	O
of	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
,	O
thus	O
preventing	O
transcriptional	O
induction	O
of	O
several	O
cytokine	O
genes	O
.	O

This	O
effect	O
is	O
thought	O
to	O
be	O
largely	O
mediated	O
through	O
inactivation	O
of	O
the	O
phosphatase	O
calcineurin	O
,	O
which	O
in	O
turn	O
inhibits	O
translocation	O
of	O
an	O
NFAT	O
component	O
to	O
the	O
nucleus	O
.	O

Here	O
we	O
report	O
that	O
CsA	O
treatment	O
of	O
Raji	O
B	O
and	O
Jurkat	O
T	O
cell	O
lines	O
yields	O
a	O
phosphorylated	O
form	O
of	O
NFATp	B-Protein
that	O
is	O
inhibited	O
in	O
DNA	O
-	O
binding	O
and	O
in	O
its	O
ability	O
to	O
form	O
an	O
NFAT	O
complex	O
with	O
Fos	O
and	O
Jun	O
.	O

Immunoblot	O
analyses	O
and	O
metabolic	O
labeling	O
with	O
[	O
32P	O
]	O
orthophosphate	O
show	O
that	O
CsA	O
alters	O
NFATp	B-Protein
migration	O
on	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
by	O
increasing	O
its	O
phosphorylation	O
level	O
without	O
affecting	O
subcellular	O
distribution	O
.	O

Dephosphorylation	O
by	O
in	O
vitro	O
treatment	O
with	O
calcineurin	O
or	O
alkaline	B-Protein
phosphatase	I-Protein
restores	O
NFATp	B-Protein
DNA	O
binding	O
activity	O
and	O
its	O
ability	O
to	O
reconstitute	O
an	O
NFAT	O
complex	O
with	O
Fos	O
and	O
Jun	O
proteins	O
.	O

These	O
data	O
point	O
to	O
a	O
new	O
mechanism	O
for	O
CsA	O
-	O
sensitive	O
regulation	O
of	O
NFATp	B-Protein
in	O
which	O
dephosphorylation	O
is	O
critical	O
for	O
DNA	O
binding	O
.	O

Disruption	O
of	O
a	O
GATA	O
motif	O
in	O
the	O
Duffy	B-Protein
gene	O
promoter	O
abolishes	O
erythroid	O
gene	O
expression	O
in	O
Duffy	B-Protein
-	O
negative	O
individuals	O
.	O

The	O
mRNA	O
for	O
the	O
Duffy	B-Protein
blood	O
group	O
antigen	O
,	O
the	O
erythrocyte	O
receptor	O
for	O
the	O
Plasmodium	O
vivax	O
malaria	O
parasite	O
,	O
has	O
recently	O
been	O
cloned	O
and	O
shown	O
to	O
encode	O
a	O
widely	O
expressed	O
chemokine	O
receptor	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
Duffy	B-Protein
antigen	I-Protein
/	I-Protein
chemokine	I-Protein
receptor	I-Protein
gene	O
(	O
DARC	B-Protein
)	O
is	O
composed	O
of	O
a	O
single	O
exon	O
and	O
that	O
most	O
Duffy	B-Protein
-	O
negative	O
blacks	O
carry	O
a	O
silent	O
FY	B-Protein
*	I-Protein
B	I-Protein
allele	O
with	O
a	O
single	O
T	O
to	O
C	O
substitution	O
at	O
nucleotide	O
-	O
46	O
.	O

This	O
mutation	O
impairs	O
the	O
promoter	O
activity	O
in	O
erythroid	O
cells	O
by	O
disrupting	O
a	O
binding	O
site	O
for	O
the	O
GATA1	B-Protein
erythroid	O
transcription	O
factor	O
.	O

With	O
the	O
recent	O
characterization	O
of	O
the	O
FY	B-Protein
*	I-Protein
A	I-Protein
and	O
FY	B-Protein
*	I-Protein
B	I-Protein
alleles	O
,	O
these	O
findings	O
provide	O
the	O
molecular	O
basis	O
of	O
the	O
Duffy	B-Protein
blood	O
group	O
system	O
and	O
an	O
explanation	O
for	O
the	O
erythroid	O
-	O
specific	O
repression	O
of	O
the	O
DARC	B-Protein
gene	O
in	O
Duffy	B-Protein
-	O
negative	O
individuals	O
.	O

Nonradioactive	O
quantification	O
of	O
glucocorticoid	B-Protein
receptor	I-Protein
expression	O
during	O
differentiation	O
of	O
human	O
monocytic	O
cells	O
(	O
U937	O
)	O
.	O

We	O
describe	O
a	O
method	O
for	O
relative	O
quantification	O
of	O
specific	O
mRNA	O
using	O
a	O
nonradioactive	O
assay	O
based	O
on	O
DNA	O
strand	O
competition	O
between	O
identical	O
sequences	O
of	O
biotin	O
-	O
and	O
fluorescein	O
-	O
labeled	O
amplicon	O
(	O
probe	O
)	O
and	O
unlabeled	O
amplicon	O
(	O
target	O
)	O
during	O
hybridization	O
.	O

As	O
the	O
target	O
quantity	O
increased	O
,	O
that	O
of	O
the	O
double	O
-	O
labeled	O
probe	O
decreased	O
in	O
accordance	O
with	O
the	O
mass	O
action	O
law	O
.	O

This	O
technique	O
was	O
successfully	O
applied	O
to	O
evaluate	O
differences	O
in	O
glucocorticoid	B-Protein
receptor	I-Protein
expression	O
in	O
U937	O
cells	O
before	O
and	O
after	O
the	O
addition	O
of	O
potent	O
differentiation	O
inducers	O
:	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
and	O
a	O
combination	O
of	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
and	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D2	O
(	O
VD	O
)	O
.	O

We	O
observed	O
that	O
TPA	O
treatment	O
was	O
associated	O
with	O
an	O
increase	O
in	O
specific	O
binding	O
of	O
[	O
3H	O
]	O
dexamethasone	O
and	O
up	O
-	O
regulation	O
of	O
GR	B-Protein
mRNA	O
while	O
no	O
enhanced	O
GR	B-Protein
expression	O
was	O
perceived	O
with	O
RA	O
/	O
VD	O
treatment	O
.	O

Microtubules	O
mediate	O
cellular	O
25	O
-	O
hydroxyvitamin	O
D3	O
trafficking	O
and	O
the	O
genomic	O
response	O
to	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
in	O
normal	O
human	O
monocytes	O
.	O

The	O
genomic	O
actions	O
of	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
(	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
are	O
mediated	O
by	O
the	O
intracellular	O
vitamin	B-Protein
D	I-Protein
receptor	I-Protein
(	O
VDR	B-Protein
)	O
.	O

Although	O
immunocytochemistry	O
has	O
shown	O
that	O
disruption	O
of	O
microtubular	O
assembly	O
prevents	O
nuclear	O
access	O
of	O
the	O
sterol	O
-	O
VDR	B-Protein
complex	O
,	O
the	O
role	O
of	O
microtubules	O
in	O
the	O
response	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
has	O
not	O
been	O
studied	O
in	O
viable	O
cells	O
.	O

Our	O
studies	O
examined	O
this	O
interaction	O
in	O
normal	O
human	O
monocytes	O
.	O

Monocytes	O
convert	O
25	O
(	O
OH	O
)	O
D3	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
and	O
to	O
24	O
-	O
hydroxylated	O
metabolites	O
more	O
polar	O
than	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

Microtubule	O
disruption	O
totally	O
abolished	O
the	O
ability	O
of	O
exogenous	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
to	O
suppress	O
its	O
own	O
synthesis	O
and	O
to	O
induce	O
24	O
-	O
hydroxylase	O
mRNA	O
and	O
activity	O
,	O
without	O
affecting	O
either	O
total	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
uptake	O
or	O
maximal	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
-	O
VDR	B-Protein
binding	O
.	O

Thus	O
,	O
intact	O
microtubules	O
are	O
essential	O
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
-	O
dependent	O
modulation	O
of	O
gene	O
transcription	O
.	O

Interestingly	O
,	O
microtubule	O
disruption	O
also	O
decreased	O
monocyte	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
synthesis	O
,	O
not	O
by	O
decreasing	O
the	O
Vmax	O
of	O
monocyte	O
mitochondrial	O
1	O
alpha	O
-	O
hydroxylase	O
but	O
through	O
an	O
increase	O
in	O
the	O
Km	O
for	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

We	O
examined	O
25	O
(	O
OH	O
)	O
D3	O
transport	O
.	O

Microtubule	O
disruption	O
did	O
not	O
affect	O
total	O
cellular	O
25	O
(	O
OH	O
)	O
D3	O
uptake	O
but	O
reduced	O
its	O
intracellular	O
trafficking	O
to	O
the	O
mitochondria	O
.	O

Thus	O
,	O
microtubules	O
participate	O
in	O
intracellular	O
25	O
(	O
OH	O
)	O
D3	O
transport	O
,	O
and	O
their	O
integrity	O
determines	O
normal	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
synthesis	O
.	O

The	O
zinc	O
finger	O
transcription	O
factor	O
Egr	B-Protein
-	I-Protein
1	I-Protein
is	O
essential	O
for	O
and	O
restricts	O
differentiation	O
along	O
the	O
macrophage	O
lineage	O
.	O

We	O
have	O
isolated	O
cDNA	O
clones	O
of	O
myeloid	O
differentiation	O
primary	O
response	O
(	O
MyD	O
)	O
genes	O
,	O
activated	O
in	O
the	O
absence	O
of	O
de	O
novo	O
protein	O
synthesis	O
following	O
induction	O
for	O
differentiation	O
along	O
either	O
the	O
macrophage	O
or	O
granulocyte	O
lineage	O
in	O
human	O
myeloblastic	O
leukemia	O
HL	O
-	O
60	O
cells	O
.	O

One	O
cDNA	O
clone	O
of	O
a	O
primary	O
response	O
gene	O
,	O
expressed	O
upon	O
macrophage	O
differentiation	O
,	O
encoded	O
for	O
Egr	B-Protein
-	I-Protein
1	I-Protein
,	O
a	O
zinc	O
finger	O
transcription	O
factor	O
.	O

The	O
Egr	B-Protein
-	I-Protein
1	I-Protein
gene	O
was	O
observed	O
to	O
be	O
transcriptionally	O
silent	O
in	O
HL	O
-	O
60	O
cells	O
,	O
but	O
active	O
in	O
U	O
-	O
937	O
and	O
M1	O
cells	O
,	O
the	O
latter	O
two	O
being	O
predetermined	O
for	O
macrophage	O
differentiation	O
.	O

Egr	B-Protein
-	I-Protein
1	I-Protein
antisense	O
oligomers	O
in	O
the	O
culture	O
media	O
blocked	O
macrophage	O
differentiation	O
in	O
both	O
myeloid	O
leukemia	O
cell	O
lines	O
and	O
normal	O
myeloblasts	O
.	O

HL	O
-	O
60	O
cells	O
constitutively	O
expressing	O
an	O
Egr	B-Protein
-	I-Protein
1	I-Protein
transgene	O
(	O
HL	O
-	O
60Egr	O
-	O
1	O
)	O
could	O
be	O
induced	O
for	O
macrophage	O
,	O
but	O
not	O
granulocyte	O
,	O
differentiation	O
.	O

These	O
observations	O
indicate	O
that	O
expression	O
of	O
Egr	B-Protein
-	I-Protein
1	I-Protein
is	O
essential	O
for	O
and	O
restricts	O
differentiation	O
of	O
myeloblasts	O
along	O
the	O
macrophage	O
lineage	O
.	O

Expression	O
of	O
tal	B-Protein
-	I-Protein
1	I-Protein
and	O
GATA	O
-	O
binding	O
proteins	O
during	O
human	O
hematopoiesis	O
.	O

Tal	B-Protein
-	I-Protein
1	I-Protein
rearrangements	O
are	O
associated	O
with	O
nearly	O
30	O
%	O
of	O
human	O
T	O
acute	O
lymphoblastic	O
leukemia	O
.	O

Tal	B-Protein
-	I-Protein
1	I-Protein
gene	O
encodes	O
a	O
putative	O
transcription	O
factor	O
with	O
a	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
domain	O
and	O
is	O
known	O
to	O
be	O
predominantly	O
expressed	O
in	O
hematopoietic	O
cells	O
.	O

We	O
investigated	O
the	O
pattern	O
of	O
tal	B-Protein
-	I-Protein
1	I-Protein
expression	O
in	O
purified	O
human	O
hematopoietic	O
cells	O
by	O
in	O
situ	O
hybridization	O
and	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
analysis	O
.	O

Both	O
methods	O
demonstrated	O
that	O
the	O
tal	B-Protein
-	I-Protein
1	I-Protein
gene	O
is	O
expressed	O
in	O
megakaryocytes	O
and	O
erythroblasts	O
as	O
well	O
as	O
in	O
basophilic	O
granulocytes	O
.	O

In	O
addition	O
,	O
our	O
results	O
indicate	O
that	O
the	O
tal	B-Protein
-	I-Protein
1	I-Protein
1A	O
promoter	O
,	O
which	O
contains	O
two	O
consensus	O
GATA	O
-	O
binding	O
sites	O
,	O
is	O
active	O
mainly	O
in	O
these	O
lineages	O
.	O

Because	O
the	O
GATA	B-Protein
-	I-Protein
1	I-Protein
gene	O
is	O
known	O
to	O
transactivate	O
several	O
genes	O
specific	O
for	O
the	O
erythroid	O
,	O
megakaryocytic	O
,	O
and	O
mastocytic	O
/	O
basophilic	O
lineages	O
,	O
we	O
studied	O
GATA	B-Protein
-	I-Protein
1	I-Protein
expression	O
in	O
these	O
purified	O
hematopoietic	O
cells	O
.	O

We	O
found	O
that	O
GATA	B-Protein
-	I-Protein
1	I-Protein
and	O
tal	B-Protein
-	I-Protein
1	I-Protein
genes	O
are	O
coexpressed	O
in	O
these	O
three	O
lineages	O
.	O

Remarkably	O
,	O
the	O
expression	O
of	O
both	O
genes	O
is	O
downmodulated	O
during	O
erythroid	O
and	O
megakaryocytic	O
terminal	O
maturation	O
.	O

In	O
immature	O
hematopoietic	O
cells	O
,	O
tal	B-Protein
-	I-Protein
1	I-Protein
and	O
GATA	B-Protein
-	I-Protein
1	I-Protein
genes	O
are	O
coexpressed	O
in	O
committed	O
progenitors	O
cells	O
(	O
CD34	B-Protein
+	O
/	O
CD38	B-Protein
(	O
2	O
+	O
)	O
)	O
,	O
whereas	O
they	O
are	O
not	O
detectable	O
in	O
the	O
most	O
primitive	O
cells	O
(	O
CD34	B-Protein
(	O
2	O
+	O
)	O
/	O
CD38	B-Protein
-	O
)	O
.	O

In	O
contrast	O
,	O
GATA	B-Protein
-	I-Protein
2	I-Protein
is	O
strongly	O
expressed	O
in	O
both	O
most	O
primitive	O
and	O
committed	O
progenitors	O
cells	O
,	O
whereas	O
GATA	B-Protein
-	I-Protein
3	I-Protein
is	O
mostly	O
detected	O
in	O
most	O
primitive	O
ones	O
.	O

Altogether	O
our	O
results	O
strongly	O
suggest	O
that	O
GATA	B-Protein
-	I-Protein
1	I-Protein
modulates	O
the	O
transcription	O
of	O
tal	B-Protein
-	I-Protein
1	I-Protein
during	O
the	O
differentiation	O
of	O
the	O
erythroid	O
,	O
megakaryocytic	O
,	O
and	O
basosophilic	O
lineages	O
.	O

Cell	O
type	O
-	O
and	O
stage	O
-	O
specific	O
expression	O
of	O
the	O
CD20	B-Protein
/	O
B1	B-Protein
antigen	O
correlates	O
with	O
the	O
activity	O
of	O
a	O
diverged	O
octamer	O
DNA	O
motif	O
present	O
in	O
its	O
promoter	O
.	O

The	O
CD20	B-Protein
(	O
B1	B-Protein
)	O
gene	O
encodes	O
a	O
B	O
cell	O
-	O
specific	O
protein	O
involved	O
in	O
the	O
regulation	O
of	O
human	O
B	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

Studies	O
with	O
5	O
'	O
deletion	O
CD20	B-Protein
promoter	O
-	O
CAT	B-Protein
constructs	O
have	O
previously	O
revealed	O
two	O
regions	O
of	O
the	O
promoter	O
between	O
bases	O
-	O
186	O
and	O
-	O
280	O
and	O
between	O
bases	O
-	O
280	O
and	O
-	O
454	O
which	O
contained	O
positive	O
regulatory	O
elements	O
.	O

In	O
this	O
study	O
we	O
identified	O
a	O
sequence	O
element	O
present	O
in	O
the	O
most	O
proximal	O
region	O
located	O
between	O
bases	O
-	O
214	O
and	O
-	O
201	O
,	O
TTCTTCTAATTAA	O
,	O
which	O
is	O
important	O
in	O
the	O
high	O
constitutive	O
expression	O
of	O
CD20	B-Protein
in	O
mature	O
B	O
cells	O
and	O
the	O
induction	O
of	O
CD20	B-Protein
in	O
pre	O
-	O
B	O
cells	O
.	O

This	O
sequence	O
element	O
was	O
referred	O
to	O
as	O
the	O
BAT	O
box	O
and	O
its	O
deletion	O
significantly	O
reduced	O
the	O
activity	O
of	O
a	O
CD20	B-Protein
promoter	O
-	O
CAT	B-Protein
construct	O
in	O
B	O
cells	O
.	O

Mobility	O
shift	O
assays	O
with	O
various	O
mutant	O
probes	O
and	O
B	O
cell	O
nuclear	O
extracts	O
demonstrated	O
that	O
the	O
core	O
sequence	O
TAAT	O
was	O
essential	O
for	O
binding	O
to	O
this	O
site	O
.	O

Cross	O
competition	O
experiments	O
with	O
an	O
octamer	O
sequence	O
from	O
the	O
Ig	O
heavy	O
chain	O
promoter	O
,	O
the	O
BAT	O
box	O
,	O
and	O
a	O
TA	O
-	O
rich	O
sequence	O
present	O
in	O
the	O
CD21	B-Protein
promoter	O
revealed	O
that	O
all	O
three	O
sequences	O
bound	O
the	O
same	O
nuclear	O
proteins	O
suggesting	O
that	O
the	O
BAT	O
box	O
binding	O
proteins	O
were	O
Oct	B-Protein
-	I-Protein
1	I-Protein
and	O
Oct	B-Protein
-	I-Protein
2	I-Protein
.	O

Southwestern	O
blotting	O
and	O
UV	O
cross	O
-	O
linking	O
studies	O
confirmed	O
that	O
the	O
BAT	O
box	O
binding	O
proteins	O
were	O
Oct	B-Protein
-	I-Protein
1	I-Protein
and	O
Oct	B-Protein
-	I-Protein
2	I-Protein
.	O

The	O
affinity	O
of	O
the	O
BAT	O
box	O
binding	O
proteins	O
for	O
the	O
BAT	O
box	O
was	O
approximately	O
25	O
-	O
fold	O
less	O
than	O
for	O
the	O
octamer	O
sequence	O
and	O
the	O
BAT	O
box	O
binding	O
proteins	O
dissociated	O
from	O
the	O
BAT	O
box	O
10	O
-	O
fold	O
more	O
rapidly	O
than	O
from	O
the	O
octamer	O
sequence	O
.	O

Despite	O
this	O
lower	O
affinity	O
,	O
a	O
trimer	O
of	O
the	O
BAT	O
box	O
sequence	O
was	O
as	O
efficiently	O
transactivated	O
by	O
an	O
Oct	B-Protein
-	I-Protein
2	I-Protein
expression	O
vector	O
as	O
was	O
a	O
trimer	O
of	O
the	O
octamer	O
sequence	O
in	O
HeLa	O
cells	O
.	O

The	O
BAT	O
box	O
and	O
Oct	B-Protein
-	I-Protein
2	I-Protein
were	O
also	O
implicated	O
in	O
the	O
induction	O
of	O
CD20	B-Protein
in	O
the	O
pre	O
-	O
B	O
cell	O
line	O
,	O
PB	O
-	O
697	O
,	O
via	O
phorbol	O
esters	O
.	O

The	O
induction	O
of	O
CD20	B-Protein
mRNA	O
was	O
temporally	O
associated	O
with	O
induction	O
of	O
Oct	B-Protein
-	I-Protein
2	I-Protein
mRNA	O
and	O
a	O
BAT	O
box	O
-	O
deleted	O
CD20	B-Protein
-	O
CAT	O
construct	O
,	O
in	O
contrast	O
to	O
the	O
wild	O
type	O
,	O
was	O
poorly	O
induced	O
by	O
phorbol	O
esters	O
.	O

Together	O
these	O
results	O
suggest	O
that	O
the	O
BAT	O
box	O
binding	O
proteins	O
are	O
important	O
in	O
the	O
B	O
cell	O
specific	O
expression	O
of	O
CD20	B-Protein
and	O
perhaps	O
CD21	B-Protein
.	O

A	O
mutation	O
of	O
the	O
glucocorticoid	B-Protein
receptor	I-Protein
in	O
primary	O
cortisol	O
resistance	O
.	O

The	O
precise	O
molecular	O
abnormalities	O
that	O
cause	O
primary	O
cortisol	O
resistance	O
have	O
not	O
been	O
completely	O
described	O
.	O

In	O
a	O
subject	O
with	O
primary	O
cortisol	O
resistance	O
we	O
have	O
observed	O
glucocorticoid	B-Protein
receptors	I-Protein
(	O
hGR	B-Protein
)	O
with	O
a	O
decreased	O
affinity	O
for	O
dexamethasone	O
.	O

We	O
hypothesize	O
that	O
a	O
mutation	O
of	O
the	O
hGR	B-Protein
glucocorticoid	O
-	O
binding	O
domain	O
is	O
the	O
cause	O
of	O
cortisol	O
resistance	O
.	O

Total	O
RNA	O
isolated	O
from	O
the	O
index	O
subject	O
'	O
s	O
mononuclear	O
leukocytes	O
was	O
used	O
to	O
produce	O
first	O
strand	O
hGR	B-Protein
cDNAs	O
,	O
and	O
the	O
entire	O
hGR	B-Protein
cDNA	O
was	O
amplified	O
in	O
segments	O
and	O
sequenced	O
.	O

At	O
nucleotide	O
2	O
,	O
317	O
we	O
identified	O
a	O
homozygous	O
A	O
for	O
G	O
point	O
mutation	O
that	O
predicts	O
an	O
isoleucine	O
(	O
ATT	O
)	O
for	O
valine	O
(	O
GTT	O
)	O
substitution	O
at	O
amino	O
acid	O
729	O
.	O

When	O
the	O
wild	O
-	O
type	O
hGR	B-Protein
and	O
hGR	B-Protein
-	O
Ile	O
729	O
were	O
expressed	O
in	O
COS	O
-	O
1	O
cells	O
and	O
assayed	O
for	O
[	O
3H	O
]	O
-	O
Dexamethasone	O
binding	O
,	O
the	O
dissociation	O
constants	O
were	O
0	O
.	O
799	O
+	O
/	O
-	O
0	O
.	O
068	O
and	O
1	O
.	O
54	O
+	O
/	O
-	O
0	O
.	O
06	O
nM	O
(	O
mean	O
+	O
/	O
-	O
SEM	O
)	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
respectively	O
.	O

When	O
the	O
wild	O
-	O
type	O
hGR	B-Protein
and	O
hGR	B-Protein
-	O
Ile	O
729	O
were	O
expressed	O
in	O
CV	O
-	O
1	O
cells	O
that	O
were	O
cotransfected	O
with	O
the	O
mouse	O
mammary	O
tumor	O
virus	O
long	O
terminal	O
repeat	O
fused	O
to	O
the	O
chloramphenicol	B-Protein
acetyl	I-Protein
transferase	I-Protein
(	O
CAT	B-Protein
)	O
gene	O
,	O
the	O
hGR	B-Protein
-	O
Ile	O
729	O
conferred	O
a	O
fourfold	O
decrease	O
in	O
apparent	O
potency	O
on	O
dexamethasone	O
stimulation	O
of	O
CAT	B-Protein
activity	O
.	O

The	O
isoleucine	O
for	O
valine	O
substitution	O
at	O
amino	O
acid	O
729	O
impairs	O
the	O
function	O
of	O
the	O
hGR	B-Protein
and	O
is	O
the	O
likely	O
cause	O
of	O
primary	O
cortisol	O
resistance	O
in	O
this	O
subject	O
.	O

FK506	O
and	O
ciclosporin	O
:	O
molecular	O
probes	O
for	O
studying	O
intracellular	O
signal	O
transduction	O
.	O

The	O
immunosuppressants	O
ciclosporin	O
and	O
FK506	O
block	O
the	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
signal	O
-	O
transduction	O
pathway	O
emanating	O
from	O
the	O
T	O
-	O
cell	O
receptor	O
,	O
thereby	O
inhibiting	O
the	O
activation	O
of	O
helper	O
T	O
cells	O
.	O

Using	O
these	O
drugs	O
as	O
probes	O
,	O
chemists	O
and	O
biologists	O
have	O
uncovered	O
several	O
intracellular	O
signalling	O
molecules	O
bridging	O
the	O
generation	O
of	O
second	O
-	O
messenger	O
Ca2	O
+	O
ions	O
and	O
the	O
transcriptional	O
activation	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
among	O
which	O
are	O
calmodulin	B-Protein
,	O
calcineurin	O
and	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
.	O

Hence	O
,	O
Ca2	O
+	O
binds	O
to	O
calmodulin	B-Protein
,	O
leading	O
to	O
the	O
binding	O
of	O
calmodulin	B-Protein
to	O
calcineurin	O
;	O
the	O
activated	O
calcineurin	O
,	O
in	O
turn	O
,	O
may	O
dephosphorylate	O
the	O
cytoplasmic	O
subunit	O
of	O
NF	O
-	O
AT	O
,	O
resulting	O
in	O
its	O
translocation	O
from	O
the	O
cytoplasm	O
into	O
the	O
nucleus	O
to	O
form	O
a	O
competent	O
transcriptional	O
activator	O
.	O

As	O
described	O
by	O
Jun	O
Liu	O
,	O
these	O
drugs	O
manifest	O
their	O
effects	O
in	O
an	O
unprecedented	O
fashion	O
.	O

They	O
do	O
not	O
directly	O
intercept	O
intracellular	O
signalling	O
molecules	O
.	O

Instead	O
,	O
they	O
form	O
tight	O
complexes	O
with	O
two	O
different	O
classes	O
of	O
abundant	O
cytosolic	O
receptors	O
called	O
immunophilins	O
upon	O
entering	O
the	O
cell	O
,	O
and	O
consequently	O
inhibit	O
their	O
peptidyl	O
prolyl	O
cis	O
-	O
trans	O
isomerase	O
activities	O
.	O

The	O
two	O
structurally	O
distinct	O
immunophilin	O
-	O
drug	O
complexes	O
bind	O
to	O
,	O
and	O
inhibit	O
,	O
the	O
phosphatase	O
activity	O
of	O
calcineurin	O
.	O

Effects	O
of	O
intranasal	O
glucocorticoids	O
on	O
endogenous	O
glucocorticoid	O
peripheral	O
and	O
central	O
function	O
.	O

Glucocorticoids	O
are	O
among	O
the	O
most	O
potent	O
antiinflammatory	O
agents	O
that	O
can	O
be	O
used	O
in	O
the	O
treatment	O
of	O
rhinitis	O
.	O

Their	O
mechanisms	O
of	O
action	O
are	O
multiple	O
and	O
complex	O
and	O
a	O
number	O
of	O
reports	O
describe	O
significant	O
systemic	O
effects	O
of	O
locally	O
administered	O
glucocorticoids	O
.	O

In	O
order	O
to	O
evaluate	O
the	O
short	O
-	O
term	O
systemic	O
effects	O
of	O
intranasally	O
administered	O
glucocorticoids	O
,	O
14	O
normal	O
healthy	O
subjects	O
were	O
treated	O
with	O
two	O
doses	O
of	O
either	O
budesonide	O
(	O
BUD	O
)	O
or	O
fluticasone	O
propionate	O
(	O
FP	O
)	O
for	O
2	O
weeks	O
.	O

Before	O
treatment	O
,	O
at	O
regular	O
intervals	O
during	O
the	O
treatment	O
,	O
1	O
week	O
and	O
finally	O
6	O
weeks	O
after	O
termination	O
of	O
treatment	O
,	O
the	O
effects	O
on	O
glucocorticoid	B-Protein
receptor	I-Protein
(	O
GR	B-Protein
)	O
and	O
methallothionein	B-Protein
(	O
MTIIa	B-Protein
)	O
mRNA	O
expression	O
levels	O
were	O
examined	O
in	O
peripheral	O
lymphocytes	O
using	O
a	O
solution	O
hybridization	O
assay	O
.	O

Serum	O
cortisol	O
,	O
osteocalcin	B-Protein
and	O
urinary	O
cortisol	O
levels	O
were	O
also	O
determined	O
.	O

An	O
insulin	O
tolerance	O
test	O
(	O
ITT	O
)	O
was	O
performed	O
at	O
the	O
end	O
of	O
the	O
second	O
week	O
of	O
treatment	O
and	O
at	O
the	O
end	O
of	O
the	O
6	O
-	O
week	O
washout	O
period	O
with	O
no	O
statistically	O
significant	O
change	O
in	O
cortisol	O
response	O
.	O

In	O
peripheral	O
lymphocytes	O
,	O
GR	B-Protein
mRNA	O
levels	O
were	O
significantly	O
down	O
-	O
regulated	O
.	O

MTIIa	B-Protein
mRNA	O
levels	O
increased	O
significantly	O
.	O

Serum	O
osteocalcin	B-Protein
decreased	O
significantly	O
during	O
treatment	O
with	O
both	O
BUD	O
and	O
FP	O
.	O

Serum	O
cortisol	O
decreased	O
after	O
1	O
week	O
of	O
treatment	O
whereas	O
urinary	O
cortisol	O
was	O
not	O
affected	O
until	O
the	O
second	O
week	O
of	O
treatment	O
.	O

In	O
conclusion	O
,	O
intranasal	O
glucocorticoids	O
at	O
clinically	O
recommended	O
doses	O
have	O
not	O
only	O
significant	O
systemic	O
effects	O
on	O
adrenal	O
function	O
,	O
but	O
also	O
have	O
an	O
effect	O
on	O
specific	O
gene	O
expression	O
in	O
peripheral	O
lymphocytes	O
.	O

These	O
effects	O
are	O
receptor	O
-	O
dependent	O
,	O
reversible	O
,	O
and	O
according	O
to	O
serum	O
and	O
urinary	O
cortisol	O
levels	O
and	O
ITT	O
,	O
leave	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
function	O
intact	O
.	O

Finally	O
,	O
these	O
short	O
-	O
term	O
systemic	O
effects	O
were	O
not	O
associated	O
with	O
any	O
of	O
the	O
noticeable	O
side	O
-	O
effects	O
usually	O
observed	O
during	O
long	O
-	O
term	O
treatment	O
with	O
glucocorticoids	O
.	O

Transcriptional	O
activity	O
of	O
core	O
binding	O
factor	O
-	O
alpha	O
(	O
AML1	B-Protein
)	O
and	O
beta	O
subunits	O
on	O
murine	O
leukemia	O
virus	O
enhancer	O
cores	O
.	O

Core	O
binding	O
factor	O
(	O
CBF	O
)	O
,	O
also	O
known	O
as	O
polyomavirus	O
enhancer	O
-	O
binding	O
protein	O
2	O
and	O
SL3	O
enhancer	O
factor	O
1	O
,	O
is	O
a	O
mammalian	O
transcription	O
factor	O
that	O
binds	O
to	O
an	O
element	O
termed	O
the	O
core	O
within	O
the	O
enhancers	O
of	O
the	O
murine	O
leukemia	O
virus	O
family	O
of	O
retroviruses	O
.	O

The	O
core	O
elements	O
of	O
the	O
SL3	O
virus	O
are	O
important	O
genetic	O
determinants	O
of	O
the	O
ability	O
of	O
this	O
virus	O
to	O
induce	O
T	O
-	O
cell	O
lymphomas	O
and	O
the	O
transcriptional	O
activity	O
of	O
the	O
viral	O
long	O
terminal	O
repeat	O
in	O
T	O
lymphocytes	O
.	O

CBF	O
consists	O
of	O
two	O
subunits	O
,	O
a	O
DNA	O
binding	O
subunit	O
,	O
CBF	B-Protein
alpha	I-Protein
,	O
and	O
a	O
second	O
subunit	O
,	O
CBF	B-Protein
beta	I-Protein
,	O
that	O
stimulates	O
the	O
DNA	O
binding	O
activity	O
of	O
CBF	B-Protein
alpha	I-Protein
.	O

One	O
of	O
the	O
genes	O
that	O
encodes	O
a	O
CBF	B-Protein
alpha	I-Protein
subunit	O
is	O
AML1	B-Protein
,	O
also	O
called	O
Cbf	B-Protein
alpha	I-Protein
2	I-Protein
.	O

This	O
locus	O
is	O
rearranged	O
by	O
chromosomal	O
translocations	O
in	O
human	O
myeloproliferative	O
disorders	O
and	O
leukemias	O
.	O

An	O
exogenously	O
expressed	O
Cbf	B-Protein
alpha	I-Protein
2	I-Protein
-	O
encoded	O
subunit	O
(	O
CBF	B-Protein
alpha	I-Protein
2	O
-	O
451	O
)	O
stimulated	O
transcription	O
from	O
the	O
SL3	O
enhancer	O
in	O
P19	O
and	O
HeLa	O
cells	O
.	O

Activity	O
was	O
mediated	O
through	O
the	O
core	O
elements	O
.	O

Three	O
different	O
isoforms	O
of	O
CBF	B-Protein
beta	I-Protein
were	O
also	O
tested	O
for	O
transcriptional	O
activity	O
on	O
the	O
SL3	O
enhancer	O
.	O

The	O
longest	O
form	O
,	O
CBF	B-Protein
beta	I-Protein
-	O
187	O
,	O
increased	O
the	O
transcriptional	O
stimulation	O
by	O
CBF	B-Protein
alpha	I-Protein
2	O
-	O
451	O
twofold	O
in	O
HeLa	O
cells	O
,	O
although	O
it	O
had	O
no	O
effect	O
in	O
P19	O
cells	O
.	O

Transcriptional	O
activation	O
by	O
CBF	B-Protein
beta	I-Protein
required	O
binding	O
to	O
the	O
CBF	B-Protein
alpha	I-Protein
subunit	O
,	O
as	O
a	O
form	O
of	O
CBF	B-Protein
beta	I-Protein
that	O
lacked	O
binding	O
ability	O
,	O
CBF	B-Protein
beta	I-Protein
-	O
148	O
,	O
failed	O
to	O
increase	O
activity	O
.	O

These	O
results	O
indicated	O
that	O
at	O
least	O
in	O
certain	O
cell	O
types	O
,	O
the	O
maximum	O
activity	O
of	O
CBF	O
required	O
both	O
subunits	O
.	O

They	O
also	O
provided	O
support	O
for	O
the	O
hypothesis	O
that	O
CBF	O
is	O
a	O
factor	O
in	O
T	O
lymphocytes	O
that	O
is	O
responsible	O
for	O
recognition	O
of	O
the	O
SL3	O
cores	O
.	O

We	O
also	O
examined	O
whether	O
CBF	O
could	O
distinguish	O
a	O
1	O
-	O
bp	O
difference	O
between	O
the	O
enhancer	O
core	O
of	O
SL3	O
and	O
the	O
core	O
of	O
the	O
nonleukemogenic	O
virus	O
,	O
Akv	O
.	O

This	O
difference	O
strongly	O
affects	O
transcription	O
in	O
T	O
cells	O
and	O
leukemogenicity	O
of	O
SL3	O
.	O

However	O
,	O
no	O
combination	O
of	O
CBF	B-Protein
alpha	I-Protein
and	O
CBF	B-Protein
beta	I-Protein
subunits	O
that	O
we	O
tested	O
was	O
able	O
to	O
distinguish	O
the	O
1	O
-	O
bp	O
difference	O
in	O
transcription	O
assays	O
.	O

Thus	O
,	O
a	O
complete	O
understanding	O
of	O
how	O
T	O
cells	O
recognize	O
the	O
SL3	O
core	O
remains	O
to	O
be	O
elucidated	O
.	O

A	O
newly	O
established	O
megakaryoblastic	O
/	O
erythroid	O
cell	O
line	O
that	O
differentiates	O
to	O
red	O
cells	O
in	O
the	O
presence	O
of	O
erythropoietin	B-Protein
and	O
produces	O
platelet	O
-	O
like	O
particles	O
.	O

In	O
August	O
,	O
1992	O
,	O
we	O
established	O
a	O
leukemic	O
cell	O
line	O
(	O
NS	O
-	O
Meg	O
)	O
from	O
a	O
patient	O
in	O
megakaryoblastic	O
transformation	O
of	O
Philadelphia	O
chromosome	O
-	O
positive	O
chronic	O
myeloid	O
leukemia	O
.	O

The	O
NS	O
-	O
Meg	O
cells	O
were	O
positive	O
for	O
alpha	O
-	O
naphthyl	O
acetate	O
esterase	O
and	O
periodic	O
acid	O
-	O
Schiff	O
(	O
PAS	O
)	O
staining	O
and	O
for	O
surface	O
CD4	B-Protein
,	O
CD7	B-Protein
,	O
CD13	B-Protein
,	O
CD34	B-Protein
,	O
CD41a	B-Protein
,	O
and	O
glycophorin	B-Protein
A	I-Protein
antigens	O
.	O

Ultrastructurally	O
,	O
the	O
cells	O
had	O
alpha	O
-	O
granules	O
,	O
demarcation	O
membranes	O
,	O
and	O
platelet	O
peroxidase	O
activity	O
.	O

The	O
NS	O
-	O
Meg	O
cells	O
spontaneously	O
produced	O
platelet	O
-	O
like	O
particles	O
which	O
contained	O
alpha	O
-	O
granules	O
,	O
mitochondria	O
and	O
dense	O
bodies	O
,	O
strongly	O
suggesting	O
platelet	O
production	O
.	O

Erythropoietin	B-Protein
(	O
Epo	B-Protein
)	O
,	O
granulocyte	B-Protein
/	I-Protein
macrophage	I-Protein
colony	I-Protein
stimulating	I-Protein
factor	I-Protein
(	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
)	O
,	O
and	O
interleukin	B-Protein
3	I-Protein
(	O
IL	B-Protein
-	I-Protein
3	I-Protein
)	O
promoted	O
the	O
growth	O
of	O
NS	O
-	O
Meg	O
cells	O
.	O

Phorbol	O
-	O
12	O
-	O
myristate	O
-	O
13	O
-	O
acetate	O
increased	O
the	O
expression	O
of	O
both	O
CD41a	B-Protein
and	O
CD61	B-Protein
antigens	O
.	O

Ten	O
-	O
day	O
exposure	O
to	O
Epo	B-Protein
induced	O
mature	O
erythroblasts	O
and	O
red	O
cells	O
.	O

These	O
benzidine	O
-	O
positive	O
cells	O
were	O
positive	O
for	O
hemoglobin	O
F	O
staining	O
.	O

Untreated	O
NS	O
-	O
Meg	O
cells	O
expressed	O
mRNA	O
for	O
the	O
Epo	B-Protein
receptor	I-Protein
(	O
EpoR	B-Protein
)	O
,	O
for	O
GATA	B-Protein
-	I-Protein
1	I-Protein
,	O
and	O
for	O
alpha	O
1	O
,	O
alpha	O
2	O
and	O
gamma	O
globin	O
genes	O
.	O

These	O
results	O
indicate	O
that	O
NS	O
-	O
Meg	O
cells	O
undergo	O
terminal	O
differentiation	O
of	O
both	O
megakaryocytic	O
and	O
erythroid	O
lineages	O
.	O

This	O
cell	O
line	O
should	O
be	O
a	O
very	O
useful	O
tool	O
for	O
the	O
investigation	O
of	O
both	O
megakaryocytic	O
and	O
erythroid	O
maturation	O
.	O

Identification	O
and	O
purification	O
of	O
human	O
Stat	O
proteins	O
activated	O
in	O
response	O
to	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
.	O

A	O
key	O
cytokine	O
induced	O
during	O
the	O
immune	O
response	O
is	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O

Following	O
T	O
cell	O
activation	O
,	O
the	O
genes	O
encoding	O
IL	B-Protein
-	I-Protein
2	I-Protein
and	O
the	O
various	O
chains	O
of	O
its	O
receptor	O
are	O
transcriptionally	O
induced	O
.	O

In	O
turn	O
,	O
secreted	O
IL	B-Protein
-	I-Protein
2	I-Protein
serves	O
to	O
stimulate	O
the	O
proliferation	O
and	O
differentiation	O
of	O
T	O
lymphocytes	O
.	O

Several	O
recent	O
studies	O
have	O
implicated	O
Jak	O
kinases	O
in	O
the	O
signaling	O
pathway	O
induced	O
by	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O

Following	O
this	O
lead	O
,	O
we	O
set	O
out	O
to	O
identify	O
transcription	O
factors	O
induced	O
in	O
response	O
to	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O

Human	O
peripheral	O
blood	O
lymphocytes	O
were	O
observed	O
to	O
contain	O
several	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
inducible	O
DNA	O
binding	O
activities	O
.	O

Similar	O
activities	O
were	O
also	O
observed	O
in	O
a	O
transformed	O
human	O
lymphocyte	O
line	O
,	O
termed	O
YT	O
.	O

We	O
have	O
purified	O
these	O
activities	O
and	O
found	O
that	O
the	O
principal	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
inducible	O
component	O
bears	O
significant	O
relatedness	O
to	O
a	O
prolactin	B-Protein
-	O
induced	O
transcription	O
factor	O
first	O
identified	O
in	O
sheep	O
mammary	O
gland	O
tissue	O
.	O

We	O
hypothesize	O
that	O
activation	O
of	O
this	O
protein	O
,	O
designated	O
hStat5	B-Protein
,	O
helps	O
govern	O
the	O
biological	O
effects	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
during	O
the	O
immune	O
response	O
.	O

The	O
role	O
of	O
shared	O
receptor	O
motifs	O
and	O
common	O
Stat	O
proteins	O
in	O
the	O
generation	O
of	O
cytokine	O
pleiotropy	O
and	O
redundancy	O
by	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
IL	B-Protein
-	I-Protein
7	I-Protein
,	O
IL	B-Protein
-	I-Protein
13	I-Protein
,	O
and	O
IL	B-Protein
-	I-Protein
15	I-Protein
.	O

To	O
understand	O
the	O
molecular	O
bases	O
for	O
cytokine	O
redundancy	O
and	O
pleiotropy	O
,	O
we	O
have	O
compared	O
the	O
Stat	O
proteins	O
activated	O
in	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBLs	O
)	O
by	O
cytokines	O
with	O
shared	O
and	O
distinct	O
actions	O
.	O

Interleukin	B-Protein
-	I-Protein
2	I-Protein
(	O
IL	B-Protein
-	I-Protein
2	I-Protein
)	O
rapidly	O
activated	O
Stat5	B-Protein
in	O
fresh	O
PBL	O
,	O
and	O
Stat3	B-Protein
and	O
Stat5	B-Protein
in	O
preactivated	O
PBL	O
.	O

IL	B-Protein
-	I-Protein
7	I-Protein
and	O
IL	B-Protein
-	I-Protein
15	I-Protein
induced	O
the	O
same	O
complexes	O
as	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
a	O
feature	O
explained	O
by	O
the	O
existence	O
of	O
similar	O
tyrosine	O
-	O
phosphorylated	O
motifs	O
in	O
the	O
cytoplasmic	O
domains	O
of	O
IL	B-Protein
-	I-Protein
2R	I-Protein
beta	I-Protein
and	O
IL	B-Protein
-	I-Protein
7R	I-Protein
that	O
can	O
serve	O
as	O
docking	O
sites	O
for	O
Stat	O
proteins	O
.	O

IL	B-Protein
-	I-Protein
13	I-Protein
Induced	O
the	O
same	O
complexes	O
as	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
a	O
finding	O
explained	O
by	O
our	O
studies	O
implicating	O
IL	B-Protein
-	I-Protein
4R	I-Protein
as	O
a	O
shared	O
component	O
of	O
the	O
receptors	O
.	O

These	O
studies	O
demonstrate	O
that	O
a	O
single	O
cytokine	O
can	O
activate	O
different	O
combinations	O
of	O
Stat	O
proteins	O
under	O
different	O
physiological	O
conditions	O
,	O
and	O
also	O
indicate	O
two	O
mechanisms	O
by	O
which	O
distinct	O
cytokines	O
can	O
activate	O
the	O
same	O
Stat	O
protein	O
.	O

Functional	O
roles	O
of	O
in	O
vivo	O
footprinted	O
DNA	O
motifs	O
within	O
an	O
alpha	B-Protein
-	I-Protein
globin	I-Protein
enhancer	O
.	O

Erythroid	O
lineage	O
and	O
developmental	O
stage	O
specificities	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
human	O
alpha	O
-	O
like	O
globin	O
genes	O
,	O
embryonic	O
zeta	O
2	O
and	O
adult	O
alpha	O
,	O
during	O
erythroid	O
development	O
is	O
mediated	O
by	O
a	O
distal	O
enhancer	O
,	O
HS	B-Protein
-	I-Protein
40	I-Protein
.	O

Previous	O
protein	O
-	O
DNA	O
binding	O
studies	O
have	O
shown	O
that	O
HS	B-Protein
-	I-Protein
40	I-Protein
consists	O
of	O
multiple	O
nuclear	O
factor	O
binding	O
motifs	O
that	O
are	O
occupied	O
in	O
vivo	O
in	O
an	O
erythroid	O
lineage	O
-	O
and	O
developmental	O
stage	O
-	O
specific	O
manner	O
.	O

We	O
have	O
systematically	O
analyzed	O
the	O
functional	O
roles	O
of	O
these	O
factor	O
binding	O
motifs	O
of	O
HS	B-Protein
-	I-Protein
40	I-Protein
by	O
site	O
-	O
directed	O
mutagenesis	O
and	O
transient	O
expression	O
assay	O
in	O
erythroid	O
cell	O
cultures	O
.	O

Three	O
of	O
these	O
HS	B-Protein
-	I-Protein
40	I-Protein
enhancer	O
motifs	O
,	O
5	O
'	O
NF	O
-	O
E2	O
/	O
AP1	O
,	O
GT	O
II	O
,	O
and	O
GATA	B-Protein
-	I-Protein
1	I-Protein
(	O
c	O
)	O
,	O
positively	O
regulate	O
the	O
zeta	B-Protein
2	I-Protein
-	I-Protein
globin	I-Protein
promoter	O
activity	O
in	O
embryonic	O
/	O
fetal	O
erythroid	O
K562	O
cells	O
and	O
the	O
adult	B-Protein
alpha	I-Protein
-	I-Protein
globin	I-Protein
promoter	O
activity	O
in	O
adult	O
erythroid	O
MEL	O
cells	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
3	O
'	O
NF	O
-	O
E2	O
/	O
AP1	O
motif	O
is	O
able	O
to	O
exert	O
both	O
positive	O
and	O
negative	O
regulatory	O
effects	O
on	O
the	O
zeta	B-Protein
2	I-Protein
-	I-Protein
globin	I-Protein
promoter	O
activity	O
in	O
K562	O
cells	O
,	O
and	O
this	O
dual	O
function	O
appears	O
to	O
be	O
modulated	O
through	O
differential	O
binding	O
of	O
the	O
ubiquitous	O
AP1	O
factors	O
and	O
the	O
erythroid	O
-	O
enriched	O
NF	O
-	O
E2	O
factor	O
.	O

Mutation	O
in	O
the	O
GATA	B-Protein
-	I-Protein
1	I-Protein
(	O
d	O
)	O
motif	O
,	O
which	O
exhibits	O
an	O
adult	O
erythroid	O
-	O
specific	O
genomic	O
footprint	O
,	O
decreases	O
the	O
HS	B-Protein
-	I-Protein
40	I-Protein
enhancer	O
function	O
in	O
dimethyl	O
sulfoxide	O
-	O
induced	O
MEL	O
cells	O
but	O
not	O
in	O
K562	O
cells	O
.	O

These	O
studies	O
have	O
defined	O
the	O
regulatory	O
roles	O
of	O
the	O
different	O
HS	B-Protein
-	I-Protein
40	I-Protein
motifs	O
.	O

The	O
remarkable	O
correlation	O
between	O
genomic	O
footprinting	O
data	O
and	O
the	O
mutagenesis	O
results	O
also	O
suggests	O
that	O
the	O
erythroid	O
lineage	O
-	O
and	O
developmental	O
stage	O
-	O
specific	O
regulation	O
of	O
human	O
alpha	O
-	O
like	O
globin	O
promoters	O
is	O
indeed	O
modulated	O
by	O
stable	O
binding	O
of	O
specific	O
nuclear	O
factors	O
in	O
vivo	O
.	O

Erythropoietin	B-Protein
stimulates	O
transcription	O
of	O
the	O
TAL1	B-Protein
/	O
SCL	B-Protein
gene	O
and	O
phosphorylation	O
of	O
its	O
protein	O
products	O
.	O

Activation	O
of	O
the	O
TAL1	B-Protein
(	O
or	O
SCL	B-Protein
)	O
gene	O
,	O
originally	O
identified	O
through	O
its	O
involvement	O
by	O
a	O
recurrent	O
chromosomal	O
translocation	O
,	O
is	O
the	O
most	O
frequent	O
molecular	O
lesion	O
recognized	O
in	O
T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemia	O
.	O

The	O
protein	O
products	O
of	O
this	O
gene	O
contain	O
the	O
basic	O
-	O
helix	O
-	O
loop	O
-	O
helix	O
motif	O
characteristic	O
of	O
a	O
large	O
family	O
of	O
transcription	O
factors	O
that	O
bind	O
to	O
the	O
canonical	O
DNA	O
sequence	O
CANNTG	O
as	O
protein	O
heterodimers	O
.	O

TAL1	B-Protein
expression	O
by	O
erythroid	O
cells	O
in	O
vivo	O
and	O
in	O
chemical	O
-	O
induced	O
erythroleukemia	O
cell	O
lines	O
in	O
vivo	O
suggested	O
the	O
gene	O
might	O
regulate	O
aspects	O
of	O
erythroid	O
differentiation	O
.	O

Since	O
the	O
terminal	O
events	O
of	O
erythropoiesis	O
are	O
controlled	O
by	O
the	O
glycoprotein	O
hormone	O
erythropoietin	B-Protein
(	O
Epo	B-Protein
)	O
,	O
we	O
investigated	O
whether	O
the	O
expression	O
or	O
activity	O
of	O
the	O
TAL1	B-Protein
gene	O
and	O
its	O
protein	O
products	O
were	O
affected	O
by	O
Epo	B-Protein
in	O
splenic	O
erythroblasts	O
from	O
mice	O
infected	O
with	O
an	O
anemia	O
-	O
inducing	O
strain	O
of	O
Friend	O
virus	O
(	O
FVA	O
cells	O
)	O
.	O

Epo	B-Protein
elicited	O
a	O
rapid	O
,	O
dose	O
-	O
related	O
increase	O
in	O
TAL1	B-Protein
mRNA	O
by	O
increasing	O
transcription	O
of	O
the	O
gene	O
and	O
stabilizing	O
one	O
of	O
its	O
mRNAs	O
.	O

An	O
Epo	B-Protein
-	O
inducible	O
TAL1	B-Protein
DNA	O
binding	O
activity	O
was	O
identified	O
in	O
FVA	O
cell	O
nuclear	O
extracts	O
that	O
subsequently	O
decayed	O
despite	O
accumulating	O
mRNA	O
and	O
protein	O
.	O

Induction	O
of	O
DNA	O
binding	O
activity	O
was	O
associated	O
temporally	O
with	O
Epo	B-Protein
-	O
induced	O
phosphorylation	O
of	O
nuclear	O
TAL1	B-Protein
protein	O
.	O

These	O
results	O
indicate	O
that	O
Epo	B-Protein
acts	O
at	O
both	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
on	O
the	O
TAL1	B-Protein
locus	O
in	O
Friend	O
virus	O
-	O
induced	O
erythroblasts	O
and	O
establish	O
a	O
link	O
between	O
Epo	B-Protein
signaling	O
mechanisms	O
and	O
a	O
member	O
of	O
a	O
family	O
of	O
transcription	O
factors	O
involved	O
in	O
the	O
differentiation	O
of	O
diverse	O
cell	O
lineages	O
.	O

Infection	O
with	O
Theileria	O
annulata	O
induces	O
expression	O
of	O
matrix	B-Protein
metalloproteinase	I-Protein
9	I-Protein
and	O
transcription	O
factor	O
AP	O
-	O
1	O
in	O
bovine	O
leucocytes	O
.	O

Theileria	O
annulata	O
infects	O
bovine	O
leucocytes	O
and	O
results	O
in	O
their	O
reversible	O
transformation	O
such	O
that	O
they	O
become	O
immortalised	O
and	O
metastatic	O
.	O

The	O
present	O
study	O
describes	O
parasite	O
-	O
induced	O
changes	O
in	O
host	O
cell	O
gene	O
expression	O
which	O
have	O
a	O
direct	O
bearing	O
on	O
this	O
transformation	O
process	O
.	O

T	O
.	O
annulata	O
-	O
infected	O
leucocytes	O
produce	O
a	O
number	O
of	O
novel	O
metalloproteinase	O
activities	O
.	O

One	O
of	O
these	O
,	O
previously	O
called	O
B1	O
,	O
is	O
a	O
97	O
-	O
kDa	O
protein	O
which	O
is	O
secreted	O
in	O
large	O
amounts	O
and	O
has	O
been	O
purified	O
from	O
protein	O
-	O
free	O
,	O
conditioned	O
medium	O
.	O

An	O
antiserum	O
to	O
this	O
enzyme	O
was	O
used	O
to	O
isolate	O
a	O
cDNA	O
clone	O
.	O

The	O
predicted	O
protein	O
sequence	O
of	O
B1	O
is	O
81	O
%	O
identical	O
to	O
human	O
matrix	B-Protein
metalloproteinase	I-Protein
9	I-Protein
(	O
MMP9	B-Protein
)	O
,	O
demonstrating	O
that	O
it	O
is	O
the	O
bovine	O
homologue	O
of	O
this	O
enzyme	O
.	O

RNAase	O
protection	O
assays	O
demonstrated	O
that	O
the	O
MMP9	B-Protein
activity	O
,	O
unique	O
to	O
infected	O
cells	O
,	O
is	O
due	O
to	O
increased	O
MMP9	B-Protein
mRNA	O
levels	O
.	O

We	O
also	O
assayed	O
the	O
levels	O
of	O
transcription	O
factor	O
AP	O
-	O
1	O
and	O
demonstrated	O
that	O
it	O
was	O
constitutively	O
present	O
in	O
increased	O
amounts	O
in	O
Theileria	O
-	O
infected	O
cells	O
.	O

In	O
addition	O
we	O
assayed	O
the	O
level	O
of	O
mRNA	O
encoding	O
c	B-Protein
-	I-Protein
Fos	I-Protein
,	O
a	O
common	O
component	O
of	O
AP	O
-	O
1	O
and	O
observed	O
that	O
it	O
was	O
indeed	O
up	O
-	O
regulated	O
in	O
infected	O
cells	O
.	O

Since	O
AP	O
-	O
1	O
is	O
implicated	O
in	O
the	O
control	O
of	O
the	O
cell	O
cycle	O
,	O
and	O
MMP9	B-Protein
can	O
confer	O
metastatic	O
properties	O
,	O
these	O
results	O
are	O
of	O
considerable	O
significance	O
with	O
respect	O
to	O
the	O
transformed	O
phenotype	O
induced	O
by	O
Theileria	O
infection	O
.	O

The	O
role	O
of	O
NFATp	B-Protein
in	O
cyclosporin	O
A	O
-	O
sensitive	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
gene	O
transcription	O
.	O

The	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
(	O
TNF	B-Protein
alpha	I-Protein
)	O
gene	O
is	O
an	O
immediate	O
early	O
gene	O
in	O
activated	O
T	O
cells	O
,	O
in	O
that	O
it	O
is	O
rapidly	O
induced	O
without	O
a	O
requirement	O
for	O
protein	O
synthesis	O
.	O

Maximal	O
induction	O
of	O
TNF	B-Protein
alpha	I-Protein
mRNA	O
can	O
be	O
induced	O
by	O
treatment	O
of	O
T	O
cells	O
with	O
calcium	O
ionophores	O
alone	O
,	O
via	O
a	O
calcineurin	O
-	O
dependent	O
process	O
that	O
is	O
blocked	O
by	O
cyclosporin	O
A	O
.	O

We	O
have	O
previously	O
identified	O
a	O
promoter	O
element	O
,	O
kappa	O
3	O
,	O
that	O
is	O
required	O
for	O
calcium	O
-	O
stimulated	O
,	O
cyclosporin	O
A	O
-	O
sensitive	O
induction	O
of	O
the	O
TNF	B-Protein
alpha	I-Protein
gene	O
in	O
activated	O
T	O
cells	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
the	O
kappa	O
3	O
binding	O
factor	O
contains	O
NFATp	B-Protein
,	O
a	O
cyclosporin	O
-	O
sensitive	O
DNA	O
-	O
binding	O
protein	O
required	O
for	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
gene	O
transcription	O
.	O

NFATp	B-Protein
binds	O
to	O
two	O
sites	O
within	O
the	O
kappa	O
3	O
element	O
,	O
and	O
occupancy	O
of	O
both	O
sites	O
is	O
required	O
for	O
TNF	B-Protein
alpha	I-Protein
gene	O
induction	O
.	O

Thus	O
,	O
although	O
the	O
kappa	O
3	O
element	O
has	O
little	O
sequence	O
similarity	O
to	O
other	O
NFATp	B-Protein
-	O
binding	O
sites	O
,	O
it	O
appears	O
to	O
function	O
as	O
a	O
cyclosporin	O
-	O
sensitive	O
promoter	O
element	O
in	O
T	O
cells	O
by	O
virtue	O
of	O
its	O
ability	O
to	O
bind	O
NFATp	B-Protein
.	O

The	O
involvement	O
of	O
NFATp	B-Protein
in	O
transcriptional	O
activation	O
of	O
both	O
the	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
and	O
TNF	B-Protein
alpha	I-Protein
genes	O
suggests	O
that	O
this	O
factor	O
plays	O
an	O
important	O
role	O
in	O
the	O
coordinate	O
induction	O
of	O
multiple	O
cytokine	O
genes	O
,	O
starting	O
at	O
the	O
earliest	O
stages	O
of	O
T	O
cell	O
activation	O
.	O

Glucocorticoid	O
-	O
mediated	O
inhibition	O
of	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
receptor	I-Protein
alpha	I-Protein
and	O
-	B-Protein
beta	I-Protein
subunit	O
expression	O
by	O
human	O
T	O
cells	O
.	O

To	O
determine	O
the	O
mechanism	O
of	O
glucocorticoid	O
(	O
GC	O
)	O
-	O
mediated	O
inhibition	O
of	O
T	O
cell	O
functions	O
,	O
the	O
effect	O
of	O
dexamethasone	O
(	O
DM	O
)	O
on	O
T	O
cell	O
proliferation	O
and	O
interleukin	O
-	O
2	O
receptor	O
(	O
IL	O
-	O
2R	O
)	O
generation	O
were	O
studied	O
.	O

Dexamethasone	O
inhibited	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
induced	O
T	O
cell	O
proliferation	O
by	O
30	O
%	O
-	O
88	O
%	O
,	O
relative	O
to	O
its	O
concentration	O
within	O
the	O
cultures	O
.	O

The	O
effect	O
of	O
DM	O
on	O
expression	O
of	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	I-Protein
(	O
Tac	B-Protein
,	O
p55	B-Protein
,	O
CD25	B-Protein
)	O
and	O
beta	B-Protein
(	O
p75	B-Protein
)	O
genes	O
in	O
activated	O
T	O
cells	O
was	O
examined	O
next	O
.	O

In	O
T	O
cells	O
stimulated	O
with	O
purified	O
phytohemagglutinin	B-Protein
(	O
PHA	B-Protein
-	I-Protein
p	I-Protein
)	O
and	O
4	O
beta	O
-	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
addition	O
of	O
DM	O
to	O
the	O
cultures	O
resulted	O
in	O
a	O
60	O
%	O
reduction	O
in	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	I-Protein
and	O
a	O
30	O
%	O
reduction	O
in	O
IL	B-Protein
-	I-Protein
2R	I-Protein
beta	I-Protein
membrane	O
expression	O
compared	O
to	O
T	O
cells	O
cultured	O
in	O
the	O
absence	O
of	O
DM	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Inhibition	O
of	O
membrane	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	I-Protein
and	O
IL	B-Protein
-	I-Protein
2R	I-Protein
beta	I-Protein
expression	O
by	O
10	O
(	O
-	O
6	O
)	O
M	O
DM	O
was	O
partially	O
reversible	O
by	O
recombinant	O
human	O
IL	B-Protein
-	I-Protein
2	I-Protein
(	O
rhIL	O
-	O
2	O
)	O
.	O

By	O
Northern	O
blot	O
analysis	O
,	O
DM	O
caused	O
a	O
comparable	O
decrease	O
in	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	I-Protein
and	O
in	O
IL	B-Protein
-	I-Protein
2R	I-Protein
beta	I-Protein
mRNA	O
levels	O
to	O
membrane	O
receptor	O
expression	O
in	O
mitogen	O
-	O
stimulated	O
T	O
cells	O
.	O

By	O
in	O
vitro	O
transcription	O
assays	O
,	O
DM	O
regulated	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	I-Protein
gene	O
expression	O
at	O
a	O
transcriptional	O
level	O
while	O
transcription	O
of	O
IL	B-Protein
-	I-Protein
2R	I-Protein
beta	I-Protein
gene	O
was	O
unaffected	O
by	O
DM	O
.	O

The	O
mechanism	O
of	O
action	O
of	O
DM	O
on	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	I-Protein
transcription	O
was	O
examined	O
by	O
determining	O
the	O
mRNA	O
levels	O
of	O
the	O
p50	B-Protein
subunit	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
,	O
a	O
transcription	O
factor	O
that	O
stimulates	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	I-Protein
gene	O
expression	O
.	O

The	O
data	O
indicate	O
that	O
10	O
(	O
-	O
6	O
)	O
M	O
DM	O
increased	O
T	O
cell	O
p50	B-Protein
NF	O
-	O
kappa	O
B	O
mRNA	O
levels	O
by	O
four	O
-	O
fold	O
compared	O
to	O
the	O
levels	O
obtained	O
in	O
the	O
absence	O
of	O
DM	O
.	O

Further	O
,	O
the	O
level	O
of	O
nuclear	O
proteins	O
capable	O
of	O
binding	O
to	O
the	O
NF	O
-	O
kappa	O
B	O
sites	O
in	O
activated	O
T	O
cells	O
increased	O
in	O
response	O
to	O
DM	O
.	O

In	O
sum	O
,	O
DM	O
regulates	O
T	O
cell	O
membrane	O
expression	O
of	O
IL	O
-	O
2R	O
by	O
more	O
than	O
one	O
molecular	O
mechanism	O
.	O

Visualization	O
of	O
the	O
endogenous	O
NF	O
-	O
kappa	O
B	O
p50	B-Protein
subunit	O
in	O
the	O
nucleus	O
of	O
follicular	O
dendritic	O
cells	O
in	O
germinal	O
centers	O
.	O

NF	O
-	O
kappa	O
B	O
,	O
a	O
50	O
kDa	O
/	O
65	O
kDa	O
(	O
p50	B-Protein
/	O
p65	B-Protein
)	O
heterodimer	O
,	O
is	O
a	O
ubiquitous	O
transcription	O
factor	O
involved	O
in	O
the	O
positive	O
regulation	O
of	O
various	O
immune	O
genes	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
NF	O
-	O
kappa	O
B	O
is	O
related	O
to	O
a	O
particular	O
cell	O
type	O
and	O
/	O
or	O
differentiation	O
step	O
during	O
immunopoiesis	O
.	O

Using	O
in	O
situ	O
hybridization	O
on	O
sections	O
from	O
non	O
HIV	O
hyperplastic	O
lymph	O
nodes	O
,	O
we	O
found	O
that	O
the	O
gene	O
of	O
the	O
105	O
kDa	O
precursor	O
of	O
p50	B-Protein
was	O
overexpressed	O
in	O
the	O
light	O
zone	O
of	O
germinal	O
centers	O
,	O
with	O
a	O
network	O
aspect	O
,	O
which	O
suggested	O
the	O
involvement	O
of	O
follicular	O
dendritic	O
cells	O
(	O
FDC	O
)	O
.	O

By	O
immunohistochemistry	O
,	O
p50	B-Protein
protein	O
was	O
detected	O
in	O
the	O
cytoplasm	O
and	O
nucleus	O
of	O
FDC	O
,	O
confirming	O
the	O
involvement	O
of	O
FDC	O
.	O

Furthermore	O
,	O
p50	B-Protein
protein	O
was	O
detected	O
in	O
the	O
cytoplasm	O
of	O
all	O
lymphocytes	O
.	O

Thus	O
,	O
we	O
focused	O
our	O
study	O
on	O
isolated	O
FDC	O
clusters	O
from	O
normal	O
tonsils	O
.	O

As	O
showed	O
on	O
tissue	O
sections	O
,	O
we	O
detected	O
the	O
p50	B-Protein
in	O
both	O
cytoplasm	O
and	O
nucleus	O
of	O
FDC	O
.	O

Nuclei	O
of	O
lymphocytes	O
from	O
FDC	O
clusters	O
were	O
negative	O
.	O

We	O
next	O
studied	O
p65	B-Protein
and	O
c	B-Protein
-	I-Protein
Rel	I-Protein
protein	O
expression	O
in	O
FDC	O
clusters	O
.	O

p65	B-Protein
was	O
detected	O
in	O
the	O
cytoplasm	O
of	O
FDC	O
,	O
whereas	O
nuclei	O
were	O
negative	O
.	O

Furthermore	O
,	O
p65	B-Protein
was	O
detected	O
in	O
the	O
nuclei	O
of	O
some	O
lymphocytes	O
.	O

c	B-Protein
-	I-Protein
Rel	I-Protein
protein	O
was	O
detected	O
only	O
in	O
the	O
cytoplasm	O
of	O
lymphocytes	O
and	O
not	O
in	O
the	O
nucleus	O
and	O
cytoplasm	O
of	O
FDC	O
.	O

Our	O
results	O
indicated	O
that	O
,	O
in	O
the	O
context	O
of	O
T	O
cell	O
-	O
dependent	O
B	O
cell	O
immunopoiesis	O
occurring	O
in	O
FDC	O
clusters	O
,	O
p50	B-Protein
is	O
mainly	O
related	O
to	O
FDC	O
with	O
a	O
massive	O
overexpression	O
in	O
the	O
nuclei	O
,	O
whereas	O
p65	B-Protein
is	O
expressed	O
in	O
a	O
scattered	O
manner	O
in	O
the	O
nuclei	O
of	O
lymphocytes	O
and	O
c	B-Protein
-	I-Protein
Rel	I-Protein
protein	O
exclusively	O
in	O
the	O
cytoplasm	O
of	O
lymphocytes	O
from	O
FDC	O
clusters	O
.	O

These	O
results	O
suggested	O
that	O
the	O
two	O
subunits	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
the	O
c	B-Protein
-	I-Protein
Rel	I-Protein
protein	O
have	O
different	O
roles	O
in	O
different	O
cell	O
types	O
during	O
B	O
cell	O
immunopoiesis	O
.	O

Increased	O
proliferation	O
,	O
cytotoxicity	O
,	O
and	O
gene	O
expression	O
after	O
stimulation	O
of	O
human	O
peripheral	O
blood	O
T	O
lymphocytes	O
through	O
a	O
surface	O
ganglioside	O
(	O
GD3	O
)	O
[	O
published	O
erratum	O
appears	O
in	O
J	O
Immunol	O
1994	O
Jul	O
15	O
;	O
153	O
(	O
2	O
)	O
:	O
910	O
]	O

Previous	O
studies	O
have	O
suggested	O
that	O
gangliosides	O
have	O
an	O
important	O
role	O
in	O
cell	O
signaling	O
and	O
recognition	O
.	O

However	O
,	O
their	O
specific	O
function	O
in	O
these	O
processes	O
has	O
not	O
been	O
clearly	O
defined	O
.	O

A	O
mAb	O
,	O
R24	O
,	O
that	O
reacts	O
specifically	O
with	O
a	O
cell	O
surface	O
ganglioside	O
(	O
GD3	O
)	O
has	O
been	O
demonstrated	O
to	O
stimulate	O
proliferation	O
of	O
T	O
cells	O
derived	O
from	O
human	O
peripheral	O
blood	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
investigated	O
the	O
mechanisms	O
by	O
which	O
the	O
R24	O
mAb	O
affects	O
T	O
cell	O
functions	O
.	O

We	O
have	O
observed	O
that	O
the	O
R24	O
mAb	O
stimulates	O
GD3	O
+	O
T	O
cell	O
proliferation	O
,	O
cytotoxicity	O
,	O
and	O
surface	O
marker	O
expression	O
of	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	I-Protein
-	O
chain	O
,	O
IL	B-Protein
-	I-Protein
2R	I-Protein
beta	I-Protein
-	O
chain	O
,	O
HLA	O
-	O
DR	O
,	O
CD11a	B-Protein
,	O
and	O
CD11c	B-Protein
.	O

Additionally	O
,	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
activity	O
but	O
not	O
IL	O
-	O
1	O
,	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
or	O
IL	B-Protein
-	I-Protein
4	I-Protein
activity	O
was	O
present	O
in	O
culture	O
supernatants	O
72	O
h	O
after	O
R24	O
stimulation	O
.	O

In	O
some	O
donors	O
,	O
increased	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
activity	O
also	O
was	O
detected	O
after	O
R24	O
treatment	O
.	O

Furthermore	O
,	O
R24	O
treatment	O
resulted	O
in	O
translocation	O
of	O
c	B-Protein
-	I-Protein
rel	I-Protein
,	O
but	O
little	O
or	O
no	O
NF	O
kappa	O
B	O
p50	B-Protein
or	O
p65	B-Protein
,	O
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
and	O
an	O
increase	O
of	O
NF	O
kappa	O
B	O
binding	O
complexes	O
containing	O
c	B-Protein
-	I-Protein
rel	I-Protein
and	O
p50	B-Protein
.	O

This	O
treatment	O
also	O
caused	O
increased	O
tyrosine	O
phosphorylation	O
of	O
specific	O
protein	O
substrates	O
.	O

R24	O
-	O
stimulated	O
increases	O
in	O
proliferation	O
,	O
cytotoxicity	O
,	O
and	O
cell	O
surface	O
protein	O
expression	O
could	O
be	O
blocked	O
by	O
cyclosporin	O
and	O
staurosporin	O
,	O
indicating	O
that	O
cyclophilin	O
/	O
calcineurin	O
and	O
protein	O
kinase	O
C	O
may	O
be	O
involved	O
in	O
the	O
R24	O
signaling	O
pathway	O
.	O

Additionally	O
,	O
herbimycin	O
A	O
,	O
a	O
tyrosine	O
kinase	O
inhibitor	O
,	O
blocked	O
the	O
R24	O
-	O
stimulated	O
increase	O
in	O
proliferation	O
but	O
not	O
cytotoxicity	O
at	O
concentrations	O
consistent	O
with	O
specificity	O
for	O
tyrosine	O
kinases	O
.	O

These	O
results	O
suggest	O
that	O
multiple	O
biochemical	O
pathways	O
are	O
involved	O
in	O
the	O
activation	O
of	O
human	O
T	O
cells	O
by	O
R24	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
Tax	B-Protein
associates	O
with	O
and	O
is	O
negatively	O
regulated	O
by	O
the	O
NF	B-Protein
-	I-Protein
kappa	I-Protein
B2	I-Protein
p100	B-Protein
gene	O
product	O
:	O
implications	O
for	O
viral	O
latency	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
is	O
the	O
etiologic	O
agent	O
of	O
the	O
adult	O
T	O
-	O
cell	O
leukemia	O
,	O
an	O
aggressive	O
and	O
often	O
fatal	O
malignancy	O
of	O
activated	O
human	O
CD4	B-Protein
T	O
cells	O
.	O

HTLV	O
-	O
I	O
encodes	O
an	O
essential	O
40	O
-	O
kDa	O
protein	O
termed	O
Tax	B-Protein
that	O
not	O
only	O
transactivates	O
the	O
long	O
terminal	O
repeat	O
of	O
this	O
retrovirus	O
but	O
also	O
induces	O
an	O
array	O
of	O
cellular	O
genes	O
.	O

Tax	B-Protein
-	O
mediated	O
transformation	O
of	O
T	O
cells	O
likely	O
involves	O
the	O
deregulated	O
expression	O
of	O
various	O
cellular	O
genes	O
that	O
normally	O
regulate	O
lymphocyte	O
growth	O
produced	O
by	O
altered	O
activity	O
of	O
various	O
endogenous	O
host	O
transcription	O
factors	O
.	O

In	O
particular	O
,	O
Tax	B-Protein
is	O
capable	O
of	O
modulating	O
the	O
expression	O
or	O
activity	O
of	O
various	O
host	O
transcription	O
factors	O
,	O
including	O
members	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
and	O
CREB	O
/	O
ATF	O
families	O
,	O
as	O
well	O
as	O
the	O
cellular	O
factors	O
HEB	O
-	O
1	O
and	O
p67SRF	B-Protein
.	O

An	O
additional	O
distinguishing	O
characteristic	O
of	O
HTLV	O
-	O
I	O
infection	O
is	O
the	O
profound	O
state	O
of	O
viral	O
latency	O
that	O
is	O
present	O
in	O
circulating	O
primary	O
leukemic	O
T	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
HTLV	O
-	O
I	O
Tax	B-Protein
can	O
physically	O
associate	O
with	O
p100	B-Protein
,	O
the	O
product	O
of	O
the	O
Rel	O
-	O
related	O
NF	B-Protein
-	I-Protein
kappa	I-Protein
B2	I-Protein
gene	O
,	O
both	O
in	O
transfected	O
cells	O
and	O
in	O
HTLV	O
-	O
I	O
-	O
infected	O
leukemic	O
T	O
-	O
cell	O
lines	O
.	O

Furthermore	O
,	O
the	O
physical	O
interaction	O
of	O
Tax	B-Protein
with	O
p100	B-Protein
leads	O
to	O
the	O
inhibition	O
of	O
Tax	B-Protein
-	O
induced	O
activation	O
of	O
the	O
HTLV	O
-	O
I	O
and	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeats	O
,	O
reflecting	O
p100	B-Protein
-	O
mediated	O
cytoplasmic	O
sequestration	O
of	O
the	O
normally	O
nuclearly	O
expressed	O
Tax	B-Protein
protein	O
.	O

In	O
contrast	O
,	O
a	O
mutant	O
of	O
Tax	B-Protein
that	O
selectively	O
fails	O
to	O
activate	O
nuclear	O
NF	O
-	O
kappa	O
B	O
expression	O
does	O
not	O
associate	O
with	O
p100	B-Protein
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

G	O
(	O
Anh	O
)	O
MTetra	O
,	O
a	O
natural	O
bacterial	O
cell	O
wall	O
breakdown	O
product	O
,	O
induces	O
interleukin	B-Protein
-	I-Protein
1	I-Protein
beta	I-Protein
and	O
interleukin	B-Protein
-	I-Protein
6	I-Protein
expression	O
in	O
human	O
monocytes	O
.	O

A	O
study	O
of	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
inflammatory	O
cytokine	O
expression	O
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1994	O
Jun	O
17	O
;	O
269	O
(	O
24	O
)	O
:	O
16983	O
]	O

It	O
is	O
believed	O
that	O
induction	O
of	O
cytokine	O
expression	O
by	O
bacterial	O
cell	O
wall	O
components	O
plays	O
a	O
role	O
in	O
the	O
development	O
and	O
course	O
of	O
sepsis	O
.	O

However	O
,	O
most	O
attention	O
has	O
been	O
focused	O
on	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

We	O
studied	O
the	O
ability	O
of	O
N	O
-	O
acetylglucosaminyl	O
-	O
1	O
,	O
6	O
-	O
anhydro	O
-	O
N	O
-	O
acetylmuramyl	O
-	O
L	O
-	O
alanyl	O
-	O
D	O
-	O
isoglutamyl	O
-	O
m	O
-	O
diaminopimelyl	O
-	O
D	O
-	O
alanine	O
(	O
G	O
(	O
Anh	O
)	O
MTetra	O
)	O
,	O
a	O
naturally	O
occurring	O
breakdown	O
product	O
of	O
peptidoglycan	O
that	O
is	O
produced	O
by	O
soluble	O
lytic	O
transglycosylase	O
of	O
Escherichia	O
coli	O
,	O
to	O
induce	O
cytokine	O
expression	O
in	O
human	O
monocytes	O
.	O

G	O
(	O
Anh	O
)	O
MTetra	O
was	O
found	O
to	O
strongly	O
induce	O
interleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
-	I-Protein
1	I-Protein
beta	I-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
mRNA	O
expression	O
after	O
2	O
h	O
and	O
IL	B-Protein
-	I-Protein
1	I-Protein
beta	I-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
protein	O
secretion	O
after	O
48	O
h	O
of	O
activation	O
.	O

The	O
increase	O
in	O
mRNA	O
accumulation	O
was	O
at	O
least	O
partly	O
due	O
to	O
an	O
increase	O
in	O
the	O
transcription	O
rates	O
of	O
the	O
respective	O
genes	O
and	O
was	O
accompanied	O
by	O
a	O
strong	O
induction	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
and	O
activator	O
protein	O
-	O
1	O
transcription	O
factor	O
expression	O
.	O

Experiments	O
using	O
inhibitors	O
of	O
protein	O
kinase	O
C	O
,	O
protein	O
kinase	O
A	O
,	O
and	O
tyrosine	O
kinase	O
-	O
dependent	O
pathways	O
revealed	O
that	O
G	O
(	O
Anh	O
)	O
MTetra	O
-	O
induced	O
IL	B-Protein
-	I-Protein
1	I-Protein
beta	I-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
mRNA	O
expression	O
involves	O
activation	O
of	O
an	O
H7	O
-	O
inhibitable	O
pathway	O
.	O

By	O
using	O
the	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	O
,	O
it	O
was	O
shown	O
that	O
G	O
(	O
Anh	O
)	O
MTetra	O
-	O
induced	O
IL	B-Protein
-	I-Protein
6	I-Protein
mRNA	O
expression	O
depends	O
on	O
the	O
synthesis	O
of	O
new	O
protein	O
,	O
whereas	O
G	O
(	O
Anh	O
)	O
MTetra	O
-	O
induced	O
IL	B-Protein
-	I-Protein
1	I-Protein
beta	I-Protein
mRNA	O
accumulation	O
does	O
not	O
.	O

When	O
responses	O
to	O
G	O
(	O
Anh	O
)	O
MTetra	O
were	O
compared	O
with	O
those	O
to	O
LPS	O
and	O
muramyldipeptide	O
(	O
MDP	O
)	O
,	O
it	O
was	O
found	O
that	O
the	O
optimal	O
response	O
to	O
G	O
(	O
Anh	O
)	O
MTetra	O
induction	O
was	O
similar	O
to	O
that	O
of	O
LPS	O
but	O
significantly	O
higher	O
than	O
the	O
response	O
to	O
MDP	O
.	O

Furthermore	O
,	O
maximal	O
G	O
(	O
Anh	O
)	O
MTetra	O
-	O
induced	O
IL	B-Protein
-	I-Protein
1	I-Protein
beta	I-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
mRNA	O
expression	O
could	O
be	O
enhanced	O
by	O
co	O
-	O
stimulation	O
with	O
LPS	O
or	O
MDP	O
,	O
suggesting	O
that	O
different	O
receptors	O
and	O
/	O
or	O
transduction	O
pathways	O
were	O
involved	O
.	O

These	O
results	O
indicate	O
that	O
G	O
(	O
Anh	O
)	O
MTetra	O
induces	O
IL	B-Protein
-	I-Protein
1	I-Protein
beta	I-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
expression	O
in	O
human	O
monocytes	O
suggesting	O
a	O
possible	O
role	O
for	O
G	O
(	O
Anh	O
)	O
MTetra	O
in	O
the	O
release	O
of	O
cytokines	O
during	O
sepsis	O
.	O

The	O
p65	B-Protein
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
regulates	O
I	O
kappa	O
B	O
by	O
two	O
distinct	O
mechanisms	O
.	O

Transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
(	O
p50	B-Protein
/	O
p65	B-Protein
)	O
is	O
generally	O
localized	O
to	O
the	O
cytoplasm	O
by	O
its	O
inhibitor	O
I	O
kappa	O
B	O
.	O

Overproduced	O
I	O
kappa	O
B	O
,	O
free	O
from	O
NF	O
-	O
kappa	O
B	O
,	O
is	O
rapidly	O
degraded	O
.	O

Overexpression	O
of	O
p65	B-Protein
increases	O
endogenous	O
I	O
kappa	O
B	O
protein	O
in	O
both	O
carcinoma	O
and	O
lymphoid	O
cells	O
by	O
two	O
mechanisms	O
:	O
protein	O
stabilization	O
and	O
increased	O
transcription	O
of	O
I	O
kappa	O
B	O
mRNA	O
.	O

In	O
contrast	O
,	O
p65	B-Protein
delta	I-Protein
,	O
a	O
naturally	O
occurring	O
splice	O
variant	O
,	O
fails	O
to	O
markedly	O
augment	O
I	O
kappa	O
B	O
protein	O
levels	O
.	O

Both	O
overexpressed	O
p65	B-Protein
and	O
coexpressed	O
p50	B-Protein
are	O
cytoplasmic	O
,	O
whereas	O
p65	B-Protein
delta	I-Protein
is	O
partly	O
nuclear	O
,	O
indicating	O
that	O
the	O
I	O
kappa	O
B	O
induced	O
by	O
p65	B-Protein
can	O
maintain	O
NF	O
-	O
kappa	O
B	O
in	O
the	O
cytoplasm	O
.	O

Thus	O
,	O
p65	B-Protein
and	O
I	O
kappa	O
B	O
are	O
linked	O
in	O
an	O
autoregulatory	O
loop	O
,	O
ensuring	O
that	O
NF	O
-	O
kappa	O
B	O
is	O
held	O
in	O
the	O
cytoplasm	O
until	O
cells	O
are	O
specifically	O
induced	O
to	O
translocate	O
it	O
to	O
the	O
nucleus	O
.	O

A	O
chimeric	O
type	O
II	O
/	O
type	O
I	O
interleukin	O
-	O
1	O
receptor	O
can	O
mediate	O
interleukin	O
-	O
1	O
induction	O
of	O
gene	O
expression	O
in	O
T	O
cells	O
.	O

The	O
type	B-Protein
I	I-Protein
interleukin	I-Protein
-	I-Protein
1	I-Protein
receptor	I-Protein
(	O
IL	O
-	O
1R	O
)	O
is	O
capable	O
of	O
transducing	O
a	O
signal	O
resulting	O
in	O
promoter	O
activation	O
in	O
T	O
cells	O
.	O

This	O
signal	O
transduction	O
is	O
dependent	O
on	O
the	O
cytoplasmic	O
domain	O
,	O
which	O
consists	O
of	O
213	O
amino	O
acids	O
.	O

In	O
contrast	O
to	O
the	O
type	O
I	O
receptor	O
,	O
the	O
type	B-Protein
II	I-Protein
IL	I-Protein
-	I-Protein
1R	I-Protein
has	O
a	O
small	O
cytoplasmic	O
tail	O
,	O
and	O
it	O
is	O
not	O
clear	O
whether	O
this	O
receptor	O
is	O
a	O
signal	O
-	O
transducing	O
or	O
a	O
regulatory	O
molecule	O
.	O

Here	O
we	O
report	O
that	O
the	O
type	B-Protein
II	I-Protein
IL	I-Protein
-	I-Protein
1R	I-Protein
does	O
not	O
mediate	O
gene	O
activation	O
in	O
Jurkat	O
cells	O
.	O

However	O
,	O
a	O
hybrid	O
receptor	O
composed	O
of	O
the	O
extracellular	O
and	O
transmembrane	O
regions	O
of	O
the	O
human	O
type	B-Protein
II	I-Protein
interleukin	I-Protein
-	I-Protein
1	I-Protein
fused	O
to	O
the	O
cytoplasmic	O
domain	O
of	O
the	O
human	O
type	B-Protein
I	I-Protein
IL	I-Protein
-	I-Protein
1R	I-Protein
was	O
capable	O
of	O
transducing	O
a	O
signal	O
across	O
the	O
membrane	O
resulting	O
in	O
a	O
pattern	O
of	O
gene	O
activation	O
identical	O
to	O
that	O
mediated	O
by	O
the	O
type	O
I	O
IL	O
-	O
1R	O
.	O

Our	O
results	O
indicated	O
that	O
the	O
extracellular	O
domain	O
of	O
the	O
type	B-Protein
II	I-Protein
IL	I-Protein
-	I-Protein
1R	I-Protein
was	O
capable	O
of	O
functionally	O
interacting	O
with	O
interleukin	O
-	O
1	O
and	O
transmitting	O
the	O
resulting	O
signal	O
to	O
a	O
heterologous	O
cytoplasmic	O
domain	O
.	O

Mice	O
deficient	O
for	O
the	O
55	B-Protein
kd	I-Protein
tumor	I-Protein
necrosis	I-Protein
factor	I-Protein
receptor	I-Protein
are	O
resistant	O
to	O
endotoxic	O
shock	O
,	O
yet	O
succumb	O
to	O
L	O
.	O
monocytogenes	O
infection	O
.	O

The	O
multiple	O
biological	O
activities	O
of	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
are	O
mediated	O
by	O
two	O
distinct	O
cell	O
surface	O
receptors	O
of	O
55	O
kd	O
(	O
TNFRp55	B-Protein
)	O
and	O
75	O
kd	O
(	O
TNFRp75	B-Protein
)	O
.	O

Using	O
gene	O
targeting	O
,	O
we	O
generated	O
a	O
TNFRp55	B-Protein
-	O
deficient	O
mouse	O
strain	O
.	O

Cells	O
from	O
TNFRp55	B-Protein
-	O
/	O
-	O
mutant	O
mice	O
lack	O
expression	O
of	O
TNFRp55	B-Protein
but	O
display	O
normal	O
numbers	O
of	O
high	O
affinity	O
TNFRp75	B-Protein
molecules	O
.	O

Thymocyte	O
development	O
and	O
lymphocyte	O
populations	O
are	O
unaltered	O
,	O
and	O
clonal	O
deletion	O
of	O
potentially	O
self	O
-	O
reactive	O
T	O
cells	O
is	O
not	O
impaired	O
.	O

However	O
,	O
TNF	O
signaling	O
is	O
largely	O
abolished	O
,	O
as	O
judged	O
by	O
the	O
failure	O
of	O
TNF	O
to	O
induce	O
NF	O
-	O
kappa	O
B	O
in	O
T	O
lymphocytes	O
from	O
TNFRp55	B-Protein
-	O
deficient	O
mice	O
.	O

The	O
loss	O
of	O
TNFRp55	B-Protein
function	O
renders	O
mice	O
resistant	O
to	O
lethal	O
dosages	O
of	O
either	O
lipopolysaccharides	O
or	O
S	O
.	O
aureus	O
enterotoxin	B-Protein
B	I-Protein
.	O

In	O
contrast	O
,	O
TNFRp55	B-Protein
-	O
deficient	O
mice	O
are	O
severely	O
impaired	O
to	O
clear	O
L	O
.	O
monocytogenes	O
and	O
readily	O
succumb	O
to	O
infection	O
.	O

Thus	O
,	O
the	O
55	B-Protein
kd	I-Protein
TNFR	I-Protein
plays	O
a	O
decisive	O
role	O
in	O
the	O
host	O
'	O
s	O
defense	O
against	O
microorganisms	O
and	O
their	O
pathogenic	O
factors	O
.	O

Minimally	O
modified	O
low	O
density	O
lipoprotein	O
-	O
induced	O
inflammatory	O
responses	O
in	O
endothelial	O
cells	O
are	O
mediated	O
by	O
cyclic	O
adenosine	O
monophosphate	O
.	O

We	O
have	O
previously	O
shown	O
that	O
minimally	O
oxidized	O
LDL	O
(	O
MM	O
-	O
LDL	O
)	O
activated	O
endothelial	O
cells	O
to	O
increase	O
their	O
interaction	O
with	O
monocytes	O
but	O
not	O
neutrophils	O
,	O
inducing	O
monocyte	O
but	O
not	O
neutrophil	O
binding	O
and	O
synthesis	O
of	O
monocyte	B-Protein
chemotactic	I-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
and	O
monocyte	B-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	I-Protein
(	O
M	B-Protein
-	I-Protein
CSF	I-Protein
)	O
.	O

In	O
the	O
present	O
studies	O
we	O
have	O
examined	O
the	O
signaling	O
pathways	O
by	O
which	O
this	O
monocyte	O
-	O
specific	O
response	O
is	O
induced	O
.	O

Both	O
induction	O
of	O
monocyte	O
binding	O
and	O
mRNA	O
levels	O
for	O
M	B-Protein
-	I-Protein
CSF	I-Protein
by	O
MM	O
-	O
LDL	O
were	O
not	O
inhibited	O
in	O
protein	O
kinase	O
C	O
-	O
depleted	O
endothelial	O
cells	O
.	O

A	O
number	O
of	O
our	O
studies	O
indicate	O
that	O
cAMP	O
is	O
the	O
second	O
messenger	O
for	O
the	O
effects	O
of	O
MM	O
-	O
LDL	O
cited	O
above	O
.	O

Incubation	O
of	O
endothelial	O
cells	O
with	O
MM	O
-	O
LDL	O
caused	O
a	O
173	O
%	O
increase	O
in	O
intracellular	O
cAMP	O
levels	O
.	O

Agents	O
which	O
increased	O
cAMP	O
levels	O
,	O
including	O
cholera	O
toxin	O
,	O
pertussis	O
toxin	O
,	O
dibutyryl	O
cAMP	O
,	O
and	O
isoproterenol	O
mimicked	O
the	O
actions	O
of	O
MM	O
-	O
LDL	O
.	O

Agents	O
which	O
elevated	O
cAMP	O
were	O
also	O
shown	O
to	O
activate	O
NF	O
kappa	O
B	O
,	O
suggesting	O
a	O
role	O
for	O
this	O
transcription	O
factor	O
in	O
activation	O
of	O
monocyte	O
-	O
endothelial	O
interactions	O
.	O

Although	O
endothelial	B-Protein
leukocyte	I-Protein
adhesion	I-Protein
molecule	I-Protein
(	O
ELAM	B-Protein
)	O
mRNA	O
synthesis	O
can	O
be	O
regulated	O
by	O
NF	O
kappa	O
B	O
,	O
ELAM	B-Protein
was	O
not	O
expressed	O
and	O
ELAM	B-Protein
mRNA	O
was	O
only	O
slightly	O
elevated	O
in	O
response	O
to	O
MM	O
-	O
LDL	O
.	O

We	O
present	O
evidence	O
that	O
induction	O
of	O
neutrophil	O
binding	O
by	O
LPS	O
is	O
actually	O
suppressed	O
by	O
agents	O
that	O
elevated	O
cAMP	O
levels	O
.	O

Tumor	O
necrosis	O
factor	O
receptor	O
expression	O
and	O
signal	O
transduction	O
in	O
HIV	O
-	O
1	O
-	O
infected	O
cells	O
.	O

OBJECTIVE	O
:	O
To	O
examine	O
the	O
inter	O
-	O
relationship	O
between	O
HIV	O
-	O
1	O
infection	O
and	O
the	O
cell	O
surface	O
receptors	O
for	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
(	I-Protein
TNF	I-Protein
)	I-Protein
-	I-Protein
alpha	I-Protein
,	O
an	O
immunoregulatory	O
cytokine	O
that	O
can	O
enhance	O
HIV	O
-	O
1	O
replication	O
.	O

DESIGN	O
:	O
Infected	O
promyelocytic	O
and	O
promonocytic	O
cells	O
were	O
examined	O
because	O
they	O
normally	O
express	O
both	O
types	O
of	O
TNF	O
receptors	O
.	O

METHODS	O
:	O
TNF	O
receptor	O
surface	O
expression	O
was	O
determined	O
by	O
specific	O
monoclonal	O
antibody	O
recognition	O
and	O
flow	O
cytometry	O
,	O
and	O
signal	O
transduction	O
was	O
detected	O
by	O
gel	O
shift	O
analysis	O
.	O

HIV	O
-	O
1	O
activation	O
and	O
expression	O
was	O
quantitated	O
by	O
reverse	B-Protein
transcriptase	I-Protein
assay	O
.	O

RESULTS	O
:	O
In	O
the	O
OM	O
-	O
10	O
.	O
1	O
promyelocytic	O
model	O
of	O
chronic	O
infection	O
,	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
-	O
induced	O
HIV	O
-	O
1	O
expression	O
also	O
resulted	O
in	O
a	O
substantial	O
increase	O
in	O
75	B-Protein
kd	I-Protein
TNF	I-Protein
receptor	I-Protein
(	O
TR75	B-Protein
)	O
expression	O
although	O
55	B-Protein
kD	I-Protein
TNF	I-Protein
receptor	I-Protein
(	O
TR55	B-Protein
)	O
levels	O
were	O
not	O
dramatically	O
altered	O
.	O

A	O
series	O
of	O
uninfected	O
parental	O
HL	O
-	O
60	O
subclones	O
all	O
reduced	O
TR75	B-Protein
surface	O
expression	O
in	O
response	O
to	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
treatment	O
.	O

Enhanced	O
TR75	B-Protein
expression	O
on	O
OM	O
-	O
10	O
.	O
1	O
cells	O
followed	O
the	O
same	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
-	O
dose	O
dependency	O
as	O
that	O
observed	O
for	O
HIV	O
-	O
1	O
production	O
.	O

An	O
increase	O
in	O
TR75	B-Protein
expression	O
was	O
also	O
evident	O
during	O
the	O
peak	O
of	O
an	O
acute	O
HIV	O
-	O
1	O
infection	O
of	O
HL	O
-	O
60	O
promyelocytes	O
.	O

Although	O
TR55	B-Protein
expression	O
was	O
unaltered	O
during	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
-	O
induced	O
HIV	O
activation	O
,	O
this	O
receptor	O
was	O
still	O
involved	O
in	O
the	O
viral	O
activation	O
process	O
.	O

Antibody	O
cross	O
-	O
linking	O
of	O
TR55	B-Protein
,	O
in	O
the	O
absence	O
of	O
exogenous	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
,	O
induced	O
maximal	O
HIV	O
-	O
1	O
expression	O
,	O
an	O
up	O
-	O
modulation	O
of	O
surface	O
TR75	B-Protein
,	O
and	O
nuclear	O
NF	O
-	O
kappa	O
B	O
activity	O
in	O
OM	O
-	O
10	O
.	O
1	O
cultures	O
.	O

Surprisingly	O
,	O
this	O
was	O
the	O
case	O
even	O
when	O
an	O
antagonistic	O
anti	O
-	O
TR55	B-Protein
antibody	O
was	O
used	O
.	O

Anti	O
-	O
TR55	B-Protein
antibody	O
cross	O
-	O
linking	O
in	O
chronically	O
infected	O
U1	O
promonocytic	O
cultures	O
could	O
only	O
partially	O
substitute	O
for	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
-	O
induced	O
HIV	O
-	O
1	O
expression	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
demonstrated	O
that	O
HIV	O
-	O
1	O
infection	O
can	O
selectively	O
influence	O
the	O
surface	O
expression	O
of	O
TNF	O
receptors	O
,	O
potentially	O
influencing	O
its	O
own	O
expression	O
and	O
altering	O
normal	O
immunoregulatory	O
signal	O
transduction	O
.	O

Human	O
immunodeficiency	O
viruses	O
containing	O
heterologous	O
enhancer	O
/	O
promoters	O
are	O
replication	O
competent	O
and	O
exhibit	O
different	O
lymphocyte	O
tropisms	O
.	O

The	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
type	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
contains	O
binding	O
sites	O
for	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
and	O
the	O
constitutively	O
expressed	O
transcription	O
factor	O
Sp1	B-Protein
,	O
both	O
of	O
which	O
are	O
highly	O
conserved	O
in	O
HIV	O
and	O
simian	O
immunodeficiency	O
virus	O
isolates	O
.	O

To	O
delineate	O
the	O
effects	O
of	O
these	O
motifs	O
on	O
the	O
replicative	O
capacity	O
of	O
HIV	O
and	O
to	O
explore	O
the	O
possibility	O
of	O
extending	O
the	O
virus	O
host	O
range	O
,	O
known	O
heterologous	O
enhancer	O
/	O
promoters	O
were	O
inserted	O
into	O
the	O
HIV	O
-	O
1	O
LTR	O
in	O
place	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
and	O
Sp1	B-Protein
binding	O
sites	O
.	O

The	O
effects	O
of	O
these	O
substitutions	O
on	O
viral	O
replication	O
in	O
transfected	O
HeLa	O
cells	O
and	O
on	O
HIV	O
infection	O
of	O
human	O
peripheral	O
blood	O
lymphocytes	O
or	O
continuous	O
T	O
-	O
leukemia	O
cell	O
lines	O
were	O
evaluated	O
.	O

HIVs	O
in	O
which	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Sp1	B-Protein
enhancer	O
plus	O
the	O
downstream	O
TATA	O
element	O
were	O
replaced	O
with	O
heterologous	O
enhancer	O
/	O
promoters	O
were	O
also	O
constructed	O
.	O

Viruses	O
containing	O
the	O
human	O
cytomegalovirus	O
immediate	O
-	O
early	O
enhancer	O
exhibited	O
infectious	O
kinetics	O
similar	O
to	O
that	O
of	O
wild	O
-	O
type	O
HIV	O
in	O
activated	O
human	O
peripheral	O
blood	O
lymphocytes	O
and	O
AA2	O
cells	O
but	O
replicated	O
less	O
efficiently	O
in	O
H9	O
and	O
CEM	O
cells	O
.	O

These	O
studies	O
indicate	O
that	O
heterologous	O
enhancer	O
elements	O
are	O
capable	O
of	O
restoring	O
Tat	B-Protein
responsiveness	O
to	O
the	O
HIV	O
LTR	O
in	O
the	O
context	O
of	O
directing	O
reporter	O
gene	O
expression	O
as	O
well	O
as	O
in	O
the	O
production	O
of	O
infectious	O
progeny	O
virions	O
.	O

Ras	O
oncogene	O
transformation	O
of	O
human	O
B	O
lymphoblasts	O
is	O
associated	O
with	O
lymphocyte	O
activation	O
and	O
with	O
a	O
block	O
of	O
differentiation	O
.	O

The	O
p21ras	B-Protein
small	O
GTP	O
binding	O
proteins	O
participate	O
in	O
signal	O
transduction	O
from	O
cell	O
surface	O
receptors	O
and	O
affect	O
neoplastic	O
transformation	O
and	O
development	O
in	O
many	O
different	O
cell	O
types	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
relationship	O
between	O
ras	O
transformation	O
and	O
differentiation	O
of	O
human	O
B	O
lymphocytes	O
.	O

We	O
show	O
that	O
the	O
constitutive	O
expression	O
of	O
the	O
T24	O
Ha	O
-	O
ras	O
oncogene	O
in	O
EBV	O
-	O
immortalized	O
B	O
lymphoblasts	O
was	O
associated	O
with	O
the	O
induction	O
of	O
the	O
interleukin	B-Protein
2	I-Protein
receptor	I-Protein
alpha	I-Protein
subunit	O
,	O
with	O
an	O
impaired	O
immunoglobulin	O
gene	O
expression	O
,	O
altered	O
adhesion	O
properties	O
and	O
increased	O
survival	O
in	O
serum	O
-	O
free	O
medium	O
.	O

Since	O
induction	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
receptor	I-Protein
alpha	I-Protein
subunit	O
is	O
a	O
hallmark	O
of	O
lymphocyte	O
activation	O
,	O
we	O
suggest	O
that	O
p21ras	B-Protein
naturally	O
triggers	O
B	O
cell	O
activation	O
.	O

The	O
ras	O
-	O
transformed	O
lymphocytes	O
displayed	O
a	O
fully	O
functional	O
IL	O
-	O
2r	O
,	O
as	O
assessed	O
by	O
c	B-Protein
-	I-Protein
fos	I-Protein
induction	O
following	O
treatment	O
with	O
IL	B-Protein
-	I-Protein
2	I-Protein
;	O
nevertheless	O
,	O
they	O
were	O
not	O
growth	O
stimulated	O
by	O
this	O
lymphokine	O
.	O

The	O
decreased	O
expression	O
of	O
immunoglobulin	O
genes	O
indicates	O
that	O
the	O
ras	O
oncogene	O
blocks	O
terminal	O
differentiation	O
to	O
plasma	O
cells	O
,	O
possibly	O
by	O
inhibiting	O
the	O
activity	O
of	O
lymphocyte	O
-	O
specific	O
transcription	O
factors	O
.	O

Somewhat	O
unexpectedly	O
,	O
the	O
constitutive	O
p21ras	B-Protein
activity	O
did	O
not	O
cause	O
an	O
increased	O
DNA	O
binding	O
of	O
transcription	O
factors	O
PEA1	O
(	O
AP1	O
)	O
,	O
PEA3	B-Protein
,	O
Oct	B-Protein
-	I-Protein
2	I-Protein
or	O
NF	O
-	O
kB	O
.	O

The	O
c	B-Protein
-	I-Protein
rel	I-Protein
protooncogene	O
product	O
represses	O
NF	O
-	O
kappa	O
B	O
p65	B-Protein
-	O
mediated	O
transcriptional	O
activation	O
of	O
the	O
long	O
terminal	O
repeat	O
of	O
type	O
1	O
human	O
immunodeficiency	O
virus	O
.	O

The	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
the	O
type	O
1	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
-	O
1	O
)	O
and	O
the	O
5	O
'	O
regulatory	O
region	O
of	O
the	O
gene	O
encoding	O
the	O
interleukin	B-Protein
2	I-Protein
receptor	I-Protein
alpha	I-Protein
subunit	I-Protein
(	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	I-Protein
)	O
share	O
functional	O
kappa	O
B	O
enhancer	O
elements	O
involved	O
in	O
the	O
regulation	O
of	O
these	O
inducible	O
transcription	O
units	O
during	O
T	O
-	O
cell	O
activation	O
.	O

These	O
kappa	O
B	O
enhancer	O
elements	O
are	O
recognized	O
by	O
a	O
structurally	O
related	O
family	O
of	O
interactive	O
proteins	O
that	O
includes	O
p50	B-Protein
,	O
p65	B-Protein
,	O
and	O
the	O
product	O
of	O
the	O
c	B-Protein
-	I-Protein
rel	I-Protein
protooncogene	O
(	O
c	B-Protein
-	I-Protein
Rel	I-Protein
)	O
.	O

Recent	O
biochemical	O
studies	O
have	O
shown	O
that	O
p65	B-Protein
and	O
p50	B-Protein
form	O
the	O
prototypical	O
NF	O
-	O
kappa	O
B	O
complex	O
,	O
which	O
is	O
rapidly	O
translocated	O
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
during	O
T	O
-	O
cell	O
activation	O
.	O

This	O
intracellular	O
signaling	O
complex	O
potently	O
stimulates	O
kappa	O
B	O
-	O
directed	O
transcription	O
from	O
either	O
the	O
HIV	O
-	O
1	O
LTR	O
or	O
the	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	I-Protein
promoter	O
via	O
the	O
strong	O
transactivation	O
domain	O
present	O
in	O
p65	B-Protein
.	O

We	O
now	O
demonstrate	O
that	O
nuclear	O
expression	O
of	O
human	O
c	B-Protein
-	I-Protein
Rel	I-Protein
,	O
which	O
is	O
induced	O
by	O
either	O
phorbol	O
ester	O
or	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
alpha	I-Protein
with	O
delayed	O
kinetics	O
relative	O
to	O
p65	B-Protein
,	O
markedly	O
represses	O
p65	B-Protein
-	O
mediated	O
activation	O
of	O
these	O
transcription	O
units	O
.	O

These	O
inhibitory	O
effects	O
of	O
c	B-Protein
-	I-Protein
Rel	I-Protein
correlate	O
with	O
its	O
DNA	O
-	O
binding	O
activity	O
but	O
not	O
with	O
its	O
ability	O
to	O
heterodimerize	O
with	O
p50	B-Protein
,	O
suggesting	O
that	O
c	B-Protein
-	I-Protein
Rel	I-Protein
inhibition	O
involves	O
competition	O
with	O
p50	B-Protein
/	O
p65	B-Protein
for	O
occupancy	O
of	O
the	O
kappa	O
B	O
enhancer	O
element	O
.	O

Together	O
,	O
these	O
findings	O
suggest	O
that	O
one	O
function	O
of	O
c	B-Protein
-	I-Protein
Rel	I-Protein
is	O
as	O
a	O
physiologic	O
repressor	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
and	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	I-Protein
promoters	O
,	O
serving	O
to	O
efficiently	O
counter	O
the	O
strong	O
transcriptional	O
activating	O
effects	O
of	O
p65	B-Protein
.	O

Dimerization	O
of	O
NF	B-Protein
-	I-Protein
KB2	I-Protein
with	O
RelA	B-Protein
(	O
p65	B-Protein
)	O
regulates	O
DNA	O
binding	O
,	O
transcriptional	O
activation	O
,	O
and	O
inhibition	O
by	O
an	O
I	B-Protein
kappa	I-Protein
B	I-Protein
-	I-Protein
alpha	I-Protein
(	O
MAD	B-Protein
-	I-Protein
3	I-Protein
)	O
.	O

Inducible	O
expression	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
is	O
regulated	O
by	O
a	O
cellular	O
transcription	O
factor	O
,	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
.	O

NF	O
-	O
kappa	O
B	O
is	O
composed	O
of	O
distinct	O
subunits	O
;	O
five	O
independent	O
genes	O
,	O
NFKB1	B-Protein
(	O
p105	B-Protein
)	O
,	O
NFKB2	B-Protein
(	O
p100	B-Protein
)	O
,	O
RelA	B-Protein
(	O
p65	B-Protein
)	O
,	O
c	B-Protein
-	I-Protein
rel	I-Protein
and	O
relB	B-Protein
,	O
that	O
encode	O
related	O
proteins	O
that	O
bind	O
to	O
kappa	O
B	O
DNA	O
elements	O
have	O
been	O
isolated	O
.	O

We	O
have	O
previously	O
found	O
that	O
NFKB2	B-Protein
(	O
p49	B-Protein
/	O
p52	B-Protein
)	O
acts	O
in	O
concert	O
with	O
RelA	B-Protein
(	O
p65	B-Protein
)	O
to	O
stimulate	O
the	O
HIV	O
enhancer	O
in	O
Jurkat	O
T	O
-	O
leukemia	O
cells	O
.	O

Here	O
we	O
examine	O
the	O
biochemical	O
basis	O
for	O
the	O
transcriptional	O
regulation	O
of	O
HIV	O
by	O
NFKB2	B-Protein
.	O

Using	O
Scatchard	O
analysis	O
,	O
we	O
have	O
determined	O
the	O
dissociation	O
constants	O
of	O
homodimeric	O
p49	B-Protein
and	O
heterodimeric	O
p49	B-Protein
/	O
p65	B-Protein
for	O
binding	O
to	O
the	O
HIV	O
kappa	O
B	O
site	O
.	O

p49	B-Protein
has	O
a	O
approximately	O
18	O
-	O
fold	O
-	O
lower	O
affinity	O
for	O
the	O
HIV	O
kappa	O
B	O
site	O
(	O
KD	O
=	O
69	O
.	O
1	O
pM	O
)	O
than	O
does	O
the	O
approximately	O
50	O
-	O
kDa	O
protein	O
NFKB1	B-Protein
(	O
p50	B-Protein
)	O
derived	O
from	O
p105	B-Protein
(	O
KD	O
=	O
3	O
.	O
9	O
pM	O
)	O
.	O

In	O
contrast	O
,	O
the	O
affinity	O
of	O
heterodimeric	O
NFKB2	B-Protein
(	O
p49	B-Protein
)	O
/	O
RelA	B-Protein
(	O
p65	B-Protein
)	O
for	O
this	O
site	O
is	O
approximately	O
6	O
-	O
fold	O
higher	O
(	O
KD	O
=	O
11	O
.	O
8	O
pM	O
)	O
than	O
that	O
of	O
p49	B-Protein
alone	O
.	O

Consistent	O
with	O
these	O
findings	O
,	O
in	O
vitro	O
transcription	O
was	O
stimulated	O
18	O
-	O
fold	O
by	O
the	O
addition	O
of	O
preformed	O
,	O
heterodimeric	O
NFKB2	B-Protein
(	O
p49	B-Protein
)	O
/	O
RelA	B-Protein
(	O
p65	B-Protein
)	O
protein	O
.	O

Transcriptional	O
activation	O
of	O
the	O
HIV	O
enhancer	O
was	O
also	O
subject	O
to	O
regulation	O
by	O
recently	O
cloned	O
I	B-Protein
kappa	I-Protein
B	I-Protein
-	I-Protein
alpha	I-Protein
(	O
MAD	B-Protein
-	I-Protein
3	I-Protein
)	O
.	O

Recombinant	O
I	B-Protein
kappa	I-Protein
B	I-Protein
-	I-Protein
alpha	I-Protein
(	O
MAD	B-Protein
-	I-Protein
3	I-Protein
)	O
inhibited	O
the	O
DNA	O
binding	O
activity	O
of	O
p65	B-Protein
,	O
p49	B-Protein
/	O
p65	B-Protein
,	O
and	O
p50	B-Protein
/	O
p65	B-Protein
but	O
stimulated	O
the	O
binding	O
of	O
NFKB2	B-Protein
(	O
p49	B-Protein
)	O
or	O
NFKB1	B-Protein
(	O
p50	B-Protein
)	O
.	O

Functional	O
activation	O
of	O
an	O
HIV	O
reporter	O
plasmid	O
by	O
p49	B-Protein
/	O
p65	B-Protein
in	O
transiently	O
transfected	O
Jurkat	O
T	O
-	O
leukemia	O
cells	O
was	O
also	O
inhibited	O
by	O
coexpression	O
of	O
MAD	B-Protein
-	I-Protein
3	I-Protein
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
transcriptionally	O
active	O
factors	O
mediating	O
the	O
effect	O
of	O
the	O
HTLV	O
-	O
I	O
Tax	B-Protein
transactivator	O
on	O
the	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	I-Protein
kappa	O
B	O
enhancer	O
include	O
the	O
product	O
of	O
the	O
c	B-Protein
-	I-Protein
rel	I-Protein
proto	O
-	O
oncogene	O
.	O

The	O
transactivator	O
HTLV	O
-	O
I	O
Tax	B-Protein
activates	O
the	O
promoter	O
of	O
the	O
gene	O
coding	O
for	O
the	O
interleukin	B-Protein
2	I-Protein
alpha	I-Protein
-	I-Protein
chain	I-Protein
receptor	I-Protein
(	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	I-Protein
)	O
via	O
a	O
kappa	O
B	O
site	O
that	O
can	O
bind	O
several	O
protein	O
species	O
of	O
the	O
rel	O
family	O
.	O

Tax1	B-Protein
strongly	O
activates	O
the	O
enhancer	O
activity	O
of	O
this	O
motif	O
,	O
in	O
both	O
epithelial	O
HeLa	O
and	O
lymphoid	O
Jurkat	O
cells	O
.	O

This	O
activation	O
was	O
not	O
observed	O
in	O
undifferentiated	O
embryocarcinoma	O
F9	O
cells	O
.	O

Overexpression	O
of	O
the	O
p50	B-Protein
,	O
p65	B-Protein
and	O
Rel	O
proteins	O
in	O
these	O
cells	O
showed	O
that	O
significant	O
activation	O
of	O
the	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	I-Protein
kappa	O
B	O
site	O
was	O
observed	O
only	O
with	O
Rel	O
and	O
Rel	O
plus	O
p65	B-Protein
.	O

Moreover	O
,	O
whereas	O
both	O
Tax	B-Protein
and	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
are	O
able	O
to	O
efficiently	O
induce	O
the	O
binding	O
of	O
NF	O
-	O
kappa	O
B	O
to	O
the	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	I-Protein
kappa	O
B	O
site	O
,	O
PMA	O
is	O
functionally	O
inactive	O
.	O

Using	O
the	O
DNA	O
affinity	O
precipitation	O
assay	O
,	O
we	O
observed	O
that	O
Tax1	B-Protein
is	O
able	O
to	O
efficiently	O
induce	O
the	O
binding	O
of	O
Rel	O
,	O
whereas	O
PMA	O
is	O
not	O
.	O

This	O
established	O
a	O
clear	O
difference	O
between	O
both	O
stimuli	O
,	O
indicating	O
that	O
Rel	O
is	O
the	O
functionally	O
active	O
factor	O
.	O

We	O
conclude	O
from	O
these	O
results	O
that	O
the	O
functional	O
activity	O
of	O
members	O
of	O
the	O
rel	O
family	O
is	O
regulated	O
by	O
their	O
interaction	O
with	O
DNA	O
and	O
that	O
Rel	O
can	O
be	O
a	O
potent	O
transcriptional	O
activator	O
on	O
specific	O
kappa	O
B	O
sites	O
.	O

p105	B-Protein
and	O
p98	B-Protein
precursor	O
proteins	O
play	O
an	O
active	O
role	O
in	O
NF	O
-	O
kappa	O
B	O
-	O
mediated	O
signal	O
transduction	O
.	O

The	O
Rel	O
/	O
NF	O
-	O
kappa	O
B	O
family	O
of	O
transcription	O
factors	O
is	O
composed	O
of	O
two	O
distinct	O
subgroups	O
,	O
proteins	O
that	O
undergo	O
proteolytic	O
processing	O
and	O
contain	O
SWI6	O
/	O
ankyrin	O
repeats	O
in	O
their	O
carboxyl	O
termini	O
(	O
p105	B-Protein
,	O
p98	B-Protein
)	O
,	O
and	O
those	O
without	O
such	O
repeats	O
that	O
do	O
not	O
require	O
processing	O
(	O
p65	B-Protein
,	O
c	B-Protein
-	I-Protein
Rel	I-Protein
,	O
RelB	B-Protein
,	O
and	O
Dorsal	B-Protein
)	O
.	O

We	O
demonstrate	O
that	O
the	O
p105	B-Protein
and	O
p98	B-Protein
precursors	O
share	O
functional	O
properties	O
with	O
the	O
I	O
kappa	O
B	O
proteins	O
,	O
which	O
also	O
contain	O
SWI6	O
/	O
ankyrin	O
repeats	O
.	O

Both	O
p105	B-Protein
and	O
p98	B-Protein
were	O
found	O
to	O
form	O
stable	O
complexes	O
with	O
other	O
Rel	O
/	O
NF	O
-	O
kappa	O
B	O
family	O
members	O
,	O
including	O
p65	B-Protein
and	O
c	B-Protein
-	I-Protein
Rel	I-Protein
.	O

Association	O
with	O
the	O
precursors	O
is	O
sufficient	O
for	O
cytoplasmic	O
retention	O
of	O
either	O
p65	B-Protein
or	O
c	B-Protein
-	I-Protein
Rel	I-Protein
,	O
both	O
of	O
which	O
are	O
otherwise	O
nuclear	O
.	O

These	O
complexes	O
undergo	O
stimulus	O
-	O
responsive	O
processing	O
to	O
produce	O
active	O
p50	B-Protein
/	O
c	B-Protein
-	I-Protein
Rel	I-Protein
and	O
p55	B-Protein
/	O
c	B-Protein
-	I-Protein
Rel	I-Protein
complexes	O
.	O

These	O
observations	O
suggest	O
a	O
second	O
pathway	O
leading	O
to	O
NF	O
-	O
kappa	O
B	O
induction	O
,	O
in	O
which	O
processing	O
of	O
the	O
precursors	O
rather	O
than	O
phosphorylation	O
of	O
I	O
kappa	O
B	O
plays	O
a	O
major	O
role	O
.	O

Mutual	O
regulation	O
of	O
the	O
transcriptional	O
activator	O
NF	O
-	O
kappa	O
B	O
and	O
its	O
inhibitor	O
,	O
I	B-Protein
kappa	I-Protein
B	I-Protein
-	I-Protein
alpha	I-Protein
.	O

The	O
NK	O
-	O
kappa	O
B	O
transcription	O
factor	O
complex	O
is	O
sequestered	O
in	O
the	O
cytoplasm	O
by	O
the	O
inhibitory	O
protein	O
I	B-Protein
kappa	I-Protein
B	I-Protein
-	I-Protein
alpha	I-Protein
(	O
MAD	B-Protein
-	I-Protein
3	I-Protein
)	O
.	O

Various	O
cellular	O
stimuli	O
relieve	O
this	O
inhibition	O
by	O
mechanisms	O
largely	O
unknown	O
,	O
leading	O
to	O
NF	O
-	O
kappa	O
B	O
nuclear	O
localization	O
and	O
transactivation	O
of	O
its	O
target	O
genes	O
.	O

It	O
is	O
demonstrated	O
here	O
with	O
human	O
T	O
lymphocytes	O
and	O
monocytes	O
that	O
different	O
stimuli	O
,	O
including	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
alpha	I-Protein
and	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
,	O
cause	O
rapid	O
degradation	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
-	I-Protein
alpha	I-Protein
,	O
with	O
concomitant	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
followed	O
by	O
a	O
dramatic	O
increase	O
in	O
I	B-Protein
kappa	I-Protein
B	I-Protein
-	I-Protein
alpha	I-Protein
mRNA	O
and	O
protein	O
synthesis	O
.	O

Transfection	O
studies	O
reveal	O
that	O
the	O
I	B-Protein
kappa	I-Protein
B	I-Protein
-	I-Protein
alpha	I-Protein
mRNA	O
and	O
the	O
encoded	O
protein	O
are	O
potently	O
induced	O
by	O
NF	O
-	O
kappa	O
B	O
and	O
by	O
homodimers	O
of	O
p65	B-Protein
and	O
of	O
c	B-Protein
-	I-Protein
Rel	I-Protein
.	O

We	O
propose	O
a	O
model	O
in	O
which	O
NF	O
-	O
kappa	O
B	O
and	O
I	B-Protein
kappa	I-Protein
B	I-Protein
-	I-Protein
alpha	I-Protein
mutually	O
regulate	O
each	O
other	O
in	O
a	O
cycle	O
:	O
saturating	O
amounts	O
of	O
the	O
inhibitory	O
I	B-Protein
kappa	I-Protein
B	I-Protein
-	I-Protein
alpha	I-Protein
protein	O
are	O
destroyed	O
upon	O
stimulation	O
,	O
allowing	O
rapid	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

Subsequently	O
,	O
I	B-Protein
kappa	I-Protein
B	I-Protein
-	I-Protein
alpha	I-Protein
mRNA	O
and	O
protein	O
levels	O
are	O
quickly	O
induced	O
by	O
the	O
activated	O
NF	O
-	O
kappa	O
B	O
.	O

This	O
resurgence	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
-	I-Protein
alpha	I-Protein
protein	O
acts	O
to	O
restore	O
an	O
equilibrium	O
in	O
which	O
NF	O
-	O
kappa	O
B	O
is	O
again	O
inhibited	O
.	O

Lipopolysaccharide	O
induces	O
phosphorylation	O
of	O
MAD3	B-Protein
and	O
activation	O
of	O
c	B-Protein
-	I-Protein
Rel	I-Protein
and	O
related	O
NF	O
-	O
kappa	O
B	O
proteins	O
in	O
human	O
monocytic	O
THP	O
-	O
1	O
cells	O
.	O

Many	O
effects	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
on	O
gene	O
expression	O
,	O
including	O
that	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
,	O
in	O
monocytic	O
cells	O
are	O
mediated	O
by	O
activation	O
of	O
kappa	O
B	O
DNA	O
-	O
binding	O
proteins	O
.	O

However	O
,	O
the	O
specific	O
members	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
transcription	O
factor	O
family	O
involved	O
in	O
the	O
LPS	O
response	O
,	O
and	O
the	O
mechanisms	O
through	O
which	O
LPS	O
-	O
generated	O
signals	O
are	O
transduced	O
remain	O
unclear	O
.	O

Here	O
we	O
show	O
that	O
LPS	O
induces	O
nuclear	O
expression	O
of	O
c	B-Protein
-	I-Protein
Rel	I-Protein
/	O
p50	B-Protein
heterodimers	O
as	O
well	O
as	O
p50	B-Protein
/	O
p65	B-Protein
(	O
NF	O
-	O
kappa	O
B	O
)	O
kappa	O
B	O
DNA	O
-	O
binding	O
complexes	O
in	O
human	O
monocytic	O
THP	O
-	O
1	O
cells	O
.	O

Nuclear	O
localization	O
of	O
these	O
proteins	O
occurred	O
concomitantly	O
with	O
a	O
rapid	O
decrease	O
in	O
their	O
cytosolic	O
levels	O
and	O
was	O
independent	O
of	O
phorbol	O
ester	O
-	O
sensitive	O
protein	O
kinase	O
C	O
.	O

Within	O
24	O
h	O
following	O
LPS	O
stimulation	O
there	O
was	O
a	O
striking	O
increase	O
in	O
the	O
levels	O
of	O
c	B-Protein
-	I-Protein
Rel	I-Protein
,	O
p105	B-Protein
,	O
and	O
p50	B-Protein
in	O
the	O
cytosol	O
.	O

The	O
increased	O
levels	O
of	O
these	O
proteins	O
correlated	O
with	O
increases	O
in	O
the	O
amounts	O
of	O
their	O
mRNAs	O
during	O
LPS	O
activation	O
of	O
THP	O
-	O
1	O
cells	O
.	O

LPS	O
activation	O
of	O
THP	O
-	O
1	O
cells	O
resulted	O
in	O
phosphorylation	O
of	O
MAD3	B-Protein
(	O
an	O
I	O
kappa	O
B	O
-	O
like	O
protein	O
)	O
,	O
a	O
rapid	O
increase	O
in	O
MAD3	B-Protein
mRNA	O
,	O
and	O
an	O
increase	O
in	O
MAD3	B-Protein
protein	O
by	O
2	O
h	O
.	O

Thus	O
,	O
LPS	O
activation	O
of	O
human	O
monocytic	O
cells	O
results	O
in	O
nuclear	O
expression	O
of	O
c	B-Protein
-	I-Protein
Rel	I-Protein
/	O
p50	B-Protein
and	O
p50	B-Protein
/	O
p65	B-Protein
(	O
NF	O
-	O
kappa	O
B	O
)	O
and	O
induces	O
phosphorylation	O
of	O
MAD3	B-Protein
.	O

Transcriptional	O
activation	O
of	O
the	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
gene	O
by	O
IL	B-Protein
-	I-Protein
2	I-Protein
is	O
associated	O
with	O
secretion	O
of	O
bioactive	O
macrophage	B-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	I-Protein
protein	O
by	O
monocytes	O
and	O
involves	O
activation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
.	O

Human	O
peripheral	O
blood	O
monocytes	O
(	O
Mo	O
)	O
constitutively	O
display	O
the	O
beta	O
-	O
chain	O
of	O
the	O
receptor	O
for	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
whereas	O
expression	O
of	O
the	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	I-Protein
-	O
chain	O
is	O
not	O
constitutive	O
but	O
inducible	O
with	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O

Here	O
we	O
report	O
that	O
binding	O
of	O
human	O
IL	B-Protein
-	I-Protein
2	I-Protein
to	O
its	O
binding	O
site	O
leads	O
to	O
transcriptional	O
activation	O
of	O
the	O
macrophage	B-Protein
CSF	I-Protein
(	O
M	B-Protein
-	I-Protein
CSF	I-Protein
)	O
gene	O
in	O
Mo	O
resulting	O
in	O
accumulation	O
of	O
M	B-Protein
-	I-Protein
CSF	I-Protein
mRNA	O
and	O
subsequent	O
release	O
of	O
bioactive	O
M	B-Protein
-	I-Protein
CSF	I-Protein
protein	O
as	O
demonstrated	O
by	O
ELISA	O
and	O
inhibition	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
induced	O
release	O
of	O
an	O
activity	O
-	O
stimulating	O
growth	O
of	O
monocyte	O
-	O
type	O
colonies	O
by	O
a	O
neutralizing	O
anti	O
-	O
M	B-Protein
-	I-Protein
CSF	I-Protein
antibody	O
.	O

Transcriptional	O
activation	O
of	O
the	O
M	B-Protein
-	I-Protein
CSF	I-Protein
gene	O
by	O
IL	B-Protein
-	I-Protein
2	I-Protein
is	O
preceded	O
by	O
enhanced	O
binding	O
activity	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
to	O
its	O
recognition	O
sequence	O
in	O
the	O
5	O
'	O
regulatory	O
enhancer	O
region	O
of	O
the	O
M	B-Protein
-	I-Protein
CSF	I-Protein
gene	O
.	O

Moreover	O
,	O
using	O
a	O
heterologous	O
promoter	O
(	O
herpes	O
thymidine	O
kinase	O
)	O
construct	O
containing	O
the	O
NF	O
-	O
kappa	O
B	O
consensus	O
sequence	O
,	O
it	O
is	O
shown	O
that	O
NF	O
-	O
kappa	O
B	O
binding	O
by	O
an	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
induced	O
monocyte	O
-	O
derived	O
nuclear	O
protein	O
confers	O
reporter	O
gene	O
(	O
human	O
growth	O
hormone	O
)	O
activity	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
indicate	O
that	O
IL	B-Protein
-	I-Protein
2	I-Protein
induces	O
gene	O
expression	O
of	O
M	B-Protein
-	I-Protein
CSF	I-Protein
in	O
human	O
blood	O
-	O
derived	O
Mo	O
and	O
provide	O
evidence	O
for	O
involvement	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
transcriptional	O
regulation	O
of	O
this	O
gene	O
.	O

Age	O
-	O
related	O
decreases	O
in	O
IL	B-Protein
-	I-Protein
2	I-Protein
production	O
by	O
human	O
T	O
cells	O
are	O
associated	O
with	O
impaired	O
activation	O
of	O
nuclear	O
transcriptional	O
factors	O
AP	O
-	O
1	O
and	O
NF	O
-	O
AT	O
.	O

Although	O
transcriptional	O
factors	O
AP	O
-	O
1	O
and	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
are	O
important	O
for	O
the	O
normal	O
induction	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
it	O
is	O
unknown	O
if	O
the	O
age	O
-	O
related	O
decline	O
in	O
IL	B-Protein
-	I-Protein
2	I-Protein
production	O
by	O
activated	O
human	O
T	O
cells	O
may	O
be	O
associated	O
with	O
aberrancies	O
in	O
transcriptional	O
regulatory	O
proteins	O
.	O

In	O
the	O
current	O
studies	O
,	O
IL	B-Protein
-	I-Protein
2	I-Protein
production	O
by	O
T	O
cells	O
from	O
elderly	O
(	O
mean	O
78	O
years	O
)	O
and	O
young	O
(	O
mean	O
37	O
years	O
)	O
humans	O
was	O
measured	O
in	O
cultures	O
stimulated	O
with	O
PHA	B-Protein
,	O
PHA	B-Protein
plus	O
PMA	O
,	O
crosslinked	O
anti	O
-	O
CD3	O
mAB	O
OKT3	O
plus	O
PMA	O
,	O
or	O
PMA	O
plus	O
ionomycin	O
.	O

Substantial	O
decreases	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
production	O
were	O
observed	O
for	O
cell	O
cultures	O
from	O
7	O
of	O
12	O
elderly	O
individuals	O
in	O
response	O
to	O
the	O
different	O
stimuli	O
,	O
whereas	O
the	O
levels	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
produced	O
by	O
stimulated	O
T	O
cells	O
from	O
other	O
elderly	O
individuals	O
were	O
equivalent	O
to	O
those	O
observed	O
for	O
stimulated	O
T	O
cells	O
of	O
young	O
subjects	O
.	O

Analyses	O
of	O
nuclear	O
extracts	O
by	O
electrophoretic	O
DNA	O
mobility	O
shift	O
assays	O
showed	O
that	O
decreased	O
IL	B-Protein
-	I-Protein
2	I-Protein
production	O
by	O
stimulated	O
T	O
cells	O
of	O
elderly	O
individuals	O
was	O
closely	O
associated	O
with	O
impairments	O
in	O
the	O
activation	O
of	O
both	O
AP	O
-	O
1	O
and	O
NF	O
-	O
AT	O
.	O

By	O
contrast	O
,	O
T	O
cells	O
from	O
elderly	O
subjects	O
with	O
normal	O
levels	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
production	O
exhibited	O
normal	O
activation	O
of	O
AP	O
-	O
1	O
and	O
NF	O
-	O
AT	O
.	O

In	O
addition	O
,	O
the	O
results	O
of	O
competition	O
experiments	O
analyzing	O
the	O
normal	O
components	O
of	O
NF	O
-	O
AT	O
showed	O
that	O
the	O
age	O
-	O
related	O
reductions	O
in	O
stimulus	O
-	O
dependent	O
NF	O
-	O
AT	O
complexes	O
corresponded	O
to	O
the	O
slow	O
migrating	O
complexes	O
that	O
were	O
composed	O
of	O
c	B-Protein
-	I-Protein
Fos	I-Protein
/	O
c	B-Protein
-	I-Protein
Jun	I-Protein
AP	O
-	O
1	O
.	O

The	O
resting	O
and	O
stimulated	O
levels	O
of	O
NF	O
kappa	O
B	O
were	O
reduced	O
in	O
T	O
cells	O
from	O
certain	O
elderly	O
individuals	O
;	O
however	O
,	O
alterations	O
of	O
NF	O
kappa	O
B	O
did	O
not	O
correlate	O
with	O
changes	O
in	O
IL	B-Protein
-	I-Protein
2	I-Protein
expression	O
.	O

Thus	O
,	O
these	O
results	O
show	O
that	O
age	O
-	O
related	O
impairments	O
in	O
the	O
activation	O
of	O
AP	O
-	O
1	O
and	O
NF	O
-	O
AT	O
are	O
closely	O
associated	O
with	O
decreased	O
expression	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
and	O
further	O
suggest	O
that	O
aberrancies	O
in	O
the	O
signaling	O
pathways	O
important	O
for	O
the	O
induction	O
of	O
transcriptionally	O
active	O
c	B-Protein
-	I-Protein
Fos	I-Protein
/	O
c	B-Protein
-	I-Protein
Jun	I-Protein
AP	O
-	O
1	O
may	O
contribute	O
to	O
the	O
impaired	O
activation	O
of	O
NF	O
-	O
AT	O
.	O

Effects	O
of	O
interleukin	B-Protein
-	I-Protein
10	I-Protein
on	O
human	O
peripheral	O
blood	O
mononuclear	O
cell	O
responses	O
to	O
Cryptococcus	O
neoformans	O
,	O
Candida	O
albicans	O
,	O
and	O
lipopolysaccharide	O
.	O

Deactivation	O
of	O
mononuclear	O
phagocytes	O
is	O
critical	O
to	O
limit	O
the	O
inflammatory	O
response	O
but	O
can	O
be	O
detrimental	O
in	O
the	O
face	O
of	O
progressive	O
infection	O
.	O

We	O
compared	O
the	O
effects	O
of	O
the	O
deactivating	O
cytokine	O
interleukin	B-Protein
10	I-Protein
(	O
IL	B-Protein
-	I-Protein
10	I-Protein
)	O
on	O
human	O
peripheral	O
blood	O
mononuclear	O
cell	O
(	O
PBMC	O
)	O
responses	O
to	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
Cryptococcus	O
neoformans	O
,	O
and	O
Candida	O
albicans	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
effected	O
dose	O
-	O
dependent	O
inhibition	O
of	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
alpha	I-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
)	O
release	O
in	O
PBMC	O
stimulated	O
by	O
LPS	O
and	O
C	O
.	O
neoformans	O
,	O
with	O
significant	O
inhibition	O
seen	O
with	O
0	O
.	O
1	O
U	O
/	O
ml	O
and	O
greater	O
than	O
90	O
%	O
inhibition	O
noted	O
with	O
10	O
U	O
/	O
ml	O
.	O

In	O
contrast	O
,	O
even	O
at	O
doses	O
as	O
high	O
as	O
100	O
U	O
/	O
ml	O
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
inhibited	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
release	O
in	O
response	O
to	O
C	O
.	O
albicans	O
by	O
only	O
50	O
%	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
profoundly	O
inhibited	O
release	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
from	O
PBMC	O
stimulated	O
by	O
all	O
three	O
stimuli	O
.	O

TNF	B-Protein
-	I-Protein
alpha	I-Protein
mRNA	O
and	O
release	O
was	O
inhibited	O
even	O
if	O
IL	B-Protein
-	I-Protein
10	I-Protein
was	O
added	O
up	O
to	O
8	O
h	O
after	O
cryptococcal	O
stimulation	O
.	O

In	O
contrast	O
,	O
inhibition	O
of	O
IL	B-Protein
-	I-Protein
1	I-Protein
beta	I-Protein
mRNA	O
was	O
of	O
lesser	O
magnitude	O
and	O
occurred	O
only	O
when	O
IL	B-Protein
-	I-Protein
10	I-Protein
was	O
added	O
within	O
2	O
h	O
of	O
cryptococcal	O
stimulation	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
inhibited	O
translocation	O
of	O
NF	O
-	O
kappaB	O
in	O
response	O
to	O
LPS	O
but	O
not	O
the	O
fungal	O
stimuli	O
.	O

All	O
three	O
stimuli	O
induced	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
in	O
PBMC	O
,	O
although	O
over	O
10	O
-	O
fold	O
less	O
IL	B-Protein
-	I-Protein
10	I-Protein
was	O
released	O
in	O
response	O
to	O
C	O
.	O
neoformans	O
compared	O
with	O
LPS	O
and	O
C	O
.	O
albicans	O
.	O

Thus	O
,	O
while	O
IL	B-Protein
-	I-Protein
10	I-Protein
has	O
deactivating	O
effects	O
on	O
PBMC	O
responses	O
to	O
all	O
three	O
stimuli	O
,	O
disparate	O
stimulus	O
-	O
and	O
response	O
-	O
specific	O
patterns	O
of	O
deactivation	O
are	O
seen	O
.	O

Inhibition	O
by	O
IL	B-Protein
-	I-Protein
10	I-Protein
of	O
proinflammatory	O
cytokine	O
release	O
appears	O
to	O
occur	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
for	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
and	O
both	O
transcriptionally	O
and	O
posttranscriptionally	O
for	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
.	O

Epstein	O
-	O
Barr	O
virus	O
nuclear	B-Protein
antigen	I-Protein
2	I-Protein
and	O
latent	O
membrane	O
protein	O
independently	O
transactivate	O
p53	B-Protein
through	O
induction	O
of	O
NF	O
-	O
kappaB	O
activity	O
.	O

B	O
-	O
cell	O
immortalization	O
by	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
is	O
dependent	O
on	O
permanent	O
control	O
of	O
the	O
cellular	O
processes	O
which	O
normally	O
regulate	O
cell	O
division	O
and	O
apoptosis	O
,	O
functions	O
possessed	O
by	O
p53	B-Protein
in	O
a	O
number	O
of	O
normal	O
cell	O
types	O
.	O

In	O
studies	O
initiated	O
to	O
evaluate	O
relationships	O
between	O
EBV	O
latent	O
genes	O
and	O
p53	B-Protein
,	O
p53	B-Protein
levels	O
were	O
found	O
to	O
increase	O
approximately	O
10	O
-	O
fold	O
4	O
to	O
5	O
days	O
after	O
EBV	O
infection	O
of	O
purified	O
resting	O
human	O
B	O
cells	O
;	O
the	O
induced	O
p53	B-Protein
was	O
transcriptionally	O
active	O
.	O

Latent	B-Protein
membrane	I-Protein
protein	I-Protein
1	I-Protein
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
EBV	O
nuclear	B-Protein
antigen	I-Protein
2	I-Protein
mediated	O
the	O
increase	O
in	O
p53	B-Protein
levels	O
via	O
activation	O
of	O
the	O
NF	O
-	O
kappaB	O
transcription	O
factor	O
.	O

Protein	O
-	O
tyrosine	O
kinase	O
activation	O
is	O
required	O
for	O
lipopolysaccharide	O
induction	O
of	O
interleukin	B-Protein
1beta	I-Protein
and	O
NFkappaB	O
activation	O
,	O
but	O
not	O
NFkappaB	O
nuclear	O
translocation	O
.	O

In	O
human	O
monocytes	O
,	O
interleukin	B-Protein
1beta	I-Protein
protein	O
production	O
and	O
steady	O
state	O
mRNA	O
levels	O
are	O
increased	O
in	O
response	O
to	O
lipopolysaccharide	O
,	O
predominantly	O
as	O
a	O
result	O
of	O
increased	O
transcription	O
of	O
the	O
interleukin	B-Protein
1beta	I-Protein
gene	O
.	O

Expression	O
of	O
interleukin	B-Protein
1beta	I-Protein
and	O
other	O
cytokines	O
,	O
such	O
as	O
interleukin	B-Protein
6	I-Protein
and	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
alpha	I-Protein
,	O
has	O
been	O
shown	O
to	O
be	O
dependent	O
on	O
the	O
activation	O
of	O
the	O
transcription	O
factor	O
,	O
NFkappaB	O
.	O

Since	O
recent	O
studies	O
have	O
shown	O
that	O
lipopolysaccharide	O
-	O
induced	O
tyrosine	O
kinase	O
activation	O
is	O
not	O
required	O
for	O
NFkappaB	O
nuclear	O
translocation	O
,	O
we	O
sought	O
to	O
determine	O
whether	O
NFkappaB	O
translocated	O
in	O
the	O
absence	O
of	O
tyrosine	O
kinase	O
activity	O
was	O
active	O
in	O
stimulating	O
transcription	O
.	O

We	O
have	O
found	O
that	O
,	O
in	O
the	O
human	O
pro	O
-	O
monocytic	O
cell	O
line	O
,	O
THP	O
-	O
1	O
,	O
the	O
lipopolysaccharide	O
-	O
induced	O
expression	O
of	O
interleukin	B-Protein
1beta	I-Protein
is	O
dependent	O
on	O
tyrosine	O
kinase	O
activation	O
.	O

Tyrosine	O
kinases	O
are	O
not	O
required	O
for	O
lipopolysaccharide	O
-	O
mediated	O
nuclear	O
translocation	O
of	O
NFkappaB	O
.	O

However	O
,	O
in	O
the	O
absence	O
of	O
tyrosine	O
kinase	O
activity	O
,	O
the	O
ability	O
of	O
NFkappaB	O
to	O
stimulate	O
transcription	O
is	O
impaired	O
.	O

This	O
inhibition	O
of	O
transcription	O
is	O
specific	O
for	O
NFkappaB	O
;	O
in	O
the	O
absence	O
of	O
tyrosine	O
kinase	O
activity	O
,	O
AP	O
-	O
1	O
-	O
dependent	O
transcription	O
is	O
enhanced	O
.	O

These	O
results	O
suggest	O
that	O
,	O
while	O
lipopolysaccharide	O
-	O
induced	O
expression	O
of	O
inflammatory	O
mediators	O
requires	O
tyrosine	O
kinase	O
activity	O
,	O
tyrosine	O
kinase	O
activity	O
is	O
not	O
obligatory	O
for	O
lipopolysaccharide	O
signal	O
transduction	O
.	O

Elevated	O
cyclic	O
AMP	O
inhibits	O
NF	O
-	O
kappaB	O
-	O
mediated	O
transcription	O
in	O
human	O
monocytic	O
cells	O
and	O
endothelial	O
cells	O
.	O

The	O
NF	O
-	O
kappaB	O
/	O
Rel	O
family	O
of	O
transcription	O
factors	O
regulates	O
the	O
inducible	O
expression	O
of	O
many	O
genes	O
in	O
activated	O
human	O
monocytes	O
and	O
endothelial	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
molecular	O
mechanism	O
by	O
which	O
agents	O
that	O
elevate	O
intracellular	O
cAMP	O
inhibit	O
the	O
expression	O
of	O
the	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
alpha	I-Protein
(	O
TNFalpha	B-Protein
)	O
,	O
tissue	B-Protein
factor	I-Protein
,	O
endothelial	B-Protein
leukocyte	I-Protein
adhesion	I-Protein
molecule	I-Protein
-	I-Protein
1	I-Protein
,	O
and	O
vascular	B-Protein
cell	I-Protein
adhesion	I-Protein
molecule	I-Protein
-	I-Protein
1	I-Protein
genes	O
.	O

Both	O
forskolin	O
and	O
dibutyryl	O
cAMP	O
,	O
which	O
elevate	O
intracellular	O
cAMP	O
by	O
independent	O
mechanisms	O
,	O
inhibited	O
TNFalpha	B-Protein
and	O
tissue	B-Protein
factor	I-Protein
expression	O
at	O
the	O
level	O
of	O
transcription	O
.	O

Induction	O
of	O
NF	O
-	O
kappaB	O
-	O
dependent	O
gene	O
expression	O
in	O
transiently	O
transfected	O
human	O
monocytic	O
THP	O
-	O
1	O
cells	O
and	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
was	O
inhibited	O
by	O
elevated	O
cAMP	O
and	O
by	O
overexpression	O
of	O
the	O
catalytic	O
subunit	O
of	O
protein	O
kinase	O
A	O
(	O
PKA	O
)	O
.	O

Elevated	O
cAMP	O
did	O
not	O
prevent	O
nuclear	O
translocation	O
of	O
p50	B-Protein
/	O
p65	B-Protein
and	O
c	B-Protein
-	I-Protein
Rel	I-Protein
/	O
p65	B-Protein
heterodimers	O
,	O
decrease	O
nuclear	O
translocation	O
of	O
p65	B-Protein
,	O
or	O
significantly	O
modify	O
TNFalpha	B-Protein
-	O
induced	O
phosphorylation	O
of	O
p65	B-Protein
.	O

Functional	O
studies	O
demonstrated	O
that	O
transcriptional	O
activation	O
of	O
a	O
plasmid	O
containing	O
multimerized	O
kappaB	O
sites	O
by	O
p65	B-Protein
was	O
inhibited	O
by	O
agents	O
that	O
elevate	O
cAMP	O
and	O
by	O
overexpression	O
of	O
the	O
catalytic	O
subunit	O
of	O
PKA	O
.	O

This	O
study	O
indicates	O
that	O
activation	O
of	O
PKA	O
reduces	O
the	O
induction	O
of	O
a	O
distinct	O
set	O
of	O
genes	O
in	O
monocytes	O
and	O
endothelial	O
cells	O
by	O
inhibiting	O
NF	O
-	O
kappaB	O
-	O
mediated	O
transcription	O
.	O

Retinoic	O
acid	O
activates	O
interferon	B-Protein
regulatory	I-Protein
factor	I-Protein
-	I-Protein
1	I-Protein
gene	O
expression	O
in	O
myeloid	O
cells	O
.	O

All	O
-	O
trans	O
-	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
is	O
the	O
drug	O
of	O
choice	O
in	O
the	O
treatment	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
.	O

ATRA	O
induces	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
differentiation	O
of	O
APL	O
cells	O
into	O
mature	O
granulocytes	O
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
ATRA	O
-	O
dependent	O
growth	O
inhibition	O
and	O
cellular	O
differentiation	O
are	O
not	O
presently	O
understood	O
.	O

The	O
NB4	O
cell	O
line	O
,	O
which	O
is	O
derived	O
from	O
the	O
bone	O
marrow	O
of	O
a	O
patient	O
with	O
APL	O
during	O
relapse	O
,	O
can	O
be	O
used	O
as	O
a	O
model	O
system	O
to	O
study	O
the	O
growth	O
and	O
differentiation	O
of	O
APL	O
cells	O
.	O

Because	O
interferon	O
(	O
IFN	O
)	O
regulatory	O
factors	O
(	O
IRF	B-Protein
-	I-Protein
1	I-Protein
and	O
IRF	B-Protein
-	I-Protein
2	I-Protein
)	O
and	O
other	O
IFN	O
-	O
inducible	O
gene	O
products	O
regulate	O
cell	O
growth	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
ATRA	O
on	O
the	O
expression	O
of	O
these	O
genes	O
.	O

We	O
show	O
that	O
ATRA	O
directly	O
activates	O
IRF	B-Protein
-	I-Protein
1	I-Protein
gene	O
expression	O
,	O
followed	O
by	O
activation	O
of	O
IRF	B-Protein
-	I-Protein
2	I-Protein
and	O
2	O
'	O
-	O
5	O
'	O
oligoadenylate	O
synthetase	O
(	O
OAS	O
)	O
gene	O
expression	O
with	O
slower	O
kinetics	O
.	O

In	O
addition	O
to	O
NB4	O
cells	O
,	O
ATRA	O
also	O
activated	O
IRF	B-Protein
-	I-Protein
1	I-Protein
gene	O
expression	O
in	O
HL	O
-	O
60	O
,	O
U937	O
,	O
and	O
THP	O
-	O
1	O
cells	O
,	O
which	O
all	O
respond	O
to	O
ATRA	O
by	O
growth	O
inhibition	O
.	O

A	O
more	O
than	O
additive	O
increase	O
in	O
IRF	B-Protein
-	I-Protein
1	I-Protein
gene	O
expression	O
was	O
seen	O
with	O
ATRA	O
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
in	O
NB4	O
cells	O
.	O

ATRA	O
did	O
not	O
activate	O
nuclear	O
factor	O
kappa	O
B	O
or	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	O
)	O
activation	O
pathways	O
,	O
suggesting	O
that	O
an	O
alternate	O
mechanism	O
is	O
involved	O
in	O
IRF	B-Protein
-	I-Protein
1	I-Protein
gene	O
activation	O
.	O

The	O
ATRA	O
-	O
induced	O
expression	O
of	O
IRF	B-Protein
-	I-Protein
1	I-Protein
,	O
an	O
activator	O
of	O
transcription	O
and	O
repressor	O
of	O
transformation	O
,	O
may	O
be	O
one	O
of	O
the	O
molecular	O
mechanisms	O
of	O
ATRA	O
-	O
induced	O
growth	O
inhibition	O
,	O
and	O
the	O
basis	O
for	O
the	O
synergistic	O
actions	O
of	O
ATRA	O
and	O
IFNs	O
in	O
myeloid	O
leukemia	O
cells	O
.	O

Effects	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
IL	B-Protein
-	I-Protein
4	I-Protein
on	O
LPS	O
-	O
induced	O
transcription	O
factors	O
(	O
AP	O
-	O
1	O
,	O
NF	B-Protein
-	I-Protein
IL6	I-Protein
and	O
NF	O
-	O
kappa	O
B	O
)	O
which	O
are	O
involved	O
in	O
IL	B-Protein
-	I-Protein
6	I-Protein
regulation	O
.	O

Interleukin	B-Protein
-	I-Protein
10	I-Protein
(	O
IL	B-Protein
-	I-Protein
10	I-Protein
)	O
,	O
like	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
is	O
known	O
to	O
inhibit	O
cytokine	O
expression	O
in	O
activated	O
human	O
monocytes	O
.	O

We	O
showed	O
that	O
both	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
IL	B-Protein
-	I-Protein
4	I-Protein
inhibit	O
LPS	O
-	O
induced	O
IL	B-Protein
-	I-Protein
6	I-Protein
mRNA	O
and	O
protein	O
expression	O
by	O
inhibiting	O
the	O
transcription	O
rate	O
of	O
the	O
IL	B-Protein
-	I-Protein
6	I-Protein
gene	O
.	O

The	O
strong	O
inhibition	O
of	O
the	O
IL	B-Protein
-	I-Protein
6	I-Protein
transcription	O
rate	O
prompted	O
us	O
to	O
study	O
the	O
effect	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
IL	B-Protein
-	I-Protein
4	I-Protein
on	O
the	O
expression	O
of	O
transcription	O
factors	O
.	O

We	O
questioned	O
whether	O
or	O
not	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
IL	B-Protein
-	I-Protein
4	I-Protein
affected	O
the	O
expression	O
of	O
transcription	O
factors	O
that	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
control	O
of	O
the	O
IL	B-Protein
-	I-Protein
6	I-Protein
transcription	O
rate	O
,	O
namely	O
activator	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
,	O
nuclear	B-Protein
factor	I-Protein
IL	I-Protein
-	I-Protein
6	I-Protein
(	O
NF	B-Protein
-	I-Protein
IL6	I-Protein
)	O
,	O
and	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappaB	O
)	O
.	O

In	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
we	O
showed	O
that	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
IL	B-Protein
-	I-Protein
4	I-Protein
inhibited	O
LPS	O
-	O
induced	O
AP	O
-	O
1	O
binding	O
activity	O
.	O

The	O
inhibiting	O
effect	O
of	O
IL	B-Protein
-	I-Protein
4	I-Protein
was	O
slightly	O
more	O
pronounced	O
than	O
that	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
.	O

Downregulation	O
of	O
LPS	O
-	O
induced	O
AP	O
-	O
1	O
was	O
accompanied	O
,	O
and	O
thus	O
possibly	O
explained	O
,	O
by	O
a	O
reduced	O
expression	O
at	O
mRNA	O
level	O
of	O
the	O
two	O
major	O
components	O
of	O
the	O
AP	O
-	O
1	O
complex	O
,	O
namely	O
c	B-Protein
-	I-Protein
fos	I-Protein
and	O
c	B-Protein
-	I-Protein
jun	I-Protein
as	O
determined	O
by	O
Northern	O
experiments	O
.	O

Binding	O
activity	O
of	O
NF	B-Protein
-	I-Protein
IL6	I-Protein
was	O
also	O
strongly	O
inhibited	O
by	O
IL	B-Protein
-	I-Protein
4	I-Protein
whereas	O
IL	B-Protein
-	I-Protein
10	I-Protein
showed	O
no	O
effect	O
.	O

NF	B-Protein
-	I-Protein
IL6	I-Protein
mRNA	O
levels	O
were	O
not	O
affected	O
by	O
IL	B-Protein
-	I-Protein
10	I-Protein
or	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
suggesting	O
that	O
IL	B-Protein
-	I-Protein
4	I-Protein
affects	O
binding	O
activity	O
of	O
preexisting	O
NF	B-Protein
-	I-Protein
IL6	I-Protein
.	O

Neither	O
IL	B-Protein
-	I-Protein
10	I-Protein
nor	O
IL	B-Protein
-	I-Protein
4	I-Protein
inhibited	O
LPS	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
binding	O
activity	O
.	O

In	O
agreement	O
with	O
this	O
finding	O
,	O
Northern	O
experiments	O
where	O
p65	B-Protein
and	O
p105	B-Protein
mRNA	O
levels	O
were	O
determined	O
,	O
demonstrated	O
that	O
expression	O
of	O
these	O
components	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
transcription	O
factor	O
were	O
not	O
affected	O
by	O
IL	B-Protein
-	I-Protein
10	I-Protein
or	O
IL	B-Protein
-	I-Protein
4	I-Protein
.	O

Furthermore	O
,	O
neither	O
IL	B-Protein
-	I-Protein
10	I-Protein
nor	O
IL	B-Protein
-	I-Protein
4	I-Protein
showed	O
any	O
effect	O
on	O
I	O
-	O
kappa	O
B	O
mRNA	O
expression	O
as	O
determined	O
by	O
Northern	O
experiments	O
.	O

Thus	O
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
IL	B-Protein
-	I-Protein
4	I-Protein
similarly	O
affect	O
IL	B-Protein
-	I-Protein
6	I-Protein
expression	O
.	O

However	O
,	O
for	O
IL	B-Protein
-	I-Protein
4	I-Protein
this	O
was	O
accompanied	O
with	O
a	O
reduction	O
of	O
AP	O
-	O
1	O
and	O
NF	B-Protein
-	I-Protein
IL6	I-Protein
binding	O
activity	O
whereas	O
IL	B-Protein
-	I-Protein
10	I-Protein
only	O
inhibited	O
AP	O
-	O
1	O
binding	O
activity	O
.	O

Activation	O
of	O
human	O
monocytic	O
cells	O
by	O
Treponema	O
pallidum	O
and	O
Borrelia	O
burgdorferi	O
lipoproteins	O
and	O
synthetic	O
lipopeptides	O
proceeds	O
via	O
a	O
pathway	O
distinct	O
from	O
that	O
of	O
lipopolysaccharide	O
but	O
involves	O
the	O
transcriptional	O
activator	O
NF	O
-	O
kappa	O
B	O
.	O

There	O
is	O
increasing	O
evidence	O
that	O
lipoproteins	O
of	O
Treponema	O
pallidum	O
and	O
Borrelia	O
burgdorferi	O
are	O
key	O
inflammatory	O
mediators	O
during	O
syphilis	O
and	O
Lyme	O
disease	O
.	O

A	O
principal	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
identify	O
more	O
precisely	O
similarities	O
and	O
divergences	O
among	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
and	O
lipoprotein	O
-	O
lipopeptide	O
-	O
induced	O
immune	O
cell	O
signaling	O
events	O
.	O

Like	O
LPS	O
,	O
purified	O
native	O
B	O
.	O
burgdorferi	O
OspA	B-Protein
and	O
synthetic	O
analogs	O
of	O
OspA	B-Protein
,	O
OspB	O
,	O
and	O
two	O
T	O
.	O
pallidum	O
lipoproteins	O
(	O
Tpp47	B-Protein
and	O
Tpp17	B-Protein
)	O
all	O
induced	O
NF	O
-	O
kappa	O
B	O
translocation	O
in	O
THP	O
-	O
1	O
human	O
monocytoid	O
cells	O
.	O

Acylation	O
of	O
OspA	B-Protein
and	O
the	O
synthetic	O
peptides	O
was	O
requisite	O
for	O
cell	O
activation	O
.	O

Polymyxin	O
B	O
abrogated	O
only	O
the	O
response	O
to	O
LPS	O
.	O

By	O
using	O
70Z	O
/	O
3	O
-	O
derived	O
pre	O
-	O
B	O
-	O
cell	O
lines	O
either	O
lacking	O
or	O
expressing	O
human	O
CD14	B-Protein
(	O
the	O
LPS	O
receptor	O
)	O
,	O
it	O
was	O
observed	O
that	O
expression	O
of	O
human	O
CD14	B-Protein
imparted	O
responsiveness	O
to	O
LPS	O
but	O
not	O
to	O
OspA	B-Protein
or	O
spirochetal	O
lipopeptides	O
(	O
assessed	O
by	O
induction	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
expression	O
of	O
surface	O
immunoglobulin	O
M	O
)	O
.	O

Finally	O
,	O
the	O
biological	O
relevance	O
of	O
the	O
observation	O
that	O
T	O
.	O
pallidum	O
lipoproteins	O
-	O
lipopeptides	O
induce	O
both	O
NF	O
-	O
kappa	O
B	O
and	O
cytokine	O
production	O
in	O
monocytes	O
was	O
supported	O
by	O
the	O
ability	O
of	O
the	O
synthetic	O
analogs	O
to	O
promote	O
human	O
immunodeficiency	O
virus	O
replication	O
in	O
chronically	O
infected	O
U1	O
monocytoid	O
cells	O
;	O
these	O
observations	O
also	O
suggest	O
a	O
potential	O
mechanism	O
whereby	O
a	O
syphilitic	O
chancre	O
can	O
serve	O
as	O
a	O
cofactor	O
for	O
human	O
immunodeficiency	O
virus	O
transmission	O
.	O

The	O
combined	O
data	O
lend	O
additional	O
support	O
to	O
the	O
proposal	O
that	O
spirochetal	O
lipoproteins	O
and	O
LPS	O
initiate	O
monocyte	O
activation	O
via	O
different	O
cell	O
surface	O
events	O
but	O
that	O
the	O
signaling	O
pathways	O
ultimately	O
converge	O
to	O
produce	O
qualitatively	O
similar	O
cellular	O
responses	O
.	O

Chronic	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
infection	O
of	O
myeloid	O
cells	O
disrupts	O
the	O
autoregulatory	O
control	O
of	O
the	O
NF	O
-	O
kappaB	O
/	O
Rel	O
pathway	O
via	O
enhanced	O
IkappaBalpha	B-Protein
degradation	O
.	O

Productive	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
infection	O
causes	O
sustained	O
NF	O
-	O
kappaB	O
DNA	O
-	O
binding	O
activity	O
in	O
chronically	O
infected	O
monocytic	O
cells	O
.	O

A	O
direct	O
temporal	O
correlation	O
exists	O
between	O
HIV	O
infection	O
and	O
the	O
appearance	O
of	O
NF	O
-	O
kappaB	O
DNA	O
-	O
binding	O
activity	O
in	O
myelomonoblastic	O
PLB	O
-	O
985	O
cells	O
.	O

To	O
examine	O
the	O
molecular	O
basis	O
of	O
constitutive	O
NF	O
-	O
kappaB	O
DNA	O
-	O
binding	O
activity	O
in	O
HIV1	O
-	O
infected	O
cells	O
,	O
we	O
analyzed	O
the	O
phosphorylation	O
and	O
turnover	O
of	O
IkappaBalpha	B-Protein
protein	O
,	O
the	O
activity	O
of	O
the	O
double	B-Protein
-	I-Protein
stranded	I-Protein
RNA	I-Protein
-	I-Protein
dependent	I-Protein
protein	I-Protein
kinase	I-Protein
(	O
PKR	B-Protein
)	O
and	O
the	O
intracellular	O
levels	O
of	O
NF	O
-	O
kappaB	O
subunits	O
in	O
the	O
PLB	O
-	O
985	O
and	O
U937	O
myeloid	O
cell	O
models	O
.	O

HIV	O
-	O
1	O
infection	O
resulted	O
in	O
constitutive	O
,	O
low	O
-	O
level	O
expression	O
of	O
type	O
1	O
interferon	O
(	O
IFN	O
)	O
at	O
the	O
mRNA	O
level	O
.	O

Constitutive	O
PKR	B-Protein
activity	O
was	O
also	O
detected	O
in	O
HIV	O
-	O
1	O
-	O
infected	O
cells	O
as	O
a	O
result	O
of	O
low	O
-	O
level	O
IFN	O
production	O
,	O
since	O
the	O
addition	O
of	O
anti	O
-	O
IFN	O
-	O
alpha	O
/	O
beta	O
antibody	O
to	O
the	O
cells	O
decreased	O
PKR	B-Protein
expression	O
.	O

Furthermore	O
,	O
the	O
analysis	O
of	O
IkappaBalpha	B-Protein
turnover	O
demonstrated	O
an	O
increased	O
degradation	O
of	O
IkappaBalpha	B-Protein
in	O
HIV	O
-	O
1	O
-	O
infected	O
cells	O
that	O
may	O
account	O
for	O
the	O
constitutive	O
DNA	O
binding	O
activity	O
.	O

A	O
dramatic	O
increase	O
in	O
the	O
intracellular	O
levels	O
of	O
NF	O
-	O
kappaB	O
subunits	O
c	B-Protein
-	I-Protein
Rel	I-Protein
and	O
NF	B-Protein
-	I-Protein
kappaB2	I-Protein
p100	I-Protein
and	O
a	O
moderate	O
increase	O
in	O
NF	B-Protein
-	I-Protein
kappaB2	I-Protein
p52	I-Protein
and	O
RelA	B-Protein
(	O
p65	B-Protein
)	O
were	O
detected	O
in	O
HIV	O
-	O
1	O
-	O
infected	O
cells	O
,	O
whereas	O
NF	B-Protein
-	I-Protein
kappaB1	I-Protein
p105	I-Protein
/	O
p50	B-Protein
levels	O
were	O
not	O
altered	O
relative	O
to	O
the	O
levels	O
in	O
uninfected	O
cells	O
.	O

We	O
suggest	O
that	O
HIV	O
-	O
1	O
infection	O
of	O
myeloid	O
cells	O
induces	O
IFN	O
production	O
and	O
PKR	B-Protein
activity	O
,	O
which	O
in	O
turn	O
contribute	O
to	O
enhanced	O
IkappaBalpha	B-Protein
phosphorylation	O
and	O
subsequent	O
degradation	O
.	O

Nuclear	O
translocation	O
of	O
NF	O
-	O
kappaB	O
subunits	O
may	O
ultimately	O
increase	O
the	O
intracellular	O
pool	O
of	O
NF	O
-	O
kappaB	O
/	O
IkappaBalpha	B-Protein
by	O
an	O
autoregulatory	O
mechanism	O
.	O

Enhanced	O
turnover	O
of	O
IkappaBalpha	B-Protein
and	O
the	O
accumulation	O
of	O
NF	O
-	O
kappaB	O
/	O
Rel	O
proteins	O
may	O
contribute	O
to	O
the	O
chronically	O
activated	O
state	O
of	O
HIV	O
-	O
1	O
-	O
infected	O
cells	O
.	O

Differential	O
regulation	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
gene	O
transcription	O
and	O
expression	O
by	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
in	O
human	O
monocytic	O
cell	O
lines	O
.	O

IL	B-Protein
-	I-Protein
4	I-Protein
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
inhibit	O
the	O
cytokine	O
production	O
and	O
mRNA	O
expression	O
by	O
monocytes	O
/	O
macrophages	O
.	O

To	O
investigate	O
the	O
molecular	O
mechanism	O
of	O
the	O
inhibitory	O
effect	O
on	O
transcriptional	O
or	O
post	O
-	O
transcriptional	O
regulation	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
gene	O
expression	O
by	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
we	O
studied	O
IL	B-Protein
-	I-Protein
6	I-Protein
production	O
,	O
expression	O
level	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
mRNA	O
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
promoter	O
activity	O
,	O
transcriptional	O
activity	O
of	O
NF	O
-	O
kappaB	O
and	O
NF	B-Protein
-	I-Protein
IL	I-Protein
-	I-Protein
6	I-Protein
,	O
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
mRNA	O
stability	O
in	O
human	O
monocytic	O
cell	O
lines	O
,	O
THP	O
-	O
1	O
and	O
U937	O
,	O
stimulated	O
by	O
PMA	O
and	O
LPS	O
in	O
the	O
absence	O
or	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
4	I-Protein
or	O
IL	B-Protein
-	I-Protein
10	I-Protein
.	O

Both	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
were	O
seen	O
to	O
inhibit	O
IL	B-Protein
-	I-Protein
6	I-Protein
production	O
and	O
the	O
expression	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
mRNA	O
in	O
both	O
monocytic	O
cell	O
lines	O
studied	O
.	O

In	O
chloramphenicol	B-Protein
acetyltransferase	I-Protein
assays	O
,	O
utilizing	O
the	O
transient	O
transfection	O
of	O
a	O
chloramphenicol	B-Protein
acetyltransferase	I-Protein
reporter	O
plasmid	O
containing	O
the	O
IL	B-Protein
-	I-Protein
6	I-Protein
gene	O
promoter	O
,	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
but	O
not	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
suppressed	O
the	O
transcriptional	O
activity	O
of	O
the	O
IL	B-Protein
-	I-Protein
6	I-Protein
gene	O
promoter	O
stimulated	O
by	O
PMA	O
and	O
LPS	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
but	O
not	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
inhibited	O
nuclear	O
NF	O
-	O
kappaB	O
activity	O
,	O
and	O
that	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
did	O
not	O
affect	O
NF	B-Protein
-	I-Protein
IL	I-Protein
-	I-Protein
6	I-Protein
activity	O
.	O

On	O
the	O
other	O
hand	O
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
enhanced	O
the	O
degradation	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
mRNA	O
in	O
a	O
mRNA	O
stability	O
assay	O
.	O

These	O
results	O
suggest	O
that	O
IL	B-Protein
-	I-Protein
4	I-Protein
may	O
inhibit	O
the	O
transcription	O
of	O
the	O
IL	B-Protein
-	I-Protein
6	I-Protein
gene	O
by	O
affecting	O
NF	O
-	O
kappaB	O
binding	O
activity	O
,	O
while	O
IL	B-Protein
-	I-Protein
10	I-Protein
may	O
inhibit	O
the	O
IL	B-Protein
-	I-Protein
6	I-Protein
mRNA	O
levels	O
post	O
-	O
transcriptionally	O
,	O
without	O
suppressing	O
promoter	O
activity	O
.	O

Therefore	O
,	O
we	O
conclude	O
that	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
inhibit	O
IL	B-Protein
-	I-Protein
6	I-Protein
production	O
by	O
different	O
mechanisms	O
in	O
human	O
monocytic	O
cell	O
lines	O
.	O

Tyloxapol	O
inhibits	O
NF	O
-	O
kappa	O
B	O
and	O
cytokine	O
release	O
,	O
scavenges	O
HOCI	O
,	O
and	O
reduces	O
viscosity	O
of	O
cystic	O
fibrosis	O
sputum	O
.	O

Cystic	O
fibrosis	O
(	O
CF	O
)	O
patients	O
develop	O
progressive	O
cytokine	O
-	O
mediated	O
inflammatory	O
lung	O
disease	O
,	O
with	O
abundant	O
production	O
of	O
thick	O
,	O
tenacious	O
,	O
protease	O
-	O
and	O
oxidant	O
-	O
rich	O
purulent	O
airway	O
secretions	O
that	O
are	O
difficult	O
to	O
clear	O
even	O
with	O
physiotherapy	O
.	O

In	O
the	O
search	O
for	O
a	O
potential	O
treatment	O
,	O
we	O
have	O
tested	O
tyloxapol	O
,	O
an	O
alkylaryl	O
polyether	O
alcohol	O
polymer	O
detergent	O
previously	O
used	O
as	O
a	O
mucolytic	O
agent	O
in	O
adult	O
chronic	O
bronchitis	O
.	O

Tyloxapol	O
inhibits	O
activation	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NK	O
-	O
kappa	O
B	O
)	O
,	O
reduces	O
resting	O
secretion	O
of	O
the	O
cytokine	O
interleukin	B-Protein
-	I-Protein
8	I-Protein
(	O
IL	B-Protein
-	I-Protein
8	I-Protein
)	O
in	O
cultured	O
human	O
monocytes	O
,	O
and	O
inhibits	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
stimulated	O
release	O
of	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
)	O
,	O
IL	B-Protein
-	I-Protein
1	I-Protein
beta	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
IL	B-Protein
-	I-Protein
8	I-Protein
,	O
granulocyte	B-Protein
-	I-Protein
macrophage	I-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	I-Protein
(	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
)	O
,	O
and	O
the	O
eiconsanoids	O
thromboxane	O
A2	O
and	O
leukotriene	O
B4	O
(	O
LTB4	O
)	O
.	O

We	O
have	O
previously	O
shown	O
that	O
tyloxapol	O
is	O
a	O
potent	O
antioxidant	O
for	O
hydroxyl	O
radicals	O
(	O
OH	O
)	O
.	O

Tyloxapol	O
(	O
0	O
.	O
05	O
to	O
0	O
.	O
1	O
%	O
wt	O
/	O
vol	O
)	O
effectively	O
scavenges	O
the	O
oxidant	O
hypochlorous	O
acid	O
(	O
HOCl	O
;	O
1	O
to	O
7	O
.	O
5	O
mM	O
)	O
in	O
vitro	O
,	O
and	O
protects	O
from	O
HOCl	O
-	O
mediated	O
lung	O
injury	O
in	O
rats	O
.	O

Tyloxapol	O
also	O
reduces	O
the	O
viscosity	O
of	O
CF	O
sputum	O
(	O
from	O
463	O
+	O
/	O
-	O
133	O
to	O
128	O
+	O
/	O
-	O
52	O
centipoise	O
)	O
.	O

We	O
conclude	O
that	O
tyloxapol	O
is	O
potentially	O
useful	O
as	O
a	O
new	O
antiinflammatory	O
therapy	O
for	O
CF	O
lung	O
disease	O
,	O
and	O
could	O
possibly	O
promote	O
clearance	O
of	O
secretions	O
in	O
the	O
CF	O
airway	O
.	O

Cytomegalovirus	O
modulates	O
interleukin	B-Protein
-	I-Protein
6	I-Protein
gene	O
expression	O
.	O

Complications	O
after	O
lung	O
transplantation	O
include	O
the	O
development	O
of	O
rejection	O
and	O
an	O
increased	O
incidence	O
of	O
infection	O
,	O
particularly	O
with	O
cytomegalovirus	O
(	O
CMV	O
)	O
.	O

Several	O
recent	O
studies	O
have	O
suggested	O
that	O
interleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
-	I-Protein
6	I-Protein
may	O
be	O
used	O
to	O
detect	O
both	O
infection	O
and	O
rejection	O
after	O
lung	O
transplantation	O
.	O

In	O
addition	O
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
bronchiolitis	O
obliterans	O
after	O
transplantation	O
.	O

Because	O
CMV	O
is	O
also	O
associated	O
with	O
the	O
development	O
of	O
bronchiolitis	O
obliterans	O
after	O
transplantation	O
,	O
we	O
determined	O
whether	O
CMV	O
induces	O
IL	B-Protein
-	I-Protein
6	I-Protein
gene	O
expression	O
.	O

We	O
demonstrated	O
that	O
CMV	O
infection	O
increased	O
both	O
IL	B-Protein
-	I-Protein
6	I-Protein
protein	O
and	O
mRNA	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

We	O
also	O
demonstrated	O
that	O
the	O
CMV	O
immediate	B-Protein
early	I-Protein
1	I-Protein
gene	O
product	O
increased	O
expression	O
of	O
the	O
IL	B-Protein
-	I-Protein
6	I-Protein
promoter	O
.	O

This	O
effect	O
of	O
the	O
CMV	O
immediate	B-Protein
early	I-Protein
1	I-Protein
gene	O
product	O
was	O
dependent	O
upon	O
the	O
presence	O
of	O
specific	O
transcription	O
factor	O
binding	O
sites	O
in	O
the	O
IL	B-Protein
-	I-Protein
6	I-Protein
promoter	O
.	O

These	O
studies	O
demonstrate	O
that	O
CMV	O
may	O
be	O
an	O
important	O
cofactor	O
in	O
the	O
development	O
of	O
rejection	O
and	O
infection	O
after	O
transplantation	O
through	O
its	O
effects	O
on	O
IL	B-Protein
-	I-Protein
6	I-Protein
.	O

Molecular	O
mechanisms	O
of	O
steroid	O
action	O
:	O
a	O
novel	O
type	O
of	O
cross	O
-	O
talk	O
between	O
glucocorticoids	O
and	O
NF	O
-	O
kappa	O
B	O
transcription	O
factors	O
.	O

Despite	O
the	O
widespread	O
use	O
of	O
glucocorticoids	O
in	O
the	O
treatment	O
of	O
diseases	O
characterized	O
by	O
inflammation	O
,	O
the	O
molecular	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
these	O
hormones	O
exert	O
this	O
beneficial	O
effect	O
in	O
patients	O
with	O
asthma	O
remains	O
to	O
be	O
elucidated	O
.	O

Therefore	O
,	O
we	O
have	O
studied	O
the	O
transcriptional	O
regulation	O
of	O
intercellular	B-Protein
adhesion	I-Protein
molecule	I-Protein
-	I-Protein
1	I-Protein
(	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
)	O
as	O
adhesion	O
molecules	O
are	O
likely	O
to	O
play	O
a	O
causal	O
role	O
in	O
inflammation	O
in	O
promoting	O
cell	O
-	O
cell	O
and	O
cell	O
-	O
matrix	O
interactions	O
.	O

We	O
observed	O
that	O
in	O
a	O
monocytic	O
(	O
U937	O
)	O
and	O
a	O
bronchial	O
epithelial	O
(	O
H292	O
)	O
cell	O
-	O
line	O
dexamethasone	O
strongly	O
suppressed	O
basal	O
and	O
induced	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
expression	O
.	O

Subsequent	O
analysis	O
of	O
the	O
human	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
promoter	O
has	O
revealed	O
that	O
both	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
and	O
tumour	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
)	O
upregulate	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
expression	O
through	O
the	O
presence	O
of	O
a	O
nuclear	O
factor	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
target	O
sequence	O
(	O
TGGAAATTCC	O
)	O
.	O

No	O
glucocorticoid	O
recognition	O
sequences	O
are	O
present	O
in	O
this	O
promoter	O
region	O
and	O
dexamethasone	O
is	O
still	O
able	O
to	O
repress	O
transcription	O
when	O
the	O
multimerized	O
NF	O
-	O
kappa	O
B	O
sequence	O
is	O
transactivated	O
by	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
upon	O
transfection	O
in	O
293	O
cells	O
.	O

We	O
propose	O
that	O
direct	O
interaction	O
between	O
the	O
glucocorticoid	B-Protein
receptor	I-Protein
and	O
nuclear	O
factor	O
-	O
kappa	O
B	O
factors	O
is	O
at	O
least	O
a	O
partial	O
explanation	O
for	O
the	O
effects	O
of	O
this	O
hormone	O
in	O
inflammatory	O
diseases	O
.	O

The	O
suppression	O
of	O
T	O
cell	O
function	O
and	O
NF	O
(	O
kappa	O
)	O
B	O
expression	O
by	O
serine	O
protease	O
inhibitors	O
is	O
blocked	O
by	O
N	O
-	O
acetylcysteine	O
.	O

Direct	O
evidence	O
that	O
N	O
-	O
acetylcysteine	O
(	O
NAC	O
)	O
enhances	O
the	O
immune	O
response	O
of	O
peripheral	O
blood	O
T	O
cells	O
at	O
the	O
level	O
of	O
NF	O
(	O
kappa	O
)	O
B	O
is	O
presented	O
.	O

In	O
addition	O
,	O
NAC	O
blocks	O
the	O
suppression	O
of	O
T	O
cell	O
mitogenesis	O
and	O
cytokine	O
production	O
by	O
protease	O
inhibitors	O
such	O
as	O
N	O
-	O
tosylphenylalanine	O
chloromethyl	O
ketone	O
(	O
TPCK	O
)	O
.	O

The	O
proliferative	O
responses	O
of	O
purified	O
CD4	B-Protein
+	O
or	O
CD8	O
+	O
T	O
cells	O
are	O
suppressed	O
more	O
strongly	O
by	O
TPCK	O
when	O
anti	O
-	O
CD28	O
rather	O
than	O
the	O
phorbol	O
ester	O
PMA	O
is	O
used	O
as	O
the	O
mitogenic	O
coactivator	O
.	O

Cytokine	O
(	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
INF	B-Protein
-	I-Protein
gamma	I-Protein
)	O
production	O
is	O
inhibited	O
95	O
-	O
100	O
%	O
by	O
concentrations	O
of	O
TPCK	O
that	O
totally	O
suppress	O
the	O
mitogenesis	O
of	O
CD4	B-Protein
+	O
or	O
CD8	O
+	O
cells	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
find	O
that	O
TPCK	O
virtually	O
abolishes	O
(	O
to	O
less	O
than	O
1	O
%	O
)	O
the	O
levels	O
of	O
NF	O
(	O
kappa	O
)	O
B	O
(	O
but	O
not	O
Oct	B-Protein
-	I-Protein
1	I-Protein
)	O
found	O
in	O
nuclear	O
and	O
whole	O
cell	O
extracts	O
of	O
activated	O
T	O
cells	O
.	O

Strikingly	O
,	O
the	O
immunosuppressive	O
effects	O
of	O
TPCK	O
are	O
blocked	O
when	O
T	O
cells	O
are	O
pretreated	O
for	O
15	O
min	O
with	O
5	O
mM	O
NAC	O
.	O

NAC	O
not	O
only	O
blocks	O
the	O
effect	O
of	O
TPCK	O
but	O
enhances	O
mitogenesis	O
and	O
cytokine	O
production	O
(	O
>	O
2	O
.	O
5	O
-	O
fold	O
in	O
some	O
cases	O
)	O
upon	O
activation	O
of	O
unsuppressed	O
T	O
cells	O
.	O

Our	O
data	O
support	O
the	O
notion	O
that	O
NF	O
(	O
kappa	O
)	O
B	O
and	O
I	O
(	O
kappa	O
)	O
B	O
proteases	O
play	O
obligate	O
roles	O
in	O
T	O
cell	O
activation	O
and	O
mitogenesis	O
,	O
roles	O
that	O
are	O
enhanced	O
significantly	O
by	O
NAC	O
.	O

Signal	O
transduction	O
by	O
DR3	B-Protein
,	O
a	O
death	O
domain	O
-	O
containing	O
receptor	O
related	O
to	O
TNFR	B-Protein
-	I-Protein
1	I-Protein
and	O
CD95	B-Protein
.	O

Tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
receptor	I-Protein
-	I-Protein
1	I-Protein
(	O
TNFR	B-Protein
-	I-Protein
1	I-Protein
)	O
and	O
CD95	B-Protein
(	O
also	O
called	O
Fas	B-Protein
or	O
APO	B-Protein
-	I-Protein
1	I-Protein
)	O
are	O
cytokine	O
receptors	O
that	O
engage	O
the	O
apoptosis	O
pathway	O
through	O
a	O
region	O
of	O
intracellular	O
homology	O
,	O
designated	O
the	O
"	O
death	O
domain	O
.	O
"	O
Another	O
death	O
domain	O
-	O
containing	O
member	O
of	O
the	O
TNFR	O
family	O
,	O
death	B-Protein
receptor	I-Protein
3	I-Protein
(	O
DR3	B-Protein
)	O
,	O
was	O
identified	O
and	O
was	O
shown	O
to	O
induce	O
both	O
apoptosis	O
and	O
activation	O
of	O
nuclear	O
factor	O
kappaB	O
.	O

Expression	O
of	O
DR3	B-Protein
appears	O
to	O
be	O
restricted	O
to	O
tissues	O
enriched	O
in	O
lymphocytes	O
.	O

DR3	B-Protein
signal	O
transduction	O
is	O
mediated	O
by	O
a	O
complex	O
of	O
intracellular	O
signaling	O
molecules	O
including	O
TRADD	B-Protein
,	O
TRAF2	B-Protein
,	O
FADD	B-Protein
,	O
and	O
FLICE	B-Protein
.	O

Thus	O
,	O
DR3	B-Protein
likely	O
plays	O
a	O
role	O
in	O
regulating	O
lymphocyte	O
homeostasis	O
.	O

Regulation	O
of	O
interferon	B-Protein
-	I-Protein
gamma	I-Protein
gene	O
expression	O
.	O

Interferon	B-Protein
-	I-Protein
gamma	I-Protein
(	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
)	O
,	O
also	O
known	O
as	O
type	B-Protein
II	I-Protein
interferon	I-Protein
,	O
is	O
an	O
important	O
immunoregulatory	O
gene	O
that	O
has	O
multiple	O
effects	O
on	O
the	O
development	O
,	O
maturation	O
,	O
and	O
function	O
of	O
the	O
immune	O
system	O
.	O

IFN	B-Protein
-	I-Protein
gamma	I-Protein
mRNA	O
and	O
protein	O
are	O
expressed	O
predominantly	O
by	O
T	O
cells	O
and	O
large	O
granular	O
lymphocytes	O
.	O

The	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
mRNA	O
is	O
induced	O
/	O
inhibited	O
in	O
these	O
cell	O
types	O
by	O
a	O
wide	O
variety	O
of	O
extracellular	O
signals	O
,	O
thus	O
implicating	O
a	O
number	O
of	O
diverse	O
,	O
yet	O
convergent	O
signal	O
transduction	O
pathways	O
in	O
its	O
transcriptional	O
control	O
.	O

In	O
this	O
review	O
,	O
I	O
describe	O
how	O
DNA	O
methylation	O
and	O
specific	O
DNA	O
binding	O
proteins	O
may	O
regulate	O
transcription	O
of	O
the	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
gene	O
in	O
response	O
to	O
extracellular	O
signals	O
.	O

CD14	B-Protein
-	O
mediated	O
signal	O
pathway	O
of	O
Porphyromonas	O
gingivalis	O
lipopolysaccharide	O
in	O
human	O
gingival	O
fibroblasts	O
.	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
induces	O
expression	O
of	O
inflammatory	O
cytokines	O
in	O
monocytes	O
/	O
macrophages	O
via	O
CD14	B-Protein
,	O
one	O
of	O
the	O
LPS	O
receptors	O
,	O
which	O
is	O
expressed	O
predominantly	O
in	O
these	O
cells	O
.	O

It	O
has	O
been	O
demonstrated	O
that	O
Porphyromonas	O
gingivalis	O
LPS	O
(	O
P	O
-	O
LPS	O
)	O
also	O
is	O
able	O
to	O
induce	O
inflammatory	O
cytokines	O
in	O
human	O
gingival	O
fibroblasts	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
determine	O
whether	O
CD14	B-Protein
is	O
expressed	O
in	O
gingival	O
fibroblasts	O
and	O
to	O
define	O
the	O
P	O
-	O
LPS	O
-	O
mediated	O
signal	O
-	O
transducing	O
mechanism	O
in	O
the	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
observed	O
unexpectedly	O
by	O
immunohistochemical	O
,	O
Western	O
blotting	O
(	O
immunoblotting	O
)	O
,	O
and	O
Northern	O
(	O
RNA	O
)	O
blotting	O
assays	O
that	O
CD14	B-Protein
is	O
expressed	O
at	O
high	O
density	O
in	O
human	O
gingival	O
fibroblasts	O
.	O

P	O
-	O
LPS	O
-	O
induced	O
expression	O
of	O
the	O
monocyte	B-Protein
chemoattractant	I-Protein
protein	I-Protein
1	I-Protein
(	O
MCP	B-Protein
-	I-Protein
1	I-Protein
)	O
gene	O
in	O
the	O
cells	O
was	O
inhibited	O
markedly	O
by	O
treatment	O
with	O
anti	O
-	O
human	O
CD14	B-Protein
antibody	O
and	O
was	O
completely	O
inhibited	O
by	O
herbimycin	O
A	O
,	O
a	O
potent	O
inhibitor	O
of	O
tyrosine	O
kinase	O
.	O

The	O
inhibitor	O
also	O
dramatically	O
inhibited	O
monocyte	O
chemotactic	O
activity	O
of	O
and	O
MCP	B-Protein
-	I-Protein
1	I-Protein
production	O
by	O
the	O
cells	O
.	O

Furthermore	O
,	O
P	O
-	O
LPS	O
-	O
induced	O
expression	O
of	O
the	O
MCP	B-Protein
-	I-Protein
1	I-Protein
gene	O
in	O
the	O
cells	O
also	O
was	O
blocked	O
by	O
inhibitors	O
of	O
two	O
transcription	O
factors	O
,	O
i	O
.	O
e	O
.	O
,	O
curcumin	O
,	O
an	O
inhibitor	O
of	O
AP	O
-	O
1	O
,	O
and	O
pyrolidine	O
dithiocarbamate	O
,	O
an	O
inhibitor	O
of	O
NF	O
-	O
kappaB	O
.	O

Both	O
inhibitors	O
inhibited	O
monocyte	O
chemotactic	O
activity	O
in	O
the	O
culture	O
supernatant	O
of	O
P	O
-	O
LPS	O
-	O
treated	O
cells	O
.	O

Gel	O
shift	O
mobility	O
assay	O
showed	O
stimulation	O
of	O
the	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappaB	O
contents	O
in	O
P	O
-	O
LPS	O
-	O
treated	O
cells	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
demonstrate	O
the	O
expression	O
of	O
CD14	B-Protein
in	O
human	O
gingival	O
fibroblasts	O
and	O
to	O
show	O
that	O
the	O
signal	O
-	O
transducing	O
pathway	O
of	O
P	O
-	O
LPS	O
in	O
the	O
cells	O
is	O
mediated	O
by	O
CD14	B-Protein
.	O

Comparative	O
analysis	O
identifies	O
conserved	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
receptor	I-Protein
-	I-Protein
associated	I-Protein
factor	I-Protein
3	I-Protein
binding	O
sites	O
in	O
the	O
human	O
and	O
simian	O
Epstein	O
-	O
Barr	O
virus	O
oncogene	O
LMP1	B-Protein
.	O

Nonhuman	O
primates	O
are	O
naturally	O
infected	O
with	O
a	O
B	O
-	O
lymphotropic	O
herpesvirus	O
closely	O
related	O
to	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
.	O

These	O
simian	O
EBV	O
share	O
considerable	O
genetic	O
,	O
biologic	O
,	O
and	O
epidemiologic	O
features	O
with	O
human	O
EBV	O
,	O
including	O
virus	O
-	O
induced	O
tumorigenesis	O
.	O

However	O
,	O
latent	O
,	O
transformation	O
-	O
associated	O
viral	O
genes	O
demonstrate	O
marked	O
sequence	O
divergence	O
among	O
species	O
despite	O
the	O
conserved	O
functions	O
.	O

We	O
have	O
cloned	O
the	O
latent	B-Protein
membrane	I-Protein
protein	I-Protein
1	I-Protein
(	O
LMP1	B-Protein
)	O
homologs	O
from	O
the	O
simian	O
EBV	O
naturally	O
infecting	O
baboons	O
(	O
cercopithicine	O
herpesvirus	O
12	O
,	O
herpesvirus	O
papio	O
)	O
and	O
rhesus	O
monkeys	O
(	O
cercopithicine	O
herpesvirus	O
15	O
)	O
for	O
a	O
comparative	O
study	O
with	O
the	O
human	O
EBV	O
oncogene	O
.	O

The	O
transmembrane	O
domains	O
are	O
well	O
conserved	O
,	O
but	O
there	O
is	O
striking	O
sequence	O
divergence	O
of	O
the	O
carboxy	O
-	O
terminal	O
cytoplasmic	O
domain	O
essential	O
for	O
B	O
-	O
cell	O
immortalization	O
and	O
interaction	O
with	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
signaling	O
pathway	O
.	O

Nevertheless	O
,	O
the	O
simian	O
EBV	O
LMP1s	B-Protein
retain	O
most	O
functions	O
in	O
common	O
with	O
EBV	O
LMP1	B-Protein
,	O
including	O
the	O
ability	O
to	O
induce	O
NF	O
-	O
(	O
kappa	O
)	O
B	O
activity	O
in	O
human	O
cells	O
,	O
to	O
bind	O
the	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
associated	I-Protein
factor	I-Protein
3	I-Protein
(	O
TRAF3	B-Protein
)	O
in	O
vitro	O
,	O
and	O
to	O
induce	O
expression	O
of	O
tumor	O
necrosis	O
factor	O
-	O
responsive	O
genes	O
,	O
such	O
as	O
ICAM1	B-Protein
,	O
in	O
human	O
B	O
lymphocytes	O
.	O

Multiple	O
TRAF3	B-Protein
binding	O
sites	O
containing	O
a	O
PXQXT	O
/	O
S	O
core	O
sequence	O
can	O
be	O
identified	O
in	O
the	O
simian	O
EBV	O
LMP1s	B-Protein
by	O
an	O
in	O
vitro	O
binding	O
assay	O
.	O

A	O
PXQXT	O
/	O
S	O
-	O
containing	O
sequence	O
is	O
also	O
present	O
in	O
the	O
cytoplasmic	O
domain	O
of	O
the	O
Hodgkin	O
'	O
s	O
disease	O
marker	O
,	O
CD30	B-Protein
,	O
and	O
binds	O
TRAF3	B-Protein
in	O
vitro	O
.	O

The	O
last	O
13	O
amino	O
acids	O
containing	O
a	O
PXQXT	O
/	O
S	O
sequence	O
are	O
highly	O
conserved	O
in	O
human	O
and	O
simian	O
EBV	O
LMP1	B-Protein
but	O
do	O
not	O
bind	O
TRAF3	B-Protein
,	O
suggesting	O
a	O
distinct	O
role	O
for	O
this	O
conserved	O
region	O
of	O
LMP1	B-Protein
.	O

The	O
conserved	O
TRAF3	B-Protein
binding	O
sites	O
in	O
LMP1	B-Protein
and	O
the	O
CD30	B-Protein
Hodgkin	O
'	O
s	O
disease	O
marker	O
provides	O
further	O
evidence	O
that	O
a	O
TRAF3	B-Protein
-	O
mediated	O
signal	O
transduction	O
pathway	O
may	O
be	O
important	O
in	O
malignant	O
transformation	O
.	O

Tyrosine	O
kinase	O
and	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
activities	O
in	O
CD40	B-Protein
-	O
activated	O
human	O
B	O
lymphocytes	O
.	O

In	O
vitro	O
,	O
human	O
B	O
lymphocytes	O
undergo	O
long	O
-	O
term	O
proliferation	O
when	O
activated	O
through	O
CD40	B-Protein
,	O
a	O
protein	O
expressed	O
on	O
their	O
cell	O
surface	O
.	O

The	O
nature	O
of	O
CD40	B-Protein
-	O
dependent	O
signals	O
in	O
proliferating	O
fresh	O
human	O
Epstein	O
-	O
Barr	O
virus	O
-	O
negative	O
B	O
lymphocytes	O
is	O
currently	O
unknown	O
.	O

In	O
this	O
study	O
,	O
a	O
CD40	B-Protein
-	O
dependent	O
B	O
cell	O
culture	O
system	O
was	O
used	O
to	O
examine	O
the	O
role	O
of	O
different	O
signal	O
transduction	O
elements	O
.	O

Protein	O
kinase	O
C	O
(	O
PKC	O
)	O
depletion	O
generated	O
by	O
a	O
long	O
-	O
term	O
phorbol	O
12	O
myristate	O
13	O
-	O
acetate	O
treatment	O
had	O
weak	O
effects	O
on	O
proliferation	O
.	O

Rather	O
,	O
tyrosine	O
phosphorylation	O
was	O
shown	O
to	O
be	O
directly	O
involved	O
in	O
mediating	O
CD40	B-Protein
-	O
dependent	O
signals	O
.	O

The	O
use	O
of	O
the	O
protein	O
tyrosine	O
kinase	O
(	O
PTK	O
)	O
-	O
specific	O
inhibitor	O
herbimycin	O
A	O
dramatically	O
decreased	O
cellular	O
proliferation	O
without	O
altering	O
the	O
activity	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
-	O
1	O
long	O
terminal	O
repeat	O
(	O
HIV	O
-	O
1	O
LTR	O
)	O
,	O
a	O
promoter	O
largely	O
dependent	O
on	O
the	O
binding	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
.	O

In	O
contrast	O
,	O
the	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
specific	O
inhibitor	O
H	O
-	O
89	O
totally	O
inhibited	O
HIV	O
-	O
1	O
LTR	O
activity	O
at	O
a	O
concentration	O
as	O
low	O
as	O
100	O
nM	O
without	O
affecting	O
cellular	O
proliferation	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
and	O
supershift	O
assay	O
using	O
an	O
NF	O
-	O
kappa	O
B	O
binding	O
sequence	O
from	O
the	O
kappa	O
light	O
chain	O
as	O
a	O
probe	O
,	O
revealed	O
that	O
both	O
p65	B-Protein
(	O
RelA	B-Protein
)	O
and	O
c	B-Protein
-	I-Protein
Rel	I-Protein
were	O
present	O
in	O
CD40	B-Protein
-	O
stimulated	O
B	O
cells	O
.	O

While	O
PKC	O
depletion	O
did	O
not	O
alter	O
the	O
NF	O
-	O
kappa	O
B	O
level	O
,	O
treatment	O
of	O
B	O
lymphocytes	O
with	O
H	O
-	O
89	O
or	O
herbimycin	O
A	O
provoked	O
a	O
decrease	O
in	O
the	O
NF	O
-	O
kappa	O
B	O
level	O
.	O

These	O
observations	O
establish	O
the	O
importance	O
of	O
different	O
signal	O
transducing	O
pathways	O
leading	O
to	O
CD40	B-Protein
activation	O
of	O
B	O
lymphocytes	O
.	O

Characterization	O
of	O
a	O
CD43	B-Protein
/	O
leukosialin	B-Protein
-	O
mediated	O
pathway	O
for	O
inducing	O
apoptosis	O
in	O
human	O
T	O
-	O
lymphoblastoid	O
cells	O
.	O

The	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
J393	O
induces	O
apoptosis	O
in	O
Jurkat	O
T	O
-	O
cells	O
.	O

NH2	O
-	O
terminal	O
amino	O
acid	O
sequence	O
analysis	O
identified	O
the	O
140	O
-	O
kDa	O
surface	O
antigen	O
for	O
mAb	O
J393	O
as	O
CD43	B-Protein
/	O
leukosialin	B-Protein
,	O
the	O
major	O
sialoglycoprotein	O
of	O
leukocytes	O
.	O

While	O
Jurkat	O
cells	O
co	O
-	O
expressed	O
two	O
discrete	O
cell	O
-	O
surface	O
isoforms	O
of	O
CD43	B-Protein
,	O
recognized	O
by	O
mAb	O
J393	O
and	O
mAb	O
G10	O
-	O
2	O
,	O
respectively	O
,	O
only	O
J393	O
/	O
CD43	B-Protein
signaled	O
apoptosis	O
.	O

J393	O
/	O
CD43	B-Protein
was	O
found	O
to	O
be	O
hyposialylated	O
,	O
bearing	O
predominantly	O
O	O
-	O
linked	O
monosaccharide	O
glycans	O
,	O
whereas	O
G10	O
-	O
2	O
/	O
CD43	B-Protein
bore	O
complex	O
sialylated	O
tetra	O
-	O
and	O
hexasaccharide	O
chains	O
.	O

Treatment	O
with	O
soluble	O
,	O
bivalent	O
mAb	O
J393	O
killed	O
25	O
-	O
50	O
%	O
of	O
the	O
cell	O
population	O
,	O
while	O
concomitant	O
engagement	O
of	O
either	O
the	O
CD3	O
.	O
TcR	O
complex	O
or	O
the	O
integrins	O
CD18	B-Protein
and	O
CD29	B-Protein
significantly	O
potentiated	O
this	O
effect	O
.	O

Treatment	O
of	O
Jurkat	O
cells	O
with	O
mAb	O
J393	O
induced	O
tyrosine	O
phosphorylation	O
of	O
specific	O
protein	O
substrates	O
that	O
underwent	O
hyperphosphorylation	O
upon	O
antigen	O
receptor	O
costimulation	O
.	O

Tyrosine	O
kinase	O
inhibition	O
by	O
herbimycin	O
A	O
diminished	O
J393	O
/	O
CD43	B-Protein
-	O
mediated	O
apoptosis	O
,	O
whereas	O
inhibition	O
of	O
phosphotyrosine	O
phosphatase	O
activity	O
by	O
bis	O
(	O
maltolato	O
)	O
oxovanadium	O
-	O
IV	O
enhanced	O
cell	O
death	O
.	O

Signal	O
transduction	O
through	O
tyrosine	O
kinase	O
activation	O
may	O
lead	O
to	O
altered	O
gene	O
expression	O
,	O
as	O
J393	O
/	O
CD43	B-Protein
ligation	O
prompted	O
decreases	O
in	O
the	O
nuclear	O
localization	O
of	O
the	O
transcriptional	O
regulatory	O
protein	O
NF	O
-	O
kappaB	O
and	O
proteins	O
binding	O
the	O
interferon	O
-	O
inducible	O
regulatory	O
element	O
.	O

Since	O
peripheral	O
blood	O
T	O
-	O
lymphocytes	O
express	O
cryptic	O
epitopes	O
for	O
mAb	O
J393	O
,	O
these	O
findings	O
demonstrate	O
the	O
existence	O
of	O
a	O
tightly	O
regulated	O
CD43	B-Protein
-	O
mediated	O
pathway	O
for	O
inducing	O
apoptosis	O
in	O
human	O
T	O
-	O
cell	O
lineages	O
.	O

Naive	O
(	O
CD45RA	B-Protein
+	O
)	O
T	O
lymphocytes	O
are	O
more	O
sensitive	O
to	O
oxidative	O
stress	O
-	O
induced	O
signals	O
than	O
memory	O
(	O
CD45RO	B-Protein
+	O
)	O
cells	O
.	O

Formation	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROI	O
)	O
after	O
oxidative	O
stress	O
has	O
been	O
shown	O
to	O
be	O
an	O
activation	O
signal	O
for	O
T	O
lymphocytes	O
,	O
e	O
.	O
g	O
.	O
,	O
expression	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
and	O
its	O
receptor	O
are	O
induced	O
.	O

These	O
ROI	O
-	O
induced	O
effects	O
can	O
,	O
to	O
a	O
large	O
extent	O
,	O
be	O
attributed	O
to	O
the	O
activation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
.	O

Now	O
we	O
have	O
examined	O
whether	O
naive	O
and	O
memory	O
T	O
lymphocytes	O
differ	O
in	O
their	O
sensitivity	O
to	O
ROI	O
-	O
mediated	O
signals	O
.	O

When	O
CD45RA	B-Protein
+	O
(	O
naive	O
)	O
and	O
CD45RO	B-Protein
+	O
(	O
memory	O
)	O
T	O
lymphocytes	O
were	O
directly	O
stimulated	O
with	O
H2O2	O
,	O
NF	O
-	O
kappaB	O
nuclear	O
translocation	O
was	O
stronger	O
in	O
naive	O
cells	O
than	O
in	O
memory	O
cells	O
and	O
it	O
could	O
be	O
induced	O
with	O
lower	O
doses	O
.	O

The	O
composition	O
of	O
the	O
induced	O
nuclear	O
NF	O
-	O
kappaB	O
(	O
levels	O
of	O
p50	B-Protein
and	O
RelA	B-Protein
proteins	O
)	O
was	O
similar	O
in	O
these	O
cell	O
types	O
.	O

The	O
magnitude	O
and	O
kinetics	O
of	O
intracellular	O
ROI	O
were	O
similar	O
,	O
suggesting	O
that	O
there	O
were	O
no	O
differences	O
in	O
ROI	O
-	O
forming	O
mechanisms	O
or	O
antioxidative	O
capacities	O
.	O

The	O
probable	O
regulatory	O
point	O
was	O
the	O
cytoplasmic	O
IkappaB	O
inhibitor	O
:	O
in	O
CD45RA	B-Protein
+	O
cells	O
,	O
H2O2	O
caused	O
a	O
more	O
profound	O
depression	O
in	O
the	O
levels	O
of	O
IkappaB	B-Protein
alpha	I-Protein
.	O

These	O
findings	O
indicate	O
that	O
T	O
cells	O
representing	O
different	O
activation	O
and	O
/	O
or	O
differentiation	O
stages	O
can	O
be	O
differentially	O
responsive	O
to	O
ROI	O
-	O
mediated	O
signals	O
.	O

Differential	O
nuclear	O
localization	O
of	O
p50	B-Protein
,	O
p52	B-Protein
,	O
and	O
RelB	B-Protein
proteins	O
in	O
human	O
accessory	O
cells	O
of	O
the	O
immune	O
response	O
in	O
situ	O
.	O

The	O
Rel	O
/	O
NF	O
-	O
kappa	O
B	O
proteins	O
,	O
p50	B-Protein
,	O
p52	B-Protein
,	O
p65	B-Protein
,	O
c	B-Protein
-	I-Protein
Rel	I-Protein
,	O
and	O
RelB	B-Protein
,	O
constitute	O
a	O
family	O
of	O
transcription	O
factors	O
involved	O
in	O
the	O
positive	O
regulation	O
of	O
a	O
variety	O
of	O
genes	O
during	O
the	O
immune	O
response	O
.	O

Recently	O
,	O
it	O
has	O
been	O
shown	O
that	O
RelB	B-Protein
knockout	O
mice	O
have	O
no	O
dendritic	O
cells	O
(	O
DC	O
)	O
.	O

An	O
overexpression	O
of	O
p50	B-Protein
has	O
been	O
described	O
in	O
follicular	O
dendritic	O
cells	O
(	O
FDC	O
)	O
.	O

A	O
constitutive	O
NF	O
-	O
kappa	O
B	O
activity	O
has	O
been	O
reported	O
in	O
mature	O
macrophages	O
.	O

This	O
led	O
to	O
the	O
hypothesis	O
that	O
some	O
of	O
the	O
Rel	O
/	O
NF	O
-	O
kappa	O
B	O
proteins	O
were	O
key	O
nuclear	O
factors	O
in	O
functions	O
of	O
accessory	O
cells	O
of	O
the	O
immune	O
response	O
.	O

Therefore	O
,	O
we	O
investigated	O
in	O
situ	O
the	O
nuclear	O
localization	O
of	O
Rel	O
/	O
NF	O
-	O
kappa	O
B	O
proteins	O
in	O
accessory	O
cells	O
of	O
the	O
immune	O
system	O
by	O
immunohistochemistry	O
and	O
double	O
labeling	O
by	O
immunofluorescence	O
from	O
five	O
normal	O
human	O
tonsils	O
and	O
five	O
lymph	O
nodes	O
with	O
follicular	O
hyperplasia	O
.	O

Nuclear	O
p65	B-Protein
and	O
c	B-Protein
-	I-Protein
Rel	I-Protein
proteins	O
were	O
found	O
in	O
all	O
cell	O
types	O
including	O
lymphocytes	O
.	O

In	O
germinal	O
centers	O
GC	O
,	O
p50	B-Protein
,	O
p52	B-Protein
,	O
and	O
RelB	B-Protein
were	O
found	O
in	O
the	O
nuclei	O
of	O
FDC	O
only	O
and	O
were	O
not	O
detected	O
in	O
the	O
nuclei	O
of	O
CD68	B-Protein
+	O
cells	O
.	O

In	O
T	O
cell	O
areas	O
,	O
p50	B-Protein
,	O
p52	B-Protein
,	O
and	O
RelB	B-Protein
were	O
found	O
in	O
the	O
nuclei	O
of	O
HLA	B-Protein
-	I-Protein
DR	I-Protein
+	O
cells	O
with	O
an	O
antigen	O
-	O
presenting	O
cell	O
(	O
APC	O
)	O
morphology	O
.	O

p52	B-Protein
and	O
RelB	B-Protein
were	O
detected	O
in	O
the	O
nuclei	O
in	O
both	O
CD1a	B-Protein
+	O
and	O
CD68	B-Protein
+	O
cells	O
from	O
the	O
T	O
cell	O
area	O
,	O
whereas	O
p50	B-Protein
was	O
found	O
only	O
in	O
CD68	B-Protein
-	O
and	O
CD1a	B-Protein
-	O
cells	O
.	O

Cells	O
with	O
nuclear	O
p50	B-Protein
were	O
negative	O
for	O
the	O
CD38	B-Protein
,	O
CD20	B-Protein
and	O
CD2	B-Protein
markers	O
.	O

These	O
results	O
show	O
that	O
,	O
physiologically	O
,	O
high	O
levels	O
of	O
nuclear	O
of	O
p50	B-Protein
,	O
p52	B-Protein
and	O
RelB	B-Protein
are	O
restricted	O
to	O
accessory	O
cells	O
of	O
the	O
immune	O
system	O
,	O
which	O
include	O
FDC	O
in	O
GC	O
,	O
and	O
DC	O
and	O
macrophages	O
in	O
the	O
T	O
cell	O
zone	O
,	O
that	O
specialized	O
scavenger	O
macrophages	O
from	O
GC	O
do	O
not	O
have	O
detectable	O
levels	O
of	O
p52	B-Protein
and	O
RelB	B-Protein
,	O
whereas	O
macrophages	O
from	O
the	O
T	O
cell	O
area	O
,	O
known	O
to	O
present	O
the	O
antigen	O
to	O
T	O
cells	O
,	O
do	O
have	O
both	O
nuclear	O
p52	B-Protein
and	O
RelB	B-Protein
,	O
and	O
that	O
in	O
the	O
T	O
cell	O
zone	O
,	O
p52	B-Protein
and	O
RelB	B-Protein
are	O
located	O
in	O
nuclei	O
of	O
both	O
CD1a	B-Protein
+	O
,	O
CD68	B-Protein
+	O
or	O
both	O
,	O
cells	O
APC	O
,	O
whereas	O
p50	B-Protein
is	O
restricted	O
to	O
CD1a	B-Protein
-	O
and	O
CD68	B-Protein
-	O
APC	O
.	O

The	O
different	O
patterns	O
of	O
p50	B-Protein
,	O
p52	B-Protein
and	O
RelB	B-Protein
protein	O
nuclear	O
localization	O
may	O
provide	O
insight	O
into	O
their	O
different	O
roles	O
during	O
the	O
immune	O
response	O
in	O
vivo	O
.	O

CD40	B-Protein
,	O
but	O
not	O
lipopolysaccharide	O
and	O
anti	O
-	O
IgM	B-Protein
stimulation	O
of	O
primary	O
B	O
lymphocytes	O
,	O
leads	O
to	O
a	O
persistent	O
nuclear	O
accumulation	O
of	O
RelB	B-Protein
.	O

In	O
this	O
study	O
we	O
analyzed	O
the	O
effect	O
of	O
CD40	B-Protein
stimulation	O
on	O
the	O
activity	O
and	O
nuclear	O
appearance	O
of	O
Rel	O
/	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
factors	O
in	O
primary	O
murine	O
B	O
lymphocytes	O
.	O

We	O
show	O
that	O
triggering	O
of	O
CD40	B-Protein
signaling	O
pathway	O
(	O
s	O
)	O
by	O
CD40	B-Protein
ligands	O
expressed	O
on	O
L	O
cells	O
led	O
to	O
strong	O
activation	O
of	O
an	O
NF	O
-	O
kappaB	O
-	O
controlled	O
beta	B-Protein
-	I-Protein
globin	I-Protein
reporter	O
gene	O
in	O
primary	O
B	O
lymphocytes	O
from	O
transgenic	O
mice	O
.	O

Analyses	O
of	O
nuclear	O
translocation	O
of	O
individual	O
members	O
of	O
Rel	O
proteins	O
after	O
CD40	B-Protein
induction	O
of	O
primary	O
B	O
cells	O
showed	O
a	O
strong	O
and	O
long	O
-	O
lasting	O
accumulation	O
of	O
RelB	B-Protein
and	O
,	O
less	O
pronounced	O
,	O
of	O
c	B-Protein
-	I-Protein
Rel	I-Protein
.	O

LPS	O
stimulation	O
did	O
not	O
give	O
rise	O
to	O
a	O
persistent	O
nuclear	O
accumulation	O
of	O
RelB	B-Protein
and	O
c	B-Protein
-	I-Protein
Rel	I-Protein
,	O
whereas	O
nuclear	O
c	B-Protein
-	I-Protein
Rel	I-Protein
,	O
but	O
not	O
RelB	B-Protein
,	O
accumulated	O
after	O
B	O
cell	O
receptor	O
stimulation	O
.	O

CD40	B-Protein
induced	O
not	O
only	O
nuclear	O
translocation	O
but	O
also	O
de	O
novo	O
synthesis	O
of	O
RelB	B-Protein
RNA	O
and	O
protein	O
.	O

S107	O
plasmacytoma	O
cells	O
,	O
which	O
express	O
CD40	B-Protein
but	O
are	O
defective	O
for	O
the	O
nuclear	O
appearance	O
of	O
p50	B-Protein
/	O
p65	B-Protein
-	O
NF	O
-	O
kappaB	O
,	O
do	O
not	O
express	O
RelB	B-Protein
after	O
CD40	B-Protein
stimulation	O
.	O

In	O
S107	O
cells	O
stably	O
transfected	O
with	O
relB	B-Protein
genes	O
,	O
stimulation	O
of	O
nuclear	O
RelB	B-Protein
translocation	O
by	O
CD40	B-Protein
was	O
observed	O
.	O

These	O
results	O
indicate	O
that	O
stimulation	O
of	O
CD40	B-Protein
signaling	O
pathways	O
exerts	O
a	O
long	O
-	O
lasting	O
stimulatory	O
effect	O
on	O
both	O
the	O
transcription	O
and	O
nuclear	O
translocation	O
of	O
RelB	B-Protein
.	O

Since	O
LPS	O
and	O
anti	O
-	O
IgM	B-Protein
were	O
unable	O
to	O
activate	O
RelB	B-Protein
,	O
CD40	B-Protein
appears	O
to	O
trigger	O
a	O
special	O
program	O
of	O
gene	O
expression	O
involved	O
in	O
the	O
proliferation	O
and	O
/	O
or	O
differentiation	O
of	O
B	O
lymphocytes	O
.	O

HIV	O
-	O
1	O
LTR	O
activity	O
in	O
human	O
CD40	B-Protein
-	O
activated	O
B	O
lymphocytes	O
is	O
dependent	O
on	O
NF	O
-	O
kappaB	O
.	O

CD40	B-Protein
-	O
stimulated	O
human	O
B	O
lymphocytes	O
are	O
highly	O
permissive	O
to	O
a	O
productive	O
infection	O
by	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O

In	O
these	O
cells	O
,	O
nuclear	O
factors	O
involved	O
in	O
activation	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
,	O
which	O
contains	O
the	O
transcriptional	O
control	O
elements	O
of	O
the	O
virus	O
,	O
are	O
unknown	O
.	O

Transient	O
expression	O
assays	O
with	O
plasmids	O
containing	O
deleted	O
parts	O
of	O
the	O
LTR	O
region	O
linked	O
to	O
a	O
reporter	O
gene	O
showed	O
that	O
the	O
NF	O
-	O
kappaB	O
binding	O
site	O
was	O
essential	O
for	O
HIV	O
-	O
1	O
LTR	O
activity	O
in	O
CD40	B-Protein
-	O
stimulated	O
B	O
lymphocytes	O
.	O

In	O
addition	O
,	O
electrophoretic	O
mobility	O
shift	O
and	O
supershift	O
assays	O
revealed	O
that	O
important	O
NF	O
-	O
kappaB	O
binding	O
activity	O
composed	O
of	O
at	O
least	O
p50	B-Protein
,	O
p65	B-Protein
,	O
and	O
c	B-Protein
-	I-Protein
Rel	I-Protein
NF	O
-	O
kappaB	O
subunits	O
was	O
present	O
in	O
nuclei	O
of	O
CD40	B-Protein
-	O
stimulated	O
B	O
cells	O
.	O

These	O
results	O
confirm	O
at	O
a	O
molecular	O
level	O
the	O
ability	O
of	O
HIV	O
-	O
1	O
to	O
replicate	O
in	O
B	O
cells	O
and	O
that	O
this	O
activity	O
is	O
strongly	O
associated	O
with	O
NF	O
-	O
kappaB	O
.	O

Activation	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
via	O
T	O
cell	O
receptor	O
requires	O
a	O
Raf	O
kinase	O
and	O
Ca2	O
+	O
influx	O
.	O

Functional	O
synergy	O
between	O
Raf	O
and	O
calcineurin	O
.	O

Signals	O
transduced	O
via	O
the	O
TCR	O
activate	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
,	O
which	O
,	O
in	O
turn	O
,	O
is	O
critical	O
to	O
the	O
transcriptional	O
induction	O
of	O
many	O
genes	O
important	O
for	O
the	O
proliferation	O
and	O
expression	O
of	O
a	O
differentiated	O
phenotype	O
.	O

Treatment	O
of	O
T	O
cells	O
with	O
the	O
protein	O
kinase	O
C	O
activator	O
PMA	O
in	O
combination	O
with	O
Ca2	O
+	O
ionophores	O
mimics	O
this	O
process	O
,	O
and	O
the	O
two	O
agents	O
are	O
often	O
substituted	O
for	O
TCR	O
stimulation	O
,	O
bypassing	O
the	O
TCR	O
.	O

Here	O
we	O
identify	O
intracellular	O
signaling	O
components	O
involved	O
in	O
activation	O
of	O
NF	O
-	O
kappaB	O
following	O
TCR	O
stimulation	O
.	O

TCR	O
signaling	O
was	O
triggered	O
by	O
treating	O
Jurkat	O
T	O
cells	O
with	O
PHA	B-Protein
or	O
anti	O
-	O
CD3	B-Protein
Abs	O
,	O
and	O
NF	O
-	O
kappaB	O
activation	O
was	O
monitored	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
/	O
or	O
by	O
kappaB	O
-	O
dependent	O
reporter	O
assays	O
.	O

Contrary	O
to	O
the	O
idea	O
that	O
protein	O
kinase	O
C	O
is	O
involved	O
in	O
TCR	O
-	O
mediated	O
activation	O
of	O
NF	O
-	O
kappaB	O
,	O
high	O
doses	O
of	O
staurosporine	O
did	O
not	O
interfere	O
with	O
activation	O
of	O
NF	O
-	O
kappaB	O
by	O
PHA	B-Protein
,	O
while	O
the	O
same	O
dose	O
of	O
staurosporine	O
completely	O
blocked	O
activation	O
by	O
PMA	O
.	O

PHA	B-Protein
-	O
induced	O
kappaB	O
-	O
dependent	O
reporter	O
activity	O
was	O
,	O
however	O
,	O
effectively	O
blocked	O
by	O
a	O
dominant	O
negative	O
form	O
of	O
Raf	B-Protein
-	I-Protein
1	I-Protein
,	O
suggesting	O
a	O
critical	O
role	O
for	O
a	O
Raf	O
kinase	O
.	O

The	O
TCR	O
-	O
mediated	O
activation	O
of	O
NF	O
-	O
kappaB	O
was	O
also	O
dependent	O
on	O
a	O
Ca2	O
+	O
influx	O
,	O
because	O
the	O
Ca2	O
+	O
channel	O
blocker	O
,	O
SK	O
&	O
F	O
96365	O
,	O
as	O
well	O
as	O
other	O
agents	O
that	O
prevented	O
the	O
Ca2	O
+	O
influx	O
,	O
inhibited	O
NF	O
-	O
kappaB	O
activation	O
.	O

Cotransfection	O
of	O
a	O
constitutively	O
active	O
form	O
of	O
calcineurin	O
largely	O
substituted	O
for	O
the	O
Ca2	O
+	O
requirement	O
and	O
reversed	O
the	O
blockade	O
by	O
SK	O
&	O
F	O
96365	O
.	O

Consistent	O
with	O
these	O
observations	O
,	O
coexpression	O
of	O
constitutively	O
active	O
forms	O
of	O
Raf	B-Protein
-	I-Protein
1	I-Protein
and	O
calcineurin	O
synergistically	O
induced	O
kappaB	O
-	O
dependent	O
reporter	O
activity	O
,	O
suggesting	O
a	O
physiologically	O
relevant	O
functional	O
interaction	O
between	O
the	O
kinase	O
and	O
the	O
phosphatase	O
.	O

Synergistic	O
interactions	O
between	O
overlapping	O
binding	O
sites	O
for	O
the	O
serum	B-Protein
response	I-Protein
factor	I-Protein
and	O
ELK	B-Protein
-	I-Protein
1	I-Protein
proteins	O
mediate	O
both	O
basal	O
enhancement	O
and	O
phorbol	O
ester	O
responsiveness	O
of	O
primate	O
cytomegalovirus	O
major	O
immediate	O
-	O
early	O
promoters	O
in	O
monocyte	O
and	O
T	O
-	O
lymphocyte	O
cell	O
types	O
.	O

Cytomegalovirus	O
(	O
CMV	O
)	O
infection	O
is	O
nonpermissive	O
or	O
persistent	O
in	O
many	O
lymphoid	O
and	O
myeloid	O
cell	O
types	O
but	O
can	O
be	O
activated	O
in	O
differentiated	O
macrophages	O
.	O

We	O
have	O
shown	O
elsewhere	O
that	O
both	O
the	O
major	O
immediate	O
-	O
early	O
gene	O
(	O
MIE	O
)	O
and	O
lytic	O
cycle	O
infectious	O
progeny	O
virus	O
expression	O
can	O
be	O
induced	O
in	O
otherwise	O
nonpermissive	O
monocyte	O
-	O
like	O
U	O
-	O
937	O
cell	O
cultures	O
infected	O
with	O
either	O
human	O
CMV	O
(	O
HCMV	O
)	O
or	O
simian	O
CMV	O
(	O
SCMV	O
)	O
by	O
treatment	O
with	O
the	O
phorbol	O
ester	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
.	O

Two	O
multicopy	O
basal	O
enhancer	O
motifs	O
within	O
the	O
SCMV	O
MIE	O
enhancer	O
,	O
namely	O
,	O
11	O
copies	O
of	O
the	O
16	O
-	O
bp	O
cyclic	O
AMP	O
response	O
element	O
(	O
CRE	O
)	O
and	O
3	O
copies	O
of	O
novel	O
17	O
-	O
bp	O
serum	B-Protein
response	I-Protein
factor	I-Protein
(	O
SRF	B-Protein
)	O
binding	O
sites	O
referred	O
to	O
as	O
the	O
SNE	O
(	O
SRF	B-Protein
/	O
NFkappaB	O
-	O
like	O
element	O
)	O
,	O
as	O
well	O
as	O
four	O
classical	O
NFkappaB	O
sites	O
within	O
the	O
HCMV	O
version	O
,	O
contribute	O
to	O
TPA	O
responsiveness	O
in	O
transient	O
assays	O
in	O
monocyte	O
and	O
T	O
-	O
cell	O
types	O
.	O

The	O
SCMV	O
SNE	O
sites	O
contain	O
potential	O
overlapping	O
core	O
recognition	O
binding	O
motifs	O
for	O
SRF	B-Protein
,	O
Rel	O
/	O
NFkappaB	O
,	O
ETS	O
,	O
and	O
YY1	O
class	O
transcription	O
factors	O
but	O
fail	O
to	O
respond	O
to	O
either	O
serum	O
or	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
alpha	I-Protein
.	O

Therefore	O
,	O
to	O
evaluate	O
the	O
mechanism	O
of	O
TPA	O
responsiveness	O
of	O
the	O
SNE	O
motifs	O
and	O
of	O
a	O
related	O
16	O
-	O
bp	O
SEE	O
(	O
SRF	B-Protein
/	O
ETS	O
element	O
)	O
motif	O
found	O
in	O
the	O
HCMV	O
and	O
chimpanzee	O
CMV	O
MIE	O
enhancers	O
,	O
we	O
have	O
examined	O
the	O
functional	O
responses	O
and	O
protein	O
binding	O
properties	O
of	O
multimerized	O
wild	O
-	O
type	O
and	O
mutant	O
elements	O
added	O
upstream	O
to	O
the	O
SCMV	O
MIE	O
or	O
simian	O
virus	O
40	O
minimal	O
promoter	O
regions	O
in	O
the	O
U	O
-	O
937	O
,	O
K	O
-	O
562	O
,	O
HL	O
-	O
60	O
,	O
THP	O
-	O
1	O
,	O
and	O
Jurkat	O
cell	O
lines	O
.	O

Unlike	O
classical	O
NFkappaB	O
sites	O
,	O
neither	O
the	O
SNE	O
nor	O
the	O
SEE	O
motif	O
responded	O
to	O
phosphatase	O
inhibition	O
by	O
okadaic	O
acid	O
.	O

However	O
,	O
the	O
TPA	O
responsiveness	O
of	O
both	O
CMV	O
elements	O
proved	O
to	O
involve	O
synergistic	O
interactions	O
between	O
the	O
core	O
SRF	B-Protein
binding	O
site	O
(	O
CCATATATGG	O
)	O
and	O
the	O
adjacent	O
inverted	O
ETS	O
binding	O
motifs	O
(	O
TTCC	O
)	O
,	O
which	O
correlated	O
directly	O
with	O
formation	O
of	O
a	O
bound	O
tripartite	O
complex	O
containing	O
both	O
the	O
cellular	O
SRF	B-Protein
and	O
ELK	B-Protein
-	I-Protein
1	I-Protein
proteins	O
.	O

This	O
protein	O
complex	O
was	O
more	O
abundant	O
in	O
U	O
-	O
937	O
,	O
K	O
-	O
562	O
,	O
and	O
HeLa	O
cell	O
extracts	O
than	O
in	O
Raji	O
,	O
HF	O
,	O
BALB	O
/	O
c	O
3T3	O
,	O
or	O
HL	O
-	O
60	O
cells	O
,	O
but	O
the	O
binding	O
activity	O
was	O
altered	O
only	O
twofold	O
after	O
TPA	O
treatment	O
.	O

A	O
40	O
-	O
fold	O
stimulation	O
of	O
chloramphenicol	B-Protein
acetyltransferase	I-Protein
activity	O
mediated	O
by	O
four	O
tandem	O
repeats	O
of	O
the	O
SNE	O
could	O
be	O
induced	O
within	O
2	O
h	O
(	O
and	O
up	O
to	O
250	O
-	O
fold	O
within	O
6	O
h	O
)	O
after	O
addition	O
of	O
TPA	O
in	O
DNA	O
-	O
transfected	O
U	O
-	O
937	O
cells	O
,	O
indicating	O
that	O
the	O
stimulation	O
appeared	O
likely	O
to	O
be	O
a	O
true	O
protein	O
kinase	O
C	O
-	O
mediated	O
signal	O
transduction	O
event	O
rather	O
than	O
a	O
differentiation	O
response	O
.	O

Slight	O
differences	O
in	O
the	O
sequence	O
of	O
the	O
core	O
SRF	B-Protein
binding	O
site	O
compared	O
with	O
that	O
of	O
the	O
classical	O
c	B-Protein
-	I-Protein
Fos	I-Protein
promoter	O
serum	O
response	O
element	O
,	O
together	O
with	O
differences	O
in	O
the	O
spacing	O
between	O
the	O
SRF	B-Protein
and	O
ETS	O
motifs	O
,	O
appear	O
to	O
account	O
for	O
the	O
inability	O
of	O
the	O
SCMV	O
SNEs	O
to	O
respond	O
to	O
serum	O
induction	O
.	O

Acetylsalicylic	O
acid	O
and	O
sodium	O
salicylate	O
inhibit	O
LPS	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
/	O
c	B-Protein
-	I-Protein
Rel	I-Protein
nuclear	O
translocation	O
,	O
and	O
synthesis	O
of	O
tissue	B-Protein
factor	I-Protein
(	O
TF	B-Protein
)	O
and	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
alfa	I-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
)	O
in	O
human	O
monocytes	O
.	O

We	O
have	O
investigated	O
the	O
effects	O
of	O
acetylsalicylic	O
acid	O
and	O
sodium	O
salicylate	O
on	O
the	O
LPS	O
-	O
induced	O
synthesis	O
of	O
the	O
pro	O
-	O
coagulant	O
protein	O
tissue	O
factor	O
(	O
TF	O
)	O
and	O
the	O
pro	O
-	O
inflammatory	O
protein	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
)	O
,	O
as	O
well	O
as	O
the	O
prostaglandin	O
PGE2	O
in	O
human	O
monocytes	O
.	O

Both	O
drugs	O
dose	O
-	O
dependently	O
inhibited	O
LPS	O
-	O
induced	O
TF	O
and	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
synthesis	O
at	O
the	O
mRNA	O
and	O
the	O
protein	O
level	O
,	O
and	O
reduced	O
PGE2	O
production	O
.	O

As	O
evidenced	O
by	O
electro	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
and	O
the	O
use	O
of	O
a	O
NF	O
-	O
kappa	O
B	O
prototypic	O
probe	O
,	O
these	O
drugs	O
probably	O
exert	O
their	O
inhibitory	O
effects	O
by	O
interference	O
with	O
the	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kappa	O
B	O
/	O
c	B-Protein
-	I-Protein
Rel	I-Protein
proteins	O
.	O

These	O
data	O
may	O
expand	O
the	O
understanding	O
of	O
the	O
anti	O
-	O
thrombotic	O
and	O
anti	O
-	O
inflammatory	O
effects	O
of	O
these	O
drugs	O
when	O
activation	O
of	O
monocytes	O
occurs	O
.	O

The	O
NF	O
-	O
kappa	O
B	O
inhibitor	O
,	O
tepoxalin	O
,	O
suppresses	O
surface	O
expression	O
of	O
the	O
cell	O
adhesion	O
molecules	O
CD62E	B-Protein
,	O
CD11b	B-Protein
/	O
CD18	B-Protein
and	O
CD106	B-Protein
.	O

Tepoxalin	O
,	O
a	O
dual	O
enzyme	O
inhibitor	O
of	O
cyclooxygenase	O
and	O
5	O
-	O
lipoxygenase	O
has	O
been	O
shown	O
to	O
inhibit	O
T	O
-	O
cell	O
activation	O
.	O

Its	O
immunosuppressive	O
property	O
is	O
distinct	O
from	O
cyclosporin	O
because	O
only	O
tepoxalin	O
,	O
but	O
not	O
cyclosporin	O
,	O
suppresses	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

Here	O
we	O
report	O
that	O
tepoxalin	O
selectively	O
inhibits	O
intercellular	B-Protein
adhesion	I-Protein
molecule	I-Protein
-	I-Protein
1	I-Protein
(	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
,	O
CD54	B-Protein
)	O
/	O
MAC	O
-	O
1	O
(	O
CD11b	B-Protein
/	O
CD18	B-Protein
)	O
dependent	O
adhesion	O
of	O
polymorphonuclear	O
cells	O
to	O
IL	B-Protein
-	I-Protein
1	I-Protein
activated	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
.	O

The	O
mechanism	O
of	O
inhibition	O
is	O
related	O
to	O
the	O
surface	O
expression	O
of	O
several	O
cell	O
adhesion	O
molecules	O
.	O

Flow	O
cytometry	O
analyses	O
on	O
cultured	O
cells	O
that	O
were	O
treated	O
with	O
tepoxalin	O
or	O
antisense	O
oligonucleotides	O
to	O
the	O
P65	B-Protein
/	O
p50	B-Protein
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
and	O
then	O
stimulated	O
with	O
PMA	O
,	O
revealed	O
a	O
reduced	O
expression	O
of	O
CD11b	B-Protein
/	O
CD18	B-Protein
on	O
monocytic	O
HL60	O
cells	O
,	O
and	O
endothelial	B-Protein
adhesion	I-Protein
molecule	I-Protein
-	I-Protein
1	I-Protein
(	O
CD62E	B-Protein
)	O
and	O
vascular	B-Protein
adhesion	I-Protein
molecule	I-Protein
-	I-Protein
1	I-Protein
(	O
CD106	B-Protein
)	O
on	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
.	O

Expression	O
of	O
other	O
adhesion	O
molecules	O
such	O
as	O
lymphocyte	O
function	O
associated	O
-	O
antigen	O
-	O
1	O
(	O
CD11a	B-Protein
/	O
CD18	B-Protein
)	O
and	O
CD54	B-Protein
were	O
unaffected	O
.	O

Tepoxalin	O
also	O
inhibited	O
the	O
secretion	O
of	O
a	O
NF	O
-	O
kappa	O
B	O
regulated	O
chemokine	O
,	O
IL	B-Protein
-	I-Protein
8	I-Protein
,	O
a	O
known	O
inducer	O
of	O
CD11b	B-Protein
/	O
CD18	B-Protein
expression	O
.	O

Thus	O
the	O
suppression	O
of	O
CD11b	B-Protein
/	O
CD18	B-Protein
expression	O
by	O
tepoxalin	O
may	O
involve	O
IL	B-Protein
-	I-Protein
8	I-Protein
.	O

Our	O
results	O
suggest	O
that	O
by	O
inhibiting	O
NF	O
-	O
kappa	O
B	O
activation	O
,	O
surface	O
expression	O
of	O
several	O
adhesion	O
molecules	O
can	O
be	O
modulated	O
and	O
that	O
tepoxalin	O
may	O
be	O
useful	O
in	O
treating	O
selected	O
adhesion	O
mediated	O
events	O
such	O
as	O
leukocyte	O
migration	O
or	O
atherosclerotic	O
plaque	O
formation	O
.	O

Nuclear	O
NF	B-Protein
-	I-Protein
ATp	I-Protein
is	O
a	O
hallmark	O
of	O
unstimulated	O
B	O
cells	O
from	O
B	O
-	O
CLL	O
patients	O
.	O

B	O
lymphocytes	O
from	O
the	O
peripheral	O
blood	O
of	O
patients	O
with	O
chronic	O
lymphocytic	O
leukaemia	O
(	O
CLL	O
)	O
were	O
analysed	O
for	O
the	O
nuclear	O
presence	O
and	O
DNA	O
binding	O
of	O
a	O
panel	O
of	O
transcription	O
factors	O
which	O
are	O
involved	O
in	O
the	O
gene	O
control	O
of	O
lymphoid	O
cells	O
.	O

The	O
following	O
transcription	O
factors	O
were	O
studied	O
:	O
the	O
Octamer	O
factors	O
Oct	B-Protein
-	I-Protein
1	I-Protein
and	O
Oct	B-Protein
-	I-Protein
2	I-Protein
,	O
members	O
of	O
the	O
AP	O
-	O
1	O
factor	O
family	O
,	O
NF	O
-	O
AT	O
factors	O
,	O
in	O
particular	O
NF	B-Protein
-	I-Protein
ATp	I-Protein
,	O
and	O
members	O
of	O
the	O
Rel	O
/	O
NF	O
-	O
kB	O
family	O
.	O

We	O
show	O
that	O
the	O
constitutive	O
nuclear	O
translocation	O
of	O
NF	B-Protein
-	I-Protein
ATp	I-Protein
,	O
a	O
member	O
of	O
the	O
growing	O
family	O
of	O
NF	O
-	O
AT	O
factors	O
,	O
is	O
a	O
hallmark	O
of	O
nonstimulated	O
B	O
cells	O
from	O
CLL	O
patients	O
that	O
distinguishes	O
B	O
-	O
CLL	O
cells	O
from	O
'	O
normal	O
'	O
B	O
lymphocytes	O
.	O

Constitutive	O
nuclear	O
appearance	O
was	O
also	O
observed	O
for	O
NF	O
-	O
kB2	O
/	O
p52	B-Protein
.	O

Constitutive	O
binding	O
of	O
further	O
factor	O
proteins	O
to	O
DNA	O
,	O
such	O
as	O
JunD	B-Protein
,	O
c	B-Protein
-	I-Protein
Fos	I-Protein
and	O
FosB	B-Protein
,	O
was	O
detected	O
in	O
several	O
patients	O
whereas	O
the	O
localisation	O
and	O
DNA	O
binding	O
of	O
other	O
factors	O
such	O
as	O
c	B-Protein
-	I-Protein
Jun	I-Protein
,	O
RelA	B-Protein
/	O
p65	B-Protein
and	O
c	B-Protein
-	I-Protein
Rel	I-Protein
was	O
unaltered	O
.	O

It	O
is	O
remarkable	O
that	O
in	O
B	O
-	O
CLL	O
cells	O
the	O
nuclear	O
appearance	O
and	O
DNA	O
binding	O
of	O
specific	O
transcription	O
factors	O
is	O
dramatically	O
affected	O
whereas	O
other	O
members	O
of	O
the	O
same	O
factor	O
family	O
remained	O
unaltered	O
in	O
these	O
leukemic	O
cells	O
.	O

It	O
remains	O
to	O
be	O
shown	O
which	O
molecular	O
events	O
lead	O
to	O
the	O
specific	O
'	O
pre	O
-	O
activation	O
'	O
,	O
i	O
.	O
e	O
.	O
constitutive	O
nuclear	O
translocation	O
and	O
DNA	O
binding	O
,	O
of	O
these	O
members	O
of	O
NF	O
-	O
AT	O
,	O
NF	O
-	O
kB	O
and	O
AP	O
-	O
1	O
factor	O
families	O
.	O

Induction	O
of	O
vascular	B-Protein
cell	I-Protein
adhesion	I-Protein
molecule	I-Protein
-	I-Protein
1	I-Protein
by	O
low	O
-	O
density	O
lipoprotein	O
.	O

Low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
is	O
a	O
well	O
-	O
established	O
risk	O
factor	O
for	O
atherosclerosis	O
.	O

When	O
endothelial	O
cells	O
are	O
incubated	O
with	O
this	O
lipoprotein	O
in	O
pathophysiologic	O
amounts	O
,	O
the	O
cells	O
are	O
activated	O
.	O

Among	O
the	O
documented	O
cellular	O
responses	O
to	O
LDL	O
is	O
increased	O
recruitment	O
of	O
monocytes	O
,	O
which	O
are	O
believed	O
to	O
play	O
a	O
major	O
role	O
in	O
promoting	O
intimal	O
plaque	O
formation	O
.	O

The	O
findings	O
presented	O
here	O
link	O
an	O
atheogenic	O
lipoprotein	O
,	O
LDL	O
,	O
with	O
the	O
induction	O
of	O
an	O
adhesion	O
molecule	O
important	O
in	O
atherogenesis	O
Human	O
LDL	O
induces	O
the	O
vascular	B-Protein
cell	I-Protein
adhesion	I-Protein
molecule	I-Protein
-	I-Protein
1	I-Protein
(	O
VCAM	B-Protein
-	I-Protein
1	I-Protein
)	O
transcriptionally	O
with	O
an	O
increase	O
in	O
mRNA	O
levels	O
through	O
activation	O
of	O
the	O
VCAM	O
promoter	O
.	O

This	O
effect	O
is	O
blocked	O
by	O
anti	O
-	O
VCAM	O
antibodies	O
.	O

After	O
a	O
2	O
-	O
day	O
incubation	O
in	O
LDL	O
,	O
the	O
binding	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
which	O
is	O
believed	O
to	O
be	O
a	O
key	O
oxidative	O
-	O
stress	O
sensor	O
for	O
VCAM	O
regulation	O
,	O
remains	O
at	O
basal	O
level	O
.	O

In	O
contrast	O
,	O
the	O
binding	O
activities	O
of	O
AP	O
-	O
1	O
and	O
GATA	O
,	O
on	O
the	O
other	O
hand	O
,	O
are	O
increased	O
by	O
LDL	O
.	O

Thus	O
,	O
a	O
component	O
of	O
LDL	O
-	O
enhanced	O
endothelial	O
recruitment	O
of	O
monocytes	O
is	O
attributed	O
to	O
VCAM	B-Protein
-	I-Protein
1	I-Protein
expression	O
,	O
which	O
appears	O
to	O
be	O
mediated	O
through	O
AP	O
-	O
1	O
and	O
GATA	O
.	O

These	O
data	O
identify	O
LDL	O
as	O
a	O
VCAM	O
-	O
inducer	O
possibly	O
distinct	O
from	O
cytokines	O
and	O
endotoxin	O
.	O

Inhibition	O
of	O
nuclear	O
factor	O
kappa	O
B	O
subunit	O
p65	B-Protein
mRNA	O
accumulation	O
in	O
lipopolysaccharide	O
-	O
stimulated	O
human	O
monocytic	O
cells	O
treated	O
with	O
sodium	O
salicylate	O
.	O

Lipopolysaccharide	O
is	O
one	O
of	O
the	O
most	O
potent	O
trigger	O
substances	O
for	O
monocytes	O
and	O
macrophages	O
causing	O
secretion	O
of	O
inflammatory	O
mediators	O
such	O
as	O
tumor	O
necrosis	O
factor	O
and	O
interleukin	B-Protein
-	I-Protein
1	I-Protein
.	O

The	O
nature	O
of	O
the	O
nuclear	O
factors	O
involved	O
in	O
regulation	O
of	O
these	O
cytokine	O
genes	O
is	O
still	O
unknown	O
.	O

Nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
;	O
heterodimer	O
of	O
p50	B-Protein
and	O
p65	B-Protein
)	O
proteins	O
have	O
been	O
suggested	O
to	O
play	O
an	O
important	O
role	O
in	O
gene	O
transcription	O
of	O
inflammatory	O
mediators	O
when	O
monocytes	O
are	O
stimulated	O
with	O
lipopolysaccharide	O
.	O

Nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
such	O
as	O
salicylates	O
have	O
been	O
used	O
to	O
treat	O
symptoms	O
of	O
inflammation	O
,	O
and	O
a	O
new	O
mechanism	O
of	O
drug	O
action	O
was	O
suggested	O
recently	O
.	O

Salicylates	O
have	O
been	O
shown	O
to	O
inhibit	O
lipopolysaccharide	O
-	O
induced	O
gene	O
transcription	O
via	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
by	O
preventing	O
the	O
degradation	O
of	O
NF	O
-	O
kappa	O
B	O
inhibitor	O
"	O
I	B-Protein
kappa	I-Protein
B	I-Protein
"	O
,	O
blocking	O
the	O
translocation	O
of	O
NF	O
-	O
kappa	O
B	O
into	O
the	O
nuclear	O
compartment	O
.	O

However	O
,	O
the	O
nature	O
of	O
the	O
subunit	O
involved	O
in	O
this	O
mechanism	O
has	O
not	O
been	O
defined	O
.	O

To	O
examine	O
the	O
mechanisms	O
by	O
which	O
salicylates	O
affect	O
cytokine	O
gene	O
transcription	O
,	O
the	O
amount	O
of	O
active	O
and	O
inactive	O
NF	O
-	O
kappa	O
B	O
and	O
NF	O
-	O
kappa	O
B	O
mRNA	O
,	O
in	O
Porphyromonas	O
gingivalis	O
lipopolysaccharide	O
-	O
stimulated	O
human	O
monocytic	O
cells	O
was	O
assessed	O
.	O

High	O
doses	O
of	O
sodium	O
salicylate	O
suppressed	O
NF	O
-	O
kappa	O
B	O
p65	B-Protein
mRNA	O
accumulation	O
,	O
resulting	O
in	O
suppression	O
of	O
total	O
NF	O
-	O
kappa	O
B	O
,	O
p50	B-Protein
on	O
tissue	O
oligonucleotide	O
had	O
no	O
effects	O
on	O
lipopolysaccharide	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

The	O
data	O
demonstrate	O
that	O
the	O
p65	B-Protein
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
is	O
inhibited	O
by	O
salicylate	O
treatment	O
and	O
highlight	O
the	O
role	O
of	O
salicylate	O
in	O
the	O
control	O
of	O
gene	O
expression	O
of	O
inflammatory	O
mediators	O
.	O

Genes	O
that	O
regulate	O
interleukin	B-Protein
-	I-Protein
4	I-Protein
expression	O
in	O
T	O
cells	O
.	O

Interleukin	B-Protein
-	I-Protein
4	I-Protein
is	O
an	O
immunomodulatory	O
cytokine	O
which	O
plays	O
a	O
central	O
role	O
in	O
the	O
regulation	O
of	O
allergic	O
and	O
atopic	O
immune	O
responses	O
.	O

Significant	O
progress	O
has	O
been	O
made	O
in	O
gaining	O
a	O
detailed	O
understanding	O
of	O
the	O
transcriptional	O
regulation	O
of	O
the	O
interleukin	B-Protein
-	I-Protein
4	I-Protein
gene	O
.	O

The	O
recent	O
identification	O
and	O
characterization	O
of	O
several	O
key	O
transcription	O
factors	O
has	O
helped	O
to	O
elucidate	O
the	O
molecular	O
mechanisms	O
of	O
T	O
helper	O
cell	O
cytokine	O
gene	O
expression	O
.	O

Regulation	O
of	O
the	O
human	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
gene	O
by	O
the	O
alpha	O
and	O
beta	O
isoforms	O
of	O
the	O
glucocorticoid	O
receptor	O
.	O

The	O
immunosuppressive	O
effects	O
of	O
glucocorticoids	O
are	O
largely	O
due	O
to	O
transcriptional	O
inhibition	O
of	O
immunologically	O
relevant	O
genes	O
,	O
such	O
as	O
the	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
(	O
IL	B-Protein
-	I-Protein
2	I-Protein
)	O
gene	O
.	O

These	O
effects	O
are	O
mediated	O
by	O
the	O
intracellular	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
.	O

In	O
humans	O
,	O
alternative	O
splicing	O
of	O
the	O
GR	O
precursor	O
mRNA	O
gives	O
rise	O
to	O
two	O
receptor	O
isoforms	O
,	O
termed	O
GRalpha	B-Protein
and	O
GRbeta	B-Protein
.	O

We	O
previously	O
demonstrated	O
that	O
GRbeta	B-Protein
could	O
antagonize	O
GRalpha	B-Protein
-	O
mediated	O
transactivation	O
of	O
a	O
glucocorticoid	O
-	O
responsive	O
element	O
(	O
GRE	O
)	O
-	O
driven	O
reporter	O
gene	O
in	O
COS	O
-	O
7	O
cells	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
analyze	O
the	O
roles	O
of	O
the	O
two	O
GR	O
isoforms	O
on	O
glucocorticoid	B-Protein
-	O
mediated	O
transrepression	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
gene	O
.	O

Using	O
a	O
recently	O
developed	O
transfection	O
technique	O
,	O
we	O
demonstrate	O
that	O
in	O
primary	O
human	O
lymphocytes	O
,	O
stimulation	O
of	O
a	O
548	O
bp	O
IL	B-Protein
-	I-Protein
2	I-Protein
promoter	O
-	O
luciferase	O
reporter	O
construct	O
by	O
phorbol	O
ester	O
and	O
calcium	O
ionophore	O
is	O
reversed	O
by	O
dexamethasone	O
to	O
a	O
similar	O
extent	O
as	O
in	O
Jurkat	O
T	O
lymphoma	O
cells	O
transfected	O
with	O
a	O
GRalpha	B-Protein
expression	O
vector	O
.	O

Transfection	O
of	O
a	O
GRbeta	B-Protein
expression	O
vector	O
alone	O
did	O
not	O
result	O
in	O
IL	B-Protein
-	I-Protein
2	I-Protein
promoter	O
repression	O
in	O
response	O
to	O
glucocorticoids	O
.	O

Furthermore	O
,	O
GRbeta	B-Protein
did	O
not	O
antagonize	O
the	O
repressive	O
effects	O
of	O
GRalpha	B-Protein
on	O
IL	B-Protein
-	I-Protein
2	I-Protein
promoter	O
activity	O
.	O

Surprisingly	O
,	O
overexpression	O
of	O
GRbeta	B-Protein
in	O
Jurkat	O
cells	O
did	O
not	O
cause	O
significant	O
inhibition	O
of	O
GRalpha	B-Protein
-	O
induced	O
transactivation	O
of	O
a	O
GRE	O
-	O
dependent	O
luciferase	O
reporter	O
gene	O
either	O
.	O

We	O
conclude	O
that	O
the	O
transrepressive	O
effect	O
of	O
glucocorticoids	O
on	O
IL	B-Protein
-	I-Protein
2	I-Protein
gene	O
transcription	O
is	O
exclusively	O
mediated	O
by	O
GRalpha	B-Protein
.	O

GRbeta	B-Protein
can	O
neither	O
antagonize	O
GRalpha	B-Protein
-	O
mediated	O
transactivation	O
nor	O
transrepression	O
in	O
Jurkat	O
cells	O
,	O
indicating	O
a	O
cell	O
type	O
-	O
specific	O
pattern	O
of	O
GRbeta	B-Protein
-	O
mediated	O
antiglucocorticoid	O
activity	O
.	O

Interleukin	B-Protein
-	I-Protein
6	I-Protein
production	O
in	O
hemorrhagic	O
shock	O
is	O
accompanied	O
by	O
neutrophil	O
recruitment	O
and	O
lung	O
injury	O
.	O

Hemorrhagic	O
shock	O
(	O
HS	O
)	O
initiates	O
an	O
inflammatory	O
cascade	O
that	O
includes	O
the	O
production	O
of	O
cytokines	O
and	O
recruitment	O
of	O
neutrophils	O
(	O
PMN	O
)	O
and	O
may	O
progress	O
to	O
organ	O
failure	O
,	O
inducing	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
.	O

To	O
examine	O
the	O
hypothesis	O
that	O
interleukin	B-Protein
-	I-Protein
6	I-Protein
(	O
IL	B-Protein
-	I-Protein
6	I-Protein
)	O
contributes	O
to	O
PMN	O
infiltration	O
and	O
lung	O
damage	O
in	O
HS	O
,	O
we	O
examined	O
the	O
lungs	O
of	O
rats	O
subjected	O
to	O
unresuscitated	O
and	O
resuscitated	O
HS	O
for	O
the	O
production	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
activation	O
of	O
Stat3	B-Protein
.	O

Using	O
semiquantitative	O
RT	O
-	O
PCR	O
,	O
we	O
found	O
a	O
striking	O
increase	O
in	O
IL	B-Protein
-	I-Protein
6	I-Protein
mRNA	O
levels	O
only	O
in	O
resuscitated	O
HS	O
,	O
with	O
peak	O
levels	O
observed	O
1	O
h	O
after	O
initiation	O
of	O
resuscitation	O
.	O

Increased	O
IL	B-Protein
-	I-Protein
6	I-Protein
protein	O
expression	O
was	O
localized	O
to	O
bronchial	O
and	O
alveolar	O
cells	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
of	O
protein	O
extracts	O
from	O
shock	O
lungs	O
exhibited	O
an	O
increase	O
in	O
Stat3	B-Protein
activation	O
with	O
kinetics	O
similar	O
to	O
IL	B-Protein
-	I-Protein
6	I-Protein
mRNA	O
.	O

In	O
situ	O
DNA	O
binding	O
assay	O
determined	O
Stat3	B-Protein
activation	O
predominantly	O
within	O
alveoli	O
.	O

Intratracheal	O
instillation	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
alone	O
into	O
normal	O
rats	O
resulted	O
in	O
PMN	O
infiltration	O
into	O
lung	O
interstitium	O
and	O
alveoli	O
,	O
marked	O
elevation	O
of	O
bronchoalveolar	O
lavage	O
cellularity	O
,	O
and	O
increased	O
wet	O
-	O
to	O
-	O
dry	O
ratio	O
.	O

These	O
findings	O
indicate	O
that	O
IL	B-Protein
-	I-Protein
6	I-Protein
production	O
and	O
Stat3	B-Protein
activation	O
occur	O
early	O
in	O
HS	O
and	O
may	O
contribute	O
to	O
PMN	O
-	O
mediated	O
lung	O
injury	O
,	O
including	O
ARDS	O
after	O
HS	O
.	O

